<SEC-DOCUMENT>0000875045-17-000017.txt : 20170425
<SEC-HEADER>0000875045-17-000017.hdr.sgml : 20170425
<ACCEPTANCE-DATETIME>20170425161828
ACCESSION NUMBER:		0000875045-17-000017
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170425
DATE AS OF CHANGE:		20170425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		17781288

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2017331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s78B78FE1117885AAF0243D7276948BEE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;text-align:center;"><img src="biogenlogostandarda05.jpg" alt="biogenlogostandarda05.jpg" style="height:61px;width:185px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act (Check One):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:19%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;21, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212,115,203</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s06DBDAFF87F454B635BE3D72E25791C7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sB0E03E68ACBEDD62E0043D72E2A9A842"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s293A6A0D71C4829FCAA03D7276A3BA10"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s293A6A0D71C4829FCAA03D7276A3BA10">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sFAE95F7795D18C643FF43D7276C4A550"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sFAE95F7795D18C643FF43D7276C4A550">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s755AC394627857EE40973D7276D136A9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2017 and December&#160;31, 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s755AC394627857EE40973D7276D136A9">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s6CBDBFB2EE2E3FC9DB4A3D7276EC9673"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Three Months Ended March 31, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s6CBDBFB2EE2E3FC9DB4A3D7276EC9673">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2D62A2273DDF627D9F693D72E3C56711"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2D62A2273DDF627D9F693D72E3C56711">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB9D98F921F028CD5223F3D72E78E31C3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sB9D98F921F028CD5223F3D72E78E31C3">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s0E4EA5A82C138962DE393D72EBC8A1CB"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s0E4EA5A82C138962DE393D72EBC8A1CB">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s39579D501B0DEF15A7DC3D72EBE8393F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s39579D501B0DEF15A7DC3D72EBE8393F">55</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s735715DDA6003924932B3D72EC1AFDC6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s548398453DCB001E698F3D72EC3C50F7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s548398453DCB001E698F3D72EC3C50F7">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2FF90924B5A0F39695093D72EC6EBC39"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2FF90924B5A0F39695093D72EC6EBC39">56</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s091EC5F40375903058213D728066A842"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s091EC5F40375903058213D728066A842">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE7FD00E057861DE85AB53D72ECC12145"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE7FD00E057861DE85AB53D72ECC12145">70</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s756BDCBE63AB158DA5D63D72ECE2AC9A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s756BDCBE63AB158DA5D63D72ECE2AC9A">71</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s033AEA637C7426AB7A073D72E278B76D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, costs and tax treatment of the spin-off of our hemophilia business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filing and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.'s) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (Recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (Recombinant), Fc Fusion Protein in the E.U.).</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, BENEPALI&#174;, FLIXABI&#174;, PLEGRIDY&#174;, RITUXAN&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is a trademark of Biogen. ALPROLIX&#174;,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, OCREVUS&#174;, REMICADE&#174; and other trademarks referenced in this report are the property of their respective owners. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sB0E03E68ACBEDD62E0043D72E2A9A842"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><div><a name="s7066A89B036405789E813D72E2CC26A9"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s293A6A0D71C4829FCAA03D7276A3BA10"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,380.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">340.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,810.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,726.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">384.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">423.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">437.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">499.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">497.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">448.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,786.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,348.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,024.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,378.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">986.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,325.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">239.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">356.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sFAE95F7795D18C643FF43D7276C4A550"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">742.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">935.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">742.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">933.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s755AC394627857EE40973D7276D136A9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2016</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">924.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,956.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,501.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,441.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">324.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">300.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,231.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,093.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,859.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,825.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,610.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,103.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,611.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,335.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21,195.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">561.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">70.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">316.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,044.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,992.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,419.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,952.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">94.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">688.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">722.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9,728.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,748.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(325.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14,781.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11,479.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11,467.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21,195.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s6CBDBFB2EE2E3FC9DB4A3D7276EC9673"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">969.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">512.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">149.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(195.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(160.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(46.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(88.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(684.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(136.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(195.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(34.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">235.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,015.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,884.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,181.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,256.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,914.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(300.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(210.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(126.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(855.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(28.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(744.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,203.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(583.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(25.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(29.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash contribution to Bioverativ</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(901.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net decrease in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,410.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(192.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">924.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,130.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s2D62A2273DDF627D9F693D72E3C56711"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s03B2A77773EDE26BC1793D727700E77F"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, which is focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method and continue to evaluate the potential impact that this standard may have on our financial position, results of operations and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 the FASB issued the following new standards, which we adopted on January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. As of March 31, 2017, the adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. This new standard will be effective for us on January 1, 2020; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div><div><a name="s98065d6231c84495a4b8f6cead256c54"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date) and are expected to terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the distribution date, with the exception of the manufacturing and supply agreement which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ and our consent. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totalling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. During the first quarter of 2017, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenues in relation to these services which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as cost of sales in relation to these services during the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we have continued to distribute ALPROLIX and ELOCTATE on behalf of Bioverativ and expect to do so until Bioverativ obtains appropriate regulatory authorizations in certain countries, including the United States (U.S.) and Canada. Under this arrangement, we are distributing these products as an agent of Bioverativ and will also provide related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations do not reflect recognition of activity or balances related to these transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. In the first quarter of 2017 these amounts were not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our condensed consolidated statements of income for the three months ended March 31, 2017 and 2016 totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$182.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="sF75E71CEAD644D81DE233D727716011E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">131.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">568.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">707.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(62.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(231.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(64.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(267.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(337.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">552.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s4FAE4FF76B8C8A53031E3D727729583B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">158.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">644.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ were related to work in process and finished goods inventory, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="sE49312A30A147B27571B3D7277325204"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(526.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,648.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,887.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(874.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,012.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,153.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,049.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,103.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$448.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$88.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. Amortization of acquired intangible assets for the three months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$353.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of impairment and amortization charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property related to TECFIDERA, as further discussed below. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of March 31, 2017 also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$349.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,418.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S (Forward Pharma) and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement, representing the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We paid the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in February 2017 and recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into the agreement, through December 2020, the last month before royalty payments could first commence pursuant to the agreement. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. On March 31, 2017, the U.S. intellectual property dispute was decided in our favor. Forward Pharma has announced that it intends to appeal this decision. For additional information related to these disputes, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continued to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">346.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">425.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">412.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">239.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">254.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2016 Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s2ADFDC5ED7B259F546B43D727768DEEE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,502.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">556.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,528.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,483.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,032.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">993.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,812.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,890.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,845.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,496.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$254.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. </font></div><div><a name="s3298A94E5057BFB6E4BA3D7277ED6FD8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">519.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,288.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,289.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,213.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,073.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,076.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,956.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,561.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,565.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,884.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,181.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><div><a name="s9D034A6F703712EAC65A3D72782CD4B0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,215.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,446.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$332.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. A net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts was recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to a net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sC77A8C81D0CA5695AE513D72786036F2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,438.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,439.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$609.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$216.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><a name="s242C8FD54B85E006FE0A3D727866C1D7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decreased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$661.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily driven by an adjustment to retained earnings of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$852.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting the spin-off of our hemophilia business, as described in Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements and share repurchases of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$583.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below. These decrease were partially offset by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$747.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock (2011 Share Repurchase Program). During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to complete this program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sAE1A575A3F94B9D934CF3D7278769ABB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:47%;"></td><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s7FCA1A9A9FF4293AAF703D7278A7E410"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s23097D9AF114279764D43D7278B6016B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13. &#160;&#160;&#160;&#160;Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing stock-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div><a name="s5FFFCC7C00A5F30BA6853D7278E6066D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities and the favorable settlement of a state tax matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2005.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div><div><a name="s71C5600A0AEBB846FB563D7278FE068A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$935.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,044.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.  As a result of this agreement we have agreed to dismiss the appeal and in the first quarter of 2017 we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these financial statements.</font></div><div><a name="s11053947CD14161E17153D72790E0DCB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the research and development costs incurred in support of the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s17E525E13D0113A5CEEA3D727912DBB7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 13, 2017, we entered into an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer&#8217;s disease (AD) and progressive supranuclear palsy (PSP), from Bristol-Myers Squibb Company (BMS). BMS-986168 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we will receive worldwide rights to BMS-986168 and will be responsible for the full development and global commercialization of BMS-986168 in AD and PSP. In exchange, we will make an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and BMS may receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, and potential royalties. We will also assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS&#8217;s acquisition of the company in 2014. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone which may become payable in 2017, and potential royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;share of the co-promotion profits or losses as a component of total revenues in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&#160;2016. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to reflect our share of an overall net loss within the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our condensed consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as these </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our recognition of income to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, during the third quarter of&#160;2016,&#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. In December 2016 SPINRAZA was approved by the U.S. Food and Drug Administration for the treatment of SMA in pediatric and adult patients in the U.S. triggering a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;milestone payment due to Ionis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets. This amount was paid during the first quarter of 2017. We may pay Ionis up to approximately&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in additional milestone payments upon the achievement of certain other regulatory milestones, including approval in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our sales of SPINRAZA in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we will make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit share with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the collaboration profit share in our condensed consolidated statements of income.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in connection with these services as a component of other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s78B0D31575978FDBED7F3D72793F84F5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from AIFA that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. In the first quarter of 2017, we reached an agreement resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015, in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016 the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016, in the U.S. District Court for the District of Massachusetts related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has announced that it intends to appeal this decision.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Petitions and Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. In March 2017 the USPTO ruled against the petitioner. The petitioner has filed a request for rehearing, which is pending.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG (Swiss Pharma) filed petitions in the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn&#8217;s disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions and in February 2017 denied Swiss Pharma's requests for rehearing.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EPO has scheduled a hearing for November 2017 on Biogen&#8217;s and others&#8217; oppositions to Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information about this matter, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. A hearing was held in the Dutch action in February 2017 and the decision is pending. A hearing has been scheduled in the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="sB9D98F921F028CD5223F3D72E78E31C3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ will focus on the discovery, development and commercialization of therapies for treatment of hemophilia and other blood disorders, including ELOCTATE for the treatment of hemophilia A and ALPROLIX for the treatment of hemophilia B, and assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017. For additional information related to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products and, unless we develop, acquire rights to and commercialize new products and technologies, we may be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and successful execution of external business development opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how by developing, manufacturing and marketing biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="sFFF9BBA84854D57D066C3D72E7AE583D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="biib-2017331highlights.jpg" alt="biib-2017331highlights.jpg" style="height:426px;width:317px;"></div><div><a name="s1FB4CA2507D9B477443E3D72E7E09653"></a></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.46</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 21.9% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our income from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,810.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 3.1% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,380.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 3.1% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by a 14.3% increase in worldwide TYSABRI revenues and revenues from BENEPALI and SPINRAZA. Product revenues, net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were negatively impacted by a decrease in worldwide ALPROLIX and ELOCTATE revenues resulting from the spin-off of our hemophilia business on February 1, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$340.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 3.4% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 2.4% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,786.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">32.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by the $353.6 million impairment and amortization charges recorded in relation to</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;our intellectual property related to TECFIDERA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">22.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of sales. </font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$235.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5,705.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions or biosimilars of existing products and other technologies. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to political and societal pressures.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our competition and pricing risks that could negatively impact our product sales, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Key Pipeline and Product Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2017 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorization in the E.U for SPINRAZA for the treatment of SMA. The CHMP reviewed SPINRAZA under an accelerated assessment procedure, which is a regulatory mechanism to facilitate earlier access to patients for medicines that fulfill unmet medical needs. SPINRAZA is the first treatment for SMA to be recommended by the CHMP for approval in the E.U.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS (Ocrelizumab)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved OCREVUS for the treatment of RMS and PPMS. Under the terms of our agreement with Genentech, we will receive a tiered royalty on U.S. net sales ranging from&#160;13.5%&#160;and&#160;increasing up to 24% if annual net sales exceed $900.0 million.</font></div></div></div><div><a name="s37B622D806BFB785E5C73D727E23C70C"></a></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,631.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,663.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">749.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">646.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,380.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">84.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">340.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">329.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,810.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,726.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">958.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">945.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">648.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">670.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">545.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">477.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,380.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,309.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><a name="sF782DFCD33A32743570D3D72E8324666"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="biib-2017331tecfidera.jpg" alt="biib-2017331tecfidera.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher discounts and allowances and a 7% decrease in unit sales volume.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to a 14% increase in unit sales volume in existing markets and new markets where we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in certain European countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TECFIDERA in 2017 on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S., primarily resulting from increasing competition from additional treatments for MS, including OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2017331interferons.jpg" alt="biib-2017331interferons.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. AVONEX and PLEGRIDY revenues totaled $400.1 million and $64.7 million, respectively, as compared to $400.0 million and $67.5 million, respectively, in the prior year comparative period. &#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in U.S. Interferon revenues was primarily due to an overall 13% decrease in Interferon unit sales volume, which was primarily attributable to patients transitioning to other oral MS therapies, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world AVONEX and PLEGRIDY revenues totaled $136.4 million and $47.1 million, respectively, as compared to $164.1 million and $38.8 million, respectively, in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in rest of world Interferon revenues was primarily due to an overall 14% decrease in AVONEX unit sales volume primarily due to patients transitioning to other oral MS therapies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline compared to prior year periods as a result of increasing competition from our other products as well as other treatments for MS.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="biib-2017331tysabri.jpg" alt="biib-2017331tysabri.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TYSABRI revenues was primarily due to a 4% increase in unit sales volume and price increases, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TYSABRI revenues was primarily due to the recognition of approximately $44.6 million of previously deferred revenue in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA), as discussed below, and a 14% increase in unit sales volume. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017, we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR37.4 million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TYSABRI in 2017 on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S. primarily resulting from increasing competition from additional treatments for MS, including ZINBRYTA and OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;padding-top:12px;"><img src="biib-2017331zinbryta.jpg" alt="biib-2017331zinbryta.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with AbbVie Inc. (AbbVie), we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy (SMA)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;"><img src="biib-2017331spinraza.jpg" alt="biib-2017331spinraza.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of SPINRAZA in the U.S. in the fourth quarter of 2016 and the rest of world in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Ionis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;"><img src="biib-2017331biosimilars.jpg" alt="biib-2017331biosimilars.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s469B91CFD7E9071D78B33D728A40F655"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA operating profits are summarized as follows:</font></div><div style="line-height:120%;"><img src="biib-2017331anticd20.jpg" alt="biib-2017331anticd20.jpg" style="height:233px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,041.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">974.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">201.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">839.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">799.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">323.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">312.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to selling price increases, an increase in GAZYVA unit sales volume of 26% and an increase in RITUXAN unit sales volume of 1%, partially offset by higher RITUXAN discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, increased primarily due to an increase in RITUXAN product cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to 39% from 40% as GAZYVA was approved by the FDA as a new treatment for follicular lymphoma in February 2016. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue on Sales in the Rest of World for RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue on sales in the rest of world for RITUXAN primarily consists of our share of pre-tax co-promotion profits on RITUXAN in Canada. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, revenues on sales in the rest of world for RITUXAN were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS (Ocrelizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is solely responsible for development and commercialization of OCREVUS, a humanized anti-CD20 monoclonal antibody, and funding future costs. In March 2017, the FDA approved OCREVUS for the treatment of RMS and PPMS. Under the terms of our agreement with Genentech, we will receive a tiered royalty on U.S. net sales ranging from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of OCREVUS will not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><div><a name="sFBFD46E32373B46FF0C63D727B81BA40"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">83.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">93.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues earned under our 50% share of the co-promotion profits or losses of ZINBRYTA in the U.S. with AbbVie and revenues from our technical development and manufacturing services agreements with Samsung Bioepis. Prior to the spin-off of our hemophilia business, revenues from collaborative and other relationships also included revenues earned under our manufacturing services agreement with Sobi on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX in their territory, which included substantially all of Europe, Russia and certain markets in Northern Africa and the Middle East. Bioverativ assumed all of our rights and obligations under our agreement with Sobi on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in revenues from collaborative and other relationships were primarily due to a net overall loss in the collaboration with AbbVie of $5.9 million within the U.S. territory.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration agreements with Samsung Bioepis and AbbVie, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;"><img src="biib-2017331otherrevenues.jpg" alt="biib-2017331otherrevenues.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty revenues were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our other corporate revenues include amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other corporate revenues was primarily due to higher contract manufacturing revenues related to drug substance manufacturing provided to a strategic partner.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="sF970AC375FD0C0AA9E943D72A8E86A4D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2017331reserves.jpg" alt="biib-2017331reserves.jpg" style="height:333px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 22.8%, as compared to 21.0% in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">discounts was primarily driven by increases in gross</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">selling prices, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher Medicaid and other governmental rebates and allowances in the U.S. and managed care rebates, due in part to an increase in gross selling prices, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return provisions decreased primarily due to a reduction in U.S. return rates based on recent experiences of returned products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="s37DE6185236910AB93BD3D72805BB150"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">384.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">423.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">437.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">499.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">497.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">448.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">405.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">334.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,786.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,348.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s2CBE9345B12B460B531F3D72E8FA9851"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2017331cos.jpg" alt="biib-2017331cos.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher unit sales volume related to our biosimilar product shipments and inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by higher royalties on sales of AVONEX and PLEGRIDY in the U.S., as noted below, and the recognition of royalties on sales of SPINRAZA. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 28, 2016, the U.S. Patent and Trademark Office issued to the Japanese Foundation for Cancer Research (JFCR) a patent related to recombinant interferon-beta protein. This patent, U.S. Patent No. 9,376,478, expires in June 2033, and was issued following an interference proceeding between JFCR and us. This patent is relevant to AVONEX and PLEGRIDY, and we will pay royalties in the mid-single digits in relation to this patent during its life.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sF95C768469EF09AC369B3D72E92CEBDE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="biib-2017331rd.jpg" alt="biib-2017331rd.jpg" style="height:800px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="biib-2017331rdpiechart2017.jpg" alt="biib-2017331rdpiechart2017.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2017331rdpiechart2016.jpg" alt="biib-2017331rdpiechart2016.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily related to decreased costs incurred in connection with our early stage programs, marketed products and late stage programs, partially offset by an increase in other research and development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our early stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to the discontinuance of development of amiselimod in the third quarter of 2016 and a reduction in spending of opicinumab in MS, partially offset by increased costs for the advancement of BIIB076 in Alzheimer's disease and BIIB074 in trigeminal neuralgia (TGN).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to a reduction in spending of TECFIDERA and the impact from the spin-off of our hemophilia business on February 1, 2017, partially offset by the approvals of ZINBRYTA and SPINRAZA in the third and fourth quarters of 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our late stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily driven by the approvals of ZINBRYTA and SPINRAZA in the third and fourth quarters of 2016, respectively, partially offset by costs incurred to advance our aducanumab and E2609 programs for Alzheimer's disease. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated. Specifically, we intend to continue to invest in our Alzheimer's disease programs and MS pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 13, 2017, we entered into  an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease and progressive supranuclear palsy (PSP), from Bristol-Myers Squibb Company (BMS). Upon closing we will make an upfront payment of $300.0 million. In addition, a $60.0 million milestone to the former stockholders of iPierian, Inc. may become payable in 2017. The transaction is subject to customary closing conditions, including the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="biib-2017331sga.jpg" alt="biib-2017331sga.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily due to an increase in corporate giving and an increase in costs associated with developing commercial capabilities for SPINRAZA and our biosimilar candidates, as well as incremental costs incurred directly associated with the set-up and spin- off of our hemophilia business into an independent, publicly-traded company. These increases were offset by a reduction in operational spending associated with our hemophilia business and the discontinuance of our TECFIDERA television advertising campaign in the second quarter of 2016.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s278E1D3CC9CBBDFC315B3D72E94E43D9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2017331amortization.jpg" alt="biib-2017331amortization.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this analysis, there was not a significant net change in our expected rate of amortization for acquired intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes $353.6 million of impairment and amortization charges associated with our U.S. and rest of world licenses to Forward Pharma A/S's (Forward Pharma) intellectual property related to TECFIDERA acquired in the first quarter of 2017, as discussed further below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and in the first quarter of 2017 we recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our licenses to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into the agreement, through December 2020, the last month before royalty payments could first commence pursuant to the agreement. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. On March 31, 2017, the U.S. intellectual property dispute was decided in our favor. Forward Pharma has announced that it intends to appeal this decision. For additional information related to these disputes, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continued to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The field of developing treatments for forms of neuropathic pain, such as TGN and idiopathic pulmonary fibrosis (IPF) are highly competitive and can be affected by changes to expected market candidates and changes in timing and the clinical development of our product candidates. There can be no assurance that we will be able to successfully develop BIIB074 for the treatment of TGN or STX-100 for the treatment of IPF, or other indications or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market.&#160;Changes to clinical development plans, life cycle management strategies and changes in program economics, including foreign currency exchange rates, are evaluated regularly. We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2016 resulted in no impairments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets and our TECFIDERA settlement and license agreement please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s1BF12EBB867E739369593D72E9D3C87A"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="biib-2017331collab.jpg" alt="biib-2017331collab.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) reflects the sharing of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our 50% sharing of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie in the commercialization of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of biosimilars in the first quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we shared collaboration profits and therefore recognized net expense of $20.8 million related to our biosimilars commercial agreement with Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our recognition of income to reflect AbbVie's 50% sharing of the net collaboration losses in the E.U. and Canada was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our agreements with Samsung Bioepis and AbbVie please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="sA622A28CF6DEC30747DA3D72E9F4DFFD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="biib-2017331oie.jpg" alt="biib-2017331oie.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in interest income and the impact of foreign currency exchange gains recorded in the first quarter of 2017, compared to the prior year comparative period.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s3FD6F033B8EE134EB5FC3D72EA257054"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="biib-2017331incometax.jpg" alt="biib-2017331incometax.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities and the favorable settlement of a state tax matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 14, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="s3410BE239F872DC187443D727CF23017"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">924.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,956.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,825.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,705.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">561.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,952.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,514.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,859.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,992.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,419.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,867.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,312.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s90E9B336EA0A04A78F903D72EACD5350"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$235.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, including: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:115px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:91px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$454.8 million payment made to Forward Pharma for the litigation and settlement charges that were accrued as of December 31, 2016; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:115px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:91px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$795.2 million payment made to Forward Pharma to license intellectual property related to TECFIDERA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$583.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million net cash contribution made to Bioverativ;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$210.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;padding-left:67px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,015.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, including:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:115px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:91px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$97.2 million in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:67px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:43px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$126.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;padding-left:67px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $4.3 billion was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2017 through April 25, 2017, we repurchased and expect to retire approximately 2.0 million shares of common stock at a cost of $542.5 million under our 2016 Share Repurchase Program. As of April 25, 2017, approximately $3.2 billion remains available to repurchase shares under this program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock (2011 Share Repurchase Program). During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to complete this program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the payment made to Forward Pharma in connection with our January 2017 settlement and license agreement, cash used for share repurchases, the net cash contribution made to Bioverativ, contingent payments made to former shareholders of Fumapharm AG and holders of their rights and net purchases of property, plant and equipment. These cash outflows were partially offset by cash flows provided by operating activities.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These senior unsecured notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, 5-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The decrease in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflects a decrease in total current assets of $1.9 billion, partially offset by a $427.4 million decrease in current liabilities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in total current assets was driven by a decrease in cash and cash equivalents and short-term marketable securities, as described above, and the contribution of certain accounts receivable, inventory, and other current assets to Bioverativ. These decreases were partially offset by an increase in accounts receivable related to our ongoing operations.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in current liabilities was driven by a reduction in accrued expenses primarily due to the payment of the $454.8 million charge that was accrued as of December 31, 2016 in relation to our settlement and license agreement with Forward Pharma and the payment of incentive compensation. These decreases were partially offset by the reclassification to current liabilities of $550.0 million of our 6.875% Senior Notes due March 1, 2018, as these notes are now due within one year. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><a name="s63B8CA734F1AAB00B03F3D72A92301A8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;padding-bottom:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">235.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,015.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(744.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,203.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(901.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17,928.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s5540A033248F77D437223D72EB225642"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges and share-based compensation charges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">the decrease in net cash flows provided by operating activities was primarily due to the $454.8 million payment that was accrued as of December 31, 2016, in relation to our settlement and license agreement with Forward Pharma, and an increase in net payments for income taxes of approximately $263.0 million over the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to an increase in net proceeds from sales of marketable securities, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">partially offset by the $795.2 million payment made to license Forward Pharma's intellectual property related to TECFIDERA, the $60.0 million milestone paid to Ionis and an increase in purchases of property, plant and equipment primarily related to the construction of our Solothurn, Switzerland facility. </font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used by financing activities was primarily due to $583.6 million of cash used for share repurchases and the $302.7 million net cash contribution made to Bioverativ in connection with the spin-off of our hemophilia business. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><a name="sAD8264A13D63460B55103D72EB422DCA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, capital leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Corporation plc (Elan) full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to another third party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay up to approximately $1.2 billion in remaining milestones related to these acquisitions. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12 month period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales level related to the Fumapharm Products in the fourth quarter of 2016 and accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of Fumapharm Products in the first quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment for every additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, until such time as the cumulative sales level reaches </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments will be due. If the prior 12 months sales of Fumapharm Products are less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, contingent payments remain payable on a decreasing tiered basis. These payments would be accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $2.7 billion, including approximately $0.4 billion in development milestones, approximately $0.7 billion in regulatory milestones and approximately $1.6 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">successful achievement of certain development, regulatory approval or commercial milestones.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate that we may pay approximately $138.0&#160;million of milestone payments during the remainder of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, provided various development, regulatory or commercial milestones are achieved.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 13, 2017, we entered into  an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease and PSP, from BMS. In exchange, we will make an upfront payment of $300.0 million and BMS may receive up to $410.0 million in additional milestone payments, and potential royalties. We will also assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS&#8217;s acquisition of the company in 2014. We may pay up to $550.0 million in remaining milestones, including a $60.0 million milestone, which may become payable in 2017, and potential royalties. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $30.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $460.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $40.0 million of liabilities associated with uncertain tax positions.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="s86E8A96EB4B23F48B32A3D72EB74A7D4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s9E9FC81ACE5EEF8AE3783D72EB96E479"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7 &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K. There have been no material changes to these critical accounting estimates since our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><a name="s0E4EA5A82C138962DE393D72EBC8A1CB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks which may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counter-parties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counter-party.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia, and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. voted in a referendum to voluntarily depart from the E.U., known as Brexit, and in March 2017, the U.K. formally started the process for the U.K. to leave the E.U. The macroeconomic impact on our results of operations from these developments remains unknown. To date, the foreign currency exchange impact has been negligible since we hedged the balance sheet foreign currency exchange risk. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statement of cash flows.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $174.0 million and $172.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $47.0 million and $50.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to limit the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s39579D501B0DEF15A7DC3D72EBE8393F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><a name="s735715DDA6003924932B3D72EC1AFDC6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><div><a name="s548398453DCB001E698F3D72EC3C50F7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Please refer to Note&#160;18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s2FF90924B5A0F39695093D72EC6EBC39"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products, and, unless we develop or acquire rights to new products and technologies, we may be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market, and revenue from sales of our product for SMA. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including lower-priced competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, or changes in, or, implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was recently approved by the FDA, and is in the early stages of commercial launch. In addition to risks associated with new product launches and the other factors described in these &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221;, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the SMA market, which may impact our ability to develop relationships with the associated medical and scientific community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value.&#160; </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products can vary significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the revenue from our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing or reimbursement for our products would have an adverse effect on our business, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility and our results of operations may be adversely impacted.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician and patient confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy, a serious brain infection, in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization, including our chief executive officer, and our heads of research and development and pharmaceutical operations and technology. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition and results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, such as management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot assure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs or products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under the agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying contract with our collaborators or other third parties may fail to provide significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation and distribution of Bioverativ. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders in connection with the separation of our hemophilia business. In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the us and Bioverativ going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business as an independent public company is intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service, or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition, or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ has agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The separation and distribution agreement provides for indemnification obligations designed to make Bioverativ financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. It is possible that a court would disregard the allocation agreed to between us and Bioverativ and require us to assume responsibility for obligations allocated to Bioverativ. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The separation of Bioverativ continues to involve a number of risks, including, among other things, the indemnification risks described above and the potential that management&#8217;s and our employees&#8217; attention will be significantly diverted by the provision of transitional services. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Bioverativ is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could incur losses. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the separation activities and related events could adversely affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not achieve some or all of the anticipated benefits of the separation of Bioverativ, which may adversely affect our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may not be able to achieve the full strategic and financial benefits expected to result from the separation of Bioverativ, or such benefits may be delayed or not occur at all. If we fail to achieve some or all of the expected benefits of the separation, or if such benefits are delayed, our business, financial condition, results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups, &#8220;hacktivists" and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the hiring freeze implemented by the federal government in 2017, including at the FDA, could impact the review and potential approval of new products, which may adversely affect our business and financial condition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities in the countries in which we operate could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies, which has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient large scale manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a large scale biologics manufacturing facility in Solothurn, Switzerland and acquired an additional manufacturing facility in Research Triangle Park, North Carolina. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to make significant investments to build or expand our facilities or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, are subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Manufacturing biosimlars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to further consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a leased property, such as ceasing manufacturing at our facility in Cambridge, Massachusetts, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes stock repurchase programs, including most recently our 2016 Share Repurchase Program. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><a name="s091EC5F40375903058213D728066A842"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2016 Share Repurchase Program during the first quarter of 2017:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">775,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.57</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">775,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,781.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">775,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">281.57</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2011 Share Repurchase Program during the first quarter of 2017:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Number&#160;of&#160;Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs (#)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,264,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">600,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">286.02</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">600,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664,156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">291.72</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664,156</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,264,156</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">289.02</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From April 1, 2017 through April 25, 2017, we repurchased and expect to retire approximately 2.0 million shares of common stock at a cost of $542.5 million under our 2016 Share Repurchase Program. During this time, we paid an average price per share of $271.26. As of April 25, 2017, approximately $3.2 billion remains available to repurchase shares under this program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock (2011 Share Repurchase Program). This authorization did not have an expiration date. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to complete this program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program.</font></div><div><a name="sE7FD00E057861DE85AB53D72ECC12145"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="s756BDCBE63AB158DA5D63D72ECE2AC9A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;25, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><a name="s07F82D0004BB84C783D93D72ED156393"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s06DBDAFF87F454B635BE3D72E25791C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Separation Agreement between Biogen Inc. and Bioverativ Inc. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed February 2, 2017.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and the other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2017, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2017331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD9CCF50B414279C619BB3D72D8452995"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;25, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2017331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9DA5CB05CAACA6DF90613D72D8EB476C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Paul J. Clancy, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;25, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2017331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9C55122F09C4B2C16EFA3D72D98C3FAC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2017 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;25, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;25, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paul J. Clancy</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>biib-20170331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:292ac99770e84b61910f24ef105787f8,x:b14f07d7424b47caa2b5fed98aef8662-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20170331" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20170331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:FinishedGoodsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramPlanToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramPlanToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_FY2017Member_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ExpectedPaymentTimelineofMilestoneAxis">biib:FY2017Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q1_biib_ExpectedPaymentTimelineofMilestoneAxis_biib_FY2017Member_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-C56F72DD44B749D3F7F287C23E57B06A" unitRef="usd">60000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q1_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-94003795EBA57AD83A1A1BAFAE6BD98F" unitRef="usd">90000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q1_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-90789D660DFA0918F4A887B6408809C7" unitRef="usd">410000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q1_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-48EA07052CA167EC9B4787B7276D5556" unitRef="usd">550000000</biib:AdditionalMilestonePayment>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9F3C2544992152B0A9BA3D72765B4E85" unitRef="usd">4800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-467C9517D530C7AEFF0A3D7276646DE1" unitRef="usd">-800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-70AC0ECC3473099E64DC3D7276466B7D" unitRef="usd">-700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-FA9B95FC8886BD6010903D727652D9DE" unitRef="usd">6300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-8C296BAB1F564ABC26FE3D72765A0962" unitRef="usd">277500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2017Q1" decimals="-5" id="Fact-4AF2E9D1DA452E1DA0953D727661590F" unitRef="usd">263500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-EF602AE4E7369FE2B12A3D7276584A88" unitRef="usd">276800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2017Q1" decimals="-5" id="Fact-80DF872047AC5CF6372C3D7276593A48" unitRef="usd">263300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2016Q4YTD" id="Fact-C66F336A26721CB9916F3D72762B0CF0">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2017Q1YTD" id="Fact-1B2281CB59A841331D7C3D72762A55AB">P17M</biib:AverageMaturityOfMarketableSecurities>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q1YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="2" id="Fact-81879011FB89BE21F31687B0E79B35AC" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Collaborationexpensesaccrual contextRef="FI2016Q4" decimals="-5" id="Fact-9E750AF4C68ADFF194641BA2A8583CA7" unitRef="usd">130900000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2017Q1" decimals="-5" id="Fact-7969F16DD742F5C90D3C1BA30A93A7D9" unitRef="usd">89800000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q1YTD" decimals="-5" id="Fact-A6607828E9E730D4A5843D7275BA05DA" unitRef="usd">0</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2FA6572A2F28321652B03D72762A5777" unitRef="usd">20800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-D9796DEEA0D941985EEA3D7275A2191A" unitRef="usd">20800000</biib:Collaborationprofitlosssharing>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q1YTD" decimals="-5" id="Fact-6886754AA19F75E3F3A03D7276492C47" unitRef="usd">707100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-143C52F74167F0A5541B3D72765F9B2F" unitRef="usd">568200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-A9BF8A6EADA5F99664493D7276530314" unitRef="usd">131300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-38D2915AEADDC50EB2743D7276501AFB" unitRef="usd">7600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2016Q4" decimals="-5" id="Fact-E1DD79DA891347BA7DC13D72760B36B8" unitRef="usd">300600000</biib:DuefromantiCD20therapeuticprograms>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2017Q1" decimals="-5" id="Fact-60BC422C928D159610CD3D7275DE4FFD" unitRef="usd">324500000</biib:DuefromantiCD20therapeuticprograms>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q1YTD" decimals="3" id="Fact-873D5E0FFA3A468B62543D7276331852" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q1YTD" decimals="3" id="Fact-3E8118E4ACAE2B87664F3D7276421C14" unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-CAED38AEF977974D01F11BAC518A98FC" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-E18230BC0405FBD562373D727643CF51" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-18EF83F4C8A5B7F154FC3D72759DBD6A">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-3B387232112DE15A4AAF3D72759EE9C9">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2017Q1YTD" decimals="INF" id="Fact-F6C1C9C64D4D6466CC003D7275C63F8F" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-58891F7D2C26DE8572FA3D727604B19A" unitRef="usd">1039400000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-93ECE0E1E4F0494E51CE3D7275FB0A86" unitRef="usd">959400000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2016Q4" decimals="-5" id="Fact-20AF0318E0AC7623D1C63D72764540DC" unitRef="usd">47400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2017Q1" decimals="-5" id="Fact-78F6EB9C32F6B2B3CD7687A820A11A8F" unitRef="usd">53500000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:LicenseFee contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-B99E1F60FEB4575466A71BAD2D6CEB5D" unitRef="usd">75000000</biib:LicenseFee>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F341DEB62FA0ECE461143D727661C4BD" unitRef="usd">294000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-CC175E38D8105F3DF84C3D72764CC748" unitRef="usd">231700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-139D1898B077E16594A63D72764F8941" unitRef="usd">62300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-8BFD64924DE5FC8074863D72765D8AD7" unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3D7FEF50DB366F8460C93D727665FB7D" unitRef="usd">337300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C50E97C5DABDBD7DC8133D72766BAB74" unitRef="usd">267500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-0EAD76E6D4EA59B3D2BA3D72764FF900" unitRef="usd">64400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2A333E97D7EDB60A61923D727647CCF0" unitRef="usd">5400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-22E3A89A99AF4C79779187AF537177FE" unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-57301EDD8A4770D3826C87AD67F6A9E2" unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7F451D5B25979F396F2A3D72760052B6" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-62C2D4666F6F1D38566E3D72760FF820" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AE5C6D2DA99C49E051143D727605CEAB" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6BFF5E67A7DA12A82CBF3D72760118C3" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-86DBEFB38A3A07AF93533D7276769899" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6442BB7DE68AC12D08673D727660C689" unitRef="usd">31000000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C2539AD0D1D59F076A473D72766DD133" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A1A055A8F59BC8F0FCE13D72765EC626" unitRef="usd">31000000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement contextRef="FD2017Q1YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-A83571AA8910ECE1EF283D7275A4276E" unitRef="number">1</biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B923C00F811FB8155C4E3D7275C5125B" unitRef="usd">329500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5F741930B688A70D53273D72759FF22C" unitRef="usd">340600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-599EEB7A7AA4D12E407A3D72768246B3" unitRef="usd">51200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FC52CA930B05DD1D1A523D727597AE73" unitRef="usd">45400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:StrategicInvestmentPortfolio contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-4E1475619568816678463D72762A78FB" unitRef="usd">99900000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-539FE9756BEC5EEC764E3D72762C8C1E" unitRef="usd">99500000</biib:StrategicInvestmentPortfolio>
	<biib:TermofBioverativManufacturingandSupplyAgreement contextRef="FD2017Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-27697430A24E179CD6822482923D9326">P5Y0M</biib:TermofBioverativManufacturingandSupplyAgreement>
	<biib:TermofBioverativTransactionServicesAgreement contextRef="FD2017Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-75788F32D03E622FDEA8247A4D7CB859">P12M</biib:TermofBioverativTransactionServicesAgreement>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-E1A10A2A40BE0FE921B23D727654CCB4" unitRef="usd">49800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2017Q1" decimals="-5" id="Fact-7BC29A19249C90E229E4878C57BB1054" unitRef="usd">26000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<dei:AmendmentFlag contextRef="FD2017Q1YTD" id="Fact-AD4FAF95DBD7E38D50093D7276334945">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q1YTD" id="Fact-E3ACC7BE0E6E301F6A463D72764B2BFD">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q1YTD" id="Fact-4C623D439F4312F525363D7275DC47B7">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q1YTD" id="Fact-775F2408DF0E105BDF213D7275DD547F">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q1YTD" id="Fact-D1C3713721CFF5CF81EC3D727611286E">2017-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q1YTD" id="Fact-553D3B87ECAFE21812343D72765D8F2F">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q1YTD" id="Fact-8FDBB2285105431A68C73D727629837B">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q1SharesOutstanding" decimals="0" id="Fact-5E485310E612870F314D3D72763EFCFC" unitRef="shares">212115203</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q1YTD" id="Fact-58B2043644F93B8C076A3D72762A46EF">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q1YTD" id="Fact-1E505C9F6D000EE754613D7275EDACAE">BIOGEN INC.</dei:EntityRegistrantName>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-0D3E21E014CEA356249D3D7276388C38" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8312F546148DC870A2D33D72762EA4A1" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4B57B5613B84104986C63D72762FAD2D" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4EABE6856B8B557E0522878BDB91E29E" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-ABE634D8985391E64D013D72763075F5" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-A840D09D46EE395D7AA63D72764CFFE6" unitRef="usd">902100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5D8CFBBB0CE074343B213D7276340C8D" unitRef="usd">59600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-0C43EF59EAB500A93F223D727639E8CF" unitRef="usd">58200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-75258684AC51086DC0023D72762E0949" unitRef="usd">1215700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-704BAA58E3A2F0A9B020878B8970950A" unitRef="usd">113100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6A2791E82F6CB9C0B1BC3D72763474D7" unitRef="usd">1446600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6BB40C76AD516B5455381B8BE6CA7E2C" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-E8D3057906F5690479C5878D138DE5B3" unitRef="usd">332900000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-337BDAB62A1E6278B8963D72764ACA75" unitRef="usd">279800000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-FEE122714CCF32CF56F53D727601B805" unitRef="usd">316400000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-401C3D8A6B7E17D9546C3D72760384EA" unitRef="usd">1441600000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-B5C034A5117F224559A33D7275D281E8" unitRef="usd">1501500000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-117F714609CCAFC458343D7276414EEA" unitRef="usd">195800000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-D5FC88C690FC52E4D89C3D72763ABFF3" unitRef="usd">181000000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-5" id="Fact-2BA9D098B6B03F70970F3D72761FE2EF" unitRef="usd">1439300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q1" decimals="-5" id="Fact-82F250B474B201D244003D72761CD9B8" unitRef="usd">1438100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-2593BB9DE7A4A23CAE793D72765ED48E" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-E8804C1814117C1EBA553D72766D58BE" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-16E766A929D3D8B40BAB3D72765339EF" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-E21DF3F734E5E6D12E613D727651CC72" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FEE5890801450B53467D3D727652224F" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1" decimals="-5" id="Fact-30760D91D5A9237FCBE13D7276560DEA" unitRef="usd">-259300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-DC1292A19E26166341093D72766ED61D" unitRef="usd">-37600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-04189ABF0084A904224C3D72766B3629" unitRef="usd">-37400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-F0A8DDFE348AC74113593D727651CC49" unitRef="usd">1700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-2B1BEE708C5AA0F99A8F3D7276586225" unitRef="usd">-186000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-35DFFED553C05644D4323D7275E21E63" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-FF6EA5C53055F0E61D303D7276256DA0" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-EADC9AC9D55FEC9782813D7276336CEE" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D79519782C5FD82105DC3D727638CE82" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-F733C84B0D57996FC5AB3D727628B303" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1" decimals="-5" id="Fact-EFCFB6642C513D68CC283D7275FADE6B" unitRef="usd">-325200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-3EC09A67244753AD76093D7276400232" unitRef="usd">-32600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A5F8B46EADF27ECBB5213D72762C9CEC" unitRef="usd">34000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-7BEA535E955B20B144623D72763BFD7B" unitRef="usd">-12400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8D789D69CED4B9361EC53D72763C2802" unitRef="usd">-314200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-5" id="Fact-7BEEC1773441CA996E763D72763D2B5C" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q1" decimals="-5" id="Fact-7BBF7B5C19FB35BF6E573D72764917E8" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-DAC6C8A34B5095FAB1D93D7275F1C324" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-A7CD17D03C1BC6097CAD3D7275D76F70" unitRef="usd">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-CB800C55D5227918E7053D7275D3CB86" unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2FA6696387E716A434203D72768136EC" unitRef="usd">30100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-9FC06E5E04FC59AEB9253D7275EA4DB1" unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-6FC83D820F578F3564CB3D7275B9A949" unitRef="usd">36000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-B7D400B5761F6DEFB4FF3D7275C58E8C" unitRef="usd">21400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-5EDA61CEC4D5BABE9FBC3D7275BE3743" unitRef="usd">-1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-18F2D28DAE6364BDD26C3D7275C5340A" unitRef="usd">34700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-4C68331B72C88928BC8C3D7275D5A5AE" unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-3940C38FA660338B4D913D7275F4CEA1" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-B950A3812FEB0C1837FA3D727644E329" unitRef="usd">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-BAC980193294D5DD17F03D7275D878BD" unitRef="usd">26900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-5197939589770F89FBF33D727674F13D" unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-B2B4456D1805CF190E443D7275BD5378" unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-8AA7112E92B5134AE37F3D7275C48D27" unitRef="usd">18700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-CE2C8EEF6BD05FBF58C13D7275AD21AE" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-0224CDDDBCE2D77FAF973D727652F715" unitRef="usd">29400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-5118DABD5A069A6F6C403D7275D200AC" unitRef="usd">54300000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5EFDDEF84B97FF342C123D727683FF34" unitRef="usd">48100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-453C164332285F3B60123D7275C1853B" unitRef="usd">88800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-56DA8339B45580407224A5ABF51CFE94" unitRef="usd">353600000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F4F932C7BA2D8BEDFCD13D7275BBE7B9" unitRef="usd">448500000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2017Q1YTD" decimals="-6" id="Fact-94010F7A688F4A138F1C3D72762352D2" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-5" id="Fact-A9869FE76A437C6C0E4F3D7275E5F719" unitRef="usd">22876800000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q1" decimals="-5" id="Fact-E7610CBD1D0C3E9039543D7275DD29BC" unitRef="usd">21195900000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-E9E60B9F6D7181812AAB3D72760D0107" unitRef="usd">8732200000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-626EF14812D2A3675B8D3D72760A0CA0" unitRef="usd">6859700000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-31AC766C5130F127D02D3D72760AC7B7" unitRef="usd">24900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-794432F973EBC849C3C53D7276038FA6" unitRef="usd">7533100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C37C0C3301E20006E0F13D7275FC92FD" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B433F9CFB3C9B4015C013D7276108A5C" unitRef="usd">7558000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FDE805F589CA7D332A8E3D727675B189" unitRef="usd">18700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6B99EE10769212C049303D72766FDB40" unitRef="usd">5502000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A0A6E3A9EE61A3F6B38C3D72766C3275" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9E48B9B152B2D4A202653D72765D5EB3" unitRef="usd">5520700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-9A7D50EB23C19BF1CEAC249F812C795B" unitRef="usd">1008300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-5" id="Fact-AEF9092EC9A25FEC7C4F3D72765CD396" unitRef="usd">5406300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q1" decimals="-5" id="Fact-98638420B59A0CADB70B3D727663759D" unitRef="usd">4786000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-5" id="Fact-A1B0F7EC3BDFA7F5AE023D7275B8002A" unitRef="usd">5398000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1E93722253CA5E6DA2883D727609D185" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-11EF0E13783F8B576F703D7275F91801" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AE06DEA2DBF3B47F4FA03D7275FDA515" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8F8ED6ABA3580B1D89893D727605E4BE" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0ADD06877510C72A7BE23D7275FB4A5A" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4F566A1C4F59025CA9DB3D72760A1567" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-166BBF71FE5BB5372B863D7275FE212F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EB831E8F0D0E51D4AB483D7275FD5F0A" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-213DD0B43CB78B9117563D727605A853" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CAC0FD366047CF5BC4413D727602BB77" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-865A5CE9B31528F950533D7276077D22" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-18545646F1B592C3BA303D72760D177E" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-1DB37122624195FCE4053D7275BBE4EF" unitRef="usd">1408600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-6B027ED8E8B59C5E7B0D3D7275AE4D4E" unitRef="usd">1255200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-87C65A47BC27903A49B13D7275B73A4E" unitRef="usd">1156000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-C0D019F5A0F7E5B35A473D7275AE4CB8" unitRef="usd">1016500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0C3300CDE0E327EE11A53D7275B6F6D1" unitRef="usd">4000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-B7E1A35B311591A3F6583D7275B8D5A7" unitRef="usd">557700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-9D8A8C3DEFAA78824C7F3D7275B800A1" unitRef="usd">24900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1" decimals="-5" id="Fact-DC2862168FBDCFE510483D7275AADDBA" unitRef="usd">4781400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F6C5AFBA4B332C7024C63D7276779C61" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E1F544A0C40A824E7F543D727666E69E" unitRef="usd">542500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F335374134035CAEF4E43D727682A5F3" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-58C8AE7EED9C1865666B3D72765F23EF" unitRef="usd">542500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-737C9893DC710EC4AB363D72766C2976" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8806C525BF21FFEA30933D727665A47D" unitRef="usd">2500700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EF266C565E395CF5DD403D727670B263" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6C7E0FB2BD883C09DFDA3D72766204D1" unitRef="usd">2500700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-83A5D1F2DA23EC26D97C3D727673D25B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-71D85845B184711A49C73D72766210B5" unitRef="usd">1738200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DBA01357699B3ED0C2A13D72766B8656" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BB56B7DAE245BD5929413D72766391BA" unitRef="usd">1738200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-235D08C1EC07BDA02B2B3D7275ADFA74" unitRef="usd">1288500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-65A6363A56AD06DA7C4C3D7275ED3667" unitRef="usd">1212200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-28B1830F0F495E6844863D7275EA1C08" unitRef="usd">664400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-B7298BD12069638580B93D7275A5E73D" unitRef="usd">1073800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-BA067EED0B7C9BB0E0A93D7275B31E99" unitRef="usd">3300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-844C3B475220C4DE76B83D7275B5F7DA" unitRef="usd">539200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-6E2C3A5AAA7DCCC111573D7275F08E7D" unitRef="usd">18700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-5D7492A52E1E27BBFD0D3D7275BA9B84" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-3FFF03289F8BBD4194013D7275B1BB75" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-5482BA7308A4E2060E443D7275B03736" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-C72D47469E7D6B7BCA8E3D7275BCE8A0" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-159D1E50263DB59D5D8C3D7275B9FA59" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-24A98CEEF9ABAE19C66F3D7275B86BC7" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-1C3E54A93386D6C3CA5F3D7275BB19DB" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-5236F455038C63A5BB273D7275ACF9E8" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1" decimals="-5" id="Fact-57544A0C474A96381B553D7275EAF5F1" unitRef="usd">4300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-AF5DC80C501F3F8E7F073D7275B42476" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-742440CF03A74431CEA93D7275A93E3D" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-85C569366F8FF42E31D53D7275EBDA26" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-7F6DD96F9EA022075F7C3D7275B546F2" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-54BCD1B333D127ED71D23D7275B503D7" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-B9396F6F068803E978103D7275EC6834" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-6D0CEEA34BD1712D7A103D7275EAC2EE" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-5D97E353193C983993593D7275B93768" unitRef="usd">11200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-CA3439D6046C0991DAD23D7275BD541F" unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-361F98DDDD73EB0753EC3D7275AF9AA4" unitRef="usd">4700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-685A58185438B6EB2CD63D7275B7CD5C" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-2903E05383C215970FF73D7275B6C03A" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-CD2259224F5AA8275D793D7275B59FBA" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-D089CE4EEF6DA1B8C3623D7275BCAB42" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-FFCF72E835A044D46C1A3D7275B9A730" unitRef="usd">9300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1" decimals="-5" id="Fact-6EF62DF5BAED7EAA4D463D7275A5B1B2" unitRef="usd">8900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-B6014D8E5D1F310BE5343D727598E5E0" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-A4B6C50CBD78C05D80983D7275B2E278" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-26723CFF2C6D7F1F05F63D7275B25B9F" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9DBC025DAE0A88908D333D7275B247D2" unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-03994514460D4630AD6F3D7275E9473A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-007321DD69C835E286D43D7275B1F9B2" unitRef="usd">1400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-89361416DFC9BDB4FECD3D7275B5EC4A" unitRef="usd">14900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-684CAED6041146705CB03D7275BB2385" unitRef="usd">5406300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-7136515E0C9487881CE33D7275B985C1" unitRef="usd">1409000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-C80DC869467BBEB47B863D7275B44D79" unitRef="usd">1258700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-A1E2BB676F54408353503D7275BAD1BE" unitRef="usd">1156100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9D11635A7AF0E55E7A8F3D7275BE82F6" unitRef="usd">1019400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-016206D475B5AC6858793D7275B7A73D" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A1405858C848F0C866583D7275BA2D98" unitRef="usd">559100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-87827C58B609C0869C503D7275B4BB9E" unitRef="usd">33500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1" decimals="-5" id="Fact-F48219FE8DC09281B6AA3D7275AAA07D" unitRef="usd">4786000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-F0C406C9AE83ADA463D13D7275B24657" unitRef="usd">1289200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-26B87C570F8C482836CB3D7275AEEB4D" unitRef="usd">1213400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-B3EF5F3F826B228916C63D7275B3263E" unitRef="usd">664600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-1050A9F8666601A5F5EF3D7275EDE6E9" unitRef="usd">1076000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-A1360FC483F1DB2AB9D43D7275AB2061" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A62BF2A3D028459AE84A3D7275B676EE" unitRef="usd">539500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-64CBE0CF9552FFD8A39F3D7275B7121A" unitRef="usd">33600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-3D45A1646083B7178F943D7276131AFD" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-F83C540736B6935F2D343D72760251D0" unitRef="usd">1956200000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-D02F2B0580C0988573823D7276602C4B" unitRef="usd">2559700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2017Q1" decimals="-5" id="Fact-E74E81E1CEB2653A37AA3D727658D074" unitRef="usd">2565400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-4FBFD86B52DDA3344F503D72765898FA" unitRef="usd">2552600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q1" decimals="-5" id="Fact-DA1625F79590F488AA2C3D7276598BEB" unitRef="usd">2561900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-6A86F8D7D64F8B66B76F3D72765A205E" unitRef="usd">2569100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2017Q1" decimals="-5" id="Fact-AE9FBB36995E2919C37E3D72765C7A24" unitRef="usd">1957100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-AC83A270D9CC01ED38713D72765C6DF8" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q1" decimals="-5" id="Fact-D2A8B5EF2BC9CE918F233D72765E9610" unitRef="usd">1956200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B0DADE6934B9867A26853D7276678BD8" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0405E75384EAF89269E33D727665B861" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B456EC078627564D8DFA3D7276629D29" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-21D26717518A829276883D727665F2DD" unitRef="usd">1900000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-08D01810F6808C46003E3D727650D762" unitRef="usd">2829400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-24098E628791B80518E13D7276101116" unitRef="usd">2825200000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BAB57E80FDB74148818C3D7276111D7A" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A6F968AEAF896165782C3D7275F7BCB4" unitRef="usd">508300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E620A395BF8157D0013A3D7275FF178B" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2646AAC59FA08C6383783D7275FFD753" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-71FBCDE6A38B33AD38E93D7276103548" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B44FFE1DD756D72ECD653D72760101FE" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C7CCFDA9DFBE6F8B5F7F3D72766509DC" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-26EEEB45E38B5A5B47C43D727664DC5A" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7545CB3D66553C76C1133D727668614F" unitRef="usd">470900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9AD7B29AFD21EDA4AB403D7275E2D906" unitRef="usd">470900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-4BE6BEE01F82685F89183D72763A0522" unitRef="usd">580800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-76659DD3EA09154B226D3D727645BAEA" unitRef="usd">516800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DE9A5FBB59FA40343B3B3D7276235F0F" unitRef="usd">246800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-290D8CD4239185043CE23D7276242009" unitRef="usd">254100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-CF312C1CD821175E375C3D7276247D5F" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q1" decimals="-5" id="Fact-6DF7E9268C7D8A5CB73A3D7275E13E26" unitRef="usd">1130700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-1030315F4FBE9032946F3D727611D040" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-5" id="Fact-A479C5649055A33507B33D72764A9715" unitRef="usd">924000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-30D77215579602AD25053D7276107095" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D44C714C95C1A6A7ACDB3D727600807C" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1C22B71D05E318E5DCE83D72760D4F02" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-67D234BBC3C3631AAF3E3D7275FCB72D" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FE02F353DF93A000A54E3D72765FA045" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C316C76F66D71826FA0F3D72765EA4BD" unitRef="usd">645100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9ACEFAE0C77980EF673C3D72766FAE53" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2A792BD2E76C587557673D727672EBEB" unitRef="usd">645100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q1YTD" decimals="-5" id="Fact-5671FEFC1715176DB7573D7275E4DE3A" unitRef="usd">-192400000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3871D222929FAD5461E73D727626E49C" unitRef="usd">-1410400000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-6DAD5D0C0668B28AEA5D3D72765614C9" unitRef="usd">2039600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-AB243382F4A8D2B47F923D7276589CA7" unitRef="usd">31000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-4EF1706C6504EE46F37C3D72765BACBD" unitRef="usd">1266900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-BBC5CF99077AEB79CC453D727653A458" unitRef="usd">741700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-5" id="Fact-0F69E2FF56A1AD01E2E13D72764D2944" unitRef="usd">645100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-94B4EEA697B7343271363D72767FEF5A" unitRef="usd">71900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-20F64236F04685D508A63D72764B53AF" unitRef="usd">54000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-0A75351FEF644014D5A23D727655CC17" unitRef="usd">519200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-50F6EA69A4F40D154B623D7275D235CC" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q1" id="Fact-247D99EF4BC659D334DA3D72764774FD" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-34A231122C9705BAF66A3D7276346286" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-01D7B419FB3DE03B8DF53D7275D69C3E" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-C20ADA8BE4E942B91F393D727665CC3A" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q1" decimals="-5" id="Fact-08AAFF4132C0C6277CBE3D7275D23896" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-4EF4F37BC2020B2FE3243D7275E1F545" unitRef="usd">935600000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-A088F4F24083EA6D18A03D7275EC2DED" unitRef="usd">742300000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-0F80E751402E6095B97E3D72764D6A3B" unitRef="usd">1700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0BE04232A065E9A418E93D72766A20F8" unitRef="usd">100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-06410800FD0B6B9E14003D72765E9203" unitRef="usd">933900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FC47A428A4EC1154D8BE3D72765E5362" unitRef="usd">742200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-77E73888F04F1EBD627F3D7276224807" unitRef="usd">481500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-19C9F4ADB62F6E99F6F43D7275CF6C9B" unitRef="usd">609800000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-4B232511D8E14C6A037A1BA2A6CBB562" unitRef="usd">134000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-2B4967B774BEF4048A081BA309AAE384" unitRef="usd">116200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q1YTD" decimals="-5" id="Fact-A6EB68B6AADF8B3763E03D72763339FA" unitRef="usd">313000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1YTD" decimals="-5" id="Fact-C865E1FC57D75E761FBF3D72759AB42F" unitRef="usd">384600000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-F9375261113AD28D459524870FBEFA1F" unitRef="usd">2900000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q1YTD" decimals="-5" id="Fact-7DBCF48755F0C1F81F4B3D727597CF3B" unitRef="usd">1348400000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-A95413ABE67AECCD08AF3D727643D4ED" unitRef="usd">1786400000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-403598608A419D0D88DA3D7276497149" unitRef="usd">4700000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-C3FE313FC768D6ECF4083D7275E87BCB" unitRef="usd">561500000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-3D65F20B78A807DA75BD3D7276122DE1" unitRef="usd">6808400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q1" decimals="-5" id="Fact-3E4268EF98B91FDF29073D727635F972" unitRef="usd">6845400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-EB833C6126DD0A0CDBDB3D72766E4AE0" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-5173455B86AD09C5952F3D7276618558" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-C230F2F1981E7B8047BB3D7276665668" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-6C452BF5A1DC779B607A3D7276638728" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-2E7974A2B7CF37972AB33D72765B1848" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="-5" id="Fact-21D52BC06BC5CC350F1C3D7275EE1370" unitRef="usd">8900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1125F78556003711EB003D72762659A9" unitRef="usd">76100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-E227685310124E0FB2393D7275E44026" unitRef="usd">93100000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-1C470E7930AEB4BBFBC43D727592ADAA" unitRef="usd">94500000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q1YTD" decimals="-5" id="Fact-BA77755970EE82FEC57F3D7275D9715A" unitRef="usd">149700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1YTD" decimals="-5" id="Fact-96D3C3A38214231A15FA3D7275F1B5D3" unitRef="usd">512000000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-CF758B8697DD8733EF983D72761D833E" unitRef="usd">50400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-FA220871F15EB9461C313D7275B0BEAA" unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C898CA00510F47BF5ADF3D7276324ECB" unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-929EAECE6E5D6C20C2AC3D72761D7446" unitRef="usd">38300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-6F903078608B0FDE1CC33D727637DFCD" unitRef="usd">2900000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-68B3E9C9509F7E46BE1B3D727636A3DC" unitRef="usd">3300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9102DE4CD3493ADC5C883D72761E841A" unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-960221F005AA3C3B763A3D7275BE4031" unitRef="usd">4600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C19BE9533197D1856E943D72762091F8" unitRef="usd">4200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-03359EED1EC22AF0AAC13D7276361107" unitRef="usd">1700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C9286FBEB625C78DBB5F3D727625CCE2" unitRef="usd">7700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-C98D018104076E285D083D72768108DE" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-F1E01F882F7680069A5A3D727618761C" unitRef="usd">8800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-95D43D323CA91CD5C82B3D727614980A" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-B9D1CFFCA8B148C764F23D727618A91B" unitRef="usd">6700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-81B1AB6B1FB9AFD4FDDE3D72761860C4" unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-30125812BE3258868A6C3D727614683A" unitRef="usd">1900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-FF4235BB1E702DFA50243D727616AEE5" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-CA541E0C7C99E63648AC3D7276174AFA" unitRef="usd">4000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-81857D50ADCD23ECE55A1B880F292477">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-E9DAA3F5986D923A517B1B87E18FB680">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-FF89A28BE852C568159E249ACC4A3D49" unitRef="usd">144700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-0B3A71549F8207C49AAF24A175E4B092" unitRef="usd">87800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-9975BF3704569F6E06322499FD7C0FB5" unitRef="usd">302700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2017Q1_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-AEC89FB797C0D5FD4538A17E551AC8A3" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-649E3CED7C7E51C9A117A17C6BED6155" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-26D796997AEEAD9C3EDC249D0F075B83" unitRef="usd">56800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-C64D3A82595235C68A7B249B77E33D63" unitRef="usd">116100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember" decimals="-5" id="Fact-8F331FC13BCF460DB26F2471380BF6CA" unitRef="usd">31600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" decimals="-5" id="Fact-69CAB018C48FFBE3E10B24703B164CDD" unitRef="usd">84500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-C360354B96B75CBDFFDE249EA79B434C" unitRef="usd">53700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-EEC5F4BA2EB9A098FB6924A2E661A25B" unitRef="usd">67700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-9924714B7668DD4371D9249C559FA777" unitRef="usd">20200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1YTD" decimals="2" id="Fact-FD5B3A1A435E52A089A63D7276383967" unitRef="usdPerShare">4.44</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q1YTD" decimals="2" id="Fact-05852E48436307D6F9693D7276332833" unitRef="usdPerShare">3.47</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1YTD" decimals="2" id="Fact-2C3437595FE7A7791A2A3D7275B0E0CF" unitRef="usdPerShare">4.43</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q1YTD" decimals="2" id="Fact-E2E6E63C9A2B24012DA33D7275958527" unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1DCB4D47882B746B3B423D7275E417B8" unitRef="usd">15100000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q1YTD" decimals="-5" id="Fact-BA722B13712AD3C4B07D3D7275E97086" unitRef="usd">7900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q1YTD" decimals="3" id="Fact-C6E19A2CC342B4FDFF913D7276386CB5" unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q1YTD" decimals="3" id="Fact-966B00C73D13C974EE153D72763460C6" unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q1YTD" decimals="INF" id="Fact-99E7FDD701A9631BFD813D7275A2808E" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q1YTD" decimals="INF" id="Fact-1D6B175CCFEB20CF89213D7275955B31" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q1YTD" decimals="3" id="Fact-F6DF40F0614121DB82513D72759A8857" unitRef="number">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q1YTD" decimals="3" id="Fact-3FCB49DA578C2937E8E43D7276561DAC" unitRef="number">-0.112</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q1YTD" decimals="3" id="Fact-54B0DD958F2CD67F24473D7276429C97" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q1YTD" decimals="3" id="Fact-D9794AF8F610E3C597C73D72761573E3" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q1YTD" decimals="3" id="Fact-0572640AB85500A375673D727599459D" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q1YTD" decimals="3" id="Fact-A6558F66B98D9B1BB3D63D72761FEA0B" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q1YTD" decimals="3" id="Fact-E9A2CD855914EDE89C813D7276398332" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q1YTD" decimals="3" id="Fact-BC99EB7FB70B69FE31B03D72759388D6" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q1YTD" decimals="3" id="Fact-0AE488205A71EDAC74593D72763E7281" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q1YTD" decimals="3" id="Fact-77B67A10C0478A299E6B3D727680255C" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q1YTD" decimals="3" id="Fact-94D9A770A360B4F82B4E3D727630CD7D" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q1YTD" decimals="3" id="Fact-F754BAD9E74F40C103243D727648D4BD" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-408D2110C35C72D0580A3D727643F975" unitRef="usd">282900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-9A443A628B1FF018EA4B3D7276423F23" unitRef="usd">160500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q1YTD" decimals="-5" id="Fact-2E0B9C943265567DEB1B3D7275F3A04F" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D6BA64CCAA73AF8BFBF73D7275F06F79" unitRef="usd">2700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-CDE348372E9D1FB662BC3D7275C43C53" unitRef="usd">15200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B060BD1F565C41B75F103D7275C19DF6" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2017Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-1C19A420FE469F5E7ACC1BA9419F8786" unitRef="number">0.067</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q1YTD" decimals="-5" id="Fact-22066677D89DD103E9C23D7275C4293E" unitRef="usd">-2300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q1YTD" decimals="-5" id="Fact-4BFF355B45FF06DC150B3D7275BD704B" unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q1YTD" decimals="-5" id="Fact-FF76C896818C2D02C9D93D7275D2CBA4" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2017Q1YTD" decimals="-5" id="Fact-16A0EAE714EC8B15890F3D727612E5BD" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E83A6DCE219F0ED5408E3D72762887A1" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2F6BBC82DB5475A8B7E13D7275F3F0F2" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2017Q1YTD" id="Fact-9FAF700F987AFED942293D727624B80B">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-C38D9A926F2415D110133D72759C181D">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-4048664F0E5E35B708EB3D7276130E10">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-5AB65D940B1E232519343D7275B12B29">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-50E24AA806A2849BECAE3D7275BF84E8">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-30D8410B05F779E3ABDB3D7275C87E75">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-9785DFBF5048C52098A23D7275965F33">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4" decimals="-5" id="Fact-48F0435028D2EAC622D13D72762B7026" unitRef="usd">3934000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-12D445240A80CC8065443D72762D42C6" unitRef="usd">776100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-E50AE2BA91096E917BE33D7276205AF5" unitRef="usd">523600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-AC9971EBFC203A6AD03E3D72763D964A" unitRef="usd">2634300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-20C46F8CBB5F6B5FC3833D7276382D1D" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-AF2A0BD0C989D7CF9CCB3D7276401997" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1" decimals="-5" id="Fact-65CE308FAEB30703ED693D72764255EC" unitRef="usd">4049500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-F2AD69EC037AEBB932BE3D72762F00B3" unitRef="usd">874800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-14ACA1091082F61C0E683D72763FCE8F" unitRef="usd">526600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-DC88A8DEFAB44FE092533D72762F361E" unitRef="usd">2648100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-38DD1F324A5729E673333D727635D809" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-3E4496185567B75E78E23D72761E3002" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2017Q1" decimals="-5" id="Fact-00A59786E800440BFBB63D727613FBB4" unitRef="usd">425500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2017Q1" decimals="-5" id="Fact-26F043E7BA4B5A8241D13D72761A3F30" unitRef="usd">346500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q1" decimals="-5" id="Fact-B0E8E067D35AD14B15A03D727640A156" unitRef="usd">216700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q1" decimals="-5" id="Fact-F2FB92E2F983EECD45373D727604CFBC" unitRef="usd">239200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q1" decimals="-5" id="Fact-3EC4D97AF71470777E663D7276174575" unitRef="usd">378500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q1" decimals="-5" id="Fact-E5754450D5DC242E96F13D727618E29A" unitRef="usd">412400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-2EA5078C7A07350B9CEF3D727630A042" unitRef="usd">3481700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-CA9DE8A13A01C62DDB723D72761CA86F" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-337ABECF96FD4F2D031E3D72762E7C98" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-2BC98754991054CF5CD83D7276329E03" unitRef="usd">3887100000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-FEEF17BC65B4F168AFEE3D727629BAAB" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-985475E100E649958E733D7276213C1E" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-E3D7018F934B166EDB8E3D72762CBD27" unitRef="usd">2705600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-991D4040BB55693AE5073D72763027BB" unitRef="usd">19700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8D2FC78C61F693417F123D7276192DDA" unitRef="usd">371000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-DC8D54B6C32EAB0759BE3D7275DA9877" unitRef="usd">2418600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-114B73FF54E8DC827DC23D727628EA2B" unitRef="usd">3012300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-6BAB045AC081469CF8603D72762900C8" unitRef="usd">16700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-ED7B3E7A852C6B8B51BD3D727631B65E" unitRef="usd">357200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-B994E5EAE5714C741C433D7275D87CED" unitRef="usd">349800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2016Q4QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-A4EF70BACF6851C4541A1BAF04430C1B" unitRef="usd">60000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-85E53D876CDB193B397C34ADF450C31A" unitRef="usd">795200000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DE40732528229AA94D8B3D7276069B89" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A35012EFF25971F4BDC53D72760ADBB7" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6E5B11F0FFD86EED76073D7276122B74" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7E2526C8DBD303704DE13D7275FFD9F9" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2936F5D75CF92C97F70E3D7276617181" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7864558D46A93C4C62DB3D7276752946" unitRef="usd">44500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C462BA9D0A274120EEDB3D72766ABF8C" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C33F9A9DB8D13B32CE493D7276609759" unitRef="usd">44500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5D2DD4DC240450810ABD3D72760FA07D" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-033FAF3C36EE7E5DFAE13D72760B01A6" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-99760866969D16017A063D7275FC8530" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-910515E5AF1DE59A01973D727603F317" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7CD63F1588E32D250C1F3D727670DB18" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-18DFD8676F7322A539223D7276649D8D" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DE8B31A97A77FD29C3523D7276730F21" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-751AE1FB2545E80E9F503D727662F674" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-313293A80297DCE23C293D7275F547D8" unitRef="usd">2100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-23BB7233256A18A5BEEF3D7275DA87AB" unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-29A6628315BF0B35D5A13D727654831F" unitRef="usd">2400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-95BD8378197DD4B14E4F3D727651294A" unitRef="usd">1600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-2F93B47633A4CC01F1F83D7275F2F428" unitRef="usd">1600000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-425D0C44980F319AE1B43D7275F60E34" unitRef="usd">2400000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-5" id="Fact-81C3563F6FFF0C13DD633D7275D69C9A" unitRef="usd">3669300000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q1" decimals="-5" id="Fact-693D6AF6F93730813CB03D7275E01EBB" unitRef="usd">3611700000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D315DE946AFA75C572483D727621EA50" unitRef="usd">254700000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-2695D0219E74A167B1433D7275E33796" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2017Q1" decimals="-6" id="Fact-E47055588B237651A05D3D7275E212F9" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-5" id="Fact-8BC26474A79AD235C80F3D7276222000" unitRef="usd">1800000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D1E99C335790AC998D113D7275CAE773" unitRef="usd">1325600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-215258D9E1BAACE319B03D7275C5308C" unitRef="usd">986700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q1YTD" decimals="-5" id="Fact-8ED0A5B1045F95324E473D7275C0ED6A" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B9E7D3124860A01D50A23D7275AEE8B7" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2017Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-8FB51C8C90275018B1BA87A596143CE9" unitRef="usd">56000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B0DD577FDD71274E00DD3D7275AE2CD7" unitRef="usd">356400000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E62D6A2F2CEC93066D483D72767E2352" unitRef="usd">-100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8374EFF54C7C023E60503D72759653D0" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EC7C3792818A5394DB533D7275BF825A" unitRef="usd">239200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-5F4B83FFB69262D08E4A3D7275E6C43D" unitRef="usd">45300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-DC88DE0FD30E6526DCF43D7275984E37" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8869727409C3C82A06803D7275941618" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F8B1F3DDE9BDCF6DBBE33D7275EA7584" unitRef="usd">160000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0656E0722FA5BCAF1B7C3D7275E9B6F0" unitRef="usd">195700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q1YTD" decimals="-5" id="Fact-69B87E11FBC90CDFA1433D7275E658DE" unitRef="usd">276800000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q1YTD" decimals="-5" id="Fact-423E3789FDE7A8B5F18F3D7275F31AB5" unitRef="usd">-195100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-43F1C22E5AF4D53F632C3D7275E9FC9F" unitRef="usd">-136700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-8FB5E995F9C4A0B963F63D7275EF3A21" unitRef="usd">-684200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6C78A501E3D35CB8F66B3D7275EFC7D7" unitRef="usd">88600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7037BD0A2DADFCEDC1A33D727627FB4D" unitRef="usd">46200000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6C9B51F1E949D6E2AFE53D72761FFDC1" unitRef="usd">36900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F2A4BA3D4D6C082CBAAC3D7275EE4AA1" unitRef="usd">34300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-6748A812BEF41BE77C863D727680F582" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-612E68F38AF1D946E82B3D727671DE84" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-5D3DA7AF2F89A1D31B733D727671F67C" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-76FD70DDF9E6F5C3BE093D727651D233" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-C6F1CE0F72A857FEAC6B3D72767617E6" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2432ED0E210CD59EB7583D72764F4E60" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-741EEB353E8AECD9B0083D72763ECCC1" unitRef="usd">648000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-0B207448F83F1D6807D73D7276379642" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-A558F8CF1660431AA97C3D727630A7BF" unitRef="usd">653700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-08C74F93A0C8C840E4C93D7276327F61" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-4649CAB0A8B400B1C0043D727631F917" unitRef="usd">7742300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2017Q1" decimals="-5" id="Fact-BF39BC77C7D345DE59423D72763EB7B1" unitRef="usd">8153400000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-3AF4EA0EE0045DF084313D7275DF755B" unitRef="usd">3808300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q1" decimals="-5" id="Fact-AB8504F1AFB1B99238A43D7275EC4277" unitRef="usd">4103900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E01E9ED11A5345D4C1983D7275E2EE72" unitRef="usd">63300000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-6283341964B7DC6D63F03D7275F3D464" unitRef="usd">63400000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-EED26FDDBA830829AC173D7275FA8DA6" unitRef="usd">170300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q1" decimals="-5" id="Fact-CECF81D673699244FE8D3D7275F6871B" unitRef="usd">156800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-5" id="Fact-C9A1760ABB1176427E7A3D72764F34ED" unitRef="usd">1001600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q1" decimals="-5" id="Fact-488F9CDAC977653413073D72764BE241" unitRef="usd">921600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-B999D3963AECCA29C4DC3D7275F901C6" unitRef="usd">37800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-7F23EE266357C107828D3D7275F8D4CA" unitRef="usd">37800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-206B5AA4EFC6C81A0F633D7275F655F9" unitRef="usd">170400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q1" decimals="-5" id="Fact-39C5D4292A00060E6AF53D7275F8066D" unitRef="usd">158200000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-B941FECC661FEDCF30C13D7275F7A485" unitRef="usd">698700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q1" decimals="-5" id="Fact-954A41BB8A55CFD7FDA63D7275FB1FC5" unitRef="usd">644400000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-27EF64328E7916DF63723D7275F5C220" unitRef="usd">11200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-439DAFEDCC11445656A73D7275F7C329" unitRef="usd">16700000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7DFCA5BCBD63DBFD42D13D7275FB0AB7" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AF06F229250DD6D7EF1A3D7276027E0E" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2B79E920DC19871BB9CC3D7275FAE79E" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3EFA060532E22C3595783D72760B40C4" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-74BC55DBE3341B50DD023D7276788016" unitRef="usd">18700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB6A811448590AAC6F813D7276665654" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3086FF294DB62E7E28A73D727672204F" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-697901EB9924C40D3B6A3D727673DE99" unitRef="usd">18700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-5" id="Fact-0194DDB1D444DA54FF2D3D72765C94AB" unitRef="usd">10748200000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q1" decimals="-5" id="Fact-0EA4115015B999EA70303D7275D442E3" unitRef="usd">9728500000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-AC54BE828E87E5828D343D7275D07588" unitRef="usd">22876800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q1" decimals="-5" id="Fact-CF889B5A49702D23C3D53D7275DB36D9" unitRef="usd">21195900000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-209A5383C2DCC877240F3D7276711A7F" unitRef="usd">3419900000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-B1BCB36DE5AAB64A16D03D7275DFF068" unitRef="usd">2992500000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B3E8FF9F39C48363361A3D7275FF23CB" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DD380D17B342D16AC5183D727602E581" unitRef="usd">13600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C4561CC420205FF4F5963D72760A5CE6" unitRef="usd">467600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BCC5583B0770B03FD5243D72760F9BC5" unitRef="usd">481200000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-577F1B77F4F8BCB5DA463D72765C341A" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7FAA33B4B2966099A0123D727676074A" unitRef="usd">13600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-36572E8A3A832F0B57113D727679FA87" unitRef="usd">470900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CF432722447DF3875FB33D727678EE52" unitRef="usd">484500000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-45D3BC708D302CDD148B24A36EFF390C" unitRef="usd">155500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:LitigationReserve contextRef="FI2016Q4" decimals="-5" id="Fact-C8983F34ED60D3F7D4371BA26AE34DE9" unitRef="usd">454800000</us-gaap:LitigationReserve>
	<us-gaap:LitigationReserve contextRef="FI2017Q1" decimals="-5" id="Fact-EFD30FC85715458A80A11BA2DD9FE2CD" unitRef="usd">0</us-gaap:LitigationReserve>
	<us-gaap:LitigationSettlementAmount contextRef="FD2017Q1YTD" decimals="-7" id="Fact-D0E2A98F702938DC961234AC8E58233A" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9D2B99F7DD8673E3BB3034AD0F67B234" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-5" id="Fact-70A25ECD4D50FE83E1673D7276012584" unitRef="usd">6512700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q1" decimals="-5" id="Fact-50B0703AD3580DE1CE963D72760FE01E" unitRef="usd">5952700000</us-gaap:LongTermDebt>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2017Q1_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-3EC87C46D574C88695AB1BA37B2D6710" unitRef="EUR">37400000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:MinorityInterest contextRef="FI2015Q4" decimals="-5" id="Fact-1445FEE2A5434AC8E94F3D727649314F" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q1" decimals="-5" id="Fact-A938077F3D9A6CC549A73D7275CDB005" unitRef="usd">1300000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4" decimals="-5" id="Fact-EDB87DA6DBE1F7386A5F3D7275FFE142" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q1" decimals="-5" id="Fact-22FFF23A64ED7CCFF1883D7276828F8C" unitRef="usd">-11600000</us-gaap:MinorityInterest>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-94A28031E0C951698A993D7276170341" unitRef="usd">-5000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-284AF3FCF5A3878010BE3D7276195414" unitRef="usd">-901400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-79BCEA27CFF82E2DDACC3D7276349C97" unitRef="usd">-1203200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-220210A3A630461E8EC43D7275E0A742" unitRef="usd">-744200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E1D06581393B2D9BC69E3D72762B76B9" unitRef="usd">1015800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3D2444D31FBC7B5FC1E93D7275EECBD0" unitRef="usd">235200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-708CFCBAAFB3843DB9393D7276826002" unitRef="usd">970900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-84497F1A9B2B4692F7673D727678B6ED" unitRef="usd">8700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-87FA1BAB00D0C325A3923D72759BCD76" unitRef="usd">747600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-77BF629FF7E8D897C1933D72767BD88B" unitRef="usd">6300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q1YTD" decimals="-5" id="Fact-373DE635B961EB198B0D3D7275995628" unitRef="usd">-1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-DAD76C03CF09098DADBA3D7276341DE5" unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q1YTD" decimals="-5" id="Fact-FABD64214A0822F0FF8E3D7275E73221" unitRef="usd">900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0A70FE5A76F0781E85183D7276554E43" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-D98932D29F22A550E6413D727640F3EF" unitRef="usd">-52800000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-681CE764FA5270A4A9EC3D7275986D07" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B2AAAFF482C9A618A5E53D727676CCBA" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0E6B6E907E02FCC510B13D7275A64D5D" unitRef="usd">-37600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-64E7056657F85F3BCC5A3D727672EAA8" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-A0B8383B185426119A3A3D72767CE50C" unitRef="usd">-700000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2016Q4" decimals="-5" id="Fact-71038D3D4B5810E363E03D7275F248EE" unitRef="usd">6499300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-A2A60784AC2ED5C1E42D3D72760B9307" unitRef="usd">6000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-6BCC66D88CAA51D04FC63D72760CD56D" unitRef="usd">1721500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-CCD02911598829B8CF0C3D7275F94156" unitRef="usd">1734800000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-2327DF65A4FF460400D63D7275CBCFDE" unitRef="usd">558500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-D5AD12DC3301ABA938C33D727614C449" unitRef="usd">993200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-71CCFC7B557EF18CBA7D3D727617F767" unitRef="usd">1485300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1" decimals="-5" id="Fact-5136F30F8FCDAE97AA0B3D7276190A19" unitRef="usd">6496500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-66467F7A8B11D8A2B33B3D727622A6B8" unitRef="usd">6300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-B0E604FBD6984F37BE7B3D7275A16248" unitRef="usd">1721600000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-95A40C8A9B93121DEAE73D7275CCF72F" unitRef="usd">1735200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-908A48E6E5719F7C02333D7276058D05" unitRef="usd">556700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-E9FE2457F52FE175C8B33D7276219650" unitRef="usd">993500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-51D5E26C5925FB80B3733D727622351A" unitRef="usd">1483200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-507F8563C4B01222DF503D727618887D" unitRef="usd">6100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-ECD13D57D10477C492AA3D72763C75C9" unitRef="usd">1874500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-67B96D5EDC3BB3E42CAF3D7276121556" unitRef="usd">1796000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-8382B33D49A79EFBD35D3D727670D72C" unitRef="usd">583700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-B02B3AEF1B4104CCD1D63D7275C2CA7B" unitRef="usd">1026600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-3D40BE1DC6AEAF71CCB23D7275CDEC89" unitRef="usd">1521500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-6312EFA298AD838D38C53D727613846A" unitRef="usd">6300000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-DDD55B3D41374DADE4353D727619D226" unitRef="usd">1890000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-DAE3F7FFE79D6A9368BA3D7275AD6F1E" unitRef="usd">1812900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-F6354C0B995DC83F21463D7276054E53" unitRef="usd">575700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-698C1ED21B7C58B0496D3D7275EE4C48" unitRef="usd">1032400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-F481ED59F0BB10B5D0C53D727622856D" unitRef="usd">1528100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2017Q1YTD" decimals="0" id="Fact-9C99DE04BC3ED38B0D393D7275CE2BA4" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A5C117196E399D3151753D72767F2A26" unitRef="usd">100000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-23D1558A2E1169E5D85F3D727683A71B" unitRef="usd">100000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-DA0F5DCCF7619C0BA8F13D72767A690E" unitRef="usd">1378400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-130070331CAED5E734713D7275B9FB47" unitRef="usd">1024300000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-0C6BC58F8565A464557C3D72763F33DF" unitRef="usd">685700000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-E9E7B6EFDD828A7E9A2C3D727626FE73" unitRef="usd">475000000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-1D340076F6E9ECCC75483D727648DE25" unitRef="usd">1093300000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-38FC0D9C9A8341E6629B3D7275DD126A" unitRef="usd">1231900000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-CE53451036130398766A3D7275DDECE8" unitRef="usd">1335800000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-1C613DF53CE36E4972433D7276014437" unitRef="usd">1184500000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2017Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-9D227466E5CD83D316C91B8EABB620CD" unitRef="usd">216000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-AA4952515B2770F6D5883D7275FAA726" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-256848D39EAB7DEEE28C3D7275DB749E" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-66F5DBCC3A0FE0FAF98B3D727671882B" unitRef="usd">-26600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C21C75C3339806143F543D727657194A" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-FC8DCDE6121964727D8F3D72764D7CB6" unitRef="usd">-38900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-04D615717578DEAA69B13D72765FEAE4" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-C5C7F111F644D4AFBDEB3D72764FFE79" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FA30B5950CF1859C52883D72763826B9" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A17D8CED85006D0918823D72762D1F92" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-66504DADA6057594DFCC3D72763E31FA" unitRef="usd">-17100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B33358B85DC5B37E4C633D72763B24AC" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-902FB06508890E8860AF3D727627B13F" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B9AAD91B84DF1F491E3C3D7275DCAA4D" unitRef="usd">-47600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B31744B7010ABD920A8D3D727652592A" unitRef="usd">-23800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-69D75024E58320E45AB73D727682D24E" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-090427C6524D974F951C3D7275D3139F" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E5931B1EAFB36237C1273D7275DBAD41" unitRef="usd">-35300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-AFC97DB9BFFF3C9D2FE73D7276566BAE" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0EDFCC95868924D4DF1B3D727653E15C" unitRef="usd">-47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-10B2C2F83FF2EFC910883D72765075DF" unitRef="usd">2500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-74E7FA8418F69FECD0EB3D72764CC6ED" unitRef="usd">9600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-4091667D7FCAA75ED6F43D7275E5C3D9" unitRef="usd">-5300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-7BF8BAD98E5DC1CA26F03D727628C707" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-05ACA7C6C4FB5ED363FD3D72762F7A96" unitRef="usd">-23800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0ACB2129DB9DED2082FF3D727635C0DE" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3840B6787E098B679B5B3D727637F823" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-4248117FED9B41763DB43D7276776B1B" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2D336A116A50FE9D9CB33D72765396DD" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-679AC8F46FE88A00C7B03D7275E45B3A" unitRef="usd">2903500000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-4E35FC38626EF9AE828F3D727611A6FD" unitRef="usd">2044600000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-0DB5B2C0D65EE0D4F89B3D72767B7537" unitRef="usd">722500000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q1" decimals="-5" id="Fact-876B8286D892F77A34D13D7275BB067D" unitRef="usd">688800000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-8FE0DB73893EC06723F53D7275F45474" unitRef="usd">11900000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-BE3BA9A2305D64AFC0AF3D7276293757" unitRef="usd">-18100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E8F29F1F9276DE2C7BD33D7275F1D0BF" unitRef="usd">-4400000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-BCD076E90B066C63D96B3D727606FE04" unitRef="usd">2700000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-2FF225D19E8A226EDF663D727641BEBA" unitRef="usd">87900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-61C51668B56A4BB15A9F3D72761DD3AD" unitRef="usd">2700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7385C95BCD8B2AEA30E63D72762936A2" unitRef="usd">90000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-B00D12F268ADB8A0242E248504943CD5" unitRef="usd">3100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-E0D1EDE6B38B6B7372873D7275CBF88F" unitRef="usd">2200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-73FD788A8AFF75F9A2411BBA5B60B6FF" unitRef="usd">5900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-AE10BF57072B2BBA72133D7275D614A0" unitRef="usd">14400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EE6E3A9D53C7E03B4F7C3D72762DC187" unitRef="usd">6600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q1YTD" decimals="-5" id="Fact-04B54D034555F57DF5D33D7275D9F7A9" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1F9810C588F5ACE3BC933D7275DF28DB" unitRef="usd">583600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-142ABEAD11C217DD03A787950EEF58C7" unitRef="usd">365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramPlanToDateMember" decimals="-8" id="Fact-D1F70653D2CCA6814F02A181CB4B1892" unitRef="usd">1200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-FC6F5339E5CCF01BAD851B977CD4D8A5" unitRef="usd">218200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2016Q1YTD" decimals="-5" id="Fact-A666BD72D8293FF881A58744CC88DA9A" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2017Q1YTD" decimals="-5" id="Fact-39B9480A153A362FB5258744ACC337CB" unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q1YTD" decimals="-5" id="Fact-AA6C7E848FA7C79D134A3D7275E628DA" unitRef="usd">29600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-5" id="Fact-A361AE725A804863776E3D7275E1D049" unitRef="usd">25500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-96F0597EC95522EE13F23D727627EEEE" unitRef="usd">1914400000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9CB5673774D6B65385B73D72762EE43D" unitRef="usd">1256700000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-BCF7EECC0E3D09ACADCC3D7275EE56B0" unitRef="usd">28600000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EC21E4DB5BEEC8E836043D7275E89E74" unitRef="usd">855200000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q1YTD" decimals="-5" id="Fact-7C239202152283EBE6223D7275DA0FD8" unitRef="usd">300000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-A9FEBFA1C189043C46353D7275E89951" unitRef="usd">300000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q1YTD" decimals="-5" id="Fact-E373C7C2523AB9A911863D7275F0BC85" unitRef="usd">126900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1CAC9657C37CBB415D6D3D727625983F" unitRef="usd">210000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-7D7DBEB068AA725F4A403D7275D6790E" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q1" decimals="INF" id="Fact-4C64B7CBCC999D4562553D7275CE37C4" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-BDB64A079F67AD74EF0D3D7275E87BCB" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q1" decimals="-5" id="Fact-CEFE5C2CC70355CA81723D7275DFCE91" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidTaxes contextRef="FI2016Q4" decimals="-5" id="Fact-2DC858DF759FB284DBFE3D7275CC2187" unitRef="usd">817000000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q1" decimals="-5" id="Fact-EA12CDED30270BCC92383D7275C960C7" unitRef="usd">935600000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-B4F1839DC5819F6E00533D72761A661E" unitRef="usd">24600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2E87664460D9E178D2323D727615BBEC" unitRef="usd">10400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q1YTD" decimals="-5" id="Fact-F58EE79EBD6D6B1ABF083D7275F2E125" unitRef="usd">1181100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9A60E32EC009F280B7093D72762874F1" unitRef="usd">1884300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2016Q1YTD" decimals="-5" id="Fact-6A1A908535A231C47DBB3D72759436F9" unitRef="usd">969200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FEA6D570CC6B323181923D72763386C2" unitRef="usd">747500000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-2ED6E147922B535CEB413D72761F64B8" unitRef="chf">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-3E307468D0E76F5F5FFF3D72761E0EA9" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-5" id="Fact-CDD7A12955BA56BA89F23D7275D40C1E" unitRef="usd">2501800000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q1" decimals="-5" id="Fact-39C6D8F3E42F7CFC02503D7275D63695" unitRef="usd">2610900000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD" decimals="-5" id="Fact-0297FA6F5A5DEE997ACF3D72766E047F" unitRef="usd">-8700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-9E4F4CF6E11B1509E27B3D72766D1D84" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-8852E8736B5EB5B00CFC3D72764D87AF" unitRef="usd">-8700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4B58BE1B1A37096EC49F3D7276662F69" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-574DD20BD6693183AA623D72764C0445" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1DE5EAF60DBEBF565DC33D72762F78B7" unitRef="usd">-6300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-30CC3BB09AB68A22EC0B3D7276341AF0" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-4989FEA0206D496AFE2C3D7276275B1C" unitRef="usd">-6700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CD110682F834BEEF5E153D7276268028" unitRef="usd">400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-9BC120F48F93F85EB4D93D72763BA069" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q1YTD" decimals="-5" id="Fact-EDF09D4F41C6A208B18A3D7275B49AC8" unitRef="usd">437300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-6D9274BEF9463B32156287B3967AFBB7" unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1YTD" decimals="-5" id="Fact-03681461D2F935195F863D72759EC16B" unitRef="usd">423400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:RestructuringCharges contextRef="FD2016Q1YTD" decimals="-5" id="Fact-7A904A4B986457AFD2E53D7275A20274" unitRef="usd">9700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5C97814CB6BB251965253D7275B15FE8" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-5" id="Fact-3177496956E0725B17993D727681FCDD" unitRef="usd">15071600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q1" decimals="-5" id="Fact-7388ACBAB1DA7FCB684B3D7275D2FEA1" unitRef="usd">14781200000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2016Q1YTD" decimals="-5" id="Fact-1DAB3A923DC1B5B597573D7275AFBB9B" unitRef="usd">2726800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1YTD" decimals="-5" id="Fact-286CD4E1838F0488637A3D7276624D37" unitRef="usd">2810700000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1YTD" decimals="-5" id="Fact-982F85F9BCC03B2EFE3E3D7275A72109" unitRef="usd">2309400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-7A41570337C0C1EA625D248DDB9CFFA7" unitRef="usd">182700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-DB0D2B30F101EEA4D6763D72767A6FA3" unitRef="usd">8800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EB0197849F437A2DAF573D7275CC77B1" unitRef="usd">2380100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-E291D80E3E137D69A7CE248D97EF6F31" unitRef="usd">74400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-8724EF98AE5B53FF13FD1BB5373EECE4" unitRef="usd">46400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-8AB6CEB980BA54F4041D87AA60EAF630" unitRef="usd">1000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A25C5C38201918F760373D72767C97D4" unitRef="usd">6700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-FDC59BB859C07252E4B2203917AEB5B7" unitRef="EUR">41800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-59E5DB8A7661D33D920A1BA408604D42" unitRef="usd">44600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q1YTD" decimals="-5" id="Fact-53AAC5D788F5CD8949153D727632720A" unitRef="usd">497300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-4A0F4EC81CF96C9B73F53D72762A4748" unitRef="usd">499100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q1YTD" decimals="-5" id="Fact-578551DFB8E6661A07AA3D7275E8C6E1" unitRef="usd">45300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-5" id="Fact-CB915EB685BB52BA39A43D727616BDAF" unitRef="usd">37000000</us-gaap:ShareBasedCompensation>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-030ADEF9B6ECD57A77AB3D727621A2B2" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-0FB2DA03A93E98EFE7F68790B97A4252" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-401B3EAD790BFFBC03E13D7275D57431" unitRef="usd">12140100000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q1" decimals="-5" id="Fact-81520AE8E8F71004A5303D7275CB9D1A" unitRef="usd">11479000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-5" id="Fact-A1DA882A4408F65E49133D727610A0B7" unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q1" decimals="-5" id="Fact-057337433F787B61FC423D7275DB37DB" unitRef="usd">11467400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q1YTD" decimals="-5" id="Fact-57280D4075B61F268D401B94BC89A833" unitRef="usd">852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9192E252E83C727B558F878EDC415E41" unitRef="usd">661200000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-7DFEC5F8BA1416CFB3FB3D7275D153D4" unitRef="usd">231900000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q1" decimals="-5" id="Fact-575571A1B307DFAE4BC03D7276208292" unitRef="usd">70000000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-A8AA7C7777DAB52A64888791314D841B" unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramPlanToDateMember" decimals="-5" id="Fact-A585AE15EF95DE512209A1817CEEC1F5" unitRef="shares">4100000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-C9CBB98A962C23E6EA781B968396C26F" unitRef="shares">800000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-7F3AADD9193C5564DE493D727602A26D" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q1" decimals="-5" id="Fact-7C25E1C2D660F2FEAA023D7275E2D6E7" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-5" id="Fact-09F69AD1166EFB719C013D727666446F" unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-1E551ACD58333DDB39F83D72760F4689" unitRef="usd">166900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-2F3321376B6363143B873D72760C04FE" unitRef="usd">438600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-BB7249C58ABC12A27FFC3D72764F365A" unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-D264036FBF0DBCC20B1A3D72766A85CE" unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-5676E46EE20BD19BB81F3D7276544FE7" unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1" decimals="-5" id="Fact-F8E4399D09E09006BC883D7276577231" unitRef="usd">676500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-5A762C1A6B2D697203EC3D72760BBEC5" unitRef="usd">171200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-C0796DE861DF677AE52F3D72760EAB25" unitRef="usd">505300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C296A440279FD769739D3D727663B1BB" unitRef="usd">552500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-2600D3B1B5D97F5A62363D72765026CA" unitRef="usd">76900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-8C62BB07E9653F6ABCDE3D7276696A10" unitRef="usd">47100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q1YTD" decimals="-5" id="Fact-C8BCA2BF238F2471535E3D72766F5303" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q1YTD" decimals="-5" id="Fact-DF25156DA79776952C8B3D72766D30E4" unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q1YTD" decimals="-5" id="Fact-3E93275F30446592699F3D7275AF16CA" unitRef="shares">219300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q1YTD" decimals="-5" id="Fact-69BB5743E11563FB22BE3D7276291584" unitRef="shares">215900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q1YTD" decimals="-5" id="Fact-9F05F77A2C6D75699A743D7275A03213" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3F629EA2806C771170D73D72766D0425" unitRef="shares">215600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2017Q1YTD" id="Fact-61C0A7E2343856E069F03D727614DB7D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;131.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;568.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;707.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(62.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(231.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(64.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(267.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(337.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;76.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;552.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;676.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-D222820C1FDB7ED8E2CD3D7275CF1AE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the spin-off of our hemophilia business, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2017Q1YTD" id="Fact-7558BE9F779BFEE7E7133D7275DCDDB7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(526.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,648.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;357.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,887.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(874.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,012.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,153.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,049.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,103.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-8ADF6F426B3BF7BED5513D7276264EE2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-F9A462DD0E123603F84B3D727614CDD8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;171.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;676.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-EC5A55D15A43492595AD3D7275C7C24B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(63.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(52.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets include prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$935.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$817.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations and milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;516.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;181.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;160.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;475.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,044.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.  As a result of this agreement we have agreed to dismiss the appeal and in the first quarter of 2017 we recognized EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$44.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2017Q1YTD" id="Fact-139EE78C52C21861BC7E3D72762E8C78">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,288.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,289.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,213.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,073.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,076.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;539.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;539.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,781.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,786.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-2E9F02C76705B54F23D83D7275CE7F98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2017Q1YTD" id="Fact-16A539F371B118E515353D72762D8EC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;519.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,288.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,289.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,213.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,073.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,076.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;539.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;539.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,781.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,786.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,956.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,957.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,561.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,565.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;263.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;263.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,781.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,786.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,884.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,181.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-C924EF534DC2FE6385E93D7275F8D5E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 13, 2017, we entered into an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer&amp;#8217;s disease (AD) and progressive supranuclear palsy (PSP), from Bristol-Myers Squibb Company (BMS). BMS-986168 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the agreement, we will receive worldwide rights to BMS-986168 and will be responsible for the full development and global commercialization of BMS-986168 in AD and PSP. In exchange, we will make an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and BMS may receive up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$410.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties. We will also assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS&amp;#8217;s acquisition of the company in 2014. We may pay up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone which may become payable in 2017, and potential royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;share of the co-promotion profits or losses as a component of total revenues in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&amp;#160;2016. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenue of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;to reflect our share of an overall net loss within the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our condensed consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as these costs are incurred. We reimburse AbbVie for their &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our recognition of income to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada was not significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;SPINRAZA (nusinersen)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the agreement, during the third quarter of&amp;#160;2016,&amp;#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. In December 2016 SPINRAZA was approved by the U.S. Food and Drug Administration for the treatment of SMA in pediatric and adult patients in the U.S. triggering a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;milestone payment due to Ionis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets. This amount was paid during the first quarter of 2017. We may pay Ionis up to approximately&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in additional milestone payments upon the achievement of certain other regulatory milestones, including approval in the E.U.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized revenues totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on our sales of SPINRAZA in the U.S. and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we will make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit share with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the collaboration profit share in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in connection with these services as a component of other revenues in our condensed consolidated statements of income, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these and our other significant collaboration arrangements, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2017Q1YTD" id="Fact-A01695C36AC888AD4DB43D727640DE66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(325.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(35.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(186.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-AFE4D437475268C64E983D7275D735FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-D07DF858B0F9D8CEA5F23D727659A6A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,215.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;113.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,446.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$332.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$902.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. A net gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts was recognized as a component of other income (expense), net for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to a net gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q1YTD" id="Fact-AFF08F5D8946681B62593D7275BF78B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Spin-off Related Equity Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing stock-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&amp;#8217;s and Bioverativ&amp;#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-F6321F5E365C070137F824BFC481437B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The services under these agreements generally commenced on February 1, 2017 (the distribution date) and are expected to terminate within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the distribution date, with the exception of the manufacturing and supply agreement which has an initial term of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ and our consent. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totalling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$302.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. During the first quarter of 2017, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenues in relation to these services which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as cost of sales in relation to these services during the first quarter of 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we have continued to distribute ALPROLIX and ELOCTATE on behalf of Bioverativ and expect to do so until Bioverativ obtains appropriate regulatory authorizations in certain countries, including the United States (U.S.) and Canada. Under this arrangement, we are distributing these products as an agent of Bioverativ and will also provide related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations do not reflect recognition of activity or balances related to these transactions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. In the first quarter of 2017 these amounts were not significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia related product revenues reflected in our condensed consolidated statements of income for the three months ended March 31, 2017 and 2016 totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$182.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Results for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, only reflect hemophilia-related product revenues through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q1YTD" id="Fact-A2BFE3F25A15182C46CF3D72766E75F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q1YTD" id="Fact-3B33531010E4248B3E773D727623D96D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;542.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;542.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,502.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;484.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;556.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,528.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,483.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,032.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;993.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,812.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,735.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,890.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,845.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,496.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,499.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$254.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$246.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q1YTD" id="Fact-A28CF8AD14EA9E5EDA733D7276236A4C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;508.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-1C99232D22DC6064EA523D7275E79818">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(526.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,648.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;357.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,887.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(874.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,012.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,153.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,049.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,103.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$448.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$88.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. Amortization of acquired intangible assets for the three months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$353.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of impairment and amortization charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property related to TECFIDERA, as further discussed below. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of March 31, 2017 also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$349.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,418.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S (Forward Pharma) and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this agreement, representing the fair value of our license to Forward Pharma&amp;#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We paid the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in February 2017 and recognized an intangible asset of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$795.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&amp;#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into the agreement, through December 2020, the last month before royalty payments could first commence pursuant to the agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. On March 31, 2017, the U.S. intellectual property dispute was decided in our favor. Forward Pharma has announced that it intends to appeal this decision. For additional information related to these disputes, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continued to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2016. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;346.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;425.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;412.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;378.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;239.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;216.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;254.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,611.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our 2016 Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-BA8F5B24A65C6DCAF5773D72767B39F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities and the favorable settlement of a state tax matter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2005.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$56.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-D86D1D031B91E482B3A63D7276109C9C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;158.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;644.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;156.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;959.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;959.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ were related to work in process and finished goods inventory, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$84.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2017Q1YTD" id="Fact-4A20E0A2C528AEE62D253D7276298F3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,956.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,957.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,561.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,565.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;263.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;263.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,781.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,786.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2017Q1YTD" id="Fact-D52BBC40A9B6A78008C63D7275CBA27A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Italian National Medicines Agency&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2011, Biogen Italia SRL&amp;#160;received notice from AIFA that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. In the first quarter of 2017, we reached an agreement resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding this matter, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Consolidated Financial Statement Detail,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015, in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016 the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016, in the U.S. District Court for the District of Massachusetts related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has announced that it intends to appeal this decision.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding this matter, please read Note 5, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Inter Partes Review Petitions and Proceeding&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 22, 2016, the USPTO instituted &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. In March 2017 the USPTO ruled against the petitioner. The petitioner has filed a request for rehearing, which is pending.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On April 18, 2016, Swiss Pharma International AG (Swiss Pharma) filed petitions in the USPTO for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn&amp;#8217;s disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions and in February 2017 denied Swiss Pharma's requests for rehearing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The EPO has scheduled a hearing for November 2017 on Biogen&amp;#8217;s and others&amp;#8217; oppositions to Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information about this matter, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&amp;#8220;Administration of agents to treat inflammation&amp;#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. A hearing was held in the Dutch action in February 2017 and the decision is pending. A hearing has been scheduled in the German action for early 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated '755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q1YTD" id="Fact-B4E4153C99CD2CC8EE2F3D7275C9310C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method and continue to evaluate the potential impact that this standard may have on our financial position, results of operations and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2016 the FASB issued the following new standards, which we adopted on January 1, 2017:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. As of March 31, 2017, the adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&amp;#8217;s goodwill with the carrying amount of that goodwill. This new standard will be effective for us on January 1, 2020; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-7EFBE819012045CF2EC83D72762204ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,438.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,439.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2016 we purchased land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), where we are building a biologics manufacturing facility over the next several years. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$609.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$481.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to the construction of this facility. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$216.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-D2638E52651A74FC05B43D72762C7CD5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,884.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,181.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2017Q1YTD" id="Fact-7C1C7740B34A2EDBA7EF3D72763C102C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:47%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q1YTD" id="Fact-649AECAB5EFF7B5E080B3D7276413BFB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations and milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;516.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;181.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;160.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;89.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;475.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,044.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2017Q1YTD" id="Fact-29AB08F1C39943EDC61E3D72763A54FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(325.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(26.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(35.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(186.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(259.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-83769E857D7E6FAA46E93D72762462BC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;575.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;556.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,528.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,483.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,032.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;993.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,812.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,735.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,890.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,845.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,496.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,499.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-51EB1CC93933C7101AD33D72762B2E41">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;519.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2017Q1YTD" id="Fact-3C9DDE70C5E8178B188C3D7275A12F94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2017Q1YTD" id="Fact-A708DA5793934E8375563D72765230A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2017Q1YTD" id="Fact-3D86B07292F4BB12FD813D72764BFF04">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2017Q1YTD" id="Fact-3ECDE8CB45ABFB62BF8E2495AC761887">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q1YTD" id="Fact-ED83AA038A7B7E51BE9B3D727677825E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;970.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q1YTD" id="Fact-BBFE31C67FC3540AF2463D72767C08E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q1YTD" id="Fact-0A089E9F3FC1F6ADACB23D7275A04E47">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;54.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(15.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;33.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2017Q1YTD" id="Fact-42E2A7281E8F1BE26BA43D727623FC5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,500.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,738.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;542.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;542.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,520.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,502.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;484.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2017Q1YTD" id="Fact-79EBED2448B0B815AB2C3D7275EE0E74">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;254.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,611.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q1YTD" id="Fact-D3837DA8B10DF3DE70413D72760DB7C3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;158.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;644.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;156.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;959.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;921.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;959.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2017Q1YTD" id="Fact-501806D2667596EAE2E23D727657C497">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,215.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;113.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;59.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;58.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,446.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2017Q1YTD" id="Fact-1D4399709BBF3BDCAE4B3D7275C9582A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(63.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(52.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-A4B2DBC6DD39C680ABD83D727614FB3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;131.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;568.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;707.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(62.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(231.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(64.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(267.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(337.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;76.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;552.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;676.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;171.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;505.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;676.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2017Q1YTD" id="Fact-76FF2F834316F60BBA9D3D7275DC77C5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;346.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;425.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;412.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;378.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;239.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;216.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q1YTD" id="Fact-6961EE81E86C09FA75C43D7275CD20FE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the spin-off of our hemophilia business, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, which is focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method and continue to evaluate the potential impact that this standard may have on our financial position, results of operations and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During 2016 the FASB issued the following new standards, which we adopted on January 1, 2017:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. As of March 31, 2017, the adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&amp;#8217;s goodwill with the carrying amount of that goodwill. This new standard will be effective for us on January 1, 2020; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-628A593CF3417FF1DD133D72763DC78D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total equity as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; decreased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$661.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This decrease was primarily driven by an adjustment to retained earnings of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$852.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the spin-off of our hemophilia business, as described in Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements and share repurchases of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$583.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as described below. These decrease were partially offset by net income attributable to Biogen Inc. of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$747.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$218.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this program. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have repurchased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under our 2016 Share Repurchase Program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock (2011 Share Repurchase Program). During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to complete this program. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Noncontrolling Interests&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q1YTD" id="Fact-EC8B8DA4ABCB79C485413D7275D76322">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2017Q1YTD" id="Fact-CE9F98C782015AE60FFB3D72759F4FA0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&amp;#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and are required to fund &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20170331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20170331" xmlns:biib="http://www.biogenidec.com/20170331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2126100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2426401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2426402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2116100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2416402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2316301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2121100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2421402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2321301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2119100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2419402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2419403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2319301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2112100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2412402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2412403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2412404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2412405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2312301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2114100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2414402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2414403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2414404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2414405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2414406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2414407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2314301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOff" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff">
        <link:definition>2106100 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetails" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails">
        <link:definition>2406402 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual">
        <link:definition>2406403 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffTables" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables">
        <link:definition>2306301 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2123100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2423402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2423403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2323301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2110100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2109100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2409402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual">
        <link:definition>2409403 - Disclosure - Inventory Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2309301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2125100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2425401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2127100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2427401 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2124100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2424402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2424403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2324301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2118100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2418401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowances" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances">
        <link:definition>2108100 - Disclosure - Reserves for Discounts and Allowances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails">
        <link:definition>2408402 - Disclosure - Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2408403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1Calc2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2">
        <link:definition>2408403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesTables" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables">
        <link:definition>2308301 - Disclosure - Reserves for Discounts and Allowances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2122100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2422402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2422403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2322301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramPlanToDateMember" name="A2016ShareRepurchaseProgramPlanToDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramYearToDateMember" name="A2016ShareRepurchaseProgramYearToDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeInstrumentsTextualAbstract" name="DerivativeInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ExpectedPaymentTimelineofMilestoneAxis" name="ExpectedPaymentTimelineofMilestoneAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ExpectedPaymentTimelineofMilestoneDomain" name="ExpectedPaymentTimelineofMilestoneDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FY2017Member" name="FY2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinishedGoodsMember" name="FinishedGoodsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HemophiliaProductsMember" name="HemophiliaProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IPerianMember" name="IPerianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" name="ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" name="ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" name="ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativManufacturingandSupplyAgreement" name="TermofBioverativManufacturingandSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativTransactionServicesAgreement" name="TermofBioverativTransactionServicesAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20170331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20170331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48ae1e41-8bb7-d139-f404-61b44b37e179" xlink:to="loc_us-gaap_MinorityInterest_0b2dda0f-483d-415e-b849-61eb9013050d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_TaxesPayableCurrent_09c3afb8-38a1-4889-4c3b-0ee54f55be27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DebtCurrent_8730cf6f-d6e3-789a-4435-85747cc6a847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebt_69e5de31-e379-3d10-54e1-db1271f781f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_30444800-bccf-94eb-16a7-6eb32a0bf8df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_027121dc-d718-d921-ddd8-bd9e54985311" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_027121dc-d718-d921-ddd8-bd9e54985311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_b3d12002-79e5-47db-0a4d-77b30be5f00c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdbab275-b995-9f6e-4d30-38c2b0ed44dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_91674616-989d-90e8-1302-b52ff7a33098" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ef024267-fc04-b9fd-6e4e-38d399da963a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f727506e-917a-c7f2-effd-742269ec6604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_c02ad689-0839-347f-dbb5-560ba41e6864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3d4b15de-b1bf-181b-e3f1-91381ce35d3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fd30e334-9842-e274-9b27-bbbf9eeb6080" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fd30e334-9842-e274-9b27-bbbf9eeb6080" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_c094319f-e455-d1ac-bba2-987bc5dff7e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11ed54de-8651-64ce-6bd2-47983535a6d4" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_11ed54de-8651-64ce-6bd2-47983535a6d4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e341d9c-b561-17b2-6b84-9236041ffef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_3a381390-93e9-e46f-fae5-3a0730fa9a87" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_3a381390-93e9-e46f-fae5-3a0730fa9a87" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0f105a40-393d-896e-47b8-344549074b13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_7888ca55-4b2a-9f3e-262a-d47103cbdac1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bc96e3-060f-f5ff-d324-c7cecf3273f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_369c90d1-6da1-8050-c604-fad527301a92" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d23b2d61-1407-f3f5-ba7b-69860a5b50dd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_eddbf4fa-a79b-3699-85e9-ca7ce5eef536" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_ccb7b808-8f93-67cc-494d-bd9e53d6ff0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:to="loc_us-gaap_OtherSalesRevenueNet_888a521b-fa37-b5b1-8e28-b2ce12b7ced6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c100c3d5-921a-ee55-568b-f12db1e8f91f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_45782c94-912f-fb4e-76bf-199e35f3c27b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_RestructuringCharges_08c2928f-d1d5-f97a-10aa-389716958b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_01f2b122-3157-76d4-112e-c7b272fecbb3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_28262A90DB45295EF65FBDAB87846837" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_ba9c144a-a131-2335-7bef-6a9a2f344885" xlink:to="loc_biib_Collaborationprofitlosssharing_28262A90DB45295EF65FBDAB87846837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5ba85eae-c4c2-72cc-f9e5-b0edc41783e5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_00a475d0-9ed4-5ca4-8e09-183f13a0aa46" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_359134c0-3512-0437-07c4-28574636fc79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57932a93-02bc-f4e7-4538-5a7fc65a1b5b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e841a58a-f12e-0adc-36de-0299a43719a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ae404dc0-76bc-cd1d-811f-e233c07e0569" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e24f9d55-d9ef-3f95-c65d-cbc9febefcb3" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9dba38ce-5067-b4c4-09f7-0cf74e4693de" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_794fc482-f400-6856-2d15-b80c897f0bac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_4f567ef5-b8d7-6688-bab2-00271c822568" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e5ea9848-5ffb-0a59-3b02-d214338777c4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ba478347-bbf1-ddfc-8a79-7775b3b62a6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_b671a380-e06c-01fd-905c-c45ee0d0ab53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_65f23050-696a-07fd-30c1-78a5110d800c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_64878df4-a4bb-ba61-aacb-ed249b31f694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_59295b7e-c316-eccf-27db-e84d9ca58730" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca7edb8-274e-a972-85d8-811b7da33e90" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_74826df9-1290-2e5d-1476-bd9e533dee23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3913e100-ff62-4129-cd9e-bd9e557cbc90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_db3b580e-d182-4945-7c2e-ce877e78a106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_01be169b-08cc-7c30-55f5-941791d17ef8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_73f419d8-d119-3f34-15a6-338e4455cd96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_854996b2-91af-6409-f56d-aae3ba36eff1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_56e289e1-500c-c77f-97ba-e406a6be2593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8e6be169-09a9-5661-71bb-cb6bce1f56f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a476c969-d3fd-cf02-0d56-ac5fad2f8a34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_592bc0e7-9233-a559-98bd-046511cfe2a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0d763afc-4281-0204-2391-400c96ae6714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_260b0554-5407-84a9-0ddc-c064bbfac41b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_260b0554-5407-84a9-0ddc-c064bbfac41b" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9d686b75-f9ca-45e9-dcb7-a314128deba9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_72b442ab-dd2f-23d7-ec24-bd9e533c7d55" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_7ea689db-170d-242a-aadc-096d31f6a174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_70724be1-cf82-e50d-0cc7-fa6194f78b70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_20da5796-2b47-ef11-689a-589894b52fb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d981c90e-1b35-63c2-c258-b2af7bf5b3e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2497ccf0-783f-7384-a80c-38649f384646" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20170331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f925ebd3-061a-e984-2203-e9a7cc583900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_7b711a15-f1f0-530a-4653-51844577a7f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_68666644-b813-08f4-eca9-be4209690838" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_5e2f7e41-cc2d-1880-9908-a0f60d8dacca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ed735562-dfa2-f50c-cfbd-c90d6a562718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_InterestExpense_4b6ddf50-6253-3349-fa29-8fc77f744f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_72f8dbcf-d3e6-9f03-ee3e-0ffce77f6746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8bd26a17-2466-c9ca-826d-1c7167e5c7f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9fa8ee46-9d2e-0b63-b65e-c559fb6868a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_cd8f1afb-536b-0ff3-edb0-41d6faa7aebc" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_7a3e2b9e-239b-1138-f935-4aa4335a528f" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_44ed1d14-371c-5f9d-c158-bd9e537d91ca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20170331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20170331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:to="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:to="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:to="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:to="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_42532346278C4205DE729B1883286AAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_42532346278C4205DE729B1883286AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_31103274C26B074777229B18832824D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_31103274C26B074777229B18832824D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0A16EF0D3D830BD416849B188329DA37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0A16EF0D3D830BD416849B188329DA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_F8B1B6B2C41B1FDC6D6C9B188329D634" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_F8B1B6B2C41B1FDC6D6C9B188329D634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EE6D79BCC732753B57A19B188329045D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_NetIncomeLoss_EE6D79BCC732753B57A19B188329045D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FY2017Member" xlink:label="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:to="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:to="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:to="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7CFB12934A55351D277FA5663945A71C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:to="loc_us-gaap_MinimumMember_7CFB12934A55351D277FA5663945A71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5D31032ABF03E73F930FA5663945A045" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:to="loc_us-gaap_MaximumMember_5D31032ABF03E73F930FA5663945A045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_0D2095F9937B813EAA3DA56639454043" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:to="loc_biib_InLicensedPatentsMember_0D2095F9937B813EAA3DA56639454043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:to="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:to="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:to="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:to="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_ABEDBE11790115025750A5663947D188" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_OtherSalesRevenueNet_ABEDBE11790115025750A5663947D188" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_962F1569307D41E0AF73A566394723B3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_962F1569307D41E0AF73A566394723B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E62864512FF6330C7A5AA56639473867" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E62864512FF6330C7A5AA56639473867" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_74B8AD50C3FE510A77B19B1882C15711" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_Collaborationprofitlosssharing_74B8AD50C3FE510A77B19B1882C15711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:to="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:to="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:to="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:to="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:to="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:to="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:to="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:to="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:to="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:to="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:to="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:to="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:to="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:to="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramPlanToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2EB16E125E6B6A8DD3173D72796A12CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2EB16E125E6B6A8DD3173D72796A12CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:to="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3692C322FD9D558D8B73D727AA59ADE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3692C322FD9D558D8B73D727AA59ADE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_AAC868996C3845CDB63D3D727AA690C4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_AAC868996C3845CDB63D3D727AA690C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D1A71F667A7B30DF90593D727AA63DB0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D1A71F667A7B30DF90593D727AA63DB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CDF7053D5D0B8491C2473D727AA65CEF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CDF7053D5D0B8491C2473D727AA65CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:to="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9CC68086C04EB35E1B343D7279A88147" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9CC68086C04EB35E1B343D7279A88147" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC65DBB1952F1549AA953D7279A98F1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC65DBB1952F1549AA953D7279A98F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:to="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:to="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:to="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_6EF0F3BF39F97ED2B991A565D7D577DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:to="loc_biib_BioverativMember_6EF0F3BF39F97ED2B991A565D7D577DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E912E981308A82BB0ECAA565D7D823A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E912E981308A82BB0ECAA565D7D823A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_845ACD7761022F587F93A69CB48C2ED1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:to="loc_biib_BioverativMember_845ACD7761022F587F93A69CB48C2ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:to="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_611C7A606C4FD0BB790EA69CB48D7142" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_OtherSalesRevenueNet_611C7A606C4FD0BB790EA69CB48D7142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_A478E4EDC562C1B4F739A69CB48D431A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_A478E4EDC562C1B4F739A69CB48D431A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:to="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A5CE1D940D2CEB140A4AA5ABB2A5D4D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:to="loc_biib_BioverativMember_A5CE1D940D2CEB140A4AA5ABB2A5D4D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:to="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:to="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_2186F60C2311EB73C9DAA5ABB2A695A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:to="loc_biib_TecfideraMember_2186F60C2311EB73C9DAA5ABB2A695A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:to="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:to="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:to="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:to="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5AC991DC9CE1E1E36A57A5ABB2A746BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5AC991DC9CE1E1E36A57A5ABB2A746BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:to="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:to="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:to="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:to="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:to="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_6FDBAC5450A40B4D0D249B5974AF7079" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:to="loc_biib_BioverativMember_6FDBAC5450A40B4D0D249B5974AF7079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_C43BF68A9F7189328DD19B597423D705" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_C43BF68A9F7189328DD19B597423D705" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:to="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:to="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:to="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_5CDF3438CA8EE6AC53ED9B1882B78AA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:to="loc_country_IT_5CDF3438CA8EE6AC53ED9B1882B78AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_44DC5CAB54C7A24D59E79BCC9B240443" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_44DC5CAB54C7A24D59E79BCC9B240443" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A8F17368FF3606D051309B1882ED2CA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A8F17368FF3606D051309B1882ED2CA5" xlink:to="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3DC359E98E0DACAF7F999B1882ED2285" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3DC359E98E0DACAF7F999B1882ED2285" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:to="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:to="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:to="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:to="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:to="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:to="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:to="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:to="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:to="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_C603DDD6881F0833A8293D727A5DB9C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_MarketStockUnitsMember_C603DDD6881F0833A8293D727A5DB9C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_08782B127527966D92D43D727A5DE020" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_08782B127527966D92D43D727A5DE020" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_770A29124E353586456E3D727A5DF176" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_770A29124E353586456E3D727A5DF176" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2D1F45B926EB51CDFBB83D727A5DDBA0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2D1F45B926EB51CDFBB83D727A5DDBA0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20170331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:to="lab_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:to="lab_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:to="lab_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:to="lab_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:to="lab_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="arc" />
    <link:label id="lab_country_IT_D07AF6CD45EF52D7BC079B1882E182C9_terseLabel_en-US" xlink:label="lab_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_D07AF6CD45EF52D7BC079B1882E182C9_label_en-US" xlink:label="lab_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:to="lab_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="lab_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:to="lab_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AIFA agreement reached</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:to="lab_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:to="lab_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50_label_en-US" xlink:label="lab_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:to="lab_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:to="lab_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="lab_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:to="lab_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:to="lab_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3_label_en-US" xlink:label="lab_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:to="lab_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:to="lab_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:to="lab_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:to="lab_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:to="lab_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:to="lab_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:to="lab_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:to="lab_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:to="lab_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:to="lab_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payment, including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:to="lab_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:to="lab_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:to="lab_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="lab_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="lab_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:to="lab_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:to="lab_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:to="lab_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6_label_en-US" xlink:label="lab_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:to="lab_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800_label_en-US" xlink:label="lab_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:to="lab_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:to="lab_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:to="lab_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:to="lab_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:to="lab_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:to="lab_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71_label_en-US" xlink:label="lab_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:to="lab_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:to="lab_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="lab_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:to="lab_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:to="lab_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:to="lab_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:to="lab_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:to="lab_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:to="lab_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1_label_en-US" xlink:label="lab_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:to="lab_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:to="lab_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:to="lab_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F_label_en-US" xlink:label="lab_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:to="lab_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1_label_en-US" xlink:label="lab_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:to="lab_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:to="lab_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:to="lab_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9_label_en-US" xlink:label="lab_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:to="lab_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:to="lab_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57_label_en-US" xlink:label="lab_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:to="lab_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="lab_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income loss before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:to="lab_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7_label_en-US" xlink:label="lab_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:to="lab_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the changes in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in condensed consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F_label_en-US" xlink:label="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:to="lab_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:type="arc" />
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost in support of collaboration agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost In Support Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development cost in support of the collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:to="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F_label_en-US" xlink:label="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F_documentation_en-US" xlink:label="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:to="lab_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:to="lab_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:to="lab_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28_label_en-US" xlink:label="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28_documentation_en-US" xlink:label="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:to="lab_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587_label_en-US" xlink:label="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:to="lab_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="lab_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to our hemophilia business</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:to="lab_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:to="lab_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:to="lab_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity minimum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6_verboseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share with Samsung Bioepis</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to technical development and technology transfer services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:to="lab_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:to="lab_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:to="lab_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities transferred to Bioverativ</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="arc" />
    <link:label id="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928_terseLabel_en-US" xlink:label="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia products</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928_label_en-US" xlink:label="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia Products [Member]</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928_documentation_en-US" xlink:label="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:to="lab_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Distributed to Bioverativ [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ transaction services agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3_label_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3_documentation_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:to="lab_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ manufacturing and supply agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8_label_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8_documentation_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:to="lab_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:to="lab_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:to="lab_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:to="lab_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:to="lab_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:to="lab_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:to="lab_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:to="lab_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="lab_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="arc" />
    <link:label id="lab_currency_EUR_0E75B11DE105BE52F8989B188382FFC4_verboseLabel_en-US" xlink:label="lab_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_0E75B11DE105BE52F8989B188382FFC4_label_en-US" xlink:label="lab_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:to="lab_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="arc" />
    <link:label id="lab_currency_GBP_BA639D23103DA86AB46C9B1883824B08_terseLabel_en-US" xlink:label="lab_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_BA639D23103DA86AB46C9B1883824B08_label_en-US" xlink:label="lab_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:to="lab_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="arc" />
    <link:label id="lab_currency_CAD_7342DD13AB2404E080199B188383B7A5_verboseLabel_en-US" xlink:label="lab_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_7342DD13AB2404E080199B188383B7A5_label_en-US" xlink:label="lab_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:to="lab_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="arc" />
    <link:label id="lab_currency_CHF_E19F1A045DA1A8B34A559B18838310E9_terseLabel_en-US" xlink:label="lab_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_E19F1A045DA1A8B34A559B18838310E9_label_en-US" xlink:label="lab_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:to="lab_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989_label_en-US" xlink:label="lab_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:to="lab_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:to="lab_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:to="lab_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:to="lab_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:to="lab_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:to="lab_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:to="lab_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:to="lab_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:to="lab_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:to="lab_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:to="lab_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1_label_en-US" xlink:label="lab_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:to="lab_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD_label_en-US" xlink:label="lab_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:to="lab_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619_label_en-US" xlink:label="lab_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:to="lab_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7_label_en-US" xlink:label="lab_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:to="lab_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivatives designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264_verboseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="lab_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:to="lab_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets transferred, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities transferred, net</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:to="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Plan To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Plan To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Plan To Date</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramPlanToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:to="lab_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="lab_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases under the 2015 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity increase during the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to retained earnings reflecting spin-off</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:to="lab_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:to="lab_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:to="lab_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities charged against equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI product</link:label>
    <link:label id="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31_label_en-US" xlink:label="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:to="lab_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:to="lab_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:to="lab_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC_label_en-US" xlink:label="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC_documentation_en-US" xlink:label="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:to="lab_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:to="lab_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:to="lab_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:to="lab_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA intellectual property charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:to="lab_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Spin Off</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:to="lab_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:to="lab_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20_terseLabel_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20_label_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Payment Timeline of Milestone [Domain]</link:label>
    <link:label id="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20_documentation_en-US" xlink:label="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Expected Payment Timeline of Milestone [Axis]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:to="lab_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="arc" />
    <link:label id="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954_terseLabel_en-US" xlink:label="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FY 2017</link:label>
    <link:label id="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954_label_en-US" xlink:label="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FY 2017 [Member]</link:label>
    <link:label id="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954_documentation_en-US" xlink:label="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FY 2017</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_FY2017Member" xlink:label="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:to="lab_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:to="lab_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="arc" />
    <link:label id="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:to="lab_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="arc" />
    <link:label id="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B_terseLabel_en-US" xlink:label="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B_label_en-US" xlink:label="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B_documentation_en-US" xlink:label="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:to="lab_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02_label_en-US" xlink:label="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02_documentation_en-US" xlink:label="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:to="lab_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:to="lab_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1_label_en-US" xlink:label="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:to="lab_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="arc" />
    <link:label id="lab_country_US_D11DDD9593166D89CEA6A5663946F1B5_terseLabel_en-US" xlink:label="lab_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_D11DDD9593166D89CEA6A5663946F1B5_label_en-US" xlink:label="lab_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:to="lab_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:to="lab_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:to="lab_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD_label_en-US" xlink:label="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD_documentation_en-US" xlink:label="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:to="lab_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments per the collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:to="lab_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:to="lab_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:to="lab_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:to="lab_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations and milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:to="lab_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued TECFIDERA litigation settlement and license charges</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B_label_en-US" xlink:label="lab_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:to="lab_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:to="lab_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B_label_en-US" xlink:label="lab_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:to="lab_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540_label_en-US" xlink:label="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:to="lab_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="arc" />
    <link:label id="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB_terseLabel_en-US" xlink:label="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB_label_en-US" xlink:label="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB_documentation_en-US" xlink:label="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:to="lab_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:to="lab_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:to="lab_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:to="lab_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:to="lab_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:to="lab_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="lab_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE_label_en-US" xlink:label="lab_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:to="lab_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:to="lab_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:to="lab_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:to="lab_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:to="lab_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:to="lab_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:to="lab_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2016</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of March 31, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:to="lab_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:to="lab_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:to="lab_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3_label_en-US" xlink:label="lab_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:to="lab_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:to="lab_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:to="lab_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Non Controlling Interests [Abstract]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">NCI, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:to="lab_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to NCI, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of net assets and liabilities acquired and assigned to NCI</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">NCI, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:to="lab_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:to="lab_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:to="lab_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20170331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:to="lab_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20170331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20170331.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170331.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:href="biib-20170331.xsd#LitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170331.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_64868A2E61C26A41B6C43D727ADCB744" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_64868A2E61C26A41B6C43D727ADCB744" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F56C354ED644D68D98A73D727ADCA763" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6292DCC90547DCD391B53D727A6C469F" xlink:to="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_56ACF259F05B53E111BC3D727A6C953C" xlink:to="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_ED4C282560F359231FB33D727A6C8CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_2DF9C1F4D6CF24EEB90C3D727A6CC9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_624B0173BA09339739EB3D727A6C20E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_38FE87C74E0DE2051DA93D727A6CDE6F" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5D66B04F1A3AB5249F3D3D727A6C3A46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5BAEEDA5B718526C79E33D727A6C9D57" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B068D75CD3FCDE0C467D3D727A6D9780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_DF12EF99D1B1A246AE9D3D727A6D908C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_6D91BCCE3686628F1E5C3D727A6DEE9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C44D895D415756656ED93D727A6DEF4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5FB1B9F9E96CC6888AA33D727A6CBDE0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C247FC1368179E9156F93D727A6D9B7B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_F0F99DBAF01B834669959B188328AF17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_F0F99DBAF01B834669959B188328AF17" xlink:to="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2AF77F2917554415E1C79B1883288637" xlink:to="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_42532346278C4205DE729B1883286AAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_42532346278C4205DE729B1883286AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_31103274C26B074777229B18832824D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_AC6257D4679A82CA837E9B1883285924" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_31103274C26B074777229B18832824D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_0A9100C3C02BB51489FF9B188329981F" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_85327093D15B3EC593A89B1883297105" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_7400E4080559E1E370ED9B188329CF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E8004C4B30079F5654E09B188328B1DA" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B280226AA1CC10634BD69B18832964B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0A16EF0D3D830BD416849B188329DA37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0A16EF0D3D830BD416849B188329DA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_F8B1B6B2C41B1FDC6D6C9B188329D634" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_F8B1B6B2C41B1FDC6D6C9B188329D634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_OperatingExpenses_BD26337BF7764F4E6A4F9B1883291AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EE6D79BCC732753B57A19B188329045D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_EB9838369A14974DC6C79B188329C895" xlink:to="loc_us-gaap_NetIncomeLoss_EE6D79BCC732753B57A19B188329045D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_15BEAAB2D2D12B9032FC3D7279C1B929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_15BEAAB2D2D12B9032FC3D7279C1B929" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_390FF484CD37656E46D43D7279C14003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_15BEAAB2D2D12B9032FC3D7279C1B929" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_67F540F65D209F8601F23D7279C2E654" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33D39368A70EFC01CC273D7279B2D347" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33D39368A70EFC01CC273D7279B2D347" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_317A1BA4F2C782B41D043D7279B2C9F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1615B5C21701D4FE2097A566393F8FD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1615B5C21701D4FE2097A566393F8FD9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneAxis" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ExpectedPaymentTimelineofMilestoneDomain" xlink:label="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneAxis_AD57E5C5AE19E01E6FC3A5663944B1A6" xlink:to="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FY2017Member" xlink:label="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ExpectedPaymentTimelineofMilestoneDomain_A42C82A1AFE58E5C84C2A56639459E20" xlink:to="loc_biib_FY2017Member_DB2C89AC0A484C29D1FFA57BB92E8954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_494F99D473642AEF1461A56639459653" xlink:to="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7CFB12934A55351D277FA5663945A71C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:to="loc_us-gaap_MinimumMember_7CFB12934A55351D277FA5663945A71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5D31032ABF03E73F930FA5663945A045" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_008D43676297F111CEF7A56639453670" xlink:to="loc_us-gaap_MaximumMember_5D31032ABF03E73F930FA5663945A045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_746ADB592121FDB78FC9A56639458378" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_0D2095F9937B813EAA3DA56639454043" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9CF578A9718922D9D187A56639457EC4" xlink:to="loc_biib_InLicensedPatentsMember_0D2095F9937B813EAA3DA56639454043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8F0424A9DD4CA0F8DE5EA56639458552" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_BristolMyersSquibbMember_202B0D3D6EE90B5F73C5A5663945A1E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_IPerianMember_AC1A13C01FD24D8DF698A56639455B5B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_AbbVieMember_62C78F747DFA7DACE94BA56639455C02" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B682887FC8C85CC83590A566394541EB" xlink:to="loc_biib_IonisPharmaceuticalsMember_50AA1FBDDBCC99461953A5663945CC5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_2549AEED6F5C33F3955AA56639464951" xlink:to="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_21FF4A80DFBEC70EABF7A5663946E98D" xlink:to="loc_biib_SPINRAZAMember_30C4F6C68BCA7A449EC8A566394631B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_B80B17F59D61DE049BC7A5663946B361" xlink:to="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:to="loc_country_US_D11DDD9593166D89CEA6A5663946F1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_AB8B155AA2C477CCE5CAA5663946EA1D" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_53265D86F958CCCD9E1DA56639464F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A2EF14073D44D1FF93FDA5663944C5F9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6FC7F1442AE59B1EE6DEA5663946EDE0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_AdditionalMilestonePayment_AB19910447FF4D72FC48A56639466352" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_DEA0E9AA1E2D99FD1294A56639479508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_ABEDBE11790115025750A5663947D188" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_OtherSalesRevenueNet_ABEDBE11790115025750A5663947D188" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_LicenseFee_12F711CFDB5A63BF25E6A5663947DCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_962F1569307D41E0AF73A566394723B3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_962F1569307D41E0AF73A566394723B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_E62864512FF6330C7A5AA56639473867" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_E62864512FF6330C7A5AA56639473867" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_04A8BC15B485DFBE9734A5663946CB78" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_4B4EDF69C5A7D26CB7B9A5663946F5D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_445D8D5EC621782FDC7D9B1882BE72D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_445D8D5EC621782FDC7D9B1882BE72D6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3134ECF77A30DA8C5C329B1882BFF8B4" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_874F374DB8A9D53C4C8C9B1882BFA887" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2C7C9B6DAF03A378FA549B1882C0587F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_AB9E63A358E8D79CDB4D9B1882BE21CC" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ED0987DD19AD5AC856209B1882C04031" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_CB83B544072DF02263B19B1882C08AB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_161231393CD5E0F0940C9B1882C1D82F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_74B8AD50C3FE510A77B19B1882C15711" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_biib_Collaborationprofitlosssharing_74B8AD50C3FE510A77B19B1882C15711" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_49CAB246D7BA775931959B1882C0D821" xlink:to="loc_us-gaap_OtherSalesRevenueNet_13BA3812AFAE961BA79D9B1882C18F2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:to="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12014B18A5F330586038246C87D1D4C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B43DD790E6C9EE840CE5246C87D1F1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_65C86217D9F3CD6F7EE0246C87D15FC8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_C2195A2DE6918B053919246C87D1F40A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_InventoryNet_7146981ADB9ED68F5989246C87D12E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_OtherAssetsCurrent_39F2C2D3133417D570FA246C87D10141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_831E12D9B97B5EE3E2A1246C87D15DDA" xlink:to="loc_us-gaap_AssetsCurrent_854D8638709580102DCB246C87D1566E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_4AF582E1D1BE54A3E789246C87D19D4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_76D92ACC5F30EFB4C488246C87D19BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_89615B9D23C47FEBCEC8246C87D16584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_Goodwill_4C312300474AAE5E9983246C87D127A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_B5439F5096F57EA794D5246C87D1AF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E262C33271386918C116246C87D1B916" xlink:to="loc_us-gaap_Assets_F387BB8BFA23258C7BE7246C87D13800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_AC6D977CFBA4BD4EBA78246C87D12389" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="loc_us-gaap_DebtCurrent_DB378D615B1DFE2C5433246C87D15BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="loc_us-gaap_TaxesPayableCurrent_5B82514779EE93555C13246C87D13732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="loc_us-gaap_AccountsPayableCurrent_6EF5F16167C5482315A4246C87D1F1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_D24FAF9ECB86A494C114246C87D18173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0B6547D3D0E782A3B971246C87D19762" xlink:to="loc_us-gaap_LiabilitiesCurrent_8189DF7D11928174D691246C87D1C10F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_LongTermDebt_C60C8149B4AE6D188E22246C87D195C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_089BABB834C99E3A54C3246C87D16442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_61A02238612A38E58C53246C87D16027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_Liabilities_00CDE28B43D50508BFB2246C87D1BD71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_CommitmentsAndContingencies_BFB1CCCEE85728013773246C87D14606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_PreferredStockValue_8AA239AF7EC6944B4E51246C87D143BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_CommonStockValue_139068339E86B1A48774246C87D1C01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_AdditionalPaidInCapital_D9CF1BF1A1654A4ADA7B246C87D119B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90D6CE078E734003A5E5246C87D16D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380146C92DA56D7A4579246C87D1F992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_TreasuryStockValue_5D54477116B93D6964FB246C87D15150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5140F100B1518C496C66246C87D19B7C" xlink:to="loc_us-gaap_StockholdersEquity_949F628CBBEA8B8A757B246C87D1D821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:to="loc_us-gaap_MinorityInterest_6D6AA422C8F4EC950B66246C87D18D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_A17FBCBFF909ED94F9FF246C87D1A37E" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6DCDB7F9187B869B6F3B246C87D1F680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_BD3729168CB19BD2CB70246C87D1A611" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_047F0858E22B9F5714C8246C87D14BC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17C36D3EF6AA9F3D0DA03D7279CCFAD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17C36D3EF6AA9F3D0DA03D7279CCFAD0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6FCAE36384E77B7065F83D7279CD8D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17C36D3EF6AA9F3D0DA03D7279CCFAD0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_C72AB511F3C9003B9F763D7279CD66D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:to="loc_us-gaap_ProfitLoss_E2A1DB15FD845CC83DD5A69CB4C555E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4E10EECF5C396D275F51A69CB4C54AD8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ABDD632DA4F3F5F55DEFA69CB4C5244A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_ShareBasedCompensation_FC8745C96C051D2F2516A69CB4C552F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_F3F062C37D8E113B5592A69CB4C54941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3D2F992D5310CE6F8B68A69CB4C529F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_EF3BB90FC05719BADF9FA69CB4C5F084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_09C681036EDE2C24AB1AA69CB4C5BA50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CA658B78700E8936E9EFA69CB4C5FF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_87065EECB739C74EC13DA69CB4C56234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_58A037876A7BA05A3D05A69CB4C57F50" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5E30B97363622D2C8D33A69CB4C572EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_A02BB8FC105FB8FE0D44A69CB4C5B83F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4BD5FBFA5F257E02CA83A69CB4C51BE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2A30776CDC00781A27A4A69CB4C61CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_C8B3E5D36D498FE5F998A69CB4C6B29D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_6C41C94E56BB9791422DA69CB4C69BA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2B18389CDD12BAD0183AA69CB4C6C46C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_99742B0B99E24EFD4F68A69CB4C62FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9C321E7CC9CE1FEBEF9BA69CB4C637CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1E3C2B9C6684A5189C88A69CB4C62EA4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_FFDC16BF5A51250B92A8A69CB4C6AFDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_50AA396A3DD341AD26CFA69CB4C6C304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4E0427ECF566062AF991A69CB4C68A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_2D8208492750650C35C2A69CB4C62F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_30E38B83E0BDCFBFA883A69CB4C608E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_036CA5CD859950DD9F75A69CB4C62CC5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1F1B4781F99725A2A1E7A69CB4C68139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_BE3A1EF1BC69F3BEE4F9A69CB4C7714B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D91C4FA4018BD888B10CA69CB4C70A5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7EAE2221C7BD49B180CCA69CB4C7118E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_080BCDA7587E87C01E66A69CB4C59259" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8BA9CDCB87E069CDDA9FA69CB4C71C81" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1366831F0FC44014BF3087D7CF117348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:to="loc_us-gaap_NetIncomeLoss_1366831F0FC44014BF3087D7CF117348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8D3289B2769F5314B28587D7CF110B04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_04429481C4D321435A8287D7CF11577B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_F12B30F27337A06DD66687D7CF11D977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7C39C8EFA3D88D99746587D7CF118F99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6D3C403CE4A70E722B3387D7CF116985" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4B19CCFEE52CF7BD05D187D7CF11642B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_78C50FA6488389245B9587D7CF1100AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8ECF9FA33DE28CF76B8B87D7CF112D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_FEBA66831B8EF2A4713F87D7CF11BF44" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2FAAEE156311A35F6BE387D7CF11A25E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_47565544CF1F04B1037B9B110B6D31CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_47565544CF1F04B1037B9B110B6D31CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_54DD037A3FC8DDCE20D29B110B6F963D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:to="loc_us-gaap_OtherSalesRevenueNet_6120E717C6A2696F225F9B110B6FC1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_976C2835F36904E936BC9B110B6CC374" xlink:to="loc_us-gaap_Revenues_510DC3B5D8459982F3699B110B6F95D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_CostOfGoodsSold_5997EACEFAE9B39B40D19B110B6FA0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0FDFDAD5708A24B049949B110B6F3963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_C49CC352D462E45B93369B110B6F2291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8BA126A5194E04B1A3729B110B709F7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_biib_Collaborationprofitlosssharing_1703C2057D9265A3ED1C9B110B707F3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_289F9A551DF8160964DE9B110B7027DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_RestructuringCharges_B54058A0917B9D6E79F29B110B701D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3D9B9305C8B385E42F209B110B6FABC5" xlink:to="loc_us-gaap_CostsAndExpenses_0D4A8BE73965EBDD350C9B110B706E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_OperatingIncomeLoss_B7336B3526FEC59F0C369B110B76DBA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_C744F85EA6910896B5349B110B763A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_B3FF8E1A432DC1E340749B110B7611F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_44971F939396680847B79B110B763CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_CA6F34A8B607DE5E7CCF9B110B76F53E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_ProfitLoss_7A7CAF3F03F6DF67A9F79B110B761CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5981FB412540F874ECE29B110B760F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_NetIncomeLoss_BB4699CF08C414692C3C9B110B766FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:to="loc_us-gaap_EarningsPerShareBasic_897E97F4C27ABAD4D0619B110B766D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB9126D801B69814710C9B110B768490" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3381594272DF1664A2269B110B772389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_704F93E5B62C9725946B9B110B6C6B78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_05C81D341AC38A8D84079B110B776A9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1EF2ACB011ED9BE67FCE9B110B776555" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_844046FC3B102AC3C4C39B110B7775A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1336D9423FF17825DA133D727971AAB4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_CC2E26884A5F00F50BBD3D727971F126" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6EC7B1E6A009260897E29B18837D0E25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6EC7B1E6A009260897E29B18837D0E25" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A9B32C791B02159886969B188382913E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E40B2EE48389DB5EC88E9B18838290E1" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_FE82069FB60FD91F34C19B188382BAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_80D6E5F09B758FB7BE819B188382F004" xlink:to="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_EUR_0E75B11DE105BE52F8989B188382FFC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_GBP_BA639D23103DA86AB46C9B1883824B08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_CAD_7342DD13AB2404E080199B188383B7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_F01C90F181B0D38083D89B188382E53C" xlink:to="loc_currency_CHF_E19F1A045DA1A8B34A559B18838310E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_773D744F943410BFCB069B188383A9D5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_SalesMember_76B0B9B79D1D3A69D13F9B188383C989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_OperatingExpenseMember_530BAFDC1AE7F5B57E4D9B1883835A81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1F4E049510C3358879F79B188383D843" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1A2E897BC5BE641C905B9B188383B44E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AE35A0D7AD40754468E39B1883841FD7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:to="loc_biib_CashflowsrevenueMember_ECC600C9A40C0EB69CCD9B188384E5B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_A46E99E245636A36706D9B18838405F0" xlink:to="loc_biib_CashflowsoperatingexpensesMember_EE4124F1AC4DEF80934C9B188384EC5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0FD0077F272C8ACB53819B1883843150" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_AAAED233BF012BE5E5A69B188384FEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4C75D944161130D71AD99B188384EF3E" xlink:to="loc_us-gaap_InterestRateSwapMember_F94B52E49EA17257E8E09B1883844C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_95DF33C165C8298CCEAA9B1883841B54" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_493213021770DD5740B29B188385245E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherInvestmentsMember_2AE4D5D70E1DCD4838559B18838573BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9510BD25511BAED878859B188385381E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_C56B0B91F1C05AA2C30B9B1883856AF9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_91B3FFBF98D2D72CC31A9B188385DD9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_623E5370047AAF9FEDC39B18838588C9" xlink:to="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_374D86A2B09CB51C285A9B1883855CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_F73E1FB7B367A87634D49B1883853535" xlink:to="loc_us-gaap_NondesignatedMember_B6FD835CF7B110E5D9B89B188385034A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8F5733C40C75F020D46E9B18838509E1" xlink:to="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:to="loc_us-gaap_MinimumMember_4DF3E9EB1C646EFB3FB49B18838A6619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_2D84D463C79AF548FA319B18838533DD" xlink:to="loc_us-gaap_MaximumMember_397E42BF15A46BB019769B18838A29B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_AEA6FC790BB72E7F36C89B18837D12AE" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_9073BFCF1C8D1485C5E09B18838B406D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_4470DF9E84604B3A0CA69B18838A3F39" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_7BB97B760774CE42C99D9B18838B9D34" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_DAA12ED2AC84908460A19B18838A5968" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_71369242EE6979B861309B18838BFE5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_invest_DerivativeNotionalAmount_9C1606B13791224FEB629B18838B673D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_DD06113BF0B03FEA175C9B18838B248B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E596A2E066D91D6D9889B18838C975F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_B2CD937827386C012CB39B18838CB9E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_53840A4CD98245EB28329B18838CE43C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_70987F6BC610C0F5497D9B18838B8264" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_D88B3B5995AB8822A0CD9B18838C7F20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_665BFCA2D4A2AB4DA7173D727A215D85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_665BFCA2D4A2AB4DA7173D727A215D85" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_9F7E602EFBA15ADCB65E3D727A22B8EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_665BFCA2D4A2AB4DA7173D727A215D85" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_A3D8B34BA582D7E044EC3D727A226D42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_665BFCA2D4A2AB4DA7173D727A215D85" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_62D137F048F0A871EC153D727A220F12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20170331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_EntityRegistrantName_D84D2CB0E84B17FCA9473D727A8978E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_EntityCentralIndexKey_F72CFA6BF4DDF8D08E263D727A899FE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_CurrentFiscalYearEndDate_2721BB65C2FF20E2099B3D727A89803D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_EntityFilerCategory_48E268571B7C1CFA5F7C3D727A893C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:type="locator" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_DocumentType_2DC7C9D3622C4AD03E2E3D727A89E3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:type="locator" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_DocumentPeriodEndDate_7948DE57BE53AE26141B3D727A8A9891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:type="locator" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_DocumentFiscalYearFocus_79363839C29246D52C6D3D727A8A71AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:type="locator" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A5A70A3884A31C2D1CCF3D727A8AB770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:type="locator" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_AmendmentFlag_0F84AB047406C2B7B55E3D727A8ACBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:type="locator" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_235648E65886E37FA0D93D727A894CE4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_C59318629D29A8D6CE6F3D727A8A1129" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6E29438340658DE066BB3D727AA7F013" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_D2423F049751611429393D727AA79CCE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8DE48837D9BB73FEA0743D727A086535" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8DE48837D9BB73FEA0743D727A086535" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01C2796DDFE1E3394FC43D727A099110" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_AD7C431B068066E2653B3D727A09885B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_91579AD76A4BA6DEE3AA3D727A09CD18" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_C5411ECD8F1A068B17113D727A0950B6" xlink:to="loc_biib_MarketStockUnitsMember_5BB567066B04FF1FFC563D727A094643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D24D986BFB398AEAD6D3D727A094896" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_079896C44FD79103CCBC3D727A096660" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:to="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_891AD8EA578E289C9FA13D727A09B286" xlink:to="loc_us-gaap_NetIncomeLoss_DEFDA799D41D6C96C4713D727A0A74FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_D726FC3285EB236DF55C3D727A093B79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_FC81A2017623DCEB81FA3D727A0A0442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_C876AE09C3388087DA1B3D727A0A5F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_726C140F53F9B37998673D727A0A61DF" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_116266AF6B38086987EF3D727A0A6B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_B2F2602D88E2036A6AB73D727A0A0776" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9DB51A494F7AC66441143D727A0A0CDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1B8FBCCEE73C850BDDEC3D727AA86385" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1B8FBCCEE73C850BDDEC3D727AA86385" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_097403800A8B457DDA163D727AA8BB49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EDFAFD86A4829E69CB133D727ADB3248" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_41F48E08EF5D432E6A633D727ADBAE09" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4472D363EC46A1BC4525878E5ADB8EBA" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4472D363EC46A1BC4525878E5ADB8EBA" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:to="loc_us-gaap_MinorityInterest_ACAF05292EF65B3087BD878E5ADB9D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_DC72E7B1EC198BAEA55F878E5AE07551" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_C7F334A8AF4963FD8CAE878E5AE083B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_0DF7265F94035310891F878E5ADBB9D9" xlink:to="loc_us-gaap_MinorityInterest_CE1341558B3FEFAAD7E0878E5AE03166" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_10BF26A31A5B4DFC1DBFA5663A3984B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10BF26A31A5B4DFC1DBFA5663A3984B9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_A9930F7E46D4B8A3C36FA5663A39DFAA" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_DD7CB05BC5AC589F6814A5663A39BD61" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2016ShareRepurchaseProgramPlanToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2016ShareRepurchaseProgramPlanToDateMember_BC60DCF054184CF420AEA5663A393527" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_90C3CD5F9D10F9A17AF3A5663A39F3DC" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_E474E26AA5087DC62ECBA5663A3AE64B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_505DD341827BB156C126A5663A392975" xlink:to="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_6D904EB53537A9BEB4D0A5663A3A4FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_6AB2C9ED098A4F3501AFA5663A3AF9B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_ACE0307234A22CAB3258A5663A3AAA7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_441657B7C52667D1E1E2A5663A3A2925" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A588D1902157E40DE181A5663A3A229D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10BF26A31A5B4DFC1DBFA5663A3984B9" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_08AE1A75A19A729C730EA5663A3AEC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10BF26A31A5B4DFC1DBFA5663A3984B9" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_9D7778194A8FEEB9C082A5663A3A6521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10BF26A31A5B4DFC1DBFA5663A3984B9" xlink:to="loc_us-gaap_NetIncomeLoss_0CD2ED6E671612A535E1A5663A3A79F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_189E77776667186ABEC63D727A8B0368" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_189E77776667186ABEC63D727A8B0368" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_C608C9B270E89C95127D3D727A8BB33B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A822D1CFDE1171BC0E733D727A2A5A42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A822D1CFDE1171BC0E733D727A2A5A42" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5C15A2448409DC1399273D727A2ABDD2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E0E58446CF89EA9C4A3A3D727969344D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E0E58446CF89EA9C4A3A3D727969344D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3C853B2A4A50D1634D163D72796A4B12" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B316A694FEFDC9C5F8773D72796A5EFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_10B58ED8FE4339C2936C3D72796A29B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6778100A80DDE8CB62D63D72796AE822" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_C4470E82271A29F09D723D72796AB294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_C7EC456A904E7D27E88A3D72796A4093" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2EB16E125E6B6A8DD3173D72796A12CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1D90FD3DE6668EDDE3CC3D72796A8C82" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2EB16E125E6B6A8DD3173D72796A12CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_302B8C849B4BE8D4AAF53D72796A0901" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_CFC2B52662E6B5A3D96A3D72796B9534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_CF6754D31598E8450C3A3D72796BFDAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_E8050E21F896FFEA7DBC3D72796BFF45" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8BF3D449D072C7BD9CAE3D72796BC29A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A6E1AEE185DA797C1BB3D7279695AE7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA507E448AA5D4E20E1B3D72796B0EDA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_BC20C8D1B3F94ADAC2F93D72796B6F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2A5A7E692FFC66BD9A8F3D72796BEEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4E56F548521C8769AF383D72796BFC37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5A9DB62C720667C7FD813D72796BD970" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_99793B9DBE0C047A001C3D72796BDA0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_08D3F02383F91A5C6F233D72796B8164" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9DD5468225D57A49B0B53D72796B10F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_030F75954146A41521063D72796BAA5E" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_BACEA700F21B1EA699453D72796BC5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_311020905868A7AC71663D72796CEC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_111A0995CFCF1574089C3D72796B7AC8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_94D02B0B175D1ACFE5D23D72796CCE01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33262859CE34938CAA753D727AA51B47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33262859CE34938CAA753D727AA51B47" xlink:to="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:to="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_DD2626DBCEF3734B53693D727AA59449" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_NotesPayableToFumedicaMember_5EB3E20F6F4A1FB0633A3D727AA5429A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_E81601244A11E57668143D727AA5D31D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3692C322FD9D558D8B73D727AA59ADE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3692C322FD9D558D8B73D727AA59ADE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_AAC868996C3845CDB63D3D727AA690C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_AAC868996C3845CDB63D3D727AA690C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D1A71F667A7B30DF90593D727AA63DB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_D1A71F667A7B30DF90593D727AA63DB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CDF7053D5D0B8491C2473D727AA65CEF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_438C6F855433A2D4B9AF3D727AA55C15" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CDF7053D5D0B8491C2473D727AA65CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_50A374B5A95C38F88D983D727AA5F4AA" xlink:to="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_9F759A943026A519369C3D727AA6E240" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_NotesPayable_4AA90E666088A5DB4D6F3D727AA6F7EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AF0CC2F66167468047D53D727AA6ABDC" xlink:to="loc_us-gaap_DebtInstrumentFairValue_91E3CDC73A82BA45DE013D727AA653A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_182A777C536EF3E979223D72795DB097" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_182A777C536EF3E979223D72795DB097" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96935609C6BADCB843DC3D72795EDB9A" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_006AC08497EE67289BEF3D72795E6FBB" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B087C264B17D79FB3B703D72795EC386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_48AD4E10EF0EF40AE3593D72795D7CEB" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_BFBF191D0607DE8EB1653D72795EDA05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_5F0756C9F402049F31913D72795ED148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_57D189A66562ADC23A883D72795EDE54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_2B599E0E01FFEA289EA63D72795E5BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3FD36C9E9B2510D9BA603D72795EF454" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5ED642927E9DDF88D8D93D72795EEB06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_82913286F38EAB21F4393D7279A8FAD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_82913286F38EAB21F4393D7279A8FAD1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:to="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_E26B328FFF222E449AFC3D7279A832A1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_C924EA3D3EA9D9E58F803D7279A874A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9CC68086C04EB35E1B343D7279A88147" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_9CC68086C04EB35E1B343D7279A88147" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_A3257C4F511CEAB81B713D7279A824F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_E28F21D7D071DCB7676B3D7279A83B5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0BD5F116A0E9716137B23D7279A8068C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_750B5DFD5D29CABDF1893D7279A9BE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3450480AD9243ACCC76D3D7279A8BFFA" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_AssetImpairmentCharges_879E10DEE599A75C1C073D7279A9437D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_3631041D42437D3B3C993D7279A96DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC65DBB1952F1549AA953D7279A98F1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC65DBB1952F1549AA953D7279A98F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_6014A0DD6105464328BC3D7279A94865" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8198790EA5597CDFA91D3D7279A9D288" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_94A6AC782FAD723A340B3D727960BD6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_5DBBF68DD4EEFC23CF343D727960398D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9AC50F1857DC11DBCFC33D72796035EA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_C7FC43E00B68470184053D727960EB91" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7FDC0DE1B65E328B30663D727A6409C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7FDC0DE1B65E328B30663D727A6409C7" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_D257F88A4DB5094CCF483D727A657244" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E7F4100E6F620790B27E879BB4A0FCCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E7F4100E6F620790B27E879BB4A0FCCF" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:to="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9795A44E3EEE3F07AC0E879BB4A03A29" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_CommercialPaperMember_CD6B6BE88D121334658D879BB4A0CB03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_MoneyMarketFundsMember_BC6E4B619AC5E7B9FF5F879BB4A089FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_BD0577E66DB624AA7FC8879BB4A04545" xlink:to="loc_us-gaap_DebtSecuritiesMember_0E3A7C934711FAC44B66879BB4A01129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_13E5089716998A4BB6B5879BB4A006DF" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_76B74E23C0CA1658F54B879BB4A0B82D" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_C47881F23F11682A2D64879BB4A09A1F" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_B420C902C0397AC176A2879BB4A092D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A43B5A88876DB5AB5EE83D727A318EFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A43B5A88876DB5AB5EE83D727A318EFC" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_219A10B3E03D437200B13D727A31DA8A" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_7106D7FBFAF732D0E6E43D727A31661C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_7099BE8D2929DC74C4723D727A318550" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_579A72B8504D87EA80403D727A31F94D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_F48AD2E90FD2DB996E383D727A319226" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_6AEC255BBB4D4E1B066B3D727A3220C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_4117838EB96826D88BD03D727A32E085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_4F8D8D7FD000DF7D3A8A3D727A3169B3" xlink:to="loc_us-gaap_EquitySecuritiesMember_F223DCF90C9C8C455F503D727A327D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_41CAC58460B54D9AC50C3D727A312E78" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1680F2A4F3EE3E69E1003D727A32128D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecurities_0A2C61017F8838C975073D727A325EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1695269BA5B4F905AD903D727A32C47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_887AB72A0D387C5159633D727A324867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_19E08654D90B927D15353D727A32DCE4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3C4F6C3CF1B2A987CAE23D727A32F972" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_037EB9DDEDDBAB7B4F543D727A61DB58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_037EB9DDEDDBAB7B4F543D727A61DB58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_875F2D3FA07ED23CC8CA3D727A622025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_80F3F303FDC80824496D3D727A62F955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A9B26F72ED333CD090443D727A6247B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_89C802E0AF53172A5FD43D727A62448F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_89D45DBBD610C41021CB3D727A629864" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F7C5D2979255A68A85943D727A62AB8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleSecurities_07E54AD552E6E1005E043D727A623CAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_E76EEBA84461EBD8C2F63D727A6166F5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_436C88DD98246E36624C3D727A627A88" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D0D6A8B3D2DAA9ADE29D3D727A67F424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_477310C019E33A5115593D727A6794C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D2101FE8851C252D794F3D727A67F7A8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_76FC7B76E8EE8087BD843D727A673A5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_650B0FFBDE51A09BBDD0879BAD10D784" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_650B0FFBDE51A09BBDD0879BAD10D784" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_371D3D522232B5882BB2879BAD107D11" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D85A52C3704C9B885E93D727ADF3B9D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_5A2EF9D6994EA2C954DC3D727ADFAF7C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_A1FFCE480C120E886F953D727ADFB147" xlink:to="loc_biib_StrategicInvestmentsMember_D985D809BDB089A064513D727ADF875F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1507FE868B5285D3A9553D727ADF187F" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_55DC9D200601C95FDE4B3D727AE055CF" xlink:to="loc_biib_StrategicInvestmentPortfolio_46DF9BB88C152F6CB5483D727AE05C5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C18E12BFD4C13355088A3D727A1C255B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C18E12BFD4C13355088A3D727A1C255B" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_83DAA5F0C7C4FD0EAC133D727A1CAB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C18E12BFD4C13355088A3D727A1C255B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_637FE61346637BA6570D3D727A1CF9C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C18E12BFD4C13355088A3D727A1C255B" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_9DFBC1C6AFE4FB58052E3D727A1C9453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C18E12BFD4C13355088A3D727A1C255B" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_39F4C038B54D4668B2293D727A1D580A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_A1609C10F4FDB691D1749B22F8262118" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_A1609C10F4FDB691D1749B22F8262118" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6757784674E56095B4929B22F834BF9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4E8FBAEE2DA50F3714C6A565D7CDF56F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_4E8FBAEE2DA50F3714C6A565D7CDF56F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_FEE102A234A690740074A565D7CF02B3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_6EF0F3BF39F97ED2B991A565D7D577DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_828C55A6B773E3E2BE54A565D7D4BE7F" xlink:to="loc_biib_BioverativMember_6EF0F3BF39F97ED2B991A565D7D577DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_88F6A151B62FAF922C2DA565D7CFE06F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E912E981308A82BB0ECAA565D7D823A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E912E981308A82BB0ECAA565D7D823A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_C6FAB0497699CE083D51A565D7D8EFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_36D44F9F6FE37BE48DBBA565D7D8F8DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_F0F156BEFC519D989E03A565D7D8495F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_F6CA93345EAD428CFBD6A565D7D83E86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_8B969D97F19B690FB0BCA565D7D86EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49D36A482A7991B54C4DA565D7D836A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_F7F93BFFAAEF398B2112A565D7D8D71D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_C9BED59EF17D6ADDC2E9A565D7D846E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_A59BEA4BC501A3B99360A565D7D950D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_F59D0772729DDC892EC6A565D7D86197" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_52E46DFB362A20C6A1EAA565D7D9F5DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_C6667901AC187C77DE0EA69CB486E0DE" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4596003FFB49986AA97FA69CB4872FDE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_845ACD7761022F587F93A69CB48C2ED1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74E4A4339F4A779CAB50A69CB48C3FB9" xlink:to="loc_biib_BioverativMember_845ACD7761022F587F93A69CB48C2ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_081D6C629D70425B1B07A69CB48C7198" xlink:to="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_E1B897E3E274AA49C1D3A69CB48C1339" xlink:to="loc_biib_HemophiliaProductsMember_6E83914A3B4EA11C60BFA69CB48C3928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_9F054666AC1BF7AC1C52A69CB487BC89" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_04BCD60621285B66E118A69CB48C65F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_1AB5B88397262813169BA69CB48C30E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_F8D9925833F6DF7E11DFA69CB48CAF5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_611C7A606C4FD0BB790EA69CB48D7142" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_OtherSalesRevenueNet_611C7A606C4FD0BB790EA69CB48D7142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_CostOfGoodsSold_8178B811215E9B9A439DA69CB48DBA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_A478E4EDC562C1B4F739A69CB48D431A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_D9B0C459022E89C156F8A69CB48CADBA" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_A478E4EDC562C1B4F739A69CB48D431A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2106DCD2BFB993BBD8C7A565D684A9BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2106DCD2BFB993BBD8C7A565D684A9BE" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_79557709DA3A7ABBD469A565D6840920" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A3684A83401C9BE5B1593D7279F76122" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A3684A83401C9BE5B1593D7279F76122" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_653B0D64F4C55A197E8F3D7279F76312" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CE9749EA99FAC93D97FB3D727A416D7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CE9749EA99FAC93D97FB3D727A416D7D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_FC6197BF9C94A82E2B853D727A41EC36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15BE9B0934AD49D694473D727A41A08A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_C75EF64491BCE74D64333D727A413874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_C69C947FBD7BA3F74CA63D727A4237D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_17084F44A49C058231C43D727A42BFEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_5506B8579A700F34DE1F3D727A42B007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_E6AAE2414BB56FD428C53D727A424D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_A2A91F3510EAD70BE0863D727A42EEEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_DB93F8B1E02A5ED792D83D727A411A98" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_BBE276F010CCBF67E8733D727A429F67" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_82AA692DA90F8B79FD249B1882F8301B" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F5A353EB37F5CE62EEC59B1882F8309E" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7E4B991D23D7B3C59A839B1882F86BE9" xlink:to="loc_us-gaap_ForeignCountryMember_F59C4E2758BCFE3EE6EC9B1882F8FA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6F510B2A45DE442326CB9B1882F8A87B" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_34637A51BEC4927619E69B1882F84FE1" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8A2B4CDBA51B748840FC9B1882F8C124" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ECD7B4AD5CC8A65DDE43D727AC5C14A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ECD7B4AD5CC8A65DDE43D727AC5C14A" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_9422A7A694A56A27BDEA3D727AC5E8B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94272B0C4BABFEFD6A3C3D7279739FC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_94272B0C4BABFEFD6A3C3D7279739FC7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_AD1D7A93E0EED454AA5F3D727973C4BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3511A2A19C8D79CE5D62A5ABB2A5EEC3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_A5CE1D940D2CEB140A4AA5ABB2A5D4D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2A5DB8D588D7F9AED65DA5ABB2A55707" xlink:to="loc_biib_BioverativMember_A5CE1D940D2CEB140A4AA5ABB2A5D4D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4647E5A6BEC28FED40D7A5ABB2A5A307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6282E32E7445BDAF12E5A5ABB2A5242A" xlink:to="loc_biib_TysabriProductMember_6C6C2D688ACD98EE6EA5A5ABB2A53D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_385D4A8B1083CC14573AA5ABB2A56F3A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1072C3DD27400E1EE49EA5ABB2A6ECF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_B4DC8FF480267AC64390A5ABB2A51471" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_410E75638C0D5AEEA330A5ABB2A628C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3007C95F81BF30C50DC3A5ABB2A6CF0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_biib_OutLicensedPatentsMember_8592BA912009F876A786A5ABB2A60192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AE6CA3CD2C4FF7000274A5ABB2A62101" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4E7195935275053B352CA5ABB2A6DFBB" xlink:to="loc_biib_InLicensedPatentsMember_ECA8CE7FA192F298C288A5ABB2A64C51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_3DEADE67FA4DAC2EF368A5ABB2A6F79E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:to="loc_biib_AVONEXMember_A13788996005A3001A9DA5ABB2A652AC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_2186F60C2311EB73C9DAA5ABB2A695A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_FA4EEDF78AE9865C7927A5ABB2A6653C" xlink:to="loc_biib_TecfideraMember_2186F60C2311EB73C9DAA5ABB2A695A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F3DA81588C65674CF8C2A5ABB2A670E2" xlink:to="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:to="loc_us-gaap_MinimumMember_4CE7DC74FD53485B637CA5ABB2A78E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_49823B0FDCCE18E53B85A5ABB2A70078" xlink:to="loc_us-gaap_MaximumMember_80D9D88D7CAAEA5FE38CA5ABB2A73F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_A88D6B43FC74756BA3D2A5ABB2A4099F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5AC991DC9CE1E1E36A57A5ABB2A746BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5AC991DC9CE1E1E36A57A5ABB2A746BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_602B2471BFE7DB89FAE0A5ABB2A7C6D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_2E05C82BAFE89E1CC430A5ABB2A7A6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_AD6C26A0933413DD218AA5ABB2A7F80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3F946BAD3E0EDCCD2F7CA5ABB2A7E452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6D7C1417360001CE2C8FA5ABB2A712D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3C478AA5D0D86FCCA630A5ABB2A7716D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_56575574CA9D63C9F156A5ABB2A7E7F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_D45845039FCE507DC11FA5ABB2A7DF8F" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6EED811CD2E5E52A6E90A5ABB2A7DC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_LitigationSettlementAmount_DD9B0AB4B3D10D3274D1A5ABB2A7A40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_LitigationSettlementExpense_0AF1040E2103D88A3957A5ABB2A72BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8CF2EEDF5A9978991DF7A5ABB2A73CFA" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_37C4DEFCAA5E03FBABE5A5ABB2A8232A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_D4FD04A8668738F40F72A5ABB2A81DEA" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_03FD15105BC98870C35DA5ABB2A81A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0237B14BFF4B90F2C11EA5ABB2A804F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12129D8CF912CDF9D102A5ABB2A803E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1C3B537999CA2E30D6F7A5ABB2A8EB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C84E26D677A04F87C0BAA5ABB2A88706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47F906BF3C2C998D5F52A5ABB2A8780C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E62FBCFFF506EA587247A5ABB2A4B731" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_B477B688D7EBB0666FEDA5ABB2A81F48" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ABA534D6E2068E8E0DDCA5663ADC7BFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ABA534D6E2068E8E0DDCA5663ADC7BFD" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_11DEF0E1FD8210ED623EA5663ADC6C56" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_603C5BDBE7F14EEEA7EFA5663ADC7A6F" xlink:to="loc_biib_BioverativMember_7F2FAC1252E22872CCEAA5663ADC927F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_5A7B2EBE39E0501BDAB0A5663ADC7619" xlink:to="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_A1A18AE05E94B72F57CDA5663ADC4CF9" xlink:to="loc_biib_TecfideraMember_C6C06148734150E5E95CA5663ADD3E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A2A8E6E10C35903B8749A5663ADDAA5E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F86D402C68449A4165A8A5663ADD2A6A" xlink:to="loc_biib_FumapharmAgMember_4B54BECD674802B5EE20A5663ADD5587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_5A5FAE892B8FB2D691BDA5663ADC051D" xlink:to="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_B800602FE7B3F26D1B60A5663ADD319B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_2A6621F092620242F710A5663ADD14C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DB81480534416E498864A5663ADD5AA5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_E2FAB43E783EDC854AD5A5663ADDE6EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ABA534D6E2068E8E0DDCA5663ADC7BFD" xlink:to="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:to="loc_us-gaap_Goodwill_9A3D5974FA2540F3E834A5663ADEF3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_E50AF090A60D872B2511A5663ADE0922" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_56B5448CE25ACD6BC98AA5663ADE0203" xlink:to="loc_us-gaap_Goodwill_8EAFF2C3B1A85DD6B40CA5663ADE76DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_27393BD22C10344F71883D7279D1A55C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_BC145AEF592967561D2C3D7279D1E53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A07676F847712C5E219E3D7279D1D20F" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6DDC68B3A2682DE34B5F3D7279D1B061" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F7208102BCC7A5E4ABD63D7279A164D5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1444E844642F003D6E5D3D7279A1D9AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_68B897EB84FE39EB47338C52A0647D38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68B897EB84FE39EB47338C52A0647D38" xlink:to="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_49AF3ADC33101DD0DA808C52A064F43A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_B2CD0A809620E3D9E1118C52A064B35C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D9982D619FD1F5337F4E8C52A0641737" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_E98F5B2D0FDEF23B9BFB8C52A0648AE1" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_35D17CB96A8C3493FDC68C52A064BA06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68B897EB84FE39EB47338C52A0647D38" xlink:to="loc_us-gaap_InventoryNet_3E1CEFE40F679432D1BA8C52A064BF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_68B897EB84FE39EB47338C52A0647D38" xlink:to="loc_us-gaap_InventoryNoncurrent_5C3D0657F7BBCEF1552A8C52A06436BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_D4990338F3845C3B39459B1884AD4872" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D4990338F3845C3B39459B1884AD4872" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_3506C720526CF8D1DC089B5B542D802F" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:to="loc_biib_WorkinprocessMember_3FD5F0EBAFB6520A23569B5C4B5CD540" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_18FF46CDD23DAD1833139B5B542EEA5E" xlink:to="loc_biib_FinishedGoodsMember_0F8FC723F653FCC7A5199B5D00FEDBDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_BBB6EC4C91D422C998059B59745A9B2D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_6FDBAC5450A40B4D0D249B5974AF7079" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B450B94AB9A21AC7183B9B59745B63B6" xlink:to="loc_biib_BioverativMember_6FDBAC5450A40B4D0D249B5974AF7079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_C918ECBC8EEC4F6086CF9B1884AD1763" xlink:to="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_C43BF68A9F7189328DD19B597423D705" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_8B6B479284C81DD3FE359B1884AEEB05" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_C43BF68A9F7189328DD19B597423D705" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A9DA6188AFA115B268143D727A7F72E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A9DA6188AFA115B268143D727A7F72E8" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3F4FA8CF16F793EBD2963D727A7F734A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_38923761B9A848DF5C263D7279B1C32A" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_4EF22DD8C8B4F3056BC33D7279B18540" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_8C7C1B31B02589EA690B9B1882D9294D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_8C7C1B31B02589EA690B9B1882D9294D" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_B5E90A8BDB721FD4A14B9B1882DA4D6B" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05D5EEBAC1C1D2C09B69B1882DAFABF" xlink:to="loc_biib_NeurimmuneMember_E065AB8EF3B888AACB4F9B1882DAD97F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96B029D18417D37B28EF9B1882D99A9C" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_DBE1EB2F82B68761BAB79B1882DA66C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_0A77F431D670D8AF82A19B1882DA74EC" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1E2EC2C6E46EFC1E12219B1882DA7A41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_9BB7DECAB46C297FA8FE3D727974C617" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_9BB7DECAB46C297FA8FE3D727974C617" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B525566FEBDE705F13383D727974820E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83D22614281616DB093A9B1882B73E3C" xlink:to="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:to="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_47DA5C78E8F322F8C9F69B1882B71784" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_5CDF3438CA8EE6AC53ED9B1882B78AA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1E1B368F02DEF65B32E09B1882B7F9AF" xlink:to="loc_country_IT_5CDF3438CA8EE6AC53ED9B1882B78AA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_432996AE82FF6C1D5FE89B1882B7CBB9" xlink:to="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_44DC5CAB54C7A24D59E79BCC9B240443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9CB23F6FABF79D04485D9B1882B75991" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_44DC5CAB54C7A24D59E79BCC9B240443" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D73BAC786E3F31397FC23D7279C8C02B" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_94857EE39F46F6838F603D7279C8617F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4925B1B0D2701F63168F9B1882EC64D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4925B1B0D2701F63168F9B1882EC64D0" xlink:to="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8470C258AB21ABCE268A9B1882EC1FC6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3DC359E98E0DACAF7F999B1882ED2285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_AEE9B73F0F83B5FA48479B1882ECD337" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3DC359E98E0DACAF7F999B1882ED2285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A8F17368FF3606D051309B1882ED2CA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C0B3A835BE055C5F6C249B1882ECBAF5" xlink:to="loc_us-gaap_StatementLineItems_A8F17368FF3606D051309B1882ED2CA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4925B1B0D2701F63168F9B1882EC64D0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_F8EEBB0DF6D6F3D35F459B1882ED47FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF6BEF62C0FB20D680D09B1882EDCAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_47AA4847AF3A7B2AAAD19B1882ED9655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7E0D0AEBB63A5B4FA6559B1882EDA83E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_6C9A86ADFA80DA462B1B9B1882ED8866" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_biib_Collaborationexpensesaccrual_CD97AFFD1FA8925103C69B1882ED8E20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_LitigationReserve_D9E8F404C0CDEA70B4569B1882EDF41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_71025D9773210AAD47979B1882ED9825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_95C0A81EB92A4A6F8A129B1882ED66A5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_E0DFE971455EF2B03ECB9B1882EE69B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4925B1B0D2701F63168F9B1882EC64D0" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_InvestmentIncomeInterest_60CDF8C213180377161E9B1882EE54DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_InterestExpense_50804EFA1345975E340F9B1882EEC22B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_0065A59611F71DDE5F9E9B1882EE91E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_DE572F3C54BEF22398F19B1882EEDEE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FBFE9D22E4413A5B9D3B9B1882EEAD98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_453758F747796186A7A69B1882EE138A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_23A90679092F4B501D239B1882EECE7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_9E247473B4CC2F2F5B7F9B1882E01FD4" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:to="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_9FA5FBD3E98ABF980BA69B1882E18455" xlink:to="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IT" xlink:label="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_2375CF76664A2463391E9B1882E1F377" xlink:to="loc_country_IT_D07AF6CD45EF52D7BC079B1882E182C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_AA1EA5F8F65D328BD2219B1882E1A509" xlink:to="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_PrepaidTaxes_C7CB8398CF44BB0508F89B1882E29812" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_E7AF1B19B6CCD45657F89B1882E1CAD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_7F22C726B7829113341F9B1882E17740" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_868B640A44B8DB2A7FAD9B1882E2B2C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62A1CB29A83358F07F3A3D727A350489" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62A1CB29A83358F07F3A3D727A350489" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_BFB7F36718932A50B8E93D727A351461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62A1CB29A83358F07F3A3D727A350489" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9D6150266D0F6FC47FE43D727A35CC0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E9DC327841C0F6AA1C983D7279B47E9F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_99BC0874D0B09BC49F013D7279B4136E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C5254D462CDC695735A69B1883545BAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C5254D462CDC695735A69B1883545BAA" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_AA831C1F8EA54A7EE6FF9B188355F3F2" xlink:to="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_054E83A3017C5D7D28999B188355A2E6" xlink:to="loc_biib_SolothurnSwitzerlandMember_5C1DC34296EB254C3D709B1883556792" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3441E8692CB86016999F9B1883550497" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5E4569B8A515FBAF103A9B1883556174" xlink:to="loc_us-gaap_LandMember_6FA0BC46297168272FE99B18835560A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9880876E19E20DF9DA529B188354BC45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_EBE79ABBA1237824E6BE9B1883556E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_04949E9C75EAED4249F19B18835538A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_ConstructionInProgressGross_5ABA81C1618D0B6FCDB89B1883550FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_584D652C02373CAB3E559B1883556F2D" xlink:to="loc_us-gaap_OtherCommitment_EBF37B1FC5709A09AD729B1883558A87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_EF92E54EC814661E1EC23D727A447977" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_EF92E54EC814661E1EC23D727A447977" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_B678FC17C2554B4240BE3D727A44B991" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_96CE654FCE4AB1C3EB729B1884DFD9B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_96CE654FCE4AB1C3EB729B1884DFD9B2" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1E67F70D5C709F2880849B1884E0B026" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_496F90E341DD321496FD9B1884E50F07" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_biib_ContractualAdjustmentsMember_91E4A0DF566E74289D749B1884E5D513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_36327D554E182F091AF89B1884E5075F" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_1BEC1F8019762C66ABB09B1884E55F81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_141AD3E2D95A4E4193CA9B1884DF3253" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_37E69E57F3D80399632A9B1884E5D7DF" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_644D75799EDAF20AC6F99B1884E58933" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_355C6E184B737D4F3B2F9B1884E50F31" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_2AC98E1BAE4DDB9D5F8A9B1884E6FA68" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_D1F51F4844019BEA1F3C9B1884E6A7E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_5D2E0B395D102F22FE819B1884E68853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_55ECF48E757136F7E8789B1884E50A55" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_AE66B4803D800AE7FC609B1884E6B134" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BE3959C4B333768F1CC03D727AC34AE9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_BE3959C4B333768F1CC03D727AC34AE9" xlink:to="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_07CAF834393AE9B4B7333D727AC3BF3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:to="loc_us-gaap_AccountsReceivableMember_07D3E765885B48BED3BF3D727AC32751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_644E9599575F7156A3343D727AC301CE" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_B03F13748A280CC528213D727AC3A92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4CEA7381A71E7B5D79AC3D727AC39D0D" xlink:to="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_02E1915146C5D26461F43D727AC32EBE" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_313C89884527202450DB3D727AC39986" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_DF1B5DF10DD0726496863D727AC458FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_9790DD6F0028D468CB3D3D727A0C9DD6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_E197AFE7FB3B348EB76D3D727A0CF540" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_B5EA1AFEFC4E8612780E3D727A0C8164" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B0CDE43E3F99440E20273D72794EB088" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B0CDE43E3F99440E20273D72794EB088" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07E34AAAF9E7D7D0390B3D72794E6FAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6289BB5FD940318035F63D727A522329" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6289BB5FD940318035F63D727A522329" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E78320D65BB8958312C23D727A5347CA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8BBCDAAE2407FE3AEC763D727A5325C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E1638E95E21E9739A21B3D727A533FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_RestructuringChargesMember_ED840E040D41FC77C30D3D727A536D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0842C91D8061FCE8CD043D727A53B7E8" xlink:to="loc_us-gaap_ParentMember_032A9555D075DA0B7D533D727A532EB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_50F30AFA16011266FEBE3D727A52033A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FFED413A8ED9F68949C93D727A535718" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6C0EDCE14C3AE4F2FBB03D727A548DB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_77ECF98EA02C8A8F67043D727A54266A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_2E80ABC7309BF779F5963D727A544A72" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_69EC691A8B5AF8D63A453D727A5484BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1152B278FD727292A4B53D727A53CDD1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3C1D421E150E3A2F00703D727A5402F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C08760854C95222462973D727A5C2F97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C08760854C95222462973D727A5C2F97" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:to="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_CA26A3F15E553878E4493D727A5CB0DB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_C603DDD6881F0833A8293D727A5DB9C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_MarketStockUnitsMember_C603DDD6881F0833A8293D727A5DB9C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_08782B127527966D92D43D727A5DE020" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_08782B127527966D92D43D727A5DE020" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_CashSettledPerformanceSharesMember_952CB5B421397C3FBCD43D727A5D3EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_us-gaap_PerformanceSharesMember_A874F0951EAED1815AD03D727A5D926F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8CF1AF2DFB1571DFD1913D727A5CD494" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_4D2F482ED0FDB3397FAA3D727A5D27B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4458D7E12A2542201C2F3D727A5C471C" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4EA1BBD946AE03BFEEB03D727A5DD7E7" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D086099EE81A252266C13D727A5DDA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_379B06538B2C5164D8383D727A5D8C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_770A29124E353586456E3D727A5DF176" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_770A29124E353586456E3D727A5DF176" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2D1F45B926EB51CDFBB83D727A5DDBA0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_DA4A3AF02F80B84CC3B83D727A5DEEA2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2D1F45B926EB51CDFBB83D727A5DDBA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_CF06EEA027E050C46DD487E3F4D94D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91E3C817C0572BA8684087E3F4D920DD" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_700D5E1BCB2CE48C2C1D87E3F4DA4D6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E598ADC327AAB2DB659A3D7279D3742F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E598ADC327AAB2DB659A3D7279D3742F" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_A24A7C8CAE37E24140FF3D7279D4DB82" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:to="loc_us-gaap_NumberOfReportableSegments_B1FB4720ABA5FC5D53373D727A70E622" xlink:type="arc" />
    <link:loc xlink:href="biib-20170331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A172EBAC3F1C1D53B4E83D727A70A526" xlink:to="loc_biib_InterestInSubsidiary_601ABAC103D638BE12CA3D727A71880B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:type="locator" />
    <link:loc xlink:href="biib-20170331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_2F1E3C1D45E4FA26F4C6247E097E58F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8523A81BE62D99AF1A38247E097E1727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_84765A2E608873D3D267247E097EA086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:to="loc_us-gaap_UseOfEstimates_663D27652C136692E8E1247E09839F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_466A26ACBE25E86EC285247E097DAE34" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_270EAC1A13206632DAB1247E0983BAA3" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-2017331amortization.jpg
<TEXT>
begin 644 biib-2017331amortization.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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MM)[Z\6>UN)K:91IE\RB6WE>&4*PA*L!(C ,I*L!D$@@U!_PN7P'_ -!"]_\
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MGEZ_AVU_03_A<O@/_H(7O_@JO_\ XQ1_PN7P'_T$+W_P57__ ,8K^8;X8_\
M!0G7;;]B?0=3\;_'WX=S_M2^+M"\6V.@:G\7/ %C\"-7\#7&C?#67XE7OC/X
MG?#_ ,5Z_8^&?&J:+X>GTO5/ M[X!EL_"/Q?O?%WP\\,Z?;&0^+]6BN?%/\
MX*5'2OV=/V7_ !+X(^,_P)T_XI>+OA_^PU\7/CCJNO>)?AO/:+X9^/?Q)^$G
MP_\ %?@WPAX8N]?M+,^(_$UQK_Q2UW6-6TJVN;/X/^#OASK6H7B:?JNH:!]E
M]I\9<;JJJ2PN3N^)GAHU'A,PC3DX-159.>)C+V$YKV=.;@I5*GNQ@W./,6\G
M\GILGO:W?T_/^FW_ (7+X#_Z"%[_ ."J_P#_ (Q1_P +E\!_]!"]_P#!5?\
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M,/5=+#XB-10J3C&3A*>,J14K;-PDD];/6YIKY+]4OU?];_7M%%%?N0@HHHH
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MJ/[ M/\ G\US_P *#6O_ ).K<HK^KQ&'_8%I_P _FN?^%!K7_P G4?V!:?\
M/YKG_A0:U_\ )U;E% &'_8%I_P _FN?^%!K7_P G4?V!:?\ /YKG_A0:U_\
M)U;E% &'_8%I_P _FN?^%!K7_P G4?V!:?\ /YKG_A0:U_\ )U;E% &'_8%I
M_P _FN?^%!K7_P G4?V!:?\ /YKG_A0:U_\ )U;E% &'_8%I_P _FN?^%!K7
M_P G4?V!:?\ /YKG_A0:U_\ )U;E% &'_8%I_P _FN?^%!K7_P G4?V!:?\
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M%T'_ .4];=% &)_9>H_]#)JO_@+H/_RGH_LO4?\ H9-5_P# 70?_ )3UMT4
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M . .J?\ R%1_K'P]_P!#W)O_  YX+_Y?Y_GV86?9_P!?\.OO/1**\[_X6OX
M_P"A@C_\ =4_^0J#\6/A^ 2?$,> "2?L.J< #)/_ !Y=@*/]8^'O^A[DW_AS
MP7_R_P _S[,+/L_Z_P"'7WGHE%1PS1W$,5Q"V^*>*.:)\$;HY5#HV& 8;E8'
M! (S@@&I*]E-22E%IQ:3333335TTUHTUJFM&A!1113 **** "BBB@ HHHH *
M*** /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOQ#_P""
MD_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H ^ ?$'_(?UW_ +#.J?\
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MAMR@'<%4-G(50<!E "@ *J(J@*J1HL<:(H"I''&@6..-% 2..-5CC151%5%
M!7SY(4C?=?\ W'_] -+2-]U_]Q__ $ TGL_1CCNO5?F?H-HO_(&TG_L&6'_I
M+%6G69HO_(&TG_L&6'_I+%6G7]E87_=L/_UXH_\ IN(@HHHK< HHHH ****
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M;;;6K;N[ON.[[O\ K_AE]Q^"G_#MO_@K%_TF=\"?^*MO@/\ _/@H_P"';?\
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M _\ \^"@_P#!-O\ X*Q$$?\ #YWP)R"#_P :MO@/T/!_YK!7[UT4?ZJ\-?\
M0ARC_P -^$\O^G7E^+[A=]W_ %_PR^X_%"+]B;_@LI!%%!%_P6Q\#+%!%'#&
MO_#K?X'_ "QQ(L:+_P EI_A50. !QP .*^U_V0/@I^V=\('\?G]K?]MS0OVP
MUU\>&1X#31?V6? _[-G_  K\Z9_;G_"2&Y;P;XU\7GQC_P )/]NT7RAJ T_^
MPO[#D^R_:?[5G\C[8HKWDE%*,4E&*222LDDK))=$EHD(****8!1110 4444
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M'NE^ ?"/AC0[GX(:9I&A?#[Q#+K_ ,2M%\27NO:KKFE:?X<T3PMXD\7^T?\
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-2017331anticd20.jpg
<TEXT>
begin 644 biib-2017331anticd20.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
MDODGF6[:999 P!\!?\%"/B'^SUX!T/X;/\<OB!XD75M?O/&.F_"/]GWPW\<X
MO@4WQW\=1Z3IEW]MU3Q/#XJ\!7=EI'PMTR*?6KSQ;K7CC1/A[\/$\0'Q9XCM
MM4\5VWP^B@_-+Q_XS\?^&O 'C.#XI_M*7WC#]H/X4?L'?LT^(/V&_&OP\^,7
MB%M"_:$_:1O5^*%IXN\1^ ]+T&>PT?X^:WXT^+>F?"_X6^++;6= \8WNJ_#J
M_P!#N-<T#0[7XF:ZVL_T0>(O!WA/Q=';0^*?#/A[Q)%9F1K6+7]$TO6H[9I3
M$TIMTU.TNU@,C00%S$$+F&(MDQIML6WAGP[9P:+:VFA:/:VWAP8\/V]MI=C;
MP:&#;R6A&CPPVZ1:7FUEEMC]@2WS;R20']T[(0#\3+_X\ZGX0_X*+?M9>$O!
M?[1EG\5?BE>_L 6NO?#'X&:W\4?"5[H&A_M!Z#\6/CRVC?"3P1\-]"GT>T@\
M165II7AZQ\0M=:/??$GQ'IPM[[Q?JMU8P:1::9I_\$R?B3<Z[\3+'2CXBN?B
M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M3'B[X)>"KSXV_"WX,^#[W3?!?PPU+P!\/OBK=^(] \'_  KTVUTWX[)\+H?
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M]K/[P@8'XGOGJ22?J>X['@4 ?,'QJ_:U^&7P'^-'[*WP*\9Z?XPN_&7[7WQ
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M>'JSCQ.U]8C6G3IRA3]I!RJ14:DG.*?]9@_X+;_L2#I<?%T=S_Q;"^Y/J?\
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MS52"WC),=M;1E@58QV\$992,%6*1J61APRME3W!Q7Z ?$#]COP'X*_:)\;?
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M_P#0Q:W_ -\:'_\ *6C^R;O_ *&+6_\ OC0__E+7\A']R'\K_P#P=#_\@/\
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MI$L:Q,ZA?V//'[, )HY8_G4&,EHV(5B5PX5A^TD>F:B$A9O$6INH,!9#:Z&
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MJ-SJVK:A.L/[/$4*S7VHWES=2B&**(22L(XT3:HQ_P#B%'_9E_Z/H_X* ?\
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M;?LD?%SXI>/O .@W&H?$?Q)\(OC'X5^-]G\7+3X@>"_BOI.L^"=*O?#YT_\
MX6E9WWA+4+/1/B-IT&N>"-(U;5=!N8=0FTVP_;ZB@#YQ_9,^!NH?LY? ?PA\
M)-4U[3=>O-"U'QQK+#P_I5WH7A#PU%XY\?\ BCQY;?#_ , :)J&HZMJ&C?#;
MX;6WB:+P#\.=(OM1NKG3/!?AS1+-C;K$EE;?1U%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-2017331biosimilars.jpg
<TEXT>
begin 644 biib-2017331biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M_P"&U_VPO^CH/CK_ .'&U_\ ^2:/^&U_VPO^CH/CK_X<;7__ ))H_P!0<?\
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M1=5<HA=5;*JY1"P 8HI.T>45_16'_P!WH?\ 7FE_Z1$_D[%?[SB/^O\ 6_\
M3D@HHHK8P"BBB@ HHHH **** "OU;_X(S?\ )ZMG_P!D@^)7_I5X0K\I*_53
M_@C>URG[:%HUI##<3?\ "H?B5B.>X>UC*_:/"9SYJ6]TP.\(H'E$8<L6&W#>
M1G__ ")<T_[ J_\ Z0SWN%_^2AR?_L887_T] _KLHK#^U>(O^@/I?_@]N/\
MY14?:O$7_0'TO_P>W'_RBK\&/Z:-RBL/[5XB_P"@/I?_ (/;C_Y14?:O$7_0
M'TO_ ,'MQ_\ **@#<HK#^U>(O^@/I?\ X/;C_P"45'VKQ%_T!]+_ /![<?\
MRBH W**P_M7B+_H#Z7_X/;C_ .45'VKQ%_T!]+_\'MQ_\HJ -RBL/[5XB_Z
M^E_^#VX_^45'VKQ%_P! ?2__  >W'_RBH W**P_M7B+_ * ^E_\ @]N/_E%1
M]J\1?] ?2_\ P>W'_P HJ -RBL/[5XB_Z ^E_P#@]N/_ )14?:O$7_0'TO\
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MBOP8_IHW**P_[+U+_H9-4_\  30O_E11_9>I?]#)JG_@)H7_ ,J* -RBL/\
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MI_X)#_\ !:7*^7G_ (P^^'V/E*Y_YN!SV.*_:AE5L;E5L=-P!Q],]*;Y<?\
MSS3_ +Y7_"@#_/B^)\'[8WC/XF?$?QCI7_!*[_@IO%I?B[X@>-_%6F1WW[-V
MCPWL>G>)/%.K:W8QWD,7Q(GBBNX[2^A2ZBBGFCCG61(YI459&X;_ (13]M;_
M *19?\%+?_$<M+_^>'7^BMY<?_/-/^^5_P */+C_ .>:?]\K_A7U<>,\[A&,
M(SPO+",8Q3PZ;M%)*[Y]=%OY^1\1/P]X<J3G4E3QG-.4IRMBY)7D[NRY-%=N
MW;3MK_G4_P#"*?MK?](LO^"EO_B.6E__ #PZ/^$4_;6_Z19?\%+?_$<M+_\
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MZR_X*6'!925_9STIAE25.&7XAD'!!&02#V-'_"*?MK?](LO^"EO_ (CEI?\
M\\.O]%18D .40DN[$[1SO=GYR.OS<^].\N/_ )YI_P!\K_A1_KMGO\^%_P#"
M9>7]_P G]_D'_$.^&O\ GUC?_"N7_P AZ_TM?\ZG_A%/VUO^D67_  4M_P#$
M<M+_ /GAT?\ "*?MK?\ 2++_ (*6_P#B.6E__/#K_16\N/\ YYI_WRO^%'EQ
M_P#/-/\ OE?\*/\ 7;/?Y\+_ .$R\O[_ )/[_(/^(=\-?\^L;_X5R_\ D/7^
MEK_G4_\ "*?MK?\ 2++_ (*6_P#B.6E__/#K[=_X)]_&/]IK]E?]H>#XL?$;
M_@E+_P %4]0\-Q> _%_AAK;PE^S#X=U36#J&OS:%)92+:ZA\5M(MC:H-,G^T
M2&\$B%HMD4H9]G]O/EQ_\\T_[Y7_  H\N/\ YYI_WRO^%88KBW.,7AZV%K3P
MSI5Z<J511PZC)PFDI6ES.SM>SZ7\CJP7 V08#%8?&8>GBE7PU6%:DYXF4HJ=
M.2E%RCR*ZNKM7UV[W_%S_A\GK?\ TB'_ ."TW_B'WP^_^B!H_P"'R>M_](A_
M^"TW_B'WP^_^B!K]H_+C_P">:?\ ?*_X4>7'_P \T_[Y7_"OF3[ _$O4/^"S
M7BZ 1?V=_P $=/\ @M'J1<OYP?\ 9.^&MAY(4+L(-Q\?V\WS"6&$QLVY;[PK
M._X?1?$'_I#!_P %H/\ Q&#X6?\ S_J_<7RX_P#GFG_?*_X4>7'_ ,\T_P"^
M5_PJDTOLQ?F^>[U7::6UUMU)<;N_-->2<;=.\6^CZ]6?AU_P^B^(/_2&#_@M
M!_XC!\+/_G_4?\/HOB#_ -(8/^"T'_B,'PL_^?\ 5^XOEQ_\\T_[Y7_"CRX_
M^>:?]\K_ (4<R_DA_P"5/+_IYY/[_(7+_?J=.L/+^YY/[V?AU_P^B^(/_2&#
M_@M!_P"(P?"S_P"?]33_ ,%H/'^#N_X(O?\ !9\@\L#^R_\ "L@XYY!^/OX_
MK7[C^7'_ ,\T_P"^5_PI&BC((V)R"/NKW'THYE_)#_RIY?\ 3SR?W^0<O]^I
MTZP\O[GD_O9^"^@?\%S-6\3S^([7PU_P1]_X+#ZW<^#_ !'=>$?%-OI7[-?P
MFNI?#WBFRT[2M6O-!U9(OC]FTU6WTK7='OY;=LD6FIV<@8B7 Z,?\%H/B N<
M?\$7O^"SXR<G'[+_ ,*QD^IQ\?>3]:_4?X'?!S4_A7KO[06K:IJFF:I%\8?C
M[XA^+NDQ6,-RDFDZ7K/@'X:>$8M+U$W2*LFHQ7?@>\NY9;3?:M;WEJJN94F"
M^_\ EQ_\\T_[Y7_"CF7\D/\ RIY?]//)_?Y H/\ Y^5'_P" >7]SR_%GX=?\
M/HOB#_TA@_X+0?\ B,'PL_\ G_4?\/HOB#_TA@_X+0?^(P?"S_Y_U?N+Y<?_
M #S3_OE?\*/+C_YYI_WRO^%',OY(?^5/+_IYY/[_ "#E_OU.G6'E_<\G][/P
MZ_X?1?$'_I#!_P %H/\ Q&#X6?\ S_J/^'T7Q!_Z0O\ _!:#_P 1@^%G_P _
MZOW%\N/_ )YI_P!\K_A1Y<?_ #S3_OE?\*.9?R0_\J>7_3SR?W^0<O\ ?J=.
ML/+^YY/[V?BTG_!937BB&3_@D+_P6FC<HI>,?L@?#UPCE063>O[0(5]K97<O
M#8R."*^T_P!D+]LR^_:U?Q^EY^R#^VK^RM_P@8\,F-OVO?@[X>^%">./^$D_
MMO</ !T+X@^.O[=/A[^Q5_X2;[4-,_L[^V-$\G[7]MD^S_:7EQ_\\T_[Y7_"
MG!57.U57/7  S]<5)8M%%% !1110 4444 %%%% !1110 4444 %%%% !117C
M_P"T)J/Q+TCX"_&S5O@O9G4?C#IGPC^)6H?"G3OLT-X+_P")5EX*URY\"636
MMQ#<P7(NO%46DP>1-;W$4Y<120RH[1L >O!E.>>GJ".!W&0,K_M#*^]*"",C
MI]"/Y]O0]".1Q7X:_ CQ3\*M,\<>"I/@A^TKXHTGX5ZU^Q;XR\4_MF?%?6?B
MS)XI/PS^+Y\1? M?A9X\^(.K_%V/QAX.^&W[0VO0:Q\>K3Q7I'BK3]#U==+T
M=3XK\(?9_!?A:'3O>_\ @CK\5O"GQ-_8C\%66C?%ZR^+FO\ @OQU\=]#\2:G
M/\3$^*'C.PM$_:1^,R^"CXVUZZUO7?$,U_JW@^RTJ^TR_P#$-T;O6M'%OJ-K
M)<6;QRT ?J=N''7YN@((/OP1D =R0 ,C/44;QNVX;/3.Q]O_ 'UMV_CG%?A1
M^V;<?#7]CS6?^":?@>]_:XU[P=I?@S]K/X76%]X(^(/QPT+P\OB7X?ZU8?&^
M[\6?$/XEOJVHV'B_QQH-A?3:9X>BF\7ZYJ/P[\/SVUC<PZ/%XGCL=3M/J#4?
M@M\(?B-_P4%\(>)_#_A:.'6OAQ\+]$_:8\=>/M'\4>*=_C3Q/\1;OQ'\)O@A
MI.VQ\1CP]/X5L]"\"_%/Q7K&EQZ=+8ZWJNE_#R[:/R--NEOP#].:*0   #H
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M=H%_I.O^(_"7B+PYXGT3[2FG:]X:\6>#]7T'Q3X<U6.TOM1TNXO=$UFPFO\
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M=T/3\N3[=1QQR* %HHI,CGKQD'@]O3CGZC(/:@!:* <C/KSR"#^(/(^AYHH
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-2017331collab.jpg
<TEXT>
begin 644 biib-2017331collab.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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MG3WUB>_O=:T0:!H"7T.IQZM;_8=O^W[^RI/<Z;8R?$JZTW4K^#XN7EYI6N^
M_B-X=U;PGI_P&UOPYH?QEU/XBZ5KWA/3=1^&>F?#27Q?X6U3QCJ7C^U\.6.C
M>&_$.C>*)[C^P-4T_4+KD?B+^P9X.^(FL_M(:M?>//$VG2_M'_%O]C[XM:Y#
M::;I$L?AS4OV0/$OPM\2^&=)TIY@6N;+Q?/\+M/MM<FOS]ILHM4O'TS]Y#;U
MQ%S_ ,$Q?A'KOC[X_>+/%WB_Q;XCT/\ :)\)?MA^!_'7A V^D:=:1^'OVR8O
MV9K;QM;Z7JT,%Q>077AJU_9IT5/#MS-!/OE\3:I-J,,PL;")@#W:W_;B_9VN
M_#XUV#7_ !RU[-XGT/PAIW@-_@Q\9H/B[K>M^*/#&M^-_#,>@?!NX\ P_%'7
M=/U_P5X9\3>,-+UK2_"=SHL_AKPQXGU9]0AM_#>NG3LC]I3]K^S^$O[(]]^U
M3\&/"-O^T/:W5Q\*5\#^$-&\22>%7\<P_$WXG>#?A\EO8:M<:!K=SIVN6,7B
M>ZN;;0=0T%+ZZ\0Z8GA/4TT2\N;FZT_Y?G_X)'?!:Z\'Z/87P^%<_C;PM\1M
M-^(?AO68/V4_V==)\ 7%UIOP[\4?"M[#QU\']#\'Z=X<^(<FL^%/&.O7^JZQ
MKFJQZMIGC">#7O <_@;3H)?#US]G1_LM^#+#X"_"[X :)J)T'PS\+?&/P)\:
M:1=Z#X6\%^&HKJ_^!WQA\%_&:R@_X1?P=H/AGP5H5CXE\0^#EM-4L_#>@:1I
M]A:ZI>/I=G%-'%N /GOQ=_P4F^&GAO\ :$^#?PSM=,TV_P#@O\1_V9/B?^TS
MXM_:'N_%$FF^'OAYX=\%>$O"WQ%\-:;<>'QX?O)-77Q-\.-:U/QGJ^HG6M,D
M\+:9;>'E_LW67\4P&R]6F_;_ /V9+=]-L)O$GC^'Q7J_B3Q/X/T_X;2_ SXX
MQ_%N?Q-X3^&\'Q@U313\)7^':_$6*^N/A=<1^/=$27PTB>(O#*7.HZ')?)8W
MZVOSA=?\$D?@A>Z/#X4N?'OQ(E\*1VO[76D#2S/H<EYIWA;]J32_ _AO0O"_
MA_5+G3K@:/H_[/7@[X;>!O"/P<M9K#4XK;1/"^E6WB&+5TCNUN_5/!_[!5E8
M?'3P%^TIX\^+WBGXA_&?PQXV\3>,?$GB2Y\)^%O"NF>+X-1^!%_\ /"_AM?#
M^@0Q67A[1O"/AS5=:\21/92WVIZSXN\1:[=7U[#HCZ+H6A 'C/BW_@KM\']/
M^)=UX!\"^ _'/CO2+/XC_L+^%8OB/%H7C"P\!^+?!W[<L&I7_@OQO\,M5L_!
M6L-X]N-&TRUT^>R\*:8B:MXUO-2DL?#S%M&UF6S^J=&_;V_9D\0W/A&PT+Q?
MXJUG4O%EH][+IFD_"/XP:GJ7@6WA^)'B'X.W4GQ<TZR\!SWWP<%C\5O"/BOX
M?:C_ ,+/M_"ATWQ-X7\26=^+:'0=7N;/Y2\#_P#!)3P1\/KKX$IH/QC\9G1/
MA!I/[$D.M:7?>&O#=Q-X[\0?L'G7K+X2Z^^I)/#+X8&N>'_$^K:/XWTFQM]1
ML]0:'1]2T>31;JTU%=9Z/Q)_P2\\-:Y&UG9_&3Q-HMM>?%;XZ?%%]<L?A[\,
M3\3O!&I?'3]HGQ7^T5KEW\#_ (Q?V)%\2_@YXFM-:\4_\(E+K^C^(=8TG5?#
M.C:9<3>$+3Q(;S6[L ^VOC'^TK\(/@-<Z/9?$?7]7LK_ %K1_$OB>'3?#G@K
MQQX]U+3_  9X*;2E\:>/O$.G> _#GB2]\,_#[P>VNZ*GB?QQX@@TWPQHLVK:
M=;WFII<WEO#)P$G[=/[+<'CC6O -U\4(+'5/#GBK6/ ^O:[?^&?&5E\/='\8
MZ)\(M/\ CW<>&M2^*-SX>C^'%EK%[\&=1C^).AV=QXHCD\0^%+74M2T07Z:;
M=*G _M:?L"?"S]J_QEX)^(GB6/PS;>+_  EX+\:?#"2]\8_"7X8_&C2+SX>^
M/]7\.:[KEK8>%OBQH'B'0M!\8Z7K'ABPOO"?C&RLYCIQNM5T_7]"\6:/?C3(
M.#\?_P#!,;X/_$G0_&GA+Q+XF\0R^"O'O[54/[3&O>%;'3='TRR,0_9*TG]D
M*Y^&-@VG16KZ9X:D\"Z6FM6VHV$%OJ.EZO(MO86\.F6MO @!H>'_ /@II\$=
M>^+GC+P$NE^-[7POHGPF_9\^(/@[79_AO\7H?B)\3/$?[0'BO]H/1]"\%>"_
M@7>?#6S^)>O"'PM\!KWQ_IWB+0=+UBQUCPKJ6JZO-!I.C^$]4U1W?M(_\%,O
M@9\%/@UXF^)W@=[[XQ:UHWP[\'?$RS\,:#H?C^RT>'P_XZ^(Z?#+PTOC_P <
MV?@/7M#^$>I:UXEL?%FE:-HOQ%70==U'7?!7BC0H]+CO]&U);3RSQE_P2C\,
M_$_Q+9?$;XO?&"\^,/Q/\-^&/@WX6\$ZQ\2_@[\)?%/@;3=.^"2_'K2= 'B7
MX5W&D1^%/&8\3^%?VAO&NG^-GO3IES-XA33/%?@R]\$3:?INDV&OXP_X)6^
M]:\!^*/A?X.^*OB+X:>!_B?\*_AI\,_C'H'@SX=?"71-+\</\'O%FN>,O 7B
M/1=(\/\ A/P]X?\ AQ>1ZCXEUO2_%&D>#=(M=(\1>'6T^".VTC7[6\\3:H ?
MJRK;@3C&&=?7[CLN?QVY]LXYZTZFJNT$9S\S-_WTQ8C\"<4Z@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/^P1J?\ Z'9U]#PG_P E-D7_ &,\)_Z=B-;2]/U1]>T445_5X@HHHH ****
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M1J?_ *'9U]#PG_R4V1?]C/"?^G8C6TO3]4?7M%%%?U>(**** "BBB@ HHHH
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M*_\ ([)_V"-3_P#0[.OH>$_^2FR+_L9X3_T[$:VEZ?JCZ\P/?\S_ (T8'O\
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M/_<7_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 ?
M/B#_ )#^N_\ 89U3_P!+KBLBM?Q!_P A_7?^PSJG_I=<5D5_&^+_ -[Q7_81
M6_\ 3D@"BBBN< HHHH **** "BBB@ KUOX*_\CLG_8(U/_T.SKR2O6_@K_R.
MR?\ 8(U/_P!#LZ^AX3_Y*;(O^QGA/_3L1K:7I^J/KVBBBOZO$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B!_P %
M)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E))_P $*?\
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M_AE]Q^"G_#MO_@K%_P!)G? G_BK;X#__ #X*U=&_X)Z_\%=- O1J&E?\%I/
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M **** "BBB@ QU]^O^?\]O2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M(S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-2017331cos.jpg
<TEXT>
begin 644 biib-2017331cos.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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MX6:Y'!+HWQ'_ .$V\-)X$U2*ZNI+&V>P\6RZG'H%TMQ>PRV</DZ@QENHY+=
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MFSXU?M:_#+X#_&C]E;X%>,]/\87?C+]K[X@>.?AO\+[KP_I6EWV@:;KOP_\
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MUU:S@\/:7\.-"\)^-M?\2:OX7T=M=\3>/-)UV]5;-9/#\'A^:\UB352S[/\
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M8/\ Y$H_X:.^//\ T5GQI_X,8/\ Y$KQ6@\@].G?I^/M7V?]C9/_ -"C*_\
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M+O\ A&!<+<^*O'/@NYOK"YT:>UT#X17=I?\ A9M'TK]KA_4^GJ?3].^.O.:
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MU31X=17N/_#/7Q$_N^'O_!X/_D*C_AGKXB?W?#W_ (/!_P#(5?3?\1=\,/\
MHN^%^G_,WPG6W_3S^\OQ/SW_ (AWQS_T2F>]/^9=B.MO[G]Y?B>'45[C_P ,
M]_$3^[X>_P#!X/\ Y"H_X9[^(G]WP]_X/!_\A4?\1=\,/^B[X7Z?\S?"=;?]
M//[R_$/^(=\<_P#1*9[T_P"9=B.MO[G]Y?B>'45[C_PSW\0_[OAW_P 'H_\
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MW%:7,EM%-]I\J2XC@D>".7[%;W5YY;RA%D^RVUQ<["WD032[(V /RW\<:?\
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M&1']BO;PY3:"_F",?,NTL=P7Y]KZ0^/W^I\*_P#7;6/_ $7IU?-]?S)XB?\
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M]IV56QN56QTW ''TSTIOEQ_\\T_[Y7_"@#^;W5/^"E/Q#O=3U*]B_P""2/\
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M TLWF7#0%#LD^.\*[ (FW'?D$KA3SC^ACRX_^>:?]\K_ (4>7'_SS3_OE?\
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MUU'']H6UMIEC;V]\%B\E1>PPV\<5V%A B N$D C 0#: *VJ* $50H"J,*
M.P'  ]@. .P  X%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1169JVLZ7H5J+W5[Z#3[5ID@6>Y;9&9I [)'D _,P1R!_LFLZM6E0ISJU
MJE.C2IQ<JE6K.-.G"*WE.<VHQBNK;20&G17%?\+&\#?]#/I7_?\ /_Q-='I6
ML:7KEJ;W2+Z#4+02R0&XMVWQ^;%M\R/.!\R;EW#MD5S8?,\MQ=3V6%S#!8FK
MRN7L\/BZ%:IRQM>7)3J2ERJZN[65U=ZA9]C2HHHKM **;O&[;\V?78X7_OK;
MM_7KQUIU !129Y YYSV../4XP/;)&>U+0 4444 %%%<#XU^*7P]^'+Z='XX\
M7:+X8?5UNGTU=6NC;F]2Q:W6[: !'WBW:ZMQ)TVF9.N>-J&'KXJK&AAJ-7$5
MIWY*-"G.K5ERQ<I<M.FI2?+%.4K)VBFW9)LY\5B\+@J$\3C<30PF&I\JJ8C$
MUJ="A#GG&G#GJU90IQYYRC"/-)7E*,5=M([ZBO"/^&G/@#_T5?P=_P"#(_\
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M\.M"A\*ZS_0LL4:F0K&BF9M\NU%'FOL2/?)@#>WEHB;FR=B*N=JJ!%]DMO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-2017331highlights.jpg
<TEXT>
begin 644 biib-2017331highlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'GAWQM+X#FN?$?A']H3P/^TCX8_: ^"<G@SP_J'C?4-)TSX!_">?1#X+\/\
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M]_R/^%&1[_D?\*P?^$6\/_\ 0*MORD_^+H_X1;P__P! JV_*3_XN@#>R/?\
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MEC^\8Z=^IZ_4]/;T]L4 +1110 4444 %%%% 'X=^/_\ E8@_9P_[1-_M)?\
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M\=_L_P!E\6-<^$?AOXI^'/$O@7XAZOX;\)^$_%6M:UX"\7^&]6\.:_H&G?\
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MG/XW7&DZAXC/@#PIJ6E^%/#GVG4-,F\;B3PS[6_[#P>5?B"OQP^($?[2*?%
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M ,K$'[.'_:)O]I+_ -:D^$-?N)7X=^/_ /E8@_9P_P"T3?[27_K4GPAK]Q*
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ML_-V^9]EMH+?S-F[9O\ )C3?MW-MW9V[FQC)R 7**** "BBB@ HHHH ****
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M^.T?V3IG_0/L?_ .V_\ C5']DZ9_T#['_P  [;_XU0 ?VMIG_00L?_ RV_\
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M1_9.F?\ 0/L?_ .V_P#C5 !_:VF?]!"Q_P# RV_^.T?VMIG_ $$+'_P,MO\
MX[1_9.F?] ^Q_P# .V_^-4?V3IG_ $#['_P#MO\ XU0 ?VMIG_00L?\ P,MO
M_CM']K:9_P!!"Q_\#+;_ ..T?V3IG_0/L?\ P#MO_C5']DZ9_P! ^Q_\ [;_
M .-4 ']K:9_T$+'_ ,#+;_X[5B"[M;K=]FN()]F-_DS12[=V=N[RW;;G:<9Q
MG!QG!JO_ &3IG_0/L?\ P#MO_C56(+2UM=WV:W@@WXW^3#%%NVYV[O+1=V-Q
MQG.,G&,F@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AWX_\
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M1JL<<:*B*%4 ,O+&SU"'[/?VEM>P;U?R+NWAN8=Z9V/Y4Z2)N4DE6V[E[$4
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M>#AJ7]H_\(YK./['.H?9/L9^W?9?M%KY_P!K8'O^9_QI<8]?Q)/\Z "BBB@
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MSMXX#>7][=:3)<75Y=LAN+F>9VDDFD=F.:V#^T?X7 )_X0/XX<>GP4^(6?\
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MM>T:WU31I]5\%_$KP_H>L1:E:ZA;:3K^FZUJ,%S=Z,;55\*U#]O7X_:/\9?
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MOPYX6\,:)/96-SINDPZA;"^8 ^:O@S^WK\0O'7QZ\#?#SQ?\.O!VD^!?BO\
M'#]O3X!^!-7T#Q!KMWXMM?$O[$7Q2\:^%9_$GB;3M0T^/1HM#^(7A?PAJ%S%
MINGWCZEX<UVR@,ESJMAKC6OASR^]_:U_: \._MN?'#X ^#7\.>,9OB%^U1X
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MN]M](CN=%\-S6^O:];OHNGRV]@+?7=:@6!8=7U%+KT?P;X-\(_#KPEX8\ ^
M?#'A_P $^!O!6@:1X5\'^#O"FD6'A_PQX6\,:!8P:7H?A[P[H6E06NF:-HFC
MZ;;6VGZ7I>GVUO96%E!#;6L,4,2( #I:*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-2017331incometax.jpg
<TEXT>
begin 644 biib-2017331incometax.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M;^'M!M(=(MK71M*MK?0 1H<%OIUG!#HP,$EJ1I444"1Z;FUEEMC]B6#-O))
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MDJ"K>U<*683Y:E%ZT'R8J2=::3G"*;CR)NK.G=*3Y6U^.NG];IZV\KG[[_\
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M^@S+_P""O5/_ )#H_P"%O> ?^@S+_P""O5/_ )#KXRHKE_XBKQ'_ - N3_\
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MA_!H_P#7JG_Z0A'*ZAXCTI["^19+O<UG= 9TO5@,F"3&2U@% ]22 !R3BOA
M?=7V51^(4 _K7Z&:E_R#K_\ Z\KK_P!$25^>:_=3_<3_ - %?BWB[_O&0_\
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M7Z_YK[SL:*X__A8GP\_Z*)\._P#PX'@O_P"7U'_"Q/AY_P!%$^'?_AP/!?\
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MH-O"U%'OJ*X__A8GP\_Z*)\._P#PX'@O_P"7U'_"Q/AY_P!%$^'?_AP/!?\
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M /A@_ 7_ ,JJ_3RB@#\Q/^'+/_!)?_I'+^QM_P"&"\ __*JC_ARS_P $E_\
MI'+^QM_X8+P#_P#*JOT[HH _,3_ARS_P27_Z1R_L;?\ A@O /_RJI/\ ARQ_
MP26_Z1R_L;_^&#\!?_*JOT\HH _,/_ARQ_P26_Z1R_L;_P#A@_ 7_P JJ/\
MARQ_P26_Z1R_L;_^&#\!?_*JOT\HH _,/_ARQ_P26_Z1R_L;_P#A@_ 7_P J
MJ/\ ARQ_P26_Z1R_L;_^&#\!?_*JOT\HH _"?]L[_@C#_P $XK7]EGXY3?!S
M_@G+^S)_PLY? .I'P4? G[/OA*?Q@-<%S9-;'P['I6BS:F=3V+*(OL"?:3&9
M5!,;2*WTW_PY;_X),.7=O^"<O[&P9Y9FP/@#X 10&E<J%1-(1$4*1M5$5%7
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MAL;6-V*P1A?;:** "BBB@ HHHH **** "BBB@ HHHH **** "D8X&?< ?4D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'Z>45^;WP\_X*=? SXH>.OA_X6\*:!XQ30OB'\,O!'Q:TGQEXFU3X7^#8O\
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MXCUGXL_#OXJ_##P[X)U[]H3X?^--?UT?#S5+#0/B]^S=X.N_B1XU^%ZKX?\
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-2017331interferons.jpg
<TEXT>
begin 644 biib-2017331interferons.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M?_E))_P0I_[.M_:@_P#6.?B#7[=I_JH_]V/_ -EK\1/^"D__ "DD_P""%/\
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MZD2/4](FO[)3YLT8/Y9_\-P^-/\ H0O!_P#X,O$'_P =H_X;A\:?]"%X/_\
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M;?\ /B'SKTGV_O\ ]6?E?R/]9<I_Y_U/_">LNW:%EOT[/L?I-7W3_P $[/\
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M_P -M?$C_H5? O\ W[\0_P#RWK]2_P!6LU_Y]4O_  =#^NOY]F?FO^LV5?\
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MN=0O=5G\26^JPZCX8U_29X]'DL[<3W5R/QP_X;:^)'_0J^!?^_?B'_Y;T?\
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M[+?^$8T?_GA<?^#+5?\ Y.H_X1C1_P#GA<?^#+5?_DZN@HK_ "U/]+C^9/\
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M,);/T?Y'^CE\$$\0GX,?"+R)M&$7_"K?AWM$UO?^8#_PANB;]WEW84C?NVD
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MF_\ X=JOE_T[\G]_D?YI?_"D_P!N_P#Z1=_\%&?_ !'JT_\ FWH_X4G^W?\
M](N_^"C/_B/5I_\ -O7^EIY<?_/-/^^5_P */+C_ .>:?]\K_A1_Q,EXG?\
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M57,JE6FJ]"<:E-SINFE./-&[BVKIVN?BY_P^3UO_ *1#_P#!:;_Q#[X??_1
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MCBNPL($0%PD@$8" ;0!6U10 BJ% 51A0  !V X 'L!P!V  ' I:** "BBB@
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MQLY/A]\2_%,7C+PWJ7P_\ ^)-4U34_%.FVNDW=R?GS1?CSXZ\"_$_P#9?O\
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MVR&"-(84W,7;9%&JQIN=F=@BC<[,QRS$F>@ K\A/^"HA(U/X+X)'^@^/>_\
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MRRB=)=A!7S4G F23&])0)%8. U '\WGBS]K/]J?XT0_#WQ=XYT>X^']S\/\
M]OO_ ()Y^$[7X$>';.\\,>*9/$/Q,_9#^"_[2GC3P+XO\3WNH+/<0/XX^)FK
M_#_3M"U:R@AL;:>/_A+VU"_TZ*VT_P!O_8;^./Q%^-O[;7P^\4>,/C-X>^)S
M>*/^":NC^.?&/ASP)HUSX8\*?"KXJ>)OC_H>H^)_A9K&A1>)O$-M;>,?AQ'?
M#PC=6'B8VWQ.T*UL9(O&X-SJULD?[J&VMRQ8P0EC,EP6,498SQHL:3%BI)E1
M%5%E)\Q5555@  "*UMH7:2&"&)W:1G>.-$9VF<22NS*H+-*ZJ\K$EI' :0LP
M! !/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-2017331oie.jpg
<TEXT>
begin 644 biib-2017331oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M_P "]!_^65?,M%8_\1/XH_FR_P#\(WY?]/O)_?Y ?37_  OS2O\ H6->_P#
MO0?_ )94?\+\TK_H6->_\"]!_P#EE7S+11_Q$_BC^;+_ /PC?E_T^\G]_D!]
M-?\ "_-*_P"A8U[_ ,"]!_\ EE1_POS2O^A8U[_P+T'_ .65?,M%'_$3^*/Y
MLO\ _"-^7_3[R?W^0'TU_P +\TK_ *%C7O\ P+T'_P"65'_"_-*_Z%C7O_ O
M0?\ Y95\RT4?\1/XH_FR_P#\(WY?]/O)_?Y ?37_  OS2O\ H6->_P# O0?_
M )95JZ/\83XAO1IVB^#M<O+TPRW A?4O#ELODPE!*_FS:F$RID3Y<Y.<CH:^
M4*];^"O_ ".R?]@C4_\ T.SKULA\0N(LQSK*\#B98)T,7C:%"M[/"N$^2I.,
M9<LO:OE=KV=G:_D.V_DK_BE^I[__ ,)-XN_Z)UJW_A1>$O\ Y:T?\)-XN_Z)
MUJW_ (47A+_Y:UWU%?NXCR+7?BA>^&!:MK_@C6K$7K3+:F/5O#-WYK6XC,P/
MD:F?+V"6/!?&[=A>AKGO^%^:5_T+&O?^!>@__+*JOQ^_U/A7_KMK'_HO3J^;
MZ_%N+N.\^R7B#'Y;@I8-8;#+"^S57#.I4_?8/#5Y\T_:1O[]2=M%9-+H!]-?
M\+\TK_H6->_\"]!_^65'_"_-*_Z%C7O_  +T'_Y95\RT5\W_ ,1/XH_FR_\
M\(WY?]/O)_?Y ?37_"_-*_Z%C7O_  +T'_Y94?\ "_-*_P"A8U[_ ,"]!_\
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M\^U_,GB)_P EAFWI@/\ U68, HHHKXH HHHH **** "BBB@ I&^Z_P#N/_Z
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M?!31/A#XZCO=-U&V\3RZ?X L];\=Z'JGC;5]%OXI[3PY8S6EY)^AO_U_?O\
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MHM/\0"\DLSIDFGP+<B^M_KU8?$ZJJ_:M".T 9^Q:EV&/^@E7044 8'E>)_\
MGZT+_P  M2_^6-'E>)_^?K0O_ +4O_EC6_10!@>5XG_Y^M"_\ M2_P#EC1Y7
MB?\ Y^M"_P# +4O_ )8UOT4 8'E>)_\ GZT+_P  M2_^6-?//[5OQ<^(/P%^
M 'Q'^*_AR#PAJNO>$=/T.XTNQUG3];ETJ:?4_&'AO09_M\5EKEC=R1)8:O>2
MQ+;WENXNTMG=GA26&3ZEKC/B#\/?!OQ4\(:SX"\?Z'#XC\)>((K6'6-&N+F^
MM(;V.RU"SU6U5[C3;JSO8Q#J&GV=R#!<Q%F@5'+1LZ, :K)XC=Y3#<Z*L/G3
M"(26FH-((EE=8Q(RZ@JM)L"[RJJI;)55& $\KQ/_ ,_6A?\ @%J7_P L:W@
M!@# R3^+$L3^))-+0!@>5XG_ .?K0O\ P"U+_P"6-'E>)_\ GZT+_P  M2_^
M6-;]% &!Y7B?_GZT+_P"U+_Y8T>5XG_Y^M"_\ M2_P#EC6_10!@>5XG_ .?K
M0O\ P"U+_P"6-'E>)_\ GZT+_P  M2_^6-;]% &!Y7B?_GZT+_P"U+_Y8T>5
MXG_Y^M"_\ M2_P#EC6_10!@>5XG_ .?K0O\ P"U+_P"6-'E>)_\ GZT+_P
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ QU]^O\
MG_/;THHHH **** "BBB@ HHHH **** "BBB@ HHHH ",T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-2017331otherrevenues.jpg
<TEXT>
begin 644 biib-2017331otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M:?Q!!'/;32V\\9M=0)CF@D:*5"5M"I*2(RDJ2IQE21@U%_PM/P#_ -#';_\
M@)J/_P AU\>:ZBQZYK,:9"1ZMJ2("S,0J7LZJ"SEF8X'+,Q9CDL222<JOP2O
MXJ9]2K5J4<#E#C3JU()NCC;M0FXINV.2NTM;)*_0>G9_>O\ (^V/^%I^ ?\
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M#V?M:2P>.JJ/M:=.M3_>4<-4IOFIU82]V;M=IVDF@M_5UZ?U]^Q]7T5\H?\
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M;\)[GXC:IX5U+QUK%Y=7VE>$?!FG:[X;\)_\)%K.FZ'J7B>_M+SQ;XOU#3M
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M%(90P'[5W[3S , 1N7]COX@,K8/=6 93U# $8(!K]L8].T_RX_\ 0;/[B_\
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MAZM*,\#[.&)H5U-RJ3K3PZIX.<'!TO88IQKSQ,:N#4(XRE.@OV$_X:1\8?\
M0%\,_P#?K5?_ )84?\-(^,/^@+X9_P"_6J__ "PKYWHKU?\ B"7A3_T1&3_?
MC?\ YK\OS[L\#_B)W'W_ $4^8_=AO_E']7?E;Z(_X:1\8?\ 0%\,_P#?K5?_
M )85]._LC_&3Q#XW^+\6A:EINBVMJ?"OB&],MBE^L_F6LNE*BYN+R:/8WG-O
M'E[N!AEYS^;5?9'["G_)>H?^Q)\4_P#H[1:\K//"/PVRC)\QS/+>$,KP>/P&
M$JXG!XJD\7[3#XBE'FIU8<^)E'FA))KFBU?=.[/J."O$+C3,>+.'\#C>(<=B
M,)B\UP5#$T*BP_)6HU*\(SISY:,96DFT^5IZZ/8_:BBBBOPX_LT^8/VE/$&A
M:%!X..MZSIND"ZGUT6QU&\AM!.88M+,HB,S+O,8DC+[<[0ZYQN%?*_\ PL'P
M%_T.GAC_ ,'-E_\ ':V?^"C'_'E\(O\ K\\;_P#I+X9K\O:]G"?1VR'CS#T^
M*L;Q#G& Q.:<ZJX7"T,%.A2^HSEE\/9RK4Y5'ST\)&I+F;M.<DO=21_/W''C
M'FO"G$^99#ALGR[%T<"L$X5\15Q4:L_K6 PN,ESQIS4%RSKRA&R5XQ3>MS]*
M?^%@^ O^AT\,?^#FR_\ CM'_  L'P%_T.GAC_P '-E_\=K\UJ*Z?^)1N&/\
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MJ]?P[:^/_P 3"YY_T3V4?^#\;_\ +3]*?^%@^ O^AT\,?^#FR_\ CM-?XA>
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MI[0S^(M<M8I)M0UO3K=8(;HI.]TMO:W/5K_P61UP(BG_ ()#_P#!:7*A0?\
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M_$#. _\ GUF_3_F9/R_Z<^3^]G\:/_#2G[0G_2)[_@K'_P"(N>%__GO5[_\
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MUM=1Q_:%M;:98V]O?!8O)47L,-O'%=A80(@+A) (P$ V@"MJB@!%4* JC"@
M #L!P /8#@#L  .!2T44 %%%% !1110 4444 %%%% !1110 4444 %%8_B#Q
M!HOA;1M1\0^(=2M=(T32;=KO4M2O9/*M+.V5E5IIY,-LC5G4$X/+#UKR#_AI
MSX _]%7\'?\ @R/_ ,9KMPV6YAC82J8/ 8S%4XRY)3PV&K5X1G:+Y)2IPE%2
MM*+Y6[VDG:S1YN-SG*,NJ1I9AFN78&K.'M(4L9C<-AJDZ;DXJ<85JL)2AS*4
M>9)QO&2O=.WN]%<!X*^*?P\^(TNHP^!_%^B^)Y=)CM9=2CTFZ-PUG'>M.EJ\
MX*)L$[6TZQ]=QB?TKOZPKX>OA:LJ.)HU</6@HN5*O3G2JQ4HJ<>:G4491YHR
MC)72O%IK1HZL+B\+CJ$,3@L3A\7AJG,J>(PM:G7HS<)2A-0JTI3A)PG&4))2
M?+.,HNS32***:SA2 0W/]U'8?B54@?CBL3H'44=>E% !12 @YZ\''((Z>F0,
MCGJ,CWI: "BBB@ HHHH **** "BBL36/$F@Z ;==:U2TTTW0E-N+F389A"4$
MI3@Y"&6,-Z;A65>O0PU*5;$UJ6'HPMSU:]2%*E'FDHQYJE248QYI-15VKR:2
MU:0&W17%?\+&\#?]#/I7_?\ /_Q-=997EKJ-I;WUC/'<VEU$D]O<1'='-$XR
MDB-QE6'(-88;,,!C)2AA,=@\5.$>:4,-B:->48W2YI1I3DU&[2NTE=I7NP+-
M%%%=@!130P)(YR/8@$^@8C:2,'(!)&#GI2YSQSV/0CK[D8^HZCOC(H 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \"_:C_ .3?OBK_ -BI=?\
MI3:5^!S,V3R>I[GUK^B_XI^!S\2OA[XK\"C4_P"QCXGTF73!J?V3[=]B\R6&
M3S_LGVBU^T;?*QY?VB+.[.\8P?@0_P#!.=R2?^%NCDY_Y$C_ /"FOV+PYXIR
M'(LIQN&S7'K"5ZN8RKTX/#8NMS4GAL-34N;#X>K!7G":Y7)2]UMJS3?\Z^,/
M W%7%&?9;C,BRMX[#4,IAAJM3Z[E^&Y:ZQF)J.')B\7AYRM"K3ES1BX^]92N
MFEG_ /!.LDZQ\5LDG_B6>#>O_7[XDK]2J^6/V<_V:F^ 5YXLNV\9#Q2/$]KH
MUL(QH/\ 8WV+^R)M2F+[_P"UM2^T?:/[0V[=L/E>5G<^_"_4]?$\;YE@LWXE
MQ^/RZO\ 6,)6A@E2K*G5I<SI8'#T:BY*T*=1<M2$X^]!7M=733?Z;X9Y-F7#
M_!F595F^&^J8_#SS"5;#^VH5^2-?,<77I?O<-5K49<]*I"=H5)<O-RRM)2BB
MOY[O^"B6C^/_ !#^VWX[O/"WP;T#X_6WPJ_X)E>)OB?IW@?Q+\8_BA\+;SPY
MXCM/CGXFA;QA\,+7X<^%O$D_B/XEC1],FBTZQ_M+P)J]U)IFDZ7I'C+3KB_%
MQ8_T(U&8HC(93&GFF/RC)L7S#%N+>67QOV;B6V;MNXDXR<U\F?>GX*^%/VL?
MVCX]4\&_"+X=?'OP)\3?&4'B'X,_L\?#S0?$7@2WU;XA?'#X:>-/V3?"'C^V
M_P""BNJ7T'C"ZUAO"-SXZUF]\::Y;V>FS_#^S\,>$_%?PYUB^N/B=J$6K:-R
M'QS_ ."G'QP7X7R?$[X9ZAH_@S4M9^$?QA^+_P -OASXS\)^%/#Z>*]3_9[\
M-Z!X9\>?#F\\5_$'Q/:ZUXH\0WGQWTWXJ>$X_A7\*_ VL?$[5O"?A_P_XPL/
M%G@[3-9T?_A)OZ =6\/:;K&DZEH\PN[&#4]&O=">\T+4+[P]K-E87UL]M)_8
MVNZ)<6&L:%>0*XGT_4-(O;*]TV]B@O[">WO+>">/)\%?#_PA\//"'A?P)X1T
M6WTOPQX-TNUT?P]8/+=:C+:6EK;O;>=/J6J3WNJ:CJ=XLUQ-JNM:E>W>KZQ>
M7=[?:K?7EY>W4\P!_,[X"^,G[2WBK]J;P_X@\ ?'S7_A#X2^)O[6W[:>C6_A
MCQC>V>K_  L\0_$SQM^PY^QSX[_9S^&7B&7Q+);6TIA\;Z_XD@\(>&=)FLK_
M %:>'Q'<>&;2TUNZO;@?O#^Q]\<O$O[27PZU+XR:EI[Z%X4\2:Y%I/@CPY=Z
M3-IFL:0W@[0='\+?$V#6OM;"]FNK+XVZ;\2_#=BTL$,,NB>&M+U&U,L.I^:W
MTKKOAO2O$.B:IH-ZES;V6K6ES:S3Z/?WNA:K:/<VQMEU'2-:T>>RU;1=:LE*
M3Z5KFE7EIJ^D7L%M?:;>6MW;031TO O@CPO\-O!_ASP'X+TI-%\+>$](L]$T
M33EN+R]D@L;*,1QM=ZCJ-Q>:GJFH7#E[K4M6U6\O=5U;4)[K4M3O+N_NKFYE
M .KHHHH **** "BBB@ KYO\ CZ2)_"^"1^ZUCI_OZ;7TA7FWC_X?'QP^EN-5
M&F_V:EXN#9?:_.^UFV.<_:K?9L^S],/NW]1CGY7C3+L;FW#F/P.7T?K&+K/"
M>RI>TI4N;V>-PU:?OUITZ:Y:=.<O>FKVLKR:3%ZV\_\ ACXR!.1R>H[GUK[E
M^'O_ ")'A?\ [ UE_P"BQ7D8^ 3 @_\ "4CC_J#G_P"65>Z>'M)_L+0]+T;S
M_M7]FV4-I]H\OR?.\E=OF>5OEV;NNWS'Q_>-?&>'G#&>9'F6.Q&:8%X6C6P/
ML:<OK&$K<U3ZQ1GR\N'KU9+W8R=Y)+2U[M)M[+6^K[]E;=+L;--<D+D?WDS_
M +N]=Y]L+DY[=:=17ZZ(_G5\ ZSXT\1Q_!$^"/B9XPTS_@H7XT^*W[3.@?MA
M:/I_BOQ3XK\2^!_ ^G^ _P!HI+R;Q5\*=0N[KPMH/@'X>>.K+X$0_LS3ZAX:
M\/Z'?G4/!:^!=2U32?'OB.7Q#\Y_LJ?M1_M)>"O!4_QVD_:%B^,=_P"!?V3?
M^"(MC\;K/QI86WBN[\7^,OC1\8/C7\(OC=X4UK5K'Q!!;^ OB'X'3Q5>0^+]
M;33IO&UWX]\&:/+\0TNTLM7T74?ZL%MK=)I+A(8UGF6-)9E11+*D)D,*22 ;
MW2$RR>4K,5B\Q_+"[VS#'IUA$)UCLK2,7,OGW 2V@43S>:TYFGVQCSI3,S3&
M23<YE9I-V]BQ /YTM4_X*9?M=67P\_:@\>2:+\-M \2_#7P3\3O$1^&/B#5/
MAMK&O_"/Q9X*_:5\"?"?P)X0UCP?X)\<ZY\338>)_!&OZS=>.]1^+6C>"=0G
M\1VUAK7PSC/AZ\FTO3OTP_:H^,7Q0^!V@?LZ^$;OXL>$_AY8?$;QSXC\)_%G
M]J[QQX3\-P^#?A_'X:^&7C7QSHBR>&M7U_2/!WA[4/B=XK\/:=X-\/W?B76K
MK2;2-[K0[8ZAXRU[PW<C] #96A:X8VT!:ZV?:6,,9-P8@JQ&X)4F<QJJK&9=
MYC4!4VJ,5)/!#<QM#<11SQ,5+13(DL;;6#+NC<,C;7577<IPZJPPRJ0 ?B_H
MW[;GQSU7XV^$?#?_  F?PYO]1N_C)^SO\*K+X Z5\-M;T'QE\6O@Q\6O@EX%
M^(GCW]L/PL_BKQ)+X\\*^"O!VN^)O&.I6>FZIH=UX?\ "WAOX2>+/ 'CNXO?
MB)JT.J>'OCSP_P#\%+_VLI/AWX#\5^(?BE\(M-\?>-?^"<GP#_;D\"?#:X^%
MD:R?%WXM?$3QIXM\+6_[+W@Z,>);+6KVZ\>1:#I&DZ=+H\USXX7Q9X@35_#U
MA!X=TF^\/R_TQ&W@,RW!BC,ZQM"LQ13*(79'>(2$;Q$[QH[QAMCNBNREE4CS
M^#X2_#NU^)U]\9+?PQ9P_$G4O .@_"^]\3I/?K/-X#\,>)=>\8:#X>&G_;/[
M'BM]-\2>)M<U6"Z@TZ+43-?R12WDEK%;P0@'XC_'S_@HE^T;\-K+]I/Q1X8U
MOP!J/B_X;1_MZZ;<?LRW/@A?^$V^"G@3]F+X)_%3XB_!C]HSQQKJ>(KK5=1\
M+_%;7?!'@$7HU'1X?!_B;1?CKX*T;P!+#KOAN^O_ !9T?Q9_;G^/OPL^.W@7
MX:P>//#'C"\TCXP_LA?"SXJ>&+[PCX!\ 3WF@_M8>//A]X?\1?$3P1H-UXQ\
M4?%/QOX>^%FG?%O1Y=)\;:-H?A?X::'J'A+4O"OCK5/B'X@T_P 976F_NFUI
M:NTSO;PN]Q"MO.S1(S30+YA6&4LI,D*&64I$^Z-#))M4>8^Y'L[6243O;0/,
M(UB$KPQM((ED298@[*6$:S1I*(P=@E190HD56 !_+!\!?V]/VS_AI\.?A=\+
M=>^)6D_%3XA>&M$^)6J>)_%_QF\1_"'PKKGCGXXVW[4GQ0\ 7'[-/C'_ (3#
MQCX=\6:;=?#_ .'GA_P;KNJZ%\-M \8_&6TB^+OP[O[;2/\ A$K#2=!\3?U3
MJ<@$\$YXXR.>AP6&5Z$@D$@D<54&G6 D,PL[83-<_;6E$$0D-YY'V479DV[S
M="U_T87&?.%N! '\H;*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-2017331rd.jpg
<TEXT>
begin 644 biib-2017331rd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,@ 3T# 2(  A$! Q$!_\0
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MLHK?5M,UV1+;3HH=)M+:T0 WO#__  4R^!NO?%SQAX!CL?&EOX6T7X2_L_\
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MB601HTTI509'+=*NCZ2FH?VLNF:>NJ#3DTC^T5LK9;_^RHYVN8],^V"(7/\
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M"-(88((46.*&&*)4CBBBC54CCC54C155%50  #^<KP?_ ,%4OVD?%/C7PO\
M#O1[SX1ZNOQ'\7?L,W_A7XCW'ASPE>6%IX4_:J^,/CSX4>.-$G\(?"W]H#XH
MV&G:KX1M] T'Q#X4T/Q%\0H?&^FWMQ=Z5XZMY[+4=+U*+SO]J;]OS]H;Q[^R
MO^VUX-U3XJ_#'X):_P#!GX*_M.^$-#\26&@^(?#'CC]J#QW\,OVB/VF_V<-5
MU;X&W>G?%2WU;X<:UX'TSX)^#O$?B33/#)^(.L:'XZ^*FCBZETOP;8Z8_B#^
MF&W\+>&K18DM?#^AVR0737T"0:1IT*PWKWSZH]W$L=LHCNGU*234&N$"S-?2
M/=ES<,TA6;PQX<N/+\_0=%F\F;5KB+SM*T^017&NI<1:U/&'MF$<VKQW=U'J
MDJ8DU%+B=+UIUED# 'P1_P % _B-^SY\/M$^&TGQO^(_BR'5_$%]XKTOX2?L
M^>$?CJOP(N?CWXZ33=*O$N=0\36?BSX>W]OH_P ,=/@FUF_\3ZWX]T+X;> (
M?$#>*_%MOJ?B&U\!+:_FGX[\;_$GPEX \=6WQ9_:7U+Q/^T-\(/V#_V:]?\
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M$EQ%Y]O/:S"*91)&);:ZBAN;>4(RB2"XABGA?=%-''*CHMF@ HHHH ****
MG'K^1/\ *DR/?\C_ (5\5_MB_#63XB6_P]5/%&J>&O[(N?$S$Z9&[F]%]!HJ
M;9ME]9X$'V;,>?,R96P%Q\WP]_PS//\ ]%2\5?\ ?B;_ .7= '[:Y'O^1_PH
M)!!!!(/!!4X(]#Q7XE?\,SS_ /14O%7_ 'XF_P#EW1_PS//_ -%2\5?]^)O_
M )=T ?H>O[&/[-4/[1,_[52_"_1!\99M#;1Y-?*3G2Q<O=W-S/XM7PL6/AR/
MQ]<P7=QI=WX]73AXIGT6233)=3:WDEW_ !EX5^+7[%/[0UY^U?XRTO\ 9=^+
M_B&1;/X*^$-?\5Z?\#O'ES_PT!X<\%67A?XI? C7?A#?^&Y FFWWA_6/VA-+
M\3^#-2N;CX<^-M)M-9LOBM=3V'@G2;3Q9H?GI_9HN!ROQ5\6(W\+K;R%T;^%
MT#:WL+H<,H?Y2P ;@FOSB^#G_!,[]HCX:>.OVC_&-E\8OA=X6MO'7B!U\+>"
M/"6B_$?2_A3\5[._\+?!VPU?Q?\ $GP18^,YHOA/KKQ>$_B'X9TA/A[:ZUJ^
MFW_CK7_$.KWOB[PK;>$O"\0!^['[//A;]E;QUX#\;Z#H?PD\2^ ;KX._'[0/
M%/Q;\*?&*;7)/B3X9^/'@+PY\/?B?X,\7_$3QO?^-O&T_CW5+#P+JOPQ\4^'
MO%4WQ#\:Z$_A-O#NEB^2WTA]&T[G_!'BC]D[]LKQQK<VL_"SXAQZY\4?@?X%
MU_P9?_%#3O%GA?1?B_\  'P%\1KSQ3X"^*GPFTVS\77-CHTOA+Q_XUTGQ/;>
M)CI'@'XV^&I/%GPZUG6;;3M+OO!$T7Y0_"O_ ()]?$[P)X?UGPC+XY\!Z/X!
M^*?C_P 3WGQ$^&WA/5OB7>Z+\,/AMXA^$S^$]2L/@]XAUV&QU7Q?X[\7>/K.
MU\4^+;GQSIOACPIIUEK^N_\ "+V<=[IMA;ZII?!?_@GY\2O"OB3X?ZO\2_C!
MH-U!\#_@K=_ 3X7S?#^U\8K?>(_#VJ7O@(ZQXV\;VGB.\L++PSK-]HGPL\#Z
M9#X,\-W/B;2++5?^$GUK_A*+FWO-$TS3 #^A3X4?!?X:?!+1=4T+X;>&_P"P
M[?7M:E\2>)-1O=6\0>*/$WBKQ#-86&DMKWB[QCXNU77_ !=XLUE-(TG2=&AU
M/Q%KFIWEMHVE:7I-M-#IVG6=M#ZED>_Y'_"OQ*_X9GG_ .BI>*O^_$W_ ,NZ
M/^&9Y_\ HJ7BK_OQ-_\ +N@#]M<CW_(_X49'O^1_PK\2O^&9Y_\ HJ7BK_OQ
M-_\ +NF2_LS3F*4#XI^*AF*49\B;C,;#/_(;'2@#]N:*P?"UK]A\->'K(RO<
M&ST/2+4SR#$DWV?3K:'S7!9B'DV;V&YOF8_,>IWJ "BBB@ HHHH **** "BB
MB@ HHHH _$#_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_R%?B'_P %
M)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7^0H X>X^*/PTM9Y[6Y^(?@:
MWN;::6WN+>?Q=X?AG@N()&BF@FADU%9(IH94>.6*15>.161U5E($7_"V/A;_
M -%)\ _^%EX<_P#EG7PMXE^'W@*X\2>(KBX\$>$IYY]?UJ>>>;P]I4DTTTVI
MW4DLTLCVI>2661FDD=B6=V9F)))K%_X5Q\//^A#\'?\ A-Z1_P#(E 'Z!_\
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M=H'C'PKK>H&&2X%CI'B+1]3O#!"4$TPM;*]GG\J(R1B23R]B%T#,-RY_.?\
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MD_6@#Z[HJ#[5;?\ /Q!_W^C_ /BJ/M5M_P _$'_?Z/\ ^*H \"^/?^I\+?\
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M]O(_]7'_ +B_^@B@#X&UU537-;1%5$36-41$10B(BW]PJHB* JJJ@*JJ J@
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MG)_Z U 'W_HO_((TO_L'6'_I)#6G69HO_((TO_L'6'_I)#6G0 4444 %%%%
M!1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_
M -!%?B'_ ,%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!% 'P1K__
M "'M=_[#6K?^G"XK)K6U_P#Y#VN_]AK5O_3A<5DT %%%% !1110 4444 %%%
M% !7J_P9_P"1T3_L$:G_ .A6E>45ZO\ !G_D=$_[!&I_^A6E 'US1110!\]_
M'O\ U/A;_KMJ_P#Z+TZOG.OHSX]_ZGPM_P!=M7_]%Z=7SG0 4444 %%%% !1
M110 4444 %-?_5R?]<Y/_0&IU-?_ %<G_7.3_P! :@#[_P!%_P"01I?_ &#K
M#_TDAK3K,T7_ )!&E_\ 8.L/_22&M.@ HHHH **** "BBB@ HHHH **** /P
M[_X*72^1_P %'_\ @A9+Y4\^S]JS]I\^5;1^;,V?V._B OR1[ER%SN<Y^5 S
M<[<']HTUTA%']C:]PB\'3"#P!U'V@X/MG@\9K\8?^"D__*23_@A3_P!G6_M0
M?^L<_$&OV[C \N/@?<7L/[HH ^!]<;?KFM/M=-^L:H^R1=DB;KZ=MDB9.R1<
M[77)VL",G&:RZUM?_P"0]KO_ &&M6_\ 3A<5DT %%%% !1110 4444 %%%%
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MJ1@J"/0@$<=.#Q1@9S@9QC..<#) SUP"3Q[FEHH   .@ Y)X]3U/U/>BBB@
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M_P!AK5O_ $X7%9-:VO\ _(>UW_L-:M_Z<+BLF@ HHHH **** "BBB@ HHHH
M*]7^#/\ R.B?]@C4_P#T*TKRBO5_@S_R.B?]@C4__0K2@#ZYHHHH ^>_CW_J
M?"W_ %VU?_T7IU?.=?1GQ[_U/A;_ *[:O_Z+TZOG.@ HHHH **** "BBB@ H
MHHH *:_^KD_ZYR?^@-3J:_\ JY/^N<G_ * U 'W_ *+_ ,@C2_\ L'6'_I)#
M6G69HO\ R"-+_P"P=8?^DD-:= !1110 4444 %%%% !1110 4444 ?B!_P %
M)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$5^(?_!2?_E))_P $*?\
MLZW]J#_UCGX@U^WD?^KC_P!Q?_010!\$:_\ \A[7?^PUJW_IPN*R:UM?_P"0
M]KO_ &&M6_\ 3A<5DT %%%% !1110 4444 %%%% !7J_P9_Y'1/^P1J?_H5I
M7E%>K_!G_D=$_P"P1J?_ *%:4 ?7-%%% 'SW\>_]3X6_Z[:O_P"B].KYSKZ,
M^/?^I\+?]=M7_P#1>G5\YT %%%% !1110 4444 %%%% !37_ -7)_P!<Y/\
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MVFD]O2D_I,^!R5WQY0LE?_D0\5;:?]2+S0?ZP9/_ -!J_P#!&)_^4_U;TO\
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M6HO^ZN+FU?<C6F/WMK-!+CD@KYFQL_,I(&/,:]7^#/\ R.B?]@C4_P#T*TH
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MXF0\;O\ HOL=_P"&KAWR_P"I/Y?U96/[>S?_ *#9_P#@JAY?].O+\7W/J_\
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M;4;ROUC QZ=2>/<D_F>I]Z /Q!_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;M/\
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M_DOZN_*V'_9,_P#STA_[Z/\ \31_9,__ #TA_P"^C_\ $UN44?\ %/;Z-_\
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M )[O_P!^U_\ BZXO^)#_ *4/_1O,)T_YK7@3R_ZJ7S?W,P_XB%PE_P!#2?\
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MGQ(U_5_A1XN^)&C+8?$F[\3WQO?&.I>&M?T.\^'?PW\-^%?"EW/JWB_0M/\
M&7BA-9O;S4AX<'A7P1XD-]$LZP4:52LY3M2Q'U9P_=*;J>QEB&WS55"FHT*=
M6K.-:=*K2C2G&K3A52IO2/#69RKT:"A3YJV$6,C->WE"-*6(I82*M"A*I5E/
M%5Z%"G/#4Z]"K*M3J4JTZ#E6C]MT4YMFYC&0T98F)@\<@>(DF-Q+$3%*KH59
M98B8I 0\;%&4EM>L> %1S?ZF;_KC+_Z+:I*CF_U,W_7&7_T6U..Z]5^8I;/T
M?Y'])/@3_D2?!_\ V*WA[_TSV5=77*>!/^1)\'_]BMX>_P#3/95U=?Q=B_\
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M*$*;E*G&#4[Q4)SG4BE;EJ2=1>^^84G))..23@ *HSV55 55'154!5 "J H
M"445TG"%1S?ZF;_KC+_Z+:I*CF_U,W_7&7_T6U..Z]5^8I;/T?Y'])/@3_D2
M?!__ &*WA[_TSV5=77*>!/\ D2?!_P#V*WA[_P!,]E75U_%V+_WK$?\ 7ZI_
MZ6S_ $GP/^Y8/_L%P_\ Z9@%%%%<YU!1110 4444 %%%% !1110!^('_  4G
M_P"4DG_!"G_LZW]J#_UCGX@U^W:?ZJ/_ '8__9:_#_\ X*6F9?\ @H__ ,$*
MS;QQ2S#]JW]I[9'-,\$3?\8=_$ -NE2"Y=,+N(Q"^Y@%.T$LO[3I/X@\N/\
MXEFC8VQ_\QV]]NW_  CO]::W7JOS _G?^(__ "43Q_\ ]CSXP_\ 4DU.N,KL
M?B(7/Q!\>F1560^-_%Q=48NBN?$>I[E1V2-G56R%<QQE@ Q1"=HXZO[.P?\
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MVDW/EO\ VNKVO:]E?>RTM^5_V&__ .?"^_\  .Y_^-4?8;__ )\+[_P#N?\
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M?]]'_&C>_P#>;_OH_P"-'_$W^(_Z-_1_\2B?_P!#P?\ $NU#_HK:O_ABC_\
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M1K:7I^J/KVBBBOZO$?._Q^_U/A7_ *[:Q_Z+TZOF^OI#X_?ZGPK_ -=M8_\
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M.O[*PO\ NV'_ .O%'_TW$04445N 4444 %%%% !1110 4444 ?B!_P %)_\
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M\;XO_>\5_P!A%;_TY( HHHKG **** "BBB@ HHHH *];^"O_ ".R?]@C4_\
MT.SKR2O6_@K_ ,CLG_8(U/\ ]#LZ^AX3_P"2FR+_ +&>$_\ 3L1K:7I^J/KV
MBBBOZO$?._Q^_P!3X5_Z[:Q_Z+TZOF^O%_\ @K'^VEJG['MA\"+C3/AUI7Q
M/Q!U#XBV\Z:GXEO_  Z-*'AFS\(3QO ;'2M4-V;PZTRR"40" 6ZE#(96"?C7
M_P /L/%/_1N7A7_PYFO_ /S)U\UF'T:O&3Q!Q=7BWA/A6CF609K[-8'&SXAX
M:P,JSP%.GEN*OA<PS?"XNE[/&83$4E[6A#G5-5*?-3G"<OSG/_%C@/AC-<5D
MF=YU/"9E@_8/$8=97FV)5/ZSAZ.*H_OL+@:U"?-0KTIODJ2Y>;EE:49)?OY1
M7X!_\/L/%/\ T;EX5_\ #F:__P#,G1_P^P\4_P#1N7A7_P .9K__ ,R=<?\
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ML/\ ^)9P=Y?]3_S?W>8?\1W\+O\ HHZO_ADS[_YV>?Y]F?OY2-]U_P#<?_T
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MO^K;/_,K_P#X T?\/LO^K;/_ #*__P" -?@_11_Q)_\ 1W_Z-\O_ !*>-?\
MZ(_7^EJ?\1T\4?\ HIO_ ##</^7_ %*O)_?Y'[P?\/LO^K;/_,K_ /X T?\
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M']Q'\T?_  <7_P#((_9$_P"PQ\;?_39\-*_F#K^GS_@XO_Y!'[(G_88^-O\
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M^@S$[?\ 7Z9_J[EW_(OP/_8'A?\ TQ DHHHKA.P**** "BBB@ HHHH ****
M/Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OVZ7_51_2+^:5^(O_!2?_E))_P $
M*?\ LZW]J#_UCGX@U^W2_P"JC^D7\TIQW7JOS _SD?VC?^3A_C__ -ES^,7_
M *LGQ/7C5>R_M&_\G#_'_P#[+G\8O_5D^)Z\:K_7?*?^15EG_8OP7_J-2/\
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M%C_^C3?V>O\ Q,[0_P#YUE'_  Y^_P""Q_\ T:;^SU_XF=H?_P ZRNS_ (F
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MXF=H?_SK*_MCP@\7_#WA7P]R'(L]S]X+-,%+-7B<,LISO$^S^LYUF&+H_O\
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M\O\ J;>;^YGPQ5:]_P"/*^_Z\KS_ -)I:^\/^'/W_!8__HTW]GK_ ,3.T/\
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MA2C&2O%N+M)-73:>Z;1]F4445RG2%%%% !1110 4444 %%%% !1110 4444
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M$D<T%Q!))#-$Z2Q.Z,K&U0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_KEWXA\16%CK%Y%%'\1-3T:]L[!4E\-$I)]PW'PUT_XE?MF>$O%FH?"_2X/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /SZ_:X_P""E?[._P"Q9X[\-?#SXP6/Q+NM?\5>$O\ A--,?P5X
M1M/$.G+H_P#;6H:%LN[JXU[2GAO?MNFW#?9U@D7R#'+YN7*+\HR?\%\OV'8X
MY)&T?X_;8HY)6Q\,M,SMC1G;&?&8!.U3@9&3Q7YB_P#!PC_R=1\%/^S?O_>D
M^+:_ VZ_X]+O_KTNO_2>2O[4\.? ?@/BC@KAW/LTCG7U_,\&Z^*^KYE"C0=1
M8FM2_=TWA9N$>2G'1SEK=WZ'\>>(/C=QOPUQCQ!D>6O*%@<MQD:.&^L9?.K6
MY'AL/6_>5%BH*;YIRU48Z.UN_P#I<^"O%FE^/?!WA/QQHBW::-XR\-:#XKTE
M+^!;:^33/$6E6FL:>M[;)+,MO=K:7L(N8%FE6*8/&)9 H<]-7B/[,_\ R;G\
M _\ LBOPI_\ 4"\/U[=7\;YC0AA<?C<-2YO9X?%XBC3YG>7)2JSA'F=E=\L5
M=V5WT/ZXP%:>)P."Q%2WM*^$P]:IRJT>>K1A.7*KNRYI.RN[+2XUW2)'DD=8
MXT5G=W8(B(@+,[LQ"JJJ"S,2  "20!7G<?QA^$LO@WPS\18OBA\.Y/A_XUO/
M#>G^#O',?C?PP_@[Q9?>,M2M]&\(67AKQ.NJ'1->N_%6KW=KI?ANVTJ^NY]<
MU&YM['2X[JZFCB;H/&EO=7?A#Q3:V,<\U[<^'-=@M(K8%KF2ZFTF\BMX[=5^
M9IGF=$B"\F0J!S7\QFF_LA?M+V?[,WP7_9QN/@1XTA^$_P"S_P"+/^"=G[2W
MPQT&+1[6X33_ !Y\4?CM^S/>?%WP!!X<MMFJ6-Y^RIJ?AW]KCXD>+K2:.VM/
M#7A7XJ_#>73K@S^'+PV_&=9_4N'0YPZG&<X8<8.#GGC!!!ST/%9&E^(_#VN7
M6NV6BZ[HVL7OA;5QX?\ $UII>J6.H77AW7FTC2M?71-=M[2>:72-7.A:[HFM
M#3=02WO3I.L:7J0@^Q:A:3S?S7^/-9_X*<W=SXTU?X<:-^U1X6;QQ\./B0_B
MWPI-IOQ)\3:]\+/C'X?_ &L/V89? 5AX6\;>,O$%U\,_%BS_  4UGXV@7O[/
M_P *O!/P6UKPO8:Q;ZE<^.Y].T^6P].U+X4_\% /A/XY_;UNOV?M-\7V_A_Q
M7\;OB:WP!DU&/Q#JWC3QI\9;W_@GK^S3X4^&/QT^)7B_Q-J$NF^._@YH_B;X
M=^-/A9IEGJ[W&EI\<=3T'Q?\0+Z;P[X4MK;PZ ?T*275M"8%EN((S<S"VMQ)
M-&AGN&C>40PAV4RS&*.2011[I"B.X7:C$2[TP3O7"]3N&!VY.<#D$<U_.-K7
MP:_:<\::7^S9\2_&MY^TCXY\*_ C]N;PI\1]#T:RT+]JKPEXQ\*^&KW]E;XT
M^ ]6US5M"\<?$#7_ -H#XG^#W^.7BCX9V_B4ZCH!M_"WAW7/BK9>"+:^^$VJ
M:QC3^%5I_P %(1\+Y)OBCXE^/-X[W_[-J?M3:-X2\&?&+1?B79W*^.=1G_:/
MU#]GSQ1XM\6ZPVI7DU@;;3M6TC]E70-/^'2_#.%M3^!M]%\1IK'3Y@#^@S0_
M$_AOQ,FJ2>&_$&A^((]$UO5/#6LOHFK:?JR:3XBT2<6VLZ#J;6%Q<+8:UI%P
M1!J>E79AO]/F(BN[>&0[:VMR]=RXSC.1UXXZ]>1Q[CUK\ ((OC+^S+_P2W_X
M*J_$73X?BO\ "'QU9_$'_@H#\=?A%XG\;E=&^)B:)J[W/BOX9>/IK[4&RVH7
MMG%97EK>ZZ_]H[H?(\6D:S#K(';:#H?[7GBC]I[X>:/X:U7]KK1OV4=7^/GC
M.\O[CXEZEXOT#Q=#IND?LJZGK>OZ=XQUR7R_%FA?!K5/VC],\'6?@5EN;7[;
MKTGQ!T+X?W,?PKUGP[!<@'[D[T )+J OWCN&!SCDYXY!'/<5BZ'XG\->)DU.
M3PWXAT/Q!'HNM:KX;UA]$U;3]632?$.A7'V36]!U-K"XN%L-9T>Z_P!&U32[
MLPWVGW'[F\MX9/EK\ M%3]ON;0/ TEV_[8T6EGPO\(/^'A2:S_:B>,C\3H_B
MOHC?%(?L-KI(-^GA,^'_ /A.1X@/P('_  C\OP7_ .$.7X6L?C296'@</@7]
MO#X1_#[]KAOA%X-_:YTBW^,'AG_@IU+\&M,T73M3;QX?C?XW^//@;Q_^S[\4
MO%#1R1G0?$NN?"-_$47@[Q[XBF2^:33=3\):U-_PG]Y::/K0!_4=/<V]K#-<
M7,\,$%O&\T\TTL<44,4:[I))9)&5(XT7YG=V55'+$#FI0RDX#*2>0 021C.<
M9]"#]#FOP#_:3^#?[2'[0G[.O_!0;X.>)-,_:^UGXZ>/OAG^V5I&CZ'I?B.?
MPI^S%KWA:/QC+??LC^'OA;J@U+2;$^(M?^&%IX0TJ^TOP1>P:CK^N7GQ8\/_
M +2>^TU+P];O[!\(]1^/FE_M:^#KO0;7]L7X@?"'Q1XJMM*M-.^,>F_&7X:6
M/PG^"\7P(6TTS5O%$_CN?Q3\+?BUIMOX\T&TN9Y/%0^&/[9\WQ#\8WT_C ^)
M_!^@R0:V ?L]12#) )&#@9'7!],C@XI: "BBB@ HHHH **** "BBB@ HHHH
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M_!7Q6\-?#;]H2+QK;ZGX=^$OB*[\*Q>#M*U#]_US@9ZX&<G)SCG)P,_7 ^E
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M=_9J^'?QJUW3?$/C"?Q+%?Z5I']BVRZ+J\.GVYLQ>W%\#+%)I]VSS^?<R#S
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M]1CT.!FEHH :54]54]^0#SC&>1Z<?3BG=.E%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?.7QD_:A^&WP,U_2_#?C2W\
M42ZAJ^C_ -N6K:%HT.I6PLOMUQI^)I9-1LVCG\^VD/EB-QY>U]_) \@;_@H=
M\!55F-E\1"$5G./"MKG"*6.,ZX.< U\K_P#!1_\ Y*UX%_[)R/\ U)]7K\[Y
MO]3-_P!<9?\ T6U?YW>+7TFO$W@SQ%XMX8R67#ZRO)LPAAL$L7E-2OB/92P>
M%KOVM98VFJDN>K/50C[KM;J?#YGQ!F&%QV)P]%T/9TIJ,.:DY2MRQ>KYU?5O
MHNG;7^H_0M8M/$.B:/K]@)EL=;TO3]7LUN(Q%<"TU.SAO;<3Q!W$<PAG02QA
MW"/N4,P&3JUPGPN_Y)I\//\ L1O"/_J/:=7=U_H%E>(J8S+,NQ=;E]KBL!@\
M15Y5RQ]I7P].K/EC=VCS2=E=V5E=GVM*3G3IS>\H0D[;7E%-V^;&221Q(\LK
MI''&C2222,J(B(I9W=V(541069F("J"20 37D?PS_:$^ OQJFU"W^#GQM^$7
MQ8GTFWCN]5B^&GQ*\%^/)=,MIG6.&XU&/PKK>K264$LCJD<URL44CLJ(Y9@#
MZ!XJMYKKPUX@MK>&2YGN-#U>"&WB!:6>6;3;J.*&-1DF261UC0 $EF Q7\PO
MP^_9B_;\^%?[.?[(5WI=IXANOB;X"_X)T_"SP=\-#X1^"\/PV\4?L^7MUXI_
M9=TG]K/X3_%&'POKE_XB\;?$ZZ_9XTG5XO@-+'JOA:__ .%B_#KXA3Q:1<_$
MB_\ AK<Z#WEG]2^]  2R@'.#N&#CK@Y[=_2EW+DC<,CDC(R!UR1]"#^-?SZ^
M,;/]M:Q^#/@G5SXQ_:E\3#3M;_:)N?!G@KP;\./VDO!>I:_;W.G_  O/PBT;
MQ?X\'C/QS^TYX>\0Z+XDL?B3_P *P\2?M$^ _%_PEUG0?%FJ0?'7PO G@WX?
M7NN:^EZQ_P %*8?BW\8O&?B71/BO+K=K;?'GQ'H'P1\*VGBM=#U_X82? W7+
MOX$?#/PK\7]9UV\_9(\+?$BW^(,G@NWU#Q_H?@3Q-\36^)VF^+K/Q%H%[\*=
M8M;JR /WRW*1D,I'KD8_/-8^M^)/#OAFVMKWQ'KVBZ!9WNL:)X>L[K6]5L=*
MMKO7_$VK6F@^'-$MI[^XMXI]7U_7+^RT;1-,B=[W5=5O+73K""XO+B&%_P">
MSX;Z1_P4 UOXQ>#_ (?WNO\ [44?[-_B;X[_ +-6MZCXPBT;XW^!/$5AX'\1
M_ 7]NVR_:&\/:EXG^-_C/QE\:-&\*V'Q'\'_ +-45[J%]-X&MM(U[Q%X=U?X
M;^%O"(UVPUBZV_$/PW_::^*WP-\(^&/B'HG[8VJ_'J']IW]A'Q1^T+)K4%E/
M\(/#GC#P7^WI\-/%7CGQE^S,UU!>1Z7X3\$_#G1]>\2V&O?#JUF^&^C?"O3O
M#>K^+P_Q>LKYT /Z$=RXW;AM&<MD8&.#STX((/IBDWIC.Y<=,[AC(ZC.>U?D
M[X>U+]K#PA^QU^U;HEYX8^.GCCQWX%_:'^.'@;X'K=>(-2L_B_K?[/\ _P +
M?TRS\%>,M.\:WVFZ_P"+O&]KX6^'>M:WKFE:EIUMJ7Q-\=>%_"\>@>%M4G\?
MWND:W7QU\-/"G[?GB_XJ67PZ\8^)OVK=/^ -IX^_:BD\->,M$7XO_"W5]9^&
MVI?LF_LP^+/A#%K^N_$?QQ\0_C5IDFG_ +1-Y\9+#PE-XX\;-XT.KV&N>&KN
MST;PDX\%Q ']!FN>*/#7AE=,?Q'XAT/0$UK6]*\-:.VMZMI^DKJWB+7;C[)H
MF@Z:U_<6XO\ 6M8NO]&TO2K4RW^H7'[FSMYI?EI?$?B?PWX/T:^\1^+/$&A^
M&/#VEPI<:EKOB+5M/T31M/@DFBMXY[[5-3N+6QM(7N)X8$EN)XT:::*(,7D1
M3_.#H_A/]MOXSZ?^R=K7[2/@G]IW5_C;8?M4_P#!.7XPZOHD&@ZCIWP(\'?!
M'P[\//@[K7Q,U?Q7H%M%;^"=!^*'A?XVW/Q2O/B9820K\5-%\000/8PP_!NP
MTQ8?>_\ @IW\./VC?BM;?M)_#RT\,?M!^-O"WBKX#_!C3OV:?"7P9MM7O?AG
MJWB^T^(^NZG^T+;?&JSL,:%<:Z="LO LFAQ?$%OL5QX12:V^$*M\0'\3*X!^
MXNA>)/#OBBP;5?#6O:+XATQ-3UW1'U'0]5L=7L$UGPOKFH>&?$NDM>:?<7%N
MNI^'O$FDZKX?URP,@N])UO3-0TG4(;>_LKFWBV-R\_,O'7D<8ZYYXQ[U_/9X
MDA_;<\/>'/"WB1H_VNM;UW1?B9^W!J'AWX/>%=#\8^$].\;SR?MZ_&C7/@R[
M?%/X=/K=AX4U?6?@7%X(TCP1;_M0_#+Q'^S1??#C7-)UZYUW1M>CUB]/IT\O
M[8I\%_%:XN8/VR(OCJWQ U]_C5;^&S;2_":#X!O^UMX1,<'[*"Z^SZ1-\5X/
MV/#XD7X9R_![?JLEZGB$_%UY/C4W@$4 ?N,&4\@@CU!'KC^?'UXHW*<X93CK
MR..O7TZ'KZ&OQ \*:;^W%;Z[IUEX9N?VCY?@Y\;OB;\1_@E\/]2^)=]J=Q\2
M?@S\'M.U+P!\3O!OQK^*,>OSQ>-?"UU>V6F?M4_"SP]XB\3D_$R[TS7OV7M.
M\9(/$-J]Q!X+X)L?^"G=W\)/$I\5>+OCI9_%75==_9&TSXKZ3X8\!_$ZRN="
M^(6M?ME_!FU^/>N_"KQA\1O%>O>"I?!'A_X'7?Q>M]4L_@-X1?X)3?#A-$\2
M7,UMKNE7>FZD ?T<@@]"#GI@TM?G-\ &^*EM^U/\7?@Q?^.?''BCX2?L_1IX
MO\.>)-?\:MXJO?%+?'_1]%D\+?#;Q5K-Q?:CXAU;5_@A>>"/B[J%S9>+)Q?'
MPY\2?@YJRRWCVXF7]&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#YR^,G[+WPV^.>OZ7XD\:7'BB+4-(T?^P[5="UF'3;8V7VZ
MXU#,T4FG7C23^?<R#S!(@\O:FS@D^0-_P3Q^ K*RF]^(@#JR''BJUSAU*G&=
M#/.":^[**_.,W\(?#+/\RQF<9UP1P_F6:8^HJV-QV+P-.KB,354(4U.K4>LI
M<E.$+O[*L<%7*\OKU)U:V#H5*DW><Y03E)V2NWUT27R1E:%H]IX>T31] L#,
MUCHFEZ?I%FUQ();@VFF6<-E;F>4(@DF,,"&60(@=]S!5!P-6BBOT.E2IT*5.
MA1A&G2HTX4J5.*M&G3IQ4(0BND8Q2BET22.Y)12BE9)))+9)*R2]$%)@$8(!
M&,8P,8],>G X]J6BM!C2B$8**1SP5&.>O&._?UHVKG.U<D8)P,D8QCITQQ].
M*=10 @51T51] !TZ?EDT;5&<*!DY/ Y(.03ZG//UYI:* $(!!! (/4$#!^H[
MT!5'0 ?0 =>OYX'Y4M% ";5SG:N>.<#/'3GV[4%5)R5!(Z$@$C\:6B@!I53U
M53C.,@'&3D]NYY/OS1M7GY5^;KP.?KQS^-.HH 3:HP !@'(&!P>>1Z'D\^Y]
M:3:O/RKSUX'/.>>.>>?KS3J* ,#0O"OACPN^N2>&O#F@^'Y/$VO7OBGQ&^AZ
M/IVDOK_B74HK:#4/$.MMI]M;-JNN7\-E9PWFKWYN-1NHK6VCGN9$@B5-^BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X;Q3\0
MM!\(7MM8:LFH-/=6OVN(V=JD\8B\UX<.S3Q%7WHWR[2-N#GG%<P?C=X, ),6
MM\ G_D'Q]O\ M[KSOXZ_\C+HW_8#/_I?<UXB_P!QO]UOY&@#]"K.ZCO;2UO8
M0PAN[>"ZB#@*XCN(EE0.H)"MM<;@"0#D9/6K%8_A[_D :'_V!],_](H*V*
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MYJ&H7MQ!:65K#+<7,T4,;NO\WGA>?_@I/JWB3PS8V,/[57ASP!\2!^Q9K7Q
MAO;'XK2>,/A7X[C_ &U?@KH'[2'A >./BGK^LIK-II_[._BOXCR>._%/PO\
M /PU^ ^O>'_#UWXL^'GA"2#1Y;ZVH_'OP+^VUXZ^"/[:OP4^(.@?MC>,?!\_
MP<_;[^"W[(.D>"3K^LZE\0_$VI>,?BOI'@'_ (:!UNY=[KQSX7\0?"#6?AIH
M/PE\2_$Z]O/"&OZ!;>//[3O-1^*$F@7UX ?TPQW%O-#%<0SPRV\T:2PSQRI)
M#+%(@ECDBE5BDD<D9$B.C%60AU)4@UE^'O$GAWQ;H>D>)O"NO:+XF\-^(-.M
M-7T+Q!X?U2QUK1-:TF_A6XL=3TG5M-GN;#4M.O+=EGM;VRN)[:XA998970AC
M^?\ ^T19_%RTU?\ 9/MK:'X_VOP+L]!\9V_Q;LOV<UU.#XF1?%./PGX%@^!4
M'B*/0=OBJ/X707"_%"/Q:D3IX:B\9CX=GXDD>!8]:(_+#]ASX2_\%"?!>D_L
MJ?"+XB77Q5^$GACPG\*OV7/ >D^$M$\%_%A]%T+X*Z9^SSX.T/XVZ+XOUWPS
MXU\._ CP=\5HOB8?B=%=>(?%NG:C\5_"VNV?@'6/A-::QX02VTZ4 _IH+*.2
MP ]20/4]_8$_@:P]/\4>&M6U77]"TOQ#H>I:WX5N-.M/$^CV&K:?>:KX<NM7
MTV#6=)MM>TZVN);S1[C4](N;;5=/AU&&VDO=-N(;ZV66UECE;\ O&[_\%*M<
MT#X6WWB"X^,7A?PMX3N/%/P*^+G]AZ'\7=4\4^,_&OP-\*6?AGP/\>M#T7]G
M_7M%^*+^ _V@/'^K?$_QG!KNDS1^'KNST/X-V_Q)L_\ A#9+U([GAOX?_M9^
M$?B/\8O%GQ#T3]H7_A&/B)\;/V)KK]IOQ[\%/"%]X1^)WQ(\%^&?^"=UMX4\
M9>(?AII/P]U/7/%MEIMG^U9IW@+3/B7I?PDUO6O$WAWPY%XDT?1=6OM$LM8O
M) #^@S<O'S+SC'(YSTQSSGMZT;T_O+_WT._3OWK^:[P5X^_;@UCXI^+_ (5Z
MMXJ_::OOCEX%^&/[ OB[X6^&[6\,WA/PR?'?[3?[5EGK6H?M9V_ADMX1M;_Q
M1^RUX#\#1?&TZXO_  C.H>(]"\5-X"+?%F+02+B^'?\ @HNWPC\4ZXNM_MEI
MXYN/V'/V[OB9INF?VMK:ZFG[4WP2_:+MXOV*/#&GZ7<6TR6NM>+OA;KFL"Y^
M'2#^P?CAX=T[3)_'^F>()=&M[F@#^D;<N2-PR.2,C( ZDCMC(_.H9+JVA:!)
M;B"-[F;[/;K)+&C3S^5)-Y,*LP,LODPRR^7&&?RXY)-NQ&8?SM^+4_X*?OIO
M[9NJGQ%\6;/XII\'/VZ;WP=X6\!> /BW>^';LR^#/&;_ +&UG\'_ !/K?B^+
MX+Z;XWTRX_X5K>Z.OPL\*7WQ/U;Q(OB_P_\ &&W@N9DU:VU/B3\%OVB[S]J3
MX2ZIXYL_VN?'/P)_9Q_;&_9S^-6A>(K'Q-\4-=UZ'3OBG^Q?^T=X&^,5WI=K
MX(O;/6_&?A/P]\>[SX2Z;XB\+:=I&JZ9\-_#_CSX@Z5IVEZ+\,?$GBW1HP#^
MA8LH(!(!/0$@$\XX'?D@?6DWIS\R\=?F''..>>.>.>_%?G'\8/\ A<Q_:\T1
M=77]IH?"@>%/@3_PHT_L]&-? _\ PL7_ (6QXS'[1)_:&-W_ ,4T?#Z?#\?#
M$V2?$G.@OX&/CD?"8-\83:@?"WV+]O?4M$UJ"?Q#^UUX4\<2>!?BE'^U3K5G
MX:U'Q?X-M/B'!^T9\,KCX3)^R9X:DU_PO+?^!M1^$</Q6TK6[C]G[7]-\9Z?
M\%]0M-6NYI_VF=.\)VLH!_0 ;JV6:*W:X@6>:.:6&$S1B:6.W,2W$D<1822)
M TT0F=%98C)&)"I= TP(;D$$>H(/OV]B#7\YMG\-?VD?$?Q0^!7QOUOPK^V=
MX/UCP3\"?^"CWP ^''C[P[X@^)_Q,U^W\3_$;4?V?/%/[._C^[^$WQ=N?!VK
M:9H6J#2/BI9Z!I/[6]DL!\3_  O^'EI\7?B%JFFP_"_Q(GZ-_P#!/;4?C0='
M^*WA_P")^A?&!_#VBZ]X/F\#_$/XM:C\6;6?QM<:CX42'QK::#X#_:#MKCXW
M>"+?P[KFEVUSJT.O>+?'/@/5M6\2S2?##Q$FB6-_I&F@'Z,4444 %%%% !11
M10 4444 %%%% !1110!PWBGX>Z#XOO;:_P!6?4%GM;7[)$+.Z2",Q>:\V75H
M)2S[W;YMP&W QQFN8/P1\&$$&76^01_R$(^__;I7L%% %>SM8[*TM;*$L8;2
MW@M8BY#.8[>)8D+L  S;4&X@ $Y.!TJQ110 4FU1G"@9Z\#G/7/KU/7UI:*
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MF_X*%? =59S9?$+"*SG'A:T)PH+' _MWDX' ]:^5_P#@HU_R5GP/_P!DZ_\
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M7Q5^TLB>'?@]X/\ BK<?VQ^SE<>!?$UG^SU8?"/QI/XOL_@!X9^*\=[)\/\
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M"]DTVP>ZCE:SMC%I44 )M7.=HSZX&>F.O7IQ]*"JG@J".." >G3\LG'I2T4
M-V)Q\J\8 ^4< = ..,9.,=,TH5020J@GJ0 "<G)SCU//UYI:* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-2017331rdpiechart2016.jpg
<TEXT>
begin 644 biib-2017331rdpiechart2016.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2/V
MW?VFKC]D?X!WGQCM=&\&:U<#XF_ KX:0CXC>/7^&'P_T1_C9\:O ?P>7Q=XV
M\=Q^'/%DGAWPMX-/C?\ X2C7+Q-!O6?3])GMP;;SOM4/">!_V[?A?%H_A"'X
MM^//A$_B;Q;)H]_'KG[.7B+XA?M _ [0O"GC;Q]J/PT^&OB3Q?\ &S3/AAX>
M\+>!M/\ &OC;1]8\):=J'C8>'M$N/$VC:UIVG:OJ$.C:K>67OO[0WP)T3]H?
MP1X>\#>(-8O]%L/#_P 8_@)\8H[C3K6RNY;S4O@+\:/ WQHTC1+F&_5X/[,U
M_5/ UIHNK2*OVB#3;ZZFM"+I(2/#OC3^P_X6^+OQ#\4^+?\ A//$_A+PE\7/
M#/PF\$_M _#C1=%\,7VC?%KPI\$?&&O^,O 6EC6=0TR;Q%X%>5O%'B#PGXLO
M?#-X'U[P7J0L+&/P_P"(K'3O%5J =7=_MJ_!N\_9D^+?[5O@4^,_B'\,/A-X
M)\?>,KJ?0/ 'C>TU#Q</AUHNJ:GX@TCP5::SX=LKCQ'>66HZ/?\ AG4[S2K>
M]TK0?$=CJVEZW>6=UH6M16/SM\!_^"IGPA^+WCG5_"OB7PQXK^%>FW$'[)J^
M"=9\3^'/'LO]HZQ^UG\*[?Q_X,\/?$(KX$M-#^$.JR>(+A?A]X97QKKUE;^/
M/$,MBOAZ9WU33[:X^E/A5^R1X(^'7[)K?LB7VNZ_XK\"7_@;XC?#_6]:N19:
M/XAU/0_B=?>+[GQ$8VTZ)[/3[R.'QEJ-K8RP0NMOY-O,T;NKJ?E;PI_P2Q\(
M:9X*\5^#_&'Q=\6>-AXQ\<?L1^*=:U"7PQX<\/\ VS2?V&[WP1%X#\.S6.E3
MO J^-O#7@+2=#\=:K9R64K7%YJFK>'+/1&EM+"R /MCX-_M0?!;X]WM]I_PR
M\47VK7-MH.E^+].&L^$?&?@V+Q;X$UN\NK#1OB)X G\9>'] A^(/P[U>]LKF
MUTWQUX,?6_#%Y+]E:+4V@U+2IK[\]?BU_P %&/V@/@CKG[<LOCC]G[X+W?@C
M]B7X5^!?BQK6K^'?CYXXF\0^-]'^+;>-)?AW86FC:K\!--TK0+FSL?!-_/X\
MN+C7]2@TB6ZMX] 'B)(Y9A],?L=?L!_"W]C6YU&3P"GA::&+P7X=^&/ABXTG
MX-?!SX>>)+;X?^%+AI]&M?&_C7P!X0T7Q5\3O%3*MA:ZMXH\3:E#;:I'I&GZ
MB_AV#Q%/K>NZQ#\:?V!_!GQH7]LM-6\=^*-&_P"&S/AA\%_AAXI_LZPT:8^$
M-/\ @N/&?]E:GX>^UH?MM[K'_"9W9U&+5-UO!]CM_LH&^7(!UUW^WY^RWIVK
M1>'M6\>:WH?B63QEX\\"3>%_$'PS^*'AWQ-IFO\ PU\,>#O'WC(Z]H&N^#M.
MU;P[HNC_  T\?>$_BG+XFURTT_PW)\+]5;XA0ZL_A33M4U.SMV?[=G[-NH>'
M)O$=KXI\7,6U3P9I&B^%IOA'\7;3XC>,Y_B18^(]5^'=YX ^&5YX&M_'WCS1
M?'6C^#O&&L^%_$'A3P[JNAZEH_@_Q=JG]H0V7A7Q#-IOD7CW_@FO\*?B9\=/
MB9\9?&?BOQ7JEE\6;WXN'QAX$BBTZQTBZT7XR_LE_!W]D7Q3H=OJ]NHUFUA3
MP7\(+/7K.]B<7<>N:_J,9/V.ULP/)+7_ () ? N'X?V?A:Y_X5S>Z_X8\;>
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M"7[7G[+'P*/@_P 7?#_P=\8?B#XZ\(#Q!X#_ &@=3U:]\/?%N[\-?$_3M?\
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M50%   ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW\4^/O#.HZ3]GE^O;W]C#]F#49_$%S>_!SPI<W/BB+XEQZU<2G5VFN9/B_\
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M&GR_$(>/-*\7?OYM7GY1\WWN!S]?7\:-J\<#Y>G X^GI^% 'Q1JWPOU'XD_
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M_<*V\UW,@![RW$XB8D<$FV'L 3D?F]^W9^U;\>_A1X9U'Q9X%\:VNC:QX7\
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M?A+QEX[36OA'\1?B7I7P#L-(\->'-=UV3Q[_ ,)QH5GX>US5YK&*W]\^'?\
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M$6]G?!F.-X^T:7>1C9QG#%!OP1PJYS@8^BX0_P"2MX5_[*3(O_5IA#P.*_\
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MYV21R"H[$U]%PA_R5O"O_929%_ZM,(>!Q7_R2W$W_9/9W_ZK,4?R%-U/U/\
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MOAG0KB_UO3+_ ,=>&;*\LH;G4EBC^@\Y_4?D<4 %%%% !1110 4444 %%%%
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M1:>DZKLJM3S2:4(/5<L7*+M-G363[[6(]U!C/U0X'..?E([GW-=UX-\<^(?
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MTB\O[:UAU;3FN0#T&BBB@ HHHH **** "BBB@ HHHH ***,_YP: /F?]K_\
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M:9XPB\"-X3U(74TD%M8ZU<7LEEJ0M_[.NOB+Q]_P28^&>L>+KGQ+\.M9\%^
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M (U\0I)I'B+Q#'+<_"U8O#WAJXC\,Z9?_;[SQ3.PU*W_ #N^&7Q+UI?VEO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-2017331rdpiechart2017.jpg
<TEXT>
begin 644 biib-2017331rdpiechart2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MP7\(+/7K.]B<7<>N:_J,9/V.ULP/)+7_ () ? N'X?V?A:Y_X5S>Z_X8\;>
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MD=&D^PV>+,?9+;&G,&L!]GAQ9,+:2S#6GR?Z,PM9I;8&#RR+>22#/E.Z$ _
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MZ5;W5]:Z9!+>711Q$LM_?6EHN5)\ZXB0@;LT =K13/,3!.> 2I.#@%20V3C
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MX=^+'BWQ;X5U/Q3X1TBPF\9>!/&7A:'QE9^&;73_  S]F^&?^"B'Q<U;P?\
M#+QWXG^!MEX T;XN_#OP[>^$XO$MSXBM-"B\7>*O S>)=#\;ZA\2]5MM#\,V
M_P );C6K/6K.ZTO4=+T;XDZ5X!T6X^*6K:;8:;*="@_6/1=3L=;T?2M9T[4M
M.UK3]6TVRU&QUC2)(YM*U6SO+>.YMM1TV:*YO8I=/O8I%NK-X[NZ1K>6,K<3
M ^8P!^ /Q%_9$_:U\31^&M&\=^$_BW\<O'EE\1_^"9OC'P5\8M3^+GAC2?#?
M@7X8_ #XE?LW^+/VB_!GC_P5%\3K?2-3^)-]XN\"_$OXCZK?^'O"?B[2/B1_
M;GAR>/Q?+J'@W2[33>\_;U\/_&'XC_MB>)?A7\,_#_Q:\5ZMK7_!.CQYJGPM
M3X?_ !/?X;Z/\-OVBI/V@M%T'X1_&?7KNX\>>!+5X/A]J.JMK&I7^E2^)_$>
MG:!9ZA%:>#/$L%\UB/W6HP/\_P">OOUH _"NS_9@_::LH]1\3?%;PC\6OB[X
M4UG]N#]IKQ'\8/A7X.^*UGHOC#XE?L^Z@WQ._P"&:;[P6MY\7?!?AG1OA]X;
M\;>)K/Q]>_"P^-?#=^JZS9:OJVGZGJ?@BPT2O(V_9!_;4U71OAQHWQP\'?$3
MXU_%/2OC'_P3>\>^'/BI:_&K39_ GPP^"OP%^.GP"\=?&GX5>,=#UKXD:;/X
MX^).C_\ "&>,O$VO>+XO!7B-?C=?7.C>([OQ4-9\/:?8Z7_1?@>@YY/'?UI:
M /YP?"W[,'_!0&PL/AMX:\4^%_BQK'A/X2_ #X:?!WXOPV?QHT"#5OVBK;P/
M^V7I7C;XL0_#R_A^*MA?VDWQ0^!(27P]XA\:ZMX*U_Q'HUOXA^%WB>;P@-7:
M2YZ;XH_L1?%35/BWH'QB\'_ []H#PW-XL_8G\?\ [.&C7/@SX]>!M5^-OP;N
M;7]I?_A:OA?0_$GC#QU\1[71)-+\0?!^74/!VGZ-HGB/Q';:9:R2_!N\^)N@
M6;Z/\38_Z&,#T'_Z^OYT8'' XZ>WT]* /RT_9+^'/Q(\/:E\*1\7/V;_ (@:
M%?>%_&_[0C_"_P 9Z-\2=5T7PC\-/AWXK\(_#J[Q\3?@SK'[5GQHAT2[\>>(
MO^$C\*_#KP-X8UWXQ>&_ ECX2_X2FRA^#K>,)_#L'ZETF!QP..G'3Z>E+0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%(S!068A54$LQ.  .223P
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M_P"RDR+_ -6F$/ XK_Y);B;_ +)[._\ U68H_D1;J?J?YTE*W4_4_P Z2O\
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M*3X\_'_XE_'%="%B=3U8N/"P^(8\,C4?M:_VQ_9/]K_8M-^W?V=:_0U?$_\
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MV?5_BAXIBM;OQ??"12)[?23&GV+PEI$NXJ=)\/I 9XP!JE_JL@,Q^M.G2O\
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-2017331reserves.jpg
<TEXT>
begin 644 biib-2017331reserves.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
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MG/S,W_?3%B/P)Q3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?Q!9>1=^,-7FLXM*M--T_P#@F7\3;C7OB5I>C/XBO_B'J/Q%_9,^'7QG\?\
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M_P"+-?\ "WA/7A!\/M1T/P;%XKT3Q\=0 /TO\2?MF_LM>%/AO\.OB]J_QQ\
M?\*T^+H=_A=XRTO5G\0Z)\0(([&YU.2\\(7'AVVU5]>T^/3K2>^?4=/BFL%M
M52=KD1S0M)ZYJ7Q5^'&B?#>/XO:]XU\.>'?AD_AS3/%K>-_$>IV_A[P[!X=U
MFWM+G2]4N]0UIK".R@OH[^R6V2\$%Q+/=6]JL'VJ5(&_#S]F+X-?%_2/V/OV
M._!GQ3_9Y_;D\(>,?V>_"WC3X;>,=%^$?Q.^#OPJ\;PS^+K?2+V&[T^]\/\
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M"D__ "DD_P""%/\ V=;^U!_ZQS\0:_;M/]5'_NQ_^RT ?S0_$O\ Y*3\1/\
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M*^ _!\/C5/$49\8^.?AOXIN=47]HY=I_P@8#_P *LV\O^IAY?B^^A_8^<?\
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M[UF2)WDB.IW.DV%G->I%)))+%#.[P1322S1Q)-+([]=10 4444 %13_ZB?\
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M*T\R3=MWO-HA5?E#')"L1QV/? /QI7VI^P+_ ,G!0<D9\"^+.A(_Y;Z$>WN
M: /VF_X2?0/^@G;_ /D3_P"(H_X2?0/^@G;_ /D3_P"(K=P/?\S_ (T8'O\
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M** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;M/\ 5Q_[L?\ 2OQ$_P""D_\
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MT>_KR22/H221^% 'R#^P?I?BS1/V7?A[HWC'X=:1\+;_ $O4OB/8Z/X5T;P
MWPFMY_!%O\4_&R_#OQA>?"4W5XOPFUOXB>!#X=^('B'X70RV]M\/M=\3:CX5
MM-+T*VTR+0=,^OZ/\_GUHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+VW2PFEGB-D\",[31>4PD\^"<%0HR-H4@]21Q7"?\**\*_\ 01UW_O\ V/\
M\@5[717@X[AC(,RQ,\9CLKPV)Q-104ZU13<Y*G",()VFE[L(1BK+9+J.[[LP
M?#7A^T\+Z/;:+8RW$UM:O</')=-&TY-S<27+AFBCA0A7E8+B,$* "2<D[U%%
M>QAZ%'"T*.&P].-*AAZ5.C1I0^&G2I14*<(W;=HPBHJ[;LEJ(*3 SGKWY)(!
M]0"<#\,4M%; )M'I_P#7QTSZX[9Z=J,#T';].F/3';'0\CFEHH 3 '08Z]..
MN2<^IR2<GG))ZT8!Z^_TY]1W_&EHH 3 ].^3[GC!/J1@8)Y&!BEHHH ****
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MXF\>_ '1M%\6>&?''B?3M+T?XPZAX:TG4M/U34O$4D5OJ(!_4F'0D ,I)R0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 8S_\ K(_E28'O^9_QI:*
M"BBB@ HQ_CU/^?PZ444 )M4= .P_ = /0#L!T[8HP/Y]SWZ_X_7GK2T4 &/\
MY/\ G_'O2!0.@ XP/8>@]![#CVI:* "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-2017331sga.jpg
<TEXT>
begin 644 biib-2017331sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
M;6_1-(?_ (2.+R/$&_3+%_[<A^S-9^5K.Z _VK&+1VM0FH?:4%NS0 >4S(><
MMOA;\.+(0BQ\"^$].6WU30]:C73/#VDZ6IU7PR\\OAV^E73K2U6XGT.:YFFT
MEK@2C3YW,UH(I0' !^5__!1[QS\'[+Q;_P *\L_VAKWP=^UIXQ^&&G)\$=%O
M_P!I&/X+> OV:;&?Q'KNG-^UQXST^#Q-X7L;_3[/6[N&P&E>*;;Q[JGQ:/@>
M'X6> _!ZZ#?_ !5U!/--'^(7B3_AH;1-5M_B'XBNOVM+[_@HUXT^%_BOX2S_
M !(\3?8$_8@M--\83^'M0/P>:^7PO8?"Z'X$6_@CXV:/\0(/"\5O)\5]2@$?
MCNXUKQ)?Z9JG[4:_\/O GBNYCO/$_@OPGXBNX8D@BNM=\-:)K%Q'#&9#'%'/
MJ5A=3)&AFE*1JX13)(54%W)Z!=*TQ+[^U$T^R7438KIAOUM+<7O]FI*TZ:?]
MK$?VC["DS-,EGYGV99F,JQ"0EJ /QC_8R\:?"+XJ_$+_ (*<_ OQQ^U /VD?
M#R?&[P-JQNM3^-6CZMXANO %S^Q]^S/KWCO4/"-M\+M8T6'P7X"TCX@:CXAL
M_P"SOAKIV@>&- U=KS3'5M<GUB>^^D_V'] \.?"/]CNZ^.-K9Z]H=C\7]"UW
M]J"7PW-K/Q#^* \%^#_$GA2'7_A_X/T+1]7UKQ'XHNKCP[\+=,\)V^O:)X?G
M6X\5>/9/%.LV%C!J7B)+>+[HT7X>> _#=V]_X?\ !7A+0[Y[2>P>\T?PSH>E
MW365U,MQ<VC7%A86\S6MQ.BSSV[.89IE661&=0PZR&"&WABMK>*."W@BCAAA
MA1(HH8HD$<4<4<85(XXT54C2-55%4*@    /YRO!_P#P5'_:2\3^,?#/P]T3
M4OA?KL?Q*\5_L+WWA;XER^'O!6H:?IGAK]J3XS?$#X3?$'0+KPE\*OCC\3-+
ML-6\(6?A_P .>)_#.A>(/B&/&FC7%[<:1XU;4+:_L-0M_-_VHOV]OVB_''[*
MO[:/@G6OBG\.O@YXE^#WP._:;\'>'_$.F^&=;\,^-/VI?B'\,/VC_P!HK]G/
M6M5^"4ME\3H]3\ :MX'T7X->$?$GB+2/#0\:ZKHWC'XJ:1=3S6'A"QTVWUO^
MF>W\->'K18TM="T>V6&Y:\B6#2["%8[MKZ34WNHUCMU$=P^HS2W[3H%E:]ED
MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M#M/UR71X[*_UC4->TC31901^(=8\.^'[_7;FQO+V+PEHNO>(-#T3Q#XO;0=
MUC5]/TW4[JZBBGXG\45*D*:CE$74G""E/"UHPBYR4>:<OK?NP5[SE;W8W?1!
MIV?W^GEZ_AVU^YQ\>O#IY&A>("/4?V1_\M*/^%]>'O\ H!>(/_*1_P#+2OYC
M?AQ_P4)U32/V)]#3Q]^T9HVF_M0^+= \866E^)OC[X"\*?!SQ%\-%TCX6/\
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M(SR2,$50TDKO+(V7D=Y&9B^BBN< KUOX*_\ ([)_V"-3_P#0[.O)*];^"O\
MR.R?]@C4_P#T.SKZ'A/_ )*;(O\ L9X3_P!.Q&MI>GZH^O:***_J\1\[_'[_
M %/A7_KMK'_HO3J^;Z^D/C]_J?"O_7;6/_1>G5\WU_,GB)_R6&;>F _]5F#
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MBD[1E5_&^+_WO%?]A%;_ -.2 ****YP"BBB@ HHHH **** "O6_@K_R.R?\
M8(U/_P!#LZ\DKU/X//=)XQ1K.""XF_LK4<1W%R]I&5W6FX^=':W;!@0H5?)P
MVXDNNWGZ'A/_ )*;(O\ L9X3_P!.Q&NOI^J/L6BL3[3XA_Z!&E?^#VY_^4-'
MVGQ#_P! C2O_  >W/_RAK^KQ'B7Q^_U/A7_KMK'_ *+TZOF^OH+XY2ZC)#X9
M^WV=I:@3:MY7V6_EO3(3'8;]XDL+'R@H"[2#+OW$$)M!;Y]K^9/$3_DL,V],
M!_ZK,& 4445\4 4444 %%%% !1110 4C?=?_ ''_ /0#2TA^ZW^X^?IM.?\
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M 6>M^.]#U3QMJ^BW\4]IX<L9K2\D_0W_ .O[]_\ .?0\4 ?B!_P4G_Y22?\
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MW_L,ZI_Z77%9%:_B#_D/Z[_V&=4_]+KBLBOXWQ?^]XK_ +"*W_IR0!1117.
M4444 %%%% !1110 5ZW\%?\ D=D_[!&I_P#H=G7DE>M_!7_D=D_[!&I_^AV=
M?0\)_P#)39%_V,\)_P"G8C6TO3]4?7M%%%?U>(^=_C]_J?"O_7;6/_1>G5\W
MU](?'[_4^%?^NVL?^B].KYOK^9/$3_DL,V],!_ZK,& 4445\4 4444 %%%%
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MVJWTD-Q<S:DGF3Y6TAGAM[F/PQ?V*O\ @LNH4#_@MEX&PH '_&K?X(=NG/\
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M?2F\5:GIFJ0:-"MW;IJ$-Q/:3PPWMI!,L:3B.>/\3?A+^Q!^TY%^SO\ LO\
MA+XI_"KP:_BC]DSXO?''Q/J/PSTW]H74(/"'[0_P[_:$TGXW6/B71+CQCX?\
M%6-YX5U3PE)\4?#]Y;Z=KVF3:1XP/AW7?#>J7^F:#XDFO* /VY^&OQ&\+?%G
MP1H/Q!\%W&IW'ASQ';W,UC_;?A[Q!X3UJVFL;^[TG4M.UKPQXJTS1O$?A_6=
M)U6POM+U71];TNPU+3K^SN+:ZMHWCY[FOF[]DGX8_$/X/? 7P=\/_BAXC;Q)
MXLTC4/'%Z<>*_$OCR#PKX:\1^/O%'B7P-\-;+QUXSAMO%WC?3OA3X)U?P_\
M#73O&/B6VM=:\367A:#5[ZTLGNEM(/I&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ,=??K_G_/;THHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ",T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-2017331spinraza.jpg
<TEXT>
begin 644 biib-2017331spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
M;6_1-(?_ (2.+R/$&_3+%_[<A^S-9^5K.Z _VK&+1VM0FH?:4%NS0 >4S(><
MMOA;\.+(0BQ\"^$].6WU30]:C73/#VDZ6IU7PR\\OAV^E73K2U6XGT.:YFFT
MEK@2C3YW,UH(I0' !^5__!1[QS\'[+Q;_P *\L_VAKWP=^UIXQ^&&G)\$=%O
M_P!I&/X+> OV:;&?Q'KNG-^UQXST^#Q-X7L;_3[/6[N&P&E>*;;Q[JGQ:/@>
M'X6> _!ZZ#?_ !5U!/--'^(7B3_AH;1-5M_B'XBNOVM+[_@HUXT^%_BOX2S_
M !(\3?8$_8@M--\83^'M0/P>:^7PO8?"Z'X$6_@CXV:/\0(/"\5O)\5]2@$?
MCNXUKQ)?Z9JG[4:_\/O GBNYCO/$_@OPGXBNX8D@BNM=\-:)K%Q'#&9#'%'/
MJ5A=3)&AFE*1JX13)(54%W)Z!=*TQ+[^U$T^R7438KIAOUM+<7O]FI*TZ:?]
MK$?VC["DS-,EGYGV99F,JQ"0EJ /QC_8R\:?"+XJ_$+_ (*<_ OQQ^U /VD?
M#R?&[P-JQNM3^-6CZMXANO %S^Q]^S/KWCO4/"-M\+M8T6'P7X"TCX@:CXAL
M_P"SOAKIV@>&- U=KS3'5M<GUB>^^D_V'] \.?"/]CNZ^.-K9Z]H=C\7]"UW
M]J"7PW-K/Q#^* \%^#_$GA2'7_A_X/T+1]7UKQ'XHNKCP[\+=,\)V^O:)X?G
M6X\5>/9/%.LV%C!J7B)+>+[HT7X>> _#=V]_X?\ !7A+0[Y[2>P>\T?PSH>E
MW365U,MQ<VC7%A86\S6MQ.BSSV[.89IE661&=0PZR&"&WABMK>*."W@BCAAA
MA1(HH8HD$<4<4<85(XXT54C2-55%4*@    /YRO!_P#P5'_:2\3^,?#/P]T3
M4OA?KL?Q*\5_L+WWA;XER^'O!6H:?IGAK]J3XS?$#X3?$'0+KPE\*OCC\3-+
ML-6\(6?A_P .>)_#.A>(/B&/&FC7%[<:1XU;4+:_L-0M_-_VHOV]OVB_''[*
MO[:/@G6OBG\.O@YXE^#WP._:;\'>'_$.F^&=;\,^-/VI?B'\,/VC_P!HK]G/
M6M5^"4ME\3H]3\ :MX'T7X->$?$GB+2/#0\:ZKHWC'XJ:1=3S6'A"QTVWUO^
MF>W\->'K18TM="T>V6&Y:\B6#2["%8[MKZ34WNHUCMU$=P^HS2W[3H%E:]ED
MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M+_H5K_PN]/\ J#\W]WF?T]ZC^Q+\"M7_ &BF_:;U3X9^(-1\<OH\EE+X8O\
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M8_Z%NZ_\&.E?_)5']IZQ_P!"W=?^#'2O_DJOXP?^&^OVL_\ HK^L?^ EG_\
M$T?\-]?M9_\ 17]8_P# 2S_^)K/_ (BY4_Z)R/\ X>'Y?]2KS?W>9/\ KI+_
M *%:_P#"[T_Z@_-_=YG]GW]IZQ_T+=U_X,=*_P#DJC^T]7'7PY=#_N):5_\
M)5?Q@_\ #?7[6?\ T5_6/_ 2S_\ B:_1/_@EW^U5\>_B]^U1;>#_ (A_$'4/
M$?AQOAIXZU9M,N;>WCB.H:=<>&ELKC=& VZ!;NX"CH?,.>@KT<I\39YIF>!R
MYY%'#K&8FEAW6_M1U?9>UE&//[/^S:?/RW?N^TA>UN97N=.#XLEB\5A\,\N5
M/V]:%+VGUSGY.>27-R_58<UKO3FC>VZO<_HJ_M35_P#H7;G_ ,&6E?\ R51_
M:FK_ /0NW/\ X,M*_P#DJM^BOU8^Q,#^U-7_ .A=N?\ P9:5_P#)5']J:O\
M]"[<_P#@RTK_ .2JWZ* ,#^U-7_Z%VY_\&6E?_)5']J:O_T+MS_X,M*_^2JW
MZ* ,#^U-7_Z%VY_\&6E?_)5']J:O_P!"[<_^#+2O_DJM^B@# _M35_\ H7;G
M_P &6E?_ "51_:FK_P#0NW/_ (,M*_\ DJM^B@# _M35_P#H7;G_ ,&6E?\
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M2T4(N+22U]UU'%7;;LI5JLO.51WNHP42BBBN4R"OU2_X(X_\GG6O_9(_B/\
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M#RK9$DE($_A5\A7DB7'R;?OY+LB@'=D?EK7ZI?\ !''_ )/.M?\ LD?Q'_\
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MH^'VA7UMH-[KGAO3VAG\1:Y:Q23:AK>G6ZP0W12=[I;>UN>J7_@LCK@1%/\
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M $BR_P""F'_B..D?_/&K[6_8#^-?[2W[+?[04'Q5^(G_  2D_P""JVH>'(_
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MYI_WRO\ A0!^+G_#Y/6_^D0__!:;_P 0^^'W_P!$#1_P^3UO_I$/_P %IO\
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M\-^'[*WO;2TT/1[6UU'']H6UMIEC;V]\%B\E1>PPV\<5V%A B N$D C 0#:
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MGACQ3)XA^)G[(?P7_:4\:>!?%_B>]U!9[B!_''Q,U?X?Z=H6K64$-C;3Q_\
M"7MJ%_IT5MI_M_[#?QQ^(OQM_;:^'WBCQA\9O#WQ.;Q1_P $U='\<^,?#G@3
M1KGPQX4^%7Q4\3?'_0]1\3_"S6-"B\3>(;:V\8_#B.^'A&ZL/$QMOB=H5K8R
M1>-P;G5K9(_W4-M;EBQ@A+&9+@L8HRQGC18TF+%23*B*J+*3YBJJJK   $5K
M;0NTD,$,3NTC.\<:(SM,XDE=F506:5U5Y6)+2. TA9@" ">BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-2017331tecfidera.jpg
<TEXT>
begin 644 biib-2017331tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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MM5&NQ>'?%?B+Q"=4?49;K3KQDDTUH_L=E''\C_\ !5;2;/X$_L'?MR^.M/\
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M_ GC)=?U&]TKQQ\/O#<LNG3, ?M#17X<>#_VT?VVOBC\/F.@:#X0MO&_A_\
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M:]XMBCCBMO'EWX1UA]#\7^*_#>HZMX7GU[0=973M:@TK3/N*@ HHHH ****
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MA?;_ -JNM[+VTU#VGLO[.I<_+>_+[2%]N9'[[45@^3XE_P"?_0__  5:C_\
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M7D=Y'(\(:L@+2,78A$B5$&YCA$54485%50 &_P##6_P0_P"@[KW_ (26L?\
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M /!7XA_^4]'_  TU\"Q_S4+3_P#P5^(?_E/7X[9/J?S-&3ZG\S7ZU_JG@?\
MG_B__ Z/E_TX]?P\S\L_ULQ__0/@_P#P"M_\O]?Z6O[N6G[?O@:S\'VG@B/X
MH^'Y-%M+N"16N_"%S=ZA<:3;QP)'X4O]0G\-M=W_ (3=K:(W&B7<TL%W;+_9
M5R\NBXTT)K'[??@#6O$MIXQN/B)X+L_%5I?/?_V]I'P^DTO4+UI+"72Y+'5&
MA\//;ZGHCZ9-+IQT&[MY-'%A(]DEFMJ?)'X29/J?S-&3ZG\S7GKP]X=C.=18
M9*=3V_M)*C@TZGUI06*]H_JOOK$*"592NJBC#G4N56[GQ_Q XP@ZZ<*?L.2/
MM<7:'U:[P[@OK/N.@Y3=%QLZ?,^1J[O^[6G?M\_#S2O$-CXGM/'O@/\ M/2-
M.M=(\/1S?#<2Z5X5TVT%_P"7:>%=&_X1M=-T*.4ZIJ+WCVD'G7\E[=37DL\\
MS2'&L_VW/A9I=[87^B^/?!N@W.F:Q?:W9-H?@)]-CBFU+1[?0K_3'B3PU(EU
MX:NM+MVMI?#%Z+G0V-YJ<ILC+J=X\GX?9/J?S-&3ZG\S5QX!R&+DU1:<Z2H3
M_=X5J=%*<52FGAK2II5JZ4'>/[ZI=?O)WE\>9ZU%.I'W*KK0_>8I.%9NFW5@
M_K-XU&Z-)\Z:E^[IZ_NXV_:[Q-^V-\)/%DVG2:M\1= BM]'TY=)T72M'\+:A
MH6B:-IHN;B]:STK1]*T"VLK..>^N[J^NW6-KB\O+B6YNIII6!7FO^&F?@7_T
M4+3_ /P5^(?_ )3U^.V3ZG\S1D^I_,UTTN#LLHPC2I3Q%*G&_+"FZ$(J[YI6
MBL.E>4G*3>[D[N[;9S5.,,SJSE4JT\-4J2MS3FJ\I2LE%7E*NV[12BM=(I):
M*Q^Q/_#3/P+_ .BA:?\ ^"OQ#_\ *>H;G]IKX%+;7+'XA:> MM<,Q_LOQ$<*
ML+LQP-'R< $\<^E?CYD^I_,U6O2397W)_P"/*\[G_GVEK6/">!NOW^+W7VZ/
M=?\ 3CU_#S,Y<68^S_<8/9_8K=O^O_K_ $M?]*;X7W5O??#7X?7MI*)K6[\#
M^$KJVF"NHEM[CP_ITT,@5U5U$D3JX#JK '#*""!W5>)_ _Q!H4/P7^$4<VL:
M9'(OPN^'NY'O;=64GP=HK#<#)D$@@\^M>O6>IZ=J/F?8+ZTO/)V^;]FN(I_+
MW[MF_P MFV[MC;<XSM..AK_*S,DHYACHK5+%XA+T56:1_IM@&Y8'!-Z-X3#-
MKS=&#9>HHHKB.L**** "BBB@ K"\3I#+X;U^.X2.2WDT35DGCE727B>%].N5
ME21->_XDCQLA9776/^)6RDC4?]#,];M07,$%U;SVUS##<6]Q#+!/!<1)/!-#
M-&T<L4T,BLDL4L;,DD3JR2(S(RE6((!_,UX-\#Z4WQT^&&I>,_!B-XSA\:_"
M)VU#Q3X5_P""#W_"2PVME-X1B\*.]WX/N7^*45M:>&K?08] ?P"3XKMM"@TE
M?A\/M<6@*/Z:QT_$^GJ?3_\ 7Z\YK\4=1^%FL^*/VN_'NLZ9\*/VB]?\+>!?
MC=\-_#V@Z]\&OA-_P3[\"_!GPKI?AGP=\+KY]'UZY^.>D6W[2/B[_A&!<+<^
M*O'/@NYOK"YT:>UT#X17=I?^%FT?2OVN']3Z>I]/T[XZ\YH _$'_ (*3_P#*
M23_@A3_V=;^U!_ZQS\0:_;I?]5'](OYI7XB_\%)_^4DG_!"G_LZW]J#_ -8Y
M^(-?MTO^JC^D7\TIQW7JOS _SD?VC?\ DX?X_P#_ &7/XQ?^K)\3UXU7LO[1
MO_)P_P ?_P#LN?QB_P#5D^)Z\:K_ %WRG_D599_V+\%_ZC4C_*;-?^1GF'_8
M;BO_ $],*.O2BO4?@II6B:U\4_!VG^)/!_B'Q]X?>\U.YUKPCX5TB_\ $&O:
MQI^G>'M9U*8V?A[2M5T'5O$<&EO9QZYJWAS2=<T;5?$&B:9J>C:;JEA>WT%U
M%TXJO'"X;$8J<93AAJ%;$2A#EYYQHTY5)1ASRA#GDHM1YYPAS-<TXQO)<V&H
M2Q.(P^&A*,)8BO2H1G/FY(RK5(TU*?)&<^2+DG+DA*7*GRQD[)^7*"P!7Y@1
MD%?F!!Z$$9!'N*7:W/RMQUX/'UK]<OC/\,[#P]^V#IMK8^ O@'I_PR\>^&O&
M?CG7=2L/A%<7MO#\./@Q)XGUSXE>(H?AG\6+6^MOA]XY33/"VH^&+'4/"4;>
M!_%SKH>LZ7<Z@SZV*\G^$D7@+XM:;HVGVOPX\._#_P =_M ?'SXE:'X0%K^R
MEH/Q1^&?AFQU31/ L'A#PI8>,M?UBPD\)^&? %Y?ZF?$T'@>QUWQ+H,&K?\
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MXAUIRJSG5=:HZLYU[JO.53FYY2K)M59-MU+OG<CTYOC9\97\(IX ?XM?$IO
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M5I_\V]'_  I/]N__ *1=_P#!1G_Q'JT_^;>O]+3RX_\ GFG_ 'RO^%'EQ_\
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M6E6%_*MJ[^8]LLEW;S.('?YVA#"-G^8J6YK6C@@A(,4,49$44 ,<:(1##O\
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M! YY]B1QZD# _'&>@YI<Y_4<@CH<=_T/0CD<4 %%(#G]>H(Z<'KU'OT/:EH
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M1I%MXYM/[,\66L7B#Q19:=JNN:1I^M>*_$%Q:>']8OODO]KC]MC]J/4/@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-2017331tysabri.jpg
<TEXT>
begin 644 biib-2017331tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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M\3?#CXD^(K;Q6?A]>#Q=XNO+R#V+]LV7]KOXA?LP?LZS:U^QSXPG\%_#:_\
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MF_XD/SCV;///6OY^9-(U:+3K?69=)U2+1[N=[:UUB33;V/2+JYCW^9;6VJ/
MMA<7">7)O@AN'E4QR H"C[;FF>&/$VM6MQ>Z-X;\0ZQ96C,EW>Z3H6K:G9VK
MI$)W2ZNK&SN+>W9(")G6:1&2$B5@(R&HEX'<%1BYRS3/HPC+DE)X_+%&,[J+
M@Y/*[*7-=.+=T]&KK5+QEXPE)1CEV22DXJ2BL#F+DXM74DEF5W%K5-*UM;V/
MW\_X;P_9=_Z*/-_X1OC;_P"4%'_#>'[+O_11YO\ PC?&W_R@K^>?]0>01R"#
MR""."".01UHK7_B!'!__ $'\1?\ A9EW_P ZO7^EK'_$:N*_^@+(?_"3'_\
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MLOBEJ_@+PYJ]GIATGX=>(/C3:>.=1T!-+TC2M!U36#XH\2Z#:W&DZ[:ZG?\
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M "V,XRJ2:E%XFFFFKV::;33/[4\CW_(_X49'O^1_PK!_X1;0/^@9!_WU+_\
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MDVVI7EOI]KXK2RCTU/$MK;031QVVO1V$45I'JT COHX(T5)U*@BWJ/C3QIK
ML1K'C/QEK"Z7=)?:6NK^+O$FJC2[Z,8COM+&H:I<C3;Z,<1WMC]GND'"3**_
M/9<&YA.6/A+-J2IXS%YUBJ=6GAZ]/&83^U<+]5A3I8AXNI.4(<]2OB'>%?$5
M88:$L3'"8=X6M][#B[ PC@I+*ZKJ83"9/AJE.>(HSPF+_LS%1Q,ZE2@L+",9
MU%"%&AI*AAZ<L3..&>*KQQ-']D#\._!6D:1=_$Z]TCQ7*_B;X-_":QTSQWH7
M[(?@/Q#^TQIOBK4_BY\2+77?$?B/]CBYT$?#/POH&O\ ASPK+X+'Q(M=5=M=
MT;2/!%SHFOZ_K7C36-&B^.?%7PB^(WA_]L/QWHWPL^ NC>/V_P"%K?$+P;\.
MO#-KX1OO$/PO@\3VWA:#7]R6FJ:;HOA<ZC\,=%\0:;X_\4>#_%=I9^%_ 5_"
M;/QGH5OX8TD6K_%R>*?%,6L3>(HO%/BF+Q%<1M#<>(H_$VO1^(KB%XTB>&XU
M]-176+B%XHXXWAFO7C:...-E*1HJPV'B'Q#I)B;2O$/B'2F@N+R[@;2]>UC3
M6@N]0A2WU&[@:QOK<PW>HV\45OJ%W$4N+^WBC@O)9H8T1=\OX4S'+YXZI_:U
M'%_7,%B,+[#$X)PP\%5IX:%"#C@\1A9^PPOU9Q]A0GA\.X8K$_4,/E<JE;ZQ
MAC^)\OQ\,#3>5UL*\)C,-B77P^,4Z\_8U:\ZTD\5A\3#V^)^L<SKUHXC$<^&
MP_UVOF4:='V'T-^U2-*M_&G@[2XM*TY/%VB?#?1=)^*'C/P_X"F^&OA#XF_$
M.#6O$,^I>+?!WAIO#WA.RO-$T[1[G0_!4GC32_#6A:=\0-5\+ZAXMM=-C@U*
M*ZO/F*M;6?$'B#Q'<QWOB/Q!K_B.]AA%M#>>(M<U;7[R&V#O*+:&[UB\O;B*
MV$LDDHMXY5A$LDD@0/([-DU]9E>#E@,!AL).?M)4:?+*:^%R<G)\D%&$*5).
M35*A2A"A0IJ-&A3IT80A'Y;,L7''8[$8J,/9QK34HP>LDE",%SR<ISJU&HWJ
MUJLZE:O4<JU>I4K5)SD56O?^/*^_Z\KS_P!)I:LU6O?^/*^_Z\KS_P!)I:]"
M.Z]5^9PRV?H_R/\ 2,^!7_)%/A!_V2[X>_\ J'Z-7JM>5? K_DBGP@_[)=\/
M?_4/T:O5:_R$S/\ Y&6/_P"PS$_^GIG^KN7?\B_ _P#8'A?_ $Q ****X3L"
MBBB@ HHHH **** ,>3P_H4NJQ:[+HVE2ZW!";>#6)-.LY-5A@((,46I/"U['
M'AB/+2=4P2-O-;%%% 'X6?\ !7&W^+'@O]I?_@E1^TSX!_9N_:%_:5\'_LT?
MM$_'/Q=\4_"O[-?@"#XC?$/3-!\:?LX^*/A]H5];:#>ZYX;T]H9_$6N6L4DV
MH:WIUNL$-T4G>Z6WM;GJE_X+(ZX$13_P2'_X+2Y7R\_\8??#['RE<_\ -P.>
MQQ7[4,JMC<JMCIN ./IGI3?+C_YYI_WRO^%&P'^<7\6?A[^V]XZ^*WQ0\<:/
M_P $M_\ @I+#I'C3XD^/O%^DPZA^SKI\&H1:7XH\7:SKVG17\$/CVYAAO8[/
M4($NX8;BXBBN%E2*>:-5E?S_ /X4G^W?_P!(N_\ @HS_ .(]6G_S;U_I:>7'
M_P \T_[Y7_"CRX_^>:?]\K_A7[O0^D9XE8>A1P]/$9(J="E3HTU+*8M\E*$8
M1N_;ZOEBKOJVWVM^*5O #PZQ%:K7J8;-G4K5)U9VS6JESU)<TK+V>BNW9=$_
M(_S2_P#A2?[=_P#TB[_X*,_^(]6G_P V]'_"D_V[_P#I%W_P49_\1ZM/_FWK
M_2T\N/\ YYI_WRO^%'EQ_P#/-/\ OE?\*U_XF2\3O^@C(_\ PT1_^:/ZN_*V
M7_$O7AO_ - N;_\ AUJ^7_3OR?W^1_FE_P#"D_V[_P#I%W_P49_\1ZM/_FWK
MG/%O@/\ ;%\!>'M2\6^-?^";G_!0/PKX8T:."75=>USX#6%AI>GQW5Y;:?;O
M=7,OC?;&)[Z\M+2/@EIKB)< $D?Z:_EQ_P#/-/\ OE?\*^?/VJ/@SJ?Q\^ W
MQ ^$NA:II>A:IXPL]%MK75-5@N9=/M3IGBOP_P"()3<QV,<ETZRP:/+ @B1B
M)I8V;"*Q!_Q,EXF_]!&2?^&B/E_T_P#ZOZ6/^)>O#BW^[9OZ_P!JU?+7^'Z_
M?Y'^>=_PI/\ ;OR1_P .O/\ @HP<%E.W]GNR894E2 R^."IP01E20>Q(H_X4
MG^W?_P!(N_\ @HS_ .(]6G_S;U_I9+$@!RB$EW8G:.=[L_.1U^;GWIWEQ_\
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ME'1_B[XA-R\3Z!>F\%P+01*]L8C.9'$7XV?\*3_;O_Z1=_\ !1G_ ,1ZM/\
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MR. :_"?]LWQ1Y7Q,_;:;XF_$#Q3X+^+/@;X'_#O4?^"<6@:%\0/%7A36-?\
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MS8D 6-U4 5NT4 5;VQL]2M9['4+2VOK*YC,5S:7EO#=6T\1()CFMYTDAE0D
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M?P.?W$?G+^V7XLE^&_[1_P#P3Y^(_B7Q?%X"^#FA_&;XW:)\4?%FN>)%\+^
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H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-2017331zinbryta.jpg
<TEXT>
begin 644 biib-2017331zinbryta.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
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M "BBB@ KXE_;H_:VN?V0/ /PN\5V>B_#K4;GXH?'SX;_  -BU?XN?%"3X/\
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M7/P-^).BZS^T[X?^)]]H/[=/[6/PNT3Q3XX^,_A[QSXPUNW\4?M;?%WP_P#
MW2[S6'UF9[J[\>:+I=O;?#?3+"WL=+UG3[6+3O NE0Z)965A;?JHWAOP^_\
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MNRYN':0K-X<T"X\O[1HFD3^3-J5Q#YVF6,@BGUE9TU::,/;L$EU-+FX3495
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M'??$7]DOX:?&/X@^)] ^/?Q(^+5OX.^)$NKZ3I'B'PI^T!X3\97&I>&?A_\
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MO"]UX8/BV#[/:ONO+J.>;Q4MC;216<?Q!^R1)HD?Q!BC3QA#X?\ ^))%JZ6
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MY;>;]KU%[_?L\O=:VUMY6W=NQ]G5=^_*YWYV[?EQDY +]%%% !1110 4444
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M#^UQ:*3(]_R/^%&1[_D?\* %HI,CW_(_X49'O^1_PH 6BDR/?\C_ (49'O\
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M.O\ 1/+O^1?@?^P/"_\ IB!_!.._WW&?]A6(_P#3TPHHHKL.4**** "BBB@
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MH _"S_@KC;_%CP7^TO\ \$J/VF? /[-W[0O[2O@_]FC]HGXY^+OBGX5_9K\
M0?$;XAZ9H/C3]G'Q1\/M"OK;0;W7/#>GM#/XBURUBDFU#6].MU@ANBD[W2V]
MK<]6O_!9'7 B*?\ @D/_ ,%I<J$!_P",/OA]CY<9_P";@<XX^M?M.RJV-RJV
M.FX X^F>E-\N/_GFG_?*_P"%&P'\6WC7]H']HSQ%XS\8>(;'_@E#_P %74LM
M?\5^)=<LDN?V7_#,=REIJ^MW^HVJW$:?%N5(YU@N8UF1))$24.JR.H#'F?\
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M]M[AX .A?$'QU_;I\/?V*O\ PDWVH:9_9W]L:)Y/VO[;)]G^TO+C_P">:?\
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M3?!#2=MCXC'AZ?PK9Z%X%^*?BO6-+CTZ6QUO5=+^'EVT?D:;=+?@'Z<T4@
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M(QGG SV.>..F,GVP.>HXH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"OCWQW^VI\"-$\'?!3PE^T>/"G[#G[:GQ0M_@WXZ^,?Q"^#ND:UXH\)?%?\
M9'M/#FH>%]6\">#?'"WWQ'F_MF^\*^&$UO3M'LK*V\3:K<)XDTUMR7'D?[+?
M[:/[15O\1/V>_@A!XTT;XH>"+'P_^R[X6T+Q;\0-:\ >'_&?[1'PP^(?P&\'
M?$'QY^T!9:'XA\<:A^T'K&N>'O$6OZ]X1\-V>@^#_%&BB\^%'C/0OBOXKO\
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MO_!-[Q/\9OC7^U'^UM\=/C?K.NZ=XFN?A+^Q;H^@?"36]#CT]/@$GQ9_9F\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biogenlogostandarda05.jpg
<TEXT>
begin 644 biogenlogostandarda05.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
MD,W#DHBH@4>^"(<G<5ZXGH7<8-NS=83S3Z&NGX19/5*J6H09*2.G2H1.#Z^H
M3X3N  ",P8  D('"J9!K@.B](XY?<.FWO(R58&NRAHLF3SJMLHHE/0"I:HF3
M*/:F2(GC#]JG!(D"  ",C(  D"S!Z)A/@)2\6Y6U<)*V\)-T8 NQNY&53NBL
MUI F/,.HDH]I*->E8Y ;$ 2EX8K4  ",7H  C\?!4*!B@$*[M9TW<$VV0)IS
M7\^Q"9@L3JZL)I9Q/)6GT)6R*,*DEI6\$"NDXXKN  ",.(  CV; U:B4?_R[
M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
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M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
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M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
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M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
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M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
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MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
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MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
M>O;%!J<P;3^_6Z/]7ORYP:$L4!:T89\40&>O=9Y9+XVK5IS3''BHX)- !H>E
MZX1J  "#'(  >MS$G:\^;3Z^X:N37PFY.*A;4"JSS*8S0(6NUZ3.+[FJL*!%
M'+.H,9-G!LBE1H26  "#'(  YA]V<',8T!MW2W/QN8!X'W3,HBIXZG6OBB1Y
MLG:A<6-Z?W>C5X9[3WB?.R]\,7F6%IU](7GHY ]TAWYHSFMUB7X;M_IV?'WE
MH,MW97W*B-UX2WW-<"YY,WWD5EMZ%7WY.@=Z[WX2%2![5'W!XC%R\(G2S)IT
M HADME]U"H<2GT9V"H7]AWYW"(41;O-X!H1"53YX]H-Y./EYQ(+$$\1YU8(+
MX&EQDY4XRLURKI*_M)QSP)!LG;%TT8Y,AA%UYHQV;;)V]HK"5"IW\HDA-_YX
MLH>W$I1XBX7LWLEP=:"=R3)QDITOLP)RJYGGG"MSQ9;5A*YTY9/X;'QV!Y%I
M4R-W"X[Z-Q5WNXS^$8]W<8D_W6QOF*P-Q]EPM*>ZL:IQRZ-_FMMRZ)]Z@W=T
M#YNT:UAU-9@S4BYV094/-D)VX9+%$+1VA(M+W$YNZ[>,QL%P!+);L(MQ%:TQ
MF;YR,*@\@G)S7:.::G)TBI],45IUE)MU-8]V)9DE#_YUOXK0VV]N;<,>Q>5O
M@;T5KZ-PB+<$F,MQF[$C@85RR:NL::1S_::V4*]U":)[-/1UA9ZU#VIU'XIL
MVLMN&\[&Q41O*<?DKNMP(<#SE_]Q)[HV@+MR3[/\:.MS@ZY]4 ITCJI)-&-T
M_:,H#O1TGXH<UA5_#G&VP>5_$'+*K/1_'7//EQ]_-731@'5_5G7=:.Y_B';V
M4#%_SW@(-)J 67D'#UB!\GD\U(Q]47Q_P+)]<WQZJ\Y]EWQ\E?Y]P'R/?U-]
M\WRY9]-^-WSW3QY^C7TT,Y!_$GUR#D& 2'V#TP![TH=0OP=\ H9"JD%\,X5$
ME(%\<81O??Y\NX.]9J)]%8,F3@M]=H*8,I-][8(E#4Q^TH&#T6YZAI(8O65Z
MO) 9J*%Z]XXPDPU[0(QI?*I[H8K=97A\#(ER30E\=H@A,:U\WH<>#'A]C83\
MS_-Y<ISIN^]YJIH+IRUY[9=!D:1Z/Y28>V9ZI9(<9%M[(H_G3!E[DXWA,-Q[
MZHQ_"\)\=X?SSK-XFZ?2NK-XU*0?I?)Y%:!QD')Y:ISF>DIYUIF18U9Z4Y:$
M2SYZS)/F,"%[%9*""RE[C8>+S:YW\;+3N;!X*JY.I.IX9:F_CVQXN:54>5IY
M+*$T8H5YKIUQ2H1Z(9I++X-Z7)AR"JIZRX<VS.1W<[WQN.-WJKB@I!!WW+,U
MCHMX)ZWK>(%XFZD)8<1Y)Z2W2>5YG*%K+OQYP9U."D)Z+8;PS%5W'LD^N$IW
M4<,CHU]W=[S@C<MWM;;"=\AX)+$O82!XL*Q[251Y)ZCR+GUY09]O"?!YKX:X
MQGZ(&'"*L_R',W&^H)*&<G+:C!N%T7/N=K>%1W4+8%R$W'8U2+2$GG=5+<6$
M]'A2"-R&3WE@Q4:&@'JXLNJ%NWKJGW.%#'L;BP>$=7M7=:J#^7NG7UN#G'P)
M1[J#:'QI+-B#LGS ""^$JGUUQ!*%#H3YL:B$7(0QGE^#LX-RB=F#+(+2=(>"
MNH)47E&":X'S1L>"1(&?*_N"A8%N!YB#.8$+PJV#QX\JL#&#%HV-G,F"?(OW
MB'&" (I\<T*!J(DV736!:X@21=6!2H<3*RR!>(9^!Q2!^(0HP52"O9EAKMB"
M#9;]FW6!>I2=ARF!!9)1<AN L) M7#6 A(Y410" :(R\*GB A(P)!J. YH1]
MP#"![:.^K;B!0*"6FE> JYUDAA2 .)I%<1Q_YY=:6U%_MI3"1$1_H9*T*==_
ML)(3!D1__H0]OT2!2:XWK,N GZI.F62 !:9+A2!_CJ);<#U_1)ZX6I)_&)N"
M0Z9^]IDB*5%^^)="!?9_/X0(OI" SKC:K!" )K0RF)E_A*]@A$Y_ JJ?;W-^
MMZ9.6=A^E:*I0PQ^=Z!P*-]^7IN"!;9^HX/<OA2 >,/!JX)_T[YCE^Q_)+C!
M@Y-^D[,U;L9^0*Y)645^(*IS0I-^!Z<P*'E]YIM>!8-^)H.ZMUR15V^QIC6/
MGG#ME"&.''(2@/2,R7,N;,N+F'145Y.*E76&0.^)X':D)H&*.W>! RJ*)'F]
MMEB/X7E3I4..1WF>DQZ,U'GI?_F+AWH_:]:*7WJI5JJ)9GLD0 J(M7N8);*(
M^GOT MN(A'UIM4F.BX+JI R- H)=D@.+DH'3?M>*4X%I:LR)-X$95;N(2H#C
M/S:'GH"Z)/J'SH"X I6'%H"BM"R-38R5HM2+RXL^D+:*:HGH?;F)*HBT:;V(
M'X>L5,Z'/H;'/FN&F(8-)%"&MH7F EF%V8&6LP6,2Y9)H<**RY0XCYR);Y(M
M?(N(.I W:+"',8YK4]^&88SE/:6%O8NO([.%Q(NY B6$RH%SL@:+A: ?H+Z*
M"9U9CIB(K)J/>Y*'>9?:9\J&<95;4Q*%F),Q//Z$]Y&N(RR$[)$A ?F#Y8%6
ML36*Z:H.G^N)<::6C<"(#Z,->KR&V9^=9P6%U9Q[4FJ$_9G4/'6$2I@^(L"$
M,)6= =6#)X$]L)**<K0GGT"(_K "C0F'EJN^>@*&5J>79E&%4*/A4<:$@Z#T
M._"#SI]?(F&#E)<_ ;B"C8$IL""*&KZ+GKR(JKG"C&Z'.[3&>5V%[Z_N9;F$
MXJO 442$$ZCF.W^#9*4Q(?^#(I;\ :""$H$9J)N:Z6\(F(Z8<W!!AZ66/'%I
M=;"4/'*,8K62:'.W3I*0U73G.-2/PG7T'J.0AG:$  "*<GM%I\J9G7@GE]*7
M/7B AM>5#GC==.23#7E'8>N1.WG%3="/K'I0.!F.E7K,'@:/-7L+  "(V7Z3
MIN^85X$[EM&6"8#*A>F3VX!E<^V1Y8 <8060'7_Q30&.F'_?-V.-@7_6'7>-
M_G_S  "'<H  I?67-HI E<*4ZHD?A,:2QX@-<O:0S8</8!N/$X9!3#F-EH65
M-L",?H4;'/R,W85F  "&.X  I0N6+I-QE,Z3[)&C@\N1T(_B<?:/W(XS7T:.
M%HRS2WZ,I8M]-BJ+C(JN'(^+T(KC  "%,(  I#25;YS&E V3+YI1@PJ1#I?>
M<22/&I6&7G>-6I-H2LJ+WY&N-9B*Q9#''".*\H^1  "$3X  HX&4VJ8NDU*2
MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
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MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
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M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
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M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
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M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
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M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
M0G?=67" 4'BF0I. >'E:*"Z _'G(!,B"#'K2N1Q_#G[-I\)^^7ZWE9A^WWZ<
M@B1^V'Z&;<]^W'Z#6'E^^'Z-0;I_)WZ2)VY_CGY\!&* D7Z2M[Q]E(C5IEQ]
MAH?NE Y]?(;^@,E]@885;)!]GX5,5V%]S(280,Q]_X/V)JA^1(.$! E_2('4
MMFU\69+AI0M\4)$XDK]\4(]_?X1\78W(:W=\@(PM5FA\OHK'/_Y\](F0)?]]
M&(D& [Y^+X*(M55[8IT,H_-[7IJCD:A[7I@>?G5[;I6;:GE[E9,\58I[SY$>
M/T9\"8]U)6A\#X\  WY]08)<M'5ZGJ=)HPUZG:0FD+QZF:#5?8IZIYV(::!Z
MU)IU5,Y[$I>_/JQ[/I7&).Q[*I0@ TE\?8(YL\QZ"[&@HEAZ#*W&C_AY_ZFO
M?,)Z!*69:-QZ,:'=5!IZ>9ZZ/AEZHYSD)']Z:IA2 QY[W8(<LUQYI[P@H=)Y
MI[>8CU9YC;*^?!1Y@ZWI:#EYJ*F74XQY[J9!/9=Z&J-\) MYS9A? OQ[7H($
MK-B+O6G:G/F*@&N[B_V)?FUP><"(J6\(9FF'\7"84>R'8G(D.^B'('.%(;&'
M]71.  "'@7<DJ_.* G-EG >(^'15BNZ(#'4R>+F'/W8(97&&C7;B40>&!G>\
M.Q&%P'AX(/:&:GC'  "%E7L5JO"(:GS;FM6'>WSYB=F&F'T+=YV%VGTA9'&%
M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
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M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
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M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
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M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
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MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
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MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
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M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
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M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
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M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
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M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
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M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
M5F*G-))^3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!
M@(    "  (  M29A4UFRH_YCT5T#DC9F+V W?X9H<6-,:]YJGV9&5RALKFDE
M02IN8FO/)^MNVFW=!KETHV[%LRI=SF1AHG%@FF:LD-1C-FCF?DMEKFL0:KIH
M#6TH5AYJ0&\N0#5K_'$&)QAL$G)>!F-U-7-!L4Y:L6\!H*I=LW!*CTU@@W&,
M?-9C)G+.:6YEK'0-5/MG_G5#/SYINW96)E%I97<*!A=UM7@BKW17Y7F!GMU;
M%GG<C8Q>"7HY>UE@TGJ7:!1C?WL!4]1EZGMK/DYGJ'O$)9=FW7OK!=5V)'R:
MK;Y5>(/RG498SH-UC 1;XX+V>=Y>Q8)Y9N)AC(((4LAD$8&O/79ERH%8)/)D
MA($1!9UV@X!MK%)3=HYFF_=6Z8T8BLQ:%(O >+A=#8IJ9<Y?Y(DH4>=B<(@*
M/+YD)8<9)&)B=8:=!6YVTX.FJRU1SYC5FNI56):VB=!8D92#=\I;F))99.]>
M@)!4421A%(Z%/"EBN(T,(_!@R(RB!49W%H.1JE!0A*,VFAY4&Z!#B0I76ITW
M=PQ:9)H[9#==5)> 4'A?\94>.YQABI-6(XY?;)'L!29W3(-[J<%/F*UUF9)3
M-*F@B'A6;*6Y=GE9<*'X8[!<7IZ94 1>^IO%.RA@?YH%(R)>198>!0UW=X-J
MJ!=HVUE)F&-JJ5ROA\]L:U_F=B5N'V+P8V5ORF7<3W]Q7VBG.B)RKVLJ(.AR
M\6S, 4Q]SV[SIH%EB&-WES1GI67DAKUIFF@Q=2UK=FIC8H!M0FQ]3K-N\6Y_
M.71P/G!%(%MP G%, 2Y^ 7/'I-YBB&V.E7]DV6\.A3=F^W!X<[AH_W'483AJ
M[W,F399LN'1I.(%M_75\'YUM+G7Y 11^+7AEHS1?UW>(D]5B4'@P@Y9DE'C'
M<E]FN'E17_YHS7G<3(QJJGIC-ZMKYGK/'OIJG7KA /U^5'QFH:A=?X%]DF!@
M&8%=@BUB?($F</YDN(#B7NAFX8"D2Y=HU(!W-NAJ X!+'FMH=( = .I^=7_4
MH&-;D(M[D2M>0HJ6@0E@N(F2;^EC"8B#7>9E0(>"2LEG-8:C-D-H6(7X'>YF
MJX7: -E^D8"3GU]9^95TD#)<O)/,@!I?/I'[;P9AFY D71%CXHYO2A-EW(SS
M-;]FY8OA'8]E,XN, ,Q^J("*GIU8NY]ACW-;B)SW?UE>#9I;;DI@;)>_7%IB
MN)5A26ADN9-I-3=ELI(W'3ID!) V ,%^NH""GAU7V*DVCNI:I:8,?L-=(Z*G
M;;)?>Y].6]!AQ)Q82/5CPIH'-,-DHICE',MC#9-X +A^R8!\FS9PLECWC-5Q
MS%Q@?6=R\5^0;+QT&V*,6N%U1&5D1\%V9V@3,O)W:&I@&5YWS6M:  "  '(=
MF>%MAV*-BZ-N[F4/?#%P06=I:Z-QC&FA6>5RT6N^1N9T!VVZ,CAT]6]@&-)T
MR6_<  "  ';(F(5JH6P@BC]L0&W'>Q%MO6]5:H5O)G#&6.YP@W(H1AAQR7-T
M,9ERI71\&&-R)G23  "  'KBEP1H!769B,%IRW9^>8-K9W=&:3IL['?Y5[YN
M;'BC119OPGE!,,=PB7FW%\IO['F,  "  'YQE:!EQG\.AV=GIG\\>#-I7G]&
M9_AJ^7\Y5L9LB'\L1#EM[7\H,!INGG\>%U)N!G[P  "  (  E'MCZHB2ADQE
MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
MDX]B8I(2A65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK
M(XG'  "  (  DMYA+IN)A+)C.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R
M+I-J+I$E%E9J%8WE  "  (  DF9@3:3SA"YB7:)G=/MD*9^$9-EEUIR<4]AG
M>IH70<%HV9A3+B)I&)=@%>5I3([.  "  (  CGQXYUBQ@2=Y4EP)<K=YX5\H
M8OYZA&(34@%[,634/YU[[V=>*SQ\Q6E;$-Y^4&E@  "  '8)C5)UX6&Z@!!V
MF61 <9QW4F:;8?UX#VC341]XSVKK/MUYE6S3*I]Z1VY $(A[A6WV  "  'H?
MC!US&VJU?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY
M$'++  "  'VUBM5PDW.R?6MQJ'3 ;RERH76M7^ASC7:'3T]T>G=+/6=U3W?[
M*8YUO7AI$ -V['?P  "  (  B9-N:WRN?%!OF7T6;@MPJ7U77KAQI7UZ3EUR
MGGV:/(IS?7VZ*-USQGW##Z%U)7V>  "  (  B(ELI(6V>T=MXX5Z;0YN_X4,
M7<=P"82"37]Q!X/_.^-QVX.9*%MQ_X-E#UISH8+Z  "  (  A[)K+(ZZ>G5L
M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
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M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
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M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
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M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
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M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
MA]E4NIV9>JI7O9N?;():9YE675Y<TI<(345? Y46._I@CY/3*0E?[Y-H$21E
M[XN7  "  (  A3!QDE- >&IREE;S:J5SLUIX6Z5TV%W)2UYU]V#G.9=W#F.[
M)9EW^677"[IZQ&8"  "  '7"@\=MTEP.=S=O,%\#:8%PA&'.6J5QS61S2H)S
M!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "  'GA@G!J763===)L 6<7:%AM@VDR
M68UN[FLI29AP0&S_."-Q7FZ>)()QO&^R"V5U@F^*  "  'V @0YG,VVP='!I
M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
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M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
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MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
MB8A"6X>>?'Y'!H<-;I=+1(9M7YY/'H7-3Y12?H5#/EA4U(3?*YM43(3$%%5=
MHH3Z  "  (  B*$_\)#_>[)$RH^M;>)),(Y*7P%-)HSS3P-0E8O0/<M2W(KY
M*RU21XK&%"I=ZXF;  "  (  A_\^$9H>>QQ##)@6;59'BI7U7H9+DI/R3J!/
M"I)%/8)119$=*N%0K9$3$]]>:8U   "  (  B!UA[$X,>L-D!U(=;+%F)E87
M79MH.5GL359J+EV1.Z1KVF#O)_)LF&.I#I-PZV1H  "  '&TAB=<^5<;>4A?
MBUIW:V-A_EVV7'MD46#33%EF<F/#.LQH*69U)T)HAVB4#D-N$6C_  "  '9H
MA&Y88F!&=[1;6V+?:BU>'&5C6UQ@HV?%2VEBZ&H#.@MDH6P-)KEDDFV9#A-K
MAVW%  "  'J+@KM4,&EI=A=7>6M":)5:=&T+6A1=,&ZZ2C]?H'!*.11A57&T
M)?E@R'*]#;AI>'+/  "  'XC@3)0:W*(=*I3]'.J9T%7*72Y6-1:#W6R25Q<
MGW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "  (  ?^M-(7NG<X!0X7P79C941WQO
M5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)#5)I?'X)  "  (  ?N%*382T<HY.
M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
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MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
M:N-A(VY&7[AC9F^D4[ME9'#M1LIG%W(6.*-H;G,B*&UHPW/G%1MJR7/: 1-^
M+G<>  "  (  :<5> W: 7LA@=G=04N=BEG?_1?1D7'B0-\UEHWD1)]EEJGEX
M%*YHFGEG 1)^,'OT  "  (  :-Q;2WZK7>U=XW[T4AM@'W\,139A\G\+-QMC
M*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "  (  :"59 X; 741;NX:/47E>"X87
M1*!?XX6)-HEA"(4I)K1@884F% 9E5(5$ 3!]_H#.  "  (  9YY7+8[&7,5:
M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
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M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
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M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
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M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
M>:N]OWBRO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO?^<.!K_FD8M_Y=10?^:4T_^G%5>]9Q:;.R;7WKDF6>'W)9Q
MDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS >:N]
MOWBRO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO?^<.!K_FD8M_Y=10?^:4T_^G%5>]9Q:;.R;7WKDF6>'W)9QDM63
M>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS >:N]OWBR
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO?^=.!K_FD4N_Y=00?^;44__G51=]9Y8:^R=77GDFV2&W)ANDM65>)S0
MDH&DRX^)J\>-C['%B9.UPX67N,*"FKK!?YZ[P'VBO;][I[Z_>:V^NWBQOK9Y
MLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFR
MOO^=.!K_FD4N_YA/0/^=4$[_GU)<]J!5:NV@6GCEGV"%W9QJD=:8<YO0E7VD
MRY*%J\>/C;'$C)&VPH>5N<&#F;N_?YV^OGVBO[UZJ,"\>:_!M'FPP;!ZL,"P
M>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP/^=
M-QK_FT4N_YE.0/^>3D[_H5!;]Z)3:>ZC5W?FHEV#WI]FC]><;YK1F'FCRY6"
MJ\>2B;'$CH^VPHF3NK^$F+V]@)W O'VCPKM[JL2T>JW$K7NNPZI[K\&J>Z_!
MJGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP?^>-QK_
MFT0N_YI-0/^?34W_HDY;]Z11:.^E577GI5J"WZ-BC=B@:YC2G'6AS)E^J<B5
MAK#$DHVVP8R1N[Z&EK^\@9S#NGZDQ;=\J\>M>ZO&IWRMQ*1]KL.D?:[#I'VN
MPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNP_^>-QK_FT0N
M_YM,0/^@3$W_I$U:^*9/9_"H4W3HJ%> X*=>C-JD:);3H7&?SIUZI\F9@Z_%
ME8JUP8^/N[V)E<&ZA9W$MH*DQ[" JLBG?:K(HGZLQ9]_KL.??Z[#GW^NPY]_
MKL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NP_^>-QK_FT0N_YQ+
M/_^A2DS_I4M9^:A.9O&J47/IJU5_XJM;BMNI9935IFZ=SZ-WI<J?@*S%F8:T
MOY.,O+B-D\&RB9G%KH:AR*J$J<FA@*G*G(&LQIN!K<2;@:W$FX&MQ)N!K<2;
M@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ/^>-AK_G$0N_YQ*/_^B
M24S_IDI9^:E,9?&L3W'JKE1]XZ]9B-VN8I'6K6N:T:IUHLNE?:O!G8.TN9:)
MO+*1D,&LC);&IXF=R*.'ILJ;@ZC+F(.KQY:$K<66A*W%EH2MQ9:$K<66A*W%
MEH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2MQ?^>-AK_G$,N_YU)/_^C2$O_
MITE8^JM+9/*N3G#KL5)[Y+-7A=^T8([9LVJ6T;%UGL:H>ZN\H(&TLYJ'O*R4
MC<*FD)3&H(V;R9R+I,N6AZC+DX>KR)*'K,62AZS%DH>LQ9*'K,62AZS%DH>L
MQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ?^?-AK_G$,N_YY(/_^C1TO_J$A7
M^ZU)8_.P3&_LM%!YYKA6@^&[7HO:NVJ2S;1SGL&K>:JWI'^TKIV$O*:8BL&@
ME)'&FI&8R9:/H<N1C*C,CXJJR(Z*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*
MK,:.BJS&CHJLQHZ*K,:.BJS&CHJLQO^?-AK_G$,N_YY'/O^D1DK_JD96_*Y(
M8O2S2VWNN$]WZ+U5?^'!7H;6P&R.R+=QG;VN=ZJRIWVTJ:&"NZ&<B,&:F(_&
ME):6R9"4G\N,DJC,BH^JR8J.K,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*
MCJS&BHZLQHJ.K,:*CJS&BHZLQO^?-AK_G$,N_Y]&/O^E14K_JT55_+!&8?:V
M26OPO$YTY\)5>]_(88#1PVJ-Q+IPG;BR=:FMJWNSHZ6 NYNAAL&4G8W%CIN4
MR(J9G<J&F:C+AI2JR8:2J\:&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&
MAI*KQH:2J\:&DJO&AI*KQO^?-1K_G4(N_Z!%/?^G1$G_K4-4_K-$7_>Z1VCO
MP4UPY<E6==S.9'K,QFF-OKYNG+*V=*BGL'FRGJM^NI6FA,".HXO$B*&2QX2?
MFLF GZ?*@9JJR(*8J\:"F*O&@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBK
MQH*8J\:"F*O&@IBKQO^@-1K_G4(N_Z%$/?^H0DC_KT%3_[9"7?>^1F7LQTUK
MX])8;=;387K'RF>,N<)MFZR\<J>AMG>QF+%]N8^M@KZ(JHG#@JB0QGVGF<AZ
MIZ7)>Z*KR'V>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>
MK,9]GJS&?9ZLQO^@-1K_G4(N_Z)"//^J0$?_LCY1_;I 6?/#1&#HSTYCW]Q9
M9\_88'G SV:*LLAKFJ;"<*:;O':OD;A[MXFU@;R"LH? ?;".PWBNEL5VK:'&
M=:RLQG>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5W
MIJW%=Z:MQ?^@-!K_GD$N_Z1 ._^L/47_M3M.][\^5>S+1%GAVD]:U-]1;,;:
M6GVXTV*+J\YIF)_&<:25P'>MCKM^M(>W@[F!M(>]?+*,OWFQD\%VL)O"=+"F
MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"
M<K"MPO^A,QK_GD$O_Z<].O^P.D/]NCA*\,8[3^/514[5X49?R.)+<;K=4H&L
MU5N/G\QFFY;&<*2/P'BKBKQ_L82Y@[6 MX>X?+:+NWFTD+QWM)>]=K2AO72S
MI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.E
MOO^B,QK_H#XN_ZHY-_^T-3_VP#5$Y\\Y1=??/%#)YT%DN^5&=JS<3H6?TUJ2
ME<QGG([&<:2*PGFJA;]^KH"\@K)]NH:T>KF*MG>XCKAUMY.Y<[>:N7.WH+ES
MMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N?^C
M,AK_HSHL_ZXT-/ZZ,3KMRC [VMTR/\KG.%6\[#UIK>5$>9_;3H>4TUR2C<QH
MFXC(<J&$Q'FF@,)]JGS @:UYOH6O=[V(L'2\B[)RNY"S<+N5M&^ZFK1ONIJT
M;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M/^D,!K_
MIS4J_[0O,/3#*C'>V"LMS.8N1;WR-5JM[CMLG^1$>Y/;48>+U%Z0AL]JF(++
M<YU^R'BA>L9\I'?$@*9UPX.H<\*&J7'!B:MOP(VL;<"2K6R_E:ULOY6M;+^5
MK6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K?^E+QK_K2TE
M_+PG*.70(23.Y"0SOO$L2J[X,UV@[3UMD^1'>HK=5(6#UV&,?])LDGO/<I=W
MS7>:=,M[G'+*?IYPR8&@;LB$H6W'AZ)KQHJC:<:.I&C%D:5HQ9&E:,61I6C%
MD:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I?^G+!K_M24?[,D:
M'-#B&2&_\"(XK_TK3:#X-5Z3[D%LB>9-=X'@6(!]W&2&>-AKBW/5<8YPTW61
M;M)YDVS1?)1JT'^6:<^"EVC/A9AFSHB99<V,FF3-CIIDS8Z:9,V.FF3-CIID
MS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FO^N)!;UP1<4U-\.$,#O
M&":P_2,\H?\M3I3Y.EV)\4=H@>M2<7KF77ATXF1]<-]K@6W=<(1JW'2&:-MX
MB&;:>XEEV7V*9-B BV+8@XQAUH6-8-:)CE_5BXY?U8N.7]6+CE_5BXY?U8N.
M7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+COZY%@W4T@L&PNX.%K'\&2JB
M_R4]E/\R3(G\0%F!]DUB>O!8:7/L7V]LZ61S:.=J=F;E;WEDY'-Z8N-V?&'C
M>7U@XGM^7^%^?E[A@']=X(. 7."%@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(
M@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@=3("0/$UPH'LOL0&:/_'"N5_R@[
MBO\X2('_15)Z_%):<O=98&OT7F1F\F1H8O!I:F#N;6Q>[7%M7.UT;EOL=F]:
M['EP6>M[<5CK?7%8ZG]R5^J"<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;I
MA'-6Z81S5NF$<U;IA'-6Z81S5NF$<\3-" &TW0@+I/\2&I?_'RJ+_RXV@?\]
M07G_2DEQ_U)0:?]856/]75A?^V-;7/EG75KX:U]8]VY@5_=Q85;V=&%5]G9B
M5/5W8U/U>6-3]'QD4O1^9%'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51
M](!E4?2 95'T@&51](!E4?2 9?^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/68
M86WME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>E
MK\AUJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WM
ME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AU
MJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AY
MY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'
M=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)R
MA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQ
MQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/
M?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.S
MLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:
MC(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9S
MNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLO^6,Q3_E4,E_Y-1-_^74T7_F592_9E;8/688&WMEF=YY9-QA-^0>X[:C826
MU8B*G-&$D*+/@)6FS'V9J<M[G:S)>:&NR'>EK\AVJK''=*ZRQW.TLL1TNK*_
M=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLO^6
M,Q3_ED,E_Y50-_^9443_FU12_IQ87_6;76SMF61XYI9L@]^3=HW:CX"6U(R(
MG=&'CJ/-@Y.HRX"8J\E]G*[(>J&QQGBELL9WJK3%=;"UQ72XM;UWN+6X=[BU
MN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM?^7,Q3_
MED,E_Y9.-_^:3T3_G5)1_IY57O:>6FKNG&!VYYIG@N"6<HS:DGN5U(Z$G="*
MBZ/-AI&IRH*6K<A^F[#&>Z"SQ7FFM<1WK+;#=K.WOG>WM[=XMKBR>;:XLGFV
MN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN/^8,Q3_ET,E
M_Y=--_^;34/_GU!0_Z!37?>@6&GOGUUUZ)UD@.&:;HO;EG>4U9& G-".B:/,
MB8^IR825KL> FK+%?:"UPWJGM\)XKKG =[6YN'BUN;%YM;FL>K6YK'JUN:QZ
MM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN?^8,Q3_F$,E_YA,
M-O^<3$/_H$Y/_Z)17/BC56CPHEMTZ:%A?^*>:HG<FG.3UI5\F]&1A:/,C(RI
MR8>3K\:"F;/#?J"WPGJHN<%XL;NY>+.\L7FSNZMZM+NG>[6ZIWNUNJ=[M;JG
M>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNO^9,Q3_F$,E_YE+-O^>
M2T+_H4Q._Z1/6_FE4V;QI5ARZJ1>?>.B9H?=GG"1UYEXF=*5@:'-CXFIR8J1
MK\6#F+3"?Y^XO7RGN[IZL+VR>K*^JWNRO:9\L[RC?;2ZHWVTNJ-]M+JC?;2Z
MHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNO^9,Q3_F$,F_YE*-O^?2D+_
MHTM._Z9.6?JH467RJ%9PZZA<>^6G8H7?HVR.V9]UE].:?I_-DX:HQ8V-K[^'
ME+6Y@YRYM7^CO+%]K+ZL?+&_I7RQOZ%^L[V>?K2[GGZTNYY^M+N>?K2[GGZT
MNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTN_^9,Q3_F4,F_YI)-?^@2$'_I$E-
M_Z=,6/JJ4&3SJU1N[:Q:>>:L8(+@JFF+VJ9SE,^??)W&EX.HOI"*L+B+D;:R
MAIBZK8.@O:F!J+^E@+# GW^PP)R LKV:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!
ML[N:@;.[FH&SNYJ!L[N:@;.[FH&SN_^:,Q3_F4,F_YM(-?^A1T'_I4A,_ZE*
M5_NL3F+UKU)L[K!8=NBQ7G_?L&B(U:QTD,JC>IW FX&HN)2'L+&/CK:KBI6[
MIH>=OJ*%I<"?A*_!F8&OP9>"LKZ5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5
M@[.\E8.SO)6#L[R5@[.\E8.SO/^:,Q3_F4,F_YQ'-?^B1D#_IT=+_ZM)5OVO
M3&#VLE%J[K17<^6W7GS=MFJ#SZ]RD,6F>)V[GGZGLIB%L*N3B[:ECI.[GXN:
MOIN)HL&8B*S"DX6OPI*&L;^1AK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\
MD8:SO)&&L[R1AK.\D8:SO/^:,Q3_F4(F_YQ&-/^C14#_J$5*_ZU'5?ZQ2E_U
MM5!HZ[E6<..]7G?9NVJ R[)PD,"I=IVVHGRGK9R"KZ67B;:>DY"[F8^8OI2-
MH,&1C*G"C8JNPHV)L;^-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FR
MO8V)LKV-B;*]C8FRO?^;,Q3_FD(F_YU%-/^D1#__JD1)_Z]%4_RT25WRN4]E
MZ;Y6;.'#8'+3OFF QK5NC[NM=)RPIGJGIZ" KY^;AK68EXZ[DY65OHZ2G<&*
MDJ?"B)"NPHB.L,"(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-
MLKV(C;*]B(VRO?^;,Q3_FD(F_YY$,_^E0C[_JT)(_[%$4OJW2%KPO4YAYL16
M9][)8FW.P6=_P;EMCK:Q<INKJGBFHJ5^KIF@A+62G8NZC)J3OH>8F\"$EZ3"
M@I:OPH.3L,"$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$
MD;*^A)&ROO^;,Q3_FD$F_Y]",_^F0#W_K4!'_[1"3_>[1U?MPTU=Y,Q88-G-
M8&S)Q69^O+UKC;"U<9JEKW:EG*I\K9.F@K2,HHFYAJ"0O8&>F;]]GJ+!>YZO
MP7V9L,!_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^
M?Y:ROO^<,Q3_FD$F_Z!!,O^H/SS_L#Y%_[=!3?3 15/JR4Y6XM5:5]+17FO$
MR61]ML%JC*J[;YF?M72DEK!ZK(VL@+*&J8>W?Z>.NWJFEKYWI:"_=*:MOW>A
ML;]ZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVR
MOO^=,Q3_FT$F_Z(_,?^J/#K_LSQ"^[L^2?#&1$WFTD]-W-Q75LS576J^S6-[
ML,=HBZ3!;9>9O'.BC[AXJH:T?K!_LH6U>;",N'2OE;MQKI^\;J^KO7&JL[QT
MI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO/^=
M,Q3_FT F_Z0\,/^M.3C_MCD_]<$\0^G.1$3>W4U'TN!36,7;7&BWTV%ZJ<UF
MB9S(:Y61Q'&?B,!VIW^]?:UXNX2Q<[J+M&^XE+=LMYVX:K>HN6FVMKAMK[6Y
M;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN?^>,A3_
MG3XE_Z<Y+O^Q-C7[O#8Z[<DZ/.#:1#K2XD=,Q^)-7KG>5&ZLV5M\G]1BB)30
M:).*S&^;@L=WHGS#?JAVP(2L<KZ*KV^\D;%MO)BR:[NALVJ[K;)GNK:T9[JV
MM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM/^?,A3_H#HD
M_ZHT+/^U,C'SPS(SX]0X,-/A/#_&Z$)2N>5(8ZSB37*?WU1_D]E=BHG29Y.#
MS7":?<EWGWC&?:1TQ(.G<,*(J6[!CJMLP)2L:K^;K6F_I:UHOZZM:+^NK6B_
MKJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK?^@,!3_HS8B_Z\P
M*/N\+2OHS2PHU> P,,?I.$2Y[#Y7K.E%9Y[G2W62X%. B=E>B8+4:)%\T'&6
M>,QWFW3*?9YPR(*A;L>'HVO%BZ5IQ)"F:,26IV;#GJAEPZ6H9<.EJ&7#I:AE
MPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ/^A+Q3_J"\?_[4J(O#&
M)"'8W2,@R.DM-;KR-4FL\3Q:GO!#:9+H3'6(X55_@=MAAWO7:HUVTW&1<M%W
ME6_/?)=LS8"::LR%FVC+B9UFRHV>9<F2GV/)F*!BR)ZA8LB>H6+(GJ%BR)ZA
M8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H?^C+13_KBD:^+\@&M[6&!/)
MZ"(ENO0K.JSX-$V>]SQ<DO%&:8CI4'-_XUE[>M]D@G3<:X9PV7&*;=9VC6K5
M>X]HTW^19M*#DF31AY1CT8J58="/EF#/E)=>SYF87L^9F%[/F9A>SYF87L^9
MF%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F/^G*!+_MQ\2YLX1#<OF%1:[]"$J
MK/XK/I[_-$Z2^C]<B/)*9G_L56]YZ%YU<N1D>V[A:WYJWW"!:-YUA&7<>85C
MVWV'8MJ!B&#:A(E?V8>*7=B+BUS7D(Q;UI2-6]:4C5O6E(U;UI2-6]:4C5O6
ME(U;UI2-6]:4C5O6E(U;UI2-6]:4C?^P'@OMQ@X(S=L+"+OS%1JL_R$NGO\L
M/Y+_-TV'_418?_9/87CQ66AQ[5]M:NMD<6?H:G1DYV]W8N5T>6#D>'I?XWM[
M7>-^?%SB@7U;X81^6N&(?UG@C(!8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8
MX(^!6."/@5C@CX%8X(^!6."/@?.]#03,SPD!O>4,#*S_%QZ>_R0ODO\O/8?_
M/4E__TE2>/Q46G#X6E]I]%]D9/)E9V'P:FE>[VYK7.YR;5OM=FY:['EO6.Q\
M<%?K?G!6ZX%Q5>J$<E3JB'-3Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT
M4^F+=%/IBW13Z8MT4^F+=,S&" "]U @#K?4.#Y__&A^3_R<MB/\T.7[_0D-W
M_TU*;O]34&?_655B_%Y87OMD6UOY:%U9^&Q>5_=P8%;W<V%5]G9B5/5X8E/U
M>V-2]'UD4?2 9%#S@V5/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&
M9D_SAF9/\X9F3_.&9KW+!@"NVP8$G_\0$)/_'1V(_RHH?O\X,G;_1#IM_TM!
M9?]11E__5TE;_UU,6/]B3E7_9E!3_VI14O]M4E#_<%-/_W)43O]U5$W_=U5-
M_WE53/Y[5DO^?E=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]
M@5=*_8%72OV!5_^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR
M=NF)?'_DA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.A
MT6RYHM%KP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:BR&[&HO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)
M?'_DA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RY
MHM%KP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
MR&[&HO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_D
MA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%K
MP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&
MX("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-
M;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-
M+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+
MC=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6C
MR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_
MC3X=_XQ,+O^44SO_E59'_Y9;5/V586#VDFAK[X]P=>F+>G_DAX.'WX**C=Q^
MD)+9>I:7UG>;FM5TH)W3<J6?TG"IH=%NKJ+0;;2CT&RZI-!LPJ3*;L2DQ&_$
MI,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I/^.+0[_CCX=
M_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN CI38
M?)28U7F:G--VGY_1<Z2BT'&JI,]OKZ7.;K:FSFV]I\INPJ?#<,*GO7'"I[UQ
MPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I_^/+0[_CCX>_Y!*
M+?^73SK_F5%&_YM64OZ:6U[WF&%I\)5H=.J1<7[DCGR&WXF$CMN#BY37?Y*:
MU'N8GM)WGJ'0=*2DSG*JILUPL:C-;[FIRV_!J<-QP:F\<L"JMW/ JK=SP*JW
M<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JO^/+0[_CSX>_Y)*+?^8
M33G_FT]%_YU34?^=6%SXFUYH\9EE<NJ5;7SDD7>&WXR!CMN'B976@9":TWV6
MG]!YG:/.=:.FS7*KJ<QPLZK+;[VKQ7*_J[USOZRV=+ZLL76^K;%UOJVQ=;ZM
ML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^K?^0+0[_D#X>_Y-)+?^93#G_
MG4Y$_Y]14/^?5EOYGEQF\IQB<>N8:7OEE'.$X(]]C=N*AI36A(V;TG^5H,]Z
MG*7-=J.HRW.KJ\IQM:W&<;ZMOG2]KK9UO:ZP=KVNK'>]KJQWO:ZL=[VNK'>]
MKJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KO^0+0[_D#X>_Y5)+/^;2CC_GDQ#
M_Z%/3_^B5%KZH5EE\Z!?;^R=9GGFF&^#X)-YC-N.@I/6AXJ;TH&2H<]\FJ;*
M>**JQW6KK<-SM*^_<[RPMW6\L+!WN["J>+NPIWF\L*=YO+"G>;RPIWF\L*=Y
MO+"G>;RPIWF\L*=YO+"G>;RPIWF\L/^1+0[_D3X>_Y9(+/^<2#?_H$I"_Z--
M3?^D4EC[I5=C]*1=;>ZA8W?HGFN XIAUB=R2?I+3C(>:S(:/H<: EZ?!?)ZL
MO7FFK[EVK[&W=KJRKW>ZLJIYNK*E>KJRHGN[L:)[N[&B>[NQHGN[L:)[N[&B
M>[NQHGN[L:)[N[&B>[NQHGN[L?^1+0[_D3X>_YA'+/^=1S?_H4A!_Z5+3/^G
M4%;\J%5A]:A;:^VG873EI&E^WI]SA]28?9#+D82:Q(J,HKZ$DZBX@)JMM'RB
ML+!ZJ[.M>;6TJ'JYM*1[N;2@?;FSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JS
MG7VZLYU]NK.=?;JSG7VZL_^2+0[_DCX>_YA&*_^>1C;_HT=!_Z=)2_^J3E7Z
MJU->\JQ9:.FL8''BJ6AZV:5S@\V<>H_%E8&:O8Z(HK>(D*FQA)>NK("?L:A^
MI[2E?;&UH7VXMIU^N+6:?[FTF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"Z
MLYF NK.9@+JSF8"ZL_^2+0[_DCX>_YE%*_^?1#7_I$5 _ZE(2?^L3%/XKE)<
M[[!89>:Q7VW>L&EVTJEQ@LB@>(^_F'Z:MY*%HK",C*FJB)2NI(6<LJ""I+6=
M@:ZVFH"WMY>!M[:5@KFTE(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFSE(*YLY2"
MN;.4@KFSE(*YL_^3+0[_DCT>_YI$*O^@0S7_ID0^_ZM&2/^N2U'ULE!9[+57
M8>2W7FG:M&ESS:QO@L*D=H^YG'R9L9:#HJJ1BJFCC)&NGHF9LIF'H;66A:NW
MDX6VMY&$M[>0A;BUD(6YM)"%N;20A;FTD(6YM)"%N;20A;FTD(6YM)"%N;20
MA;FTD(6YM/^3+0[_DST>_YM#*O^B0C3_J$(]_ZU%1ORQ2D_RM4]6Z;I67>&]
M8&34N&=RR*]M@;VG=(ZTH'J9JYJ HJ25AZF=D8ZNEXZ6LI*+G[6/BJBWC(JS
MN(N)M[>+B+BUBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FT
MBXBYM/^3+0[_DST>_YQ!*O^C0#/_J4$\_Z]$1?JT2$SPNDY3Y[]66=["8&#/
MNV9QP[-L@;BK<HZNI'B8I9Y^H9Z:A*B7EHRND9.4LHR1G+6(CZ:WA8^QN(6.
MMK>&C;BVAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRX
MM?^4+ [_E#T>_YU *?^D/C+_JS\[_[%"0OBX1TGMODY/Y<974]K&7E_+OF1Q
MOK9J@+.O<(VIJ7:8H*-\H9B?@JB1FXFMBIF2LH66FK6!E:2W?Y6NMWZ4M[>!
MD;>V@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM?^4
M+ [_E#T>_YX_*/^F/3'_K3XY_[1!0/2\1D7KQ$U)XLY82]/*7%[&PF-PN;IH
M?ZZT;HRCKG27FJEZGY*E@*>*H8>LA)^/L7^=E[1[G*&V>)NLMW>;M[9ZE[BU
M?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM/^5+ [_
ME3T>_Z ])_^H.S#_L#PW_;@_//'!1$#HRTY"WM-52L[-6UW QF%NM+]G?JBY
M;8J=M'*5E*]XGHNK?J6$J(6J?::,KWBDE;)THY^T<:.JM7"CN+5SGKFT=INY
MLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYL_^6+ [_ESP>
M_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*' :XF7
MNG"3C;9VG(2S?*)]L(.H=ZZ*K'*MDZ]NK)VQ:ZRHLFFMMK)LJ+NQ;Z.[L6^C
MN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L?^7+ [_FCL=_Z0W
M)?^M-BO_MS<P\\,Z,>;00S#<WTHUS]]21\'86%JST5YKILMC>IK':8:/PFZ0
MAK]TF'V\>I]VNH&D<+B)J&NWDJMHMYRM9;>GKF2WM*YEL[VN:*V]KFBMO:YH
MK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN:*V]KO^8+ [_G3D<_Z<T(_^Q
M,RCYO3(JZLLW*=S=/BG0XT8ZQ>)-2[C>55JLV5QHGM-B=Y+/9X*(RVV,?LES
ME';'>9IPQ8&?:L2)HF;#DJ5BPYRG8,.FJ%_#M*A?P<*H8;K!J6&ZP:EANL&I
M8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I8;K!J?^9+ [_H#4:_ZHQ(/^V+B/P
MQ2TBW]@S'-#C.B[$Z$) N.5)4*OA3E^>WE5LDMM<=X?88X%^U6J)=M1QCV_1
M>91KSH"89\R(FV3*D)UBR9B?8,FAH%_)JZ!?R;F?7,C#HES(PZ)<R,.B7,C#
MHES(PZ)<R,.B7,C#HES(PZ)<R,.B7,C#HO^;+ [_I# 8_Z\L&_B^)QODT287
MT>(M(,3K-S.WZSY%JNE%5)[G3&*2Y5)NAN-8>'W@8']VW&F&<-AQBVO5>(]H
MTW^29=&&E&+/C99@SI287LZ;F5W-HYI<S:V:6\VWFEO-MYI;S;>:6\VWFEO-
MMYI;S;>:6\VWFEO-MYI;S;>:6\VWFO^=+ [_J"L4_[<D%>O*'!'3X!X3Q.LK
M)K?Q-#BJ\#Q)G>]$5Y'N2V.&[5)M?>A;=77C8GQPX&N!:]URA6C:>(ADV7Z+
M8M>$C5_5BHY>U)"07-.5D5K3G))9TJ236-*LDUC2K)-8TJR36-*LDUC2K)-8
MTJR36-*LDUC2K)-8TJR36-*LD_^A*PW_KR,/],(7#-;=$ ?%ZQX8M_8I*ZGW
M,SR=]CQ+D?=$6(;V36)]\%9J=NM><6[G9'9JY&MZ9N)R?63@=X!AWWV"7]Z"
MA%W=AX5;W(R&6MN1AUC:EHA7V9V)5MFCBE;9HXI6V:.*5MFCBE;9HXI6V:.*
M5MFCBE;9HXI6V:.*5MFCBO^H(PG]N18'UM$+ \;J$ NV]QX=J?TI+IS^-#Z0
M_SY+AOY'5GWX45YV\UEE;O!?:FCM96YDZFMR8>EQ=%_G=G9=YGMX6^5_>5GD
MA'I8XXA\5^.,?5;BD7Y4X9=_4^&<?U/AG']3X9Q_4^&<?U/AG']3X9Q_4^&<
M?U/AG']3X9Q_4^&<?_^Q%0/4QPD!QM8* [;W$@^H_Q\@F_\K,)#_-CV%_T!(
M??]+477]5%AM^5I=9_9@8F/S9F5?\FMG7/!P:5KO=&M8[GAL5^U\;E7L@&]4
M[(1P4^N(<5+KC'%1ZI%R4.F5<U#IE7-0Z95S4.F5<U#IE7-0Z95S4.F5<U#I
ME7-0Z95S4.F5<]:^!P#%RP@ M]L)!:C_%!*;_R(AD/\N+H7_.3I\_T1#=/].
M2FS_5%!E_UI48/U?6%W[95I:^FI<5_EN7E7X<E]4]W9@4O9Y85'V?6)0]8!C
M3_2$9$[TAV1-\XQE3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,
M\Y!F3/.09L3"!@"VT0< J.T+!IO_%Q.0_R4?A?\Q*GS_/#1S_T8[:O],06/_
M4T9>_UE)6O]>3%;_8TY4_VA04O]L45#_;U)/_W)33O]V5$S_>55+_WQ52OY_
M5DG^@E=(_8981_V*6$?]BEA'_8I81_V*6$?]BEA'_8I81_V*6$?]BEA'_8I8
M1_V*6+;)! "HV00!F_\.!X__&A&%_R<;>_\S)''_/"QH_T,R8?]*-UO_4#M6
M_U8]4_]<0%#_8$%._V1#3/]H1$K_:T5)_VY&2/]Q1D?_=$=&_W9(1?]Y2$3_
M?$E#_X!)0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*0O^#
M2O^"* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-W
MZGB+?>=TDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<
M9<V2U&;1DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"
M* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+
M?>=TDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2
MU&;1DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_
M@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+?>=T
MDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2U&;1
MDL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_@CD6
M_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+?>=TDH+D
M<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2U&;1DL]H
MTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_@SD6_X-'
M)?^,3C'_D%4]_Y%;2/^085/^C6A>^(AO:/*#>'#M?H)XZ7J*?N9VD8/D<Y>'
MXG"=BN!NHHS?:Z>.W6JLD-UHLI'<9[B3VV:_D]MFQY399M"4SVC0D\MIT)3+
M:="4RVG0E,MIT)3+:="4RVG0E,MIT)3+:="4RVG0E/^#* G_@SD7_X9&)/^.
M33#_DU0\_Y181_^27E/_D&5=^(QM9_*&=7#M@7]XZ7V'?N5YCX3B=96(X'*;
MC-YOH8_=;*>1W&NLD]MILY3::+J6V6?#EMEFS9?0:<Z6R&K.E\1KS9?$:\V7
MQ&O-E\1KS9?$:\V7Q&O-E\1KS9?$:\V7Q&O-E_^$* G_A#D7_XA%)/^13##_
ME5$[_Y961_^57%+_DV)<^8]J9O.*<G#MA7MXZ8"$?^5[C(7B=Y.*WW.:CMUP
MH)';;::4VFNMEMEIM)?8:+V8V&?(F=%IS)G):\R9PFS,FKUMRYJ];<N:O6W+
MFKUMRYJ];<N:O6W+FKUMRYJ];<N:O6W+FO^%* G_A3D7_XI$)/^32R__ET\Z
M_YA41O^765#_EF!;^9)G9?..;V_NB7AWZ8.!?^1^BH7A>9&+WG68C]QQGY/:
M;J:6V&RNF-=JMIK6:,&;TVG+F\IKRYO";<J<NV[*G;AORIVX;\J=N&_*G;AO
MRIVX;\J=N&_*G;AORIVX;\J=N&_*G?^%* G_ACD7_XQ$(_^52B__F4TZ_YI1
M1/^:5D__F5U:^I9D9/22:V[NC71VZ8=^?N2!AX7@?(^+W7>7D-MSGI78;Z:8
MUFROFM5JN9S4:<:=RVS)G<-MR9Z\;\B?M7#(G[)QR)^R<<B?LG'(G[)QR)^R
M<<B?LG'(G[)QR)^R<<B?LG'(G_^&)PG_ACD7_XY#(_^722[_FDLY_YQ/0_^=
M5$[_G%I8^YI@8O66:&SOD6]UZHMY?N6%@X7@?XR,W7F5D=ETG9;4<*6:T&ZN
MG<ULMY_+:\.@PV['H+MOQZ&U<<:AKW+&H:QSQJ&L<\:AK'/&H:QSQJ&L<\:A
MK'/&H:QSQJ&L<\:AK'/&H?^')PG_ASD7_Y!"(_^81RW_G$DX_Y],0O^@44S_
MH%=6^YY>8/2;96KMEFQSYY!V?.&*@(3;A(F+TWZ1DLYXF9C)=*&<QG&IG\)P
MLJ+ ;[VCNG#%H[-RQ:2N<\6DJ73%HZ9UQ:.F=<6CIG7%HZ9UQ:.F=<6CIG7%
MHZ9UQ:.F=<6CIG7%H_^')PG_B#@7_Y%!(O^:12S_GD<V_Z%*0/^C4$K^HU54
M]J)<7>^@8F?HG&EPX99T>=J0?8+1B8:+RH*-D\5]E9G >9V>O':EH;ASK:2U
M<KBELG+#IJQTPZ:G=L.FHW?$I:%XQ*6A>,2EH7C$I:%XQ*6A>,2EH7C$I:%X
MQ*6A>,2EH7C$I?^()PG_B#@7_Y-!(O^;1"S_H$4U_Z-)/_^E3DC[IU11\Z9:
M6^NE8&3CHFAMW)US=M&5>H+)C8*+PH>*D[R"D9JW?9F?LGJAHZ]WJ::K=K.G
MJ7; J*1WPJBA><*GG7K#IYMZPZ:;>L.FFWK#IIMZPZ:;>L.FFWK#IIMZPZ:;
M>L.FFWK#IO^()PG_B3@7_Y5 (?^=0BO_HD0T_Z5(/?^H3$;XJE)/[ZM85^>K
M7V#@J&EIU*%P=<N9>('"DG^+NXN&E+6&CIJO@I6@JGZ=I*9[IJ>C>K"IH'F\
MJIUZP:F:?,&IF'W"J)9]PJ>6?<*GEGW"IY9]PJ>6?<*GEGW"IY9]PJ>6?<*G
MEGW"I_^))PG_B3@7_Y8_(?^>02K_HT(S_Z=&._ZK2T3UKE%,[+!75.2Q7ES;
MK6AFSZ5N=<6==8&\EGR+M9"#E*Z*BYNHAI*@HX*:I9Z HJB;?JRJF'ZXJY9^
MP*N4?\"JDX#!J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"
MJ/^))PG_BC@7_Y@_(/^?/RG_I4$R_ZI%.ORN24'RL4])Z;564.&W7U?5L65E
MRJAL=,"A<X"WFGJ+KY2!E*B/B)NBBH^@G(>7I9>$H*B4@JFJD8*UJX^"OZN.
M@\"JC8/!J8V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J/^*
M)PG_BS@7_YD^(/^A/BC_ID P_ZQ#./FQ2#_PM4Y%Y[I52]Z[7E30M&1EQ:QK
M<[ND<8"QGGB*J9A^DZ*3A9J;CXV@EHR5I9&)G:B-AZ>KBH>RK(B'OZR(A\"K
MB(; J8B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J/^*)PG_
MC#<7_YL]'_^B/2?_J#\O_ZY"-O>T1SSMNDU!Y,!61MF_7%/+MV-DP*]I<[:H
M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
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M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
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M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
M3K5NB%*R:X]6KVF76JQGGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:9O5A
MF&?V8)9H]F"6:/9@EFCV8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"(0+_
MBRD$^9$Q!^^5. OFEC\0W91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\3JYR
MA%.J;XM7IFV36Z-KFUZ@:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1CD6OU
M8I!K]6&0:_5AD&OU89!K]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_CB<#
M]94N!>N9-0CAG#L,UIA#%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W@%.C
M=(A8GW&06YMOF%^8;J%BE6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T8XIN
M]&**;O1BBF[T8HIN]&**;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"\IDK
M!.>>,07=H#8)T9Q!%<>732&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<>(58
MF':-7)1TE5^1<IYBCG&H98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R]&.$
M<O1CA'+T8X1R]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG N.B
M+ /8I#((S)] %,.:2R"ZE54LLY!=-ZR+93^EAVQ'H(-S39N >U.6?8)7DGJ*
M7(YXDF"*=IMCAW6E9H1TL6>"=,!H@'35:(!U[&=_=O)F?W7S97]U\V1_=?-D
M?W7S9']U\V1_=?-D?W7S9/]E&0+_=!0!_X$7 ?^-&@'YEQX!ZZ C =^F)@+2
MIS 'R*,^$[^>21^VF5,KKI1;-J>/8S^@BVI&FX=Q396$>%*0@7]7C'^'7(A]
MD&"$>YEC@'JC9GYYKVA[>;UI>GG1:7EZZFAZ>O)F>GGR97IY\V1Z>?-D>GGS
M9'IY\V1Z>?-D>GGS9/]G%P+_=A0!_X06 ?^0%P'UFQH!YZ0= =NK'P'.JB\&
MQ*8]$KJA2!ZRG5$JJIA9-**483Z<D&A%EHQO3)")=E*+AGU7AH2%6X*"C5]^
M@)=C>G^A9G=^K&AU?;MI<W[.:7-^Z&AT?O%F='WR975\\V1U?/-D=7SS9'5\
M\V1U?/-D=7SS9/]I%@'_>!,!_X<4 /^3%0#QGA4 XZ@6 -6N&P'*K2T&P*D[
M$;:E1AVMH5 II9Q8,YZ87SR7E&9$D)%M2XN.=%&&C'M6@8F#6WR'BU]XAI1B
M=(2?97&#JF=O@[AI;8/+:6V#YFAN@_)F;X+R97"!\V1P@?-D<('S9'"!\V1P
M@?-D<('S9/]K% '_>Q(!_XH2 /^6$@#MHA  WJT. -"Q&0#%L"L%NZTY#[*I
M1!NII4XGH*%6,IF=7CN2FF1#BY=K2H:4<E" DGE5>X^ 6G>-B5YRC))A;HJ<
M9&N)J&=IB;9H9XG(:&>)XV=HB?)F:8?S96J&\V1JAO-D:H;S9&J&\V1JAO-D
M:H;S9/]N$@'_?A  _XT0 />:#@#;IPH T[ + ,JT%@# M"D$MK$W#JVN0QJD
MJDPEFZ95,).C7#F,H&-!AIUI2(":<$Y[F'=3=I9^6'&4AEQLDI!@:)&:8V60
MIF5CD+1F89#&9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C9(ST
M8_]Q$ '_@@\ _Y$- -Z?"0#3J@D S+,) ,2X$P"ZN"8#L;8U#*>S01B>KTHC
MEJQ3+HZI6C>'IF$_@*1G1GJA;DQUGW51<)U\56N<A%IFFHY=8YF88%^8I&)=
MF+)D6YC#9%N8WF-;F/!C7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U8O]U
M#@#_A@T ZY8( -6C!P#,K0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@D+-1
M*XBP6#2 KE\\>JMF0W2I;$AOJ'-.:J9Z4F6E@E9AHXQ:7:*67%JBHE]7H;!@
M5J'!8%6BW&!5H>]@5I_W7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z# #]
MBPD VIL$ ,ZG!@#$L 8 O+D$ +7!#@"LPB !I,$P")J_/!.1O48=B;I/)X&X
M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
M(_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_AP(.
M_Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D  %[3
M  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX &/\C
M !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$ _X$!
M /^/ 0#_FP$ _Z<! /^I 0#_J0$ _ZD! /^I ?\L+P'_,"P!_S(L O\S, +_
M,38#_S!! _\O303_+5H&_RMF!_\I<PC_*'X*_R>("_\GD0S_)YD-_R:?#?\F
MI0[_)JL._R:Q#_\FN __)L /_R;)#_\FUP__)N8/_R;P#_XF^0_[)_\/^2?_
M#_DF_Q'X)O\1^";_$O@F_Q+X)O\2^";_$O\N+ '_,RD!_S4J O\V+0+_-C0"
M_S4_ _\S2P3_,E<&_S!D!_\N< G_+'L*_RR%#/\KC@W_*Y8._RJ=#_\JHP__
M*JD0_RJO$/\IMA#_*;T1_RG'$?\ITQ'^*>,1^RKO$?@J^!#V*_\0]"K_$O0J
M_Q/S*O\4\RG_%/,I_Q3S*?\4\RG_%/\Q*0'_-B8!_SDF ?\Z*0+_.S("_SL]
M _\Y2 7_-U0&_S5@!_\S; G_,G<,_S""#?\PBP[_+Y,/_R^:$/\NH!'_+J81
M_RZL$O\NLQ+^+KH2_2[$$OLNSQ/X+N$2]2[M$O$O]Q+O+_\3[B[_%>TN_Q;L
M+O\7["[_%^PN_Q?L+O\7["[_%_\T)@'_.2,!_STC ?\^)@+_02\"_T$Y _\_
M103_/5 &_SM<"/\Y: K_-W,-_S9^#O\UAQ#]-(\1_#26$OHSG1/Y,Z,3^#.I
M%/<SL!3V,[<4]#/ %/,SS!3P,]X4[3/K%.DT]A7G,_\7YC/_&.0R_QGD,_\:
MXS+_&N,R_QKC,O\:XS+_&O\X(P'_/2 !_T$? ?]%(P'_1RP"_T<V _]&0 3_
M1$P&_T%8"/\_9 O[/F\.^3QY$/8[@Q'T.HL3\SF3%/$YF13P.* 5[CBF%NTX
MK1;L.+06ZCB]%NDXR1;G.-L6XSGJ%N X]1C=./\:VS?_'-DW_QW7-_\=UC?_
M'M8W_Q[6-_\>UC?_'O\[( '_01P!_T4: ?]+( '_32@!_TXR O]-/ 3_2D<&
M^DA3"/9&7POR1&H.[T)T$>Q!?A/J0(<4Z#^.%>8^EA;E/IP7XSVC&.(]JAC@
M/;(8WSV[&=T]QAG;/=@:UCWI&M(]]1W./?X?S#S_(,L\_R')//\AR3S_(<D\
M_R')//\AR3S_(?\_' '_11<!_TL7 ?]0'0'_4R0!_U0M O]3-P/W44(%\4Y-
M".Q,6@OH2F4/Y4AO$>)'>13?18(6W42*%]I#D1G80ID:U4*?&]-!IAS10:X=
MST&W'LY!P1[,0= ?R4+E'\5"\R'"0?XCP$'_)+Y!_R2]0?\EO4'_);U!_R6]
M0?\EO4'_)?]"& '_21, _U 4 /]6&0#_62 !_UHH ?=:,@+O6#T$Z%5)!^-3
M50K>46 .V4YJ$M1,=!;02WP8SDF$&\Q(C!S*1Y,>R$>:'\9&H2'$1JDBPD6Q
M(\%%O"._1<DDO4;?);E&[R:V1OLGM$;_*+-&_RBR1O\HL4;_*+%&_RBQ1O\H
ML4;_*/]&%0#_31$ _U42 /];%@#_7AL ^6 C >]@+ 'F7C8#WUQ$!=A94 K1
M5UL/S%1E%,A2;AC%4'<;PT]_'<!.AA^^38XAO$R5([I+G"2X2J0FMDJL)[1*
MMBBS2<,IL4G6*:Y*ZBJK2O@KJ4K_*ZA+_RNG2_\KITO_*Z=+_RNG2_\KITO_
M*_])$@#_4 X _UD0 /]?$@#_8Q8 \F4= .=E)0#>9#$!U&(_!<U@2PK'758/
MPEI@%;Y8:1F[5G$<N%1Y'[93@2*S4H@DL5"0)J]0ERBM3Y\IJTZH*ZE.LBRG
M3KXMID[.+J-.YBZA3_4NGT__+IY/_RZ=3_\NG5#_+IU0_RZ=4/\NG5#_+O],
M$ #_5 T _UT. /]C#P#Y9Q$ ZVD5 -]J' #3:BP!RV@[!,5E1PF_8E(/NF!<
M%;9=91FR6VT=KUEU(:Q8?".J5H,FIU6+**54DRJC4YLLH5.C+I]2K2^=4KDP
MFU+),9E2XC&74_(QEE/_,954_S&45/\PE%3_,)14_S"45/\PE%3_,/]/#@#_
M6 L _V + /MF# #P:PT Y&T. -9N%@#,;R@!Q&TW!+UK1 FW:$\/LF58%:YB
M81JJ8&D>IUYP(:1=>"6A6W\GGUJ'*IQ9CBR:6)<NF%>@,)56JC*35K4SD5;%
M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
M_RH  /\R  #_/   _T<  /]4  #_8P  _W,  /^%  #_EP  _Z0  /^R  #_
ML@  _[(  /^R /\B*0'_(R<!_R,H ?\@*P'_'#$!_QH] ?\820'_%E8"_Q1B
M O\3;@+_$G@"_Q*" O\2BP+_$I("_Q*9 O\2G@+_$J0"_Q*I O\2KP+_$K8"
M_Q*] O\2QP+_$M0"_1+E OH2\0+W$OH"]1/_ O03_P/T$_\#]!/_ _03_P/T
M$_\#]!/_ _\D)P'_)B0!_R8D ?\D)P'_(B\!_R Z ?\>1@'_'%,"_QI? O\8
M:@+_%W4"_Q=_ O\7B +_%X\"_Q>6 O\7G +_%Z$"_Q>G O\7K0+_%[,#_A>[
M _T7Q0/Z%]$#]Q?D O07[P+Q&/H"[QC_ ^X8_P3N&/\$[1C_!>T8_P7M&/\%
M[1C_!?\G(P'_*2  _RD@ /\H(P#_*2T!_R<W ?\E0P'_(T\"_R%; O\?9@+_
M'7$"_QU[ _\=A /_'8P#_AV3 _P<F0/[')\#^ARD _D<J@/W'+$#]ARY _4=
MP@/S'<X#\!WA ^P=[@/I'OD$Z![_!>8>_P;E'O\&Y1[_!^4>_P?E'O\'Y1[_
M!_\K'P#_+1P _RT; /\N( #_+RD _R\T ?\L/P'_*DL"_RA7 O\F8@+])6T#
M^B1W _@C@ /V(X@#]2./ _,CE03R(YL$\2.A!.\CJ 3N(ZX$[2.V!.LCOP3J
M(\P$YR/@!.,D[03@)/D&WB3_!]PD_PC;)/\)VB3_"=HD_PG:)/\)VB3_"?\N
M&P#_,1< _S(6 /\U' #_-B4 _S8O ?\T.@'_,48!^R]2 O<M70+S+&@#\"MR
M ^XJ>P3L*H0$ZBJ+!.@JD@7G*9@%YBF>!>0II07C*:P%X2FT!> JO07>*LH%
MVRK>!=8J[0?2*O@)SRO_"LTJ_PO,*O\,RRK_#,LJ_PS+*O\,RRK_#/\R%P#_
M-1( _S@2 /\[& #_/2  _SPJ /X[-0'W.4$!\39- NPT6 +H,V,#Y3)M!.,R
M=@3@,7\%WC&'!=PPC@;:,)4&V#";!]8OH@?4+ZD(TB^Q"- ON@G/,,8)S3#8
M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
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M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
M_Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5)P#_$2X _Q Z /\.
M1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5 ?\*FP'_": !_PFE
M /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8 \PG_ /(*_P#Q"O\!
M\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_%RP _Q4W /\31 #_
M$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.
MJ '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_
M >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!
M_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T
M$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5
M_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_)B4 _R0P /\A.P#_'T@ _QU4
M ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9D0'N&9<![!F= >L9HP'I&:H!
MZ!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32
M'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$ _RPK /\I-P#])T, ]R5/ ?,C
M6@'O(F0!["%N >DA=P'G(7\!Y2&& >0AC0'B()0!X2": =\@H '>(*<!W"&O
M =HAN +8(<,"U2'3 M$BYP+-(O0#RB/_!,@C_P7'(_\&QB/_!L8C_P;&(_\&
MQB/_!O\L$@#_+@\ _S 0 /\S% #_,QL _S(E /HP, #R+CP ["Q) .<J50'C
M*E\!X"EI =TI<@':*'H!URB" M4HB0+3*) "T2B6 \\HG /.**,#S"BK \HH
MLP/)*+X$QRC,!,4IX@3!*O$&OBK^![PJ_PBZ*O\(NBK_"+DJ_PFY*O\)N2K_
M"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4 X#)" -LR3P#5,5H!
MT#%D LTP;0++,'4#R3!\ \<O@P3%+XH$Q"^1!<(OEP7!+YX&OR^F!KTOKP:\
M+[D'NB_'![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S
M# #_-@8 _SP) /\^# #]/1  [SP5 .0Y'P#;.2T TCH\ ,TZ20'(.50!Q#E>
M L$X9P._-V\$O3=V!;LV?0:Y-H0'MS:+![8UD@BT-9H)LS6A";$UJ@JO-;0+
MKC7!"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_
M.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_
M802T/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\
M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
M *A> @"A7Q  FV > )9@+ "18#@!C5Y" XE=2P6%7%('@EM9"H!:8 Q]66<.
M>UAN$'A8=1)V5WT4=%>'%G)6D1AO5IP:;E:I&VQ6N!QK5LL=:E;F'&I7]QMJ
M5_\::E?_&6M7_QEK5_\9:U?_&>M,  #85@  R%X  +QB  "S90  JV4  *-B
M  "<8@X EF,< )%D*0",8S4!B&(_ X1A2 6 8% '?5]7"7I>70MW760-=5QK
M$'-<<A)P6WL4;EN$%VQ:CQAJ6IH::%JG'&9:MAUE6L@=95KD'65:]AQE6O\;
M95K_&F5:_QEE6O\995K_&>A/  #360  Q&$  +EF  "P:   IVD  )YE  "7
M9@T D6<9 (QH)P"'9S(!@V8] G]E1@1[9$T&>&-4"75B6PMR86$-<&%I#VU@
M<!)K7WD4:5^"%F=>C1EE7I@:8UZE'&%>M!U@7L<=8%[C'6!>]1Q@7O\;8%[_
M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
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M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
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M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
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M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
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M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
M0'L&?C^$!WP_C@AZ/YD)>#^E"G= L@IU0,,+=$#="W-!\0MR0?\*<D'_"G)!
M_PER0?\)<D'_">D\  #510  Q4L  +I.  "P3@  ITL  *)&  ";1@X ED<:
M )%()P".2#, BD@] (='1@&$1TX!@D95 H!&7 -^16($?$5I!'I%< 5X1'@&
M=D2!"'1$BPER1)8*<$2B"V]$KPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK
M1O\*:T;_"N5   #/20  P4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,
M) "'3"\ A$PZ (%,0P%^2TL!>TM2 GE*6 -W2E\$=4EF!7-);09Q274';TE^
M"&U(B EK2),+:DB?#&A(K0UG2;T-9DG4#F5)[0UE2OP,94K_"V5*_PME2O\+
M94K_"^!$  #+30  O5(  +)6  "F50  G%(  )5.  ".3@D B4\4 (50( "!
M4"P ?E W 'M00 %X4$@!=4]/ G-.50-Q3EP$;TYC!6U-:@9K37(':4U["&=-
MA0IE39$+9$R=#&)-JPUA3;L.8$W1#F!-[ Y@3?L-8$W_#&!-_PM@3?\+8$W_
M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
M/X!, 3V 5 $\@%P".G]E CA_;P,V?WP$-'^*!#)_F@4Q?JH&,'Z]!C!^V@8P
M?? &,'O]!C![_P8P>O\&,'K_!K!L  "D=0  E'4  (9U  !Y=@  ;G<  &-Y
M  !7?0  3X$  $>$  !"A@P /X<3 #V('0 \B"< .XDP #J).  XB4  -XE(
M #:)3P TB5@!,XEA 3&); $OB7@"+8F' BR)EP,JB*<#*8BZ RF(U ,IANX#
M*87\!"F$_P0IA/\$*83_!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2
MA0  28D  $&,   YD 4 -9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R3
M2@ KE%( *I1< "B49P GE',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z
M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
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M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
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M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
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M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
M                 0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ
M*RTN+S R,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C
M969G:6IK;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=
MGI^AHJ.DIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76
MU]G:V]W>W^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________
M____________________________________                      $#
M! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\
M/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U
M=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VO
ML+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?H
MZ>OL[>[P\?+T]?;W^?K[_/[_____________________________________
M_________________P ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?
M("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,
M34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY
M>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6F
MIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3
MU-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M
M9G0Q      ,$(0   0                    $                    !
M     0(#! 4&!P@("0H+# T.#Q 1$A,4%187&!D:&AL<'1X?("$B(R0E)B<H
M*2HK+"TN+S Q,3(S-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!14E-4
M55976%E:6UQ=7E]@86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^?X"!
M@H.$A8:'B(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VN
ML+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=/4U=;7V-G:V]S=
MWM_@X>+CY.7FY^CIZNOL[>[O\?+S]/7V]_CY^OO\_?[_  $! @(# P0$!08&
M!P<(" D)"@L+# P-#0X/#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A
M(B(C)"0E)B8G*"DI*BLL+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*
M3$U/4%)355=86EQ>8&)D9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>H
MJJRMK["RL[6VM[FZN[R]O\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9
MV=K;V]S=W=[?W^#AX>+CX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T
M]?;V]_?X^/GY^OO[_/S]_?[^_P ! 0(" P,$! 4&!@<'" @)"0H+"PP,#0T.
M#P\0$!$1$A,3%!05%A87%Q@9&1H:&QP<'1X>'R @(2(B(R0D)28F)R@I*2HK
M+"TM+B\P,3(R,S0U-C<X.3H[/#T^/T!"0T1%1DA)2DQ-3U!24U576%I<7F!B
M9&9H:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\
MO;_ P<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'B
MX^/DY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\
M_?W^_O_:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1
ML**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'
MU:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:
MRPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?
MB-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;
MZ,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FK
MG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T.
M.NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<
MJIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,
M$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+
MWJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<
MR Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:
MC>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2
MR[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&G
MF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HR
MK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_C
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W
M4+3 LVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
MLVB\NZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\
MNZY[Q+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[
MQ+6HB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6H
MB,NSI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2
MYJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NS
MI8?1L**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67
MDN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2
MYJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1
ML**'U:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:E
MEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67
MDN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3 LVB\NZY[Q+6HB,NSI8?1L**'
MU:V?B-FKG8G<JIR+WJB:C>&GF8_CI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+F
MI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN:EEY+FI9>2YJ67DN;9
MRPD;Y\X-.>C-$&#<R0V2R[LPJ\:X3[3 LV>]NZY[Q+6IB,NRIH?1KZ.'U:V@
MB-FKGHG<J9R*WJ>;C."EF8_CH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0
MY*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.2AF)#DH9B0Y*&8D.39RPD:
MY,X-.>?.#F#:R@R2R[PNJ\6Y3;3 M&:]NJYZQ;6IA\NQIH?1KJ.'U:R@B-FJ
MGHG<IYR*WJ6;B^"BFHWBGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9
MC^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^.>F8_CGIF/XYZ9C^/8RPD:X<\,
M.>7/#F#9R@R1R[XLJ\6Y3+6^M&>]N:Y[Q;2JA\RPIH?1K:.'U:N@B-FHGHC;
MI9V)W:.<BM^?FHOAFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;
MF8[BFYF.XIN9CN*;F8[BFYF.XIN9CN*;F8[BFYF.XIN9CN+8RPD:W- +.>/0
M#6#8RPN1R[\KJ\2Z3+6]LV>^N*Y[Q;2IA\RPIH?1K*.'U:F@A]BFGXC;HYV(
MW:"<B=Z=FXK@F)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWA
MF)J-X9B:C>&8FHWAF)J-X9B:C>&8FHWAF)J-X9B:C>'7S D:VM$+.-[1#%_6
MRPN1R\ IK,*Y3;:\LVB^MZY[QK.IA\ROIH?1JJ.&U:>AA]BDGX?:H9Z'W)Z=
MB-V:G(G>E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C."5FXS@E9N,
MX)6;C."5FXS@E9N,X)6;C."5FXS@E9N,X)6;C.#6S D9V=$+.-K3#%_4S N1
MR< IK<"Y3K:ZLVF_M:Y\QK*IA\RMIH;1J:.&U*6AAM>BH(;9GY^&VIN>A]R7
MG8C=DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<
MB]Z3G(O>DYR+WI.<B]Z3G(O>DYR+WI.<B][5S D9V-(+-]C3"U[2S N3Q[\K
MK;ZX4+>YLFJ_M*U\QK"IA\RKIH;0IZ2%U*.BA=:?H878G*"%V9B?AMJ4GH?<
MD)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0G8K=D)V*W9"=BMV0
MG8K=D)V*W9"=BMV0G8K=D)V*W9"=BMW4S0D9UM(+-];4"U[0RPJ5Q+XMKKRX
M4;BWLFK LZU\QJZIA\RIIH;0I:2%TZ"CA-6=HH36F:&%V)6@A=F1GX?:CIZ)
MVXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;CIZ)VXZ>B=N.GHG;
MCIZ)VXZ>B=N.GHG;CIZ)VXZ>B=O3S0H8U=,+-M34"U_.RPF7P;XPK[JW4[BU
MLFS L*U]QZRJALNGIX7/HJ6$T9ZDA-.:HX35EJ*$UI.AA=>/H(;8BZ")V8N@
MB=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")V8N@B=F+H(G9BZ")
MV8N@B=F+H(G9BZ")V8N@B=G2S@H7T]0+-='3"F++S F9OKTSL;>W5;FRL6W!
MK:U]QJJJALNDJ(3.GZ>$T)NE@]*7I(/3DZ.$U)"CA=6,HH;6B:&(UXFAB->)
MH8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFAB->)H8C7B:&(UXFA
MB->)H8C7B:&(UXFAB-?0SPH6T=0+-\[3"F7&R@N=N;PXLK2V6+JML6[!JJY]
MQJ>KA<FAJ83,G*B#SI>G@\^3IH/1D*6$THVEA=.*I(;3AZ.(U(>CB-2'HXC4
MAZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'HXC4AZ.(U(>CB-2'
MHXC4AZ.(U(>CB-3.T H5SM0*.LK3"FC R ^AM;L^M*VU6[NIL6_!IJ]]Q*.M
MA,>=JX/*F*J#RY.I@\V0J(3.C:>$SXJGA<^'IH?0A::(T86FB-&%IHC1A::(
MT86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1A::(T86FB-&%IHC1
MA::(T86FB-',T D8RM0*/L73"FVXQ1:EKKE$M:>U7KNCLG# H;!]PY^NA,69
MK8/'E*R$R9"KA,J-JH7+BJJ%RXBIALR%J8?-@ZB)S8.HB<V#J(G-@ZB)S8.H
MB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)S8.HB<V#J(G-@ZB)
MS8.HB<W(T0D;Q=4*0K_3"G*QQ!ZGI;E)MJ&V8+N>LW"^G;%]P9NPA,.5KX3$
MD:Z$QHVMA<>*K8;'B*R&R(:LA\B$JXG)@JN*R8*KBLF"JXK)@JN*R8*KBLF"
MJXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*KBLF"JXK)@JN*R8*K
MBLG$T@@@P-8)2+C4"GBISQ>8GKY'KIJV8KJ8M7&\E[-\OI>RA,"2L87"C;"%
MPXJOAL2(KX?$AJ^(Q82NB<6#KHK%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%
M@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6!KHO%@:Z+Q8&NB\6_
MU <ENM<)3J[:"W"@VQ.'E\TYFI+#6*B1O&RRD;=ZN9*T@[V.LX:_B[*'P(BQ
MA\"&L8C!A+&)P8.QBL&"L8O"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",
MPH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,+WP! 5
M^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VS
MDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6
M,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0
ML8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F]
M(%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+
MTK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/J
MMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",
MC=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\
MS*A$JL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2O
MBI#6KHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$
MJL:E7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6
MKHB3V*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E
M7;3"HW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3
MV*V&F-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"
MHW"ZOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&
MF-FLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"Z
MOJ)_O[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_
MO[R@B,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@
MB,.YFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=KWP! 5^, 6,?F](%/JMRA\S*A$JL:E7;3"HW"ZOJ)_O[R@B,.Y
MFXC&MYB(RK65B<VSDHK0L8^+TK",C=2OBI#6KHB3V*V&F-FLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=KWP \5^, 6,/F](%/JN"=\S*A$J\:E7;3"I'"ZOJ)_O[R@B,.YFXC'
MMYB(RK65B<ZSDHK0L8^+T["-C=6OBH_7K8B3V:V&F-JKAIW:JX:=VJN&G=JK
MAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&
MG=KWP0\5]\$6,/B^'U/JN"9\RZE#J\:F7+3"I&^ZOJ)^O[N@B,.YG8?(MIJ'
MS+.7B,^QE(G2L)**U:Z/C->MC8[9K(J2W*N)F=VGB)S;IXB<VZ>(G-NGB)S;
MIXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-OV
MP0X4]\$5,/B_'E/JN25\RZE"J\:G6[/"I6ZZOJ-^O[NAB,2XGH?)M9R'S;*9
MA]&PEHC4KI2)UZV2B]JKD(W<J8V2WZB-FM^CBYS<HXN<W*.+G-RCBYS<HXN<
MW*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-SVP0X4
M]L(5,/>_'E/JNB1\RZE!K,:G6K/"I6VZOJ-]O[NCB,2WH(?)M)V'SK&;A].O
MF8C6K9>)VJN5BMRIDXW?IY*1XJ21F>"@CIS<H(Z<W*".G-R@CIS<H(Z<W*".
MG-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-SUP@X4]<(4
M,/; '5/JNB-\RZI!K,:H6;/"IFVZOJ1]O[JDA\6WH8?*LY^'S["=A]2NFXC8
MJYF)W*F8B]^GF([BI9>2YJ"6F>"<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<
MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
MI8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"E
MC]+LP0L,]<(2)/;!&D3WO2%JVK0IELV\**F[NT.SKK5AO*BQ<\&EKG_%H:V$
MQYNL@\F6JX/*D:J$RXZIA,R+J87-B*B&SH:HA\Z#J(G.@:>,SX"GC<^ IXW/
M@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<_?
MQ D+\L40(_/$%D/TP1QIWL(5C\' (ZRON4RVIK1EO:*R=<"@L(##G:Z$Q9>M
MA,:3K83'CZR$R(RKA<F)JX;*AZN&RH6JB,J#JHG+@:J+RX"JC,N JHS+@*J,
MRX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,O:Q0@*
MZ\D-(N[($D+OQA5HT-(*A[&^+ZZEN%2XG[5HO)VS=K^;L7_!F;"$PI2OA,.0
MKX7$C:Z%Q8JNAL:(K8;&AZV'QH6MB,>#K8G'@:V+QX"LB\> K(O'@*R+QX"L
MB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\?5Q@@)V<P*
M(.7/#4#8U0M?O=8+B*7$-*:<MUJXF;5KNY>T=[V6LW^^E;*%P)&QA<&.L87!
MB["&PHFPA\*(L(?#AK"(PX6OB<.#KXK$@J^+Q(&OB\2!KXO$@:^+Q(&OB\2!
MKXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\32R @'T\\*'=74
M"SW"V0MCJ]X0@YO.,YF4Q%.FD;YGKY"Z=+20MWVYD;6$O(ZSAKZ,LH:_BK*'
MP(BRB,"&L8C!A;&)P82QBL&"L8O!@;&,PH"QC,* L8S"@+&,PH"QC,* L8S"
M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,+.R@@&SM$*',;7"D&O
MZ@YAG>8<>)#:,HB+TDR4B<M?G(C&;J.(PWBHA<!\JX._?ZZ O8&P?[R#L7V\
MA+)\NX:S>[N'M'JZB+1YNHFU>+F+M7BYC+9XN8RV>+F,MGBYC+9XN8RV>+F,
MMGBYC+9XN8RV>+F,MGBYC+9XN8RV>+F,MGBYC+;)RP@&R-()(K/?"4*@_!5:
MD_ H:HOF.7>$WTF"@=A;BX#3:9%\T'&6><UVFG;+>IUTRGV><LE_H''(@:%P
MQX.B;\>%HV[&AJ-MQHBD;,6*I6S%BZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%
MBZ5LQ8NE;,6+I6S%BZ5LQ8NE;,6+I6S%BZ7$S@<*M]D')J/[#CV6_QY.C?HO
M6X;R/V> ZTYQ>^5;>7;@98!QW6R$;MIRB&O9=XMIUWJ-9]9^CF;5@(]EU(*0
M9-2$D6/3AI%BTXF28=*+DV'2C)-ATHR38=*,DV'2C)-ATHR38=*,DV'2C)-A
MTHR38=*,DV'2C)-ATHR38=*,DV'2C)/_L1@)_[$C'O^N,3K_J3Y9[:)+>=F:
M7)?(E7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9
MQ[B F\BX?I[)MWVBRK=\I\JT>ZG*M'NIRK1[J<JT>ZG*M'NIRK1[J<JT>ZG*
MM'NIRK1[J<JT>ZG*M'NIRK1[J<K_L1@)_[$C'O^N,3K_J3Y9[:)+>=F:7)?(
ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
MUH\: ,R.+@3#BST-NX=*&+2#52*M?EXKIWMG,Z)W;SJ=='A F7* 195OB4F1
M;9--C6R>4(IJJE.':KE4A6K/5(1K[E.#;/]1@FS_3X%K_TV :_],@&O_2H!K
M_TJ :_]*@&O_2H!K_TK_5!(!_V$, /]N"@#]> D Z((( -R)"0#8CPL T),7
M ,:3*P.^D#L,MHQ(%ZZ(4B&GA%PKH8!D,YQ\;3J7>75 DG=]18YUADJ*<I!.
MAG&;48)OIU1_;[95?6_+5GQOZU1\</]2>W#_4'MO_TY[;_]->V[_2WMN_TM[
M;O]+>V[_2WMN_TO_5Q$ _V,* /]P!P#P? 4 W(4% -2," #0DPD RI84 ,&7
M*0.YE#D+L9!&%JF-4""BB5HJG(5B,I:":CF1?W(_C'QZ18=Z@TJ#>(U.?W:8
M47MUI%1X=+-6=G3(5G5TZ%5U=?U3=73_475S_T]V<O]-=G'_3'9Q_TQV<?],
M=G'_3'9Q_TS_61  _V8' /]S! #A?P$ UH@$ ,^0!@#*E@@ Q)H2 +R;)@*T
MF#<)K)5$%*213A^=CE<HEHI@,9"':#B+A' _AH)X1(%_@4E]?8M->'N6471Z
MHE1Q>;%6;WG%5FYZYE5N>OQ3;WG_47!W_T]Q=O]-<77_3'%U_TQQ=?],<77_
M3'%U_TS_6PX _VD$ /9W  #=@@  T(L# ,F3!0#$F08 OIX0 +:?) *NG30(
MIII!$Y^63!V8DU4GD9!>+XN-93>%BFT]@(AU0WN%?DAV@XA,<H*34&Z H%-K
M?ZY5:'_"5F=_XU5H@/I3:7[_46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY
M_TS_7@P _VP! .9Z  #6A@  RX\" ,27! "^G00 N*(. +&C(0&IHC('H9\_
M$9F<2AN2F5,EBY9<+8638S5_D6L[>HYS076,?$9PBH5+:XB13V>'G5)DAJQ4
M8H:_56&&X51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_
M80H _V\  .!^  #0B0  QI,! +^; P"XH0( L:8+ *JH'@&CIR\%FZ4]#Y2B
M2!F,GU$BA9Q9*W^:83)YF&DY=)5Q/V^3>41JDH-(99".3&&/FT]>CJI26XZ]
M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
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M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
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M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
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M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
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M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
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M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
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M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
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M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
M7:@4 %NI) !9J3$!5JD\ E.I1010J$X&3:A7"4JH7PQ'IV@.1*=S$4&F?Q0^
MIHT6/*:=%SJFKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?
M_QS$>   M84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(.
M $ZR&P!-LR@ 2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.
M-;*:#S.SK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[
M@0  KHX  *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]
M$0 _O1X /KXK #R^-@ [OT$ .;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7
M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
M /E&  #E2P  W$X  ---! #12@D RDH4 ,)-)P"\3C<!MTY% K)-4 6O3%H(
MJTMC"JA*; VF270/I$E\$:%(A!.?1XP5G4>5%YM&GQB91JH9ET:X&I9&RAN3
M1N8;D4?Y&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+
M  #=40  T50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F4U8(HE%?
M#)]09P^=3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+Q1Z)2^(>
MATSW'H9,_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #5
M5@  RED  ,):  "]6 , N%<. +%9'@"L6B\!IUH] J)9206>6%,)FU=;#)=6
M9!"556L2DE1S%8]3>Q>-4H0:BU&-'(A1EQZ&4*,?A%"P(()0P2& 4-TA?E'T
M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
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M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
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M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
M<8@@ &Z(+@%JB#D"9X=#!6.'3 A@AE,+785;#EJ$8Q%7A&L45(-U%U&"@!I.
M@8T<2X&;'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\
M_QS680  PFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\:
M &:/*0!BD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH8
M18J9&D.*JAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-
M9P  O'0  *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7
M(P!:F"\ 5Y@Z 5281 -2ETP%3Y=4!TR77 E)EF4,1Y9O#D25>A%!E8@3/Y27
M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
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M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
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M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
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M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
M?&XE 'AN,@%U;CT"<6Y&!&YM3P=K;%8):&Q>#&5K90]C:FT18&EV%%UI@19;
M:(T86&>;&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E
M_Q7B40  RET  +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A
M ')S+P%O<SH";'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL7
M4VV9&5%MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=
M50  Q6$  +=J  "L<0  HG4  )1T  ")=   ?',  '9U  !Q=Q  ;W@= &QY
M*P!I>3<!9GE  V-Y205@>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@63727
M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
M6(<X 56'0@)3ATH#4(=2!4Z&6@=+AF()285L"T:%=PU#A(,/0822$3^$HA(]
MA+43/(3/$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[
M  "?@@  DH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S
M $V0/0%+D$4"29!. T:05@1$CU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.
M-H[,#C:-[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9
MAP  C(@  '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9
M-@!!FD  0)I( 3Z:40(\FEH".IID S>:;P4UF7T&,YF,!S&9G0@OF; (+IG*
M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
M@U@G (!9- !]63\!>EE( W=84 1T6%@&<E=?!V]79@EM5FX+:U9W#6A5@0]F
M58T19%2:$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3
M_PWG1   SU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD
M 'I=,0!W73P!=%U& G%=3@1O7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L1
M7EF8$EQ8IQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC
M2   RU,  +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B
M+@!R8CD!;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6
M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
M9&P] 6)L1@)?:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QGH1)+
M9[(226?)$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G
M  "F;0  EVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z
M 5QQ0P)9<4L#5W%3!%5P6@92<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 1
M1&['$4-MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A
M<0  DG   (5O  !Z;P  ;G   &5S  !@=0< 7782 %MW'P!9>"L 5W@V %5X
M/P%3>$@"47A/ T]W5P1,=U\%2G=H!TAV<PE%=G\+0W6-#$%UG0X_=:X./G7%
M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
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M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
M;%9  6I62 %H5E "9E97 V167@1B568%8%5O!UU5> A;5(0*6521"U=4H Q5
M4[ -5%/%#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58
M  "H6P  F5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL]
M 65;10%C6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-
M3UC##4Y8Y Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C
M7@  E5T  (E<  !_6P  =ED  '!:  !K7 T :%T8 &9>) !D7S  8E\Z &!?
M0P%>7TL"7%]2 EI?6@-87V$%55YJ!E->= =177\)3UV-"DU=G M+7:P,2EW!
M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
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M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
M<$@; &Y))P!K2C( :DL\ &A+1 !F2TP!9$M3 6)+6@)@2V("7TMJ UU+= 1;
M2G\%64J,!5=*F@952JH'5$J]!U-*W =22O8&4DK_!5))_P122?\#4DC_ U-(
M_P/400  P$L  +)1  "@4   DD\  (=.  !^3   >$@  ')*  !N2PT :TT8
M &A.) !F3B\ 9$\Y &)/0@!A4$D!7U!1 5U06 );3V "64]H U=/<@153WT%
M4T^*!5).F 903J@'3DZ[!TU.V0=-3O4&34[_!4U-_P1-3?\$3DS_ TY,_P/.
M1   O$X  *Y4  "<4P  CE(  (-1  !Z4   <DT  &Q/  !H4 L 95$5 &-2
M(0!A4RP 7U,V %U4/P!;5$< 6E1. 5A45@%65%T"5%1F U)3;P-04WL$3E.(
M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
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M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
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M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
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M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
M'?^X2"K_P5 \_L594/?(8&;KRF=\W<-MD<^\<:7%M'2UO;!YP+:L?\BNIX7/
MI:&*U9R<D=J5F9S<CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/
ME)_8CY2?V(^4G]B/E)_8CY2?V(^4G]B/E)_8_Z$B!?^?+0S_I#<4_[ _'/^Z
M2"K_PU [^\A84/7+7V;ISV9\W,EKDL[#;Z;!NG*UMK)VP*RL>\BDJ'_.G*2%
MU)2@C=B-GYG;BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8
MBIR?V(J<G]B*G)_8BIR?V(J<G]B*G)_8_Z$B!?^@+0S_IC83_[$_'/^[2"G^
MQD\[^,M74/+07F;GU&1]VL]ID\C%;::ZNW"TK;-SOZ.M=L>:J'K-DJ5_THJB
MAM>$H)'9A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<UX2BG->$HIS7A**<
MUX2BG->$HIS7A**<UX2BG->$HIS7_Z$B!?^@+0S_IS83_[,_'/^]1RG\R$X[
M]<Y63^[576;DVF)]T])HDL'&;*2SO&^QIK5RO)RO=,23JW?*BZ=[SX.D@=1]
MHHO6>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NCE=5[HY75>Z.5U7NC
ME=5[HY75>Z.5U7NCE=5[HY75_Z(A!?^@+0S_J#82_[0_&_^_1RCYRTXZ\M-5
M3^K<6V;@X&%]S--GD;O(:Z*LOFZOH+=PN)6R<\"-KG;%A:IZRGZH?\YXIH?1
M=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])UI8_2=:6/TG6EC])U
MI8_2=:6/TG6EC])UI8_2_Z(A!?^A+ O_JC82_[8^&_W"1RCUS4XY[ME43N;C
M6678XF![Q=5FC[3*:I^EP6VKF;IOM)"U<KN(L77 @:YXQ7JL?<ETJH3+<:F+
MS'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,<:F+S'&IB\QQJ8O,
M<:F+S'&IB\QQJ8O,_Z,A!?^B+ O_K#41_[D^&OG%1R?PT4TXZ>!23.+I5V3.
MY%]ZO==FC*W,:IN?Q&RGD[YOKXJY<;6#MG2Z?+-WOG:Q?,)QKX+$;JZ'QFZN
MA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'QFZNA\9NKH?&;JZ'
MQFZNA\9NKH?&_Z0A!?^C+ O_KS40_[P^&/3)1B7JV$TVXN=/3-SO56/&YE]X
MM-IEB:70:9:8R&RAC<-OJ(6_<:Y^NW2R>+EWMG.W>[ENM8"\:[2%OFNTA;YK
MM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNTA;YKM(6^:[2%OFNT
MA;YKM(6^_Z4A!/^D+ O_LS4/^\$^%^W/1B+AWTLTV.M/3,_S5&*\Z%YTJ]YD
MA)W4:9"1SFV9A\EOH(#%<J5ZPG2I=,!XK'"^>Z]KO("R:+N$LVB[A+-HNX2S
M:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-HNX2S:+N$LVB[A+-H
MNX2S_Z8A!/^H*PK_N#0-\\<]%.3811[6YDDUR_%.3,3W4U^Q[%UPH>)D?97;
M:8>*U6Z/@M!QE7O-=)IVRW>=<<EYH&W'?:)IQ8&E9L2%IF;$A:9FQ(6F9L2%
MIF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F9L2%IF;$A:9FQ(6F
M_Z@@!/^N*@C\OS,+Z<\\$-?A0A[*[4DUO_A-2K?[4ENF\5UIF.EE=(SB:GV#
MW6^$?-ISB7?7=XQSU7J/;]-]D6S1@)1HT(269<^'EV7/AY=ESX>79<^'EV7/
MAY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>79<^'EV7/AY=ESX>7_ZH@
M _^U*0;PR#$'VMTS#,OJ0B&^]D@ULO],1JG_456;]UU@CO!E:H7K;'%]YW%V
M=^1V>G/B>7UOX7Q_;-^ @6G>@X-GW8>%9=R)AF7<B89EW(F&9=R)AF7<B89E
MW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&9=R)AF7<B89EW(F&_ZT? _F_
M)0/?UB("R^@R#[[T02*P_T4SI/]*09S_44V/_EU6A?EF7GWT;F1V\G-H<N]X
M:V[N?&UL[7]O:NR"<&?JA7)EZHES8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT
M8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT8^F,=&/IC'1CZ8QT_[8< NC-% ',
MYAT$OO,Q$K'_/B*C_T(OEO](.HW_4$2$_UQ+>_]G473^;E9O_'-9;/MX6VGY
M?%UG^']>9OB#7V3WAF!B]HEA8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,
M8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB\\0/ ,[:"P"]\QT'
ML?\R%*/_.A^5_S\JB?]&,X#_3SIX_UM <?]F16S_;4AH_W-*9O]W3&3_>TUB
M_W].8?^"3V#_A5!>_XE17O^+45[_BU%>_XM17O^+45[_BU%>_XM17O^+45[_
MBU%>_XM17O^+45[_BU%>_XM17O^+45[_BU%>_XM1S,L) +[F# &O_QX)I/\P
M$Y7_-1R'_SPD?/]$*W/_33%L_U@U_^)]$$E#0U]04D]&24Q%  T29_]C.6/_
M:SMA_W$]7_]U/EW_>3]<_WQ 6_]_05K_@D%9_X9"6/^(0EC_B$)8_XA"6/^(
M0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"6/^(0EC_B$)8_XA"
M_YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;
MDH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?
M!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64
MU(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6
M*PO_E382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,
MGL^%D:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_
ME382_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%
MD:;+@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382
M_Z ^&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+
M@)6LQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^
M&O^H1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6L
MQWR9L<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H
M1R;_KE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9
ML<5YGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_
MKE$T_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5Y
MGK7"=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T
M_Z];1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"
M=J.YP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&__YD?!?^6*PO_E382_Z ^&O^H1R;_KE$T_Z];
M1?^M95?XJ6]H[:-X>>.;?X?;DH64U(N,GL^%D:;+@)6LQWR9L<5YGK7"=J.Y
MP'2JO+UQLKZY;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&__YD?!?^7*PO_ES82_Z$^&O^J1B7_L% T_[%:1?^P
M9%?WK&UI[*=W>^&>?8K9EH.7T8Z)HLN(CJO'@I.QQ'Z7M\%ZG+N^=Z*_O'6J
MPK5QKL.S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!
MLW*OP;-RK\&S<J_!_YD?!?^7*@K_F#42_Z,]&O^L1B7_LT\T_[191O^T8UCV
ML6QKZJUU?=^C>XW5FX&<S9*&J,>+BK'"A8^YOX"4OKM\FL.Y>:''M7:IRJUU
MK,:K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:M
MQ*MVK<2K=JW$_YH?!/^8*@K_FC02_Z4]&?^N1B7_M4XT_[=81O^W85GUM6IL
MZ;)S?]VH>)#3GWZ@RI:"K,2.A[>^B(R_NH.1Q;=_F,NT?*'/JWBESZ5YJLBD
M>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1Y
MK,:D>:S&_YH?!/^8*@K_FS01_Z8]&?^O127_MTXT_[I71O^[8%GTN6EMY[9Q
M@=RL=I/0I'NCR)I_L<"3A+R[C(G%MXB0R[2&F<ZRAJ31I'RDT9]]J<J>?:K(
MGGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>
M?:K(_YL?!/^9*@K_G#01_Z<\&?^Q123_N4TT_[Q71OZ^7UGTO6=NY[IO@MJQ
M=)7/J'FFQ9]]M+Z7@<"YE(K&M9&2RZ^-F,^JBJ'2GH*CTYF!J,R8@JG*F(*I
MRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*
M_YL?!/^9*@K_G301_ZD\&/^R123_NTTS_[]61OW!7EKSP69OYK]M@]FV<Y?-
MK7>HQ*5[M[ZA@\"VFXG&KI6/S*B1E<^BCI[2F8>BTY2&I\V3AJC+DX:HRY.&
MJ,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+_YL?
M!/^9*@K_GC,1_ZH\&/^S123_O$PS_\%51OO$75KSQ65OY<-LA-B[<9C,LG6K
MPZU\MKFE@;^PGH;&J)F,RZ&5DM";DIO3E(ZBU(^*ILZ/BJC+CXJHRX^*J,N/
MBJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+_YL?!/^:
M*@K_GS,0_ZL\&/^U1"/_ODPS_L-51?G'7%KQR61OY<AJA=;!;YK*N72JOK!Z
MMK.I?[^JHH3&HIV*RYN:D,^5EYG2CY2BU(J0ILZ*CZC,BH^HS(J/J,R*CZC,
MBH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,_YP?!/^:*@K_
MH#,0_ZP\&/^V1"/_OTPR_,941?;*7%KOS6)PY,UHAM/%;9K%O'.JN;1XM:ZM
M?;ZEIX+%G:*(RY6?CL^/G);2BYRBTX:5ILZ&E*?,AI2GS(:4I\R&E*?,AI2G
MS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,_YP?!/^:*0K_HC,0
M_ZT[%_^W1"/_P4PR^<E31?/-6EKLTF!PX-!FAL[(;)K OW&IM+AWM:FQ?+Z?
MK('%EZB&RI"DC,Z*HI71A:*ATH&<ILZ!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:
MI\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,_YP>!/^;*0K_HS,0_Z\[
M%_^Y1"+]PTLQ]LQ21/#265GHVE]PV]5DALG,:IFZPV^HK;MTM**T>;V8KWW#
MD*R#R(FIB<R#IY'/?J:<T'VDILU\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\
MHJC+?**HRWRBJ,M\HJC+?**HRWRBJ,M\HJC+_YT>!/^;*0K_I3(/_[$[%O^\
M1"'ZQDLQ\]%10^O:5UGCWUUOT]MCA<+/:9>QQ&VGI+QPLIBU=+N.L7C"AJU]
MQH"K@LIZJ8K-=JB4SG:IH\QWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*
M=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,IWJZC*_YT>!/^<*0K_IS(/_[,[%O^^0R#U
MRDLO[M900N;A5E?<Y%MNR]YC@[K1:)2IQVRCF[YNKI"X<;>&M'2]?K!XPG>N
M?,9RK(/);:N,RFVKF<ENK)_';JR?QVZLG\=NK)_';JR?QVZLG\=NK)_';JR?
MQVZLG\=NK)_';JR?QVZLG\=NK)_'_YX>!/^=*0G_J3(._[8Z%/K"0Q_PSDHN
MY]U/0.+I4E?2Z%IMP>!B@+'49Y&ARFN>E,-NJ(F]<;" N72V>;9WNG2T>[UN
MLH' :K"(PF>PDL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:P
MEL-FL);#9K"6PV:PEL-FL);#_Y\>!/^>*0G_K3$-_[HZ$_3'0AWHU4HKW^1,
M/]?L45;)[EEKM^-A?*C89XN:SVN7C<ENH(/$<:=[P'2L=;UXL'"[>[-LN8"V
M:+B&N&2WC[ECMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;IC
MMI&Z8[:1NF.VD;ICMI&Z_Z >!/^A* C_L3 +^\ Y$>S.0AG?WT<HT^E,0,KQ
M456^\EAHK>9A=Y[=9X22U6R/A\]OEG[+<YQXR':A<L9YI&[$?*=IPH&I9L"&
MK&*_C:UAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N
M8;^/KF&_CZYAOX^N_Z(= _^F)P?_MR\)\L<X#>'80132YD8JQ_!,0+[X4%.R
M]5=CHNMA<)7C9WN*W6V$@=AQBWK4=9!TTGF3<-!\EFS.?YEHS(.;9,N(G6'*
MC9]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/
MGV#)CY]@R8^?_Z0= _^M)@7[OBT&YM T"-/B/!;'[D8KN_E*/K#^3T^F^E=<
MF/%A:(SK:'&#YFYX>^)S?77?>(%QW7N$;=M_AVK:@XEGV8:*9->+C&'6D(Y@
MU9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5
MD8Y@U9&._Z<< _^U(P/NR28#U=\I!\?L/!FZ^$0KK?](.Z/_34F:_U=4C?EA
M783T:F5\\'!J=NUV;G'K>G%MZ7YT:^B"=FCFA7=FY8AY8^2,>F'CD7Q@XY)\
M8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@
MXY)\_ZL; O? '0'9W!(!Q^LH"KKW.QJL_T$IH/]&-I7_3$&-_U9+@_]A4GO]
M:U=T^G%<;_AV7VSV>V%I]7]C9_2#9&7SAF9C\HIG8?&.:%_PDFE?\)-J7_"3
M:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J
M_[<5 =;/"P#'ZA,"N?<I#:S_.1J>_SXFDO]$,(?_2SF _U1 >/]A1G+_:DIL
M_W!-:?]V4&;_>U%D_W]38_^#5&'_AE5@_HE67OZ-5UW]DEA<_9-87/V36%S]
MDUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-8UL0(
M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
ME9/8?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340
M_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8
M?)N9U'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[
M%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9
MU'B@GM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@
M1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@
MGM%UI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_
MIDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%U
MI*+/<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]
MKL-IO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM
M_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/
M<ZFES7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-I
MO:[#:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9
M//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFE
MS7&NJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#
M:;VNPVF]KL-IO:[#:;VN_Y(=!/^0*0G_C340_Y@[%_^@1"'_IDXM_Z=9//^E
M9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R E9/8?)N9U'B@GM%UI*+/<ZFES7&N
MJ,QOM:K*;;ZMPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VNPVF]KL-IO:[#:;VN
MPVF]KL-IO:[#:;VN_Y,=!/^0*0G_CS00_YH[%_^B1"#_J4TM_ZI8//^H8DS_
MI&Q<]9]V;.R9?WKDD8>&WHF-D-B#DYC3?IF?T'J=I,UVHJG+=*>LR7&MK\=O
MM++!;+FTO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[L;QLN[&\;+NQO&R[
ML;QLN[&\;+NQ_Y0=!/^1* G_D3,0_YPZ%O^D0R#_K$PM_ZU6/?^M8$W^J6I>
M]*5T;NJ??7WAEH.+V8Z*EM.'D*#.@96GRGR:K<=XG[+$=:6VPG*KN<!PM+NW
M;K6YLV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-ON+6S;[BULV^XM;-O
MN+6S;[BU_Y0=!/^2* G_DS(/_YXZ%O^G0R#_KDLM_[%5/?^P7T[]KFA?\JIR
M<.>D>H'>FH"/U9*'G,Z+C*;)A)&OQ'Z7M<%YG+N^=J._O'2KPK1OKL.N<K.\
MJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK<[:XJW.VN*MSMKBK
M<[:X_Y4<!/^2* G_E3(/_Z Z%O^I0A__L$HM_[14/?^T7D[]LV=@\:]P<N:I
M>(/;GWZ3TI>#H<N.B:S$AHZUP("4O;Q[FL.Z>J/%MWFKQZQSK,:G=;&_I7>U
MNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6ZI7>UNJ5WM;JE=[6Z
M_Y4<!/^3* G_EC$/_Z$Y%?^J0A__LDHL_[93//^W74[[MF5A\+1N=.2M=8;9
MI'N6SYN I<>2A;'!BHN[O8>4P+N%G<2V@J3'L'ZJR*5WJLBA>;#!GWJSO)]Z
ML[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\GWJSO)]ZL[R?>K.\_Y4<
M!/^3* G_ES$/_Z,Y%?^L0A__M$HL_[E3//^Z7$[XNF1B[[AL=>.R<XC8J7F9
MS9]^J<68A+2_DXR\N(V3P;.)F<6NAJ'(JH2IR9]\J<J;?:["F7ZRO9E^LKV9
M?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]F7ZRO9E^LKV9?K*]_Y8<!/^3
M* G_F# ._Z0Y%?^M01[_M4DL_[M2//V]6T[VO6-B[KUK=N*V<8G5KG>;RZ5\
MJL*=@[2YEHF\LI&0P:R,EL:GB9W(HX>FRIF J,N6@:[$E8&QOI6!L;Z5@;&^
ME8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^E8&QOI6!L;Z5@;&^_Y8<!/^4)PG_
MF3 ._Z4Y%/^N01[_MTDK_[U1//R_6D[TP6)B[,%I=^&[<(O2L72=QZA[JKR@
M@;2TFH>\K)2-PJ:0E,:@C9O)G(NDRY6&J,N1A:W%D(6QOY"%L;^0A;&_D(6Q
MOY"%L;^0A;&_D(6QOY"%L;^0A;&_D(6QOY"%L;^0A;&__Y8<!/^4)PC_FC .
M_Z8X%/^P01W_N$DK_[]1//K"64[RQ&%CZ<5H=]V^;8S-M'.=PJMYJK>D?K2N
MG82\IIB*P:"4D<::D9C)EH^ARY"+J,R,B:S%C(FPP(R)L,",B;# C(FPP(R)
ML,",B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;# _Y<<!/^5)PC_FS ._Z<X
M%/^Q01W_NDDK_\)0._C&6$[PR%]CYLAF>-C!:XW)MW&=O:]WJ;*G?+.IH8*[
MH9R(P9J8C\:4EI;)D)2?RXN1J,R'CJS&AXVPP8>-L,&'C;#!AXVPP8>-L,&'
MC;#!AXVPP8>-L,&'C;#!AXVPP8>-L,&'C;#!_Y<; _^5)PC_G2\-_ZDX$_^S
M0!W_O$@J_,5/._;)5T[MS5YCXLMD>-+$:HS$NV^<N+)UJ:VK>[.CIH"[FZ&&
MP92=C<6.FY3(BIF=RH:9J,N"DZS&@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!
M@I*OP8*2K\&"DJ_!@I*OP8*2K\&"DJ_!_Y<; _^5)PC_GB\-_ZHX$_^U0!S_
MOD@I^<A..O/-5DWJTUQBWL]B>,W':(N_OFZ;LK=SJ*>P>;*>JWZZE:>$P(ZC
MB\2(H9+'@Y^:R8"@I\I]FJS&?9BOP7V8K\%]F*_!?9BOP7V8K\%]F*_!?9BO
MP7V8K\%]F*_!?9BOP7V8K\%]F*_!_Y@; _^6)PC_H"\-_ZPW$O^W0!O]P4@H
M]LM..>_35$SFV5IBV-1A=\?+9XJYPVR:K;QRIZ&V=[&8L7VXCZV"OHBJB<."
MJ)#&?:>9R'JGI<EWHJS%>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!>)^PP7B?
ML,%XG[#!>)^PP7B?L,%XG[#!_Y@; _^7)@C_HB\,_ZXW$O^Y/QKYQ$<G\<Y-
M..K;4TO@WUE@T-I?=L'098FSR6N9IL)PI9N]=:^1N'NVB+6 O(&RAL![L(W#
M=JZ6Q7.NH<9RK:W$<JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!R
MJ;# <JFPP'*IL,!RJ;# _YD; _^8)@C_I"X+_[$V$?Z]/QGTR$<EZ]1--N7C
M4$G9XU=?R=]>=+K79(:LSVF6G<=MHY' <:R&NW6S?K=ZN7>T?[URLH6_;;&-
MP6JPE\)IL:7!;+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*]
M;+2RO6RTLKULM+*]_YH; _^9)@C_IRT*_[4V#_G!/Q?NSD8CY-Q,,MWG3TG/
MZ%9>P.1=<K+>9(*CU&F1E<MMG(G%<*5_P'.L=[QWL7"Y?+5KMX&X9[:'NF.U
MD+MAM9N\8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>F
MN6.WIKECMZ:Y_YL; _^;)0?_JRT)_[DU#?+'/A7EU48?VN-),\_K3DG&[51=
MM^I<;JCB8WV:V6F*CM)ME(3,<9M[R'6A<\1XIF["?*EIP(&L9;Z'KF*]CK!?
MO9>Q7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\
MGK%>O)ZQ_YP: _^@) ;_L"P(^< T"^G//1#:WT(=SNE),\3Q3DB[\E):K?!;
M:9[G8W:2X&F!A]IOB7[4<Y!WT7>5<<Y[F6S,?YQHRH.>9,F(H&''CJ)>QI6D
M7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<
MQIND_YX: _^E(P7_MRH%\,@R!]S;-0S.YT(?PO%(-+CY3$:O]U%5HO5;8I7M
M9&V*YVMV@.)P?7G>=8)SVWJ';ME^BFO7@HQGU8:.9-2+D&'3D))>T9:47-&;
ME5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N5
M_Z$9 O^M(0/XOR8#XM0E \[E,P_"\$(AMOI',ZO^2T*B_E!/E_M;6HOU96."
M\&QJ>NQR<'3I>'1OYWQW;.6!>FCCA'QFXHA]8^&,?V#@D8%>WY:"7-Z:@US>
MFH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#_Z,9
M O^V'0'IS!<!S^,> \+P,Q*U^D BJ?]$,)W_23V5_U!(B_];4(+]95=Z^6U=
M=/9S86_T>61K\GYG:/&":6;PAFID[XIL8NZ.;6#MDFY=[)=P7.N;<5SKFW%<
MZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ_ZP5 ?/#
M$ #1V@L P>\?!K3[,Q.H_SP@F_]"+)#_2#:'_T\_?_]:1GC_94MQ_VU/;/]S
M4FG_>55F_GY79/V"6&+\AEEA^XI:7_J.6U[ZDEQ<^9==6_B;7EOXFUY;^)M>
M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
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MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
M*D?_A2M&_XDK1?^.+$3_E"Q#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM
M0_^:+4/_FBU#_YHML<(! */2  "5ZP,!C/\3 X#_' 9T_R,*:?\J#F#_,A)9
M_SH54_]"%T[_21E+_U$:2/]8'$;_71U$_V,=0_]G'D'_;!] _W ?/_]T(#[_
M>" ]_WP@//^!(3O_AR$[_XPB._^,(CO_C"([_XPB._^,(CO_C"([_XPB._^,
M(CO_C"([_XPB_WH= _]V* ;_<C,+_WPW#_^$/Q7_B$@=_XM3)_^)8#'_AFT[
M_X)Y1/]^ADS_>Y%3_W>:6/]THEW\<:AA^FZN9/AKM&?W:;II]6C!:_-FR&WO
M8\UO[&'3<.=?W7'B7>5SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;
MYG/=6^9S_WH= _]V* ;_<C,+_WPW#_^$/Q7_B$@=_XM3)_^)8#'_AFT[_X)Y
M1/]^ADS_>Y%3_W>:6/]THEW\<:AA^FZN9/AKM&?W:;II]6C!:_-FR&WO8\UO
M[&'3<.=?W7'B7>5SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=
M6^9S_WH= _]V* ;_<C,+_WPW#_^$/Q7_B$@=_XM3)_^)8#'_AFT[_X)Y1/]^
MADS_>Y%3_W>:6/]THEW\<:AA^FZN9/AKM&?W:;II]6C!:_-FR&WO8\UO[&'3
M<.=?W7'B7>5SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9S
M_WH= _]V* ;_<C,+_WPW#_^$/Q7_B$@=_XM3)_^)8#'_AFT[_X)Y1/]^ADS_
M>Y%3_W>:6/]THEW\<:AA^FZN9/AKM&?W:;II]6C!:_-FR&WO8\UO[&'3<.=?
MW7'B7>5SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9SW5OF<]U;YG/=6^9S_WH<
M _]W)P;_=#(+_W\V#_^&/17_BT<=_XY1)_^,7C'_B6L\_X5W1O^!@T[_?8]6
M_WF87/QUH&'Y<J9E]V^M:?5LLVSS:KEO\FC <?!FR'/L9,UUZ&'4=N-?WG?;
M7>-YU5WE=M5=Y7;57>5VU5WE=M5=Y7;57>5VU5WE=M5=Y7;57>5V_WL< _]W
M)P;_=S *_X(U#O^*/!7_CT8=_Y)/)_^17#+_CF@]_XIT2/^&@%+_@8M:_'V5
M8?AXG6?U=*1M\G&J<?!NL'3N:[9W[&F^>NIGQWWG9<Y_XF+6@-E?W8'07^!^
MS&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[S&#C>\Q@XWO,8.-[_WP< _]X)@;_
M>B\*_X4S#O^-.Q3_DD0<_Y9.)_^56C+_DF4^_XYQ2O^*?57^A8A>^8"29_1[
MFF[P=J%S[7*G>.IOKGWH;+2 YFF\@^1GQH;A9<^(V6+7BL]AV8C(8MV"Q&/@
M?\1CX'_$8^!_Q&/@?\1CX'_$8^!_Q&/@?\1CX'_$8^!__WT; _]Y)@;_?"X*
M_X@R#O^0.A3_E4,<_YI,)_^96#/_EF,__Y)N3/^.>E?\B85B]82/:_!^EW/L
M>9YZZ'2E@.5PJX7B;+.)X&J[C-YHQH_:9M&2SF+1DL=DU8S!9=N&O6;=@KUF
MW8*]9MV"O6;=@KUFW8*]9MV"O6;=@KUFW8*]9MV"_WT; _]Z)@;_?RP*_XLQ
M#?^3.A/_F$(<_YU+)O^=5C/_FV% _Y=L3?N2=EKWC8%F\HB,<.R"E'GG>YN!
MXW6BB-]QJ8[<;;&2V6N[EM=IR)G,9,N;Q67.E\!GTI&Z:-B*MFG;AK9IVX:V
M:=N&MFG;AK9IVX:V:=N&MFG;AK9IVX:V:=N&_WX; _][)@;_@2L)_XTQ#?^5
M.1/_FT(;_Z!*)O^A5#/_GU]!^YQI3_:7<UWQDGYJ[(R(=>>%D8#B?IB)W7B@
MD=ARIY?2;:^=SVRYG\QKQ:##9\>@O&C+F[=JT)2R;-6-KVS9B:]LV8FO;-F)
MKVS9B:]LV8FO;-F)KVS9B:]LV8FO;-F)_WX: _][)0;_@RH)_X\P#/^8.!+_
MGD$;_Z-))O^F4C/]I%U!]Z%G4/&<<5_KEWMMY8^#>MZ'BX;5?I*1SWB9E\IT
MH9S'<:J?PV^SH<%NOZ.Z:\6CLVO(GZ]MS9BK;]*1J7#6C*EPUHRI<-:,J7#6
MC*EPUHRI<-:,J7#6C*EPUHRI<-:,_W\: _]\)0;_ABD(_Y(O#/^;.!+_H4 :
M_Z=()?^J43+YJ5M!\Z9D4>RB;F'EFG9PW)%^?]*)AHO+@HV3Q7V5F<!XG9Z\
M=:6AN7.NI+9RN:6R<,.FJV_&HJAQRYND<]"3HG34CJ)TU(ZB=-2.HG34CJ)T
MU(ZB=-2.HG34CJ)TU(ZB=-2._X : _]\)0;_B"@(_Y0O"_^=-Q'_I#\9_ZI'
M)/VN3S+VK5E![ZMB4N>F:V+>GG)STI5Z@<J-@HO#AXJ3O8&1FK=]F9^S>:&C
MKW>JIJQVM*>J=L&HHW/#I:!UR9Z>=\^6G'?2D9QWTI&<=]*1G'?2D9QWTI&<
M=]*1G'?2D9QWTI&<=]*1_X : _]])0;_BB<(_Y8N"_^?-A#_IS\8_ZU'(_NR
M3C'SLE=!Z[%@4N*J:&36HG!TS)EW@<.2?XN\BX:4M8:.FJ^!E:"J?IVDIGNF
MIZ-ZL*FA>;RIFW?!J)EYQZ"8>LV8EWO1DY=[T9.7>]&3EWO1DY=[T9.7>]&3
MEWO1DY=[T9.7>]&3_X$: _]^) ;_C"8'_Y@N"O^B-A#_J3X8_Z]&(_BU33#P
MMU9 Y[5>4MVN9F30I6YSQIUU@+V6?(NUD(.4KHJ+FZB&DJ"C@IJEGW^CJ)M^
MK:J8?;FKE'O JI-]QJ*2?LR9D7_0E)%_T)21?]"4D7_0E)%_T)21?]"4D7_0
ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
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MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
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MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
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M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
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M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
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MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
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MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
M %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K_U0&
M*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_WPL:
M_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4  $;_
M!0! _PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#'?].
M QK_5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8._[H&
M#O^Z!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_   T
M_PD +_\. "O_%  G_QH!(_\A 1__)0$<_RH!&?\O 1;_- (4_SH"$?]  A#_
M1@(._TX"#/]6 @G_8 ,'_VP#!/]X P/_A@,"_Y$# ?^= P'_H0,!_Z$# ?^A
M P'_H0,!_Z$#_S8M O\Y+@+_/BX#_T R _] . 3_/D$&_SQ,"/\Z6@K_.&@,
M_S9V#O\U@P__-(\0_S.9$?\SH1'_,ZD2_S*P$O\RMQ+_,K\2_S+($_\RTQ/_
M,N,3_S+M$_\R]A+_,_X2_S/_$O\S_Q+_,_\1_S/_$?\S_Q#_,_\0_S/_$/\S
M_Q#_,_\0_S8M O\[+ +_0"P#_T,O _]#-03_0CX&_T!*"/\^5PO_/&4-_SIS
M#_\X@!#_-XP1_S>6$O\VGQ/_-J<3_S:N%/\VM13_-KP4_S7%%?\UT!7_-> 5
M_S;K%?\V]!7_-OT4_S;_%/\V_Q3^-_\3_C;_$_TV_Q+]-O\2_3;_$OTV_Q+]
M-O\2_S<L O\^*@+_0RH"_T8M _]',@3_1CP&_T5("/]#50O_06(-_S]P$/\]
M?1'_/(D3_SN3%/\[G!7_.J06_SJK%O\ZLA?_.KD7_SG"%_\YS!?_.=T8_SGI
M&/\Y\QC_.OL8_#K_%_HZ_Q?Y.O\6^#K_%O@Z_Q7X.O\5^#K_%?@Z_Q7X.O\5
M_SDK O]!)P+_1B<"_THI _]++P3_3#D&_TM%"/](40O_1EX._T1L$?]">1/_
M0845_T"/%_] F!C_/Z 8_S^G&?\^KAK_/K8:_SZ^&_\^R!O_/=8<_CWF'/L^
M\1SX/OH<]3[_'/,^_QKR/_\9\3__&?$__QCQ/_\8\3__&/$__QCQ/_\8_STH
M O]%) +_2B,"_TXE _]1+ 3_4C8&_U%!"/]/30S_3%H/_TIG$O](=!7_1X 7
M_T:+&?]%E!O_1)P<_T.D'?Y#JQ[]0K(?_$*Z(/I"Q"#Y0M A]D'B(?)"[B+O
M0ODB[4+_(.M#_Q_J0_\=Z43_'.A$_QOH1/\;Z$3_&^A$_QOH1/\;_T E O](
M(0+_3R "_U,A O]7*0/_63,%_U@^"/]620S_4E40_U%C%/]/;Q?^37L:^TN&
M'?E*CQ_W29@A]DB?(O1'IB3S1ZXE\4:V)O!&OR?O1<LH[$7>*>A%["GE1O@H
MXD?_)N%(_R3?2?\BWDG_(-U)_Q_=2?\?W4G_']U)_Q_=2?\?_T,B O],'@'_
M4QP"_UD> O]=)@/_7S $_U\Z!_]=10O_6E 0_5A>%?A5:AGU4W8=\E& (>]/
MBB3M39,FZTR:*>E+HBOG2JDLY4FQ+N1(NR_B2,<QX$C9,=Q(ZC'82?8NU$O_
M*]),_RG03?\FST[_)<Y._R/.3O\CSD[_(\Y._R/.3O\C_T<? ?]0&@'_5Q@!
M_UX< ?]C(P+_9BP$_V8V!O]D00KZ8DP/]%]9%>]<91OK67 @YU9[)>14A"GA
M48TMWE"5,-Q/G3+93J4SUDVM-=--MS;13,(WSTS1.,Q,YCC)3?0UQT__,<51
M_R[$4O\KPU/_*<)3_R?"4_\GPE/_)\)3_R?"4_\G_TH< ?]4%P'_7!4!_V,9
M ?]I( +_;"D#_VTR!?EL/0GR:4<.ZV94%>5C8!S@7VLBVUQU*-99?RW25X@P
MSU60,\Q4F#;*4Z XQU*G.L51L#O#4+L\P5#)/;]0WSV\4? [NE/\-[E5_S.X
M5_\OMUC_+;=8_RNW6/\KMUC_*[=8_RNW6/\K_TT: ?]7% '_8!(!_V@7 ?]N
M'0'_<B4"^W,N _)S. ?I<4,-XFY0%-MI7!S3968DSF)P*LE?>B_&7((SPUN*
M-L!9DCF]6)H[NU:B/KA5JS^V5;5!M%3"0K)4U$*P5>I!KE?Y/*Y9_S>M6_\S
MK5S_,*U=_RZM7?\NK5W_+JU=_RZM7?\N_U 7 ?]:$@'_9!  _VT4 /]S&@'_
M=R$!]'DI NIZ,P7B>#\*V71,$\]P6!S):V(DQ&AL*[]E=3"[8GTUN&"%.+5>
MC3RR7)4^KUN=0:U:ID.K6:]$J5F\1:=8S$:D6.5&I%OV0*->_SNC7_\WHV#_
M,Z-A_S&C8?\QHV'_,:-A_S&C8?\Q_U,5 ?]=$ #_: \ _W 2 /]W%@#[?!P!
M[G\D >2 +0/:?SL(SWI)$L=U5!O!<5\DNVUH*[9J<#&R9WDVKV6 .JMCB#VH
M89! IF"80Z->H46@7JM'GEVW2)Q=QDF:7-])FE_R1)IB_SZ:8_\YFV7_-IME
M_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00 /][$@#U@1< Z(0>
M -Z')P'1A#<'R']&$<![41NY=ELCM')E*Z]O;3&J;'4VIVI\.J-HA#Z@9HQ!
MG6241)ICG4>78J=)E6&R2Y-AP4R18=A,D6/O1Y)E_4&29_\\DVG_.)-J_S63
M:O\UDVK_-9-J_S63:O\U_U<1 ?]C#0#_;@P _W<. /]_#P#PA1$ XXD6 -:+
M(P'+B#4&PH1#$+J 3QJS>UDCK7=B*JAT:C&C<7$VGVYY.YQL@3^8:HA"E6F1
M19)GFDB/9J-*C66O3(IEO4V)9=%.B6?L2HII^T.+:_\^C&W_.HQN_S>,;O\W
MC&[_-XQN_S>,;O\W_UD0 /]E"P#_<0L _WH+ /&"# #HB0T W8X. ,^/( '&
MC3(&O8E!#[6$31FN@%8BIWQ?*J)X9S"==6\VF7-V.I5Q?3^2;X5"CFV.1HML
MEDF(:J!+A6JL38-IND^!:<Q/@6KH3(-M^46$;_\_A7#_.X9Q_SB&<?\XAG'_
M.(9Q_SB&<?\X_UL/ /]G" #_<P@ \WT( -Z&!P#9C D U9$+ ,J2'@#!D# %
MN(T_#K"(2ABIA%0AHH!=*9U]93"8>FPUDW=S.H]U>SZ,<X)"B'*+1H5PE$F"
M;YY,?VZI3GQMMT][;<E0>F[F37QQ^$9^<_]!?W3_/8!U_SJ =?\Z@'7_.H!U
M_SJ =?\Z_UT. /]J!@#_=@8 Y( # -F)!@#2CP@ SY0* ,66&P"\E"X$LY$]
M#:N-2!>DB%(@GH5;*)B!8R^3?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,
M>7*G3G9RM5!T<L90='+C3W9U]D=X=_]">GC_/GMY_SI[>?\Z>WG_.GMY_SI[
M>?\Z_U\, /]L! #U>0( WH," -.+!0#-D@< R9<( ,"9&0"WF"P#KY4[#*>1
M1Q:?C5 ?F8E9)Y.&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17EZCTEV>)E,<W>E
M3G!WLE!N=\10;7?@3W!Y]4AR>_]#='S_/G5]_SMU??\[=7W_.W5]_SMU??\[
M_V$* /]O @#H?   V88! ,^.! #(E08 PYH& +N<%@"SG"H#JIDY"Z*5112;
MD4X=E(Y7)HZ+7RV)B&8SA(9M.("$=#U[@GM!=X"$171_C4AP?9=+;7RC3FI\
ML$]H?,%09WS=4&I^\TEM@/]#;H'_/V^!_SQO@?\\;X'_/&^!_SQO@?\\_V0(
M /]R  #A?P  TXD! ,J2 P##F 0 O9X$ +:@$P"NH"<"I9TV"9V:0Q.6ETT<
MCY-5)(F172N$CF0Q?XQK-WJ*<CMVB'E <H:"1&Z%BT=J@Y5*9X*A362"KD]B
M@K]/88+:3V2$\DEFA?]#:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V
M  #<@@  SHT  ,65 @"^G , MZ$" *^D$0"HI"0"H*(T")B?0!&1G$H:BIE3
M(H276RE^E6(P>9)I-760<#IPCW<^;(U_0FB,B49EBI-)88F?2UZ)K$U=B;U.
M7(G635Z*\$A@B_Y#8HO_/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5
MA@  R9$  ,"9 0"XGP$ L*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>
M62=XG& M<YIG,F^8;C=JEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'3
M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
M +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]ZCUXE
M=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%ZC]<
MAOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3
M  "PF0  J)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,%WF85!UTEUPB<)5C
M)VN3:BQGDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9 4XW+0%2-Z3U6C?HY
M5XW_-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "J
MG0  H:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@4AINGUD?:9U@)&6<
M9RAAFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)/$Z6Z#I/EODV49;_
M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
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M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
M_XH  /^;  #_J   _[$  /^Q  #_L0  _[$ _R4K ?\H*0'_*2D!_R@L ?\C
M,@'_'CL"_QI' O\750/_%6(#_Q-P _\2? /_$H<#_Q*1 _\2F0/_$J #_Q*G
M _\2K0/_$;0#_Q&[ _\1Q /_$<X#_Q'? _\1ZP+_$O8"_Q+^ O\2_P+_$O\"
M_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_$O\"_R@I ?\K)@'_+"8!_RLI ?\H+P'_
M(C@"_R!$ O\=4@/_&U\#_QAL _\7>03_%X0$_Q>.!/\7E@3_%IT$_Q:D!/\6
MJ@3_%K$$_Q:X!/\6P /_%LH#_Q;; _\6Z /_%_0#_Q?] _P7_P+[%_\#^Q?_
M _H7_P/Z%_\#^A?_ _H7_P/Z%_\#_RHF ?\N(P'_+R(!_R\E ?\L*P'_*C4"
M_R=! O\D3@/_(EL#_R!H!/\>= 3_'8 $_QV*!/\=D@7_'9H%_QVA!?\=IP7_
M':T%_QVT!/\=O03_'<<$_QW4!/X=Y@3['?($]Q[[ _4>_P3T'O\$\Q[_!/,>
M_P3R'O\$\A[_!/(>_P3R'O\$_RXB ?\R'P'_-!X!_S,@ ?\R)@'_,C(!_R\^
M O\L2@/_*E<#_R=D!/\F< 7_)7L%_R2%!?\DC@;_))8&_R2=!O\DHP;_)*H&
M_22Q!OPDN0;[),,&^23/!O8DXP;R)/ %[B7Z!>TE_P;K)?\&ZB7_!NDE_P;I
M)?\&Z27_!NDE_P;I)?\&_S(> ?\V&P#_.!D _S@; ?\Z(P'_.2T!_S@Z O\U
M1@/_,E($_S!?!/\N:P7_+78&_2R !_HLB0?Y*Y$']RN9"/4KGPCT*Z8(\RNM
M"/$KM0CP*[\([BO+".LKWPCG+.X(Y"SZ".(L_PG@+/\)WBS_"-XL_PC=+/\(
MW2S_"-TL_PC=+/\(_S4: /\Z%@#_/10 _S\7 /]!'P#_02D!_T T ?\]00+_
M.DT#_#A:!?@V90;T-7$'\31[".\SA GM,XT)ZS*4"NDRFPKH,J(+YC*J"^0R
ML@SC,KL,X3+(#-\RW S:,NP-U3/X#=(S_PW0,_\,SC/_#,TT_PO,-/\+S#3_
M"\PT_PO,-/\+_SD6 /\^$@#_01  _T43 /](&P#_2"0 _T<O ?Y$.P+W0D<#
M\3]4!>P^8 ;H/&L(Y3MV">([?PO@.H@,W3F0#=LYEP[9.)X/UCBF$-0XKA'2
M.+<1T#C#$LXXTQ+*..@2QSGW$L0Y_Q'".O\0P3K_#\ Z_PZ_.O\.OSK_#K\Z
M_PZ_.O\._ST3 /]"#P#_1@T _TL0 /].%@#_3Q\ _4XI ?1,- 'L2$$"YD=.
M!.!%6P;;1&8)UD)P#-)!>0[/0((0S4"*$<H_D1/)/YD4QSZ@%<4^J!;#/K$7
MP3Z\%\ ^RQB]/N(8NC[R%[<__Q:U0/\4M$#_$[-!_Q&S0?\0LT'_$+-!_Q"S
M0?\0_T 0 /]&# #_2PH _U$- /]3$0#_5!@ \U0B .E2+0'A4#L!VD]) ])-
M50?,2V +R$EJ#L5(<Q'"1WL3OT:#%;U%BQ>[19,8N42:&;=#HAJU0ZL;M$.V
M'+)#Q!VP0]D>K4/M':M%_!JI1?\8J$;_%JA&_Q6G1_\3IT?_$Z='_Q.G1_\3
M_T0. /]*" #_4 8 _U4* /]8#0#W61$ ZE@8 -]7) #45S4!S%5$!,944 C!
M4EL,O5!E$+E.;1.V3786M$Q]&+%+A1JO2HT;K4F5':M)G1ZI2*8@ITBP(:5(
MO2*D2,\BH4CH(J!)^!Z?2_\;GDO_&9U,_Q>=3/\6G4S_%IU,_Q:=3/\6_T<+
M /]- @#_5 ( ]UH$ .M=!P#G70L X5P0 --='@#*73 !PUP_!+U:3 BW6%<,
MLU9@$:]4:12L4W$7J5%X&J=0@!RD3X<>HD^/(*!.F"&>3:$CG$VK))I-N"69
M3,@FEDSB)I5.]2*43_\?E%#_')11_QJ44?\8E%'_&)11_QB44?\8_TD( /]0
M  #[6   Y5X  -UB P#68P< U&$* ,IB&0#"8RP!NV([ [1@2 BO75,,JEM<
M$:9:9!6C6&P8H%=T&YU5>QV;5(,@F52+(I93DR244ITEDE&G)Y!1LRB.4<,I
MC5'=*HQ2\B:+5/\BBU7_'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L
M7   WV(  -1F 0#.: 4 RV<( ,)G%@"Z:"@!LV<X ZUE10>H8U ,HV%9$9]?
M816;76@8F%QP&Y5:=QZ367\AD%B'(XY7CR6,5YDGB5:C*8=6KRJ%5;\KA%;5
M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
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M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
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M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
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M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
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M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
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M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
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M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
M@/\0QFL  +=V  "L?P  HH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0
M% !8D"$ 5I$M %.0. %1D$$"3I!) TR04 1*CU@%1X]@!T6.:0E"CG,+0(U_
M#3Z-C0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.
MOW(  +)]  "GA@  G(H  )&.  "&D0  >I,  &V5  !?EP  5)D! $^9#P!.
MFAH 3)HG $J:,@!(FCP!1II$ 42:3 )"FE0#0)E<!#Z99@4[F7 '.9A\"#>8
MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
MX ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*
M$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H7
M6@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU
M ,P8P0#+&-( QQKH <,;^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"
M_RL, /\K!0#_*P, _RT) /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5
M(%\ T2!H ,X@<0#,(7D RB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TB
MNP*\(\H"N2/C K4D] *S)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\&
M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
M *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\1&H$
M>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%_PAL
M1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5   )E*
M @"221$ C4H? (E++ "%3#@ @DM" 7]+2@%\2E(">4I8 W=*7P1U268%<TEM
M!G%)=@=O2'\(;4B*"6Q(E@MJ2*,,:$BR#6=(Q0UF2>0-9DGX"V9)_PEF2O\(
M9DG_!V9)_P=F2?\'Z$,  -)-  #"4P  MU@  *U9  "D6   G%4  )-.  ",
M3@X AT\; ()/*0!_4#4 >U _ 7A/1P%V3T\"<TY5 W%.7 1O36,%;4UJ!FM-
M<@=I37P(9TR'"F5,DPMC3* -8DRO#F%-P@Y@3>$.8$WV#&!._PI@3O\)8$[_
M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
M@%,8 'Q3)0!Y5#$ =50\ '-31 %P4TP";5)3 FM260-I4F $9U%H!F51< =C
M47D(85&$"F!0D0Q>4)X-7%"M#EM1P Y:4=X/6E'U#%I2_PI;4O\)6U'_"%M1
M_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H >E<5
M '97(@!S6"X <%<Y &U700%J5TD":%90 F965P-D5EX$8E5E!6!5;0=>57<(
M7%6""EI5C@Q959P-5U6K#E95O@]55=L/557S#555_PM65?\)5E7_"595_PA6
M5?\(VTT  ,57  "X7@  K6(  *-E  ":90  D&,  (-<  ![6P8 =5L2 '%;
M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
MQQ\( ,$<$P"Z'B( M!\Q *\@/0"K(4@ J")2 *8B6@"C(V( H2-I * C;P">
M(W< G"-^ )LCA@"9)(\!ER29 98DHP&4)+ !DB6_ 9$EU@&.)N\!C"?_ HLG
M_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@  NBL"
M +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2*W$!
MD"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N_P)_
M+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4  *DO
M"P"C+Q< GC$F )DR,P"6,CX DC-( ) S4 "-,U@ BS-> 8DS90&',VP!AC-S
M 80S? *",X4"@#./ W\SF@-],Z<#?#.U!'HSR01Y-.8$=S7Y!'8U_P-U-?\#
M=37_ W4U_P-U-?\#\#,  -T]  #*0P  OD4  +5&  "M0P  ICT  * V!@"9
M-A, E#@A ) Y+@",.3D B3E# (<Y3 "$.5,!@CE: 8 Y80%^.6@"?#EO GHY
M=P)Y.8 #=SF+!'4YE@1T.:,%<CFQ!7$YQ 9O.N(&;CKW!6X[_P1M._\$;3O_
M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
MN@   +L   "]    OP   ,$   #$    QP   ,L   #-#   SAH  ,\O  #/
M2   T&(  -"   #0G0  T+@                       $#! 4&" D*"PT.
M#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'
M24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!
M@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZ
MN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T
M]?;W^?K[_/[_________________________________________________
M_____P                     ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@
M(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA9
M6UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3
ME)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,
MS<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________
M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
M          $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8&1H:&QP='A\@
M(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,
M34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY
M>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6F
MIZBIJJNLK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1T]35
MUM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\  0$"
M @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<
M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
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M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
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M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
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MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
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M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
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MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
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M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
M        ,&OB@[QNR#/,6V3M-5SVS":6+*,JCB<O+)E-\I52T4DZ<RHLEHQV
M;OF*B)_]TG(NO+PZ4=2^7+7WVV892RZTUFB;<[FQJKH^YUL7]R0R)K]*DM[^
M=NG_ '2OHX22YS<SVP)V,T<[_AN3YJ>TU??!CNL5-KR<->Q=4]6G'V4+"V^+
M5&^UV^UQU]C0@DX< 7IL-)]#AZ-4]/N>OX2N[=#V</1Z%]CW "]-BH$<C.&J
M</N%=VZFUY>'#V_D4B$31- 7;M-KYFMU;PX:\.WU)ZBL:.DU1.'#V/:7M *J
M2T:,U[M?9\_9[?PDX^I?-UY?;\_N>D^N5W;HOEZNT%,W2VHUKOF\.*>QV^_J
M2JKI>5%X?F>L^06EOM(C>?YNG;KV::]B^\4;<(=->WCP^3BO  LO?H/I^WJB
M^VGG]LH6XQ_2T3U\?2GQD.O#@"RU]C^GJGI7XD]S0H2XMTYO.O'R]X L]>F:
M<ZKZ_C4HBX-[4]WX_<(<%IKPU%Y_95/A^#0HZN3M]:_& 6ONR=J^M4*3K$U1
MWMI[JK\AQ/[?:^-06ZN7Y[VRF:GS^W_]4? *%KTX>RJ_"4_4)YO:^% "DJKM
M=[/QH2:;M]M/@ *>J?/Y?U)*W]OM?&IQ/[?:^-02F5$5'HJ:HNJ*B^=%7BA!
MJB.16JFJ*BHJ+YT7@J>VAQJB.16JFJ*BHJ+YT7@J>VA"5]#1W2AK+;<*>*LH
M+C25%#74D[>>&JHZN%]/4T\S%X.BGAD<UR>=%*3J*?NI7L35$1=6Z\=6K]$I
M*IINYF?&G8B_-U\[%XMX^P4G4TW<ROCXHB+JW7BBL7BWWNWUFL#OYMY6[);O
MYEMY4]]]2M=R=58]53KS.K\8N:?7K%5K+IR2S)0RMCG5O!M3%(WM:J$(YGI3
MVR#='[2^\03H_5I\"_(6ZH[KV?.]'O\ R(<#V>GVE(9\?JT7T>92&?'ZO:\R
ME84%TXI\[L]?H(9[/=\R^DA7L[>'#SIZ"$?'[GOH5M;;E]'YWH\Y"O;ZN*>^
M0DC/N+\2D'(SU<?A3XRO[;<47EU5/,0KV^K@O:0<C.WA[*?&0,C/CT^0N':Z
M]5Y=%T3@0;V^;SIQ3UD%(WWN*>P0,C/:1?>4N-:J[Z/SO1Q^1#DM]:ZWUD=2
MB*L2_H=0U$5RNA>J<^C4DBYGM5$<U%<C5>U-=4U0J#"LJK,(RFU9'1\SDHZA
MJ5E.U=/KEOE5(ZZD754;K- J\BKP:]&NTX'5'K/Z7,-ZR>FK=;IXS5M-3TN?
M8W4P8_?IZ5U7)A^<6[2XX5F-+%%-3SR2X[D=-3SRPQRQ?6Z9LM,]W=3/1;S8
M1D\^/WB@NL"N=]7E3OXD73ZQ2R?-J('+V)WD2KIKV.T7S%YZ.-LK&21JU['H
MCFO:YLC'(O'5KXW.8Y%]**J+YO,95[37T=WMU#=J"5M10W&D@K*.5FBI)!4Q
MMEB=P541>1R:IYEX'ES[D[;Y?M!N+G&U>?VE]CS?;G++_A656A[V2_4+_C5S
MJ;3=(8ZB-5AJJ9M72.6*:-71S1JV1BJUR*O?R@J8+A24U?2R)+2U<$53!(G9
M)%,Q)&+ZOFNXIYEX%0TT"\.'EP)TQGW5^(I.-GW5^(CBHZ6F[-$U]HC8V=G#
MV$]'K4CHV>7H3Y1V\$*EI*;BG CHV=GG^-?3[!,(X_5I\2?*ISM31/7YRJ*.
ME[.!'1QZ_'ZU^1"811^K[B?*I^E4T=+]'AZ"8Q1_#[OJ]A"811^K3XONJ<S6
MZ)Z_+@5;14G9P_-)A%'\/N^KV$)E%'ZO+T:GT5=14FNG#WB8Q1]GE[:^HF<4
M79Y>W\AS-;I[)6%#1_1\OS>TF44?9Y>VOK4F<,79Y+^:I]HFJZ%94-'KIP7U
M_=7T$SBB[.'EZ/9])-88O/Y(<R(B)HA6=#1_133T=B? GM$SAC[/+L^)":PQ
M=GEY>LY&-UXKV>;UE:T%%]'@OF]GVU\Q-(8NSAY?*3:&)?+R[?@.4N18;(ZK
M>FJ+' S3O)-/G+V:1LUX<[D7_J4X^A%G%+3J]?0B<57Y/7Z"LL>L$EUFU>KH
M:.)4[Z=$U<Y4T7N8$<FCI514U5>#&KS*BJK6NYFMT]DN[1P,B8R.-O*QC4:U
M/0U$T3V>"$Y8U$T:B:(GP)\I?FVTK(8HH8V\L<3&1L:OYUC&HUK?81$X>@^B
MX>$9'<<,R>Q95:G*VOL5RI;A"WF5C9TA>G?TDKFZK]7K:=SX9$\\;U0CZ:9]
M/40SQ_3BD:]/0NB\6KI^=<W5%]2G8C8#=C*=@]WMN-Y<+F=%DNW&66C)Z"/O
MI*>&X1T%0U;C9*Z2)'/^]E_M;YJ&J1$7GIJA[=-%!GAL-ZH,DLEHR"UR=[;K
MU;J.YT3UTYEIZV!E1&V1&JY&2L;)RO;KJUR*B\4+JQ2MFBCF8NK)6->WV'(B
MIKZTU/2)VUW QO=C;W"-SL.J_KV+9_BMBR^P5*]WWKK7D%MI[G2,J61OD;#6
M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
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M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
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MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
M      T9Z2.>AJIZ*J:D5323RTU1'S,?R3T\CHI8^:-SV.Y)&JFK55%TX*81
M($?!*^&5.62)[HI&ZM71\;E8]O,U7(OST7BBJA1X+AVFHTY?/V>==?N(5-1R
M:*GQ>OT>O4 N7:JK3E^=Z_8T^X551S::<>'M>7 Y&+YO<!<>V5VB-3FTX^7O
MH5/2S]G'V?N:><Y 5S17'1$^=Z//P]S\\A4$%5HB<5 )_%=-&_2_ZY.WV]"9
M,JUT[4\O9X 'S-=."_.]CC[?FX*?CZO@NJHGE[@!3==<]45.;TIZ?D0E515]
MO'[ODH!0=SN&O-\[T^?W_24]5U/;\[CZO, 6WNM=]+CV=J?F%+UD_:NOLG$]
M=5T]'P@MK=JO7FX]NOEZ"E:N;7F74^ 6TNM3Q=QX<?5\::E*UDO%>/EZP"W5
MSGXNX^GSHGW"F:N3M3Y/+LX' Y=55?<]@% W&;MX^GMX^^4[4O[?5P]OU^7G
M/P%%UTFNOO>KU>P2&=W;Y>KWU4 I.K?Q7S_<^30E$SNWV_/_ %/R@$@J'=OQ
M^Y\I+9%U5/+M.)Z\=/0"52+]+U\/+VB$7BJKZ5/@' ?@  !#53M(^7SN7WDX
MZ^Z0=8_EB1NO%Z_]:G%5]W0A:MZ-C1OG<O9ZDX_#H8O?%5W-IL;V+L^V5/4)
M]^-T,GHEJ*1LG*_]B^(3T]\N%2]&HY>7[_MMD;4=RH]'/5%7D5"4O=Y_,G9Z
M_P TDDC_ #^9.">R261_;Q]E?B,!%KHM.7@OF[4U0@WN]U>WR]9!2.^52!D=
MV^OWD+D6JCTY5T]'K]'G[2#>[M7S)V>7K4@9'=OK7WB7R.U]OX/NES+32_1X
M>7J]T@GKYO3Q4@9'=ON(2^5VOMK[R%S[13?1X>CX_8^(@I%[5]/!/@^ @)'=
MOJ33VR7RKKKZU]Y"Z5HI].7AIV>7J(*1>/L)]T@9%]Y/?)?*[WUU]I/273L\
M'T>'H\O20,B]B>O4E\B^\BKY>X2Z5?A55+JV>'Z/M?=XD%(O!?6O#R]A" D7
MXU4ETJ_&JEU;/#]#AZ/+R[#N-T"RR,ZDK QCW-;-CF5Q2M:JHDD:6F29&/1/
MI-2:)KM/2U%\QVKZ()9&=1.+L8]S6SV?*XYFM71)(TL-;,C'IYVI+$UVGI:A
MB>\:>G@G\.K>Z2:*.22CNVT]32O>U'.IYW[MX32.EB5?H2+2U,C-4_.O5/.=
M@-M&*R_4JIP18*I%T\Z=P]=/8U1#/69R31D.PX   !SM3@B>=?C!RQMU7V>'
MQJ"-C3XD0$U@9V>7P>I 3*%OJ_,3[ISHFB(A/Z6/L\_DH)O WL]7;\*^^<C$
MXZ^@J2DC^CP^[^:"=4[.SR3RU.9$U5$*KHHOH\./EQ^4$]IF=GM?%]PYT]"%
M84,7T>'EZOD!4%,SL]KXON$0B::(A6E!%V</>^% 5%2Q]GEY+\A$(G8B>P5S
M;H?H\/1ZE]Q> *DI8^SR\N/PD0U.Q/:*\MT'T>'O(OP J>CC[/+V/<["*:FJ
MHGF3X$*_MD'T>'H_.Z?"#N%TN1.2\91(C5Y&VNA8YWF1SZN16-5?2J1N]PG]
MG3]$F7S(QJ>Z[[AGX\#ZCF3<;?*J;&[ZO%@V+T\LJ:<K)JF_5<D$:Z?GI64D
MBIZF*#N:3\V.
M
M
M
M
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MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
M_P!=9XM_^\:ZP/X<<X_74?RA=\OWU\[_ ,HKC_;@!_KK/%O_ -XUU@?PXYQ^
MNH_E"[Y?OKYW_E%<?[< /]=9XM_^\:ZP/X<<X_74?RA=\OWU\[_RBN/]N '^
MNL\6_P#WC76!_#CG'ZZC^4+OE^^OG?\ E%<?[< /]=9XM_\ O&NL#^''./UU
M'\H7?+]]?._\HKC_ &X ?ZZSQ;_]XUU@?PXYQ^NH_E"[Y?OKYW_E%<?[< /]
M=9XM_P#O&NL#^''./UU'\H7?+]]?._\ **X_VX ?ZZSQ;_\ >-=8'\..<?KJ
M/Y0N^7[Z^=_Y17'^W #_ %UGBW_[QKK _AQSC]=1_*%WR_?7SO\ RBN/]N *
MNM/CQ>,19:&.WT?B'=24T$3I'-DNV8QW^N599'2.22YWV@N-RF:CG?-1\KD8
MW1K41J(A'0=2N_-/&D4>ZF6N:BJJ+/7I4R<5U76:IBEE<FJ\-7<$[ "]&/?:
M7/' QAZOMO7CE52JTK*/3(=H.G/+F=TQ8U:](\KV>O3$JE6--9]._<BJBO7F
M=K4%+U=]1=&NL.Y=:_YB1_W58L4KDY4TXZ5MAJ$Y^'TOI+Z>(!VQP/[7QXQV
M(3MER'*NGC=2-LBO6FSS8NV6Z![5FI94A<[;"^[<5*1HRG?&BI(C^2=Z\W.D
M;HZWMG77OW0.1U56XK>DUUY+GC<,353F8O*JV>IM+]-&JG;KHY?/HJ =_P#:
M?[;UU.VAU,F^?0YL/N"Q.%8[:?<?<'9UTFL4+>>F9F%'OFD/+.DC^5[G\S'-
M9S(K5>^Y]D\13,8%9^R3;G&KHG_;%LEVNEA5?FM35B5\>1\NCM5T55U1437A
MJH&6O8G[:%X<N>ST5LWPV5ZE]@;A4QQNJ;S3V3$-VL$M\G(SZQ'477&<CM&<
MS<LKE2)8<:D21C5<[NUT8M\,:\0+:BYNCAR/'LOQB5Z(KJAE/07RVQ+HG,CY
MJ.K@N+M%7ARTBZHG'3L ,]72[XO?AF]9DM#;^G?K0V/S+);GW"6_ KWDSMMM
MS*YU0Y(VMH=LMT*7#<^K^[F>V.1T%ND9'(]C7*BO9S=F,-WVV@S]T<6*[@XY
M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
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M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
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M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
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M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
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M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
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M']S+-OP[=^U^S &YZ9 0
M
M
M
M                                  #76\</9!U'==JNHNTTB)!<8)=K
M,SFAB5O)74?U_(<+K9E8JMEFJZ)]TIY)'HU6LI*=FKD5J,QW];N$K#5XKN)2
M1:,J6.Q:\N:W1$GA[^XV69ZMU1SYH754:N5$5$BC;JO!$D5XAXQSHG!?T)_L
MIJYB^O5-?<!@+@J>SCY?*="HY?7Y>M/.20$TCJTX<?+Y5(MLWEVI\H!&MJ^'
M;KZN/#VDU.=)_7\"_#Q0 Y/K:Z>;R]\^N^7U^X@!POK.'TN'LZZ>CV#X=/Z_
M?^%$ (&6K]?N^^<#YO7IY>A.W0 E,]5V\=?+S$')-V^_]WT $DJ*KMX^GVO2
MOLD!+-V\?+XD )%4U';HOEY>7HETDGEZ?6OJ *<KJZ&GBDGJ)HX(8VJY\LKV
MQQL:GYY[W*C6H2NJJHJ>)\T\L<,,:*Y\LKVQQM1.USGN5&M1#CEEB@C?-/)'
M#%&G,^25[6,8GI<YRHU$.&HJ(*6&2HJ9HJ>")JNDFFD;'%&U.U7O>J-:A:*^
M[C4D:NAL\:U<G%%JIFN93-]<;%5DLRZ_\!OH54+87G<&DCYH;.SZW*BJBU,R
M/93-7L56,7EEF5%]*-;ZU*!NV>TD/-#:8_K<J*J+42HYE.WMXQL^;+,J+_P6
M^A5+'Y?O/2V]DM+BU+]\JM.9OWPK&21V^)4U170P\T=35N1W#CW;/.BN0M?6
M72MN4RSUE0^H>NNG,NC8T7\['&U$9&WU(B%M:NZ5EQE6:LJ9)WZKIWBHC&(O
M:D;&Z,C;ZD1"WU7=*RXRK-65#YWZ\$>J(UB*OT8V-T8QJ^A$.I.57"_956NK
M[_<:FXU&KDC25R)!3L<NJQTM,Q&04T2Z?18UJ+IQXJ0Z2)Z50X$D]E/8\D.%
M)=/.J=G!>)0=19^*_-]XY$D7U+Y>HY$E]:+[/#Y#D27V-?4OYI*9;-Q^C[WE
MQ^$^N\]7O_</OO/5[_W#[[WUN^'X5(%]F_K?>^)3]YT]?O?*.\]7O_</WOE]
M?N(<7WE_K%_XJ_*?G>>KW_N#O/5[_P!P_.]];O@^!3D;9OZSWM/>3CJ?BR+Z
MD]D^5E]:)[';\9\K+^:JD;%9NSYGO>]]PXUD]:KZD\D0XUD]E?@.-9?7[GRD
MU@L_9\WWO+4XG2>TAPND]?M(<+I?:]CBI/J6T=GS/>_-.%TGH]U3A=)[7PD.
MZ7VO?52I*2T]GS?>\NPX'2>VOO$.Z3VOA4AWR>7G4JNBM79\WSIYO/\ =0[^
M=''AR[^=8=PI;M9[=)@&TC*A&73=C*;?4I:)HHYEBJ:;#+6KZ2JS6[1+'(BM
MIWQ4,,C%9454#E8UW9_I_P"DK=#?^K@KK?1NQ; VS<M;G%ZI9DH9&,D6.:''
MZ)703Y%7,5CDY8G,IHWMY99XW*U%L[N3O-B>W,$D-;.ETOZLUI\=M\S%J^9T
M:21/N,VDD=KIGH]JHZ1%D<UW-'&]$72[&)X#<;TYDK8_JE BZ25L[%Y%T71S
M:=G!:E_!>S1J*G%R&VCTJ]&.QG1_BCK#M7CW>Y!<J:.'+-Q;\E-79OECV/;+
MW=PND=/ RBM$4S4=#;Z1D%'&K4>K'2J^5^=39#IXVUV"L:VS"K3SW:KA9'?,
MLN:0U.1WQS7-?R55:R*-M-0,D:BQTL#8Z=BHCE:Z17/=CKW%W3RG<:O^LWRL
M[NAA?S4%EHUDBM5 B(YJ/C@5[EGJG->[FGD5TCN96HK6:-3L38L=MF/T_<T$
M/Z(YJ)-52Z.J9U3C\]Z(B-8B]C6HC4]&O$[4/?[GPE[W.UX)[:EJ)Y]->/E\
MI/2%>_SK[2'&2>:;MX^7E[@.I.\73I0Y(ZJR/!HJ:V9!(Y\];9M6T]LN[UU=
M)+3+HD=ON,J^Q#*[B[D<KGK2MWQUE3S5%"C8IUU<^'Z,4R^=6^:.1?\ BJO;
MIVF+;JPZ";+N ^Y9_LU36_',XE?+6W?%5='08[E4SN:2HJ*%41*>Q7ZH=Q7@
MVDJ9%UD[I[GS*.A-PM]=::VIMMSI*B@KZ.5T%51U<3X*B"5O:R2*1$<U=%U3
MTHNJ<"A)(WQ/='(QT;V+HYCT5KFKZ%1>*&$F^V*]8Q>+AC^16NNLM[M-2^CN
M5JN5-+25U%4QZ<T513S-;(QW*J*BZ:.:J*BJBHH(9B<=?0?!*D3540$5&GOK
MH@(Z%NNGEV<$]\$PB;\GM)ZSD8G%5)W3,[.'O>7DH)K"WL\NWY$.0J*DC[/+
MU_=!.8&=GE[GM(<Z)HB(511Q=GE[7R G=.SL^3X_97WCF8G#7TE74479P_-^
M)03^F9V?=\O0<[$[5]HK*@B^CP][X4!4-+'V</+V_5\!$,3M7VBM[?#V</1Z
M%3W.T%24L?9Y)V_+\)$,3M7VBNK=#]'S>ZGO<05+21]GEZO:(EB<-?3\17UM
MA7YO;YO.@*HHX^SVO-V_FD2Q-$3U\?=+A6R#Z/G[/3P]Q 5?;*2:IG@IJ>-\
ML]1+%!#$Q-7R32O;'$QJ>=SGN1-/61;&JY6L3BJJB)IYU^52ZF+6.XWRZ6NR
M6BCFK[K>*^CM5KH*9G-4UMQN%1'245) Q5U?-4U,S6,3SN<@,E&)V&+&,<M%
MCBY56@HXV3O;]&6LDUFK9F\$7EEJI'N37BB*B%5PQI%$QG]2WCZW+Q<OMJIN
MI]/FTU#L;LOMWM91=R]^)XY24UUJ8/[%7Y'6+)<\FN,2JUC^YK[_ %M3+&CM
M7-C>UJJNFH*B.0O(          #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K
M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
M     !USZM-BZ3J/Z>=S]HI6Q-N>1X]-48K52N9$R@S2ROCO.)U<D[VN[FE^
M_E##'4JW174DDK-4YE+=;LX-%N/M[D^(N1B5-QM[Y+5*]6M;!>:)S:RTRN>J
M+R1?7H&-D5-%6)SDUXG!4PI/!)%YW-^:OH>G%J^ZGN T6JRGK[-<:^T76DJ;
M==+76U5NN5!61/@JZ&OH9WTU91U<$B-D@J::HB<Q['(BM<U47B8,YF3T=1/2
M5<,M/54L\M-4T\S71S03PR.BFAD8Y$<R2.1JM<U=%14T*/5%1514T5%T5%\R
MIVH#DCJO7Z/7[&IR-F7S+\2_=/P$4VJ]?L\=/@T0Y4F\E3Y #[^M>OW_ +JG
M[WR>KW% .%U7ZT]?G7W]%/E9E\WR>WKQ4 @I*OMX_&OH7@0[YO7[_#VU]L E
MDU5KKQ\O)2%DF]?EZD *?N=VH[=!)55U7!24[$^=-42LA8G#5$17JU%<NG!$
MXJO82FON-)00/J:VJ@I(&?2EJ)61,3SZ*YZHBN7S(G%?,0]564M#"ZHK*B&E
M@9]*6>1D3$7S)S/5$5RZ<$3BOF/E[V1M5\CFL:G:YRHB>ZOG+)9#N_01=Y!8
M*=UPE15;]<J6O@HVK_5,A^94SHG9Q[I/0JIVVCONZU##SP6*!U=+Q3Z[4M?#
M2-7TLA^943(GH7N_94MO>-RZ*'GALT"UDJ:HE54(^*E3^N9'\V>;3U]W[*E)
M7;*/JS7LM]/]8E35$FFYF0-7TI&BI+)IZU9[)9JZ9%=[Y+WMRKI:C1RN9"JI
M'3Q:JO\ 8X(T;$Q=%TUTYE\ZJ6EN6076]2))<JV6H1%58XT5&01*NO\ 8X(T
M;$U41=-=.94[54MI<+[<[O)SU]7).B*JLA72.&/77^QPL1L;5T737155.U2S
M&0376\OYKC5S5#6JKHX57D@B7TQP,1L3%1.&NG,OG4ES9/7IZE[/D(%LGM^M
M.W\T@VR^W[/!2@*NT=OS?>]PY4D]/#UH<S9/7KZE[3G;+Z_:7Y2G*FT=OS?>
M^X<J2>A=?9\M3E233SJGOH<R2Z>E/?0DD]G[?F>]Y:'WWGI0Y$E]:+\/N<#D
M27UI\"DJELW;\SU=GE[A]=YZW)Y>R?7>>KW_ +A]I(J>E/84@GV;^L][7WEX
MZG[WB?U2^^.\]7O_ '#][WUN\O;./[RI_4+_ ,5?E/SO/6Y?+UJ.\]7O_</Q
M95]:IZU_-.1MF_K/>T^#B?/>>A/+WSY63MXHGPGPLOL>[J1<=F_K/>\M/A/A
M9/6B>QV_&IQK+KYU7WD/A9?6J^\A-(+/V?-][R\WN'&LGLKZU.-TGKT]]3A=
M+Z]/4G%2=TUG[/F^\A<S:/9?=;?O,*/ ]H<&O^>9/5JQ5H+)2<]/;Z=\B1??
M"]W6H=!:;!:HWJB/JZV>GIV*J(YZ*J(M78+M]F^Y]_@QG L:NF37JH5J_5K?
M!SQTL+G(SZW<:V5T=#:Z%CU1'3U,L4+57BY-2G\@R:R8Q;Y;K?[I26F@BU19
MZJ3E=(]&/D2&GB:CIJJI>QBJV*)KY':<$4JZSXQ6W*=E-0TLE1*NG"-O!B*J
M)SR/72.*-->+G*B>LV5.C;P4<!V[=:\\ZJ*RU[HYE$L%;1[9VI\[]M;#,FLC
M8\BJ9HJ6MSNMB=R<\#F4UJ:Y'QOBK8U;(9?NGWPZL8Q1:+*-[:BCS3(&+'4T
M^'4+I'8A;9$U>UMVFD9#49+41KR\T:MAHD5',<RI8J..E&Y74W=+HE1:<#CF
MLM ])(I;[4M9]^:ICFHQRT,2.DBM3':NY7ZOJ-.5S5A<BH7YQK;.AMZ1U-Y[
MNMJ4T<VD9JM'$O;I*JHCJIR+YE1&=J:.3B9TZ*BH+50TEKM5%26VV6^FAHZ&
M@H*:&CH:*CIHVQ4])1TM.R."FI:>)B-8QC6M:U$1$1#)G2TM+0TU/145-!1T
M=)#'3TM)2PQT]-34\+$CB@IX(FLBAAB8U&M:U$:U$T1#J)6ULU3--45,TM14
M3R/FGGGD?+--+(Y7R2RRO5SY))'JJN<JJKE4NDUK6-:QC6L8QJ-:QJ(UK6M3
M1&M:FB(U$[$0^GO]SX3[<[7@GMJ26>?37CY?*?1"O?YU]I#C)/--V\?+R]P$
M,]_G7M\R>7F!*IINWB"&>_3UJOO'&YVO!/;4E$\^NO'R^4%I]R-JL7W(I.6Y
M0_4KS Q6T5^HXV?7:?MY8:A%5K:^D1RZK%(O#CR.8JJI*;A:Z:XL_1$Y)D31
MD[$3G;Z$<G#G9KYE]K0ZP[_]-NW._MKY,BH_O3E-)$K+/FEJ@B2\4*(CN2FK
M$7NV7BUHY=5IYG<%U6-\;E5P,?6=;8Y1MY5K#>*3O[?+*YE%>J-'RVZL1%U8
MU9.5'4M2K.*Q2(UW!>7F:G,4#7VRJM[])F:QJJHR9FJQO]''\Z[3S+Q,%V]/
M3IN1L7=G4^56SZY8:BHDAL^76ILD]BN;4=^ALDEY>>V7!T:HKJ:H1C]4=R+(
MQO.HHF-OO)I[:DO+.P,[/S?4GN F,+?-[7QK[IS-31$]U2?4L?9Y?#Z/B!-X
M&]GEV]O;YT0Y&)J[V./E[94E)'V</N?F? "<T[.SR]?%#F3CP*JHHNSA[7Q?
M(">T[.S\SRU34B$X<"KZ&+L]K\Q?6"H*9G9]WR])SHFB(A6E!#]'AZ/)%]6H
M*BI8^SRX_#V_"1")HB(5S;X?H\/1YOC0%24L?9P\O1Z>SX"(:FB(GEK^:5W;
M8?H]OF[%3X^(*FI(^SA]W\TBFIV)[7M%P+9#]'@OF\[0531Q]G#R^[\)$L35
M?8X_(7#MD'T>&O9QXK\@.R^PF(K=LB=?ZF)5M^/M26%R_0ENTR<M(Q.SF^K1
M*^5=/HO1FO!Q.+;#SRK*J?-C[/6]>SW$XF8WPG.GN3<3>>;=J^6^23$-H(6U
MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
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MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
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MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
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MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
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M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
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M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
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M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
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MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
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MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
MZ EL           #U;OL@VSE7MAX/./YE64LE.[J"ZB-ZMWJ1TS9&R3V^U38
MULA3RM2555*=\NSDKH^5$8J.5Z(JN5SLU_0G8'V?8:EKY&*Q<HRK(;ZQ7(J*
MZ*%U'CK')S?G5=8%5--$XZ^?50-HH[D@      &F%]MH_$%Z4?ROZ?\ B8W1
M,?WB'?N983^';?VOWD \T0Q$           'I=_8E_Q!>J[\K^H_B8VN,N_A
MX_N99M^';OVOV8 W/3("               =;>K#JZZ>.B#9/*>H/J=W,L.U
M^V.*0Z3W2[RNEN=]N\L4TMNQ7#[!2MFO.6Y=>%@>E);J"&>IE1CW\J11R/92
M6;YUBNW6/5N4YC>*:S6>B;\Z:=RNFJ9W-<L5%04K$=45U=4<J\D437/=HJZ:
M(JH!YCGC%?:<NJ;Q#ILLV1Z<Y<BZ6^CNO=46NHQVSW)M'O+O#9W(^GE?NSF=
MDJG_ 'GQV[4ZKWF+V:=MO6*9\%PJKJU(W1X>]^NL+,]TW5V.XFZKPS I%="Z
MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
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MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
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M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
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MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
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M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
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MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
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MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
M            0E;;Z&XPK3U])3UD*Z_H=1"R5J*J:<S>=%Y'>M-%0_%1%X*B
M+[)364X;B><6Q]FS'&[)D]K?S*M#?+;27*!CW)IWL+:J*1:>=$^C)&K7M5-4
M5%!;>[;38_7*Z2W355HF<JKI&[ZY2HJ]J]Q4/29./8C96M3T'"^!KDX*K?8X
MI[BG1S<?PXME\L6:KPNY9!MO<)'/<V&CF7),?1\B\SGNM5XJ&W)-'?1;%<(8
MVHNB-TY=!;2Z;1Y12<SJ!]%=6<51(ITIJA4]<57W<2*J>B1Q#.II$[-'>PNB
M^_HAT5SWPW-_<=6:?$ZC%-P:-J.6*.VW5MAO#FHJZ][0Y$E#;V.5J:Z1ULJJ
MO#V1;VXXWD5LU2NLMSIF)VROHYE@7THVH8QT+M//HY3B6-[>UCD]I=/=[#IO
MFFQN]&".D_9;M;G=EAC546OJ,;NDMJ>J(G,D-XI:>>USJU%37DF=RZIZ04R]
M^OJ1/?.!SM>">VI8^>?MX^7E[@(9[_.O9YD\O.<9*9INWB"&>_SK[2 E,\_;
MQ\OC500SW^=>WS)Y>8^'.TX)[:^7G)1--V\?+R]T$,]^GK5?>.(E,TW;Q\OE
M^ '""6O>KUU7L\R _6M<]R-:U7.<J(UK457*J]B(B:JJJ#]AAFJ)8X*>*2>>
M5[8XH86.EEE>Y=&LCC8CGO>Y>Q$154%6VW LRNZM^HXW=7M?IRRSTSJ&G=KZ
M*FN^K4ZIZ5YN!S,IYG_1B>OK5.5/==HAV'P?I&ZF=Q7PIBFR6X%3!4*Q(+C=
MK'-BUFEY]='1WS*G66SN8FG%R3Z-X:JFJ N59]@LDJU:^\7*W6F)=-8X>\N5
M6WSJCHV?5Z5/0BI,[V/3%,M\J\7N:Q/0GSG>]HGOG>+;CPA=[,@=!4[DYOA>
MW=#)RK)1VU*S-LBBX*KV2TE*MGL#=>"-='<YN.JJW1$YA=ZQ;+X59^22JI9[
MY4MT59+I+S4Z/3MY**!(:=T:_P!3*DOLD9'0P,XJBR+Z7+P_XJ:)[NID:VG\
M,/I@VX^JUN06.[;JWR#NI'5F=U_>6=E0SB]:?%[0RW6>6DD7_M5<VOT3\\H+
MJ4]-3TD,=/200TU/$WEB@IXF0PQM_J8XHVM8QOJ1"+1$1$1$1$3L1$T1/81#
MO]9[+9L=MM)9L?M-LL5GH(DAH;39Z"EMEMHH4552*DH:**"EIHD5?HL8B YC
M])F                                #S@_MO/XT_0_^3_N%_&+ 8F_$
M3_PTVZ_!>Z?JLT T@S'6           >EW]B7_$%ZKOROZC^)C:XR[^'C^YE
MFWX=N_:_9@#<],@(                  !CLZO_ !9O#JZ$J6Z-ZF>K#:?"
M<IM4<RR[8VB^MSO=Z:>*-[HJ9FU>"QY%G-+]:E9W3*BJH:>C;(OZ)-&U'.2U
M6=[W[4[;,F3+\WLENK8$=S6>"I2Y7USFM548EEMJ55Q9SJG*CGQLC1>UR=H!
MHY>*9]L"WKWXM&3[,>'-A^0=->WEUCK;1<NH/,*BADZ@;]:YV/I978+:;/4U
M^.[.?687OY:^.LN]\8BQS4M1;*ABF.7>?KOR')8*S']J*"JQ&U3))!-E->Z-
M<HJ87(K'+;8('RTMAYVJNDB23U*<',?"Y #2WNUVNM_NMSOM]N=PO5[O5PK+
MM>+Q=JRIN-UNUUN-3)67"YW.X5DDU77W"OJYGRS32O?)+(]7.57*JF/N>>:I
MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
M   #>@^RE>!S7;BY9B?BC]56)=QMOA5T=<ND';^_TCTGSC/;-6-CCW\NU!4Q
M=VW#\&N$$C,8:Y%EK[["MQ;W4%OI'U^1_HHZ<I+K74.\N:4/+:;=,LN"6NI8
MJ.N5SIY-$R:>)[=/J%ME:J4:+QEJ6]ZG*V)BR@>BP960          #3"^VT
M?B"]*/Y7]/\ Q,;HF/[Q#OW,L)_#MO[7[R >:(8B           #TN_L2_X@
MO5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!         -&[[7UXME3M;@%K
M\+_8G*_JF=;M6.W9CU5W>R5JMN&-[3UDJ5.'[13U5*JR4%PW/J*;[Y7BG[R*
MH_8]!30RLDHKRY'8Y.NS?%]FMD.SF-UO=W*^4T5?FL]/)I+2621>>@L3GLXQ
M2WAS.^G;JUWU5K&JBQU"Z@><P8H@            #,EX4'@?]8_BSY>^?:FS
MT^V?3YCMX9:MP^I;/Z"L3!+#51MBJ*W'L.M<#Z:Y[F9Y%12)(EKM[XZ>E62'
M[XUMOCJ(97W]V2Z=,^WOKE=9*=MGQ:EG2&ZY?<XI/O;3/1$=)2T$+59->+DV
M-=>YB5&,U;WLD2.:Y0/2'\/7[.?X9OA_6W'[Y;]G;7U%;Y6RGIY:_?+J$MEK
MSJ\1WEB02RU^#8-74\VW^W,=-6QO6AFH*!]YIX']U-<JGB]V6?:WI2V@VOAI
M:F*PPY7D<+&K+D>4PPW*=*A$:KI;=;9&NM=I1DB+W;HXUJ&-7E=,_M4#.ZQC
M(V-CC:UC&-:QC&-1K&,:B-:UK6HB-:U$T1$X(AV31$1$1$1$1-$1."(B=B(G
MF1 #Z/T     ZR]3G1CTI=9V'/P/JHZ?MK=\\<;#+#;V9[BENNE[QY9UUEJL
M0RQD<&5X7<GIJBU=IK:*IY7.;WFCG(M'YAM_A.X% MMS3%[-D=(C7-B2YT44
MU12\WTGT%:B-K;?*O]7!)&_35->*@&B/XN7V0;*=M;7DN_'A<W/(MR\5ML-7
M><@Z4,TN;;KN3:J&!LE15+LQF<[8';@PTL*?H5ANO+?'LC5M/6W.JDCIC&QO
MGT)UMHAJ\EV:FJ[O10M?456$W";O[O!&U%>_]C]>Y&K=&L;]&FGTJ51-&23/
M5& &C3=K3=;!=;G8K[;+A9;W9;A66F\6>[4=3;KK:;K;JF2CN%LN=OK(X:N@
MN%!5POBFAE8R2*1BM<B.14,<<\$U---35,,M/44\LD$\$\;XIH)HGK'+#-%(
MC7Q2Q/:K7-<B*U4T4 EYQ           &=K[/IXJ]S\+GKDQR\YC>JB#I=W_
M *BP;7=25J>Z62@LUEFN4L>(;O1TS)$3[Z;2W>ZS54KVLFEDL57<Z>*-TU1$
MK>R?2[O5-LUN-25%?4/;AN3NIK-EL"JY8J>G=,J4-]1B+_9K'/,Y[E1'.6F?
M,QJ*YR: >PM25=+7TM-74-33UM#6T\-71UE)-'4TM72U,;9J>IIJB%SX9Z>>
M%Z/8]BJUS514544SQL>R5C)8GLDCD8U\<C'(]CV/1',>Q[55KF.:NJ*G!4 (
M@^@      #1\^VL=8,V&=//3%T1XW=)J>Y;VYU=][=RZ>DDY'.P':B!EDPRR
MW5KG?HUMR;.\HEN$36M54J<7:KG-1$23'1XA.>.M^+8=MW23.;-D-RGR*[L8
MNBK;+(U*:WT\Z*OSH:RY5CI6Z)].C3BGG \XHQ/           %V=A]D-RNI
M7>?;#8#9W'9LKW0W@S;'\ P>PPR,@96W_([A#;Z1];6RZ4]LM-%WJU%;63*V
MGHZ2*2>5S8XW.2>8UCMWR[(+/C%AI75MYOUQI;9;J9JHU)*JKE;$Q9)'?,A@
MCYN:21VC8V-5SE1$50#V@/"O\-C9OPM.DC!^F_:ZFH[KD_U>ER;>S=#ZFVFO
M&[>[5=04T62976JY'5%)8Z62)**R6]SWI;;3!#$YTL_?U$^P'LOM'8-F<&MV
M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
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M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
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MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
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M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
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MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
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MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
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M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
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M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
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M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
M                                           !DB\,?Q2>I[PK-^Z3
M>7I^R#Z[CEZDMEMW>V;O]54.V^W?Q"BKF54EEOU&ULZ6G(*2)9?O5?:6/[X6
MF6:3D62GFJJ6HNUL]O-F.RV3,O\ B]5WE)4+#%?;!5/<MKOM!'(CUIZF-$=W
M%4QO-W%2Q.]@5RZ:M<]C@/7Y\/?K^Z?O$HZ9\+ZFNGJ_MK+%?X6VW,<+N-50
MNS/:G/:2G@EO^WF=VZCGF^]U^M#YVOBD_L%PH98*RF=)35$3W9V=K=S\7W<Q
M"WYABU4DE-5-2*OM\KXUN%DN;&-6JM5RBC<[NJF!7(J+]&6-S9&*K'-50.[I
M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
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MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
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M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
M               ,+GVB+!V[A>"SU_V%T$E2E!M)9,X2.*AEN#FNVRW,P3<E
MDZP0RQ/CCI7XFDKYU564K&+,YKFQJU>OO53;DNG3YN?3*Q7]U8Z>XZ)&Z546
MSWBVW9'\K5:J(Q:+F5W8Q$YEU1- #QJC 2           5'AV3W#"LNQ7,K2
M^2.Z8EDECR>VOAJ)J25EPL-SI;K1OBJZ9S*BED;44C5;)&J/8O%JHJ(1=!62
MVZOHKA JI-0U=-60JU[F*DM-,R>-4>Q4>Q>=B<4XIY@#WQ[9<J&\VVWWBV5#
M:NVW6AI+E;ZIC9&,J:&NIXZJDJ&LE8R5K9H)6N1'-1R(O%$4V:89HZB&*>%R
M/AGC9-$]$5$?'(U'L<B.1%1'-<B\4U (XY     #SM?M<'@UW/#<UN/BH].V
M+S5>#9S56JU]7N+6.W(C,*S=[:&Q8UOA%3T3$C9CN>*V"W9!(K&+3WY(*R1\
M[[K4.I\5?7)L%-07"7>C%:-S[=<GPPYW14T7"WW%4CIJ3(T9&FB4EST;%5+H
MG)4\LBJY9W*P#11,;8          !56#YSF>V688SN%MUE>18+G>&7JWY'B.
M98E>*_'\FQJ_VJH95VV\V.]VN>EN-KN5#4QM?%-#(Q[')JBD;;;E<+/7T=UM
M-;5VVY6^HBJZ&OH9Y:6LHZF%R/BJ*:HA<R6&:-Z:HYJHJ* ;\?A4_;$[(VSX
MWLQXI^-7*FNU$VCM-OZMMKL=6Y45TIT1(OKV\VU5C@;<:"NIV,YIKMBL%8E6
MY[6_>:!625$N3397KTIT@I,?WHHYF3QI'!%G%FI>^CF;]'O+_9:=J2Q2,1-7
M3T39.=51/J[=%<X#=IZ>.J_IFZM,0BSSIFWYVIWSQ5T-/+4W+;3-K#E,EH?5
M1MECHLCMEMK)KMB]V8UZ))17&"EJX7?-DC:Y%0R'XKFV(9Q0-N>(9+9,DHE:
MQSYK1<::M6!7HBI'5PQ2.GHYT1>,<K62-7@J(H!V"*H       ,3'7%XX7AF
M>'Y0WFFWRZF,/OFY%ICJF,V-V=JJ3=;>2KN5,QLC;-78MC%9-08-653%7N9L
MHKK#02*U4^L(O!;(;C=1>T&U\=0S(\OH*F[0(]$QRPO9>[_),Q$7ZO)14<CH
MK=(]/HNK)*:-=/I 'G5^,?\ :0>J;Q0H[OLS@%#6=-/1XZL5';4X_?):W-MU
M(*=S4I*S>O,Z-E%'=[>LC%J(L=H(H+-32/:E2MRGIZ>L;BHW\ZL\SWD2?'[9
M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
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M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
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MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
M !L[_9$LB99/&6P&VON$U$[+]AM^,=BIHDJ%9=GTV-4>6+;ZA86/C;#''B[J
MI%E5L?>4S41>=6-7N'T+U24^_P!;(5E=']>QK):5&)S:3JRCCK>Z?RHJ<J)1
M\_SM$U8GGT /6!,VH    !YP?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6:
M :09CK           /78^RKV-]I\#KI)KW5+9TR?(NI"^1Q-C5BT;*?J7W:Q
MI:9[E>Y)G.?CSIN9$:B)*C=/FZKG/Z+*98.G/!Y5>COKE7EM2B::=VC<OOE'
MR*NJ\RJM+S:\/I:>8 V(#M2                   : ?VYS_P"5W_TV?_A'
M,8?B/?\ H:_]8?\ YC &@&8PP          #U>OLAO\ L;<+_* WV_5RUF;+
MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
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ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
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M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
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ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
M^^=Z/]%H_P!7CN;_ ([8)_QL@_68 ?T)CK[_ )UW1_\ WSO1_HM'^KQW-_QV
MP3_C9!^LP _H3'7W_.NZ/_[YWH_T6C_5X[F_X[8)_P ;(/UF ']"8Z^_YUW1
M_P#WSO1_HM'^KQW-_P =L$_XV0?K, /Z$QU]_P Z[H__ +YWH_T6C_5X[F_X
M[8)_QL@_68 ?T)CK[_G7='_]\[T?Z+1_J\=S?\=L$_XV0?K, /Z$QU]_SKNC
M_P#OG>C_ $6C_5X[F_X[8)_QL@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';
M!/\ C9!^LP _H3'7W_.NZ/\ ^^=Z/]%H_P!7CN;_ ([8)_QL@_68 ?T)CK[_
M )UW1_\ WSO1_HM'^KQW-_QVP3_C9!^LP _H3'7W_.NZ/_[YWH_T6C_5X[F_
MX[8)_P ;(/UF ,LO@H_9C^J'PT>OO >KK>;?G8'/\4P7"=S+%2XYMG4[C+D<
MU[SG$:[$J2J>S*,$L=KEMM+1W:H=*GUEDB/Y%:CM%:M[NGKH^S+:'<ZV9S?\
MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
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MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
M)X1(                    !Y:'VQ;J6CW>\46P;&6FX_6+%TJ;#X5A]SH&
MO=)#2[C;G/J=U\EJXW<(TDJ<+R+&*>1K=5:^C5'+S:M;ADZ]<O2^[RTN.02\
MU-A6-6Z@FC1=6LNMX5][JWIYD5]OJZ-JHG8L?'T(!J;'2(           WKO
ML1?3B^Z[Q]:W5M<:)S(,'VYP3I\Q*ME8KH:RMW)R.3</.64J\6,JK+2;8V%)
M'<'I'<T1J\KGH9)/#MQ-9[_N%G$L:HVW6FVXM0R*FK9)+O5K=;BC%[$?3LL]
M-KY])O6H!Z)1E4   ,2'CI]8=SZ&O"OZMM\<6NDEHW&JL#AVHVLKJ2IEI+M0
M;@;RW:@VWM.16.HAFIW17C!:'(JK(87<Z<OWH5>5ZHD;[&]2.>S;<;+YQD=%
M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
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M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
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M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
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MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
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MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
MPTVZ_!>Z?JLT T@S'6           >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<
M?^6'[?,H ,_QV>                   - /[<Y_\KO_ *;/_P (YC#\1[_T
M-?\ K#_\Q@#0#,88          !ZO7V0W_8VX7^4!OM^KEK,V70K^X';_P *
M,D_[X@ -GX[C   '2;Q%>M[;SPZNC?>[JYW(IW76V[78RC\:Q2&?ZM69UN'D
M%93X]M]A%+.C)I*5N199<J6&JJFQR_4*'OZMS',@<A;S=;<6U;4X#D6<W9JS
M0V:CUHZ)KN22Y76JD;2VNW,=HY6)5ULK&O>B.[J/F>J*C5 -##P=/"LWD\?_
M *FMSO%-\3;)KYDVP4NXE?0P8M!4W>P/WPRRQQP.@VWPIT56E9A73YM71U%/
M;Y74-1WT\D2VVFF2>.X55/C0V$V6O_4]F%XWGW@K*FLQAUUEC;1M?/3+D==3
M(U6VBWJU_>6_%K+&YD3EC=S.5O<L=S)*]@&0?$_M@_0CTU69FQ.T?AS;E[<;
M?;7UEQP_'<0V^R':G%,2M=+9*ZHH'_>FQVJW4M)2QU,L#I7+R=Y(]ZOD5SU<
MY;I477AMMB$"8U8]J+O:;79I):"EH+7562BH864\KHE[BFAA8QB/<U57AJJK
MJNJ@%SL.^VV=$MPO4%+G?2%U0XM8I'1MFN^,W;:O-*^F5\C&ND=9KAE&$QRP
MQ1JKE5M6KUTT1JZDXH/$/V\EJ&LN>"9E14RJB.GHY[+<)6:JB*JT\M9;D5J)
MQX/U]0!<'KN\+GPYOM$_21>.NKPU;O@>-=4D<EX6CS>QV;]@<6XV>V2@IKC>
M=ENIK#I8*!;'GE5!7TWU;(:B#Z_3I4TE4ZHK[1+%SS3<K9K:CJKP:?<G:*>V
MT>9HL_=W&G@^]K;M<Z>)DU1C^7T"MC^K7-[96<E4YO>MYV/5TL"MU Q\>$!X
MI?4KOQX?OB;>#MU#KN!=NL[9#H?ZP,;Z5TN3K@S>'(9L0VCS? [KT^5BO?#D
M%=NIM1E\M(VQ-:^:Y2VWZQ O=LL['26NV(WFR[)=K]X-A<J^^D^X&.[=9Y28
M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
M      -B7P&O :W/\5[<^+<O<N+(-M^A[;?((J?<;<:GB=07K=&]4#H:FHVF
MVFJ*F%\-1>*B%[$O%X1DM+8:65%5)*N2GIY.U733TTWC>R\-N]W;56G;FTU3
M6W:[-:L51>:B)6O=8[&Y[5:ZH<U4[^?1S*9CO.]6,4#UF=L=LMOME]O<,VGV
MHP^PX!MMMYCMLQ/"<+QB@BMEAQO';-3,I+=:[;1PHC8X8(8TU<Y722/5SWN<
M]SG+F\L]GM>/VJWV2R4%-:[1:J2&AMUOHXFPTU)2T[$9%#%&W@C6M3MXJJ\5
M5555 *Z)D         :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$
M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
M      8'/%+^T(^'YX9[+_MKF.0R=0W47%1U%)/TX;255IO%SLT]13O:VCW>
MRRK=48KMG1SL>U)J.K^N7U:>=DT5JGA=SG6K>;JDVOVA2JM%?5+E.5MC<QV)
MV-\%1-3N<U4[N^USU=16B-R*G-&_O*GD<CDA<U=0#R9^J/>'"M_M_MT-XMN]
MB-O>F?#L_P FJK_9=DMK*O(:S!L%AJF1]_0V27)+A754;:RJ:^IEBI64-L@F
MF?'04-#1MAI(<(>9WZWY/D]YOUJQJUXA07.L?54^.V5]5);;:UZ)S1T[JN61
MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
M           !D:\,OPO^IOQ3^H"V[)]/V.R4M@M=1:Z[=[>.]452[;W9G#JZ
M>=CL@RBMB="E=>*^*BJ&6BRP2)77>IB<R/NX(JFII[L;0;.9AO1E$./8O2JR
MEA?#)?;_ %$;UM>/T$CG(M562)R]Y/*V-R04[5[R=[51-&H][0/7_P##U\/_
M *?_  U>F;"^F3I[L?U:Q6"-;GF.:W.EM[,TW5SRNAA;?MP,[N-!34S;C?+F
MZ%D4+-.YM]!#!1TZ-IZ>-J9V]K=L,8VCP^WX?BU-R4U*G?5]QF9$EPO5SD:U
M*FZ7*6)C$EJ9E:C6I]&*)K8VZ-:B '=\N*           ><']MY_&GZ'_P G
M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
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MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
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M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
M                                       -U;[&GX@M?M;U/[F>'KFM
MZ<FWW4K9;MNCM%1U4_Z%:-]=N;$VKR>W6Z%[XXHF[@;36BIFJY%5[UGQ:BCC
M9^BR.,A/0'NC+9LQO&UMQJ%^]>74\]YL4;W?-@R2TTR/K(HFJJ-:ETLD#W/7
MBO-11HB<54 ]*(RW@      '6WJSZ1^GWKAV,S#ITZFMN[3N3M;F<,;JNU5_
M>4MSLEYI&R_>C+,1OM(Z*ZXOEUBEF<^CN%')'/&CWQN5T,LL;Z2SC!L7W&QN
MOQ3,+5!=[-<&HKX9=634U1&CNXKJ&I8K9J*NIE<JQRQJCDU5%U:KD4#RHO&>
M^S[]3'A3Y/<=P\<AOF^_1I>+H]F*[YV>SNDNN!I657=VW$]\[1:XG08G?&K+
M'!3WAC(['>)',[EU/4R.H(<*W4!TO9?LI62W6D;4Y+@$\RI19)! JS6SO'Z1
M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
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M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
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M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
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M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
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M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
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M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
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MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
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M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
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MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
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M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
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MR)NLU+(Y7L5%5JR1\LC@,4Y90
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M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
M%-JMR<Y=$F)8-D]]BF71E;16BL6V)ZY;K+'';8&KKVOE:@!L8])?V-/Q#=W9
MK3=^J7<O9WI(Q2I;%)<[-'<4WSW:HD=J]8(\:P6XT&VKW<J<KGKF"K&YR+W;
M]%0[7X/T";IWUT$^9W>PX/1/Y5FITE_9)?(T7BK4H[;+':%73@J_7^"KV* ;
M771#]EE\*KI FL^49EMQ>NKS<^VN@JOV5=2=5;\EPVEKV) Z7[S[-VBAM6V[
M[:L\"/ACO='?JN%7.1*IR*=U]NNC'97!'4];<+349U>85:_Z[EKXJN@9*G*K
MOJ]@@CAM*P\S=6I4QU+V_P!6H!L86FTVJPVRWV2QVRWV6S6FCI[=:K1::*FM
MULMEOI(FP4E#;Z"CCAI:*CI86(R.*-C6,:B(B(B':Z"""FABIZ:&*GIX(V10
MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
M(*YI_P!D7^;3O=?T7]A/WR[WO-5UY?\ -UP[SF^EZ_I &LWU)-^R*NEG;M5+
MXJT#W32-IINGZ# JJU0JL<J0RSTW5?44=UJ+;'+RJ^-LL52]$1$>W57)U!RU
M.AA5>EE7>IJJY48[%VVQ\+>#N57,S9\<SX4735.9KU]* &,7.L3\#.X+/_FS
MW\\6#$6N;5I3)G72+T@;B+$Y[(4H5G6P=;>UR5#:9[9%E1J1+,CFHU8N55?9
MZY473A+S?>C)M[:'5'\GWRP;!+KRJJ-[OF^J[B6;G1BZ\VG+S:IIRZ<0.JV5
MX;T(4;ITP;J0ZM\B8VHB;3.ROHHV<PQTM*L6L\T[+1U_9XE/41S_ #61-=*U
M[/G+(U?FE%UUOVUC5WWMRS.:M$>U&+7;>V"WJYG+\YSD@W.N?*]'<$1-45..
MJ=@!9.ZVK9V&KJF63.]R[A0L_P#M*INNT^+6:KJ/T)JK]:HJ3>B^PT?Z,JM^
M943_ #41W:O*E/30V!KWI3W*\2QI_8WS6.B@>[@GTXV9#4MC^=PX.=PX^H M
MH2<     NG9[1LG/6M9?]P=T[9;^[D5U59]G<2OE:DJ(G=,;05N^>/0.C>OT
MG?645OF:XG4$&.ND1*FZ7J*+1=7P6&AJ)-?,B1R9)2M5%\Z\_#T* 7^P["/#
MNJNX?G_4]UHV']!CDJJ?#NA/8[+-:A)F)+205EZ\1?"^6%U/S*VH= KFOT18
M53B5/06[:M_*MTS'<&F^:BO;0;;8Y7?.YDU8V2HW6M^C59KH]6ZZ_G0#N+M_
M8OL]MM?3KNINEXRV91MYOK;=O]A>B/;1\^L\KF?5Y,CZD-V6TO+2JQB\S9M9
M&N?P1R,;7MKINEN)6??J\[_7!J:\Z6O&=N[0KOG.5.1:O+;VC/F:)Q1W%%7S
MZ(!FRZ2?Z&']8M?^<O\ E:??+O+?]6_E;?Y\OJ_U_P"LS]U]]/Y)7_WJ=WWG
M=_6/K?\ X-[KE[SYG?G8;!_]7_SP_??]G'>ZQ<G[./V1\G>\[M.^_8/_ '%I
MKIS]Y^@Z::\.8 VP>AO^C?\ /9/Y$_\ JR/V7_6(_O-]1_S._P"?+O\ O_[G
MT_SE?_[I_P#MG^P][\WFTY/,=VMN/Y)FM/\ YO/\S_U[G3ZOW?WA_9'S\WS/
M_NO_ /?!]/Z.OG[ #/7#W7=1=QW?<=VSN>YY>Z[KE3N^ZY/F=WR:<NG#3L.S
M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831491440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Apr. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,115,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831976096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">329.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,810.7<span></span>
</td>
<td class="nump">2,726.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">384.6<span></span>
</td>
<td class="nump">313.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">423.4<span></span>
</td>
<td class="nump">437.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">499.1<span></span>
</td>
<td class="nump">497.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">448.5<span></span>
</td>
<td class="nump">88.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,786.4<span></span>
</td>
<td class="nump">1,348.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,024.3<span></span>
</td>
<td class="nump">1,378.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(37.6)<span></span>
</td>
<td class="num">(52.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">986.7<span></span>
</td>
<td class="nump">1,325.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">239.2<span></span>
</td>
<td class="nump">356.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">747.5<span></span>
</td>
<td class="nump">969.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="nump">$ 4.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816884480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(23.8)<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">742.3<span></span>
</td>
<td class="nump">935.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 742.2<span></span>
</td>
<td class="nump">$ 933.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832197536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 924.0<span></span>
</td>
<td class="nump">$ 2,326.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,956.2<span></span>
</td>
<td class="nump">2,568.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,501.5<span></span>
</td>
<td class="nump">1,441.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">324.5<span></span>
</td>
<td class="nump">300.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">921.6<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,231.9<span></span>
</td>
<td class="nump">1,093.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,859.7<span></span>
</td>
<td class="nump">8,732.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">2,825.2<span></span>
</td>
<td class="nump">2,829.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,610.9<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,103.9<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,611.7<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,184.5<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">21,195.9<span></span>
</td>
<td class="nump">22,876.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">561.5<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">231.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">316.4<span></span>
</td>
<td class="nump">279.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,044.6<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,992.5<span></span>
</td>
<td class="nump">3,419.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">5,952.7<span></span>
</td>
<td class="nump">6,512.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">94.5<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">688.8<span></span>
</td>
<td class="nump">722.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,728.5<span></span>
</td>
<td class="nump">10,748.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(325.2)<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">14,781.2<span></span>
</td>
<td class="nump">15,071.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">11,479.0<span></span>
</td>
<td class="nump">12,140.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">11,467.4<span></span>
</td>
<td class="nump">12,128.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 21,195.9<span></span>
</td>
<td class="nump">$ 22,876.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804401488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832760016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 747.5<span></span>
</td>
<td class="nump">$ 969.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">512.0<span></span>
</td>
<td class="nump">149.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">37.0<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">76.1<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">18.1<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(195.7)<span></span>
</td>
<td class="num">(160.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(46.2)<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(684.2)<span></span>
</td>
<td class="num">(136.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(195.1)<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(34.3)<span></span>
</td>
<td class="num">(36.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">235.2<span></span>
</td>
<td class="nump">1,015.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">1,884.3<span></span>
</td>
<td class="nump">1,181.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,256.7)<span></span>
</td>
<td class="num">(1,914.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(210.0)<span></span>
</td>
<td class="num">(126.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(855.2)<span></span>
</td>
<td class="num">(28.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(744.2)<span></span>
</td>
<td class="num">(1,203.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(583.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(25.5)<span></span>
</td>
<td class="num">(29.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">10.4<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(901.4)<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,410.4)<span></span>
</td>
<td class="num">(192.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,326.5<span></span>
</td>
<td class="nump">1,308.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 924.0<span></span>
</td>
<td class="nump">$ 1,130.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822488016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method and continue to evaluate the potential impact that this standard may have on our financial position, results of operations and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 the FASB issued the following new standards, which we adopted on January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. As of March 31, 2017, the adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. This new standard will be effective for us on January 1, 2020; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804251792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off Hemophilia Spin Off<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Hemophilia Spin Off</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date) and are expected to terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the distribution date, with the exception of the manufacturing and supply agreement which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ and our consent. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totalling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. During the first quarter of 2017, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues in relation to these services which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as cost of sales in relation to these services during the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we have continued to distribute ALPROLIX and ELOCTATE on behalf of Bioverativ and expect to do so until Bioverativ obtains appropriate regulatory authorizations in certain countries, including the United States (U.S.) and Canada. Under this arrangement, we are distributing these products as an agent of Bioverativ and will also provide related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations do not reflect recognition of activity or balances related to these transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. In the first quarter of 2017 these amounts were not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our condensed consolidated statements of income for the three months ended March 31, 2017 and 2016 totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$182.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822459328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for discounts and allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">131.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">568.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">707.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(62.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(231.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(64.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(267.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(337.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">552.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811503504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">158.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">644.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ were related to work in process and finished goods inventory, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822464400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(526.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,648.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,887.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(874.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,012.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,153.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,049.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,103.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$448.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$88.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. Amortization of acquired intangible assets for the three months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$353.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of impairment and amortization charges related to our U.S. and rest of world licenses to Forward Pharma's intellectual property related to TECFIDERA, as further discussed below. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of March 31, 2017 also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$349.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,418.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S (Forward Pharma) and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this agreement, representing the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We paid the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in February 2017 and recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into the agreement, through December 2020, the last month before royalty payments could first commence pursuant to the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. On March 31, 2017, the U.S. intellectual property dispute was decided in our favor. Forward Pharma has announced that it intends to appeal this decision. For additional information related to these disputes, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continued to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">346.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">425.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">412.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">239.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">254.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2016 Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811494240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,502.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">556.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,528.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,483.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,032.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">993.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,812.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,890.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,845.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,496.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$254.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822465984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">519.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,288.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,289.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,213.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,073.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,076.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,956.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,561.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,565.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,884.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,181.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822506768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,215.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,446.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$332.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. A net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts was recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to a net gain of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41641-113959<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624258-113959<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708775-113959<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5708773-113959<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5580258-113959<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624181-113959<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822464944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,438.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,439.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), where we are building a biologics manufacturing facility over the next several years. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$609.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$216.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804301520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> decreased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$661.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily driven by an adjustment to retained earnings of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$852.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the spin-off of our hemophilia business, as described in Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements and share repurchases of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$583.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below. These decrease were partially offset by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$747.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. All share repurchases under this authorization will be retired. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this program. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock (2011 Share Repurchase Program). During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to complete this program. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6603942528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e640-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e716-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e709-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reclassification Adjustments<br> -URI http://asc.fasb.org/extlink&amp;oid=6522872<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822536768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822466528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing stock-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662294688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities and the favorable settlement of a state tax matter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2005.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$56.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804251792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$935.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,044.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.  As a result of this agreement we have agreed to dismiss the appeal and in the first quarter of 2017 we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$44.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804178672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of Alzheimer&#8217;s disease. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822506768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 13, 2017, we entered into an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer&#8217;s disease (AD) and progressive supranuclear palsy (PSP), from Bristol-Myers Squibb Company (BMS). BMS-986168 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we will receive worldwide rights to BMS-986168 and will be responsible for the full development and global commercialization of BMS-986168 in AD and PSP. In exchange, we will make an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and BMS may receive up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties. We will also assume all remaining obligations to the former stockholders of iPierian, Inc. related to BMS&#8217;s acquisition of the company in 2014. We may pay up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone which may become payable in 2017, and potential royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;share of the co-promotion profits or losses as a component of total revenues in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&#160;2016. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;to reflect our share of an overall net loss within the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net in our condensed consolidated statements of income. We also record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as these costs are incurred. We reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our recognition of income to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, during the third quarter of&#160;2016,&#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. In December 2016 SPINRAZA was approved by the U.S. Food and Drug Administration for the treatment of SMA in pediatric and adult patients in the U.S. triggering a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;milestone payment due to Ionis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets. This amount was paid during the first quarter of 2017. We may pay Ionis up to approximately&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in additional milestone payments upon the achievement of certain other regulatory milestones, including approval in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on our sales of SPINRAZA in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we will make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI in the E.U. in the first quarter of 2016 and FLIXABI in the E.U. in the third quarter of 2016. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis. This profit share with Samsung Bioepis is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the collaboration profit share in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in connection with these services as a component of other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804217552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Italian National Medicines Agency</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011, Biogen Italia SRL&#160;received notice from AIFA that sales of TYSABRI after mid-February 2009 exceeded a reimbursement limit established pursuant to a Price Determination Resolution granted by AIFA in December 2006. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. In the first quarter of 2017, we reached an agreement resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods for an aggregate repayment of approximately EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in In re Biogen Inc. Securities Litigation, filed by a shareholder on August 18, 2015, in the U.S. District Court for the District of Massachusetts. The amended complaint alleges violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5. The lead plaintiff sought a declaration of the action as a class action, certification as a representative of the class and its counsel as class counsel, and an award of damages, interest and attorneys' fees. On July 1, 2016 the U.S. District Court dismissed the case and in September 2016 denied the plaintiff's motion to vacate the order of dismissal. The plaintiff has appealed. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are also defendants in an action filed by another shareholder on October 20, 2016, in the U.S. District Court for the District of Massachusetts related to the matter described above. The complaint alleges violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeks a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has announced that it intends to appeal this decision.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding this matter, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Inter Partes Review Petitions and Proceeding</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 22, 2016, the USPTO instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 patent on the petition of the Coalition for Affordable Drugs V LLC, an entity associated with a hedge fund. In March 2017 the USPTO ruled against the petitioner. The petitioner has filed a request for rehearing, which is pending.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On April 18, 2016, Swiss Pharma International AG (Swiss Pharma) filed petitions in the USPTO for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of U.S. Patent Nos. 8,349,321 and, 8,900,577, relating to specific formulations of natalizumab (TYSABRI), and U.S. Patent No. 8,815,236, relating to methods for treating MS and Crohn&#8217;s disease using specific formulations of natalizumab (TYSABRI). In October 2016 the USPTO declined to institute proceedings under all three petitions and in February 2017 denied Swiss Pharma's requests for rehearing.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EPO has scheduled a hearing for November 2017 on Biogen&#8217;s and others&#8217; oppositions to Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information about this matter, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. A hearing was held in the Dutch action in February 2017 and the decision is pending. A hearing has been scheduled in the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for September 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2016, we received a subpoena from the federal government for documents relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 5, 2016, we received a subpoena from the federal government for documents relating to government price reporting, rebate payments and Biogen's co-pay assistance programs for AVONEX, TECFIDERA, TYSABRI and PLEGRIDY. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804202864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. Our research is currently focused on additional improvements in the treatment of MS, solving some of the most challenging and complex diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), and employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, which is focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method and continue to evaluate the potential impact that this standard may have on our financial position, results of operations and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2016 the FASB issued the following new standards, which we adopted on January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. As of March 31, 2017, the adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. This new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. This new standard will be effective for us on January 1, 2018 and will be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. This new standard simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit&#8217;s goodwill with the carrying amount of that goodwill. This new standard will be effective for us on January 1, 2020; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The amendments also provide explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822567200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off Hemophilia Spin Off (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and liabilities charged against equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.32163742690058%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804278672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the changes in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">131.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">568.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">707.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(62.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(231.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(294.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(64.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(267.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(337.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">76.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">552.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in condensed consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">676.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804548112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">158.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">644.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">156.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">921.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">959.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804186400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(526.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,648.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">357.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,887.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(874.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,012.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,153.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,049.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,103.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">346.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">425.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">412.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">378.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">239.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">216.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">254.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829871440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,500.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,738.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">542.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,520.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,502.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">484.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">575.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">556.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,528.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,483.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,032.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">993.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,812.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,890.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,845.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,496.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">508.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804135328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">519.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,288.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,289.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,212.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,213.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,073.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,076.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">539.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,956.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,957.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,561.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,565.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">263.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,781.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,884.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,181.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663731488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,215.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">113.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,446.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821979600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock', window );">Reconciliation of equity attributable to noncontrolling interests</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804267872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(26.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(35.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(186.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(259.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812587408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">970.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812620288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822446816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804214336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(63.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">505.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">181.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">160.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">89.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">475.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,044.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831633712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831908128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hemophilia Spin Off Hemophilia Spin Off (Details) - Bioverativ - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">$ 314.1<span></span>
</td>
<td class="nump">314.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets transferred, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities transferred, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833279184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off Hemophilia Spin Off (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">$ 87.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">384.6<span></span>
</td>
<td class="nump">313.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,380.1<span></span>
</td>
<td class="nump">2,309.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 74.4<span></span>
</td>
<td class="nump">$ 182.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativTransactionServicesAgreement', window );">Term of Bioverativ transaction services agreement</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativManufacturingandSupplyAgreement', window );">Term of Bioverativ manufacturing and supply agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativManufacturingandSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Manufacturing and Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativManufacturingandSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativTransactionServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Transaction Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativTransactionServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833249760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">707.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(4.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(294.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(337.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2017</a></td>
<td class="nump">676.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">131.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(62.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(64.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2017</a></td>
<td class="nump">76.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">482.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">568.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(231.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(267.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2017</a></td>
<td class="nump">552.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(5.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of March 31, 2017</a></td>
<td class="nump">$ 47.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820023600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 676.5<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">171.2<span></span>
</td>
<td class="nump">166.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 505.3<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829899936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 158.2<span></span>
</td>
<td class="nump">$ 170.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">644.4<span></span>
</td>
<td class="nump">698.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">156.8<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">959.4<span></span>
</td>
<td class="nump">1,039.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">921.6<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 37.8<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817098112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory Inventory (Details Textual) - Bioverativ<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">$ 116.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834801440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="nump">$ 88.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,153.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,049.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,934.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,103.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Payment made to Forward Pharma</a></td>
<td class="nump">1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA intellectual property charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2017 (remaining nine months)</a></td>
<td class="nump">346.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">425.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">412.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">378.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">239.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">216.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">353.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="nump">795.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(526.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(523.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,648.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,634.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 357.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 349.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,887.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,481.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(874.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(776.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 3,012.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,705.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 653.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,418.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831961792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">$ 254.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">239.2<span></span>
</td>
<td class="nump">$ 356.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">3,669.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">3,611.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="num">$ (314.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834740224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 4,781.4<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">645.1<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,520.7<span></span>
</td>
<td class="nump">7,558.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">470.9<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">$ 508.3<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">484.5<span></span>
</td>
<td class="nump">481.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,500.7<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,738.2<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">542.5<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">645.1<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,502.0<span></span>
</td>
<td class="nump">7,533.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">13.6<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,500.7<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,738.2<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">542.5<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">470.9<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">470.9<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Trading Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Available-for-Sale Securities<br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819924096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 6,496.5<span></span>
</td>
<td class="nump">$ 6,499.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,845.4<span></span>
</td>
<td class="nump">6,808.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">575.7<span></span>
</td>
<td class="nump">583.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">556.7<span></span>
</td>
<td class="nump">558.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,528.1<span></span>
</td>
<td class="nump">1,521.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,483.2<span></span>
</td>
<td class="nump">1,485.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,032.4<span></span>
</td>
<td class="nump">1,026.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">993.5<span></span>
</td>
<td class="nump">993.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,812.9<span></span>
</td>
<td class="nump">1,796.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,735.2<span></span>
</td>
<td class="nump">1,734.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,890.0<span></span>
</td>
<td class="nump">1,874.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,721.6<span></span>
</td>
<td class="nump">$ 1,721.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804270224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 470.9<span></span>
</td>
<td class="nump">$ 508.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817206640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Changes in valuation techniques</a></td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 254.1<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834748464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 645.1<span></span>
</td>
<td class="nump">$ 2,039.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">519.2<span></span>
</td>
<td class="nump">741.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 54.0<span></span>
</td>
<td class="nump">$ 1,266.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832539248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,781.4<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">4,786.0<span></span>
</td>
<td class="nump">5,406.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,288.5<span></span>
</td>
<td class="nump">1,408.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,289.2<span></span>
</td>
<td class="nump">1,409.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,212.2<span></span>
</td>
<td class="nump">1,255.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,213.4<span></span>
</td>
<td class="nump">1,258.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">664.4<span></span>
</td>
<td class="nump">1,156.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">664.6<span></span>
</td>
<td class="nump">1,156.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,073.8<span></span>
</td>
<td class="nump">1,016.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,076.0<span></span>
</td>
<td class="nump">1,019.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">539.2<span></span>
</td>
<td class="nump">557.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">539.5<span></span>
</td>
<td class="nump">559.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">18.7<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14.9)<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831619792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">$ 1,956.2<span></span>
</td>
<td class="nump">$ 2,568.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">1,957.1<span></span>
</td>
<td class="nump">2,569.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">2,561.9<span></span>
</td>
<td class="nump">2,552.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">2,565.4<span></span>
</td>
<td class="nump">2,559.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">263.3<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">263.5<span></span>
</td>
<td class="nump">277.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">4,781.4<span></span>
</td>
<td class="nump">5,398.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 4,786.0<span></span>
</td>
<td class="nump">$ 5,406.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804318720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,884.3<span></span>
</td>
<td class="nump">$ 1,181.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (0.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812184032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">17 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804170320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 99.5<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835853744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 332.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">902.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">38.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,446.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,215.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">113.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">59.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 58.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64830801&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820545712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,438.1<span></span>
</td>
<td class="nump">$ 1,439.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609.8<span></span>
</td>
<td class="nump">$ 481.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland | Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Land purchase</a></td>
<td class="nump">SFr 64.4<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822452224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract', window );"><strong>Reconciliation of equity attributable to non-controlling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, beginning of period</a></td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Fair value of net assets and liabilities acquired and assigned to NCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, end of period</a></td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820403120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Equity increase during the period</a></td>
<td class="nump">661.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Adjustment to retained earnings reflecting spin-off</a></td>
<td class="nump">852.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember', window );">2016 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases under the 2015 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramPlanToDateMember', window );">2016 Share Repurchase Program Plan To Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember', window );">2011 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Spinoff<br> -URI http://asc.fasb.org/extlink&amp;oid=6749415<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Reverse Spinoff<br> -URI http://asc.fasb.org/extlink&amp;oid=6524171<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramPlanToDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramPlanToDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833079968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(26.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="num">(6.3)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(35.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(325.2)<span></span>
</td>
<td class="num">(259.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(12.4)<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(17.1)<span></span>
</td>
<td class="num">(38.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(23.8)<span></span>
</td>
<td class="num">(47.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="num">(37.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(32.6)<span></span>
</td>
<td class="num">(37.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(334.2)<span></span>
</td>
<td class="num">(195.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">$ (314.2)<span></span>
</td>
<td class="num">$ (186.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831606640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">$ (37.6)<span></span>
</td>
<td class="num">$ (52.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">239.2<span></span>
</td>
<td class="nump">356.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,380.1<span></span>
</td>
<td class="nump">2,309.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">747.6<span></span>
</td>
<td class="nump">970.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835918720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc</a></td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 970.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">219.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821490384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="nump">$ 54.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">45.4<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(12.4)<span></span>
</td>
<td class="num">(15.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(18.7)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(29.4)<span></span>
</td>
<td class="num">(34.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (33.0)<span></span>
</td>
<td class="num">$ (36.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832489056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 48.1<span></span>
</td>
<td class="nump">$ 54.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">45.4<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">30.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6690038976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(11.20%)<span></span>
</td>
<td class="num">(8.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804484848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax payment, including penalties and interest</a></td>
<td class="nump">$ 56.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832192464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations and milestones</a></td>
<td class="nump">$ 516.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">676.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">181.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">160.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction Payable</a></td>
<td class="nump">116.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses accrual</a></td>
<td class="nump">89.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">475.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,044.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(63.4)<span></span>
</td>
<td class="num">(63.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on sales of investments, net</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(37.6)<span></span>
</td>
<td class="num">$ (52.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 505.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804428256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 935.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 817.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,380.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">AIFA agreement reached | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 37.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 44.6<span></span>
</td>
<td class="nump">&#8364; 41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812546720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 53.5<span></span>
</td>
<td class="nump">$ 47.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement', window );">Research and development cost in support of collaboration agreement</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cost in support of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835838912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,380.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,309.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">46.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Royalty payments per the collaboration</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Royalty payments per the collaboration</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_FY2017Member', window );">FY 2017 | iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedPaymentTimelineofMilestoneAxis=biib_FY2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedPaymentTimelineofMilestoneAxis=biib_FY2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804231536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2012</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">87.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share with Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804142528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Litigation (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">AIFA agreement reached</a></td>
<td class="nump">&#8364; 37.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M7'_X781=,'9K_['Q65"V\.LNY!=02P,$%     @ ;H*92IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M(N>L]_CPMSJLBP)N0W68I3::LS-[*ENAK(\"Y,%#NQD1AP&!9@@X(0+E>Q)
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ME.;8#Y>IO6ZGHXGIIF\N\[%+>#_[V?P/4$L#!!0    ( &Z"F4K1J;]LG0(
M  4)   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL?59AKYL@%/TKQN]3
M :W:V"9MEV5+MJ1YR]L^4TM;\U0<T/;MWP_0^BS@OE2@Y]Q[SA6Y%'?*WOB%
M$.&]-W7+5_Y%B&X9AKR\D ;S@':DE?^<*&NPD%-V#GG'"#YJ4E.',(H688.K
MUE\7>FW/U@6]BKIJR9YY_-HTF/W=DIK>5S[P'PLOU?DBU$*X+CI\)C^)>.WV
M3,[",<JQ:DC+*]IZC)Q6_@8L=P I@D;\JLB=3\:>LG*@]$U-OAU7?J04D9J4
M0H7 \G$C.U+7*I+4\6<(ZH\Y%7$Z?D3_HLU+,P?,R8[6OZNCN*S\S/>.Y(2O
MM7BA]Z]D,)3XWN#^.[F16L*5$IFCI#77OUYYY8(V0Q0II<'O_;-J]?,^Q'_0
MW 0X$.!(D+G_1T # 7T08FV^5Z:M?L8"KPM&[Q[KWU:'U:8 2R2+6:I%73O]
MGW3+Y>IMG41%>%-Q!LBVA\ )!(R(4 8?,T!7ABVTZ/ YP<Z!0.X,R.D!:3Z:
M>IA1&#OYL>;'$WZ<&#7H(:F&M!J2QFFP,(S8J#R-@MRM)7%J26POT,U?./D+
MRTN"#"\]))NH_ 0L*S8(!HE;2.H4DMI"8D-(:@N!*,@,)0[44^F?M&1.+9FM
MQ7S!F94E"H"AQ(69>3FY4T=NZS#JONTAR;3NQO>XRRT9^5PY0.3^Z"-;2&I^
M]9%=]R0P]M+.A4)3V+.<F3,(V'(R4PZP$J4QM/78L%SJF2N/\\3: &CKR4T]
MT#9N[Q@7"@3IC!KWZ0:0I69A'='(<3[!P#QH'; <(>N "B?-HR'LK/LL]TIZ
M;84ZIR>K8R_?0-5\C/6MZO&Z*7V$Z2\(/S [5RWW#E3(UJ8;T(E20:3**)"[
M_R+O)..D)B>AAJD<L[XQ]Q-!N^'2$8XWG_4_4$L#!!0    ( &Z"F4JHS_NZ
MC@0  &D6   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULA9C;;N,V$(9?
MQ?!]),Y0XB%P#'1=%"W0 L$6;:\5FXF-E2Q74N+MVY<ZQ)4X0]<7UND?\N?I
MTXB;:]U\:X_.=:OO57ENG];'KKL\IFF[/[JJ:)/ZXL[^R6O=5$7G+YNWM+TT
MKC@,0569HA JK8K3>;W=#/>>F^VF?N_*T]D]-ZOVO:J*YI\OKJRO3VM8?][X
M>GH[=OV-=+NY%&_N=]?]<7EN_%5Z*^5PJMRY/=7G5>->G]8_P.-.ZCY@4/QY
M<M=V=K[JF_)2U]_ZBU\.3VO1.W*EVW=]$84_?+B=*\N^)._C[ZG0]:W./G!^
M_EGZ3T/C?6->BM;MZO*OTZ$[/JW->G5PK\5[V7VMKS^[J4'Y>C6U_E?WX4HO
M[YWX.O9UV0[_J_U[V]755(JW4A7?Q^/I/!ROXQ.=36%\ $X!> N ^P%R"I!!
M0#HZ&YKZ8]$5VTU37U?-.%J7HI\4\"A]9^[[FT/?#<]\:UM_]V.K8)-^].5,
MDB^C!&<27"IV5*'^DZ2^_IL)9$W@$"_G\9*/EVR\'.*S>7P6-&*4@!@TYT%C
M,1#M1I&>:5"B2G+>2\9ZR:B7// R2LRL&K"Y2L)>I3+,E4D4[R9GW>34C0K<
MY-1-+B )3.\8699!S(UBW2CJ1@=N%*E&8D;,,"HA8EXTZT53+R;PHDDM%N<M
M'KU0%0@1[1C#FC'4C W,&%H-2D@"V8Z1"2N3R'*RK!M+W&@1N+&D&F5RFP2C
MN:,RHR4F_BWS^0/>6+]0.5J)_U]=DV:Q;@SF9'GQ.IMD$4<1?@+M+ )0H#4I
M$&3L.%V_%$W$$0]30.H(0T=(:LI 2.J(ZJ01)C:=@,<S4#YK&3J2M"8%0&84
MJU,VZHB'-%!*Z_"- 0RFP5 6<3HI\^BH\: &2FI-9C9E,()_==!A8X1HM(IZ
MXG$-BKR7=01KP$,6*&5U2'R@ ,T5??\PLFPV.Y9N>,H"Q:P.F3]I\EDU(?QV
M0"&[1/'2# ]98"@;,A\H/R6H)$Q;&!EJ&QMLY-&*%*TFI#XRR!191EZ)G,YZ
MO$02*>31BA2M)D0K,LBT%LGL870R QL;,XSDJ12M)D0K4F3F-D<",D:G<L#8
ME$8>K4C1:D*T(D6FI1CC5#(1=OZ+6.,9BY2Q)F0L4G8J8Q(3>J,RC1B=3CQA
MD1+6A(1%"DZKT=#.8K)AH3.3Q#Y[>, B38A-F)YS&C*7[FJ63GA0HR:H-S%^
M\'!%"E<3\@PI7$.VWI4L??!<1<I52SA&@2D2")W<%RT_2WFF2LI4&Q)LTMSK
MD[N2I0^>I)*2U(;<DI20#Y))FUE=G*22)ZFD)+4AMR0E)&3: +7$"'.AH]]@
M,K*+0%EJR38"I>0#6JW)[&&%RX1VZ8F'J*00M2&T)LU\>H#OJ# IE$R>BI#%
MYS2/44DQ:D-F28K'!Z!?SA%9!.N29ZBD[+-ABBGI?H'O(:5))L4)$3"ZZ2)Y
MFDJ:]MHPT9PTB\TF-IGGA&PRG\[V_/I-V-^*YNUT;E<O==?5U;#)]UK7G?.%
MBL1W_=$5A]M%Z5Z[_E3[\V;<_!PONOHR;>RFM]WE[;]02P,$%     @ ;H*9
M2F1]0&+( 0  9@0  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R%5-MN
MG# 0_17D#UASRV57@)2EJE*ID5:IVCY[85A0;$QL[Y+^?7T+92E*7K!G?,Z9
M,[Z0C5R\R!9 !6^,]C)'K5+##F-9M<"(W/ !>KW2<,&(TJ$X83D((+4E,8KC
M,+S%C'0]*C*;.X@BXV=%NQX.(I!GQHCXLP?*QQQ%Z#WQW)U:91*XR 9R@A^@
M?@X'H2,\J=0=@UYVO \$-#EZB'9E:O 6\*N#4<[F@>GDR/F+";[5.0J-(:!0
M*:- ]'"!$B@U0MK&J]=$4TE#G,_?U;_:WG4O1R*AY/1W5ZLV1_<HJ*$A9ZJ>
M^?@(OI\;%/CFO\,%J(8;)[I&Q:FTWZ Z2\695]%6&'ES8]?;<70K=UM/6R?$
MGA!/A"C]D)!X0K(@8.?,MOJ%*%)D@H^!<(<U$',GHEVB-[,R2;MW=DUW*W7V
M4FRW&;X8'0_9.T@\@\37B/)_Q.T_"-;U)Q/QJHG8\I,9/PK#=8%D52"Q NF5
M0+1HPV$BUVIO0>$F7,+*3V%7=M)5.^F*G<6>[1TFBA=UPIN%G\]QSA">G;AY
M@4]$G+I>!D>N].6Q1]QPKD!KAAM]K5O]Z*> 0J/,]$[/A;OZ+E!\\*\:3[^6
MXB]02P,$%     @ ;H*92CL_H?=7!   )!0  !@   !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6R-F%MOXS80A?^*X?=(FJ&H2V ;B%T4+= "P1;;/BLV$QLK
M6:XDQ]M_7^H2Q^8<MIN'Z.+#X>&0_$AQ<:F;;^W>F&[VO2J/[7*^[[K38QBV
MV[VIBC:H3^9H?WFMFZKH[&/S%K:GQA2[H5!5AAQ%25@5A^-\M1C>/3>K17WN
MRL/1/#>S]EQ51?//VI3U93FG^<>++X>W?=>_"%>+4_%F_C#=U]-S8Y_":Y3=
MH3+']E ?9XUY7<Z?Z'&CXK[ H/CS8"[MS?VL;\I+77_K'W[=+>=1[\B49MOU
M(0I[>3<;4Y9]).OC[RGH_%IG7_#V_B/ZST/C;6->BM9LZO*OPZ[;+^?9?+8S
MK\6Y[+[4EU_,U" ]GTVM_\V\F]+*>R>VCFU=ML/_V?;<=G4U1;%6JN+[>#T<
MA^MEBO]1#!?@J0!?"]BZ_ZN F@JHSP)#-L/1V=#4GXJN6"V:^C)KQMXZ%?V@
MH$=ED[GM7PZY&WZSK6WMV_<516H1OO>!)LUZU/"MYJH(;?1K%8RJ6+,HSO<5
M;(!"X1H4;(0:RJN[1L0X0 P#Q$. ^"9 ["9AE*2#Y#A(TC@-M-,2J<J3/&#L
M14,O&C1&XP )#)"(QE"4.*T9-?K&IR:W5T9-=J.A. ]2;"6%5E)@)76LI,**
M<B2;5#B)=> 9(1DTD@$CF6,D$[6D21#EMW^.+UDB"W)L*X>V<F&+W?3DLA>R
M@!PC4O1 Y+-"$29!! :>+X0')B333)%+$P)F<QVXG3[I])TNB3R&('J>B(6A
MQ.WV27/G)TX"=S8@698%&H^/>W.86J1 MLAUIV2U219+>T!'*O%-5\(<) E"
M<KFPGD2B ]U!"71L9U3F<81I2!HX$@N4EHY4'"C7$)(EWFF"Z4H KQ2[AB0[
M66G9:0"Q$6EOBC!D*943ESPK!F$\$N CN6L&2=Q1EH$T QUE%'@V#8312)*-
M1"X<"8&/=2)A@H0YQ8%GF\"8D1P!4RY0)M'=BA8Y%-S\C^C>#*8M(]KFKAE
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MCR\;^]\8XP&E'&YPA#K\8*NAH/'A^ '/=AZSV?!F6'X06[]Q^1=02P,$%
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M['^%Z,!+65WY$6K\!YL,"94+QQM_-L.8#8;#=OQ!;/K&^7]02P,$%     @
M;H*92ASTG@ZV 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6QM
M4]MNW" 0_17$!P2;==+MRK:4312U4BNM4C5]9NVQC<+% ;Q._[Z '==)_ +,
M,.?,F6'(1VV>;0?@T*L4RA:X<ZX_$&*K#B2S5[H'Y6\:;21SWC0ML;T!5D>0
M%(0FR0V1C"M<YM%W,F6N!R>X@I-!=I"2F;]'$'HL<(K?'(^\[5QPD#+O60N_
MP/WN3\9;9&&IN01EN5;(0%/@V_1PS$)\#'CB,-K5&85*SEH_!^-[7> D" (!
ME0L,S&\7N ,A I&7\3)SXB5E *[/;^P/L79?RYE9N-/B#Z]=5^ ]1C4T;!#N
M48_?8*[G&J.Y^!]P >'#@Q*?H]+"QA55@W5:SBQ>BF2OT\Y5W,?IYGH_P[8!
M= ;0!;"/><B4*"J_9XZ5N=$C,E/O>Q:>.#U0WYLJ.&,KXIT7;[WW4J:[KSFY
M!*(YYCC%T'7,$D$\^Y*";J4XTD]PN@W?;2K<1?ANG3U+M@FR38(L$F3O"-(/
M)6[%?%1)5CV58-HX3195>E!QDE?>96!O:7R3_^'3M/]DIN7*HK-V_F5C_QNM
M'7@IR94?H<Y_L,40T+AP_.+/9AJSR7"ZGW\06;YQ^0]02P,$%     @ ;H*9
M2E_H<&FU 0  T ,  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL?5/;
M;M0P$/T5RQ]0;YQ05JLD4K<(@032J@AX]B:3B^I+L)U-^7O&3AHB&O%B>\;G
MG+EXG$_&/KL.P),7);4K:.?]<&+,51THX>[, !IO&F.5\&C:EKG!@J@C24G&
M#X=[ID2O:9E'W\66N1F][#5<+'&C4L+^/H,T4T$3^NIXZMO.!P<K\T&T\ W\
M]^%BT6*K2MTKT*XWFEAH"OJ0G,Y9P$? CQXFMSF34,G5F.=@?*X+>@@)@83*
M!P6!VPT>0<H@A&G\6C3I&C(0M^=7]8^Q=JSE*AP\&OFSKWU7T",E-31BE/[)
M3)]@J><=)4OQ7^ &$N$A$XQ1&>GB2JK1>:,6%4Q%B9=Y[W7<I_DFY0MMG\ 7
M E\)QQB'S8%BYA^$%V5NS43LW/M!A"=.3AQ[4P5G;$6\P^0=>F_E_3%GMZ"S
M0,XSA&\@R8I@*+Y&X'L1SOP-G>_3T]T$TTA/M]&S=%\@VQ7(HD#VOPK?0I(L
M^R<&VW14@6WC+#E2F5''.=YXUW%]B$_(_L+G6?\J;-MK1Z[&X[O&[C?&>,!4
M#G<X0!U^K]60T/AP?(]G.P_9;'@S+/^'K9^X_ -02P,$%     @ ;H*92F2R
M$X"T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL?5-A;]L@
M$/TKB!]0$L=IJ\BVU+2J.FF3HE;;/A/[;*,"YP*.NW]?P*[G;=:^ '?<>_?N
M.+(!S:MM 1QY5U+;G+;.=0?&;-F"XO8*.]#^ID:CN/.F:9CM#/ J@I1DR69S
MS107FA99])U,D6'OI-!P,L3V2G'SZP@2AYQNZ:?C632M"PY69!UOX 7<]^YD
MO,5FEDHHT%:@)@;JG-YM#\<TQ,> 'P(&NSB34,D9\3487ZJ<;H(@D%"ZP,#]
M=H%[D#(0>1EO$R>=4P;@\OS)_AAK][6<N85[E#]%Y=J<WE)20<U[Z9YQ>(*I
MGCTE4_%?X0+2AP<E/D>)TL:5E+UUJ"86+T7Q]W$7.N[#>+/?3;!U0#(!DAEP
M&_.P,5%4_L =+S*# S%C[SL>GGA[2'QORN",K8AW7KSUWDNQ3?<9NP2B*>8X
MQB3+F#F">?8Y1;*6XIC\ T_6X;M5A;L(W_VA\'J=(%TE2"-!^M\2UV)N_DK"
M%CU58)HX39:4V.LXR0OO/+!W27R3W^'CM'_CIA':DC,Z_[*Q_S6B R]E<^5'
MJ/4?;#8DU"X<;_S9C&,V&@Z[Z0>Q^1L7'U!+ P04    " !N@IE*BA<F(;4!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q]4]MNG# 0_17+
M'Q"S+&FW*T#*IJI:J956J9H^>V$ *[Y0VRSIWW=L"*4-RHOM&<\Y<V8\SD=C
MGUP'X,FSDMH5M/.^/S+FJ@X4=S>F!XTWC;&*>S1MRUQO@=<1I"1+D^0=4UQH
M6N;1=[9E;@8OA8:S)6Y0BMO?)Y!F+.B.OC@>1-OYX&!EWO,6OH/_T9\M6FQA
MJ84"[831Q$)3T+O=\92%^!CP*&!TJS,)E5R,>0K&E[J@21 $$BH?&#AN5[@'
M*0,1RO@U<](E90"NSR_LGV+M6,N%.[@W\J>H?5?0 R4U-'R0_L&,GV&NYY:2
MN?BO< 6)X4$)YJB,='$EU>"\43,+2E'\>=J%COLXW>RS&;8-2&= N@ .,0^;
M$D7E'[GG96[-2.S4^YZ')]X=4^Q-%9RQ%?$.Q3OT7LM==LC9-1#-,:<I)EW'
M+!$,V9<4Z5:*4_H*GF[#]YL*]Q&^_T?AAVV";),@BP39FR5NQ-PF_R5AJYXJ
ML&V<)D<J,^@XR2OO,K!W:7R3O^'3M'_CMA7:D8OQ^+*Q_XTQ'E!*<H,CU.$'
M6PP)C0_']WBVTYA-AC?]_(/8\HW+/U!+ P04    " !N@IE*L\L&B;0!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q]4]MNVS ,_15!'U#%
M2M(5@6V@Z3!TP 8$';8^*S9]077Q)#GN_GZ4[+INY_5%$BF>PT.*2@=CGUP#
MX,FSDMIEM/&^.S#FB@:4<%>F XTWE;%*>#1MS5QG0901I"3CF\TU4Z+5-$^C
M[V3SU/1>MAI.EKA>*6'_'$&:(:,)?7$\M'7C@X/E:2=J^ '^9W>R:+&9I6P5
M:-<:32Q4&;U-#L==B(\!OUH8W.),0B5G8YZ"\;7,Z"8( @F%#PP"MPO<@92!
M"&7\GCCIG#( E^<7]B^Q=JSE+!S<&?G8EK[)Z TE)52BE_[!#/<PU;.G9"K^
M&UQ 8GA0@CD*(UU<2=$[;]3$@E*4>![W5L=]&&_VR01;!_ )P&? 3<S#QD11
M^6?A19Y:,Q []KX3X8F3 \?>%,$96Q'O4+Q#[R5/]DG*+H%HBCF.,7P9,T<P
M9)]3\+441_X/G*_#MZL*MQ&^?:/P/P2[58)=)-A]6.):S/9=$K;HJ0);QVER
MI#"]CI.\\,X#>\OCF[R&C]/^7=BZU8Z<C<>7C?VOC/& 4C97.$(-?K#9D%#Y
M</R$9SN.V6AXTTT_B,W?./\+4$L#!!0    ( &Z"F4K!,=Q)M $  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U386_;(!#]*X@?4!+B9%%D
M6VI:39NT25&GK9^)?;91P><!CKM_/\"NZVW6O@!WW'OW[CC2 <V+;0 <>=6J
MM1EMG.M.C-FB 2WL'7;0^IL*C1;.FZ9FMC,@R@C2BO'-YL"TD"W-T^B[F#S%
MWBG9PL40VVLMS*\S*!PRNJ5OCB=9-RXX6)YVHH9OX+YW%^,M-K.44D-K);;$
M0)71^^WIG(3X&/!#PF 79Q(JN2*^!.-SF=%-$ 0*"A<8A-]N\ !*!2(OX^?$
M2>>4 ;@\O[%_C+7[6J["P@.J9UFZ)J-'2DJH1*_<$PZ?8*IG3\E4_!>X@?+A
M08G/4:"R<25%;QWJB<5+T>)UW&4;]V&\.1PGV#J 3P ^ XXQ#QL31>6/PHD\
M-3@0,_:^$^&)MR?N>U,$9VQ%O//BK??>\NT^2=DM$$TQYS&&+V/F".;9YQ1\
M+<69_P/GZ_#=JL)=A._^4+A?)TA6"9)(D/RWQ+68PU])V**G&DP=I\F2 OLV
M3O+".P_L/8]O\AX^3OM786K96G)%YU\V]K]"=."E;.[\"#7^@\V&@LJ%XP=_
M-N.8C8;#;OI!;/[&^6]02P,$%     @ ;H*92O7(9-6W 0  T@,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL;5-A;]L@$/TKB!]0'"=-L\BVU'2:
M-FF3HD[;/A/[;*,"YP&.NW\_P([G=OX"W''OW;OCR 8T+[8%<.1526USVCK7
M'1FS90N*VSOL0/N;&HWBSINF8;8SP*L(4I*E2;)GB@M-BRSZSJ;(L'=2:#@;
M8GNEN/ES HE#3C?TYG@63>N"@Q59QQOX#NY'=S;>8C-+)11H*U 3 W5.'S?'
MTR[$QX"? @:[.)-0R07Q)1A?JIPF01!(*%U@X'Z[PA-(&8B\C-\3)YU3!N#R
M?&/_%&OWM5RXA2>4OT3EVIP>**F@YKUTSSA\AJF>>TJFXK_"%:0/#TI\CA*E
MC2LI>^M032Q>BN*OXRYTW(?Q9G^#K0/2"9#.@$,$L#%15/Z1.UYD!@=BQMYW
M/#SQYICZWI3!&5L1[[QXZ[W78G/_D+%K()IB3F-,NHR9(YAGGU.D:RE.Z7_P
M=!V^756XC?#M&X6'=8+=*L$N$NS>$'QX5^)*S#YYEX0M>JK -'&:+"FQUW&2
M%]YY8!_3^";_PL=I_\9-([0E%W3^96/_:T0'7DIRYT>H]1]L-B34+AP?_-F,
M8S8:#KOI!['Y&Q=_ 5!+ P04    " !N@IE*7&329;,!  #2 P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q]4]MNW" 0_17$!X0UNTU7*]M2-E75
M2*VT2M7FF;7'-@H7!_ Z_?L")HZ3NGD!9IASYLPPY*,VC[8#<.A9"F4+W#G7
M'PBQ50>2V2O=@_(WC3:2.6^:EMC> *LC2 I"-YMK(AE7N,RC[V3*7 ].< 4G
M@^P@)3-_CB#T6. ,OSCN>=NYX"!EWK,6?H+[U9^,M\C,4G,)RG*MD(&FP#?9
MX;@+\3'@-X?1+LXH5'+6^C$8=W6!-T$0"*A<8&!^N\ M"!&(O(RGQ(GGE &X
M/+^P?XVU^UK.S,*M%@^\=EV!]QC5T+!!N'L]?H-4SR>,4O'?X0+"AP<E/D>E
MA8TKJ@;KM$PL7HIDS]/.5=S'=+-/L'4 30 Z _8Q#YD21>5?F&-E;O2(S-3[
MGH4GS@[4]Z8*SMB*>.?%6^^]E-EUEI-+($HQQRF&+F/F".+9YQ1T+<61_@.G
MZ_#MJL)MA&_?*/P/P6Z58!<)=A^6N!:S?9>$+'HJP;1QFBRJ]*#B)"^\\\#>
MT/@FK^'3M/]@IN7*HK-V_F5C_QNM'7@IFRL_0IW_8+,AH''A^-F?S31FD^%T
MGWX0F;]Q^1=02P,$%     @ ;H*92G(>Q@"R 0  T@,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL;5-A;YLP$/TKEG] G1":3A$@-9VJ3MJDJ-.V
MSPX<8-7V,=N$[M_/-H31C"_X[KCW[MWYG UHWFP+X,B[DMKFM'6N.S!FRQ84
MMW?8@?9_:C2*.^^:AMG. *\B2$F6;#9[IKC0M,AB[&2*#'LGA8:3(;97BIL_
M1Y XY'1+KX%7T;0N!%B1=;R![^!^="?C/3:S5$*!M@(U,5#G]'%[.*8A/R;\
M%##8A4U")V?$M^!\J7*Z"8) 0ND" _?'!9Y RD#D9?R>..E<,@"7]I7].?;N
M>SES"T\H?XG*M3G]1$D%->^E>\7A!:9^[BF9FO\*%Y ^/2CQ-4J4-GY)V5N'
M:F+Q4A1_'T^AXSE,_%?8.B"9 ,D-@(V%HO+/W/$B,S@0,\Z^X^&*MX?$SZ8,
MP3B*^,^+MSYZ*;;[-&.70#3E',><9)DS9S#//I=(UDH<D__@R3I\MZIP%^&[
M#PKOUPG258(T$J0?"/8W+:[E/-P488N9*C!-W"9+2NQUW.1%=%[8QR3>R;_T
M<=N_<=,(;<D9G;_9./\:T8&7LKGS*]3Z!S8[$FH7S =OFW'-1L=A-[T@-C_C
MXB]02P,$%     @ ;H*92A 1&>:U 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL?5/;;MLP#/T501]0.4[69H%MH.DP=, *!!VV/2LV;0O5
MQ97DN/W[4;+C>9NQ%TFD> X/*2H;C'UQ+8 G;TIJE]/6^^[ F"M;4-S=F XT
MWM3&*N[1M USG05>19"2+$V26Z:XT+3(HN]DB\ST7@H-)TM<KQ2W[T>09LCI
MAEX=SZ)I?7"P(NMX ]_ ?^].%BTVLU1"@7;":&*ASNG]YG#<A?@8\$/ X!9G
M$BHY&_,2C"]53I,@""24/C!PW"[P %(&(I3Q.G'2.64 +L]7]L^Q=JSES!T\
M&/E35+[-Z9Z2"FK>2_]LAD>8ZOE R53\5[B Q/"@!'.41KJXDK)WWJB)!:4H
M_C;N0L=]&&^V5]@Z()T Z0S81P ;$T7EG[CG16;-0.S8^XZ')]X<4NQ-&9RQ
M%?$.Q3OT7HK-[3YCET TQ1S'F'09,T<P9)]3I&LICND_\'0=OEU5N(WP[1\*
M/ZX3[%8)=I%@]]\25V+NDK^2L$5/%=@F3I,CI>EUG.2%=Q[8^S2^R>_P<=J?
MN&V$=N1L/+YL[']MC >4DMS@"+7XP69#0NW#\0[/=ARST?"FFWX0F[]Q\0M0
M2P,$%     @ ;H*92M.WYZVT 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL?5-A;]P@#/TKB!]0+ERVJTY)I%ZG:9,VZ=1IZV<N<1)4"!F0
M2_?O9TB:9EO6+X"-W_.S,=EH[)-K 3QYUJIS.6V][X^,N;(%+=R-Z:'#F]I8
M+3R:MF&NMR"J"-**\=WN/=-"=K3(HN]LB\P,7LD.SI:X06MA?YU F3&G"7UQ
M/,BF]<'!BJP7#7P#_[T_6[38PE))#9V3IB,6ZIS>)<=3&N)CP \)HUN=2:CD
M8LQ3,#Y7.=T%0:"@](%!X':%>U J$*&,GS,G75(&X/K\POXQUHZU7(2#>Z,>
M9>7;G-Y24D$M!N4?S/@)YGK>43(7_P6NH# \*,$<I5$NKJ0<G#=Z9D$I6CQ/
MN^SB/DXWAW2&;0/X#. +X#;F85.BJ/R#\*+(K!F)G7K?B_#$R9%C;\K@C*V(
M=RC>H?=:)(<D8]= -,><IAB^CEDB&+(O*?A6BA/_!\ZWX?M-A?L(W_^A\#\$
MZ29!&@G2-TO<BMG_E82M>JK!-G&:'"G-T,5)7GF7@;WC\4U>PZ=I_RIL(SM'
M+L;CR\;^U\9X0"F[&QRA%C_88BBH?3@>\&RG,9L,;_KY!['E&Q>_ 5!+ P04
M    " !N@IE*5XY(V+0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q]4]MNG# 0_17+'Q#O KEH!4C95%4K-=(J4=MG+PQ@Q1=JFR7Y^XP-
MH;1%?;$]XSEGSHS'^6CLB^L /'E54KN"=M[W!\9<U8'B[LKTH/&F,59QCZ9M
MF>LM\#J"E&3);G?#%!>:EGGTG6R9F\%+H>%DB1N4XO;M"-*,!=W3#\>3:#L?
M'*S,>][",_CO_<FBQ1:66BC03AA-+#0%O=\?CEF(CP$_!(QN=2:ADK,Q+\'X
M6A=T%P2!A,H'!H[;!1Y RD"$,G[-G'1)&8#K\P?[YU@[UG+F#AZ,_"EJWQ7T
MCI(:&CY(_V3&+S#7<TW)7/PWN(#$\* $<U1&NKB2:G#>J)D%I2C^.NU"QWV<
M;M)TAFT#DAF0+("[F(=-B:+R3]SS,K=F)';J?<_#$^\/"?:F"L[8BGB'XAUZ
M+^7^-LO9)1#-,<<I)EG'+!$,V9<4R5:*8_(//-F&IYL*TPA/_U!XO4V0;1)D
MD2#[;XE;,3=_)6&KGBJP;9PF1RHSZ#C)*^\RL/=)?)/?X=.T/W+;"NW(V7A\
MV=C_QA@/*&5WA2/4X0=;# F-#\=;/-MIS";#FW[^06SYQN4[4$L#!!0    (
M &Z"F4JA+E8XL $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;'U388_3, S]*U%^P&7+!CNFMM+M$ ()I.D0\#EKW3:Z)"Y)NA[_GB3M2CDJ
MOC2VZ_?\[#C9@/;9M0">O&AE7$Y;[[LC8ZYL00MWAQV8\*=&JX4/KFV8ZRR(
M*H&T8GRS><NTD(8668J=;9%A[Y4T<+;$]5H+^^L$"H><;NDM\"2;UL< *[).
M-/ 5_+?N;(/'9I9*:C!.HB$6ZIP^;(^G?<Q/"=\E#&YAD]C)!?$Y.I^JG&ZB
M(%!0^L@@PG&%1U J$@49/R=..I>,P*5]8_^0>@^]7(2#1U0_9.7;G-Y34D$M
M>N6?</@(4S]O*)F:_PQ74"$]*@DU2E0N?4G9.X]Z8@E2M'@93VG2.4S\-]@Z
M@$\ _@K QD))^7OA19%9'(@=9]^)>,7;(P^S*6,PC2+]"^)=B%Z+[>&0L6LD
MFG).8PY?YLP9++#/)?A:B1/_!\[7X;M5A;L$W_VE\'Z=8+]*L$\$^_^VN);S
M[E41MIBI!MND;7*DQ-ZD35Y$YX5]X.E._J2/V_Y%V$8:1R[HP\VF^=>('H*4
MS5U8H38\L-E14/MH'H)MQS4;'8_=](+8_(R+WU!+ P04    " !N@IE*[4NF
MR;,!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q]4]MNW" 0
M_17$!P0ONTE7*]M2-E652JVT2M7FF;7'%P48%_ Z_?L"=APG=?,"S##GS)EA
M2 <T3[8!<.1926TSVCC7'1BS10-*V"OL0/N;"HT2SINF9K8S(,H(4I+Q)+EA
M2K2:YFGTG4R>8N]DJ^%DB.V5$N;/$20.&=W0%\=#6S<N.%B>=J*&'^!^=B?C
M+3:SE*T";5O4Q$"5T=O-X;@+\3'@5PN#79Q)J.2,^!2,KV5&DR ()!0N, B_
M7> .I Q$7L;OB9/.*0-P>7YA_Q)K][6<A84[E(]MZ9J,[BDIH1*]= \XW,-4
MSS4E4_'?X +2AP<E/D>!TL:5%+UUJ"86+T6)YW%O==R'\>9Z.\'6 7P"\!FP
MCWG8F"@J_RR<R%.# S%C[SL1GGASX+XW17#&5L0[+]YZ[R7?[).470+1%',<
M8_@R9HY@GGU.P==2'/D_<+X.WZXJW$;X]HW"_^3?K1+L(L'NPQ+78MZK9(N>
M*C!UG"9+"NQUG.2%=Q[86Q[?Y#5\G/;OPM2MMN2,SK]L['^%Z,!+2:[\"#7^
M@\V&A,J%XR=_-N.8C8;#;OI!;/[&^5]02P,$%     @ ;H*92CR11I"P 0
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MHVW'-1L=;[KI!;'Y&><?4$L#!!0    ( &Z"F4J -*2#M $  -(#   9
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M+Z?6GPPM^GFJD66TYG\ 4$L#!!0    ( &Z"F4JX(IE MP$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;&U3VV[<(!#]%<0'!*]W-TU6MJ5L
MHJB5$FF5JNTS:X]M%&!<P.OD[P/8<:W4+\ ,YYRY,&0#FE?; CCRIJ2V.6V=
MZPZ,V;(%Q>T5=J#]38U&<>=-TS#;&>!5)"G)TB2Y9HH+38LL^DZFR+!W4F@X
M&6)[I;AY/X+$(:<;^NEX$4WK@H,56<<;^ GN5W<RWF*S2B44:"M0$P-U3N\V
MA^,NX"/@MX#!+LXD5')&? W&CRJG24@())0N*'"_7> >I Q"/HV_DR:=0P;B
M\ORI_AAK][6<N85[E']$Y=J<WE!20<U[Z5YP^ Y3/7M*IN*?X +2PT,F/D:)
MTL:5E+UUJ"85GXKB;^,N=-R'\6:_GVCKA'0BI#/A)L9A8Z"8^0-WO,@,#L2,
MO>]X>.+-(?6]*8,SMB+>^>2M]UZ*S>UMQBY!:,(<1TRZQ,P(YM7G$.E:B&/Z
M'SU=IV]7,]Q&^G89?7N]+K!;%=A%@=TR?I)\*7$-\[5(MNBI M/$:;*DQ%['
M25YXYX&]2^.;_(./T_[,32.T)6=T_F5C_VM$!SZ5Y,J/4.L_V&Q(J%TX?O-G
M,X[9:#CLIA_$YF]<? !02P,$%     @ ;H*92K7O!-7% 0  -P0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL;51ACYP@$/TKA!]PN*QN+QLUN;WF
M<DW:9'--V\^LCDH.Q *NUW]?0,^S6[X(,[QY;X9AS">E7TT'8-&;%+TI<&?M
M<"3$5!U(9N[4 +T[:926S#I3M\0,&E@=@J0@-$D.1#+>XS(/OK,N<S5:P7LX
M:V1&*9G^<P*AI@+O\+OCA;>=]0Y2Y@-KX3O8'\-9.XNL+#67T!NN>J2A*?##
M[GC*/#X ?G*8S&:/?"47I5Z]\:4N<.(3 @&5]0S,+5=X!"$\D4OC]\*)5TD?
MN-V_LS^%VETM%V;@48E?O+9=@>\QJJ%AH[ O:GJ&I9X,HZ7XKW %X> ^$Z=1
M*6'"%U6CL4HN+"X5R=[FE?=AG>:30[:$Q0/H$D#7@/N@0V:AD/EG9EF9:S4A
M/=_]P'R+=T?J[J;RSG 5X<PE;YSW6M*$YN3JB1;,:<;0#6:W(HAC7R5H3.)$
M_PNG\?!]-,-]"-]OU=,D3I!&"=) D/Y3XOZFQ!@FC8MD49$L0I#=B,0PAQL1
MLFF<!-V&)VM0I<8^C,O&NT[% PV-_X#/(_6-Z9;W!EV4=<\G-+E1RH)+);ES
MN71NBE=#0&/]]I/;Z_DMSX95PS*F9/U7E'\!4$L#!!0    ( &Z"F4KQ+;UN
MMP$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;&U3VVZ<,!#]
M%<L?$+.&)-L5(&431:W42JM439^],( 57ZAMEO3O:QM"2<*+[1F?<^;B<3YJ
M\V([ (=>I5"VP)US_8$06W4@F;W2/2A_TV@CF?.F:8GM#; ZDJ0@-$ENB&1<
MX3*/OI,I<STXP16<#+*#E,S\/8+08X%W^,WQQ-O.!0<I\YZU\!/<K_YDO$46
ME9I+4)9KA0PT!;[;'8Y9P$? ,X?1KLXH5'+6^B48W^H")R$A$%"YH,#\=H%[
M$"((^33^S)IX"1F(Z_.;^F.LW==R9A;NM?C-:]<5>(]1#0T;A'O2XU>8Z[G&
M:"[^.UQ >'C(Q,>HM+!Q1=5@G9:SBD]%LM=IYRKNXW23TIFV3: S@2Z$?8Q#
MID Q\P?F6)D;/2(S];YGX8EW!^I[4P5G;$6\\\E;[[V4-+G-R24(S9CCA*$K
MS&Y!$*^^A*!;(8[T$YUNT]/-#--(3]?1LW1;(-L4R*) ]J[$_8<2MS!?/@0A
MJYY*,&V<)HLJ/:@XR2OO,K!W\1')?_@T[3^8:;FRZ*R=?]G8_T9K!SZ5Y,J/
M4.<_V&((:%PXWOJSF<9L,ISNYQ]$EF]<_@-02P,$%     @ ;H*92AX'@973
M 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL=53;;MP@$/T5
MQ <$F_6ZT<JVE$T5)5(CK5*U?6;M\44!XP!>)W]?P([K;NF+888SY\R,&;))
MJE?= ACT+GBO<]P:,QP(T64+@ND;.4!O3VJI!#/65 W1@P)6^2#!"8VBE C6
M];C(O.^DBDR.AG<]G!32HQ!,?1R!RRG',?YTO'1-:YR#%-G &O@.YL=P4M8B
M*TO5">AU)WNDH,[Q77PXI@[O 3\[F/1FCUPE9RE?G?%4Y3AR"0&'TC@&9I<+
MW /GCLBF\;9PXE72!6[WG^P/OG9;RYEIN)?\5U>9-L>W&%50LY&;%SD]PE+/
M'J.E^&]P 6[A+A.K44JN_1>5HS92+"PV%<'>Y[7K_3K-)VF\A(4#Z!) UX!;
MKT-F(9_Y5V98D2DY(37W?F#N%\<':GM3.J=OA3^SR6OKO10TCC)R<40+YCAC
MZ 83KPABV5<)&I(XTG_":3A\%\QPY\-W6_4D#1,D08+$$R1_E1A?E1C"_"?+
M?5!D'R#878F$,$E8) V*I &"_95("'/=+K*Y'0)4X^="HU*.O9_)C7<=O3OJ
M;]<?^#RWSTPU7:_161I[1_U-JJ4T8%.);FS!K7TJ5H-#;=SVB]VK>6!FP\AA
M>0O(^B 5OP%02P,$%     @ ;H*92BWRA$[3 0  G 0  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL=53;;MP@$/T5Q <$F[UF95O*)HI:J9%6J=H^
ML_;XHH!Q :^3OP]@QW4WY,4PPYES9L8,R2#5BZX!#'H5O-4IKHWI#H3HO ;!
M](WLH+4GI52"&6NJBNA. 2M\D."$1M&6"-:T.$N\[Z2R1/:&-RV<%-*]$$R]
M'8'+(<4Q_G \-U5MG(-D2<<J^ GF5W=2UB(S2]$(:'4C6Z2@3/%=?#AN'=X#
M?C<PZ,4>N4K.4KXXXWN1XL@E!!QRXQB872YP#YP[(IO&WXD3SY(N<+G_8'_T
MM=M:SDS#O>1_FL+4*=YC5$#)>FZ>Y? -IGHV&$W%_X +< MWF5B-7'+MORCO
MM9%B8K&I"/8ZKDWKUV$\V>RFL'  G0+H'+#W.F04\ID_,,.R1,D!J;'W'7._
M.#Y0VYO<.7TK_)E-7EOO):/Q+B$71S1ACB.&+C#QC""6?9:@(8DC_11.P^&K
M8(8K'[Y:JJ]OPP3K(,':$ZS_*W%_56((\X7()BBR^4Q HRN1$.:+3FZ#(ML
M ;T2"6%65R)D<3L$J,K/A4:Y[%L_DPOO/'IWU-^N?_!Q;I^8JII6H[,T]H[Z
MFU1*:<"F$MW8@FO[5,P&A]*X[<[NU3@PHV%D-[T%9'Z0LG=02P,$%     @
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M2M(4@6V@Z3!TP 8$+;8]*S9]0271E>2X^_M*LN-YF5\LDC[G\"(JZ=&\V1K
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M-Q-*?,_,_@N_\$K)^Y$HCZVH.OWO;<^=%+6)HH92%V_#L6ST\3K<86"ZX1W
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MOA?;86(K3&R!6:39&4T^2Y/&\2R-@;&HBMS+[#")%2:QP$0+F&25)DA2+U_
M6%1R9R([3&J%22TPBYIWZ2I-D12KG5FK C\J_G=.F94FL] D"YIL31,&7KJ@
M6:L"WY_+'FAR*TUNH5GDV>6KGS/*5N?TCLB@H-D%H2[L;YA=FXX[1RKD7:-O
MA NE J2A[\F3K^4;,0T(7(3J9K+/S$UI!H+VXR. II>H^@M02P,$%     @
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MR[/TN(I;K@Z1=DTC)4D!E>502E+O1$KQU+M"/>Z6LU$J4#TL(&W,7_XF#83
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M\L[3Y: N3OW[7(OK2V7K_P%02P,$%     @ ;H*92BWA1-$R P  2 X  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULE5?;CILP$/T5Q < -C>S2B)U
M4U6MU$JKK=H^>Q,G00N88B?9_GUM\*: QQ5Y"9B<&9^980[CU95WK^+$F/3>
MZJH1:_\D9?L0AF)W8C45 6]9H_XY\*ZF4BV[8RC:CM%];U17(8ZB+*QIV?B;
M5?_LJ=NL^%E69<.>.D^<ZYIV?QY9Q:]K'_GO#Y[+XTGJ!^%FU=(C^\[DC_:I
M4ZOPYF5?UJP1)6^\CAW6_@?TL,5$&_2(GR6[BM&]IT-YX?Q5+[[LUWZD&;&*
M[:1V0=7EPK:LJK0GQ>.W<>K?]M2&X_MW[Y_ZX%4P+U2P+:]^E7MY6OO$]_;L
M0,^5?.;7S\P$E/J>B?XKN[!*P343M<>.5Z+_]79G(7EMO"@J-7T;KF737Z_#
M/]F[&6R C0&^&:#DOP:Q,8AG!N' K _U(Y5TL^KXU>N&:K54OQ3H(5;)W.F'
M?>[Z_U2T0CV];&*2K\*+=F0PCP,&CS!XBMC:B.P?)%0$;BPPR +W]O&$!8$=
MQ*"#N'>03!P4LS &3-YCFH%D4F1!.HL%A!5!#--)0#J)3:>(9G0&#!GO0Y(T
M2&9T(%A$1K )G12DDP)T$.P@ QUDR^N3@PYR@,'L)7K,[4A'61^R 6$<D1"0
M"%GPHI %1 9,.L; - J01@'DP_&&H0ANW&AY39"C]]&"JAC0.!MIG@;Y7 $
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M<\F4SRA0:3BI8]UM4;&#U+>YNN^&L\VPD+PUY[;P=GC<_ 502P,$%     @
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M4!2SDD95.[4GLF7">BW#/"O<JR0:,3N-"688?T*X@GT*$9A"[(*5>W ?8&]
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M;_1&F8:;3+1&SIFT5R>_2L7+CD6G4I*7]EY4]MZT;^*X"X,#<!> ^P"M_:^
MH L(W@)":[[-S%K]1!199X(WCFB_5DW,3X$> KV8N9FT:V??:;=2S][6H1]E
MWLT0=9AMB\$##.H1GF;O)3 DL<5WX?B]P.X>$6-8(0!-!#8^&,0':0H3A"!!
M: G"=ZL0CU:AQ2#?@BH+\F&-"-2( (UDI-%BHO]+Q*!$?"<1)&@DT6*2@02.
MPL4(M0-08;Q8PLDD8#+)?3)I !,L08+E_*^:@@0IL.++T7) F D1\^FA"O(!
MH^$$Q401HOE6$5AD&X1GF(5 :.(/0W"IH0!P&TU0P,6&P@^XA6L)0<5TYQ8
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MPV\8DZ \;@+5KE:-POE H)%Z^Z#VW X$>Y!LF&8=F@=N\1=02P,$%     @
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MHH-J940T&1P#R@&@AEB .8:*IS=4BZ'B8,<*J\V":EED_!L@"X@@=CZ!X10
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M@;!^XT?^S?'2G&NI':@L.GR&'R!_=GNN+#2R'!L*K6A8ZW$X;?RG:+W+-=X
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M5O-X- B<I-[F:L_M5+*&9-TP<-$X]<M_4$L#!!0    ( &Z"F4KUKBGO[ (
M #T+   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;)56[6Z;,!1]%<0#
M@&TPD"B)U*2=-FF3JD[;?M/$25 !,^PDW=O/-BXA^%*U?\ VYW[?8^[BPML7
M<61,>J]568NE?Y2RF8>AV!Y9E8N -ZQ67_:\K7*IMNTA%$W+\IT1JLJ0()2$
M55[4_FIASA[;U8*?9%G4[+'UQ*FJ\O;?FI7\LO2Q_W;P5!R.4A^$JT63']A/
M)G\UCZW:A;V675&Q6A2\]EJV7_IW>/Y C(!!_"[810S6G@[EF?,7O?FV6_I(
M>\1*MI5:1:Y>9[9A9:DU*3_^6J5^;U,+#M=OVK^8X%4PS[E@&U[^*7;RN/0S
MW]NQ?7XJY1._?&4V(.I[-OKO[,Q*!=>>*!M;7@KS]+8G(7EEM2A7JORU>Q>U
M>5^Z+^G,BL$"Q J07D#9?D\@L@+152!^5R"V O%'!:@5H".!L(O=)/,^E_EJ
MT?*+UW;]T.2Z[?"<JG)M]:&ICOFF\BG4Z7E%$5Z$9ZW(8M8=A@PP5T2HM/<F
M"&1B31QQ<FM@ R"B6\B]"Z%HI.8!PD2PIQ&8C,@HB&X4Q+""&%00&P7QC0(Z
MRF:'20VF[C!9%"2CE'0HC 8P!'M"04\HX,G(QKK#9 ,328(# IM)0#,)8"8=
MF4D<,QDE00:;24$SJ6,F'J<U==*:QJF35A<U2U$P@WW)0%\R(.2)8&:@@MG'
MNTS7'R(M GR8C1AC03<M1!&:Z"(\<3U@UQ)&X_L!.Q5&4_7%X!UQA\D'F&-!
MP^H1G$TU+(8YCB,@HHG[#,,LQ_$G*@C3$P/\=//J$C0.IER%^8DA@CIY3=Q.
MP62R4V"*8I>C%$^5!F86SCZ15YA;> 9X,?J7/%@0'?;11+ $)B !".B4SX*&
MY</!Q/^(P/0C /V<\EG0D!910H-QXL+!2%"Q]F#F,^%M^:F6^J\Y..UGP#NB
M1XK1^1K/-]TD=U73#98_\O90U,)[YE(-+&:LV',NF?(2!2K=1S7+]IN2[:5>
MIFK==@-=MY&\L<-JV$_,J_]02P,$%     @ ;H*92@Y[_6X/!   YA,  !D
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M:UP */7B;/&'B2606 *(:0NQ3<PQ(X,8 /$Y:L$EA5Q2DPL%&I<4#$.1I^L
MP"C*;'0R2"<#="QR[5]29 G!\W)B%E=A3PAJ BW298&GO6 [!)NCEGR@!;TR
M>D)2$RA:3+].A@PRY-GF!IL5XT^H:@+-QPF\4"?##<*!A0JV/89\3]?1!%HN
MDQ?K7$R4?6*P[3'@>X:2&+ U1N;4F##F)18ZV/P8<#\B2PAL4RSY'TK"[L*
MO9A*,HTC2DPAF:A.;K:,L+LP8"^FD#*P1HFG;U (QE//LA$0-BL*GE#3!-(V
M*8WV#J&>W*4(VR A&]3U1<#?B!NKAV!A8MO/"?L@ 1\T)$:F#W)=7V3ZX!>>
M>)8RA[ 3$G!"6^%'V,$H?%YAA&V'4+FE*XR [7 R7R$$2VR;%6'C(51VZ1HC
MLZ0*#(5!D$7PA"V,4*EEZ"MYL!%-5!Y!ED2P$1(R0D-+IL6!64$@VZQ@&R14
M91DZ0OY&QLX)859A<VR#'-B@[:.#8[/B['DI<6PO')59NI0XL@X>&L4PPK$L
MLDZ,Y=,055NZF+A92.FKN>-F1999N6"SXJC<TK4T@1YIZ2%D201;'D>6IVN)
MFY^8YJ28?F>?%.QV')59NI0FD/;Q#=Z9&'Q]LU1GY,].1RK1G(:#I-;9RVNM
M^G.(6>O]L.J5^M,5K7W+7G;CD=./,.,)V.]Y<RKJUGF72LEJ.&$Y2JE$QS+P
MNED[B_QP?RC%4?6W27??C"=/XX.2E^E4S;\?[6W^ U!+ P04    " !N@IE*
M!L!94/("  ","P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6R55MMN
MVS ,_17#[[5U\;5( C09A@W8@*)#MV<W41*CMI7)2M+]_219=1V+;EH_Q))R
M2!Z2(LW9F8OG=L^8]%[JJFGG_E[*PVT8MNL]JXLVX ?6J'^V7-2%5%NQ"]N#
M8,7&"-552!!*PKHH&W\Q,V?W8C'C1UF5#;L77GNLZT+\6[**G^<^]E\/'LK=
M7NJ#<#$[%#OVB\G'P[U0N[#7LBEKUK0E;SS!MG/_#M^N"-("!O&[9.=VL/:T
M*T^</^O-]\W<1YH1J]A::A6%>IW8BE65UJ1X_+5*_=ZF%ARN7[5_-<XK9YZ*
MEJUX]:?<R/W<SWQOP[;%L9(/_/R-68=BW[/>_V G5BFX9J)LK'G5FE]O?6PE
MKZT61:4N7KIWV9CWV>I_%8,%B!4@O8"R_9X M0+T32 RSG?,C*M?"EDL9H*?
M/=%EZU#H2X%OJ0KF6A^:V)G_E+>M.CTM8A+/PI-69#'+#D,&&-PC0J6]-T$@
M$TOBB)-+ RL 06$+%'2"&GEZX40"*XA !9%1$ T4T'P4A Z2&DAC(#<T#9*1
M)P J)D$&<XE!+K'+)1YGI,-D S.$YL$XK"Z*QDD0P602D$SBD'%N1P)PR5"
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MD9D81\8D*(W^D^HVE?J(F#84CE(O4[7FPR0=-I)UXU>"-WVJY/\!4$L#!!0
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MZ^TN*]DU@&;-(6GXC8;OBD7#D+\DX:M)> 1L/B3)UP'%*J"(@.(#@*\#-JN
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M"_2#!EW-Y,@R"P%7#""* 5NJN!: C6"+:P',AF7J%CYL6==A<+T (@6P+/J
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M?D+P4:AA*L?,M"LS$;2UK=CKOP>6?P%02P,$%     @ ;H*92F"!FNZI 0
MG0,  !D   !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL=9-M;YLP$,>_BN4/
M$!.@[10!4M-JVJ1-BCIM?>W $:SZ@=E.Z+[]SC9%:<?>8-_Y?[][P*XF8U_<
M .#)JY+:U73P?MPQYMH!%'<;,X+&D]Y8Q3V:]L3<:(%W,4A)EF?9+5-<:-I4
MT7>P367.7@H-!TO<62EN_^Q!FJFF6_KF>!*GP0<':ZJ1G^ '^)_CP:+%%DHG
M%&@GC"86^IK>;W?[,NBCX)> R5WM2>CD:,Q+,+YV-<U"02"A]8' <;G  T@9
M0%C&[YE)EY0A\'K_1O\<>\=>CMS!@Y'/HO-#33]1TD'/S](_F>D+S/W<4#(W
M_PTN(%$>*L$<K9$N?DE[=MZHF8*E*/Z:5J'C.J63XF8.6P_(YX!\"<A3+RE1
MK/R1>]Y4UDS$IMF///SB[2['V;3!&4<1S[!XA]Y+<UOF%;L$T*S9)TU^K<FR
M1<.0OR3)5Y/D$5"^ Q3K@&(54$1 \:[*_P#*54#Y;P5E^:'-I-DFD8ZBXFY3
M?DC#KB8;+NYW;D]".W(T'G]2'&5OC <D9AN\#0.^E<60T/NPO<.]33<F&=Z,
M\V-@RXML_@)02P,$%     @ ;H*92F(FHI$-C   ?C8" !0   !X;"]S:&%R
M9613=')I;F=S+GAM;.R]:7/CR)4H^OF^7X'P+=^F(B U=TK=,Q/!4JG:FJE%
M(ZFZ[7GQ/H D),%-$C1 EEK]Z^]9,T]BH:BJLL<3\3ZX70*!7$Z>//OR+V6Y
MC7;K[&^[]#S?K;?_^H?Q</2'Z+?5<EW^ZQ\>MMO-#]]_7\X?TE52GN2;= V_
MW.7%*MG"G\7]]^6F2)-%^9"FV]7R^WZW._Y^E63K/_S;OY39O_W+]M_>Y//=
M*EUOHV2]B"[6VVS[%%VN>80L7T?'4?F0%&GY+]]O_^U?OL=O^+M!]#Y?;Q]*
M^&:1+JJ_OD^*DVC0BZ-^MS>I_CC=P(_]EA^?6\__.YV5VR*9;_^_ZI?R\G5Z
MG^$;,,2'9)56WWI]^?&GBP_1Y8?SDY8!SF'V(EG"K(OTM^@_TJ?J>^>[HL 5
MOLW*.;SWES0I$ K1FV1;F^[XN-<_'O1:IGJ;+=,B.H?O[O.B-L^[I+A/H^E\
MGL);\,Z"WV^%V.W3IC9_KWO\GZT?7*5%EB]:UZZ'^/_\K_^U]Z0L'-["PQJN
M5-^4>1O?_<\:K*;PZ8(_7R;WU5_ODF596[F>9+Y: <K<;//YKW%T0W@<?=QM
MRRT@5[:NC76>PY&O2P T_*O,E]F"H'ZSA?_#!911?@=H,<]7:=3YM$YVBPQ^
M/X([\NGF3=1Y=21W)<K6T?MLN01\+>/HE?USWT495W^\3C^GZUU:_E#]X:K(
M%[OY-H[6Z;;MH^BNR%=PB[;9\?F;?C?:/@ 2;=+=-IM'FR*_+Y)5;34?\:7J
MP]M\"V=6R+!UF)5\5]/?-@B[^F+I#0!<F2Q3 $?ZVWRY0^A'R2HOMMGO?*_A
MA63^MUU6 ,"S-1S0?39;IE%2ENFV-NEU6@*RS1]HX@6L;)EO\("J[]VD /7U
M?1S=I^L4[S2^GRQ6V9I(Q#;[7$.=Z1<OZCQ?+I-97O"G .*[;!MUEGE9,EXT
M(%SG)R#%1Q&^$\$W=TE61)^3Y2X%<*_2I-P5A'>XCCE06Q@!_X)_EMDBY8D:
M0+,M #=V.%\T?T :4ELJ'^F\>G35UP35"9& M?"$S4@#X.%K(6,=->*F##A+
M@9ZG^LDV^4U7P*L!@,/EA4O#<+F#?WZ&7:4IC8D/X).6H<U@-:+P1>-^@%]X
MH>V_Z"DGVVV1S7;;!)%DFT?K?(W'5N2$A8A!*5"';7G8?+7A7F<YG#\2H!KK
M,E_!.3$9JEW$UTD)=Q\NSAI64_H77S+1FVRY0YKX=:/\DF;W#S#,<?(9L J8
MG-#-74D7+0(F,=\M$T3X!G)R )$&R@]RSP.\!U=\/\G>2Y[=J*V#MLLC?"_F
MP4=\1K4]?5J#D+;,?H=]W -%*!FA4D IH IE.H?+O,T /LGG)%L2?.$"$4'=
MATI[1YTGY4-TM\P?HX=T<9_NQ<F] ^%=0X(W Q*+%"^?+;-[HA3[AF09:OX4
MH:16+IEF)HN_[LIM$R%G@I6W0E1NX-X9FSY[ <XV?O\-+W[3^ ?B_NMDF:SG
M*4@X(.677X+G;])YNQBB\BZSO?J%1$Q"PDTHA=0;6!A>Q 99Y]>48>1QNL9_
MYW-4<TK@@/,41IH)CM=6O$N_1,*Y!)*_WC8(VW);@ZVVL,V][X!H!B1Q^Q1'
MFV4B:@S"A.23%J98$2P:W_HISQ>/<'I-&^([4])<?$?VK;]%>I%=+;-DEBWI
M:.HG+>]L4$1B\6B=;X$N;9(G.E:_@+ML#2A)4EX!-_R>27-M0<EO_NM63&C_
MO=BE7GKQL^\_-[/#&AO]JMV\2>_2 D5%%$)TEA9$6^;K^V.@"JM]R^%U[WD!
M%9S,'+X3$N?UE]%D\$.Y2>;IO_X!"$V9%I_3/_Q;5!,2A (NTCF106;-#_D2
M!,[R.Q'.ZDBO6R]9U]HD*LB^ZIYTNSTO)C1M 9E<XW?=4?N'TP60.,!"@- F
MR1;')#9L,H!8 Z+L5BA.I(M&%H(TO"Y&;X'3&4&G=C8%R>=/NO)D2_)T\Q$:
MMA+ \__\[]-^;_)C"U0_M'"1YCF:QZBAD!&QOYZ[=*X2O%(/*9#<9(G<YE7T
M?8O!*!"EWO*%0EM 7F;/&';:L>M 9/HR$1*YV5L0D+Z(H9ZK>%4&ZA-2D#FH
MG<WT=>KDGQ*E"." @ $94**U%^]1NH"_YE\R_IL4L!Z@SL(6JL)&V:V=%Y[B
M\2Q!,.%] 8 UON>HGE?G&@C5 U)-,HR8E1(CHH48!"7N5P=-72PXG!\<0OJ-
M_MB\KA:!X84;:U+<S%F"V/(95/M%-'MJ/-+GT(PUVF?0 $24>9HNY!,RR]!:
M5\E6%0W _]4ATMK5K@ (E"_XXKS%C@$'RQ0:$/SM;I5L /U6T?0G-L PC=@[
M^V:?X%7'%3>H6 *>,>Y4SDD5U29X/W=&1IC8<T9V:]N U]1>39Z89!@(9F6Y
M(Z*-=C?\B!7&EBL=2#7[T908$JHZ^!DK3)_I!#\?"+&FW3=]"O('[CIE<\"!
M&L;%W5TZ)P:3_L8W,T+#N;NE^0O&:E5K8E!U[[,U2@5T. ]D<\GRFA-DSP@I
MDJ9]W][L5G"=GO"EF^Q^G=T!@P6D%C*(4U\!WVH0\_ZMX94]O-7,4YIY$C_(
MIF6>PU<8O=Z5($N59?01<.5SECZJ0)0!X8GNE_D,!(%9EM.=!P%U1^($H6BR
M?@+4G1/VP.DMLG*."$=&73'\TK]7R7IWEZC9D\W"RXS?%,405P(8NTGS#5QS
M^!%_>LRV#T"MX AV)2#^#H2M_)YFQS'HP2)EZS%:BW$!B)7E2?1Q5PC%@Z5M
MV""/? "MVVET>W'^]O+-Q?4TCJ8_?_QP\><XNGIW\=/UY9N_Q-'M7VZFKZ\O
MX^B_+C^\OO[+[90F>SM]?_67ZRG=5!!7MQDNLYPOTP)$)!!"WM\<Q='-U>6'
MZ^E_\5N(/D@;MBI6E0 ,6/IJ5Z+Y#-1 $!XW#T]1Y^;]](@G^?1^"LMZW_(]
M0+1(D8#^#43P39D760)SGT2_ %U<EGGTD  ,YD!F03B.9GJL./"=D^@*M.V5
M#%F0 S=X(P'NUY>WG_X\_= \\3I?'_\I7]S_FJV_*Z/ETVKSD*^2&"YND:]!
MG><G\R=4[9?I[M=TE251Y_S=NR/+Y4&L8Y(>1S]-_^LO/T_A.!9PF'A"C=/"
M +QX%+$99'[NC^?7%S]_NGENC$V1T3T@BP-  ['D_0V(QE=P8#0ZTN5-B=B&
MSZ_I'/VJ-Z!SPGTAC LM&8BP.Y!4X1QA;]:YD,!,+$L3E'\"_ 3E8/X0LXK1
M<0]PIN@1M(WETW'^B/K,*EW-8$0A/M?Y'/[[4Y'O-G3(Y6Z#RGV4 W(OBMV]
MNW!/55=+E-X!.%!0A2/:W3_0<'.GCU8)"D &QISS%72#QOB\T9/C##CT@\,T
M^T9.2]VM1;@":7_+9[A\(K!DR-?@LN)2<#\ET"* ,"RHB5P@M-9,=I*-D]GX
MFKM%PC4447(9D*7$ZZ+9"F4X42-@"35\>7\31Z!S$/4I4>24HUBA-P88U1)8
MQ+VN"DG@,OW-D9U8" S^/EW^_I!FJ[2 &R._ Y$!BI2!3K/V#T72?\J)&. %
M F1&9YBA+=-WBI0I3)@_L;ZYSC\SU2/@$&4,#] @K]MC2=>D((\ C(>T$V\M
M?)(7J//:+:R!%3PF3T[((;:A>W68A4/(E7CB S%+8RPU:"%@ [@@-5)/GA<V
M$"D$KOB^R-HP*#"@,EME2 0,PW@ Q1XT"H+A?(XX"/M?I4 2$"/E?@/M3^4"
MP"'.=K#1-8'A(4V6VX<Y3ED^E:!="BV%OY<I^3Y(BB!68C'2XB#-\>LZ?SQ^
MR!\)^KQ;B\6I"/#(CLQ&/ QOX"KM8&!@O.DF@T/ .?^:@]P;H4$41R!28MY[
MAXRP!!7Y)'JW70!5,;\1DRR/3J)/1)]P, ]S3Y[BZ#'55>$"RW2YC%Y??+BX
MFKZ[1'R+0%\ WCI/-W;9$2G\*8N)%\ B+]XQ<KY]=_GGZ6O^,EO?+;/?@/;.
MVKZ\OGA_>0[<+M9[>+%#'0&^_;1&G.A<G'PZ@3W\*5WAQ0!5+;H!!GK\\>XN
M^KB.WJ:S8H>472)5:#.,."1EPX#(;X]S>%U(S(,?24E6;$1DH<[^ =ZYDC>S
M2$$<7Q#,-KL9<*,E^486(JJ#',2H/[<6"R!,("@PA7/^V0H[WJB!1423A4 #
M",-.S1K$.MDB$HSO1RF];01 O"2>#@ P7-\LI1D2="& O(G$ZW'SWP&-$<X:
M+W02O<4W#4TU\3]&R3GX!.#$D YB(%2$)MZH'S<=>BR#ENE+X'$2H5^5-GZ%
MC (T25KH)>,<RJ=B*X?KFMS+O<"?4,BFDT5D_;*S4'$3P>J]9[!ETJU9,R7Q
M"L"'9X3<BW6O.>#VDI0])&H(?CH>CD'8V(T(9!OGQV_(+IFMW+$BWX6=%0M2
M0(FJ6'4"YI^C:%MJ4 8@.E+6S=:A)MY/9Y!#\]O)S0E(=-,KN*RW#VF #R%6
MPSG\#7 )%@2C%BG+,FO$IU6$H5"@ N>[)9!\P094+O/U7W?K.0U&B\VKMZQQ
MYR0S5 ^1O2%V23C8= WXO8RN:\OY#R=1/F'L%-[_1?0&#H1$-'7'11W^/_?5
M$5."!AV-&,LB+>>@HGMHHI6YW_TQ8N\&X'A@]?2F6&/_I$]Z/^H.POEI[[L-
M?4X$S.%0[$[!09Q/#/=WG*Y;D7LF-F:*4XS@6:(X*&(W 5ETL,VN *(&6WE,
M4"(LX-E"K* (%KE&3:<&JOL.AL_A6SBJX/:@2+/,,>(&*9S$_(!DX'"/-]),
M<9UB\ ",#R0Y"HSDXWQ/@J.2-CH@G%I!EBV?5,' K8DLZ$U_.I_.<+>#M1*V
MP .ZL: @LR)1[F8E+!QEH/!*DLC!0Z)Y"S#0SE"F]\*J038D$?>?4]_V2(LW
M55CABYE6&R5#B@PXI<0N4)D0L-DB@\-*]=[+JZH)?X;?R.ZI/IH(I6(2WAX?
M4*-^9)F/[#VB+W*\!"RC>&*&%VRB_CVL!<\<AP%Y-"^9!RY)(GT $:+7[?Y1
M\0<=!_D*)#226="/4"RL$^&%80M*!EH 7@9^$YD",!&U@EQM7'/D)_=I=86X
M)81R43YD&P^^0MUO,'.Y [1T\( KN>5[B(8%1)'*JDD/1(2YQ,'4AB0$1LX/
M8TZ2N4A+"- EB(_K1#C0W&(:C@.XC:[:C$Q^<"!TW?8?*84.KGG93W0*R6:#
MG [Y$\CUC-WPK,B3^0.K&3H+G[I.0B:7&5SQJ-,[XNGR1_B)U+!"!3&%)['3
MT)+G%!\%/0?'(B Z?1[1Q^S@L,D,5+59Q#$^\%4<"?$ARXYXIE)<O\3\L&$[
MMJ/3AN;$:YV.N$0(!8LC]$CDMCP1A67AR_L%2M2H$]DEZ(H$2N9\1/\0+]/?
M1-0Q5I+/*8N*. 2@5A <8:S=1!O9;;X#DH0GA+LN7W+,;=<?QW*F9]BJ6V:X
M,"3D.]+  KQ<)4]"_1$G@5H:M$2IKD 3>?@(Z3IHDAA;*73, R0O:":\'7C;
M0'-C$G8!2UJ1F'5+6TR9S7JY[V54EA@G6OM)34Y^!830">+HK[O%O9>> -"[
MU88W2UB .T[8@L]7'.6EE+R4.R$N&B 3N-78FQV[$.4@IM59X' DS^0K(;7-
M'KL35 /A%N?K^QP!/"-!'S B1;<R<E/"OK8-K@"#\H6830C1T/42?H-,%N0E
M.!YB@KAJ8#,H"A&^,FM!7NGB>D*8/>(E7&;I9R+@+-:6H#11V-0V%%B8P:/H
M3+_P;LC:G/R*VS.KG^4[/H0Y7!82;<F1WG8&-F[7"<9T:OA!X[F<1%.0'HSB
MB*>_R.#X"Y;E6!'S@&)+*+\A1^9 D5OC[TGT(7T,_! %T$80\05)W]+H&?O2
M\?]CLD,%.DKP =Y_=*BQ0(A[\S*SF>8&LPJ2 C2@USG\7]1Y.[UY?40,CN4S
M^1W$GRU],,L7SL2$9&:1;[91XN@T,C@@E"@,T*4@<0A @4878OLT[",(2(37
M.SB6!7&:14XBIL,+'!\'%$)*)S)G&Z9LJW1+IY=52'U*MV9NC#YC;I2@JQCP
ME,V=-.:Z(EDYJT->M,C,NPT93O.-X[+O 0- 2!XRB %XNKQ&('\B!23J3&\^
M'8%J<T*?'G?/XD@R(!B-T-^,GB]Q2)R#B@SB"1##SBV(LO-HW!T?J>Q;[F!Y
M $5$U>72TFL>$ 6I^W4F=@@B=2(\>I,FF7%!HH=YBJ=C.<-Y=+_+2!]F+0+Q
MS:&#(YJ)\WA)\ ?,]7OJ9@>.!.KNEKG$'6[A/D=]&QV[Z%83X_K<[3 CXB7W
MD Y6I.!2;)76_>ZP1-> %W7N E&(W;,2@K)O;6;>%QW: Z"PUT4\DB6:QT-C
MPK'94^/Y";L(]Q,4(0.T]Y(;'P ] Y12ZQ%K6*=$9WGM),O0I6):XK%\5XJ:
M L>UX#L&$F>1.YF22;>)J=L1M7!TG\4PM7T["85 "$35G2T2-=I4ZP6)]QCQ
MC$YZ$KUA58M4\>H%(<T06'W^J%9UMU?%;24PK->%0)O\P K_^$=[+./C[CB.
MWJ!^3?(4K^E/Z8)LUG)]3GNCHQ\B$]1QM6-3[SG>H(]"GP$3WZ2S+5QR3$X1
MP:MYR@GZL'Q(ZW$D:1OO_8G\.YFM?V:SM;O(@_X 5G(#9[',[I[T?&\]PH@N
M$HX'0/?4I6U-0%/.;;C$,:>4A0]E&9/>*2SCTGJ!8.(+\JJD*2>A';^F$ P)
MW @6@+=(B:(P@@!S%]F"2/-+Z7 ;FN6%E]]()G(1&S]&#Z!G@$8OQDJSJ IT
M9&AO< )ZL03V3%*^?J.J,@C1,"=9,%2N>XEV:2)*D-;E:Q9G<AY!PKQH=&O#
M/(ENA!"C%A*[F>&=SQF+_7+7>!/KPV-7K$&:=1%V$B6_N8P(#K-JB[UA_2Y-
MUP9L/-SZ9;%A&M&WJ\0"T1 8(LL<!-D@AI^2[8?3;HBNPX+M3VIDBP\%TG/+
MBP_?Z3YXO\ Y8"].@Q, :-_A,2P_/"-4Q@X'#[79+YJ-JR0)*7EN)/;A[8-=
M>&G4T%<@4AAM@U2X<[.;;9E:]T?'O2[0IVLCR2#:O ^3#8U\ZQ4C__"=59%J
M\@SQ^=)=^*1D.8)R*1WX0O862%/XI@=<YK=DQ2PF,^XC,2-HAI_G'Q*%DBS0
MT*H&%LZ@<LF6)>I-DFZYP$!NDX=)WYL@SR!%4R0T.DDGO'U7-I/:!D@Y0S3;
MAC!NSV9S,+3$ ,[J#UE8>)<KQ\ ,6)V )N*>F@\"DY8J&)K^>!)=U ''%JG<
M,YMG@8BR3CL@\=)RB'P$'^_8K),5[+(GSY5:^DU$[0S%2YH(V 9)F5.#&B[%
M@A<+<E?+W T>*9*8S.J8MV7&]L_JM/="E&P92<E@OR\534WU)DN&? .<A,)1
MB<(H VS"L\(S)'81ON<O@=<HYK!(8"Y%5OY*-$-)8DP&*113Z7*C4"BN%?5\
MJ13+%GZ;M")F$$-&7<;A,6SK&&.%X0N0Y$Q2(J'7:H;V4^]#(_ TC-UP"TBO
MG%EQG_"]K,NII^1KY75;?N_Q-A+V5=:%EE PS_CBL:+ 6_UFJJV1G+(M;\_?
MQ.?D(W,'Z5A=%,(!O* ?1^\X=$:E\V'_:)_&R=H^K _M"2D),ZIU$O@:K6)J
M(T## ^'JDN<D)3(%A Z=>8;2IZ'Q&WZ O]%2R@\L)W<6*!@/QZ_F7GT5'IVY
M(!P?S2670GG+X2I=(PK$3?A24^FF]%7H(?SFB(NR59,^@)Y0W(M^AG3-6]HK
MQE=:A\D>9&6\FEO$LLMNG1Z K+U!N^!RSJ3M'3L@G'XW!L&E(JB$;Z)KO6G(
M!F1Q9GDY:^%$JWR1+MDFBIS*P\UL6V\JT[C,3O/),6D[6>R]5RI=-P[,#CI'
MRK!0@0;"&:-<*!:$C$XC:HRKCYP7%58FEAY\2X[7HM,L);<!_0TX:GD(\6<&
MN7B']-(%/$?<,VS8E!<6&"2W54>]&(@Q^8CT(8R:TRB:,*Z(X$-^9%Z^6WEH
MF=8]/;,?(5+5\;^&FO2[35K[/XK7T)6;[NY!?CKDTHUB'^5137+C:]8?H'YP
M7N-/YX+U],4U&@0W@K;T1)-0FJ[:$GC%'6)_@TI QKYF T15W*_S3))$R&7%
MAA3RB<T0TDC'=UGYL.(\(TJ]1[/[TLWS>UKDQX"G&Y*!9EM[D;W-OO8+ZP/\
MF?=6DX/"W5)XWRB3V=KY^]0$Y7$J&$+A,<N+@BQY<6O5EVBC23^K! -8[K84
M)>Y"[8Q A@J\S?<BB >@@/7N"KK? .)L53[_!<C2&W0JIA(AL<SN4C.,AB/%
MR.Y<NI#F[BD-"/48548DX%M=K,LP"D'%3HGJM0[3)DT44Q8\^O$!J5->!6+G
M=8]2],1;,7_!\>*<T4;AZQ'1@%3CR]E#5C[PSO1"B,%%#D@H3D#>ULE6?)#X
M%ZEVRR>.^U7LIXL-EW^G7O"U&'+K\[FIF*KXRT6>8 H.0=<PW9^*#8V7NV9W
MD=L[V7""#8M4@N$*H(E12E5X&QTP-^G:45FQVGC];)G]FK*B.U.7>KK(49D$
MO HA'*Y3=:H,",77JA#?F%BWVB?K#JZ/\VV.D7T'$.IQK 5FN$:"6I>'2)TO
MT:5U?,%H?"ON(#+,LC#!J:FW>/"NW@7N&_=FP>;"7E@.8G4-ZZR(QHJUE BB
MFB,)LVI\AW-"<: +LVDFFH1QF9_X6:E(D"=4/DQU*"1]Y$V:LY!'PS<LYMFU
ML 64]N8^F0-%*9N@\P*DHGOD1*'-9IE)7DB;?XFI@8IK220%"N"G8Y[.1/-*
MF,]2W(*5N@3&8=R2EDA0<6CX+/9_K691\1O<449:ZA(S]VLW!,.0B BM],9M
ML@_6 V:JAM/)OALV(<.IRTL\]^S2Z\[=$0M"A7$GO0&N)&93BOS1$9KPQS(>
MNES!ET'RG-C.T05<@GR=KCG-0QD382TC?7K/!+KD.D)&>S". *%A?A(^=ADZ
MU/YI;'37;A,-TD*#@,KAQD3&3^X++)ZF\VIQO Z*7EG)88GYW1%E2N5KC#(H
M-*P.]@9@Q"@IRU?ELJ+T<H]I:)PXQLD<]1?%KH.?-&[R*^ZPP5N-NE.':8BC
M?.$J'M28)<.-N>-$!^8^J@ZC$)ORV P2OQ2'A\@E-',=-6>M$D08P6Q U>=1
MM\D]FG)M1O?=I=.%F\!9\N>LR3X:6:IB.-WBL/<Z)B4)>!T;9 ME/!S1D6ZB
MOI<TW6?F$QSO1-\4(R^E#C>\2\7]8 Z.&#?V'"+*(4(G8N?@!(QL*_582C^P
M,Q8[==,81/#^Z)M?A7T8G>^P+Z4,1D<C,ZJQM\JVI([_-VN:;*LZ #,G-9?Y
M=;I59\UK#1MU/O.1\YGK@06Y-+ 0K G =6/A@RNI.>>*CX:_PM.B-AN]W'I*
M@KU>1V"'/5&UY/Z^2.\U[$,B7MAH@4B68ZZMQU_O&: ?"(K(*=4;/)=EI#8@
MAC05X0)X?*@_;5W0$ 4)<NZ?M8*TK$0#\ Y9B'<PD+#E-7'B*&CW@;F73_NF
M:QJ5!7RXY5Q2@\Q&7)M)-#<&0-,*U;RST=,,!EZAG:/-+>..8(E,$U4%X7&:
MYQ'L@.(K=UO4J5EN?$(VR#9-C_@4!D^P$7'D!3'P_V2*RM_MKI_&;! B3QUR
MH0_YNDCO0*TEQOU6E7KF1W@-2^.3'O2ZQWWD37#C5]EN%845>->1ED+AF"(:
MDH*);IP+JNE6BQ?:&!K%<,(R,:&DAJ2X">8Z0=7']9 NR6Q*:4FTRAD9$(IM
MNE:*U3:-Z+GTE1J @,1GR"/GE'I$09U_7W_&MPE6DV#J)HRIE@>IY%=&F%3;
M\*Q>7[;4@#M F# <[@T)F+ <JE>PKZK) 1/]PY)^7Y+B2W^R,*(J<_FTFN7+
MZ ^O+W_^^0]*A#XDY2+Y6_035TZY22FUB<MKBJBO:\04.4Y17&;E ^W EVNP
MUCFB@8!PI!RC3I#[.ND:)T26/U]A#?\VR<V^?*HM<8?QA[FW_*$ABLL%AQ\'
MXR*>IU1T8ON8F\EE>/NN;-=G+8B3S>\+(: EL9U#8)O\=GR'N7JN+)(LEQ[<
MI0LJD&!,$!H.=6(732'HZ4(5)O(&<O$38BXNJ4:#U\.,C(9"'C>/*:S](?I8
M;-!N@5-E:'J.IJ^%7]4&(-_LG(MG5P8#O0!H$HY"I2_0>$()Z)<4#[).3<YK
M%1MBA36.;W:<DC&6BJ'GJ- 9N+O)\9-*UH+^!G3?V_03&\WK(IA-[8"$( _<
M;(L'$_Q03S_$RB4H-INWG!27-@["^C0YAC /0>N'U=]M\/HU%3LHCS2!R>SW
M'D&W%OFI'4E59K.908"GV\=4[56/N1 )9$><C@*H^@ATFV9]"D5(QW?2@GSJ
M6@I,H8PZ&%J[?8FE0DQ(4L3YSHB0G!CNC4F8,U$).?'T"FT6WK/3@!]!000T
MB?,UX:N)1'*U!@45^1RGIL#J:L$'R*DH.E\ ADP./@9X>[.*"3S47"[ O1W%
MHW 0*D;L%>([J5\ @ZBP!*3<$F EMB=<S[T19AUL'2PJF."RW0EYX$3(Q%5E
M.%&G1IE1/N!*0I+\Z00^B<3:.H=$KZ_9QW("M8%B?^$Q5-4&&A]PJ\0'\: L
M+>/:+UC'EJ+V/G.J-\9#<N*_?X9>.5';X 0]#GQ78CD<SF%!K4UN WRY*QC]
M&D:@P2TE=L1Q79+MX@ :Q[5)T'OFXT_;R]O%T6+GK EW60&X)Y4&<.<2N8'*
M R6AOAIT^R>3:,7502/&$!^A+T42*?HT^UTLA/NB;1XQ"9B;.0!HJ B["W?$
ML]  (Y<Z]*R(\D/4 1C) LLC=1V0,_=5Q,MO*+H9]89#^,6Y%:)>;WS2BYZO
M>@T@.NE'S;6NH]'XY-3;H :](0Q)VH+\/,#%\ +5<%]@LA/^^ IN3K=[>C*P
M8:G1RXJ!PB"G$UC"GMK,T7@"B[!3-*UD-#H9&7_'(6SJT;Z6VI=\R+P4E^,:
M/ZS<E2%ZNOR0/>CY&,2LOAH D!5!R4DM67IUAW5IJ)NK$B"Y1.F"$3 P"#"@
M[8@O3!_W%><X>1W7VS\Y<^O%Q%K;5N:913]W=4]0R<2*F5O5T!P;HY(2GHI7
M"$_,7CY1$ PIU1OHC<E>K>$"6DQGTFCZ[NKZX[O+/]/I7KS[>'X[O;U SC!+
M'Y+E745.UA1*SFY:@'2<1QC[N[0OY;,MM6FP_MHBO4</$U[99+<%S54T58[?
M%$RCZUYD:2WVHJ$@RY$$?ZR31>)]?%C1T8?IQ9H^[>DN#UBF!JN)ER3W@CN5
MS;(UV\HV&IU*!-O7U/&GG=5I/R.)=1?5HDLX1$B.L##V#"^;H1%612FQ[L^$
M<S&==%8SJC704+#I)2JU1E]KZ0J;?4A1W^)<SPM?W:"6 !%ZR*:2'8+.0WC+
M2VU8?[&56+E!_5C.E&:N1E*D_K8*4\(3U@!7LOL$J=F91HR::@[:"<C;\&))
MO.=2*51#+-O?T\G-$'\1Z;E<MU,*E>L$D,27\9!,Q$]04$QA)]CN::(GGU]0
M7.,%]68 .!QN@+()DM')\&3HZ2C\_*IW:F65V)S&\NDDNJY4H'E^SIAMQHJW
M7O@X;H5&>RFPJV1+F[]2D?U@$\QCRL>3H)*4>IV4 XY\S4%;-=!;1N]$#XPV
ML@!SM1R5QJ^4?@,-?(X5".&3 6EQ1HAPQ5+H=TH? (DQRT.B6#.T77,K!SZ@
M-P$IFCI25"O>2_30O8T&7+CWZ^IG,0EE^RQMP>QMA/"+EDR1I^MD^63BIGQ6
M1''(O"BF."&;:!*+X#7AUZ]!T\71(F#+\2M\I)\#T]M8?,'UDEVOHDGO!/]O
M2'?K533J@?3[*AIW44!T?520HY42&N?U6"?1!/F,O4$/9-S1^!0&FL#8D^X$
M!#B[1CN&3[,LHRZLH O2;6<, QQ%G2'\^\A%;'[/ ;V'+*$S[O,(?5C+!/Y!
M_M+^C_#@;'C2/7A0N[C.&.D1C@D"]@C_,>*_!X,)35:!=876 *#'(!<"@$=]
M^!P CE !0,/C$6E=6VE?*/B2S. F*?-_EOH&J0QP':B0YR$8Q:']_-]KRP:3
M!IT*%(<)XT=OC+LYM[)TTJ[)C ";!M%P< KH<!MN4R$@*-?:!HE07Y+PVF^Y
M?_WV(:TX['QPU9<!)WDT.@VJ4*<,B4D7\."7O/B5,2:GM-KQ$+%E?'8*Z/<6
M.3Z:M+D808^42/QL(,#P*WL5G8W.X$/2%0?XKZ"I227<^0>CWL*7?;[)J&7B
MO_8U7(H&J$72?YY?PCNG9KJW-%G?"SQ2QY'KMX3 B)&\63S.]JWL)7A^HN#Q
M%8PY! ?O3O,]C%5;\[5!79!'F."DHE.%\UFC8+/MIIVS[A$#S%;:)R1.;/A[
M!=!:4-5BFSDR)UF=#N'"!9+5 !&F1;#:TP;,)-VVM?T* GWJGQYXJ_?-V#!J
MB_6&B91KL63]H+&-S)%FI"*PFV*E>PA'4XJ4/&PHE!E0&:ULM8C>87@ZQ8K8
M5E"!GQD#2)Y_X^-N>RS>EH63XWJ#X_Y N!GPH>$ "- K8&/],1S^$1%U%@'\
M+P/]Y0Q^><.Q8.G"E]E^ FKF!QT Y4%"W^G'X^$IL+>C:#": )6T/PR&Q"T'
MP$BZ<%#'BKNM!=:QO36%)*9B0*@7S1Z3X4V9//^%*^CZ9_37+3HQL<RS*Z\'
M-"99D;_)33(>!M_!'_4G4XTGQ&'@;CM8&[>:@GUXW#MU #H]1;;?.9VP; .
MZ:&H,HB'IRBI=":3,<&M'T\ 8F-'G2OXC'; N ?[1#K=&<;=X1G))"!6Q+WN
M@ 2-23P9]OD@!_'9@.6>5[@&,D*^?8&:='@#9$]DA@#QD:$I9 G#2#<F7:].
M3P$"QJS'T0>NYD901U6J@Q[>\OA%2J"P)@#J8#0P=!!E!I/[O0XIAJ,2E;H:
M5(=5;"5;X89+Y_LD:^A;]H=%5]1&Y+NRQ;]G!C9=.I#HB,/!5=/"$EKYX\E!
MUVGF.:84E:U*YCPE=C[.[E6PGC]5.M7<+=%1K5$X+V;#_ZQ,^+F:':(A'*S;
M_YTK>GN2?.M)<B.=]I(:GW&I^,I=7]32X:HP):6WD;6 &(CP/1N<V <O33V(
MT;^Y.!?TUBXYJ+)R,I9<^'X7")5$$P%:YOFO-H [D]CM9O3!Y;T: -$[-:ZK
M@"A?&J)\[8FR6FE>0L"KH%/(F89?&I12 '?AZJLR#MY=;J+#47\7<$\"0&R6
M\Z\"0C\>]DX-T:I'9C^F]6@(ER/7')8!MX[;)V!DQ<UC!O3D?6!T_6DU^Y,+
MO:#ZM7QU 3W_))G#V(HAKI"Z:/K]3=0)GQT%40O.\,;%<2TZ^O RAD;5(5WW
MC83.*W8VP-C?C$);T_Q7T'0Z,J6N[(G A=-+F^2I"L-7H(&/HIGGG.A?"-UJ
M.3*(BD5X7/6K48C@,:4M$2?#]UX-1T-SIP(K?19$I12IA+:Z28. =;P?BE<U
M>+KH]688F9@0#.28POU;4OF]6 I#4?QOP4&U[,8V_%$MM#6I^_""3.%.ZR2\
M1S'C04/;<]O0]EL66?HEY9)8")#:R=N:&Q-!:7^^ZYI<1$<\.1N!2!YZ_/E7
M=Z820%A/JGGQU7GFJ)NN@S>V5Q#!4C5.KR&YSF><5BE=A0;4, /S&7B@98(Q
MVS3:+$7))RKRIV0)*W0YJUPCFGTM&AB#T7;-%(<.CJM$/N8MF\<\I-TV%5]M
M"+>8 A"URX1"W3S#EC QIRY1?MV+Z,W'=6,Q#YIG[UJED\$\,QA[EWS.BY,J
ME>+(&ZX\MI#H=J[W3]'..?HE4PS)P=N&(Y84H/22FFD*OZ:2::<Q*-,:]Q1]
MJ7@UI2+*6%<NR9;I(C@/23UGT)L8]-C675:'+/4FT")0P5UB]J[2",D(%4CJ
MM69WY;INJ.#RH2C$APE P<UU4YAI4<JWA9U(&J\4EM'P+*]!E $8ENE]LM2C
M\-$001"!%M!0[[2(2$T23RN)J:MX7^".!$ETF?W.7F-?V1^_DPK-7%?EQ)AD
MWG(0757UK-N<J-.)?4L=Q(#?,RT&19I.T[QY0VM7:=V(QIZP3D,5$DEH%312
M/<)1Y4^-8SB1/B]87U+B38A;HY67 B(H-(I.:/XT7[)$(O&9% !A?%V8BCG/
M-C0SUE:@:M6.?J/MO+8.R8%PHV225"1]6HC%8TPU%8CV)0\^:[T+4W9MGA7S
MW:K<LNKY2 3:0&H95&E_=JEI1DJU@,D GXM0$X"B)@ 14?2A]ZH"/V3%HBJ#
M:5TP"L:A5;&7A_#"X9P$;K[ ZE))AYZESSHU.(337$:$,MM)R$HT1*<,I8P/
M^R/^YUDT[/5/AL0VH\'DE)[V>U%_< 8"!?P3_D,F1&>9;0HF-"G$V E#@X-#
MSZF[W2Z_4<P6S9O1"2L=;T5N0)O7>'QV,@#M*S RN,'1$SNWUZ>I*UB'P_V.
M4,OECK_PLANB/\)P0X[+ZYD@0=="URZFA[:^V[K5PXWF)#$..>+EX4NS$'W8
M)O%9Y)X-ESJK26U-NTG:(V__QUE!;CDQT+5A=F TX73/&P+9Y.&HZ*M!MWO2
MM19*4^,&GL)US:FQXOP!J]<OH@ZH<,M=*=V10),"A+/V35]HMSS2<BC:T(:U
M-F#JE20/5'-MCW'LU.A_DI@DLC2<".XY8Z:M!;K7E'=PI5HA2P8,3CC^)EOX
M$E7K&VI:C1X<"8O$6M:![ZB2QQV:@5VJ==61]1:OYL]T-4U]N%K8B7GMC>GV
MU>X@:QF7PPHX.) LQ"XKMU[!D Q:>\LH:F@F)GW[^J54EZ<H,&4]+/'&AC7N
M2,PZ%HJ0MB"1>1FN4(& =\*Q+]+&_6[_ADSZ424XB4UUT@%U7O+#M7CC0L[!
MGI7_W.5X:%>%!F1.V<3$.6I ]-_1JGM'0=UEOFH??=77RS6(O^[M?OCVIW7>
M]N9 X]E_X(!VTWL=(R* AF",B+J>ZD]XF4V9H#\X*V,]2;0?C[I=XS"K_OT3
MY0))K*K[JA=/!ACRH&]5_WX/TLH]=LZJN/2!9\U_)5N-&VHTQ!@8_3#\RVQ)
M\@;L&C">@OZCK^O_^_+_G!M!G32&0S-P\,?54NOO2&265H -2IX/>L;Q%_S!
MV/,J&L6C?I>\IK0J>M#MPXO^C$PH_@_-RX2/!Q2ZX0^Z\N"\K;R:S=T;3KHG
M9S7 \%-=[Y!\_PTS\6N'.:S_!UR=/L6NA#"M/_O2ZS,>#T#$\]<G_+OY^O3C
MWL3B>?7OEUR?<<_<@/"OO=>G/X0SIO\<='W&%N.#/PZ\/O;&!7\H.D[BT>B4
M;@NMBAX,!@&)^\==GS%&*]:N#SWUUX?#W^K7AU^C'HB^?< Z#VL<L,3@TS48
M@ <PTQ<)LI64QZTT9J0 <"L6-O)8ZI-+]\RQ6K3"NBIJFNMI%K<RI6Z)R9<O
M7>]M( T0?(0<1+:FI>G%@!IW]=9SUE';C68(.)G!)IBCHHX.)_*2SKG7J'8+
M(M%86M4Z4PT>'LRJ9>K)%+B0CJQ."N1*\$&[B7U3?7WCAQ8I\!N*R-7>./[@
M%'4K+=APD&II4O7IH42IIQRTR?O[1%D9Z)SK0OG/]E^X$;'1T]YB&CT< 2HR
M((U1=(W^EZ)Y,5KHY'0R^F-TDZXQF(6'6.Q26;46XAM-1D"U1R.TEXQ.!_1O
MLJB<G&%_U-K7-]AWFO:'M7')!-,#V0.CK'KQ$ ;HT]\]& +_1N43*%._:2&U
MH?H4ZHFFG;.S 0W0I9@P_*L?#4^ZHX-6A!^>]C#[#47#$:UH<H8@P;_1KPC/
M#MK<D(8ZZ_*G%-<*?T^&M+8);5(I\C@^'8XH#&H<#\\DDIA"G/09&GY" J.8
MN=YWO.1R=B8Y;L3%U,6V>V!::1W!OM:_5,REH,SG-/ &"DAY[[)2;$3,3P/8
MM9$T7F=L%\IY(T614T4&E">HBNG!RG_S3:Z3K%Y,L70S^(QM/]^,^!@F?AXP
M\8^&B7^!Q;$"=EGL\_*"K=A4"B4;6&:()%D\F+?$!-\S$PSI$I$PWJM;2)L=
MDZ4,4#*Z>*NF<FAE36@Y;^P#T\/[A!&!FOR B18V.\(NH&JU9/T I\;@P48Z
M3*5O:E0XYNS.W^@B+9^B5V@I[87AQ_WAV$0=A/''\8L.A5:OU[7I3#2&VN0$
MAVD"^9[4ZI?$IOLX*6]D-^F/[3G)[7D4=7M24Q.!IIP(%\%,')P2>%DY\+6I
M]IF7&ML?/%,I("S,)*(NP62%A5)=IV??&/RL&RV2)U/+6SLG:MVK@$20^.>J
M6%LY4%TK<RD:P@V7#SBR?>D?Y[Z0RB:!6\&94W@CR"X 5SM]4OZ %<5 2^NA
M6V0R1.WL!BMP,3Y5Q=+1D+A<GQ)J'%<3.X^JK+<UOZZA5>'"@H(@@DK*BV*4
MPZOKI 3:]O69VQMJ)&JXS@K[N3_<QEH2)L^-5E^5U[4>0Z"WQA7)O][KYR"+
MGY'S?J+BL)_6P+A8Q_F)\M!KCZ5?Q]1U@*#0^W;3@";,8?),__24I)$NG62G
M2P'?_ ,BQH=\?:RR CP#N:D/Q+D7=084'X^/,+R[V9B@\XPI*0T+5G2ZE(V&
M#\:5L;L3M$Y08MV @L#QT9B0]F"3@TZ(BZMR&WQF9QR1/["'>^G1HO"!2FQ[
M%#0,7I^<]DAP&W+@^BG<B2/Y@5:\Q[H14W+XW)\ &^2\JM[I#66X 2KM+U8;
M_A%(,^R>$H?ODID!#E7R+^"',]A_!6E&)&3CZ0^)D>.C4W+ [D.:7HPI:%U%
M&\8V?-2K(DX/Y>DN_*\SH(/$1Y@1]@6(8U,HG&VELJ/1:*(9H'@; '%&9["H
M Q!G% _.Q(Y$-+G3Z]$ ^,NPBQK:2S!';%%LU^V<$80(:496'[<9N.\=U0-*
M%% G3&"V7/8V]/2'_I)*IQFA\'MVWM#UC"H*^Y4)/=Z;]/A-<I?,1:E@_B'O
MO.'N=QC@1ND?><&" :+^&:!F7_XU$;:(Z<5C^1?B"'[/!;+<$*H,F6)/^#8R
M;?Q_5!KA_T=]& ?_GS*<W"CVHS$2./PO:.<3%%3[DXFC9PTGT$;2A(99;%7L
MI!A,#!&[3_V)?='Q-V=;-$KF5'(QD,WA53'4X1>^1E>UU,)5T';%7*U*O5/:
M5]BCQ0A_)'A0JC45,6C?I2L\PCW.A<S><^D8=%8RP=V#X2_2PZZ>7S BX^DI
M,RF@G:?([*[#A;V*V%2,?-G])"M% B6L2/CV#96?O\_F0=KNB]0L[O&APYC^
M7+Y @P8J89S(0G.B72--Q&>J"79V5LT/A2=GK?J9-^?]G9)\/SZ_,Z>'VVEA
MEKH/Q"07S;+<9,CXJH7LN@[&P? S"G[@ZM B.C^2:1T1R[3&"39.0&E>1<OL
M-27/^#SV:'G-;]%6M!/ZU#=>."CMMF7(MV++.E=;EL:KGCN/S+&;TW[XQJD,
MT3T7A/7MA1 ;;%="Z4GJM!P7J$>HY$I>>QW9UO1QY2 H&-_T5W'QI0NL35JP
MAN),@L_-X?PT,+X9A:+OR,E"@>/E;O97J7KUDA"<2RQR356.<KAH%+F<:BR4
M#(/A#V5:'TKM6=XC!F,LL3YMMJ[,@_<OGV<<:,EU#TWW5U+98730J+>J-;J\
MGF>@<^+P8L^Z<#W2->8EE WC;Q8[UPG^+NKA#GNGRIZTG*F?R+O@@"; HA(U
M]6C7H^@!$)2<#>M%+$UWL>G'D\:@<0W'K<\ZBJF\YFY=X3\HJ+BFCGQ>!QP0
MHZMTKLS606C1GHZ]'9SJ",,V?2HD[&KZ\?PRR+R4<)^CDRI3,MQ2DRM\6I7!
M! JHJ2[7=I$6;/!]BDCX0%N-5$S2IF,*@UF*V$)07W!5/I.HPC;?^HUSH[M8
MZ@-&11( &!&<8K8VYTBO!T7"&D4)>S[:0I-/059S1%4%)'LOEVOBJ,DAU]15
MS S35G)9HKF+S]&F]@)"'W1E7%.M1K[W&;TN=D7.)HO>B)2ATPE:LUXC$\/6
M<3 @B(D]=-@[TS/6V<N UC)QC$9GQJG.J81WV'PO&MG8(9:E#P 9J<+#,<G^
MO!@2,<,.UK4(V .I)AU'$GHB7G8S$3]I*\+QO9T7DQV$8MQ%K_IC$UI*$E:0
MR_HBZAB*YK]HX5W*1_6;LU726PJC<. X)X?"9C^[7FB_;0VQ)3T5**%F9K\8
M1CR-[]O+(<Z^BQ@U#V/JDA=U7*<MJ@.@DJE"016NPNZ.8J(YD53RT&PS<M=B
MM18O;0@?<ET,$)?*MSZ#A[QS[,F'!:>_@6BW3:FRL]6^C6NB)<"T[53M0A?9
M@FKW"2=OSK9\'L&?-<AZ=G @ 0N9ZX/(?$&#TA<GZ;0H:Q>5R!&L<D+VM^\[
M;&\[PMX>WDQ,NILP1CB@CPZ-I%MAY\+QO2NF'D<M8WJN!^/@*SK"I6<J?HQW
M&JGO]<F&1]>"X!@Q0'35U?2M\ABRA79)FSPSNW"$GS3(GJJ2^(_6<3I=L8F)
MT>]2/=37*&L^)[UK/F/ JL*VL.5CLK$DQ]=K=9UB@SJ?).M2751"$E@JJR2U
M@44";JV6C=U>M-XIN8Y/SBIA!G$M.;2^='%/48U7;:3D^+KOIO5J/!D9ZJWZ
M+ZP>^S+!DWJHAJ8H[ $6%9^M7:>T;.!I1JW 7^J;C9(M9W1H7(/Y(NP%?!+=
M9 @WSN1(YQA?)"6%D3 U[)[>)&"MDNU<BI6CP<:*8C'E>I:N[X2D)$4/V?T#
MMGQQUX;E'"F&6-U8G3#SQ/7ZK6%-YT8$X+-=Y]QRG#F&51BUINH46!MW)1<X
MA0V,J1&1:Q'"R/?<L5I1M[9:][41<5]<"/8@E9SI@E?J2Y>L2?>";X5KI/ ,
MZ8]!%:4<0H9KH)WEFDFF5MRXJM36)R ^9\)-'.&PIB!7B[CTZ=746DID+,$F
M'QLG.DZMO#"96_?=<?[(RDRU%?LSYF(D@Z#L-QG-NGT;Z/#E,MW428]$?VRM
MMEI2=+BLO:BW1ZEY4?VD2F6G)%QMWU3Q/:S,D_&Q!-CZD $U<^U--+C0OY"$
MUA=8!2&!*?,M5* N'A)[D#+6^=T=NK+\R&UY,2\S8CX3+E$A>)0?9CL+OBCT
M1 UJ!G\MH&Q!\;QLXCL5,2Z(+0W5Q; ^I1-U&F7=!K'B!P[B#Y;'A$K=<:[@
MV0 #C_86M7Q%KF@-&'\*!MW39P$EK/[>E@JOHHE+[C0H^8+%(W'X@H6A@OME
MH*]3E:^#_@C]%,] ']7RYDWN!RZ&+'P-<%% _@+@GIUTJR9OWQ[DRK4'N=#V
M(-'>7U\V5+O5_1M.LK?9246,VH)P5F[S DMUD?>YL63F O.2T7Y,Q3JF+;]$
M'!._9VYBF;T8*P)70@'QX9G)G/T*MGF3+^&H=\4Z1L/3]O>T6.*';Y,Y(\HS
MC4C&5/? M5Q<BIFR951DF&-;L9YM76_1UE5&G4H,Y+AO/&Q'L3B2I ?%;)<M
MI?'8+$/O4#8O*QU:[G0/H96FQ,()<'[DN'ZAP4'R7%^-NX$EBFQ3I[V@E&/H
M_G,-4S6:<LU=[(1KP;Y!T"JK+1_"][3:F>[KN6Q<:V.9F_S@_*X6;=JSIC85
M:_9/7KUE'"O9_'3/3987;JU!L!&=%RGGKB/TQSU3G,F*5?4SDTH:^C5=*E^K
M;@%4,%UC.$B#>4TJH6%[#4 GMDF>COI!Z:^@&LQ!:?Y4&P@396:L4WWS5'^)
M513KO%Q-7CWF4-@2QL%:I#PF>XD\O/#.D0!(BHS(?3/5_T@LKFK2KN3=_(2+
M:0TG0?&]&UK<M5D<EN/;+9_XR!!TKW,)/G^3 <4$DENZ1C<I5V6#"Y.L^*!<
MZ.MN0T4)T/*@!<!, &BN'2D[-$UU%<@)<,PC+;YB&^N W)MRBUYNR[MF4T9B
MZD%,03FO@WUG6ND$ VI#6.YMO0AJTQVB4#S:>182_T%#47"80KNEV2=UO]7X
M*;C_I^9"F24+F/=3FL_A2FS@^D&SXV6>!7.[S(:V,R(CERWLUOMJK.G;0A8M
MZ^[03'L0Y^O.L&=8^D&0&U" EGZRS5V!G<KIO6!9PN74FF[ 1#VUFU<5G%H[
M@$XPD)&X4LX5"=6XVAPGCW(7$#<TOPMCZ&#]Z7FV/:J1G'4X<.8&[GPXOSQZ
M86P3?-*67((QDUQ#&LT6'SP-%+]-=5TTE,B(6-Q$S,\=[KCQ-C#>K=-MFQ:=
MV$JL:+Z_7S/#@_&=?Q!S3VB^:EH*+EI"9$\&509LY5/MZ6W]4FK(?T?[>]';
M7S45>R]@&[< MG;YX1^WH$.,$\8X^R)_7X CLR=O@JHZGFN!U<X)0S9U%SKE
MXFM)FL/XV@">>X>A2@%O,?[C3Q+_$7R)45TI=X_;$2FX G+$K(=DI]?2=1:5
MK?#;6[0O2EL_V^KFX#8\G9XF"(RP*P<6;>_31<)_#8;JN1GTSBAP\..S;E:M
M8^F<8G.QT';ZE 30Z4WHON*M)0:!:2S:=ZVHN=)>YN-%8T$EN<RUX.'F/@@[
M5>2U8^_S@2]\V3O] <'*+;TS.J@#3X?*EW%Y,_*I(8S'"E@/X_Z(_OG_HR>#
M;A2DKTAF O6.(7#USD8*Q'Z?NPQ\!7;V*=N \SYP*@P?Z4B'BF^%G0X53YLQ
ME!]_$8;2\DDG,,L?/(^>8S'V,62'@H@3!6R/(L<9QB-.2#B 9"=?":\JA1:>
M<:/ZF+$YRDP-+OC#^%"C$./%%KDJ2W]5FJ+@Z<91(-H^'S@353ULF=]49S/O
M=TVV4WT)U6!"]>J7Y-0GEW[=7Z]2TEY?/?Z(_]N[.(>N/)3VU:I<J(#]:K$"
M0/":L4)- 9C;2%)NZQM7^L8^VT=M.*Q\F<VY'46VW&VM^6&C1>/(_C5/EG-M
MT?.E,?P?=BL$?5[\8"79?=K\JXAU^5?1&:4ZOTFQ2NN:Q_@EQ0IUZ>)8DS36
M.Z*01EL0]<&X7#!H;ARA GH67;BP&MH\8KXM-G1#ND:^81I(ME+0=O*G-!4U
MQ.D;:$TU8G$ONLU6Z3&:Y5,NF5MD<W84L_:"$4E(B/!_G*A1^8DQ[8VN:I-C
MP&0F=C6_,;P*R-5O^,]=*7'6<E;D8FH_5@3%&?P729?K[?J;1-FY?%\W&!LW
MC!EF0]U.>'@><9;.$XR&Y@14CBB0Y&ZL]'KLP$R/X.K:OJ?D_VUN>W*@L<MI
MD6PS"<O\X$&+IU.AB0:Y^L%+8(1&LZ6N>&P%$GL@6]%7:[9+.J]C+ANJ>?^U
M0'^?#<"9SKZ$T[5 !I.T@)8TC;:'"C2^;A\&<UU(!,0SG*TTWP?EIGP$Q4$M
M$U\0?-9&9:[;FNRX[-,^YG[='- )N(]YE0-,X[Q.V33-A@WM,N2H?8_DKIO=
MC --J<_6"#.1SHT=OA5&W-RXPZI%9T"<X^8E .59R4P3M$BF(BS4/-0P+0DF
M5+F[TV/!^D43'FB,I?Q,E.D'*"E]+0I5TR2"6BQM'XM-ZJ6LJH$JOXJX3AUE
M@!] X/M8.V" =)PT" WAE:+=Y"3F%P>4S]M'%E[Y!6OKX"@7^_@.FMBQ5-$_
M'?:]BJ0($&'@+S[%MB58UI8,J9XU_EZ'G*LTT0[<1#I9L8F*4(:CG!$'18/0
MI%17K=OWXCF)SEE2II 3PYV<IR18M?7>TESJO=SZQEJ5@#HYTH+ZH2/X7&(N
MB"UTPR3.SNS-M<)&*JK!5S?*()4]B*O+JI:V&0_Z%!2ON%NUZ;!2#<MLC/ \
MA"532[^'U'8KEK?3WX#04K$UA$ 3LMD@(;(24[2?ZT)6.PT5 &E.BI=LB+DI
MK507MUS>^%FT<B$+]EY1L_"2Z\QQ+UT-1BQ0V)E7NC_PV]D*ZUNQ9U0T<&)%
ME/)LP<Q5H>#R;_+2QZ B$1*K,2.D.C5I]-@T?>#3IM/-"RUQQZ<I1!L>ZY^N
MNRE&V6.C<^=(KH]V5UG6+'=#NE8SN"4_K'L<+-9C5I 8P;_)S%+E_#/UH1 _
M.Q:K=MYOV$1VGU'6CT"&;SFEK/I1=VNAWC(\[D&O@^EL)]-5V[W"8N!OD4[=
M4.8M'O4DN'PADC['N!0D.!WA/9=/"OW&Y!"LUI]_K.I%*$<2((C(-'DHU07?
MZZ*4"\0R*;CL#T<%:O:="Q'6(D !%="K_CE?@J)77X;47FR=JWEA3EYX=@%\
M/RKWF_/-L!9/Z580WC^&<+Y@^PA%OV,O!Q<6F1[C!,]=8BW"SWXQ5C/*+7]J
M27RNC?E8X8%9 <VH;9$6\6R.LI9Y*D==0P4]@QP0R1PYOUUK*D"W&Q4FU90:
M^@H3"[I-?DL;:ECI;X=V#/9C15/G;I/P)+M]2N2]2Q<DEZ-*L*,NV"B]4CRW
MIA-Y?' _M>?</6/-NG'3T#@#=.K_4?^/K&LX2<K:.9KE>1^Y3R-VBJ 6.NEP
MN]USZ69/P?MH]W$&*+1;24E7!H)8PCK\_97SU-:;BZ *@P4.PA: "]<LOM-7
MQ]^I,VG!O,##*/42E*R2:JET79A?CZK/#**+.E#[:(;_(TNT?WQ1DUH;+$-W
M-5FYUF'4;I(<P)ROX'M%M)QM)9:&,]<3@")<8=]U T;'UC#)O2-U[F X'2),
MFE5\BR45@J;[*X"S7&1S+M:;4)<92<W&=]#PX2"-](P0-HP&2WQBOUY*:LK%
M:H]O]HC14:SVTLPLB9W88K(TP5K$'F"6V3H*KM(O_D*4NUF9@3!!A2E)&@5.
M"H(8YG?\EG ]RMD34!8X@%V)$])2.6:!ZX/]@H%W2V=")^"GL*>UE"?F+VG#
MM&JMS!!>6B\?Z>VP(,5I$)IWZ2-:G%(EUA)KM\XI*C4M;.1X,#SIL;2AQ)T!
M%X81"0H0:T!2#BXQQL1[3/PKJ*:0=%3S"K$?J&P:J3LBJ! 3-LTUI#!');1M
M9"/;!.G?)-C]G0CE5$#]%'5N_F-Z>T3SX94N2[5Z22(+_G '9#7!-HO=LYA#
M'1"NM#=,DZ#L>,++!^GOR11*\8WD-D4R%9LI5$&*\(6)7]D:./=GCG&4)2=W
M=T2@121=\Y%J4J?^6&KZ)XF&U 5".M,1CS*[H]TNEUY8%=F,AI^E2VS:PBF_
MPD&EEN8V^35UX?8F)A87@!<;L89J/]<8F+HWC(W)5T[T3I,W&'VWK'U<W ,<
MM!F]'T2#,*]L,@#LJ6'D?9:X%ZU-J+3+E'29(=Q\OEXMLS&'9&\AYQ=92%RB
MHLSC.M7WV-Y4R:#JC+E:66?,I?30<Z/^N3PH3,/.D3[QM['+HG(E,^X#EP^_
M/*0:JCT&D7X_P0)L0^>$V9=8$[CU*.)26:962M-^<DVQ[MJS&T1%[@I*E["-
M0)P-1B8XD4)Y3WL3FWG^%3E)$EE_82/K><U[@N[)TEUN?5:CRMQ[2V^J$]9G
M^1]4"Y;JP?M&36@<&E-HQ>@4O=GBK7,&#E&CI:$!D$-V4TAR8O[(E5M'773F
M8N#Z.+JF'J'*=KD)*G%1U.NP*%0W0N?XJ3>JA6H7$2+N" 48C77V^J>8*'+>
M%D+=ZV$EM!Y%+YQC?869MI%VL#[%Z.W>@)IYR#GXSJI+WQ*SI0=TU=S,_8#Y
M7(>4]SH^Q5(04OQL7WI%/^X.AU*D[:R+EL<K*7F/00G2E! %#!CI*3J.II=O
MIQC[V!://Y&@PF3^0-%BQH+DE/DK9]NZ3K/5;%>4_ +WD-JF3L?!2;%*Q0<M
M;_,>"W^C'2F:WE-^7P?___<LT5>Q"< R>DLMS?,8&3PN^ C11ED9<QM\_!TU
M*\A69= OS14[,[M'F:1T]Z$(5HW-X<3D0;JQ<C!B;39+&:G!DQ/Q B)P\>DZ
MHH@"TR>=*F%30347^VY@*7&OO@<UW(555DI( 7=M%3FL]:@JK:9Q$<.>"=VM
MYD,0HKA\"%-@IG0^_=(U^2VX)2L*ARB;2RT<#>_6H(?J>XJK#+Q%:%;6PCG<
MCQ$?$<H_4QQ=Q2*24$)D)&1^[NP)\Y_M7FM"Y1O;W^VI]XR3_ S<5]KG")^\
M -J)5.N+/]RK>!\Z1B"+['GO8[L';U\9><%-?8'1G0[@L\[E4Z]UKLQTDDZD
MLAMK@4]"J6&P KC?AQ14C-5JMT[1%_(1_F_Z$](N$)\GM4H#&-5L:74%51K'
MZOBG1Z@N.FV+TF+-)].?8F?FLAY(KO>OI:%M%U'8["Q?9,8\%@COT^7O#T"%
MTL(93N'^(X(&N\83P6:RQ#5)?D#;_0(A>?=D@@CP%B6;%#3#N9T95R<P1K$"
M6;C&[U0V$E=UW=9]+9>FQ:W4B!%4$=KJ4,!LA"J\A#T4J"C3OO.O#*&A"$HY
M69]X3'T)4DXYLCA 9+5PO6F] D_35WO^ OF2N )V, &Z/GF[MO83MJX#DEH(
MNA)=3?T;L5H3-N!PW*;%?<U^.KA)NT*"$LK=!L4O_;(%H4]<<(?[=O9D075'
M]1-:9O7%K)Z;CQ)"A%/2%#NA]S"-!F(<GL$NBNY8&A&UQ*E7T*;@T@.V,;-T
MNO!$1Y5*KAKAL,_7.43LDTH9[6#)C6;HZQZXMD+K7&=D1F,6:2H?&D9H<N>6
M3QY!A&^>H/WG0-+\BTN187-T^9!I$16>>@^IU6LF2??VLO*57";S7^U5VGMA
MVN^*7HYR-S>"5IFZE:C<$&Y"N4BE#.@AE4/=0;9<DI<F9A(2L]^[UMD=\:VR
MQ+:ET1!PGJ]&@VIUUZ&5#ZN*'K7!3D!4VZV""CUD4*Z5G]C'7$L6:+V%]MG]
M>'3W=4J4JSX+9D9$/;$]"PN2;VL$4P<(F*M#/Y]4V/1KK2CN<[3O"T*6I#;9
MD\ZU8V'X63KQ['E]&?4XO)M0!6\M<75:9/OR6L3F@^7/;]>8J"H"&\7\<VK,
M(M>6P'S11UAXL=SFR^/W3QA!<0.PG\W(((<&UH_K: K"RA*T_]CKRZ$D:H5/
M*ELG':OA*-4"\/K]S?'9Z;@W/D6Y\XJ"?_K'".4GPE(X)+1#+J.5:,Q\S[S(
MAYU VV1(T*K?2/-KL6E00.1N4X"0-U]B19@-7'70OJ]NKD#PI=#0O;ONP'J/
M3LRJB9NN5=A$3UYQG[(6ENQB#1#9IJ3V):1>KTJ1.HEAEZ3<HQ-LF5)G+_IQ
M5E @2"56:/K&(.L:,#A?I!SD)^ZD7;Y)0,&F,GMX[<L(-G:"_Q&NG["+GR\,
MKRB18-85J*(L @,]!I(>1QS6(C(P<#R:!*C4G&6#3VLMB>A.F7! 6LJ3M3]Z
MS(OEXA%(@G3=II@##SV2S%W^;ETTO]MA7_6*HB'EG!OE<GLR:P48 >'2FUK]
M,E?)KY2#O-O V?L6XYP3&G1DIS"/]S?PQ9/;G&1)#WN5UNV&(CF+H'.PQ(R0
M#H$+->L1%:55$?OA:F:D:/B63D%'L+ +.KKB3:OS["I#R70=<\"BH8:P"Q^\
M@NF0*C:J\,NHSD[,H7B(GG#]+BU\5-FP7Z"W@ :=@;#0@_G$0X458!P?]!J*
MO9;^>#S]9 ^T;A_"LKKD(/?5L'<P :E2&B3B0\KLTCB,PF6@:U#"9@,4BA;R
MF&0VI&[GL/Y/2;$]OIGGV^WQ->B9P/&F2.T+F#BZ7"$G%(H^Y5#\WMED7/'+
MKJF,L(O.PV4O<U]XN$1Y<E&U=H% -YO]G*5\L$YDV:_VVT\Z_ =0Q@S+Y2$-
M6'Q65GVH8O]?EQ]>7__E=HIK?7^C90E=DP=U]-44?D3$32G>7PYD@UMEP$(#
M)E+!P%C^+DX^T6^NO$$[!<*O9,-B.?#+G>?'L+Q5SD#RLE-P,#07CN+J"V\Q
M9 J=<YA4$QK#;^6G)U=9Y7D LLHKG(DL\N2]>J"( I!R4-SAL"XDG8*4+=,Z
M[S((%BE)22$=?=EQ.HJ,]SV) #:X)+YV5'Q6 $L%WL*(!'0XL>%1@(G)2EA>
MFH(/TA2]X^<6_%>Z][5K8W1ICT&F<J;=TMMIT:= 4Q$5U#ZWQMCC/B(A"EN*
MN@P&IG)F'7H&OKIZO7S=5A*>9/XOJ9MX6S,MS%)0MN&:<ZZ]O5+V-K!= ?=8
M*1GT9642?(T^.K'"Q7N80NM4X\14&#11OBZVC\U[%*N(3 K'(BT-Z8TFEMC=
MGNCAAK<K"9=UR!&SDXKNM;X=2^3^RT]%RU)R>+-8JC0(N12:9<JA\YK(VT>A
M]$&^G>M19\(VERBU<ES2%^M;5+BF="T^C-KE+%-Z6X3J9B]'^JSQ>*2(2^@K
M"DOJ4Q2UQ6L>6[W@N :N)?%%I\.79)L;'*F>OL>5"F>RC&//-7I)X!?W!Q&!
MF(FGAMSX2\)G\5WISL ',A.BAN#:"W\7RACDE%WF:S@#T)?004@&;T!BD?5N
MKBX_7$__:QIUUA2L#H>V/J+*0*#V2)F7?I.VYA0T([9SO*DPCCT"QKX%=>C'
M(Y&=6%*@4&IO+R*6(YRJQJ4DW :DJU+,%A0!?:_>U$6Q _$.XY\7%!2E (B;
M19";]U,K.[B ^HH@$725;T ;5G@E G<A/66<N;UU*^YTB/MC6 6##F3DH-*S
M:LAW:=J6IB#3Z1JTW!+7E:T79/T[F(.(ICLS(H>;ZOX"69#:T0M+>YOG7'_E
M#9[;U&2FY>O6$R.B3^D$A>3U)@MT*8/"FZG]Q<T []S?I\5^U4-U/0FWI%.P
M<JRM-,?A96&DZB$LIUZ6-3P@.O_%_LJ DT %8V1A1:P:@/,2-=2$6L\?,#JM
M&D['5H8BO<<D(8P>;E'MZ(39$..HUTOH:2B3.(KN^X,-Q\9>G#.X';%WV&:/
MGTL[&F"T?I6'$C9];5.)&GSMBB?6@J#BL0FBE(,BTKG&PH&>I'HYV2Y%LB"J
M$C?%!VL(>:_W1]I<;_1'K/Z6K,H=?/,ZR],-S/7O.>!H]'/*O<.F;MF5"E\-
MI#_Z*WVJ;<<J.S;S<'G(&'.Y0#G.R@?)W& G85Q=4FQ(H76MID9^0A="F<%)
MH34N9!^MU=*(UCXB9WO(-MY:6V\Q.#Z9_-'5S!?FS.8WWWG"7!-)VG&6Z]!'
MKTG8)(;.LPT5JZ.K*6D5* T[#N#+??GQ.5\"RWI6CH[]4_EN*=%?Z&*D]#0)
M'0\W;-0N)@3#LY.S/XI#T>6$:+"-+"ESDKFV-R_RI8B05E4*),9F/V*K:;UI
M:TATE*!EE/I&0<BNV9*9PKN;U1KDBFWH&6:5;N9R8AD+4<R8*&DI#4I1? EG
M$]T*2])P$14+'!'9,)XJ7:2+@QQ,1#3*'2@&1 D5['2%/(ZH!JIZ>!!]G(.2
M#V(4-2M]3*48*:?EH>.E,A1ZE.#1B6TG[LE"LVCM-$ C4;^^^'!Q-7UWV211
M-]>RI<JW[R[_/'W=^%&+&$ZXR )THV3OUF&'_WMJA^)A_0:*X1?,_8PNJ1>H
M735D9!WY" Q1RT3CJUYC+Z;N80!XI46,D=%XEJ;W_G%:XI?+&VP#40$8S1[]
M;E"7ME)%N&']#( O638[W6XX7[6,;K(54,)DG6(>BA/RO4<3I84J?WUL<E8G
M3GDPZ@Q(%NBHI^P"*_R7.KT_=)*NJY%0SZ#$EQ_!J[XIF=JLZ92I669+9XFO
M,,W5FDJ\PB#[E[61.,P3S7O1I";)LS9!/145.T@3KWN@S^+H($_NW\_[[.-&
M:[\@A3G7P/GY$YH"/$A@R;NMB3K%EN:4I]\>ZVE>_D4J-W&D/H;@4((/KUH3
MN20BF@*K@,TMM3,TBG55!Y!6":C5<,93M4>9E$XK\&EL&P I]7ZU$;B'3K]C
MLJ/%$:3T@X-;2^Q!;-N6W!@$,MEU5[*L;W?ZG-LF[(C"C)%/$2^IK!A5 JV)
MH<P'7B/MF04UN+"4]2*R%)IO4+:>:4XX#+>4=EU$=1XPGV=7;#G7Q9V( 25;
M>S#G;8/R8B<[$IF1CP+>1'LUNDM0K"IW0$\^4^HP!\Y]1JHE=!W]0O/T1Q@C
M.PK.GRLHY3.I:*X1EY2_\3DMGNB3RC>)<]6*A/)=M$A6">8]&"21$$02&C"$
M9LWS?SZR7VI?0<8H^($<4C_2 )WPU>]LSH7I9$1.B#VX68M*=G>+^(Q&JH%J
MLURF5.Y#$V#GH"'$G*Q&O0+@+! *\]3T,>0%;E-7!DMN"U5!D7!:P/=LDY*D
M0[D(.4;22?/<;S'O0[HD>Q117Q=2Y3;&L"%[E94J-8(03A;YH98"DT&QDQ=Z
M4='6ZLJ;D$:HTY=I .4YZ7J2%H&WC7>[RKWNY2L$X,;;*W\A[%Q5DKQRS5L"
M0=>+AL#1'^C.J![%.^/H%>+&[CHH7*E,ME=.X%10(S5QB]Z]*BA*=\/$6%C6
M)W<B]BY^0(1T[5.>OD>YU1M%ZWZADZC"=/##YU-O- DH1^I244J T&K9)QHG
MNKE^YS-9L977/)7*DYB"P=&AU=P++GBRRA;'Q@S3/?/*8]*8B>-L+/#&QI:W
MD;RC-Q)%KJ73X-"Y ,(]4-8MVUQI55E@HNV.3[A+P)J2B8?\CC/4)IQBQ"-A
M(BQ.<1]IZFI!A0C6>7/N$!7[="5>K-%IX+Q_+TRV^I^7\'10$@]99ECL:.+O
M ) 7Y=!^0Q[_G[LLNDU65CC[*%$7XUBM(7!^6;1-5I'$WF!B/;4HG*5 H.^<
M/75- ;@W/IU>28-DV*/%;@<7FF*%K8_@3<;5BP  <"V=5\ ])JM@60+"[)#/
M:9<]7@VR".007B-W;D]*([1!'Y^SW%<^)/R43/RWP._2Z)S1#$-XB$M3.8-E
M\AB9CF["FLHT_17FS#"2CS/5BQ3E'4?8YC#MTM.TV!DN8ZPUEQ?K],EQ>")P
M+ J6VU+BHG.?S,$Y<JB%IV+CN:W!^\'50%E0D!M-AS9>'&61SBF\CSC7U\EJ
M1!G0B)FA4FN*4U=$=G/\+M%XO=  MAQHS9Q*=5$$S1W6SQ&_SB7>G*#^7N,D
ML: A-J%AK9SCX1 OI[M[C,O"H%U&8>LO^$)D6[%Z2ZTBT 3L\,[A%!$>5^[%
MKQD02!N:]$:TAO.3Z/_\[]YX\N/D]*^=&0>MZH-M)^$'H#R?G[P]N=9W^\/N
M2:\[.Q[Q@I9(/W@IV1TP5Q1-L<O% JOT5N+;YBJ:)A&5\)4G,9V0J^?++Q2I
M[PWXV0<3\&<8H$5MJ/$:4^MJ_D$>Q%)?@<O\X+?N.CBS/;VA%^ [0OT31W,T
M,Z'ML.0J.!.LJ->9;8Q+ X!(G<E;#D;?E>92?4[FFKR%=>Z(-\GHR9(A[('[
MP*X&(ES?_ J]\+*08![>F&0=4F;JRV3*NOF+\7&^S1E&L7BUO^9F5 UFS.&,
M7DT9KQH*]2WNS==<&T.V7W1+OA2GOS&:L(2@EA/*.="26U=.U6 ;FG;HY?@,
M)*@<O$_U]KWGDT5^7/MM ?.A'3OZ2*@6=3[=7-U^/!(PL926V2G51QE.Y2*-
MA4\%$TTYRI9 ^B$_B7J][T>3<7PZZ3D3F7T=7SF-!V=G\0C$U@XN^SO\%VLJ
M1XQ5YHF*.DY8)!W=Q738 (/W-PRGX6DW6MWSS5^EVX<G=**LDD(2Q5QZRQW9
MA6B%IMY!,DN7).>RQ9.LG01<!%U4[/ F)E3F8UL!TTGUA(B^P-GO +22)9IQ
MF^@UUV&4U/BM]&037OX-9,\16NHTU*'4^B!X'C_E^0)M)U_63>V$,10.L]AR
M]?HL?8RNTFWF=5*#MA\=%/M*F#PH$8+9EHI4$PZ2!LCAH3BHW"V+"A+KL)'I
M?$AMLLQ<W,GT#OZ[H*AO#$TIHY^C=^_.8^_@KF5D)-(%&CUMAYZ\70<F_=\&
M?[.ABXAV0@E/2$TXD?4A)0^)<84ZX<]GXYPJM+@CI+OP *6UJL"8\6U_/I()
M-^XPE ?0\AG9&\$<7L^2[N?P+![TZ0;'\.=9MQN/)I,XU-2T^3NBY\[0?%@B
M1MS E9M%'5'CCEB&J%."4Y#C^H-Q.#3>6E7BZ(KC<[C>%%!7Y _K6I(0!UZ\
M;$ETUIYUJGQ"X$(*F4E7*8>H@?&'.1CJL^PMV027( O#-28JN=@3^ZY4W"A#
MY#B)+G;8"Q505F E]/OCQA>=,NH_+[SEF\[%%5!\F'5'V/A88%$3KSK@G5?[
M ,J L()EQIX8[=0A/G WOMQ&J12*Q64FT0C^)\0<_B7$//9&2+9\.5GK-GSS
MOXG(XRH .G1;2[1:\!6/Y!CHVP^8 2((,D$*U% YEHV0JO7EYI  >UI8:?6T
M\#;TH]-N+QJ,1C:"34[.)U2PQ$/I+JS]>A3NBQ+14JG')/*)(50]CDWR11;$
MFDY,$SPTYDCM8%R<EPN(XK!765F EFU 9W]U?.2#%/> )C"FJ7@<6B#NUKDZ
M72?#J:\E0V^OEYBJMZB^0+Y G_X3<]U4S!(CKK9TQ1LDIGT/QV4GUWYNV^_%
M4BZ(K3-$I@(#YC<T[0B^7/O[R<)CR"N$^<P#3E!1!-#(1BE0]]@G//?'W1-]
M[<@!^B>JS2ESE_)])U=6.=#WB5J2%5^UL#>[K02KRAC6YE(C+7H9F+3TX):/
MHEX?2 O>FW[WQTJ<*5KR[C56C\@$GMTR6?'AT4>]'X^:KY-2SYYZZT 70^I=
MFZ*1>?@9W]\(^^>UFXMI.$!_ )J#(RRX$/)@Z,$PD%P&1\@Z]! <R;9"@Q\4
MJ=@,A7=/RF1X@7SB*X(BE:?13T^B[R:CD0(^M!<2P6%9I.MLZ.^G$@_.6BP,
MHS8=6)_^>N2D'Z\@OE E_0#"R;^C*^:)54NF+^RW(1H&ZO#KY G0Y$]PX[</
M<]2B*Z'KLE)Z[2CJF-C%(I8 'RG(CND[;"UX?7$[O;FX_OA!HH#\)_CKQ9]O
MIS]?3@&E+MZ_P:B/?)UK@+Q_<NA<UQ>O+]_"6%=WV>]</1&&F>?'[G7W#GT(
MO B=)+4(?8!BL8$O]7>:OG%"7;Y>O*H\-HE'IZ<Q(D3'H(6[0,*=\:C$Y:W:
M(UF-MPFS6TS)SU?YPK6C,5)<$GW."DK\E43.6!Z()(>U[==D%<&O=JN\**N6
M!E;V5R!H;_&.&+U=_?%+#.W:F,0TDW'*.(,=P4V)@CJVJJ"_\ZT0L#CP'/$U
MCG*Y'!.]'+@FWIZ:(##:^J^[Q;WGM\#B7-]DZX$,;B!?=BTQ*M)1J535&ZDI
M3U=!4&!MTCL7S8?, DEC:+J(3<*BAK0I:/$2/D@G=L>>2/9ZS,E@L\O40DX^
MGKO4E5W'-Y3/<)Y3),0Z<'O8/4ZES*[09SX2O06Q1W.<SE\JK>JQE-,21B(X
M*7M_;DX'NZ9CLBY3 3CIB^L%5>:UU.=%!^'A7CN2RA8I05T0%#9+33H\;OK]
M'H1O5=3"E(.U<ZN#?LSEVIVO!?D%A>+2CY)TZR],*2GM8C%G@[%>%]0'84E2
MLL#:X0#%R-?MV5/*!#\P[4Y.HI]0YE_3\M4<IGG16.7!%=IB]PW94<6X>.^^
M1-G0EXO6T ?-,Y*Z>\T>)0T8*;VGWOF(U2!:[F:;/%TGG.;/=1A\O707[>?7
M<^)-($/5Z1_-P(D;TK<TJ^^*,X#S^4Z+,(<Q%[8,$2\"L=7%B?I24!( (;H1
M=4[&CA-S\OR[')QMPA>$C"=PF<CPK%T!7K!M:_D/=\T^-',P&,*3 L=$E?]@
M,+":78G0,V!IK"^M?46J-7\>'W) "D ,C6JW7>HX@%@C>Z;2,.*]%0VNN'=#
M2XX7A2M@EA E2UVG,\1@UP;\!3!U(0"COPLVF9>X-8/;-=IG:-4N.X9(%6$%
M.O+S8THU]QBEG:W8)O?SQP\7?XZ]!A[[N JT&+Z[^.GZ\LU?O@P4_;-F6+1C
MV3=$LH8Z9JE60_+A_&A+(D46T[0;"M)Q#*_4K],@V<.A<261\N\RC>KQ,:3O
M*#;LRABN9%2)!/,QEQIOOW2CF! S=CO5 \VD/1V%;\ZIF"/:LQDV:X3:TC1;
M,B6P?GG *O[DIO-]I-H#K9P'!;O0%ARUL<'&%9A"$INB<+Y*.XBH2W'3F&"8
MZBRNS9-&CW+^3C502Z/"-.&H'K#E=7DGV=8;*QX<[OF"R-"HH_^J-73_^!E1
M*7VL/A>%C?)5I0[/+,O#O"U70N8.[H*("1HA2?1 PL_IW_5ZFPLX!V_"*Y*-
MM*[<I/D&'6799X?-9<JQOE0+B7+3Q,)3+XXD.H*&4K".LW!!AR[^S] 9)3U*
M8QSEB<-R&6^G[Z_^<CVEZX\1_!DNLYP#0\B!ID6=]S='/B>Y.<$5N^E@FN:N
M1,X!JM>V *!B+X7W4U;@WGYZ/X5EO6_Y'B!:D'_Z;SOXOQ*DF*3,2E_=@+#2
MU1.T/<Q,U5JNT/18"?*]OKS]].?IA^:)45SX4[ZX![X/M'SYM-H\Y*L$](4'
M$$JSN3R9/V%%UF6Z^S5=94G4.7_W[LC0!EN9YZ?I?_WE9XQ90[:W35NJR,
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M<+(IM]<J^FV=X-M2X78[ES#RI#ZW!/4.\/]I#08?4@10O_JA1_K4!\CQ-68
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M0>0,VBD[=H=F+!JQW$)56E'4.H4OX2?:.<T+U)2JI:EQJ[.WJSR1*??*G"J
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MS ;Q]*R&XY5:G,24]8C_.>.+_?ZC=OW) ]/92:':TB+D/U)@Z%X?2(!B:W.
M^#?!;SJ#^4$(M[5U-#;K4SX8?!P,F*1+1D=28\V.0#G\G0Y<%Q]^OCW)>N^
M1\6=EY*K6"I,=?<Q&\@)B0 LV3@[)PJQFV(DUDM_O8#"SW.0]__!9*[0CKS2
M'&5*X-5U2)_Z;3'XG]=.:/:E^A-2\#ZDSN6QS/G#G*?(VP4KP\;)*][U1#*5
M&F*9HF5KJBU(4'.VYT*(B,I'TWDA2]836GYR-GE,XMK3H>:AUDO*M.N(LZ3I
M-SJY#N?*Y6B"9M(XG'TJ"E"82_T@4I,*=0<",FS%.\ ?L4XWXQZQ],+6@$?=
M6HATP9TH-Z3"LO/4TG.&\4)4<3I"Q*K7D1>4O";RL9TLAEN<9%CKD%\_[E(R
MVI(#0<3'%4=!"BJS<1"D"+*1M8,D"CH?CI$GG]7!**I_68,H\I0\62A%_BD,
MHBWIP?45&T3NN!*68<--&9\M>WNPI&?Z;AL08N9-L=T4)N]HI8%OVF(BM5UQ
ML7_868"AU6" 20@%'DN)L$&' D**SB^!&E29_7@M]-.G!>N#UG A.P4/\]D3
M[R(0HM)J6Z-'J57^=7ZW0VG%UL(>3PUENG).R@NAMIPJ1!H?GHWD9%4OY0>B
MZ=SBM/.3LZY/%CP;*O7)O/.3S#&ER<7CL2*P&<QH249H8JJM!SS+IS RZX,K
MKEX<KN^"5]>KI_U3&(,)CMSI9STQ#MS"N>$Q]._MH?<M_O2]KPBTX@/Z2KDG
M/+(\H&>&6O'W-W#W_)?/5Z?_QEF[,P&T0?<*#GGD'W'+MOT3H0#%. -02<=N
MY\9Z3JQ8SZ^7J!@S46@AH#WB,4[<E[C?55_WCTB<D:<#(&U>DTNBNS,.=W':
M\&-VA4!MS=UGC?WU=O[CS;E6!;^W06_KN#NW4%GULS&=P0>C%?#7>Z/_H9=Z
MDSG#-SOID^%=_#M@3BR>8:_/YC\Q*?<*8#&FE86 P-IJ2<)>U#8J\W1)7!R/
M79M8'&:ZV7?ZB=#J0G\5T^_SN<3*]6,EEWQP'.6%:6PI"#1>Y3'BV&%3E@(<
MTV'R!,4%*X"[-><M\NW65'H];[W]!D2HO@36R('AVE/885MOLP0'?W/2:AW\
MK=T7MAV 5Z?5?8-7M%GBMWE]TCJ_S:L/L]AQ_+57+_0!FN^ZR(=Y=>L%/LQK
MNR]NDP+20A'$8T],Y554'W1 OOHU%#-OPPZ861CAE!J^YNAA#3T(MQB"%O-Y
M,$) 8C[/0P@IS.<Q",&! 0 8BX@$\+X X:OUZA?)JZ]/*T3C1!WC;NE+QXZ^
M%",.C7W%M"\?]%4HON =:QB!*W9[U&QHG,.VL3RJ">1P[I'9\*'C,JEC$X1S
MLK.?XGVTS2X2$?O(E5T$NF07 ^!B;:V?1M2QC;",\:C/-X,?JP-R,7N'(7*Q
M001!N=K-6@N1;1EA)PI@2]:'WB9L&<S0]F(@-=Y%Y4:,#1R4%S[=#8!)Z0]8
M($/<<Q"!2DJ[.=)Z>Z"D5[00Z4<#.:7O 18;VO'52POP:.Y@WD M6H32 L@^
M?2\*4O+#+E*2[[%&-*"^%YBH8U-Q0O?A"J5/ '\R/OH$8*)^9,1)C\?'VT",
MPV1B;,8&JC_AP@(%OWWTBJN&?BLE@$DY66.CL;9<@"5[WOQ9-/DD\(6_0VG=
M;,/S>(3RPVII(R>D*(=1%="T:M)-,0'SZT;T(N(??)4:$<1R:@[$PD[W VQD
MF"CM%/\W0^EX G&UY-EPKK =Y&W_ID#LYP:SE:" :R]/4.PVD)QHDZL=H:B0
MGY2%SMH(X,(82Q^+JY&P*">K?J,7<..[T(?:O<_:^TZ"P$X>?)((#6)?;-/4
MFUL8Z'^7.8MBG[2?DD@B=OO&K'E1\!G?&N<FVH,N,Q0#>6D_)I8QKQBI0UOG
MMD67[?Y8/'=H1"%3?>?)_*IK";**$JN<M#5UTJR5]@UI]/*(6U/>4JLQCL'@
MLV+C-KT.%")_IT(JZ,"NKSO_ZMG0!3-BS D @."MT9![*X,SY@L@)@W$ \_7
M8DR(N1>YOP.=N7A]AVV[CO=WV-9MP,##MFR.S;W6Q^:>JF-SL_BW1M.Y/=O:
M&DX_/;-Y?/PO9UE//!^M7!@'4@?M^'/HGO@8HAY!*\WMOGK>5LN5-YY[NWD4
MTGV_7?<!V?'EOZJM>!'SV(7J6WS!7F7#0CK(2FZ-2I@M[7;T@0-+W)K2>B;(
MY,+3P0M,X)!%<8P=)6!66^6V#;#741*R5PA,RR<46V%IA7VQKP#3\O8^ZMFM
MS;3/D2L! ](Y[K9Z%GPR\.?TVXS&\@WQO%.L0,(*W1B[:&@!H-1MI8MY+00'
M:",PWI7*U;FG,@P@:_\$F<1YF.,M3-/:QD385E\A%Q8:4:>0,Z\REJ0B;L*-
MZ>@UE50'DZ7F^Y??-K(J4A5:2/0%,]Q=!N!$Q*J(&11Z#>>4T(SUY8*W&P6F
MIGS99">@F86&!$O>?B*.K<XI8ER8R7'7GZ_?6P+$M95/\S3 I!C=U^",8.$=
M\12FY @\%-8NA\"A/$[KU^%!/7J2UMO!/OE:\$R,E'P1YK8Z##VP'/;&3I3%
MP1<^!+]Z ]:M-"66AB3H]"]"M*Z^8A2X#CH6:_D$LB;%7P=IS"KIB3WKQR#[
MG^"2%C$;!JME26&)L)78AQ@KA<"[TII^-2T)Q>AM>]"=& _>-8Z:Q39F#UB5
M1[RV5D8,<%1$90NCP-0?4L!160O@*#;4*'84LSH:D)QXB+4#H!/W3;?!K_(_
MC> K+'K2B/CBC]_&[O C3K6.KUM@+<<VAL"I'XJJ'0"5@I7AEGPJMDRLORW
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M:M2L0@2P;G_&,<F9O?9X];4Z_ U02P,$%     @ ;H*92N/V9>WZ!   )#
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MO]P_47H8MV1W?;WY_^DZ]4^$FU:4I]]02P,$%     @ ;H*92K0&;_$1 @
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M4$L! A0#%     @ ;H*92E#2I3KO    *P(  !$              ( !F0$
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ;H*92IE<G",0!@  G"<
M !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !N@IE*K*$8!54"  "O!P  &               @ 'X"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ;H*92@%R_VX$!   !Q(
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M965T-BYX;6Q02P$"% ,4    " !N@IE*RWA&%;4!  #2 P  &
M    @ '?'0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M;H*92B&<=Y.V 0  T@,  !@              ( !RA\  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &Z"F4H<])X.M@$  -(#   8
M          "  ;8A  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !N@IE*7^AP:;4!  #0 P  &0              @ &B(P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &Z"F4IDLA. M $  -(#
M   9              "  8XE  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ ;H*92HH7)B&U 0  T@,  !D              ( !>2<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !N@IE*L\L&
MB;0!  #2 P  &0              @ %E*0  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( &Z"F4K!,=Q)M $  -(#   9
M  "  5 K  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M;H*92O7(9-6W 0  T@,  !D              ( !.RT  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !N@IE*7&329;,!  #2 P  &0
M            @ $I+P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( &Z"F4IR'L8 L@$  -(#   9              "  1,Q  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ;H*92A 1&>:U 0
MT@,  !D              ( !_#(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !N@IE*T[?GK;0!  #2 P  &0              @ 'H
M-   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &Z"F4I7
MCDC8M $  -(#   9              "  =,V  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ ;H*92J$N5CBP 0  T@,  !D
M     ( !OC@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Z"F4JX(IE MP$  -(#   9              "
M 8%"  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ;H*9
M2K7O!-7% 0  -P0  !D              ( !;T0  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !N@IE*\2V];K<!  #2 P  &0
M        @ %K1@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( &Z"F4H>!X&5TP$  )P$   9              "  5E(  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ ;H*92BWRA$[3 0  G 0
M !D              ( !8TH  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !N@IE*S!(9,]T!   !!0  &0              @ %M3
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &Z"F4H2&QSM
MSP$  )P$   9              "  8%.  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ ;H*92F#S%MVV 0  T@,  !D
M ( !AU   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !N
M@IE*[HN.8\$!   W!   &0              @ %T4@  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &Z"F4K[<47UN0$  -(#   9
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M970S.2YX;6Q02P$"% ,4    " !N@IE*A]31+5P"  #?!P  &0
M    @ $Z7@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M &Z"F4H]ELTPK (  (<)   9              "  <U@  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ ;H*92D1L[\YC P  ^ X  !D
M             ( !L&,  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !N@IE*F^9H+P "  #R!0  &0              @ %*9P  >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( &Z"F4J^\;3 + (
M )4&   9              "  8%I  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ ;H*92OJ?D>/A 0  *04  !D              ( !
MY&L  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !N@IE*
MS306FX4%   )'@  &0              @ '\;0  >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( &Z"F4I<9_5XF0(   @)   9
M      "  ;AS  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ ;H*92HRC6[+&!0  8"8  !D              ( !B'8  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !N@IE*+>%$T3(#  !(#@
M&0              @ &%?   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( &Z"F4KB?(_95 (   \'   9              "  >Y_  !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ;H*92GD04M:.
M @  M0D  !D              ( !>8(  'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " !N@IE*IWJ4VC0"   3!P  &0
M@ $^A0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( &Z"
MF4I*I1AYEP0  ,48   9              "  :F'  !X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ ;H*92N+BY6-C @  O0<  !D
M         ( !=XP  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M    " !N@IE*[]R;8PT"  !\!0  &0              @ $1CP  >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( &Z"F4J5X2M(UP$  &X$
M   9              "  561  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL
M4$L! A0#%     @ ;H*92M $(G_  0  ( 0  !D              ( !8Y,
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !N@IE*/U\"
MNLT$   6&@  &0              @ %:E0  >&PO=V]R:W-H965T<R]S:&5E
M=#4X+GAM;%!+ 0(4 Q0    ( &Z"F4J9M?W\:0(  *P'   9
M  "  5Z:  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M;H*92A]RZPDE @   08  !D              ( !_IP  'AL+W=O<FMS:&5E
M=',O<VAE970V,"YX;6Q02P$"% ,4    " !N@IE*]:XI[^P"   ]"P  &0
M            @ %:GP  >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4
M Q0    ( &Z"F4H.>_UN#P0  .83   9              "  7VB  !X;"]W
M;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ ;H*92@; 65#R @
MC L  !D              ( !PZ8  'AL+W=O<FMS:&5E=',O<VAE970V,RYX
M;6Q02P$"% ,4    " !N@IE*8WFIXZ,"  #""0  &0              @ 'L
MJ0  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( &Z"F4K9
MM:)BO@(  %4*   9              "  <:L  !X;"]W;W)K<VAE971S+W-H
M965T-C4N>&UL4$L! A0#%     @ ;H*92G[WC''. @  U0H  !D
M     ( !NZ\  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Z"F4HO,-8;]0$  #,%   9              "
M 7J]  !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ ;H*9
M2JR NBNT P  MQ$  !D              ( !IK\  'AL+W=O<FMS:&5E=',O
M<VAE970W,BYX;6Q02P$"% ,4    " !N@IE*(^7Y/6H"   ;"   &0
M        @ &1PP  >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0
M   ( &Z"F4I@@9KNJ0$  )T#   9              "  3+&  !X;"]W;W)K
M<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ ;H*92F(FHI$-C   ?C8"
M !0              ( !$L@  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ ;H*92O[:\DV+ @  8P\   T              ( !450! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !N@IE*X_9E[?H$   D,   #P
M    @ $'5P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ;H*92D1]_<1@
M @  8RP  !H              ( !+EP! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ ;H*92K0&;_$1 @  8"L  !,
M ( !QEX! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %, 4P"W%@  "&$!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>235</ContextCount>
  <ElementCount>288</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</Role>
      <ShortName>Hemophilia Spin Off Hemophilia Spin Off</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Reserves for Discounts and Allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</Role>
      <ShortName>Reserves for Discounts and Allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</Role>
      <ShortName>Hemophilia Spin Off Hemophilia Spin Off (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Reserves for Discounts and Allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</Role>
      <ShortName>Reserves for Discounts and Allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails</Role>
      <ShortName>Hemophilia Spin Off Hemophilia Spin Off (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Hemophilia Spin Off Hemophilia Spin Off (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual</Role>
      <ShortName>Hemophilia Spin Off Hemophilia Spin Off (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails</Role>
      <ShortName>Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Inventory Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryInventoryDetailsTextual</Role>
      <ShortName>Inventory Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2418401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2423403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2425401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2426402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20170331.xml</File>
    <File>biib-20170331.xsd</File>
    <File>biib-20170331_cal.xml</File>
    <File>biib-20170331_def.xml</File>
    <File>biib-20170331_lab.xml</File>
    <File>biib-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0000875045-17-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-17-000017-xbrl.zip
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M=WCU$T%8(DKQJ_KY[G R&%<WMQ])7_7C"![^,OSZ4_UF^I!XC?#KN8]-J@I
M6?6Y^MTE'^P5Y?+/P!OI<7;_\>)[]W+Y\^F=)=]?#KX6H_'RC\S>2Q^B"Q\:
M#1G!\AYNTT\.JR_P.*(_U4\T'^B7@[_6/)W>_MP9%<WC@T[9'2U?T_2MM"1\
M?TF#X6 PN5K^&[UQ]=/XYKKX"1YZ#4\55=F]_=S#'[K_@:JX6$F)^ G>;1X<
ME=WE), ;2P@8C:^K%<_#.TL^,!F]_M+I7-]^YJ(S^CQ=2/W&$F;#.]6P7XR6
M?F;ZSO(/)1R6?VCZSK(/C:OBRTJ<]$_P?O-H>J.W(.2W>,[>O/?H>.FC?/;H
M>/[1<IV #D;CSJ![*W+?,Q']1J=/8ZWU3]-W;Q\=]98]"%^+?_K/W]Y^[%X6
M5YV[A\N''WY]NYI?_O?_^EOZK9]'TS<^%!<_3'_[Y\NIW"5M];I123_"0E[5
M;R<^_-NK47EUW0>2?DI?,U-UW>%@7'P?_U#"FJ-/'_T#_^.33S_4/ **N!S?
MI!>:5T#[P6L795'],%U'<8^$1B[=F__[ZA<$_Z<D1XS_[:?%#T]_XZ?%'ZE_
MXQHVU; W_ZL 037V8 ]^2<M,\H1P\_&[]^8^4 QZ<X]3$+^[7^LU#S<OW?Y>
M\T*-S'*HWLR0^GC9J8K1N\DXL2<9M%/$;28\XQH&]IK<PM"\LS,,4XD1YR$Q
M8CN)$7N6F%B+S"GB=%]"YLE^O(2\F4H(.W&RQ6M,#D#VJ7-;'(+;_.2YS??,
M[7IKVW((84YG7'[]9^UC_?,-!#I7Q<<QJ(X4T-A./YGQCY=%,3:#GNGURC%$
M19V^+T?=_G T 6MB;^"/Z^&HT_^U&DZN1_ 5_4FR+>D9^-%R,"EZ[ZZG/S0<
MC,SW<O3/9/?_>??SOQ57GXOJR9APJVZ++XG(Z4NSUWKPR]^O^V6W',_6]$.O
MA$=FD6"-T<]/@]&K7Q)(/R^"]+>?EJYS1M9/&5T[*U4R9WKV8W9GCEHK::VD
MG9)CO$PTWU?#WJ0[?E=]+*JO9;>X$Z2_%U?#Z\NR7W;J9T;G)5#+**O9OXJT
M%R0&HA6#8XO!L8.>)=K@WSO]R519FGY_^"TIX!$HWP_%"+ K1I]NKN<$P\%W
M59WN>-+IF]Z_)J-QPN/,A&,S>FMQ64?P"]$<M3.]K;PTCW_L](O1AV(\J0;I
MN;L//4^I:9Y_@.RG<G,/DCMH1>'L1.% ^92=1:%^(PXKUQE=3GWWR6#\O.5@
M'<WG*02[>Q.M2CB.2C@IS^+QXM.JD:=2(R<E.#NZI&T(\W0AS FZH2W[C\+^
M@[B>CPA(6YMQ!-?SX#I@_NS@[; [ V>>[>_&ET7EIH5[X[=EYW/9+\?EN?F9
MJZB\X_1:,I_'?F]9?2JL/OZN-MVI)H-8JEN47SN?^\5SX_(J"E_(7FX9?%8[
M^#0K;^Z./">? <H_Q[6J?#/X"DL95C=W'YUV,@RNJR&X5&=F,4ZVFF*;D]LU
M#*I_>0F'SK)HZ.RW2BP'Y>BRZ/TZ'/;:K7**6V4)A\YRJV1N0UM<=\8R?K+.
M2R9F:?^,B[?EUZ+W9@#?_:4$[\R,1L48H/JM\Z]AY?J=T>B>P^J+KT5_>%WT
M/A7=R\&P/_QR\Z'\<GEN.<8M2+]S91^@_7R%8CXF?3/H%1<[",:GJM,KKCK5
M7RE5-_WC]\[5N64EMB3^3C364G^^L>R\8&RC+::6Y=UD_+;L L1%[SUHZ;,[
MA]A*1TS-Q"J*7YX M.;B-,S%P3-<K;DX3W-Q4LYE:RZ>WER<G@"\&;PP_J\@
M^'S9OX\XXLW@_2SWF0[U.U7W$C1D;4D3Q><E$SL;B(U0>-D>1"LHIR4H!]<H
MK4$Y98-RD.I[8/^SG/5R#ZK]%PS;R:@<@$XPW?^>E*/RMNI@NBL^W8PZGZNR
M[@]=.!9[:7ML!5+U?EH&U9Z.M\YK<^]=M]>]$7]LU*_]J>A> ->KSGG)UIHV
M[06*#L?#D^IK6-(0LU93Q<E5Y_JR4UV9+XNG]\]-5M;KH0R(?9VQMQ+ZY">D
M&\BP^?=WOX?_/"\!?NH,^7ZD?![ILS:D\SKUD$+[ ;[N?K_);_!K5Y.K5EKW
M)*VW"-_]\#V(7X@F/KY<=[ZW<GU@N9Z'N)7K1Y^4O6AIWOE$K97A<Y'A9^]I
M'$N&6_^B/8@Z\X.H4Q>N?2766_VX0QZ\58]'5(]MI=\1*OU.79B>0AV^C)#G
MZ=7A"XQX%DM1?/%Y_&8P&E?3>^/NI/1C,2B'U>_#<3'Z=%D5Q?MA.1A_++]_
M^C:,P-/W106L&OM)\>D;_/>F^=_A>0EI3GTMBX\C_SS+5!:/C%K1.%?1.'@!
MVR:B\6TX1>;W<K "DV<H#QO2?+[Z81,AF$+QOG.3)J1\&D9XMU=VSZR*826W
MUQ'WO-DZ)^=Q.*FF@OY?1;5&Z:5WG@G;'T/\^8K%EMX &,$I,"&=N7TLOA:#
M9?!,WRV*P?.3C%WH/U]_8$OAF$*1T$E&<@&2.*R>K;;8G.SS%85MS4<K"J<@
M"J=@,MHHX<A1PM%,0QLEG!U;MU3SK3MXHN[@*2C^-H0\N1#R\&VOG;)* _$+
M>W/[S[\#ZJG&XN9MJK"X=^QU^\R;P?5D/)H^0!8.R^:^\K>BDV;C)0QB5?SW
MI!AT;Y9_W]R3:9COI*K*P9?SDK+-H+P[ZEJ#Y9[.US;@Q)+EK&'%^:K"%3+_
M4@6T%8>]JD#:JL"]J4#:JL GE?EI_4=>6/7GQT_5%(4;,^C]F@;4#NXJ+5OW
MX:![YSY+[N1S+4_VOV%:+^:%;>%VOQUUO[72O8UTNV%U/:PZXR)%]Q\3!G,W
M..W30.%VPVRZ8=;RY(0,%&ZW\"ELX2?S,=LM?*HVK]W"9[*%VZUW_-1(*_,G
M8;:F+]M.]Z^B=TB_LTTJ;FRTUG#DA$Q6F]D\Q^W;[K4C[K56LD_0,+49^]/<
M+&V^_KRW[Y-E--L-_.PRFNT6/HDM_&09S38X?'89S38\/(DM_&16N-W"S\X*
MMUOX)+;P$\7![='&,XN#V_.5D]B^6UO@=K<=U5R^=.F^=Z=+*Y5G) Z'OZ;X
M=,*-UELY5?W9^BOGO87;8[=3V\#G$6ZT.?NGW;[MQCM^"6,K\^<A\VURNLT*
MGZO,'SO2:NW%LXNT6K-U'F:K37*TV85SE?FV7/WL4P&M9&\CV6VQW.EME[98
MKMW"IQA3M5OXV<54[18^B2W<3HDZ+Y/92O=)^IAMYN%4-TR; #GO+=Q6<Y_:
M!CZ/\HIV^Y[$]FVKN<\KGFNE^P2-4YO^>&;&J4U^G,3V;:?<G]X&/I?PL*T)
M.= 6YNU=/6<J#OPPS:-M>]UYBH,X].UUOW7^-:P^W5P7HW<7*3H"@Q'^>P(K
MO//\IB(QO>EP11SU^W#@ )E;"W,N(K$A[?5-AQL2_T1B<> 6\ZW$XL[#>&DR
ML0GE+U @?AM6XR^=+P4\]&Y\651+ \J7(2$[0=&*S'*<6GE9@L,+%)9E:O<%
MR,:#9+] 45CAE;T :=B$\I<E$,WSBV\^4REH/K"<W)?%^JDN^#A.V^%+V7TS
M^%J,QM.@_9GR?JH!5M-[OLR?/WQHF7^ZS#_XR5/K$)Z+0WA:HM#F'LX@]W"&
M(M/*2ZM?VF3W222[3TL@VD.Q$SD4.PNQ>+DR\8(%HDU,/75BZB"LGT],W47=
M"9%[7%Y69'XN/,[)NF/GML7SIYUHVI"9;GAU553=LM-_WX%?>3[<7$K8^;)S
M7BVW>_-E*-K?AH/BYK=.]5<QCI-![QFQ<SEESWYWM@P]EQVZ(4-;ZWE^[+2=
M?F?0+3Y>%L7X[;#;&0,H]Y@ZS0W6T=PT1;C8K??WHO>E''SQQ:C\,L@_W[Q>
M],RH?O0-4%%-[GI4SD5$5F%U)RBKP%HG*ULL8#G4\W[!@UB?K]3.NPD/2JWI
M=JM)T7M;=CZ7_64]I@]([>_#0>\6S.<FI:O >2(I78+M\_!U-M.EV0E^JTE7
M:=*MBAU:/7HHB84-VYW9M)WUZ<N3W36@M5+\Q-Y *\6M%)^D]["]%#\B$GO6
M/NV1(Z]GY=-N+Y6M3]OZM.<EL6U&ZRSTZK.6VJTBL<=FM%Z4U!XYPW4J4GLB
M^8/69SU)W7HLG_7X4MF>#IRN[GPV4NEGH[C^\<G/V>"J_ HT?RWNS,&'<O37
M_3%<PZH \L/W[F5G\*5P\)U5ISM>D-!E7S7ZM5,.W@Y'(WM3H_RAZ$\A'EV6
MUW/%RIW1Y45_^&U4%5^+01I[=>^KWPRZPZOBXQ@8D+YU;49M"*# N\F^I0^%
M[]? [^*\ML0ZKLP-"5O'ECWMC=V8VA1B+^7JGE:V1B;RC.$ZH3C<7H;]6HT]
M++">I(;A_]U^X^U[<Q\H!KVYQ^<W?_/.XS:_/-CFWVB'-DQH]^032/Y2L)](
MUN5VLBX/(>N',W2MK+>R?EIZ_;BR_K'3/[=2]C,3\#F$7Y!4'\Y;:4.59[B3
MVE#E.;EO)[[Y;[E4S/BSF*YKU<!YJX$5_&T5PC.,YUJ%T"J$5B&TX4$;]+[P
MH/<4S-R"5'](/+C?H]SY7EY-KLY+]&[)F.M(GJ>C9? <@\O!\V#P/!TOA,&+
M=1\;&:4W\ 55,1I_@-_^^*US_6*KZ#8S4,OA:NOH]ENS_'SKC4ZUW.?@!;TM
M2\^^@FN1I;-2S?K6Q&[]QS_=W^,APJ*78XCF87WU2X/KSX#K 7,2QPG%6H.W
M=BO]:M^W6^D 6PEP;;?2<^T<6KZ5PI\?VJUT@*T$N+9;Z3E9I8>W4FN56JO4
M;J6].'C.'.0(Z<5O)<"UW4K/U<%K-\I9'[^>BQP?R22T@4H;J#RWK73P&3=M
M)KK-1+=;:2];J=THK7=UKG*\P>%D&W"W ?<SVTH'2P-/>PQBIYO&WMS<JT.>
MW3D_[ _'EY-J\/%;.?Z?HNIW!F=2N3$MKE]&6'.[_$K*SI.A=0?+'Y_\[CR]
M56;OJ]0",+YY#^\UMR!>)X+M378#SML7+A);:)L-8+U3/6^?0"!/JN6B\5);
ME70<E72@L(/>=;1<=JKB0W$]J<"BCPK8#5^JSM4=9TUZ?OE#_R@ZU:=A$K#S
M8/5MB\E*DFN>;T'S$PD!TJ\IVJ]=6NA(>(0<),WYTN1@D>8G,@?'[G38K^"T
M"N3%"$XR.W@N2[")U.#E#SU#65E+Z9.8&'R(T&<'3='R_"5IA243'CX4W7YG
M- )6S%SQ=Y/QNPO3[4ZN)OV4\IG-JAY>75?%9<(]I:M26_&]\'?7+UF(N&];
ME5-,.+Y)'Q@.X,_1O1^;^][?B_&?@ZKH],O_*7IW%VPT8P?.2XH?PXF[B/EQ
MK-A3C+^6D?<F3F_%R1>2 UC6OWS\7=INH_ULH]:<G+(Y:11.K(97=^<>[ZH_
M)J":+F[*P9<TJR;VA]_22<BYS28Y];UQ:!.S&W=;L]/NYG8WM[OY[&SS,]O-
M;:CW7';NR81ZI[!+3\^#;K?1R85ZQW8.TWD"GZN>?=GZ^^R4WMS) S],A0/>
M730^59W!:#87UO3^-9DA\]P%8@W13U7C</!K[[:6!%]<E(.B9XL!_&.<SOQ'
M+T<B-B#^A1B;?8A2JU1:T6D31R\EVW)LL7NT>]Q:OF-9OI-VC5M5= ZJZ-3=
MZC;V/IF$XRD8JD=II-90G8"AVKN6V4=ZKS54YV2H3M+7::W4*62(3T^[M,F<
MYQ(-R?:@X,S$X.##=UM#<:Z&XB#S&Q:;F%HE<:I*XN0J:1XK.FUL>Q+'C\]!
ME%H;=3(IMV.+T^+@P5:6SDJ6GG(F96NQSL9BG;18M#[P<Q&#1P7*K78X >UP
MDD%R>UQS#L<US\Z-;67NY&7NI U:*T)G)D)/8?P,K*A7]B=IE/;'HCNIRG%9
MC,+W;G_2*WH)E 3C9#QK[KH(G6H D(S>%]5T(I2]6?X%<\-6Q\/N7^^NT\='
M:6#MU75_>%,4TY??-].DP+\X+U$[(&S-*->M<'LA9O08 OQ;I_JK&$]Q_W-0
MCL],)QY>4)?CTPKDP03R$W#YWXL16*D/\+]5V85_M>*Y2CPW0>L%":MHM>=)
MB>=1M>>QZZF/(9"M/_J,_-&7*,"M^3]3\W^*POJM4_6R^W@ WHMA==49=(LI
MS.<F5/-$W:5]5E#5,K^XTRW/Q1K>EX"I(F@-UJIX-1>#,W?:EW"_35*T>__8
M>_\4Q.!A$_"LW,LELM ZA%OJA58@6@W1>@<O70ND0_"/Q7C<+WK/*SR<"L##
MU+4:H!6&EY@S6*L9VH31\]8$"\R?36Z^K;*Z=[%R\PSX4$4' BP#"RB^%OWA
M]';J\/T:0#^S =EKR)V??_T@O2](8,3V O,>=M:YU=-O)!GSA+U<@]&*P,MK
M_]U!"TQ#[TEW/*E2P2U8V[,K/M[46JP@L]40K7@<7SQ.07OL(!X?BWX?$/NU
M&!15IP^NF.E=E8,2P.RDPH#:&WN.$K,5Y2](B'8P0:T0G9(0G8*AVLV/:</?
MHX2_QQ:8Q?:\&7R?.M_-9'PYK("6>X(2AU51?AFXX60PKF[.43(62;L3BF6T
M'4X*CC)M[]=B^*7J7%^675"8B:_=&;'_?//I7+BXDI97O]3$_/SFTWFR;5V3
M?\NY9^?L+;#ZWSM5V?G<+][ 8Q5$5"&15!8C>^/N7U5X,7WGYNY<Z_<"(J^K
MJ\G@S$SU+A37AUV+)+]<L4D'0.\N3%5U!E^FN^M.+LSGS_]>GIE,+"6G9OH\
M/2^7X>^K86_2';^K/A;5U[([=[[]\?V;WS^8_S(S*#:P(<T3=V_X%#Z5GR=I
MV]7^T,*WK9&W-T.(OMY?=JJK3K> KX"?.;.X<QFV32/1/7#7B=]^3&+SR :\
MV=-BUFV]U:Q](1LQ<ZE!4'N3/@ VF]KQ6P$QQ=RDPOS5HOB]<S6_6SM7H\G@
MBRV'H_*J['<J\Z4JIKB?UYYY#!+-WGH BF?CSN]1=S?^_Y\?6]7\Q*JYB5;^
M_-AJWJ.X0/O:%>?H()^*7+Y 9[SQ 69]1]^OBU1S_[YSD^A*Y?C]<E ,+WXK
M^V#CAH,YY1[_D3ZYA2/]'A9V+AU,LU:EC="H16<>CJ?0H/-HGJ\K(?Y@?\SI
MP%@.RG'QMOR:YF/#UW\I/_<+,QH5XY&]^:WSKV$U3:+,"=7@+9C-P2@Q:0ST
MC!;D<5/?Y-3E\3:=OSE C: L1VA/(KH7!V:O)T\8;77R=&\PY&'L>AM4/8>@
MZJ2,]DQUTC\V2YF>?YQTTK&$>(WD=J?=^C5%IY5._9" O9<^_:WSO;R:7+6)
MTL-%X[>@WR5&[Z'>!N)/%_X\MP#F1<40K;_US/VM4RLHV]J^MG;S&1NT4S]O
M6>+<E8/6N7MZYVX>]6>Z%\[5N;-5.1H/^[_=%-7H(]C%SY_/2[S7R<$JVLY2
M(R:%2/[ L?C<>GS/V.,CKQ'90G5,'R=Z[TF5#3-LK?9X3C9D,BAG4E O?YZ+
M5T5G-*F*&33U^\T7->_=?77ZIB7?V[V\6/:=Y6C(")8_N[_'K;]R,NJM^\H_
M/_JMOW(P613AYJ,UD/#/K;]T-)W>LOI+9^_O0GXSB'K^NWOE5]@G\Z*2/O'[
MY*JH.N/AO+.U(63_Z]Y"[G_1W"_X8C"\*@<K?V,]K?=_9.&[FK=N27L F?#G
MAW6" 6\_#/:L-J+7*U.59J=_>_Q='XS_4.^@#\7%\0H*?N@5W?(*/-Q_>_6:
MOYHI\4YW_-IQ$27QGC$KF?8TRDB4=(0&+BT2YM4/B<KITJ=[2*#9__WMIP>H
MWAF8)TXBK )&,X2HU#Q8PZ7QBAILL#71!&&]5G$1&/UDP.QB:%=2B:327@CD
MHT$:J\B,4M(*AI1"VLE%*AD^!3(W$VVF@D$2<>(,%C(X;9D$VB21PG/.Q2)M
MG.] 6W/1[.C3L!;8#\778C I4KMI!2[DAR)=53SX\FGXL0/?\F;P'NQK]8^B
M4XWNTW^7REC-K4@=X8QI33 G%AEM#?6)(&Y94#SCEKI/SV,6>V":YUJB^I-9
M]VZ_/_R6)IJE.SR:;UX8[@??50$PDTY_;E4/B8603G,L/:?(21-B1#6(@@D?
M\"*(KY\OB/.MX/!&'%9IH* O1].JP@=PE,@X%)RC3%*D=1#,NQF.3 @K?8:C
M?/8X3G_@0S&>5-.+9^X^] "4$3:RYM$II<"X"(211O6^)E[[D!EA>@@HOW8@
MGOW<3V*0GKJ[H\07G\>_=<;-C247XZ**Y==B^G%S-:S&Y?\4/3<<+5'HX@^V
MDFKEB!;66!RY8,8Z(F*HJ09;),@BU41*?H_NQR_XL,2#,*W60B:2H#WVAG$2
MX#](\UH+8:Y1YEX004^,^-@IJ[0_BNVX'J) Q 06)!4Z!F(Q:6R82LY'SG6A
M'D_X[6(/1_0Z;BOPKY0DB$GCN(N"2E+K2JZI83G1@M+#$ T!V9>B_L#-NXO9
M..GTS7=?F6M%X.?4+;F+&H2(E I#A"386:TQ_#VE![P2%]&K7]YC\MOMXC?X
MT<<NL?&<;I>(+2$*UL:U40Q3BKVL(2>&<V/3$N5N2[3E\$LQF(:GPXON\+H:
M7@V3D8!_7)3CT;#J#T>CU8O<NDMA3JK(O%!A)37".%JE;2 X4BS OT5!:DNY
M<7-"U>0JT(^\$:D-B;@EV@W[(('#:FH.BWK.3J?;K<#YVDX#Z !ZW$3FA#(^
M1JR98!!9$:.XHLYD,0<&]V)^,ZQ;R8[+7;=WI08]A87WDI'(G4:>.E@N!>^;
M&NGUXG*55H];[8P#"?[$';#:RS;DVCC!0$ G%5$!H*;(,P.J=2K[W!K$?1;4
M+UUKMHR=5_M 5$.B$5P20R)1E&"1(IO;G2IE)@\$K09XWXM^RD.45?AX#2+H
M P2S7C.L%8=_SKAI"-8XX^:.^$RJ- $4_,>O9<I^;^Y+UI],)F=KW@OP>"5G
MQF =)0\T4E/SGFGB6,9[B22^1]P^5OTT&#Q=A(L9=9Q$R;"0$-QR#NJU]C:B
MMB3S+;E0Y(6 ^JB(%Z*TJ(P(QAL 4@O!F*YQI8ABEALN3%\8KKM&P%1YHC$W
M@*UW' 5+)*NA1=A$F^D!<3A@_:2X &^H,QB7#A 97X)O>#W-&H/V_%*!&M\R
MXL'@.VAOE,:420L^@\,SVI"EPF;./\C,/>H>7L^CEK[.]X$5.D:(TT1Y"$L%
M1L[/3(\/+,8LQT,)XSLN/5Q<%-TTP_%V9-N'SA@8!^OMEOUR*H._=0:3BTX]
M=-87B<'PZB;N$9WWFR7U/* 8#81>0EE!>"UK$"4H3I;XS:_1CPBKFJC=5WH0
M8G,+.T\L#0IC%9AQ!F)ME9*<=:3&('*[I[/FB25XC\0N=9C>?1L4U>BRO'Y?
M5%WX>QI^3:O[[Y%XG'J6.3#?_![G U\3/%4F1"VEELPC'#$$ XYC9;2*RV,N
MIG6#YI90/(#AZ/;\<.K63<]W3\R3O0]?P(I0T"F((1ZMYX)064LC=9'CY2'K
M6O"687 +VYM!K[A8W1/ZYZBXF/3?EA</H_; -V7MMW>?@W6!_1LM'S_: ';G
MNZD0%87@6!EN9<2<Q5G:@FMOO3"O?KE;"8 U+E,T>W4%@E-V^N7_3/=CC=?&
MQ)\07)^J3J^XZE1_)>]A^D<2O5$&$[5420+1(B8^@-\ $42L80I!.ST/TR/@
MF,VH>S/X./D\*GMEI[K91/_>E_DH'';:">:93T<CSJ%9B,.=H/'>07(C\_C'
M6PNZ; US"P3O9CRL;@;%N#OS9#J#W@!4\^R/[?P4KL!#B=(31R#<5!"2QSHS
MBYC%.HLS,:+ID!S-K77]<AZQ[G5.BJ;!!10P>"2(:18X=K-S!% QR*CLG%?S
M1RQ[IG3>#$#YC8ONY6#8'WZY23>_=P8E^,.7G;&I"E\ TZ[*0='[-+3%GV Y
M!Z-AO^R!Y>RM&H"X':\(,A%"#A60<1*TJ,<@3#-%RAGR+CL)EAG)!Z/D6'BM
M3>*I*(+5CI(H++'4>2F4-!#W&HQ-7LW![Y^V/ U>]22"6"S1KWMI9UZ%CM4Z
MX"A0#)9QR4%)&0E>C2=>N&!YYN;7YW -.G?KOB6E+I2X#06OK_MET3-?.JG
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MI^RBM1:Y@"0#_]F21I 8<BI3<ER+XR)\=A8:.0:.-M>@ZB!<-II&4B<UJ X
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M6>H.C?WAM^2?/=C#B$4 X(PFZ51"@:]I33/EDD*,GFLB1)X1F'=U!'=U1PW
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MIOHK*!*7U)?@_'KB<T!IG]X5%@2!O4_VR3BA8&LU>3QIEC37;#'D[-P VSQ
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MG=82!QL=01!T&8]H<\CFM6!9VQ(18/E/&KTW@UYQL0."TRL]4ZO0AV)4="!
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M?<,E76 2;;D0)W1'$_!%'[$5/!%@S$6N2P9A25P/9VU7D C?>Y->%>Y2>+8
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M5C"_Y/O]VOS5L24DX@[CK0$&9'3&<ZIM9TL507XDV6O;?/_UFX'&EV5U@C0
MIP7 49J#$T-5FS*0I'$4>8X+NI_4MRUH2S(.TUB*5/,T-L@*(KEF;6L":Y!?
M%_#&!5J[!&X9?V%L7;!&<]!)(DFL1;(),T@L%PQ3 N#NV\O+@'N?3USSF8]5
M^:T8Y(/X^K>Q2RVWQ0AL"J!:W0?5_[@."8IJ+"."3)0HAKB26C49[RYET\_A
M>\/NZX'U@>MJ2:MZ.$JJ+;&)91IL2!FAJ)GXS9%B%'DB^(V*T'V1T.FB9L<=
MV^V34'%B-!9 6Q(;-_P]:8LZJ$J4YRR\03@B]X,*Z\/7U:I6;16.0+J!!\1)
M1#DRTB1M%GFDQ0*F%M1K:]'IHFY*_[?8*H/2B#.)B"*@@F#?N&KH#\>"Q_[Y
M&*B+^W;*^N!UM:@5.T52[$[2B&MX(V)F$V14VVPAB?W&<:['7U=KNNW#N3G;
M1#*QKC,$>)(22"M61+6"&22P1V#*]['O + Q9,?4>NOA[C*4*F&15C&.*5?8
MBM9H%3+F?GJY=Z#[6!RMZGHCK)OU#99'&B4$@SQ73<(E<%4JO,BRH%YD>3O(
MGL3N"1%;CI6UPLA4*I$@U49-XE1*?T+Z?:-M/1S=+>=U*>=N%DHY'-;#$1Z9
M4DM<R@ G+ 8/U,1(R3AJDN"58MP?>?#&:XB_,8P=+W!5.WT-=)I$)+$@6)2$
MK[%N];8;.;:R#^IVZUMX1=OVQI6>M\TL@>S.FK:^F[>HTW'**4941Q(LX0A,
M%-/H!C<\RJ\#N;_$QT"Y@V6NZF"G!7C+3 MN(R'!6+DY2V2,&NIE;W2\PK+5
MDS-R>&P17*JD<J/5E'5CO5AD.&VBSB[GP/@MT1CVC).'@-D*XF.2M<?4291+
ME!A7Z*5=3$93K4S2=A+E:>2/* R[M:>6HC'68%A:*G&B-'>]BMN>:B#RP>A<
M+A ZW915HLMPL.-4)$R$;9(P<(F;8@7-:<H\ P_TLF=([03B9T-&73,]-2)B
MG#-A);/$)12T.9;8:.V/@@J[M2>FUU$LB20QDHQBCI#2I-V9Q##_".V-9["N
MMS63![JXKCR 0!%QA:0T9A)%AG!BVCIR3*7Q0OV<*F_DU?S;-X+J!MWND.!V
M8MKM2>7\$[Z4%OXZ@-U?A7*L.5A<5"?8I"Q!AK:YO!'X\[X&](97[&X]G_-1
M45;U<RP0Z,>R&$V^?"\_YE4?KDNG^9?O\.^U+2OX#URPBNUC5]L)3ENB-4-I
M1&W2GM,D*5M0H2JP%^7>SV++:54O]K_SJJQ7?F_%S;I7+SE)T@@KA,":D5C%
M$AREFT)MBMB"3@+$.]7;RY(_%W_4*S;%UXO)Y_Q;/EJT[OJO>;ZJ!1HF6*26
M,TW!?N"N3CIMJF"3.+%^^VC&O$3PO2SZRT65SZ@:E@^$_?!6PQ]7Y6(RG2*<
M)H1$2,?NJ"EIXA2(N@F"GINH_ #V7M8,_.M6_!X<LL5K716004EB7924N8I%
M"9:@2-LS%1=:\TB:2F]2P^-6NO0,&!%N262E35)ME-"@R=ICD4@C#_V@&'@W
M-#=_U-NI8N"<<L"HEC%"J=0X)B1N1\%I'GM6DA_YVMEZ.E8,,5CPH WBE"M)
M+1&Q$4WW;(TXZ/5%BL&WX/>QV,X4@P+A&"52*]#Q"*/4:-.>12=68"]0 8K!
M/W+8QY([50PJDAK,-&Z80,K60WH:(1DQF?HG\(QY5?M[6727BL&XO"@*K@[#
MUB#87]FF_6'D9- "Q; _P=2E8@"3CAG,$Z8PL[$$^=LV!L:8,#]E&13#HU3@
MQIGQG4IE%CFGE9.$QA'"&*<W0]>1E%)X1BSWG=>E2]GYJCN6W29QG2&82%%$
MA4BHPKH] DB V!?52WIIK<>$DLXD/!>QXL 18!+&,0&O+M%-(A3(>[;(]%=+
M7;L#(Z93/2"):^,.;KS20AE0_*29T0OB'O[QP@Q,>DT\CP@U76J+. +$:#"L
M8PH,!>XCNG&=@(#$@LI>S)>90H=&S;9*!6@DB@U*$ZZ-ML[WB'&;LV<2Z8L7
MMCQFT#4^=F?]@UEHK,9*ZE2ZF)=,VI$F1%)_-NU2Z_\0J^Y8SZ1IRAAX!101
M05.=&DI:?*@4XP4M-F8'L<>*DL[T#+B[Q IKC5 IUXIPV9S!,YURZV<_(XFP
M?T9]-(CI5,]83AA-HE@IEB:26(S:*KJ(4<.\0VTFO+%L1X2:+O4,>-H),BEV
M@^J8C",*MLK->*%D@<L=$>RED1X1:K;5,Y9*0 =3-HIC%,4LC5IQB[%<%)MF
M6&YCV4\=-*ZCWQ7(/W?#Y_SKTH$+\Y!'\RYUHE1J(AHGQ("2<!E&3>IB8G"L
M[PS(F;T"@)^#^4% YL&]R6)L#G.>1$+@,9UX:I8@),#?-\1U;D4,B?8PW6*]
M0'O=(RUO S;<G6=VPMGQ[H!%"1Z9U-@@Q)5AJ6RJ+[@D>E&SY$?MSA:)OJF.
M+&BPQ#IK!_29EK8MIM5<^:T"P4:2]Z7U C@V!G-%(H8KF!$1(2C1($N-(%0T
MB1BQLC%=D,R#O:EUJ\!T1.5/=GQ47YHHX7'BIDDP=U3%*6,WHR0L.*?^* GI
M60?+P=D&\*4UF,J(F!N;IM(UZC)*-X,_.>9@!WIF#15>7<NF@-<M[!^%992Z
M7NZ"6PY@)TDB&&U'\,C48+_J*E)>9WH?ADTA7-HY6=HD2D&1:DDH,IQCU1P_
MI"G"OJN%,$'W+>BU(7QLR^_$N+;^8(:!_Q<1)05O^I(!D"8QOL%&B%=WL1",
M1\"Y#)DH 0!3RTAB"#=4"4S;$#^BU!\-CI!?YKX>G&X:4U$GMRPV'V<3Z[.^
M(^WK7\J9DIJS'LMA.;F85J//WXO)O_)JF(T&JXXOP-$4E'/#$O#)08WS1*%8
M&AW''$=^[7-[2G5_:;>0+UK4?7U9IT9_RXIA;5>6U>=L.#\H:_ _TUF*3]TB
M^DOVQ\;:16NJ&&:(Q5B(R/*4-?5]S&HM?./$:WW5%>3[P<:JJBW&)4@FHF!;
M16J,P3)IVZL)ZG>.?>,=1>X;'7%^7E;Y?7-L_&AZX!R,C3A)B';UTU9;)6]F
M;DJ)/7/HC1^"W +<':_Z\79GZD8?Y8,X'\&'B9L$.+=GJ_* ,'*G(82 Y(XX
MHL2RIF>2.PGU.\[</Q=[COCLWHZWB4R3U+@#%L4I8#>5;>UY*I+8$V2@^1?J
M\>>'Z"U20B.:<@14*I@ >TV#O]%D5W-FC39^_^A-M,-31>F7"KA_.+,HUI8!
M+!$6(60YI2G5-DY-W(ZY<=%;+Q'@*0C555/,-8EBIEB46"292AAN6P<0B1=6
M"S^9-1]&D6@$0BTQJ4N8Y&FDG$)N7+\46>65_'JABF>(SQT4*' 6N4,FS2,F
MF**IO>E'8 BRGKI^@\0+0?0V!47$N:2Q9&G"8B(,39H)2YRX-EU^;0%^"<+@
M,9I$1=C&$="H!/O%2,FC-K4$"U#.?H\=[R1T#YA,\ZKXYKJVY>-;+M3C&?\]
MVC>)E=:I<[J!)Y&E"AG2>F<)^+%^K9=?-+\UT#O&P J5&A,D*(U%A"(=IPI'
M6K:]WS%3V)=-F"R, ^T# ^#DYB"+9Q&Q_G5-Z[ &1^NCQ93_>*=5I8)%F!KF
ML@H-9>"]M[TP4OAY*^OJ\>LX!*96E4NJB&*1 +G05+F!P RU+$0045M*C]VC
MZM$D8I@B*$;&M4OAF(@$8=%&=G2ZH!L4\0H7UH&KJW4<R,"TB1)IK&)K+4E4
MBFV3F,X9Y['V^&B32,7Q8*A[DS$RSDA43'*I@+&<>FJ\.T8,8KYULYEB.BK4
M;6$$HBC&";:26(L-D!J*6H>016[:PE;1A.-!TF.L.D&-L%I2)"U7UB1I=!,?
M2)(%?8HVTF#=H6;57$;P23D7J;!@CPEF4F[;IF<,U(SG\;\YD(P]I!,O8BM!
MXRAIP&I%B<:\F8;-L4S$ZJ873P-#.Y"Q3"<:+)>$VA@HBW!B&],76Z&5']_=
MS/0]*M1M$['528P15J#%4P/@2&P;]Y"P)/++;S<[P3H>+#U&R!))HY@+*4RD
M)'Q0,6N$+!%68B]U8C/C=U/<?'0_U)9Q?=7'<CRI\DDQ:RR_6+0\VOJEF$J$
MA#6IBBD2;JYK<P0E!(_])*<WFUAV6RSD(+A:=0:<$L(U0ER[/M<J54E;L\>(
MXJD?9=A$0G>)JVU3H( !="(MY=9(J:,H$7'33P,\Z-AOE8Y5Y%4G/@#(HV!=
MEEE"#6$V(9)C;JS2;H!;6U"%-+=^]D5$Z4+!MAFLCTW8B5(0+1CD+6?&1"FU
M4K6GZ+%@?B*,P(MMW86@/!;@9?B5( 8 ISR5KD>FT(2V,Y_C..(+*ANE7*A=
MUP/8_0ET_W;MWJ0%S,:"2$5, C!B<C/SGC(JO+-)M#AO:Q$LCP1X5?#.D%@K
MC4G$4D[!U[Z-W"HBV()&QUZ6^480=]16STB+E77G2X*G!H.42$F#9Y1&L=]6
MSYMJOQR@;4!?A7'PHX3K#@8TS%V_&<4;-HQ Z$7^\?7"%,_U(7=)/>-/KFYE
MFH/8WAC58*N!($B1,E)CD'2IY4W)"D6Q\=NN2;&0I.^!\5@P;XVS_D4^F [S
M#^<SZ^S7?')1SIFF_J]Y_CYK,L9G^7;9Y7@Z^AH7Y;BX+(99I;]6>;Z&R<91
MPL"EE#'CFL8Q8EJU<C]-B?;E_L(=W!HA*^@,A!!+% -RDS'61I/(\!O.YMKO
MQ;S8L.P(S.,>U.-:'B-L,9<ZC<'LP!0;L$Y91!4E2>JE!).%,K!K5!V0Q$&+
M(9,:D$S@DX ^$UBVW4!B*Z4?%5MHFW>.D)6#2W[[?'/QE^LKP)RNP"?[FM^M
MT])G9W\O5O9Y!E]>@ TJM;6N.Y;&%*$XUBSFX+!9#P7>1-M5*/B87<]F,I?5
MQZKLY_F@#DO4MW4QPT ;!)J0B4C@& /@ J-&1Z;<-0_VVU_<UY$;0MCIXE9(
M-V.X(5JEC"3@.9.8VK94 J<)\J>Y>0FAW:SM4WXUK?H7V1A(#;RKRW)43R[>
M>*\B&C.:1H0RQF#+4LM:>R95+I*TI+?I:FBVA7U5D8U58!,F#,0"TPG8DXEJ
M8;=8IIX?SZ0WO7!?:[B5)!>9RRAH;P8* 'ER.2<AX!:T^*)5YPD4Z]CH%*$$
M(Y'"GFH!)A&+C+%,)AYA$LZ6L-WQ8(,OOLC%!;Z4*<CE!7B1\Q5CR(J(@S.$
MDT1SB:B-L 9G(HEIC.2"/+$VT/5$$?.//*L>1,S='&$./B)1QC7:BE"L4\E0
MK(1P4\VD]FP/C.1]9?LXO, %V54QJ4VM69_[QW2CUYSS&+@]E6!66K -D&92
M4)HD4J;@6:XAN18"L@7$JV:KJ%A1-R60$4TXMC'#-<1NQ \1_@1P$GD&_,:0
M?\IG >+R2_;'?Q:3"S?:'O2+J[EPU!/#?@U<= X\N,<-!=":@R*45%HM$J%2
M1&A3C64X".$%<;.'9/"FH.YFN2OV4+NQ[49@IF5$)2<"/.IFN:Z/JZ<OL3=8
ML\OE?BEU'VSQ*G^XF&;S26'<1DP) RX<P]@81&R;5RN,\1L+(_6P_;8&?)TM
M:\7&J02\9O G!$UY#.I LC8K"M9(B=_6 /L=][I:UKO1!'P#-W%P5MJW>>Y?
M8F$ODB0"VHN43G3:9.4R8QB/_2E-\B&F>Q"F+1>PRHH&&\50%Q>&94CC#+/V
M;%PJXX<K)?-Z/FZW@MF!0U4.IL[2?NP^B 03Y6:; :=(8F+C&OS-+% =V=0K
M124/FQ;+(>MB+:LDF[(FMAHEKE\0)0GE35LAMR6*>3EANUD+7'R55Y-K9]ZY
MN(P+-5SYE:WK1&J) !<MP0P3'2NM$))-_S ;Q8GTJZTQO^](KP]=5VM:Y?$D
M.E'<%>>#N1!3! YU>^S/W*SD!T:*=K"F*C_/JRH?U$;=QZSZ4-4QD4'=V>5C
M/M-9*X^%WKVW\]R3BC0V<<2E*ZYEEFH:M7$"X?5R:%\"EMQI%,TU;ED/MBY6
M<^_,Z.YJ:,)I#-N2)$JIE#+8$M:VGX'MHGM:37W99N=S<1ISJB.A+!<Z%=38
M=CB7D2+V[=+H(6CK=V\,VK*3N,18X_K])2(BC"5:(M$*6)L8Y0FEC4"[RHH!
M&%_WC8E5Z,(I2 ^96L&4C;$$+69-V[ 8+X@ R6:6V5W8;EZ^/E!+&V%HA)/4
MI+7/X&@0DZ9R'01&Y'O_BC#/)'@0J-LHU9S#5\OV+D;3QM0B252:,(F !$T4
ML;9?//AX?MLV[)UE;PAAIXM;E3]A7'\*=_R>*H.$3#%IK&G$XMAXR; H\FSI
M;A;GS%.0[K]F$V>A7G\X[]!EL$P:(Y2)01WQ&.G81FW;!&S0@L8F2*+[!QF/
MA'4GRUWE2F@.AC<V210IBV44BTBU28L"B-GO,RB]YC[=+/>\F#RJBQ+72*M(
M,L(T)BBAH(>;/B^*$FX7%. JS_R^>?NZ,*TJD#7:S7:/DH3'P"- (LT04$Z(
MY(D7IQ-M+Y\U8%ILX+1G?HOQ][<OZ>,;I]P$\AY\>7SMSHGN)/3]LKKO"C8I
M-X@*A7$,NY>8N)WJYXJI[TQ"Z%^<N^$."\3)"FP\5]P10R)!N4PC([AE\']M
M,B@RD?&/.KB7A=01[KP3QY4=C])4@'Y7C,4:W'LME6VM(!HE"S0DB]#]A*1E
MT#P>ZJ7-I%3"7=L)0[$5B4TBS&[,>\*5'U_FR!O*O"[4]VLTG5A=HP%?D_0&
M5G51#AZ=3QIA):P&DM(L-48IH9.&L,"8H<+/"?+F*G<)_K[1<IC" 66HI0E8
MBPC%B$7*X&90"N<I2J470'KQR.Z^!D%*YJQ;PF-F8A9'$?!XVV-&"AW(?B<E
M#6[>7VR Z#4!LY.;A+8Y8)QCRY<=V+],=#^F-H()FL*[P9_A"BQ1HC7';0%:
M1*FGNIX\DE?%'5/#C+;@Q,8FMHRSM!WI!JI=QGZRKM>#_RFCY3 :CH G1.(X
M4CKF+@$6W,VV/H<B;;TSGA>/[.XU'%5@:1L=X8BG5'%MS4UW6<%BY%<R>R>&
M+W8GMM!P28I0Q*4KC::Q2UXRJ&U SV6$O4.U^Q[NR\3YH[KGQ G"D:72*F(E
M6'$T56T?(AT=R)88YUG5OP!?+\V_Y<.R]O::$@/S1Y-_W1Q= 6W5<;3Q."G'
MCS@A3&VD4O C4,(UCF2,9).Z$E-7#.81&A&^6GLTN#M;M9C%7]9(1XZK8CPI
MA[]>Y]7X,SS[[&Q5 4*JL "FM(H"B1",F MYQD1QL/=CWPY8<$9\I!A;ZM\3
MES;(48J!3QA2S+8GR<HDB'OG8Q037R9UM>I)->V[.#&HLHNL^OJ(:+W0*J*:
MQDIRRF#?4FR:@TI@ NSG7BA?J?E0; [E"J2S1 G >A+S.,;,S8?$#93@[UN_
MR_=&\$TR9Y:9K!K!%>-[!EN_V# \1Y 08!XHQDTD,, G5"-&);*)7R.+6"2\
M0O/50&V[A&6Q.D&DU$FL8Y1J80'IDK:-WS%80/Z1!H7-N7\DL.D2ZMJ$S>D7
M0(R)=H<#"8I9S)1@38F(DT'*8T<LG-UP']39R]<#:-49G^1)2@WXB=)&5+JL
MP&;P(\<T]>M;W;P<GZ=\@.9+.'XNR\'X,55TRAE2S(*J3R(28V,-:4ZK75U&
MY"<LDDC=EUZ+ 'DLH//1?9<6]*'ZG%??BOY<\=!_Y)?EU44Q+++FFE46H] 4
M,3=N0R0N' [..I ME6D:J\1:[7<1D5YB[4Z6&(;+W)W=$D<ICDED482,T33E
M@M_,;K':ZSCA%55WLTFK4A/C"('JH<J"O:=QJBV[F4<M1.R)0M=9Y?YA=I>
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M:?%&O'XWZL'#ABX@W%UM]S%C^G!$;\:3XM*%J]:-,!T%U+\4YWE0#MTK!W(
MW; "E\=*@DDYG@02#"1X2(/E]K#A24EO/7<P$E@HL- !2?%]'H1XH,!@1P02
M?,$D&.R(P$*!A?9E1X3F8P_EL4_>#(O^+%_N*G-5 )LT+3\RKMYWN6[]/$3>
M8+)QN_<CP]S1R</.\?/@45\C4.ND.D^:'C'_[K0 ?XOZ^EW@\V#=FBC9PU"^
MHZ' T)'DI0O#(.^>>S^1UPSST[7/U\,\I= !/8B^(R2^(/HVQQGB>YC,^E+L
MM2";NL?/$8N@;H7.$Y<MW?N&06H$J1&DQ@N0&N!^D>[<K^?F977K5P5A$X3-
MBQ8V2'7G\#P7"^4IG 3O@S;26?^N?+"F7-DS>#>MZJZ?KC8X#,^S-YC<[FDX
MES[41,87-G&1G$01V\-AZ7/10^%0(#!A]X=[^(13V>$@E7"\%S@Y</(AU"D3
MIS@HTV"X[IW3G@-#[<(B#;P2>.79\HHS' GMCEF>FWT8#B8"BVVKC@0ZC8(R
MNKO.IQ"-/X2H>3=Z<U65]:2/AT;K;$U*!\?F_GCOW6B0GQ>C8N)&&$R*H3^;
M)8CVX-/OVJ?GC(0$U! @#RQX.!:<85-BA'=/AX$1 R,&1@RZ,,3LCHK3G@-#
MS5B(RA!0")P2.&4EI^S Z@O\$OCEV?)+T"Q/-%2]#^+XXF;,NG'*XUMNRD;'
MFD;N@!UEE_D3SH$^<,3\Z2+NZ6J2%Q<-H-WIFQ<?# CQN,"!(3 >&#$PXE-D
MQ* *0_0B1"^VBUZ$X$5@E, H(2P>^"7P2U L(2J^!]K0_7].BRH?U%G:Q>AF
MJ,8M:]6PCX\S3'XG?A_&@#P&A?0-DF$*2(@2[*O;BI1B#WT>GHN:"J&ZP(2=
M,^%K*>BIW!L)/I=:VM!K)?#Q4?$Q.8D0#JW+0G D!$>VZ;9")0KM9@.O!%Y9
MW6U%"-Z=\_;<[,-N+<+ 8"^0P?")B%AW8Q:>BS+:,EB/]AV]W9NT^5).LF&O
M&$VRT=?B;)CWLO$X?\HA\*.300$_VWB4LP'!S>K)U1^]03EU9-H."7X, H]_
M'/$Q34E<M0-A8O;LZ?($,7)*#X_WHZ'B<*P1)&Z0N$'B[NP4BIY$5)VRXT'\
M1H&(9T3[X10KB.TG2KI!;.\;X_0$1>14'1[O1T/%X1CFI0G68Z&\@PX:71NU
MSU$PUL\3)X)VF7^Q4A0>"]T%B1<D7I!X+U#BO28GBG19Z+TN1E^$:QX2"(*@
M#(+R60A*<B(C&4S#G:6!_#C)8/D+KU_P^<\_GA7%V=MW-WD2NDZ3,'_TAU-'
M=S^7Y>![,1Q^<0_] AB(AV7_][_^[__UY_J^3WF_'/6+85%/7/EP;OXY+2;7
M>C*IBK-I#<B7\CU< 2NHRB%0RE=X4U[EX\GX[A-[[A+X\BD__\LKF^((B;^A
M?WQ)7_6* ?R0]2=OI$XMMQ3SF,16Q"9E#)%48,$QI\;@5W^]MV'SR/]27.;C
MWOO\>^]3>9D]+(#G;@=H\S<7>2WO$8[^=(<U.?!A31#%".3YY"UQC+D/]OER
MD??. 97E=P"E5Z.X5S6[ "O,ZPWHO7:M_OK%Y(=>-K<7O4G9&]W9#9<@,]N.
MWNOWR;L?WBXEN&7(60.A=[1&= ^![OO\0T=E=9D-[^ <N6MN'CQ;43\?#IMK
M_O(J>E5_!Q[NM]\W)X7OQ6!R 1]A38WH +$PS*[&^=OVPT_W1<$M4/,Y6#?B
M1"[,J%L_BVL&DB!_6BVO%DK.9DE;WK[M_4_Z]OV^?K.LOF.HRKZG$66WXD]N
M9>O>+$*LJI*Z8TOXUL*.DVG[N1/&N\5B_>W[3,2>E</![/FVK'H34"Q?+JH\
M[_T*UUR,>P_9) 8$]J#W:SW CJ"31Y@HZ]/T+G;D"='\XMUZ_6[4@X<-P>(:
M;^(3WRR,;,D'.S[,7M]B/SP_W3T&7+Q?SI@-H8O.0A>=D?$.<'EX@GR0!-<N
MG7@*_7\.$0,"_^BD=Y9_+48CYSF5Y[TKN+8<')*UCS\%X)@264*>RLQ^0*C#
MW,*0.KCCU,&@\G<@-Y\HG74K$)^SW)N9/1WVTSH6B@G5I(>P_?))KQCUR\N\
M]WI8CL=^7+VV#D=P&=B%D^R/Q_@SH8G//3LEVD,[O$>9*4=,KL$2V4_PX<4T
M7GC=80N@Y\9LF[%7T*X/8-!F1=7[E@VGN=.>3HG.FC74G9>'1796#(M)D</W
M^9;,< U "5]FVC=HW# RZA V<U":06EZSXNZ*P-[+GP2CA66'"ODH,\Z/U (
MI;,'/W$(I;/K'TETUMLMM#L(D8+#&SVAPB)46!S&^$2ANN*XJBLZJY*XJ;OX
M/+V\S*KK#^<?JW(P[4\^Y=_RT33_E -5?,O'[T:N?",?O!LEY:C>DVR2#^)L
MF(WZ^>>+/']$^855FG*<II%!F/"(6$GC6?D%HDF:RKV67]2QL(/57TSJWJ)5
M@^Q>=@;*Y\2=#]5(AP^]<EHYE [J@6'NT\TF],YFN] ;U]MPTLLJ^%QO)[S(
M1;6:\HYQJ,4(M1@/W?ZTBRF>U.)#WGK(6W^2F<#KI*;KL0L[/60?W=1X/'A%
M2&T/J>T'3FU?3L)IWL\OS_)J%16'[/@M[>)/N?-#0+2[W<CZ?9"RD[&K3,Z+
M;[7+=$ I$6+6(4M^8X0B@4[QSI%Z-!08CLB/-UH<@L$AP_VA6"_GG7></3S-
MA#R$_?-<4EY> 3)'D\: JZ;YH)?_<>5"F+-,/'A67CW&FUF99K=/O_W8\H46
MF!XL8KLZPMD N<^%X8/UL3].?0X,63^/$KFKA)2@6A]2K?*YZM8O=PX,=T-6
MN\[O.V(</]D4OF-V+Q8@E0M^#$.)GHNX#(;)$<J_(Q9SQY<G=\SR:R:QP)/:
MG\1Z+H)IVWRWKK/37-K;=/SF:Y9=O=5 A.Z8*1O:8@0W%-GPW>C<)2BY7]-B
MW!^6XVFU46J;29AF+$5,4T(59HKIM$YM8XE(,(WWF]HF[V:RX8YY ]_J=B8D
M4OR!<]4/+MK3F]^AW@W&>Y\G\,.E"Q:E^20KADLIZ]%)?8CO/JGOULPA9UGS
M1_?0MP68[$5_*7+>-1TAS"Q*]L,)D,&D$U0<K+WT312P/E6O(WXWC2_RFV6.
M\DE(7 R)BT>?NW=DMS^!Q,7@<X1VT2M3KD*[Z)!V&])N0T?HHY/8(6TV=(3>
M8RRNK=)K/*1#<O11!,N/Z=CFY9S*(-Y=@[:C(*-PYG*\9R[A2&6[;--CEBTS
M:=)AUOMS$1K!_EEA_S21X<>8[*$%X[U.2)R<TKU90<^E$6OH9;0?!_O%-'!T
M;-A9"O9SX[;-^"MHS\4(_#F#ZYMI N6H5XR^@2IU9^KC^H U*-/M=0#>@RI]
M+D9N4(-!#2YH)==9$<1SX9.@SAYHXE]6.;P0?,'^13;ZFO>^@GX;SQ1</OXA
MZ+2.=!H]C8)."SHMZ+0C& KW7/@DZ+3%I%*G^>Y.<X6R]WO>6G?GF*'H/6B^
M??'I<V#'6="3=A@O61-I(28:*N6]2ODE=2>[H<\P'.>95=8_V:Y>BXZ$B0C#
M<0Y/^.% >4\Y9F$XSE$7_3]9T3H3I@R?RKVC\T7(S$>;P \W&=B;Z_QL:]23
M:56Y.GU=3U3N! <'*TZ?K:C?K*B9$=V,W>E=5?E5!HPRR?[(Q[,1/0!P+[NZ
MJLH_BLMLD@^O>][Z.Y72BK!3WM;:[?15=3_.W2Y&(G$:[6DQ-RW\=_:.NO[T
MUE1QTP 6%N$]K4UJIQMX"_/=A2Y?>^):V5WE_4GQ#9CJ]*4)5MTTQS7SS7$_
MK&R.>_3B53_8]+>>8%:,9TU!7.7WK-,'0!QZ?32]/I0ZE1&+N,28P_HD"YT_
M[M[^M%MW/*G%A]X)H7?"DRQ57Z=W0AA9=E21O-![(8PL>Z)GC6UHY*JLVL%E
MKE<D+,+]6IN\0+'9[&]G %O]<686PTOS\02VH[-NWIV>-QXQZD/7AVYFA"#>
M81S[&.@HI$,=[Y'<UBE.QR6#NI4Z3URXS,2)C+H3)\]%:@3#Z:%9KW4_[S=5
M/JS[0K>#37KG9=4;%.-F^*NSDS(7)W1]O3>QDT+MST-*O]/!8$'IOWBE__*J
M?SH=[/5<."4HN@<477F=#2=%<Q0V+/KY:.R2"L[SH,\Z:5TH4:AF#?HLZ+,M
M.C0H%ARWH,_6(Q9S>34LK_,<0+MT.1ZSV+;3;6?Y*#\O5B0(!JVV9D/>J,.A
M8T&K!:WVXK0:EOA4!:T6M-IZ,\M&XTDU[=?*#&Z]JLJO53X.NJP+789X=_V@
M@RX+NNSEZ3)$.FS9]5PX)>BRAW39<)B=E4W649N)'S39]II,JI O$Q194&3;
M*+(H.&5!D6U63/;%)/9=:C[IWK"8-"FTO7$^F0QG\\-O#];R7O\BJ[X&;=>%
MMIN)-(D1[DSF!Z47E-[+4WJ4T7"^%I3>!@TJ=J*^0JO8NTW0!>LP<20TBPV*
M;U^<^AP8LGX>EVQ__9J?"Z>%OJ]+^[YF#W8@V0VAA;:OH>WK<8C41>WP3R)*
MCZ'QZ]%0<;"!CK="-#1MW5E]:6C:BD]41#K,J5PI"H^%[O9DBS[I!JS.)MZ/
M=F9$8L*:/[J'MGT"Z_=]K K71<ZU$?GRC\\Z_O3.):.]@RNN>V]Z^IW5G2#@
MICW@'%D=I%W@N]&L%6!1C2>]?TZS:I)7;O&NP=))[WO>J_*L?P'6?#;J95^K
M?';>\[V87-3W.73EM8'_*2\NSZ;5>'9!4EY>%I-)GK>]!AT&"WC&^_KL"+R$
M7_.!PS2X!_IK/NI?]UZ[?_]59.VE66^0#WLVJRZS?GG2*ZL:^S^X.N5R^,WM
M438<NL>[G__/&"@U*R['O;J<V?UU4O;&V3 ?W]O*_(]^/KYI@5C=@7I8 -!U
M_?-55;C_ MK*P:PBNEX_(.!K-G&W7677]2WPG+O-:<UOGSP*Z7+#B#BE>VGH
M>MKK:?#='+ZGP\D,8<5XG@CRWD7V+9_],G#X'A3CRP*0ZS +6,F=,PBD42RA
ML1F)]<NO(WC[8.?8H^A4[J<=[NM]]BQV+L9>EO6#V\QJUCE@QA<S'OL.#[B
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M!,9/NJ%Q6'Q8_!-8?.B$W6W/VMOVRK4'=O#VV#O8BN7H/US38)L5:\^7. J
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M!7MXU_NJ.QJ/9[P KD]#5D[J@D\%3'.1C7HJNM4)@^QZ/-/O3O8Z@\%="U9
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M^%DY@J()WNP93X1:AT>[[>Z>ENS9^;\K D42-@C0.*26/_V36060X"4>*H
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MS;0X];&>SRZ[ BWG,*.EC J 3,%DJI^$RM #IF!\[ LI>:#[F/@&<!9(?&5
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MHN%OH%61S<T(R#7E/GA$X'X@,\P5\!*+H-" U6/[/"U&?#8#<TF2]9G;TK!
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M,@GR$79YZ^023':YSH"=D0L$G")@AW5P9+L=>*2J17ZBZ-RY@811UU;?@4"
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M%*?>;M6N]6PE?"\POA>A F-%C-8BH_P&FETT<FBJL"Y_V1'R1+Q''GN!\:W
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MDV$<#CLE!>E,RMF>26GU]66 %X*-J&9(P91H\>AS"LB_=T%+AFK31/:VERJ
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M+,6.TB6V?<#:)-0/'*<,>YG@XN!%F;+&7UJ-9KV7% 7/]%7*&'ZE%8ET_(-
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MCET;FQZM$5DG"?[2JANYG =7M>6>A!N)377F@E3A#%6AP0Z2,KBJ$B67)5:
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M9%]G0>.S/U1!ADY6*;$$C 2,E7(#"1X)'@D>"1[+"8]:<V<(%PD7"1<)%RN
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M5SPMQ3-*NRS8VA<SC$^XX9Q<W/87R@@57B+=:UP]+RW;^^LV;DT";RIFQZY
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MP<BVV4*5LW=!_"<<K,+PV=NREI8=S"*,,LEHT3(KU)CGBB1 /6>DU'>W]5_
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M=J1[XG&9-ZESW:T56V(D\Q).@3P4KR(F>-%P^4BT*J;^%!=+FOEVL*G<TX8
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M2V\GW]9Q8C3X(/$#U"./A8-S > 7'LHS%UY@JT<+^6_"3:SKS Y"H"%2!A\
MC2-*[P-PTF1;_.G74*27T:8?X 4\_VDWM.G+7N?2N&PTC8N^,6KUS(OFH*/0
MIHU&?]@?GBC:=$Q3O6;Q$"-84)X\5[(XL+:=O)CD2\TPT1NL_E)VH^28T/U^
MO==H-SH]T^S ^_7:^A"B>^5 B'[GZ0=&B#ZEE]\)X?< J)]E0@!>K=K/KMW$
MPPJV*5I.7ZQ)J,":48&S.2NK<H,I&O;:(PA5N!A4X?=R>B49>A<6OH3(:3Z&
M\.0-+B9@XG<ZO#?\$5-]\#MWM%5W[[0C5X:JKC+-*7['&.(R;V"NJAUL]_8
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M2"-Y&HQB,(A1Y@!O"PI;Q=18EYDZSC+S9WL.SP]CG8)!]N&P*PC)!!LJ(S.
M6\K@&!^;.?R1R126\-$[CJ.G0(C?X)ZP>HZ:WACZ0LYH3'QO"V[K9&XW9@S@
M"F#DX?PP]'Q7/"T%UM(/5YF] -_P*\Y^])+P'T+]N0V&#=077!*91M%@F>:8
MK<!TALQE<%?=$L>!XE4FPK(#^" #K/>E2:1O (\"UQ!5%_?;;-YF527^GV))
M6N.DN0IM0:M+MPU"2TQ_8QIC(J; @EQ9 G3SX+O$?7:M.EM)L5JL-4#L.0MF
M<)T9Q%X2.(D-HOL(?$2CEVB<> +U>W0#6*J)G*0Z7X!0X]O$:B)5 =)+3.0_
M-U45Y!W5%#Z;T9;/, 1G*8X&NG_N]OY]-OZHY@WGO@S/N/K2Z+)A_:I^DS_'
M;#7J1F-\WE8/YZ#'H1[+GD+HCLD\>$"44(?[2_HIT7% >72!<:RSI<B)JR4#
M_NP \%M!P<#2<9E7C"\1GP:/9H<R6P(:V,$3U _Q%TJKH1O\"+X2GIMJLD1Q
MJ2,2W?4GJ;% 3\7F(A[/M7;A8@TFTY?P4.AYR6=R@5\681*MP 6 ]^WXJ)1&
M$ !DNO"!6ZBY\ "Y'2L?5EV=.XK"&7%1)8(++VU.*37?L6H!F<-<5@7<7?80
M4-9=F1M\+O%?K=!3"ZZXYGTBGY^"GNW5Y;;JY!![Q1EZ%((N?9!S);82_UV%
MM83\_V8$^7RKO#PY0Q6\Q:4)%7>#KI&OIL!:KB78MS3]SAYQ;PYB/\F(WT#*
MY[Q::A'\F\'"!U<>79-,1WU3.7V4LCL?) /'M+.O4D&RLU]NO]U]_1@+M,IP
MV7GZC47X*,!=>D:W+!I(O?REFPT6"R<Q^#][=688/[:[G5JO:\CGP% \?S@>
MTJLU^_U:VVBQ,WST/^$GM1WQ4>G#W#=)7)\FV^3F8E(  ?$-#Y.DV)=;M?"M
M7H/-[Y4!GHMP]N2P:31')290:6&.T48W;"J+).03WHV&5]>7HYL!Z-6Q<&2>
M4$V9Q<2@(C"2C_D1VA!^#\H:U-DRJ>K/_E9F'C15!.2=J.RE'4JBNQ.YO:%\
M *6\TDB(4F#/4V#MO6? 0+& P4$+!($W^(>A\E5_\KP)[I@7G_-2.XJ6AXL5
MR)#AC?Q7U2->J>I!B?B84K@1#[9X9-]$:&<;GIG^KY:N_YJJ(C/Q2S-]A&K(
M#B/DBCV+B+0=<FMV12NQ5G'PU6K'KF'>-GC*/U_$?) <,O3@,97+#\IG,(7_
M3K"2DUWZT7W ?F6?/P]570Z$8R'$ T'@@3@A$:4! <TM)N!N3L&_WM04Y)]#
M^'' E_ZM2G9D_($1\>\1.L/X<!!_".[+BAU5E9'+I57,$'Q-?)8XI0)\?/N(
MZ</86DH)=Y-]W\%/["S_\\>8?(M4YI/@3"X&TO($!&#9DPJD*]7JUYJF=+9J
M\&>_T:BUN]W:\J;D IP+\ )ES!SE DL@-[S0'^ =C=E9O&/Y465=7CIM/:-=
M,YN=Y4NC@Y7L5TIO#+\'3PPO,?2]F;OD0$[L0-IV+&>YW_*QI"1F,7J2U9'+
MCTZMJD+S,I6X5)"C0F7<O@UGOA Y/HH3/OF-XFZ2[\ESX)^"1'*#9=&MNND=
M1;X'?JJ;<$,<4'Q=I&5TU3*XN<($Q6-K"' V^@;Q%#!()-7ZHV^#_YIM::#/
MEE0N8)(3F,6Q!?+-@V>E"16,/M+KQV;-C53BD1G-+FO#OW&8!)_B,*F6U?"I
MPK$TF7BW?.2!PJ>*F2XD*BRVM.(!EH<HT\]B!2!)\3,0-LD7=]$S4;L/2^I/
M!L2R+#&_R>9E@H3ZZY7X^SDCHEXV6:]AL&:[G?($#Q*FM-%U>5)) KRW^+ZP
M?;7IF"E2,]X R-7'RLK1N!0OJX))2B3E:-C$5WH6\L*5_X>[.3UJRPJEN()&
MY<?EPV7)!&G'[2"GK>7]'U7F]\7U,7A&,BVP[DCY7;@T<K<3/M\):^9BCQ0L
M;)R&'*@H.SEBY#K<OX?G?W9 C:FL/&8SQE@UC=:-_X95F1AP.2#8N5HGU6.Q
M)K#E8R\*WPAJ36/O4>W0FP/)5+F$M,]>KK*P4!>F5M8ZCL.G=U^WO;&@WV0V
M0V5VJV5QE^* .$RREKS\9[LO6%\'W_Z=WT=@A[U,Z1CQCM_'5-Q_ IE--680
MGW_F)4%=,SE>>HZRRCS9Q[N,0CA YGW4-?(%%R]L=Z*2E>TVP(RVF6&"[4XT
MN-GX\V "Z@/?)#7__%X^%69\T!:C%G'X7*F1]$3CSQ]7*_?$33&2[BL+(BB0
M[1>W6>E09W?]<AL'K.H=<F8BYQ6;S3H;I"8/'T16VB<+I(BE-H)>N-/)8J2^
M4;YD)+LHVM<QYJ S(QM?/EZ!9"</FP# G9)7[U7=__Y3M]U.V*NJU1XRR?64
ME3>;*D?02&N@OPQ4'<>9VO:%I4^J.X"GDE\_ICF6;$<UMX>;77Z#S5QLJ_T?
M[/=X4INRRE51S2'2'1K#(_ GD/6_@_,0SBS<?U8JS!*1;-,.XD>6AWUD9\#!
MT12[C'WT"'!S!CV*>+L5[B&+!BY&=X/;T<W7G^7W^5/PU]'_W0U^O1Z /AA]
MN62WPO=<KQ;?)OMFTWO=C"ZNK^!:WZ:P&GY\&<L[3P]/CY$G@HN+G1C!B]<<
M>OX"SDQ^E[=?></D\1/M^3S)T*VU>[T:\OM9CNM3[1?',+A4<?]ILH,EZ_Y"
MKH*2^3QRO;DWB9*RNEQJ@K,'&[?2,;5NJZ(5]46<FJCAYK*L)\"SHKD7MQ#E
M.$IMC<\]%VX("BZWRYTTQSI>(#MKIG;L::4]+_689V98;(-Y'2\*@)=?LFV2
M5XQ2$QCP.3X%\&N->;%CWTVD!)])O5ZR8>_!H_T[FMQGKCMXRQ-/J&*\?)L3
MRRL8I:EYF&NI0F4=F\:LS!!OEI+ %Q#93I,'10F5MFUYH[^FB@B30 2#BY2T
M*(2H_)?<0QFA/GJRU"&RDQI'6:,/*Y[45> 1B;/ %6_D+.Y2$7/^/0?JE'K.
MR%8L:)6,ELAV+1->)&*F*N+\@>/$/!C[.+&DQ2OZ%A53CEC%?/ENLYB-9-+=
MQ<C0/<_KU*W8*^.F%XSV[!7QST3LX&6QPR,G<=G[;B1%SP7&QMQBVI'H"#;F
M@2I$5K4\Z,*(WX%_Y8^H=B(KS-1 H&J6DM) 50V7* %,W<(CL2!"WRI?BP."
M(]L$,X])*#.V5+?6K;IK]!-FLURY.#HK7DKC%OTSSN\A8HJ;U!"H"G!9 A?7
MA=VG9, \1Q3.O+A*+&[PQ?*J>V7_T.JN+DI/6KV#K!\U;3)+:MF":+SPA,M!
M<2=@%E[<=YJ4W:!\9,]3N51@NAO;2C:Q'G-TXBF%5!]:OIH_(XH4U(EG1?.5
MC=+J;U"K,WNA:(IZ4KD3X)7<<]?^(]XKD?P09V1Q&Q/\5_1>9'X,#E&Q)5>J
M6>Y]@AJ7)9#*>=YX%:NWB/GRX.4U5#T2.:E!9 0!_C3N<FV\J&I7*5_KLKS(
M2ZGWM"5%^ ^XLY#F7 .U&H\S#R06I!;<TL<9:'OPNJTHOJ#T+T4"F#" Y\$V
M[2_YP$'V:DIK#O;'5>W>V3K+%EMN3^3V.+L18U0OWWSOWN?S7,QTLJR2]JVV
M"Q'YW$$+V5.;+B;NM,K%B#L_%5<IT<7N4^\<?LB+_4(MFMJ?'/SZ]>?1_]6R
MS9E:U@R,Y3*?1S_=7%_^ZX1U0-:0W%^]LNM5@49-D%?WL;S+NA2TWTJUX\&X
MORVW-03XCSPMMUYN)HZ!4Q(]LKF5KEQ6?<NBZ6\*FX1]MA/P"R2N*J664&^Y
MZK+JN9AIYT0>CRR&:V%.2I(<K(SJGW@)+@.*"85!0IM9B-R##FG,YRY*@)-!
MF61-D,"F,PC'5/-,#*[B35\!5TG+_[EE1;YJ@E_X:,; 295"//&8.@0BQWC;
M,7+B'H,<ML#SNXCOH$IE[!DCJSU*')?GX"P)$HR83L5JD)9L:RM--+TN9"^A
M"C>"&,QC$OXL'C-<LV\8^6+AL51"$N3L2?UW&WC"B]:H9;2;PWY_>&D.A[W1
MR+R*X0G[3:,QW"L\X9LB8^ZKI%GJ?G@[F8."_]>8"V^9A]9;HKX*P]2N3=QA
MG/73YZ#H;L&*3[@/?J;:FCZ[&MQ>?$1VBON5XM_E5CV>,/8F>>PB/O$6(2;!
MXCK(N+X*[JH859HOX.$Z^\5U)*/B91_M0$)_61$VPJV6GCCOD8 23:615!"&
MZK6"]-'EP?C">(4G$>;N+<'&7@<Z>HE:)+M_5J(<10LT@OC.>RR;WQ>/7:>E
M&RW%,, *";%7LLPO"[EQ>3:X_>6C*@R!4\\;X-G<P!HBAI-T61*DT]C3&$9!
M".H6--W9G;> 9^LT.FFZ'=P)5'-8/80)PE0Y^O$%@0F\>]>.O9K?(]M7_)Y/
MA<\Q%0[$@_OX3^=IQ=]]9$_0954)8)2>E+GC*P5Q.ASU<^@E]_I#I'>7@1!6
M@ !U@RF^PKV'E8C +XG_(R&LTC>,FP'G2#O%IKZ8.@)I(;L_@:?L2<Q=&<\G
MSX I:TMMU<8>8KQMY 7BY9W5>\E%DT5#T3C VL&\R,B4WSS9_H5ERZ^:NK^4
ME33WORS$<7\_O+M:@$G</I?NA-?4YBBZ@.K99<>)5!'*V&4RJ\HQ99<B:!2I
M,7P1^IX$-Y1H@++*,X?Q&4."/7 G2K;+%Q[F0W,B'9/0#K*UG0-+RY=:*^ZU
M5R#-4$DY7@ AK?9VAT.+^V4D-\#3DL.\N"^#Q>5E)<C5 <J558GG91;H?GJ5
M5G%>6CA.3)F_?FA\D'\'L(K)W_%KOB#>:_:>K2/<JE%MC_8DG"FO]TVXZF5L
M[,T/WGI:W#; V2\8[=G;+\&^HRM3"!^EVUF=U[>S-H$7QW%Y[Z+ (9#H<WJT
M<]Z B/X2#GV0H;M2(G\7$[F7']N[GM'^^"FKA O9MTAM@@[1Y'U=I%5(EV(<
MLFL7S)B*Z]_(;&\"6TZB1Z)76='K8EE*"K;/SMD(-T&?V)?,E?@?#S<Y?X7?
MT:0G$MDTFR"1M^!$./;T*7%,[C)/)][X7[X>EO&F;C'))LDFR>9ZV82@< AA
MC7 #%>R<0QR)":&E+V-Q[!H]$,?KN83F3,.5$4BG]R0$NT4,E?,+6?/P+0:H
MU"J(Q^?+2ZBG."V1I1:S:"OIB=@V$[(N-/+\K'Y>[B;R8,9P8%+P9S;S'B%<
M]E7+</ZAGC%$?.FLX-875CP?)>M52K8I%5+ID^!^'$T'2;'^FH;U7'G_TO/%
M$-.RHB=I$(@1?N35,^0HK'BYC9,'F%^NI7?.5='%\:%Z"5>$^3M%\=<Q67'?
M- /ART'UX#/$>*TA_\[&PA73!%56X@6=J_H>*R\J<B5E&4Y&-G6Y9T^1-D\A
M/GFZ(Y-[$EG.%+]9[JGD)1:X1RNS'IBZ0=PBV42)#Q7W7\(#YW]:1#[PC@3:
MWHQ(;SU>;?,W?8W>>RL*V5M"^#6,BSP*5%X/K)R/LN^6H,WGHWR2+DS^AZ4<
M=U'/_=[VH4*?JX+C4_:8W\XU"KY,>BW;)Q",;,<D%X2#Y_+U0>XXLK/;:!RJ
MD-YLGQL-<%IN<OEI5*Q?0-PB/[63N3V8#.(E^S+9"[:3;.Y2EEIF;X-L%$*@
MLL.XH9B)R'+2<BE'+F'=TGO9V2L]G_&4.TEE5(6*>^Q<</6H9M'PB8T*/FE3
MQ !FRFT?9V=@PR7"I2D*8,EL[B=UOC7C<NX&*NWLIS3O+B4J3<G+9O@5SL@*
M2J4UY]A;^13W6:6/'E,K[B=67?KXVO%;SM/H+D?6-.T>)_&3(1N9=LB!@:B;
M"5%/ L;\W>4%XMVNN.+Q#2)B!GL](=$.A+(RF<')6+L/U+)]U50[^7<4)"^:
M([8WQDT#>2-9_X.(>#G6R/;?51%_L.[><B"'A5 G6 J45GGDGTYY?W:0,-4D
M'N(3^UGHJ8D%CS?4\='DMB,N.8(=0/S]( >IX/Y\TC(C2Y4R:H<>[OBKMTL+
MMO/<A&LE6Z;1H5H^+A.";)_(PEU]6&,[^$WB/R16%@&@U>9#C+;L/<K7#F9R
MPQ[>*=F;D!EQA(3TY?N"B\25M.<L,W_@MH,K< ZO=8Z%=G#&.,SC+4KVFH^3
M20>2O(H\*ZZ]0@KDWN<XOXDC^3UXF:_O87%X7$*>]X@SOF6Q@Q>\=.N7MUML
M)7AJ^T>]JK;MUUQL 0LD7R^3Q+<BB)P,5M"PY7L?W[)L9HU]1B\P37_U6N;'
MUW9%U?XZ4!MW\(4,7I*=4<D,F2ES,@.6[,KC5K^4/$?=4P$H@7B.N1/+CQ!A
MWFX)G)(!%U'%;_C#[S@#)/EB5=<[7@^O+RV@+Y$[XXSY.Z2BG]6RI>,38Q%/
M+.7FVXXK&;JVBON?;SN"JZ"07F7O<+S!IET,,99:%?^/HU"^2W(::NGDI9.Z
M49$$D/(YI#K.\83ZPLF[-M63OV7TEK6R9S37>Y5#97=P %,^,]T!K_*9%[E\
M)"S@RDNNX/W$!4A8-W83YMY$.%(,9.E$Q@:Y54S4J#) =OXVOZ0>5/YFM:RD
M-$D.K+PP,E[.SL M8D6Q5-6S[+,M>R')&$!U)>DJX&G/_8RXN */BKDU+QUC
M++MP'/FW&KV6&GCI/"F2.XKDB0Y9<@C4$\:54?$!$RR=E4^=U.["K<%[^4.H
M^0;8N66GQ5//Z"-;*M3CIT]N@7:3&Q3JU>-W>N-]$M"Z9]=_CW(T&S&^_$$<
M@0H:\!C[?P,5TJ[E!N*@-L ,V)7,@,5*PVQB*#I\X0H-8QF69]Q@1=$B@67!
M;^)<^DK%X8 AGZ(LKX@^9;70ZFSP\\CRI7LFG=Y%;M*4K[Z"98"3(CN8R:]E
MYV4M#Q@$Y_XA?.\<I&XAW>UQF%=+60GCBU]4Z*E.2V'"?3DX)-4Y<'PN-V4G
M)?395F F(4N72.@Q]GQ?%L_4LMFLX;-ZK[3%0B&*R]EA/"OIS?G^M:06.=<.
MM$P*>-[(E]HJ&;?ZUAD0MH'MAD<^]QZQS\^QIR)WF612<PU]D="WQY'*_*>M
M"O*RRR%S$O<JGE)Y[#C7H$@D8YHDPODCIB?NLL;=U*N2'E@DGK&?6J 41C..
MO9+0.6ZTS4>4*,APJHQU U SEHR8L94?V2".&R3#^GF!B+/?\0+%^G-)6;LX
MM#U=;YE%<*1FSKA?AH^@RB*>EG3$H (O[I?>2NG(3+CD^$YX:S7/4V'?+V]H
MJ,=-RM.3=Y<)]:47CEU&'.,&03_RZC-I3(F),"G).\<I]"P5X-B_"953&<=%
M>& :/<Q;H#Y<HO#R<R;ANPV*XKW1JF;3LW:SJ.KUOB^P+=>;G8[$_$#GZHY_
MSQS4;@MMS356^)Z/E%#>Q=6Q<L]/.7JJK>4.V1@K-%QL<L=5Q)7*,X' V81N
MK(I%G.?@3IKJX=]C_@AB) ZX:ZP*LII<V6$1NU#*!$CYL;,;O^FQQJ*P'.?&
MOB4^!"IR65QK*0=< =N_?)@WGT5MKLEW2T_!!I-@%76V$!&%6Y&XJ8@P%P,$
MK"NW5;HM<:4YA+P*'O5!G,<M)RJ9*,W'Q ;*A$Y<)1U/X\9^<=DKDW4#C!'#
MQI7YTWC(AAPU*:F2"-7;LOS>(/;9EK1"UDOZ:*9O!-*2ALLJ,=;\V;ZI3*Q'
M\LLE:U8]?;$$M/B*ONC*_9.+Q)499JY,EG1JM)63ZN=*KB[!8W!38&V>7F&5
M-.2= JDJEL[,>KX4Y@!N,F-]?P"1G%"CY%*G0<I@/)OB7AE/*:_3?)R:'Z 7
M;RZD-XG1+-6EE]-F\MI8BQ]R6:GN/"4#79]GRM4W]SY.FTGN:\4Y\S-TB^U@
M(3?1O2E"P"KL-50Z8;)1$D_A6_)Y8M6#GB5<.EJH&=G  ]Q?<6"<WL535K[D
M.S123@I3"-FX?GQ9XI3Z>%907E->^R*GL7AN"@@FU-VG;-$G<"/'6Z@=K$PD
M3ULB6VC!LR$3Y^ELB5SG:9)V:C=6%41BE -KDYYWG>:05C%'H$Y7&:#'G-?^
M;#<HQ,O>)]=4<%II;@J\V,0I4,U'8L',+*9)3\N=@M>K)T?&.U<H^JN.E;.=
MX!YRC]'/I76EP5P63Y[#/(A URSAY*873W?!TE1-+C>*&B$Y\EWR9#9R\J1P
M"5,;)H$.$:DV3-"9*4NCK3]N:2K#>EGKOBAWO!%ALJ=^H2J\,A]:-@2H>L>$
M!;_EZM 4-F#(ODGO"4[XAANC\/W0BP><+?\*W_HO[B8/7LMSL3QF\;4JMI16
M)QL(KFR# @R1Z4L4&XA+W3"3R&P#5_Z@P/5%F):U6?%CB'PWFHSR$U 98$;,
M/81IQQ[R'FJ09_G0-4^2 ']N\B#9/K!T[;,LEK3XF &&>SM/K]UNU555< QZ
M2ZI:E4#F"UD$]0?/O-Y53Y@D>A?):BY=>(XYPG6[Y^D2H#S),#OV0>("I>4W
M4).R0LQ')3WI 9:SA"K<RFKQ8MK$SN]&Y9;JE)(%^:2Y-M)<O9I*#<OR$/02
M?O9<7^!<&NDF7B7IO61B.V;ULD*HIM$X-]%W /TUMZ,Y&ZC]CEB/N>Q;!,\A
M:PVPVTF-R,$$;38L=Y6.BDN?<ALH<0I5Q9-2P))*X?0&5G*#YX45$D08]1S*
MD7S*L4PE^J%P$_V[[C9QQDN>E:2"Y90%5 KHV:MN]V*WG?7TO<9H+EOS_TO<
MB&UA(/(0$M\0S-H/G[XY$" -W F63$G'_3+= ]\&/J([NKH8]8Q^ \2QU1Y>
MF:-A3\)'=$SX8G2Y5_B(Y^@SIF8!-W.@A5UXZ<YZK!E)XQJ35%9@E0F=M>BZ
MT@!E9*^Z2%]5)*\JI0J3>OY$;0B#Q(2>+T&.T"C6I.E5E7\J_R5D/AQ.L6.[
M/5CS"XK9XM5[(WQYH96[_VW46LU>W6!P!6<57+?6,F%\N>)?IU]O[NEUI HL
M]![2!&?@=DDISY$O4X)H]N+%BBU3EYU)<2K(>3IY-+%;."N<1;XK)]R%?PC?
MD:7EW)*%O-72\3%RA4KF^^!X_1[A2#RYVR)WLAY%S@UTXFEK:TA4Y!@_^;2=
M5KVU'QVF9IK@J1;XY'*G][O$'P,/LEA5W3'K[;V\HP0*$F#%'Y6+/(YL55O&
MV=B&!;ZWK2 WP4!6G<4RP!![,(ZOOV,\(+LX9-=?6F1)^O]X]+_<12C:!^DT
M^O5>51RJ5L_8DY@N6^=:EOT2<G\'4T>A'Z63>R2(+.[;++<N+A^79( 2>:ZL
MS*:LC=$N J=%,CS)!JEA@+)'Y6X:G7IC/S*09%A>7_@MLQ/;9!CRF8D;H3CV
M)VZ[6&O]U<VAB]QA9FF;Q,2EV6GV1FVSTS8&W=;5L-&^:,6)B6%W>-D^35S+
MNYEX5JDXQ^J*K#-=#0[ 0C@YWF=E/B_+8RFHP%C1R'$VJBU%E6VCPQ#([N-$
M$2F,L^!UN+(MH$56+<02W$CCV5@+_#M_4858NQR5-/(0)5N!Q&S!0@KUQ6C
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MI[$VEK,JB%-1/D%5Y.5(S7Y<!V+N4G!3=1>@U+3:/,%>[#[06WJJU$0DABN
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M0ZW3%.8>YJ[LI"=*S+?D7)4=>^/4I-CHU@T28Q)C$N-C%N/&'H28]M%( $D
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M:[.[X%"'T1J<%2\4 5OP)[DM$7KL*IJ+"9""#7XZI%):FZHZUKW4Y?R4YBJ
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M#G>W+K%N#ON7EZ-N8]@>]8QN[\+H]8:RQ+H],,RK?FNO)=82%N(Y"Y6QYCK
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M<);E(I1\#/X.D,^Y!*<QL7$;GVP,HCF^1_'T8!)/"79XMS8.,J2P*&!MQ$#
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M#7R#FQT(N6$4ID!B;]BCTX:&9,O07M, 3ZBT.()V5Y*M&0GC;)H$PJ?E<!\
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M!*;2))+)&#Q+U#<PK]; 51,S6^5@LRT:0A9FYGW1I4T (8WUUJ","V?E,7V
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M+65W 9!7L/1=TYX:,:88DK %/V(V$?8YYY8>,ZM$,,H+;B(*4$_LV:E!$.,
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ML?_^;__Y"L?QW^"___[_4$L#!!0    ( &Z"F4I#A NDQ!(   OE   1
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MC*]G\WG'ST#\5HJ+)J:?G[JZ=H <49@M<?N/<5I;?+N*/S^=UY=7$\#ZV:F
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MT1%7P2%L>4!*.89=% GC1Z)C]K,PQ\&JW"6A#6F0MANBVXI54D?E&4P$XW1
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MA  C3@QB&G#".4<[Y!"Q[;>F(T=4^Z%:%!#/M2O8U%.H,7J[=)L )2$ !AN
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M:UC))Y1NOT\S7 ;,</2( 6'/%%GL:M2N0YV?RA#H:>38UT,"&41A[9786.J
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M*RK;V$\U]^O5M4N<(Q 1#Y4AUGD!)"9F-WXSQJLOA])K/PB=TS3].%W\WL(
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M]-W^#FI2*P=\:P*@05PR:[V##F-)O"&5<B2$,4M7GI2L>2Z./CT].!K51#N
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M<^<\=.H VGFSEPY=Q#CXX4Q\KA<?+_$\W.OKAS2J2S'?MJLO?>^I4&J-M @
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M.;MZ1/1/IHW2 G^)!.MI]_']:OEV.@DX91<?TF59@>#X#N2AYQ-!)=)*0@2
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M?T%QM^' ]A]/U;_]<?+F\QX]W_\RH<9Z3,I+DX5S3!F*W6Y-%0U+9L=U5GO
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M; OS2*O$<8$1L(QJ+205&"*#*E61X/V/=A?SO%3)AT(XEB%Z8,2U6U]'VR5
M$&0DM ($<]\X82P@E:R:.S'N7=%>M-B,&9WP>MT<&>4.Z?BH<1Y*E Y'>-=U
M<#)L\-)F^?H0OOM63K3U6Z8-6B=":V.5<H@ [AU6SG!6R8VHB4J/9IL?/>EQ
MSP&9?K&*=HPBFX4^KW[)YEF1SDIW].(FJ*/TT)?3K]E6A :'*D[I)W&08>$D
M=0@ZR;%4".H*"^SMB#)3A^7-D*A%G&76I5A619#$!(/NJ@%=#C=*G!4$.$!
M\$J\X=Q@8"LI6?C=>')*!Y]3^H$H6F6LM(P:U*K^X6,)*(^44$HMX-0JH+FE
M>#<I.CW"XC;#*+L#*-%6BAI?K4PSG*6+Q?1RNOG!F_GS>TB.16:&>5$"(44:
M<>%+!)%$BFA:H6ELA[5F,!ME-#L\YU1$M&2"C3C9Q7YIMTOPL=2"1ATDS !G
MC8/$!-./>.2U!EOIB;"ZT>7#D>.$9U+_T^2$(? =%[O>9<OWEY_3;YU95G64
M<.Z,E\(I@(Q0PC.^6X<(8JS]3N%@!O:+8EM+G&.QKI\%Q*2WTV4Z*W^Z.4HP
M>+#KV1L3Y 10VG ,I/:<2T]EY303HGC["R,&<P9&PN-Q**1]"M"QK^]ACL%B
M'4.O'.6#^3[MNDN8=(9)J(2FR@O+L")TMZ@0W3XG;##WY,STBXCVJ";3L!;H
M;!XTO?1!):<9D/V\(,$&6H*@@Q0XK) '@.\,((!\^XH4O9]3&PE7SXI_A'RC
M@\DWYSNQ]G*S;XA34&LK"5,.8.V=V[D7UG+7:*/JS^R;P\%\0J@(.$*D4+"<
M@Z@&;3/-J2$<ME]I1YY]TYA74;)O3M/"J+-OU!]I<=&@;NVCYQ*C$%/80^K*
MVP.X<(146V5& QLS&7<$&3:-Z?#4B>Z Z9FWLXNB/"F_7BWUW;,5="W8O73S
MB[+$_;OTIOYRJB%>EPCCH?+(>@TI___M74UOXR 4O.^O@<?WI1+PS*U2I.YN
MCU8W=5JK32TE[O]?W-;N915[J6,3J1>?C SS!@R/8: 8D!K:(XO<9'X76B)+
MIB6IUP#VF[KS(9REL.B"&3M37N;Z[O!4M3=MLWWZ%:$?\5_]]]NEEW&*@RBU
MIH%HQJR&'CATQF=T"VP>(6OFAC0Y_#]C5_E='=OJ_DV=4&^[1/E$,DPI6Y+8
MC\!14 *4D1(-8)]/QX) ^B[9TOL6*U#C#  G$Z7SB;ZIVO;Y;5:Y:P[[]_-?
M$8<QS^;1DJ41X)UP'"@SRK/@_&<;6.'2CUPNO2FP DEFAW<Q==%D&HV4**U6
M/! C:'=A'-546!R6W 9DNO__TDG]9>DS+ZS)(\NPONU&MLWK8?L8V]PU[?2P
M,E*LY B!:RB0!'0L$C]8V]<>E,O(Y2TK4IP!VZ_;!IS<?[+'8]-=25K=W];M
M(]:[7?5A OMPN-M/=PZ8XR,E6FZ9#02")DYS[YG3P]^XL!G.A-?.?ZX>A+R4
M0U_7I2'1DAA3%)I:$ !2>CH$P/*,CG"L&?HT3=K_89L7L^;7I#%E')&":0=>
M4,E1LP%L[77Z!O5Y[,@OB6F)&&<EH;@(/9I2Q(*AP LFF-"2"]F?.<9 549+
MSXPXG$<P+EV+!D@#%RXNI0HGJ(]3]$_TT=GTU-AYS,_7I=Z"2*^BY%G"*F@(
M8!W[8B?!BLO'=Z/ ^N5ATSS7VSJ+*DQ[Z[3Q4'[UG0#P!]^ZQY](CJL??P%0
M2P,$%     @ ;H*92@0#P0+'Y@  C>P+ !4   !B:6EB+3(P,3<P,S,Q7VQA
M8BYX;6SLO?MSW#B6)OK[_A6\/3?N5D?(57R K]Z9V<"#K%5<E^VU53TST7$C
M@\JD)$ZE2#7)M*W^ZR_ 5SZD3 $@0-*[^\/TN&R)YSL?@.\<'+S^^;]_?]P:
M7].RRHK\7_YD_6S^R4CS=;')\OM_^=/O7][!+_CZ^D___5__RS__7^_>_3OZ
M_-X@Q7KWF.:U@<LTJ=.-\2VK'XQ_VZ35'\9=63P:_U:4?V1?DW?OVE\RFC]L
ML_R/O[#_N4VJU/A>97^IU@_I8_*^6"=U8_NAKI_^\LLOW[Y]^_G[;;G]N2CO
M?[%-T_EE^*VS/\'^ZUW_8^_87[VS['>.]?/W:O,G@WJ85XUM#B/]CW]_\?/?
MG.:GK3 ,?VG^=?C1*GOM!^EGK5_^_;?W7QH_WV5Y52?Y.OW3O_X7PVCI*(MM
M^CF],]C___WS]5ETX2_L)W[)TWO&]Z>TS(K-ESHIZ_?);;JE,)JO/93IW>N?
MV);ET1<80R%CR/(80__TQH?KYZ?T7_Y498]/6TK/+R/P2P"N7X+5A:XAX8,,
MR$NLGGY0,=X;.G13M8A??E(QYK:C1?E&1_\]_:QB[&HA:^T919UL%?>,%Y\\
MBWG+?NH]_5/W@^SK%^2W,=Z)ZL&'T^]UFF_232.:1Y\VLLV__(G^:;6KWMTG
MR=/J8WF?Y-D_FF""B[PJMMFF^0^8;SZ5:44C5O.?'^_B+*="G"5;*G5URD)9
M!6^KNDS6]8KX#H+8#[S(B1W+"?T8VP[Q;3_$ 39MM&J,K]+\W>]?>JC-7\T!
MYD\BW+YL-8JCV)7K-N11+UC$;QW[UT/\5\:1!T:2;XQ#'XSBSAB\,/9N&'_K
M'?G__OF7/5%'+5FL7^N:#?R[I+IM?.@XI;Y8WB_IMJ[ZOWG'_N:=:76!_I^4
MDG_:N,5ZIL9MVVK+TJ2B[(;8T4B Y=HHRDU:TO2M_Z6D7+_1*;J?^&5=T)SD
MJ7YWU#]8&C>KS\6<PZEEG!+T&MLO= =N-AFSG6P'V]?Y75$^-HA(5JVW1;4K
MTQNJ98A2^L<J!('K1Y$3QL"+O< )8L_L<7B6'Z]H.GY;="'X3:E1;U]$5@ZA
M\JM+_9"6!ZI"YQ"O"(A!TCK)MF>U8ZK6X%/\>9M!3-WW6 ]X/T!K[.$:?V.
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M UA?M&0^&HV35\:!F\8WZJ=QZ*C1>FH<NWIE#,X:C;=7^T<5KPSFL?'3^R9
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M"FG;!I:6DCGN.)RD#2^$J"7VI&4$O44R\^K]C@O#*!&8*;(N_J,T3^^R>@5
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M\S[+T^LZ?:Q6#O <'[H6BC (;=^SPLCK;8(XLL:6=/@MS53680"-!J&"VHX
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MT\Q*#_PY+ /V'O4/B@T^L5]Z>2F.W%&"J5N<3]\7W-AB 6".=M82)]2VR(5
M,E/3+R/2S.5\L8CA)YC@CX.&GE__0+,7W+2P[8<>(7%DT4E)"&(,>L2A99DB
M@6M.G)JCF")%NS)NG\^JH\SQE%F[!N<,Y@?I%8+S';E&U#.ST<?PI7G0 MIU
M&;%L$4R<SK&6@$E!E/N0/*;=L0'L LN*, EB"YI>@"S?LGJSKHF$YEBCC<T3
M;ZX,!E'R8-%X@L<(OB9NE:@V+ZT3JO>>+F$)EF!ZR3HJXPZ7&$KS]):BW6;9
M[>I+7:S_^/C4O/C,MK<\/FV+YS1M_OH3[9X/295^HIVS.[H B4]%U$+4NNEY
MD>VY#NH1!(&+^)8P=5C6OH+9 #.*%G"SDR'M(!M5\T]/'6CCB?X>G^9I:8++
M\C<W]X+E&B'2WSXCI9_]3;'>L0UC3<:RV%8X0JFI-<Y?VW82H!@9+.SXIM,%
M'0EZ7HD_.DF>-Q1I]:S0WT4% M1-]IC^E;TEO?E,_[?,UNRZ,6;^]SRKJ\YN
M:+E^2(U[$"#HD2AR(.SM8F)Q/J>BSI[V8,10OFN>V-X8Y8"S&X4[AE1  M50
MS!%V)N=6+-@P>$:+S]@#-%K5:R#*!!@U[ J$E<E9E@LF#=L7N_#8 ,)#Q+FP
MH93$!00+M?X4NKJ;0&#X+2G_2.L7EER$7,^GT0>9((ZM.,:N-ZQM>, 1" 62
M%K2+?XM+4NQE:>.0]PGX$A/TCJB1 B[+F(!D3\"<G$B_[&IC1?EU5\_)\$AB
M%B"\8STHU'6329=SWP]'QTT_#$(/ Q 3/[1,!V.$>WB>YTVY=LL/ZL=8J!UQ
MK<5TS3O)^JN>EE6SV*JE49>X1/N>XR*.R=MYR8L&.MU6N](JRSM7*M\\S@'S
M37>;_-D7>JD5=J6\';@1LAV/Q*X[F':0S_EHI5*3VI/]]BTB5FO=G'T[0R"9
M548UQWQ@#H[%%+LEET(<WFU[38[?/OVOD6>!6<0<?,M-*W@Z]=B)!B<;YV8>
MJLE<P%1$N4N%QLXG-EGYD-;M32OL-,;^W830@B2(H.L'D1V$.(SAL%Z.[, 3
M.W K9T-[@/A QU_).I7@VY^2E/%E\_JY$A-ZBL?HKF_ZB4'ZLP%/GIOZ1#MI
M7L]VU<NKA%U(H\<1O(R<>*0/A<HN-T)N5B2*"?3#D "+>)CEQGYO _HT31XA
M,V]^6[^\T)&3M2/G_ MM,XX5WC'"S>0"QP8_]DMC0I !/>_*QCBP($O6/-LA
M.$*!%?<+0= $0.BF:[66-5?\AD?W^D>\\^'1/=I CT7>O^I=[($OXLD]S8^:
M\C;+,H:E)M]&/6HJQB#OL"8O-]7W,95F\-@"9NPZ<8@<*BB!Y_<&/8O$8O%N
MA"'MP2^ZNTO7-1NC0UVW&F *YMMC".5+NB=B4BSS)B\+XE=&SVO>/MXL6771
MHH+G2;P@>0J87X:^J7"D4-XKA2^5+M.F)K7%361M=?-PPG=3M,>'DBK=?&IO
M4X9E2;MM\WO5"@>^!R,SQ(X3L,L<"+3Z?8S0C4W.0O.$@+0KX1?1S293M@:?
M/"ZL&<1D] "\T:+OWVH^+60,@KL/7LU/OKME7AF=6\:A7Y-?43VR'2XH\82-
MO S%GM+AEW=;3\OUJ"GIN:>JX>8_=^T=ORO+\FS/@[&'' K&"P,_BH=XA%QO
M51?4UQ&34P48A*:I USQ=.VIJ"F<C,K-T?143/RU-02?XB^A#<1D?J@2=)"-
M%O.P/-EI_@%L8X][ >6"M\D5+1PH;*YE"+9V+WF*"<I9'5DM/(=G%1+D6A"$
M(/8A]CP + L,Q0U,HM&2/,*V9BGNQOJ.96U9;JR3[7JW3=C3/#);0:8L&9YC
M5+QH.+IM%CSF57C'5SA4Q"+WI85U4C?YW<>[.,N3?$VSB$]%E;$M(L/<G]HC
MH>_C&$& "(@0] ,;>#0A));M!+R3.B6V],7S 1Z;A@T C1[A;%4N'MHNC%:E
MK"]CB*IUZ?3^-O5\<6_CKZJTWI?<(MNSZ63+]BV'QG0KP"S,=T90: ENB1'\
MN/8J%?SR);KY(K@17I @/EW2R(R8 K5 9A.:8QXN[0N7(VP9XB$+_G2/]A@.
MQ 0![TJVWVF_3\:Q(LLF(0I]Y$:1$]G0ZFVYA$ 971"UH5T>.D!&TL 37+^3
MY$U$+G02)J,:5T;/V+SR<<++FRHBR^.2Q$3:AU<U91PCO-*"D^H!YAOV_]@[
M:5^3+2ORPAHG9?E,YQM_3;:[=&71M@;("J ;.X[I!I[I#'D. =@5DQHU-O5+
M#\77;'A?LS^D>Z1B(J2(83Y1FIY:,9$:.&W^< #QRDAJHT=I-#"GE2TNYB[(
MF%KFER%KBGTJ=/9552_;=+*[0L AQ _-R,-A% 7 Q)';VXTM!%2]_,5K3[O<
MM2?5FR7I_88I5>_8<+/*F7M-2J=@'G;YO9H.X%)>J.G@7,K/E'&]#%%3Z _W
MZS-R3'&+V7I=[*AT?D[7*951"N!#6O<F/1<'GFWY)(P=3+S8CR)S2!MCS'G/
MFA)3^FM)'3JC'.!=&7EZ?K!IH)-3P*;B45"[>@(_'Q!(D<TE6Q=8NJ18*LA=
MB%@I<>54I]3QPW57 -FES+,DKS-,;+-^2,OD*=W5V?JI+.[+Y+%:8=L*76B3
MB!7-D.DZH14.P@A,SEJ6*FO:A8IB;&\682C?,9C& 4ZC!RIP>%T%QY>E:PYR
MQ=1KF:P*W 8P,;MR%P'L58.';(,FP0;]5+O5@2VITI^B_YJ^JY/OQKIX1W_P
ML6@65NF?[MA];_=ISDY']Y?OL%\^^KEDOQNQ^7KS,#S[\N?KF]__'7X8>PO!
MVZWP2NQ1W7X+N'M I3>%GEXN>LK@*^TS1?E,P]W*MX 7!A8D*(R(%\1N& PF
M[,@1?-E;Z-/:P\N 9NI=XGL2+J1G4EPM(QV3@_YB#[:T_[P]_2,;5$?+""LG
MC&UL$\=R'$"S.]<W8]@;,BU@B?5W"0/:>WV#R5@?+1B*S?QD:..;[VGF2RQ/
M:HDZ62^<5BI>\G%!,$:0MPS9&.- H:PCC=ASL I<0 +/"7PS= /3,FV"T3 K
M]#RA/;UB7Q89!A([=F_8KXP2#4&B..M#VC@2+ C-*1*\^B!'UC*D01+[I1T#
M@@R,7S+[0%WM3 ,8NX$=6<1"D0N@$_G[="8D0/!>'24F?^R%,Q%NQZZ=:2)5
MZ?+9'N-25M#VB*06T21(7XAR*76)>RE-FB]>G?M4%D]I63^S-Y)J]H#2WW?9
M$RLV-=,UCX0VQ-B-'3.*$< @&'8CA AA,7T;94J[KO7HKIJGP>KV\; >H<2Z
MVCAB^<1M,D;%1&U/Y:>!RFA/Y8<+5&I1LTLT75 Q)>PN0[W4N%)HZ'VB-<V:
M=K2,*F6; U)+[07A67[_:U%LOF7;[2H(/<M%(;$=#/PX0CC"@VG/#03W,BDQ
M.4$-M$?9S>HD%$L-N7S*-3FK8@IV0&<_)V373/XT8#1ZD'^>NNC\-F\7B]$*
M:5^&M*EUZ47Q6CE?O%(W?!Y@Q[(=TP0^@#!RHS ,G*%F[D/! W'<G]4N63T2
M,9'BIX5/B+3P(28V;Q*A14DXU$*8FV4H@CCL8F2?D%ZN.IC>(1<X8>R:H1>[
M?@3]$)!ALR2,??D5*P$;DRS5MK=WM*\S%\W:S,C%*Q$2A=>O-+$W9@EKKJ+0
MJZSP+61)L+@,+1GIP_GE+&E&Q%:T5K$3^ @%*(:V8[L!]E'D]Q]W M,47\IZ
M\Y.3K&')KUV]38G(HI52-F16J^98I'IS=8J;E66,<E'0KZY'"?K,.X[?9\EM
MMFVOI<W;=XL?BBTEI&+UEOIY.#&+B./;H>4%&%DA(C9&_K"5&7J68 *AS*SV
MG.+]-437[Z]OKJ,O!OQ C.A__GY]\Q]BRJ".9#[MF(5=,74Y@#@4<.OGV<[9
M\S)V09J4D[X,\5+O5J&YLTH+X.DE 2;R7. 3AYB1']C00:$_7!(0^IXM+7FB
MAK2+7'_-Q7:/4?!VD#$T"HN:3OZD96S^RT+.,\0G6[*T+DZHI!TY+TWCN.%^
M="2]'<Z.$>3X 6&U7XO$D8WI-&ZH#KE(])H0D2]/)C=/1=D_ YT7-<T$GI+G
M9NO/OGASUUX7E]\?GE01G)@)L<HG1KKH%%,?AF*F[80'!%P0%QF:EJ$F4LA/
M7_Z0]IY7+VZ2[VGUJ1TTO247!;9K =\/HRAT7-?%UF#)\1W!K$7&@G;]:$#U
M8B&F!5*,\6F";JK$M*'EJ(,SDTB\PL@%L1C#WS)$8Y0'A;K>)'?CQ8DQ+XK=
MV/(LSZ=B%=B.Y4*POUX#1G)W70@:T2XEPR4-4FHB2QUG"5@_9X(EX9ZL>67E
M=5XN58W'$;D,<1GKQ)E[*T9Q(K0F_7(VM2(VB&$<1A@%'KN&'5O68"VP?$=B
M55K"RA0B4^[8<P7?G]*\2@\6IR56I65H%%B7ULR?S,KT:T66&=:F7S+SUNKT
M""Z7H3FCO7AMA7HT*_*EW55@!2&)Z5>MT*8?!L0+A[(-MLQ89+U:XO.3K%WW
MYR\/BKEC:[EO\R9;PU5*V?C:[=P%6Z%"+3=WRQ"3,0Z\69@5Y();0HK\_B8M
M'UDI9X4]$P<6"!& D4>%*8AL>ZCYNEAPY[_0I[6G*!\TUE_%2.14$EWL"6H(
MA?&NIC@,!F1B]3B@X))NR#"U$,60@GZJ%?+^\R_;W*54A38WR?<#93K8@V<&
M(8((!0[ 81@YT 5X*-QX  C69$>;TZXF/4*#W4O6YR'G+U#21"KO4LZ$;(JN
M[W0T4FS'LZ#F&M&Y=NJ^Q=C%!2%%9"]#H-2Y\V+I2"E/LG6: X.>!4W;=@+/
MLJ$31&Z W;U!TQ:\XFV$(>WBU18=MD-DEYY'C6%3KF*CB<;119M9SQ2(:I0"
M4I>A3BH<>:. (\V-1 UG9;(G.>V W?ONFJX9H!@-R1LBOB59O'GSNY-4;514
M:]YF2+A,HY0<Z?K,;&49OGH,-TG+T 4IY.<K,(+><S^F53P^9NUA/O:P39&S
MEY_3?,TL4@L6QCB* M>W ]-R?'_0&N"9@H>6QUC2OU=N#ZY]/^L0GN#C66,8
MY5..J:@44Y)3#C$7AWI>QCI/T 6M44'K,K1'B2>G;U\I8X?_A>_34PK7>7=O
MPZ=V3RNLZS*[W34WV=T4+$VBL"A1]*/WUSF=5Z35?C,QM/P8813'H1E&) 1Q
M&,?#R0;'%]QJ,S$X[0K8^B!X'F'J%N*3QP4WC9BB'CKR7[O#6U?&X(S1>6,<
MNF/4A7'LD-%[-.,[\"H;Y(*"S]3RRQ#]N9Q_\0K]C&T@'UH&@ZX%S-@R362Y
M5H!!Z&%O> \[1+[@?8DC#&F7?)05-( ;UYMTS43EY_;!DT%OT@;NV(# SZNL
MN&LA=+Q0OU#E3\FLY]:DCMLJ8'NIXBCNR)M")\D-_S6OW7I%8[E]:S: T'9"
M&/L1]D( $(C<84,&<! 2O=U5W()VF1I &15#=64\):7QE6$S_F_S9].TC*>T
M>ZQ)]'97"3[Y5$HWD6+RM&?P2\M@ XAFDE6U2S=3W^/Z@ID+^C.&QV4(SR@/
M7ES6.I8-D;)@D1^8L9S0] +'":/ 0Q8$@>\/>T>Q:0GJC/#G)RD TIG4ZPIC
MNK(2(\XC?P50&X'B93_*W/S*<LK)&Y4^*?J6H2GR\%^IZ8W@@?OLVV:3L8E?
MLOV49)OK'"=/69UL5R3$L85B"UJ>"R" !/K#JQ\L3Q(\_"9I1;NV[(%18<DV
M[[+<6+?8!,_!R=+(IRE3\"<F+0?$,4@&)0Z_09R>HW"O,W-!8,9RN0R=&>W%
MZ6DX):P(G+C=/>ZV[%G69D,%%;NG,GU(\RK[FE[GZ^(Q?5]4[#KHCW<WR?=5
M:!(/1Z8?1+X#*%O0W;]T[Q%?</NH:NOZ56H/N-N5OCZ$;&PI6N%SNVH;@%/'
M9F1>4-\.*&_W<QUA-5JPQD\,[I_;V^N+.[9-=?*3P"*$7I)%34VS$+G4Y=W+
M0\4:6>25U\]IG61YNHF2,L_R^^H %4GOLG56KYS M*B=T";0I88@</W]F\AA
M**BH"@QJ%]$>HY%V(,444P6G?"(Y,9EBNCBPV*,S?CJ4R@[@Q*]VO,W8!>%3
M2/<RM$ZE0X6VKBEXSU.9)M6N?#Z8#[O$!<#W+<M#H4.\T /Q_EU*RS57>7K/
M@/$IF(0!KD$6MH/L$ O_OM@.4U_Z2FJ:]U6"KP[),,>G4[HHD[OMJ>?JL-@U
M\65/+_BXH#HCR%N&RHQQX/2FI[%<R&\M6(4@C#T[P A%,$ !]-W]_)8$MM"6
M>HG/BPP(Z9WU_6:"TWT$_\\_403^?U.TF^!M*F5W$2AE4=ON@;FW# AM%>"F
M=!EB,\:!-[<&"'+!*S:_97E1-ENLVFU3*X]X$ +;QD$,(ARZ)MKO/ B(*UA2
M%_Z\]@G6R=;&K ,F.,\2IXU/5K3RI4%4SFP4G59E3DF[H#'2_"Y#8>3A%XKZ
MV1P;\"DX3) ?AU;@H\ +D1<[@_3%7B#T?-%$D"9)F=2D1'J:1#:-FKTUQJOD
MB!WV<Z=G,NP+I71:FW<9(CVUTUJVSPMRKNH=JY4)_-@,7';A#PICU[? _AE=
M@' H>7A<SM@D(GYPHKPY]2@CZN-IY9/K21D5$^+77ZI:UO-4%Y12&;/+T$!U
M[@@^0R7($Z]NM8NB-\EWDE7K;5'MRO0F_5XCZO,?*\]UD$D\$ /LNM *_2B(
M'>+;?AC[GF,)KE*.,J5]^MSM*&BNO1?3J'$4\NG39-R):=.>-&,/S/@;@V8T
MV"8^R7.)I@L:I83=9>B3&E<*#;U/3)?B)"N;M8B]R6HX1!1"[)JQ%;@^P99%
M$(ZQTYKT3,>-(.>@&F5#WZ!BL-H%M(-!5<UV.NX22Q?&E!)RES&FU+A2:.A\
M@D6K]4.ZV6W3CW>#\?9M7YIP'*0?OS7+@>GF8_XY99=KT<D32JJLNFFF5<.X
M#P'T(/8#.X84F0,=8*(>(R(>%#P-/"DV[=G$E]WC8U(^LTV)[5/>3>I^.",J
MTS7KN!NVK>".C?BO%Y?,E]"@G)6OQ;:D8 &L\X.UX5Z2KPRX;\_#J5GOCU'D
MQN"1T;A$$Z*F.C9;6J2T22Y5Q69I^F4$B9E\/ZV1S=@"XF$()V7Y3&TW.!G$
MJ*JS1[93:T!??;QC%V=?YS0R[IHKEDXPN@2AV L( 5$48]O!L0.&4!D&1#8,
M38%MRC#4Q)CF K?.L>X8)_VG#77"R/9>R :A29I3- @MK1WE@U#O21N(NF)@
M[\Q!B*K8#S.'C ./%A2#%+0(5PR:LN67%H,F]?UL#)J^!83+"QQ!\?>\N*W2
M\BO#=9T_[6KZS[0]Z&\E;-%I#Q7[,09.9)K("X!O6@$PW1YJA$)++!3- E%[
M1(J'J0Y3J>$R4;:U.J\R.CZ2]D7NVVUVW_Q1,!K-T[""]::EMJALG>J*=R9T
M91SZ932.&<>>S1ZH=+023YULCDZQC+ U+P7GZG+SM<=;0>PVRVY7I%@W\9)%
M52JB;#/$75$^-H:'.J+MN!X((L\- B]R_!B:)&SLPB $.'KKL2MUAO2I4 ^O
M38<;@,8!0IZRN2YR-]U7FE];&,E'V%21_3.O4C.?F?[ZIM.I+S<+KTBI>@;G
MU44-_A2Z^AJ?8FW2;-7:^IS>9\Q$7G]('M,5"0"Q,3*C ""+BB0,@=^;\8/H
MK<Q*^KOZ]*@;%7L\!@,DD\)4Z?KG^^+K+]1)EKT ]@<V:,!!TG*.@%=&R6BN
MYAT4X^$7BOJ,:)?'=*R5R?8ZWZ3?_]_T>17[-HZAAV) 2!P0,XALK[<3QM%;
M.XSE/ZR]TW> C :102'I[_8G'%SL][)\+:7C2^-_T?/',<'3];MG<>.L6B?;
M_TB3,LHW)*G3E>W;%D*>B^TXMLW(-L,0]:8"TWFKP#OJV_H&0 ?):#$9#!3-
MCS8&@Z5S$)RCXLPX&,W<_$-AO N%PIXD&@OB;)N6F%JX+\KG%6#C+'!]"_G8
MH@/0C7W<6W%P^-:KYK*?U1X'&CA&CT=_$#AR_V((D"-J_EX_"OT+^1_# D]?
M[V<8-_0W5C;!/@Z)X]DV!I"83F1'_><C!_&D^$+?FZ#4P'#H[-6'_I[ISE*4
MS-^/Y6 7([N">,_]E)99L>FC@1^"@$2NCR+7@72P6,#JHP$,@S?K__(?GJ O
MMX F259>Y>"-_BW'UW(ZNB3^5WK\&"9$NOX^&8KIWU34DN,Y@1-BFUTD15P;
M>Z2WY%N0)V&7_?0$W?\P86] 33$ 3GAX8PC(LK:<02#MP2O#8!P;X@.A'7:M
M+>A"WX1.$ #H6-@F%L9Q;POY/D_E1O[CTPV&+B1,/!P.N. :$#+<+6U(2/EP
M=E#(,\(S+" UM&F,;9/[E1G3+R,3^,#TL(U\Y+I]Z@4Q0F^=NQ7_H+[N/^ P
M&!"='?[(XS.=7(Z5^3NV).YB;'\0KL;O'W;XPBYCJS[NZJI.<G:-P J[H6,%
MGAT2.X0!NQO8&T:-9=D\O5J!%?UU^J.'25J Q@'""<KV%_BY7,-70>S\HT6E
M,R^K^^HXXGX5*:D>V/^QL^I?DVWW%/)O2?E'VMS&\87MFVGVTNPWQ1#;]>,@
M@( @UPP!#5 @:)%XKF\#(/APD@8$^G=#9GF2K[-FR4QR^[T6YB_+W%(H%URB
MH4BO#/:_Q@'@JV8KRQZSL0<]XSEV"68O;#'4V4[+V$&HU</3EZ&TL\G]C,O7
M)-LRDW%1?DD.+;,M];\E=?=?PZ:>R/>B",$  ,^*$ FP'7?+O)[E>;$K^(Z+
M:O/:Y?;@.!1F-T-14#NJO7NH?S$&I][=%>4[YM:!(@@^\J*\>?AD>=9V$9QZ
M';%=';-]U1YBV@.>[0H$448O:+&VQEF&$.MS[_2E%[T\JI;@?\OJARS_F*=-
MX;+?8KX*?#>VB1-#TX^([6 <8-B!LFW3UB3(DF"TRS/9I>PANR)/C6=6CR]*
M8YM65 ?2X92C[$T)NMM)K3)/T$ Z=9J]QT43YYMOZ?9K:OQ&(^T#_;O]<:%E
MBO?KI"N0\I&M^6,)^UAG)65>"<=:11\^LCM*_Y%N<%'5J\",G=@QG9C@P SH
M#"#L5ZT\.P[=*81?#-!\XI_T."5>WYFBI31*O[XFFE[^!U\,YDQ['/0'" 1'
M3: Z&,BU[P\<$"0=5A$4QG"MO"!S5Z<EQ77S4!:[^X<X^]I K/:!"X;(]F+?
MCHCC.)B8H0E CP_XPN]_3X9KDC"1,)C[2%&W:(T[]C L^QNJ-J_=BZ*I>C.^
M+167=29M1+V!I-F6=?.M,#IG#.;-\J<2;S:!B@*1LF;^L>*)0K]E2TJ*F9\J
MNIQ$P)!&/CLR8>PZEF]#-R9[C""(IXTP8MB6$F6.<]IIXXM@:TX38_0UXRQQ
MYL>9LW UB,:H(]?P_VM$'DG?%4>?,2W =>&,$,!7@F(0$L N<R.>96)@F;:%
M40\I##S.[3Z30)DPOAR&$_EECFD:Z'(,65S+2(8,@T(W3A;^7ZQ$-_B;*-'$
MCDIXFCE-BPG<0+2DEI.[G.CF(:N,K$X?C3)]HC_77'M:/Z0'HVFX[;8ZR :^
M/63K!R,I4R/]_I2NV?BK"^.1>?QRE!HL?C1?O4VH]75J5 ]I6AL;.FZ;K63[
MKZW; [9-_I"G&?V=TD@JXR'=;M[5Q;O'EM)G(Z?]K2Z3YE6]/:ZQ=RF-;,]7
M<H5)N\D";F":S-5BAF&H/? ?YR.QCUUBAWYHNR[T ABXX9"/0!0@[<%?#,Y,
M"8#,4M=T3:0M_.MKFTE3 )EJP'2MIST5T->*"M.!%\$_J9NQ=D4C=-V\UK+Y
MSUU5MU>F/R8;FCS0KI"LUV7*C ]#-&G_JV!!_5W]D.3OJ*&GHF2[2[/')RK'
MC_O=Y0_IYIX&]RLCH]_/G_]/QG&VVZC-.N1ZY ^;>4BZ.S[[&,/S^.+WRO0C
M%T#BNG;D199INI$Y&'0P1"(OZXXP(Z)HTF_J)B\+FX=JIGZQ\VUVQU:6E1*K
ML$R\E$*O5-66F]2EEV#Y'>&NIPIR(ZM03#'W1H\TLEE(6 ''PT% 2,B>\8T<
MS[,![F'X, C&Z-9HXTM0,Y7+:^-;0T[G)FV(T>K7S'&^G&V"):R O46H@%PJ
M:YMEBJ@Z]]Z05L4\\@HN2<OL*YV(?4T/#D_#?/,_VND67--_:G/7X875X320
MY3@>"8'MQ+'E![9+H-4]L.I;$"+>$] Z(>@;^'O41R^$L;ED!]S8(S]ZV'NF
M\W<C:+X@!U,TWC*481)/B^F'AG:].'C!!=OLEM0 0#<VS=@U$2(]I-BR/;'M
M4EJAZ"]>OZH?8OF9WL;0IMYZ6F$J^9[M/HLQ3*M5</$&_&$E7,+5\1HNRR^W
MB ^6/M[AXO$IS:NF%O\YW;*=,RSGK)I+CVZ3*MU\2IY;S'UD":W(P8'E8]/U
M;00#+P!FX$=.#$AHFX3W>5G-*#1JQUX-FDLP]M"-#GLST:NZ6\'>-?B-WH'Y
M$L!1?%]2D&D:<B$:,I&SIRHR)<?BCY!'CT_;XCE-OZ3EUVR=-D@00W*(%6Z;
MQJ-_^GC''OF[S]D,M[UPLW'@0/=BTXLB:-I^9+HF!AXAH,<+B"/X"NQ\.+6G
MD8<*LSY4(K8HFE?L./!ZN]O0?\UR]CSLAOWEIGDHMMAFFT:LJIK^OU:;J)[1
M7R@NO+6UM([ %VM^C!X@%H8.GS7OO3(ZMXXBSZ%G5\;>-_:+>^_Z&XL;_V9_
M0%9;@UV(8_-WDF6$N 7P</8U]'E;1CPP'L)BIEFU=\#<A6E8EG1<MPI\"/UU
MYQH'T/,GJ@4GK[S[IDG<R$(8V3@" ;:Q13I?("">X&FT9?J@/Z#NK[>KWHJM
M2545ZZR)H=^R^L%(D_4#^T7Z[3._G-\;3V5Q7R:/@J6>9;:&</1=$OAI(O/1
M]+!9_V.;X5Z9&!J'?I^&Z7/AO(O6M\\&(V!!47O"AN:*Z$OL>$N+]HODZ&PF
ML$BT0EG"KT6Q^99MMS#?7.<U!9I1H["JTOJU]1QH^I[OQ0'P?<O&;F1;87N7
M?T@L8IN\6JS6J#X-[7$V)?D]4J.%NH0%52$F+XB4GA99AKAH\JV8HD\+G.XY
MM1I]9T47FNWUR$[TQ/:=T$'$ICIB.@#$OA4$/03HNEC@)(]JT]H3[(.QG#2(
M!0YY*.?YLF;.3K"89+Y4R0&K,<BI0(HX ?\"!VKF; >YPS,O>CJ=./;M<=^!
M'GM>1)"5<V=#=)&[@',@VEPK)NB<<F6GXB[.\JQ.WV=?TQ<1,=ZQ$U+PX A6
MU)8S3B B; $71K$;VJ'GNQZ-C;B'R-[+7-5I*5I+F@28T*[KP0?N4;V_%>]N
MUYXU.T#<G73[^RXKFR47J5 W3W.*E7(6UY+R%9K6D7>-)R]G&E=&ZXUQZ([1
M^;.8@HN*YN"HHTS:ZLN8P<SC^IFJQPS\BR]Y#"%OL.@1@KT .=#V IM$#D!N
MW%M$IB>]FB]N:<KE _J1+8L'WY)RP_Z;G3Y>/[!Z5,46X_L,4'8=0()FT6J]
M7G[E%5MF,J.YWOV"*JZJM#S!RQ+'49Z<K?".98?[T.&:SNYVS3ZJC^RX/ZL)
ME^D#E<YFTR;;#O.^J*H/:?WQ[B;Y/A22/#NT"<:AZ0*?8.*$%G*[$SD8>"'W
M?9&:S&L\]+9';#20C2/,1@O:^(G!_C.[R;ZY%8)BG^_Q*3F.+YV#T]QJRQC@
MVKT\/14W":O<.4V_,:X),RL7P2@BT$5TMN[:'O;#R.F-A,3UA6;$8I_6/*<=
MT'01E;,F*,L39QZBCR+!U(.;'3U)QA$/E_(*.<*6H32RX$^SAS$<".L">[ZT
M>2KZJ<B;->;O6;5R/8ACVPUCTZ4B%%F6A?!@TW6PE$Q(6=)="6LP&7M0-+Q3
M6++B(4>FH)9HYU%,6H0IU*LPK['#(SBC6%V8_HSSY9P<*6"(5YU.3)'B,<GR
ME1/$4>!C'T0FB6S3M0@,>ULD\F(159*S,+$:&7]K<0G*D21[?#*DG[AQ\O,V
M9UKTYU5:+NC..!J7H3<C?2A4=BSI<@F=A_V>EVFR9?OKK_.O:7OKXZ_4.)NF
M_98^WJ;E*B( VX'M>F;LN*'M6#$:DK  8R0B/<J-:U:EPU()JX/L$1M[R ;#
MW)5+!&]H4MX6PC6KZ9M!OEC%6N!UV@U8UV5VNZN;@G)=&)^2LA'$%O]\Y2HN
M>OGJ5&I;:ADRJL^]\Y4I'3S*B6]O,J:\D+3*[O.F<E;^SQT%=_><Y?<XJ1[B
M;?&-W3:0]M!L$H?8B@'Q:/H)H@B%YI!WXA!9\H*L"=#$(GVH"\W%P7M7V).Z
M>V<,YHW!W#%:?\:HMZ[&E%'T!;3C.)5_T82G+;5DP9=CGSL(:&[<)08&W2Y?
M#!:3\"T10$AZE^7I!J4Y_4/-CKU4<+BYO0/AV0"9EN\@:(:.$_I.&/5/86#;
MC&S)4*'"](1!H8-K='B;PW9400;$TK*OI F$!7YJ]N6E_"WB%ZOB'!3SZ;7*
MMEJ<,BMU[KP&J^=00FUO2FIVV]Y/<&K<)9Z'3!!;T('(M4$8._U+ZMB!P)-4
MV3$F)U37 Y@J-'44T<):.A7'\AH:%V5*<PX#[TJJC>OG'T$^+[#*)YLJFF5Q
M<JG$J?,RJ8XSQ3OOWE/UOJ[3QVKEQLA"81Q&(<V!O2 ((!R**HA$IJ10JC$^
MH60V;R8U]XKL=]VU%W<9?V. C0:QX-*7^M805M/I&T)>5]_<^<C7%'/N=QPH
M';_14;QU%B>OBMV3V]HHRZ.FS<XK9'H!\5U,G!A3HQAX?B_\)/0#<_747*OU
MI4[*6JGN<B,0&>VG8+D'/FJ?C;MB3\%U9SENT_LLSUD5N/N+]N.+'.@]F>HV
M-',WRP\US,6]&[>!69!%WD%^R31*[^B$X'.ZWB95E=UE[9TX>T0DMNPH#MF)
M"@O:P(-1N$=D!D+;%W7BT)QM?3R?86TI>CKZ&7RC/,4OEG)I;2B^[&LI;226
MB'$<.^E:Z 7ZPP,ITXKU"*HO"/<4#;@,$9_$TV+ZX2$F[J?VV+(21]AIRS]U
M>POJ )$"L1#&D>,%GF<'L16Y_2(3B:)02.TG!:9[LOU8[-AV[+V^LPL?V$)R
MPC<-9T%"+!9,VZY\P6&Q32H6+4[=:%N2;S)_U15.Z^Z"[/G"A\K&N!!/9FGS
M9028>5PO%C#FU,TO!M,8 !*$+@&6Z[N>YWH1"0?3,8A4322X#6H.&4P6UIU4
MM*4 M?%!#>GC)P5:^%:>_2\QQQ^9S L3OPQ15>N20'HNR9>N2BJV@1]CBRJQ
MY8=1:+E>/* (D8^Z2FJ4;_344=^R+UY'[:&.J:*F^>9_S_HI;W,L8Q!K\VYD
M_52,Q=D>MFH/HYNQ8\(86IYI6;;GQ1%J+QZ&KFTZ<C<J3HM0<P8UP8M&HH?3
MY^D(?$G:\ON 6%8W:_/_&*]8O74#R*P]8AF1:F8.=+]<)=$BO%&O#:_#E07O
M.R3-5061'SBV23P7(9I)!XYE8[NSZ  ?"\6N,78T1Z!N$KF_\:<')W6UR2A"
M^6+ 5%R**;DTC5I4^ )'%[14!;/+4$0EGA3J^YT2=>JN.C #8./0(H'I63&.
M DQ,T-M$?A0HT"=.2_,IE-1])R-I':52&AA5IE.S7(1RD2=QK1+D=]%J)>H+
MGUY),<2_4%^E]&<?8+XAZ==T6SPU-T&UEW)W^^H#A#"!,+*!Z<>1 R/L>[UE
MV\6!V-78*BR*C#:I*[)[D,W+7IL]3-'5<@7D\BZ"3\NJZ-KV 9T'^/9O%,QR
MF(>#M(MKT.HH7X:L*?7HQ8JQ:K:X"Z7I=LM>N4GSM$S8^VMP\YCE&;N5M\Z^
MIAV$X4H4RW."*&1/KD7LA"6T+=1C<&(B^@Z 4MO:9:^#>V7<MX";\9H<01:L
M3:KEGK/F.!OI@K7$GNU?#]@^QMH+9#630@I1>:GHIZ5)EJ&:FGP[+=)I9% @
M6:S+W;K>E>P^D(>DW%\$$I$ F)$)3 )H=NK[V#%);]"C_R:V1U/:C.:)[1$R
M]E!**7R?TA@.N5/!*>@3S@ /F.M0S9?VG2'H<K8WEM5ER)4*1U[F=FJXX16B
M]@J SH3IV#!T79>8ODN@B7SB.D/6&"%?+&,3^K3VA.RFJ&E>4!VL*ZX/5F*,
MM%7]*R-O=Y+5%W:2*2"23W^T,2BF.+->$W'(P051D:)J&3(B![U0T%4$;QI7
MLJ3Y?CCQ',<1E3('!A$)8R\(08C#'J7K6T)%_*FQ:<Z.U.^'>"][3<3DK<XG
MC4MN<,&YZYFF-6!9LN<#F^K>[?-1%_B4/+<7^K#7!J^.?XTY-N-=%(H;YH+D
MS]4%EA$U9O/^]"[Z65N!NW+Y!BR8;_#1,9SK/,[R)%]GR7981JJ&!\@LR[61
M[0<Q V:'-@3] V2N@XEP:7-:</IKG^<4K5^CR'+V7GKS9#;-PO.JV&:;YEQ>
M-7C#@EE[=D:P3#IQ0W/649?;PFJ"U5$>PHJOQ^ZPAAX<VB_ 5[.]$*FV02Z5
M:^=I^67$J+F</RWXSMD&W.>+6CCIYG6TG72N/&Q&!$<6P Z,0&S'")F=<1 0
M9*[R])Y]A2_R*#+*I3=AJS>'^*1DY[6RC>#-=XJHYM/^*3F6N^6N!WAVEMD'
M[HD/:W$1=T%[%3._#$U5[=3IB2P=G*G5P.$TF.]'. Z#")HV#F 0>_ZPCPO8
MG@=7-:OYJE1";M-"]:$!);\>[FZ;W]*A>_STJM0_+<SJTL'YSIN+D3E:&X5;
MY4?22''GI+12DL-IJ_(X><KJ]HFK]BZDE1T%)D38=\P0Q;X?QF[8[R # /IV
MGVC>3%VD%X<JD9[>B-?L#W"=7V9<,P_F*,!+-/"4A7A-C2KW3*KBQ9<KX[!K
MM.[]B#7Y%VVDO38OWRN6$8=F9T%+K7YLJ[P5V6ZS[/9,S:8+J===_?@Z;P#!
M?--OVEMY882]T((!<F$<$,^!P!TF)@!QW7"H%8#FE>.W*B5'M?=F#M'&I*9H
MV_T,9X#2VTZ7H\]BFDBB?&Z@\RLC/6KZAV[EG@(?MBXOH5TVQ7K'ZJ'-]Y;?
M/D=P!=N)<Q2]'#\_\X9W1A,+VK[I="%[#'&OQ.-)VF'>8#N-B\6$_5K#!)#.
M/[OWT-C]DJ]5]!QL$6!;D>6:D0/MV#3]H:)GVK$KMK P$2CM"P_=D>$Z^6ZD
M=W?I6O#8XE1MHW"J-E&CZ)Z943>,_AG)]D7@V=<SU- _=M*EKGU_H#F60J=E
MIE2J.>?>]91LTXIDU;JYW?QS6N_*G$4D-L7[QJYFK'XMBLU^93NR0A_&D1\C
M!SD@B)#O=4<,3!Q3(+R[712;U9B/,Z3& /7*Z,"VYP<'N%=& WB^W2IBA%[:
MCJ*I:9:A!=J\.]U0HI5%KOH(S)/M<Y55'^_:&@S]__D&/[ -P]?YI[+8[-;U
MY_1KFN]2=EZ\_)JVEXG=I-]K1#G[8Q7ZH4F(1Z7&#@CP HR< 51(_X%O#^-$
M8+3O6>Q=Z&^G73?H*S:_*SO( K/O"5J'HSZRK&817(SMV^/C75<R;_[$=A8V
M#K "2>>"T?E@]$YTMS\:S ^C<83SS,-4;2=00UE6&\I54P['5M*V)?L3;<MV
ME+%!]M2U9=FU93_HQI921O-WKJ@R7<,LH+PRH;/%+)U?9&5B]_B8E,\?[UX'
M<%C_V>]L[ZY"__*0IO4I1N1&T*+I08Q!%'B6[0=FU&,,+ \(!.+)L6F/R^VQ
MW5X-3D\.;-CD:7-\AN"V=<>H&G]$2N:3-RS/&L>26U1PLM6ZPN+XV<A]O/YQ
MT*J=2T;KT[@(/WU#BRR:++G!)5=3NH9GJ74SG,\%^_,'@XX']>CU%<4<GUUX
MF:LM%Y RS.=[L831)/L"Q5^3,F,6K_,ZI<.BCO(ZJ[,NKUF%'C+MD%@!L'SB
M^,@.HCA$5A#8) RAV/N-JFSJWM!P\$Q #]3HD1H]U+'O/8RDG;,N.@/C@B%:
M#=F:7U>XR-ZEXJ=B_A=2]%3MU=DW#52RQJN,YVRBY^,C>Q_OFG]Y;JXDIR(=
MFC! !/FV%1, +8 Z*! 0#XG(I!8 FC7STM"5>-A 3QOP:>;L](L)J#SS6C13
MAKT+ JJU,9:AIGI=+";LW&(Z>VKP56C/W07JR'2)&T4(8@M;Q,9FB+P>0@Q1
M+**O2@W/HZO/5Z?7'<@]SJ"V#?CT=3;ZE>BJ!/-:=%:$Q0OZJJ4QEJ&K>EPK
M)NC, DL#'])=F3T^[O+^&O;(]%R(:"+LH" ((,0(]#DQ)*$?"Y3VA;^MO32_
M1R10>Q6GB*-(KI4;,:':0WG[ODP5[ A4EK6R)%<9WD,:6](]=>Y<25::A 64
M5.6Q%RJZ@8*)^_/[X9XW$_I^#!R+>+Y) A@'-K1ZJSZ(A$J98VW-E#:.N)5S
M-+LC9M^:B%63$,YX\^4;9(G.JR5H7D:JI\P;GMFR-$M<"=WK3^VP@SW7^9?=
MTU-1UA_O<+&EOU"4[>G9^S)M[@M;$119$;(I#.0%OF<AB/P>CN=AKG<<M(/0
MK'SG'O]JSLRQ1=ZJQ<_6&]:''AA)[X) ]J2UM3C2T*4TE)B2#FT$3UX4:RX2
MOLZ-#CK;MW$$WH!+:R.!9'@I;267-XN,JV8W\^MC:VS2/8+$<_GY%.VR@%1^
M$C>+B?N[0&"]SK_2",Z^?IVCK*C3]4->;(O[9W8X*LG9HN)#4L,R)2D-.X\T
MQF]N"I3^GA_N"CI7/E]9D1UA&WL1\*(86Y%EV_M,  +.ZYD7 %1[#6?O'E.-
MVT,'FX/OC8=40I+:8"?B-X.31ET8MZFQ._+3^-IGY5F?E:>=JP(A8N:^P1'H
M?YQ.(98*_)_>\*(W"*04/TZOD$LZ)NL=8],2K0UQ+G%91NLO(+59"!'%XD:F
M[)90=I;T6[;=MMNL7.C&, I"&P4QLHD76HA U_,<2+#I6D1N"ZB8C0FW?/;
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M\K2JX/KONZQJ%D6:O _:,(B\R#*QXX:F@P(?A+TU.KV,1/(P61NZ"V$=+.,
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M"_>>TY$2+=$X/XX8RS@G(;O2'*H4V ]%ODG9#9'9[3;M=C^3]*E,UUWA)]_
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MZ=Z!8+UN/./LN;+1E)L95(W&+E06VXK*.]3_\?D3_?]Z=??#-,L@3 "(40B
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MXO7$2.N9,I-S5"MU)T:U2),3;:7Y.+S!#G,<A"QA"+,4$A!%64QZ@['\L,3
MPK0=1N#R&F"7[C4#0RH]1YW6F?8>#4?>ZT&ZW*C/R^35AG^C$C-#WPJTV_%&
MU]Q,5?/1QB=.R)EOW_"_U;R>$--);7=' 65^!-*01!'Q&8,A(RA.DA!&41XS
MI5Q_ 7B.ZX3368,7/GFG3K7/<%7;7U;G?L0[]4ROU+A$[%4GA&89=OUYHNDB
M[GC^R%9<I*:5)F\$\\@OER3@["34A6(A]1)ZOUVENR'YIGPL^(\6U=WOY::H
M]]6V0/^4XKG).*5Q'B/J0PI\FK \["UC'TGMD+=I;ZI-//W%T3U.(4@#4N]/
M@54R@UAE>SPE7(IH-8V?.\<*#Y]?@&N]5\_M<"[WYKD<*6\D,Q>4SN"U<]L>
M5>X:H-7\02IQ!<,"14&>!<A'C,89!Y%%>=#9CB$-I*XWL&MQ)CFD16M7X60Y
MMY)''-#M)I-<DFFKV<0!XWKYI*>TV5LQK^32(M-/+XH<_Q )1M4GM12CQ9A4
MDF'_*5K [\7C;;%;$,P_'Z(<H$A\-!0#(12G&,. 9C"6>B]9_5,=)POVG\V=
M9PK2I,:)A- [HT--S#LFO#];)"IJK4:)@B([HT9/==]K+'(2>NK4.9G4<GP&
M4JB'NS(-N=HZP@W_Z<]W)Q,^38V>,1 %$8*$1#D"+",TIKU\9G$<J"P%Z%EP
M+'4"E*@(3J=I^XG<Y=FI6X59 $-^Y:;;W5.K)ILN6'4R'_XF<2-3VF9$SV-6
MVM"'RF;34].H[V>KEV]/4'=*B9,LR+*4Y5F>Q7F>A;%XO[!%$?D4JZB7;=N.
M=>W-E:GS74]I,.HL'')B=\E(J,F@Y2 X44!%-D>TT55<YJ&:SKRKIFG="@-<
MO"OY$'KS^S.7G>M_'<K;V\Y6  (,2$@22B' ,4O#/.YM(9_*K[MI6W"LFAVN
M7QI@7HM,8<BG3YS$B'@2SM3T[2VZ=(;*^KPI#)LGX4]O"*W'H]S ^IS;YP;9
MQC3-8,!M[D-EL^$H2.\'\:S9<ML90+F/_# '/B-!1#+"$ICU!F(<2]6O&A_K
M6&3+%HR"/BBR(B&F[@A14]"."QW15"1%02G=D:,GC](DR2GB"_?.R: >!S/0
M/DW@E7'\%50.W=[^1UETGY\$>9JQ-$H)0RE!.841'CX_!U)3C.J?ZGKXW6!1
MZ,UJE$@HG#,V%(? #0P=?5-C1$'>G#&CIV[O-!4Y33OUZ9RD:?D] T73PUV9
M1ERE:JNV9?WE8;E[7*Z*P[Y<+3?]\#P&"/D,$X+S',(H\6'<;W+BH_58ZAEN
M4QN.M:Y!YKV"IE71&- H4_--PZ":/LZ"/)7:<!H2]:14DTS)LO&LYV=K2'.N
M9B"_-KRH[+8@!6F^_O+ATU?T?U!G(01YQ)(\R7".Q!T:D.9],9N$/O:EY5CQ
M<QU+<(]&02]4B9$06(><J(EJ#T1'1U5Y4=!.A_SHZ:4\3W(2^=+!<[*H2<,,
MI% 7>67>".0DK[E(:/>\^.-Z07R?$ )C&/I)0C*84Y3T'\Q\+/72J\+'.1:X
M/WZ]_E6N$ZM0,*YICKQ7D[(_/GVXH<2[OD$W]%IG9;@N5K_>5]_^K?.F71CN
M_O%Z3?CH\1M]5X..RW99'<"5=NC5=K+\5E3WN^730[DB9;W?E;<'(=RLVA7E
M?3_Q%H=!$I,L83#.\CPGD/K]^<HD8J'4T-&F/<==_&M1[\6>L;^KW6:M^)*]
M#3;'Q>!21*JIQ1&==PKORNL *B=Z2^_6OT_:R+X2FY3/8R^)58]>OU)OG2U9
M3;-PL/SC<%D*B! OB?P8BUM2&*8P#:,>8HY3I:<;)@7F6"4MWC_Q4>+2H1D$
M6DZ79QMC-0&?.+Q.U-YF*$;2PD4B/H_\<1G7JQGT.+6,)"[;YC_[P!&1XENQ
MJ9X$@NY-#/I/=[,Z6OWK4.[$.QI?=M6J$/=WU?M%PO*4^5$4(!I#[%.:D'X'
M>T()E3HA/@4.]U5Y [V1G_41_+228D#@B(),$99Y",8DGE;3-WJ5/2?K=2E$
M9[D9C@AWAX<7"/L0^B"*4L8BD@8LCX8YN"24.^1F:L/U?I0!F?<XG'U_:K%)
M/C=@S*+$"L)$!*K59"?<'>\-Z&!-1)W*[I9I*-3<ZS+2#,_/[TIN@3GK^-D-
M,>94S6!1PH87E=T&I'+6I*SN>4)X6.Z*ZFY5/7'?*F&=_^6NW-?5;E/5=5$O
MN/X#"A'R:4 @9,0/8%\@IC &4O,!5@TZ%NP6IM?@%+.BJ^J7 :K78>4-RVO1
MJIRUL$6XA)Q?@FLU;9\_S2HG7"Y M^:!%SNT2YZ D:/E7):PS>H,4H9UERJ'
MK5 AF7PL5V)PP8IBX0<L]?V<$1RC),0LB&F_;)>2'!/I?*'PF8Y30H?$XU 4
MA$B%$PE)=T2'FFJ[9T)!=1TQHB>L,LS(J>;1K7/"J.'X#+1/!W5E%FX%!?M2
M\+CRH-\7G^^^5L_+S;XL:E3S+Y],M_(6&>&(BI,X>8Q2$H@I4@R'70DQD3^)
M;<N@ZVG(!MKS,&7A/14[;_]0>*M3E IB8(UH"<V\!,=J@GI$Z'V^\P:,'JH]
M_BTOOS3)"G)\";+UM/J$=%X"[P;2EVWK?M&R32=')%DY)_6V29U!'K#N4N6P
M$>H^"8,/=;DMZKJ99:^;:9T:/Y_\:WBJ9L__5I?K[EWA[MFG#)&(^H R_K\(
M(!K&L'E\$L8DS=6N3YH*D^,\=/H42.^(=^J)=_M\^N^KXTM/>^^%.Z8OOC@.
M[7A:FW-4U3+?A %U_*"+401&5DFGCO$\5DPG]_KL>RU3LBZ;8=BRW(G'C O\
M_'NQ%$\6B_*'[8I_'<0;ILT5@#"!H7A_/D\PXJ.A+ I)WEFFA*<YE>QAPY[C
MS'""RQN :=T4:H5<.?V>FE<U;=:BU(G*2O THJ V69Z'.EKUJ'+7)C55[2V[
MW7WR "0H!UD$4TJ3-,@@IJRWG#"L5!/;L.=8U01$K\%XY9WICEI7AUJA6E'C
M)F)93>,L$.Q6\<ZS)J-X%CB?F>+9\.B<XEECRT3QZJ_%ZK#;\8JROV$49&D>
M)!'V4Y)"AD.<@MYT'F;)XENQNZU,1$_9I$I_/$5GVBWK*V^ :BYXZDSK*YY3
MBJU(WBFW%SJG)D.<HNII\SY?V=-W24+W#/F2%;XW!M5GAM$?AS,*(2-ADD,*
M<1#[@$",D@$)B^2>^G%IW_6.M#=FQ\9FPS[J'B]S$ALYY;QT6-2$U$5$G.BJ
M!JTC,NLR2/-07:<>5M,U>3U-SJO'VW*['$6RO"TWY?YY@1EF/O0)2$!*:$:Q
MG\3#1  "\>*IV)75^GJ_W.W5E-DF"A4)> U8K:SZUI95M\5]N=V*0JJZ\]I/
MU--@J[%0T^!+!4!3@T_@GM?@*V_ ?!D%5B!50H%=A&A>"NS$PS,*[(Y-D^F
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MDM6M+X?;3;GZ8]_M@13SWEO.[C/ZIZP780R2/ U ''!;&?%)#C*(8QQ' <E
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MKMJ[V)40AIR/".]4T9R'3$_F;769/C/-:M K<$G*X@BP)"8!@"Q+@,^"#EQ
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MQ@RSD$01)" -\A03F"/:6\P#B-1TRL22<Y7ZO=KM[Y?W1=/%V@.,RV:P=ML
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MC'**4@!8X&.?H@3":%#?/,:^E7E;,P@_[N2M(?5&,[C3<6YI&O=D-_7S+ I
M'6+5)W3MQ&D>ZNK61;FI79M\RBHO/M3EMJAK/KR^+;?-Z%K *;?WQ7;/_U:7
MZ^8]^&H[@%N$O@\" $&<)1GBHI_Z2;\1.Z>YCU56_5W8=[P5X(A/:.X1H%?=
M;LK[YJ\3[[/1('&DM[L,R3PZNU,/J^D:N,UQY0)&! 1\!.NG,?%1SFA,^NMO
M\YR*ZVC%1)"-T>2[II0Z\(#*Y8R6*7<V!HU6:5.L?'C+W:[*Y:8_5GPW?.']
M<>2<!H_:@T9I\N>A<+:<41HD*G(DJUOB1K /6S[^;%:=VK<^8X#"-,(QXB/1
M,&-91F"[<PBAF$5(Z5H(G<]W7&)<KQZ*]6'3+(9]K+;WO_#/>&SOP#LBU7Q,
M68M..?URS:2::%DBT8E*O<'4B#29\#H//3+RH++7RA0VOWRJ]D7]9?G</&)?
M,6YL7:Z6W=4Y,<4A#0!+^(?[#(,D[*[YXO8BZ4NWS.TXGV!JT'D=/&]?>3U
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M8H.#J0[;?7V\RZ$[Z17YB(0T(.*X!HU\&.8(8C_+(L+"( Y5EM'M6G:\J#Z
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M4 CIMBU8JZ[OK_=U5:>[#9&'A'S4WPC$;]E-4>5U<^AV])(C)IF^:2,<00O
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MR/J )BAMUU_+!"X*'.@0;\;TE5L[",-^)&@CIF:G4W[^_&K+U;UO$G4"BJN
MM<F:.Q]A$W17 7$_K_*>;54H@SH-U9?7@DOZ*\0&DP)_*;9%_;@O=U^^Y_6?
M64D^FTW7^@'$5A([KAUZ*+*!2TL]S'XTSP_9,]X)8RA6X@'9E3'"QB$J4^AC
M4.*9F.,\$CI)FDA3KRGL<<CR3"R*2;,HFVPB?-[T<T(L@2P-Q%B&%87<3XAO
M0_;LKD?T/#3@=ES70H$7VG$4>*;ED6 P).2F&_H\>[$RQEMR&_:*J4>].JK9
MMF'G9EGB#BP;P4JV81E8N[ #*Y-S/39?I5I4J/M")2D>';=+@ %R@1=& 006
MP!'$ENG 06LMWY6B>!SCZ:!X7"MAJ61/U#Q%/"O0O+<HGE?U#KR)J)X ZYJK
MGHA%K*HGS!9S@=$AD?0P-*/8]>S0M[S ]FV,AM6]9T*'1]PX?JQB#?O(O* 6
MH81-@A2QP:<T'T66=9)J>2ZM^B:0I(<PB  _+KT1M7UR<O-QZ/0' C?Q@!V;
MMN,[,8P<!, P,+83*;D-^W#+UM1\%.UA*H/HB7F-&HXEIC4+MB5]FS21G(:?
M<3V42Z9!K!F-*%>L2@?7Z_W7_9;>84^RIS);M]7:Y-?;K.M\"K\699W_V?SY
M69PK%"$_A%$$+8(OL.ES/&B ARRN2L/90"E6S9$=QF9D")]&SN<B-B75TCM\
M>CMVS-B&*V.PHM'@L1U7QI%*7[V4Z7F56983+NCW['[60^7G-[M8>'Y)RHWA
M9M,^I+,RW= -41C[ $&4N+8;8JL?V E@("4W9A]NAB6S\43^Y6-:<=YTE,'E
MQ/17#8U2=_4&B)HDOP,>D>27GV\]9%&F0:S)KRA7K%(6%\T=]C4=HVE(_$ ^
MTNJWLJA(N@TC&%BQY5E!8D8>CI,H&$Y-<&3Q:-B4<12+UQA:U[6[ <>G8Y.(
M9!.PN3CD4ZYC^GI<5T:#;%[!ND#1!:620:P>$B7%DD+^9\<G2M?U8U;&Q=>O
M>=UE<=CQ(PO'P#=#2/Z7^/V-&4"4CZMLA/=GJQ>?YOG7?;HUU@.JOKRU>6OO
M,+NZY_ONNUI+/H'B)I5-E%3RR2=$#1+C &5>Y3GBX8+:B#*FA\((HR_D?#<<
ME<(O7U^XOJ=)5?T,Z[K,[_9U\QA#\:G8-5.PV)*?\O"A>7BYJBMX5S73<F4F
MV+<]@$/7=(!CF4%HX< /$(!)%(5)R-%,?0XX/+-+QKLX1)&RQ@PC'=E!WZS>
M%;OWZX,I]"WKUA:.:MM9''A9YK3T')\N'KGL^MYH\1MC VB3&&*",;+!&(PP
M_MF;P5,K/8OW.(JJ=?.B6/7U] DXM5.,!!Y/1,?97:1!S?>LYA8+306^U/_W
M?%>4!$L_W@K&$)O #FV$/1 Y9N!'23],F%A^UPCF2YV6-=L*@'L(GDE]C(9Y
M7G^*/UP9=]E#OMO1V4KF=?NCYLUBC[FYD,8*TZA''BL.OY#T.?%-C$]9W3XM
M1I] ?C53UZ]GZBJ)?1N1E!K%5AA$$$$ N@F*3!\ B^^-+_GC*\]5">3N&7KC
MW;9YU_PX1C:3;I<U[\W6Z8]YYQHWHQ<FHSKOZ#%;%=I7S/6=<\[WDX,1:&66
M5ADF#$7[*M]E5446T7?YKDV 8Q\[C@L#B-W0<W 2Q!#U6 (GXJK(58- \7X:
M/KP03N8TG=II565U^U(=R7?NZ,X9?:<N79.<AS99HO^"_)W\84=^TVH"W\::
M(D^Q;;\M[R2^Q>A+O,,2\\KH(1MT\AL]:&.$>F9U%B'VDD(K=90F*JW6QF.E
MGH%1X65+C"S'M0 ((@<C#"'M/M$/XUB>Q]N_DGL _D4+=ZO*)GO*B'S^A(L5
M5OKTF%CB\-]:K/#QP/PXY^$M_#:9:EX'_?I49H_9KAI>21[V$H+$L8,PLGTO
MQ,"QW,@.0. G?HPMRXQ,UHM[LH=5%P9?=+IX ;%_J9QARU7-"Y)\'%Z8<ZJ\
MH<>45&;=\;.22EGD/9$_'I8NDLB*Z?K^-OUQ0PLRB]W+-=--6M(JIAX=1A'T
MO,"QH@!A&[J^Y> >781=EV]/8BY4RG<JVJ/K]0L=:'<N_BIVR*_<3WS% 3HY
M2+"HX+5"M[WRKHQ/[?X1,>7*Z(QY>;1&%I6M/8N)NB0_,!0US.5I/8+ [%:?
M*:*8EW4900-^2_,MQ8*+\DNZS;YDZWW9[,S S;_V55,3TENP,EW7#MW BET2
MW"S7 3"P>WC ]R-Y44,J+.5AXX\=6>IN\S^SC?&0YKNJW>;.JE]HI]9J@&ZD
MO55-65E%[&+:]5[8J=-#S&+>E!YC!DO>$P^^IQXT#L88!VO&T4B?$,/C!\$8
MH\35^@<9-69S1!F%O,L(,X=>?=5_[XE4WC_GNP=8_3W;/&1#A%QARXX<$]N^
MX_C0])+$(\&PPY6$OB\OOLC!LVQ@6:?5HW&_+;XW/<*S2DTLD>2YZ4%D?I=)
MCQXC$XR##;3+^]\[#^H8-9B(%PP7<IVJ?YR0;"]'@%#!M(S(<$/_H+E)W/RM
MFX(LA;(Z+YN]MBC;9?=Y36_CG8IC?NR$,5DIT?;B01*&ONL->VP!#L/5+GN@
M=Y>GQPN5*)DD*6PE:6R0G"CRU%IFW+5&&,7=MFO.IR:>*/7W]"BSN*.EQ9YW
MK5&_&-2L*Z,SK"FS:/_Z2]N,SKCFWG-UI?U:9H*C!&/5')^&_A%L%A8XXMI\
M7I$1[<CJ+,L?=O&^++/=^OFV),#2=?>41O.[;=LVYS58+W%BUW1BY$+?1+Y-
M K73@_7" ,A;'"D$J7S%U(,VZ@-.(QV RHMC*CTY/8QIXD+I*ZC.+F-P\\BR
M)K2-;-,^A(D[23""S?!5Z!_ YB"!(W[-YA.9)08K-[+".,8( 3O&?I28(+&&
MH5T[6M5%G6[E50^\.2!7.?. C5F:;NE_8A1GRP.ZBPW+76)@(7'BL3&S#_37
M 'Z3! Y\.?EB?RGHU:B'A#:(@8FAYP:!$X2V"Z+P4'1DPH1G6DX91_%LC$_-
MP.,[15%>/&0[FD"<OV@KGV"VU&TN;OGR+^;JFM-5-7._,'26P@LZ)X-X/>1-
MBB6O7AB2Q8X$,6.Z\Q6@&(=D_>XDR Z(R'I1$/6H[,1U^': 5:-1OM-[4AC/
MW+G<O;P!-#Q+(+[MJ]R9D\5U/B_.*\!G;G-IH\@3;]7.Y5'ME5VNM>SJKX!E
M"1&"_&Z[WQ ()TLKSZ"T,80(6<!S+ LZ 'L1&A;-T 9(4HJL!-L":;6T"*#&
M69,CPN)^4A0A!KO.EL+K'C-$/",60Y1^ ]K'%+76L\>8&;P@<&TR3JM'O"V^
MC]Y;"LPH3J!/5C\H\&/30IX'O3".W!B$-F M0I@TACJ!>7DADE88-LATN ;Y
MBJ8+LUT*NWI,73FFG+_-.)4?CH>3Z% W9?$MWV2;Z/F/*MM\V%T_965:TUJT
M=9U_:RN6>R NLDQ$LDH0.Z&7V#[ P.J!N# )N%].D@U _7%V7^-;M>]Q%#U8
M(QW0<EY-5.$'-LE;V %\0DB3J8;]'JYQ]VR\HXA)9OR+,8 V#J@7$TE^8B](
MIT(OZ2&H*@U\_8B56BXY.N7<YS5=)ZR0#:TDL@!. A?$<> D">@'  #9?*+*
M\8.5B^7AG;G9N[-T'%R85@)$Z3%=1("_[JHB9CMSZ\"A.**Z+?I'5;,73\C=
M%KPS$9IV% 4XMDR R3^1F;AN#S4*',PW41:!J'S*C:RB>PIE;U=SAM"=/]"S
M!O*[M?Q49AFWLR4[VON;+QTZ<O1@4+/I]&(?BO[KGR5Q4N&D"S%@T6]"CVBR
M+ 7'[0V7]P=KA&-IO[B"49)XCIU %SN8)(X@0;@?VB8H^"*6E"&51Z QRO8-
MT1$\OG BAV.V\# [N7QRS]J)=EZY9B'M@OQ*Y5P/.95K4J'P&^7<@7],RRQ*
MB=C2$X-L5[6#X3CPR;(A]&(36(F-;6 -.Y/ QIQ/J0L.HES2&ESO[RBPIMBX
M1\:G9J(4,AY?J.>.\^!B1%K,0IJ:XXJ3M%PZJ)C&HQXJ--6(X\,)&9RP)U;W
M65G2I(ZF?+?I#_2##IEU5P=71-5,SXX=/PF093D1 *$][,>%+J?D3!UMAG2J
M!3@LWM,?&6<'ULF,LF90\U')FSQU'';K8H+-Z, 9[SIXO\R=.5TDZV+2)(=F
M/91*FC6O4B69+'%=U:*5$62)VH[<#;MRB#Z&H9W0AE Q\G 0><&0E84X$'@9
M0V@<Y17/#32!6[UBK+$IDV*Z)MRM[4 -&W8=KIG%Z"P_%V1H.J=Z") $.TY=
M19/ #*OH?.@:.R19^\_1;EB</N5UNAVVPD  3<</? _Z$30!=!)S..SQ,3#Y
M<B>) ZNOVW@DO\LJVH=]=,YQL@-.<]^"\^!#I@_8-&TA\OE$K@=IO.MA_D(]
M<#ARZ* N=M[ SN(%*53@"CVT485AA?+/>*IZPO6ZV._JZG.VSO)OM-IUA; 3
M1:&)R4+7M\(()O1>13<T-@.7+WN3,J3R1*['1,^0.U!3-5&$65$U5$6I3!T<
M*/[\-L4SR=]KVKB$;P+KNDK>%)/>%+O)?(G+W(?=MVQ'J"89S\H,8R^P3,=#
M";)CVX61!8<C4DARDDY!;MF;)$X;4$#=;OE[(O:(GJ<*&Q>7HHHFG3^94C8"
MM[2$C:!P:9<(O[J*EI M;ZJ5.$.3LK%R3W*7P_IL%4,/!!')!$T3!2%!$!Y.
M.#$V(YY>KE(&Y)EM JU;.T1&UFXCM O6[NFCYI6J>KQ\E9"D<1,^(4E3R;6L
M)*UA_R,#Q?,E:4>T\29IHJSKJG=33&))TJ;Q-5G]AE.,K+I)GYLTD0SM 83B
MR'?"V'=1;#E)C\"S'5>*" J,JU@+/PRGH&=V[R3)GPCC$U50,=F2TKS^ )6$
MH0ZE)FKXFCX149S@!,VU<8IEK!(YF;T)9QXT'SK>._R4U2N '#,*?<=S/-M.
M[#A('&?8-K01GKIW)SSP/$>QQIKSY&/RP8>P(X0//I1Z0.K!1^.1T8V+@QL^
MCMWPZ8(;YCH'.4,JWSG(5,_HJJG3#7O['$0.=_)? UBY40)PA"' -O"1:<<P
M& !8$?)X7FR2."Q7YLG_&-.GEU?FGD:7J4[=G%/U!L#;[+/)Z$+$\\FHP)U_
M72_Z7]!-!:[00S=5&"9\H9^3NXFZ2;=*JS,7TBSDQ'84QIX7N!!801@'?1F0
M9R/(V>M= 0#UU3A'5X_S'JST5U0F^6&2DL[E *F*.H#6X3(P/['\(BO#2UJ+
MK10#V417'I<<KZBLLVQ38<(&;;(+=YO?TYKVV7V^OC_?@7=E0\?T?2].8M/T
M PO:/NRO!'M6''/V35>%0KD,]\!;$:;-L]NUZ-<6/9W[Q3WY7?GOK'VE\M Z
M??8'7408OB 'JGVFAR8HM_+UNS(SL,JL#NES]Y0 7/_?/B^S"PCB('(02!PO
M<<, (X##<-"GR X3OEU"F2,KWR:\(7_^F%8BDUT][6PIV.Q\"^5>/4KZ($N'
MTQB OK\ORO=4@HTO2XDL.XF7A%6!*S014Q66'0NH,O:$1;/MXED6FSW-ZK)V
MRWKEQ:X5ARX"7A2%?FBYMMT?ZWAA!&V>XV=)0RH^>8Z+'<UM:;4-^6 JDOB6
M[1LG9;:EHDMG-=Y_39\>T_*K 7\C2UEB3)7S/Q0@RP6"VJF>_>FRV35,'D!V
M)RD+"^9)YGBT<AKUFLKD1*/>4D@9G F+(QGW*2OK9]K0N";9+B)_^D3_RLJ.
M+-J7*4X2RXY@8I+?]?61!)L73TPHQ0>>-Y]\ZG!>&4\4:;.\S'JL$V5Q OF"
MTJB8=6GR>#.PWB"]:FA';](^CTJ>)9%'*:=[0E.UE&#86XHIBSMAU?RPJ\D7
MG).LME-KVNG=CLPH#)'M(IRXV#OL#F+D"MP_F3ZH@% *W$&!ARRQ$<Q\@-D5
MZ4P427ZN!;51#;_2)/$ 3X]<\9@N'O$3IEI3S1.WYRVIF\@4K\*11?IX"[1)
M34^<BJS"V+$MY,=Q&",+HPAADI-V*!P_%MQME#7Z/(6)8KHFC6$^E9N5VFF:
M=U^4QKL7)SN_=,OE4X>[RZ@@(YT,FBC;,7HII'3KSNBE&A;EE]"L,$YBRXLP
M@,"R 9%Q&P[R#7'"U2Q2XK#SEA[NVVJ-DU4SJHIFWF:>35 7(IU/2P6*9'2M
MC)%2$</L"CW44X5APA4PG-Q-U$R<[]+=^G0)CNEX,01Q$H P!&:2A-@'0^H;
MQT!*V>$4 +.7'=[W8*67'4[RPR0EG<L!4A5U *UQV>$%8OE%5H:7M!9;*0:R
MB:X\+@66^Y^SI^ZXX_H^+KY^+79?ZF+][Q4P(71"#SI)XK@63&POQL-.JF-.
MV=&<,.H\6YHO#H!J>IUI7SX;%46XV'+S#&-L*\RI=.LQ4V4:='X=*8<KWIGX
MN:W!N"UNTQ__F]>/C\66=JZF13.GWZYWD>G:/FWKZ'FF9T,<AGU71R^ /A#;
M@9,.0_UA;;]M-*IBR:MJ3Q0UH].WF;7-GE)UI@F&D98EO6'<_!B!&\3J7,BW
MQ;>,[Z;M]7T^.(V^:3^"W;A,CQ8<H@0S:+,RG^FEV.K,/*/CBGGE57?:$[VY
M_ISD)*_+[_;-F'82V&;@AK8/3 ^8L0-B>\CM2)XG4H(H-I+BRL-A^X]\-@,H
M.N>CO/C65"%^$Y-<05[Y=%4]I8+B2:);__ST&-HRXGB2)08%G,:N7C(WT98S
M6B:#(9'[:*.<N#E/.;%,73DF<H(H<) 9)3&]FQP,5Y(],T 6EX1)'ENQJ(F<
M <MFEU'(%B264]I>W.=[-SX2[L^ 3^VT+7>7CX'.2QJHR#&:J*(JZR[<V9//
MHOSSC)6%K<CU XODF+X-H TMY ^YIN6$$LZ 189=Y@SXU!&&JA.,MYF7?7(A
ME73E)Q:Z'E-(.9Y@=H4>ZJG",.'C"$[N6#63C@YW&_H/6L+]+=U2[;[)RKS8
M'+\GMHJ00T8E.&(OQ$Z$D(O##H+O6V[$HYI2!YY!-S<=%BJ8C8;2ZQ#-+[(#
M?#[5E,L]FVXN1CN?<L8]P\TO1DBOC!:K<>)UQ'FUDX?)"^JIQ"%ZZ*<:TXH9
M/F@^#47W]]FZOKY'/]IW4C^G=7:].PULE816[&+HFE80)4$01)89]Q!,"&*^
M"AJI0RNOG6G1TDVSK,-KE 3P\+QL(4U:Y;J$35H7\P6?M!Z<T ,U*%)*_EG5
MG5=9>8B\H*Q*_*&'LJHQK9CA>Y:1G4*2,Y?E,TF/_R?=[K.5CR"R;=N*_2AQ
MP\@*S'@8V[("M'IJHL&7.BWK*<DI[[@\<_@8(G^F="R85\9=]I#O=G1]26MH
M'C.C'42'-.F(2N[\2-05>DQ?R38Q9433&),[88,(AG$21X&/3(_>%(9#>SK?
MB@.KF[!HQU@Z(V=4_NG: Y0Q63/:C^D_?9JRNN!GFJ;,-@E-4S[&V,\8L_NL
M++--4U=WDY;7)0D]=;9I!B6+IZ9$8^7A&"+'<P(7^7Y$FW#@P$E\VR= @L3W
M>9^XE#*H\E7*@+,M7+LRGM+2^$8Q\AXURB&9]81Q=G9Y#Q9[6K^TM!*,!BTP
M:U :#4RZN=-6G,U]GLA"WL5C1*GLZZ%_LHUZ=6BH@#/F1.505GQVY-BW800L
M"SMQ2.B+0NQ[_<B>EW!>=I(QHG+M:T%.%#XIW#)N9\],*N<N=LNF?GK'0-NE
M7$\BZ7HHG52+CO,\Z6R]I7%W>7ZWBO95OLNJZIKHP+<\^WY3;//U\VWVHXZV
M]"Z%C>ESZE;B N1B:'N8%JVY),L,?00"[+&)FY2AE*M:#XQ-QN30=UF_9N>-
M3[AZ9$8/S?AG"\Z@Z(P&WOD;E0K8W!3K/:TJ:BO%M6'U!2QF=I.L6I?Y7?-0
MOE'T#'>+?WHM)MT]-[L$.:TP?NK>B*U^98T1E :J_+[I=+K/0LP)P9?*Y[)*
M+]>40L'WQI>_1FF55]?W<+TN]LV;PNVPQX,'P'9@0#L3V4D80FQ!)^@'MTA\
MX4MA)0VJ7.\;G.W+H5G53T^^'%86OVQI[ +$<@:$GM$#1)+0MB&!)S0HR6;9
MV+N0T$JF7X^<5K91A=)/EG?UOJO(0)MF8K\:TO4] &WDF4'@.XF3V)[?#PG-
M@#&SE3+4#.OU$3K>5?H4#EF7YS.1Q[LN'\'21\<NL75Q.2Z!9#TT2XXIKQ;@
MTOAAU:<_Z,L%J*KSKV2M7ZT\LIBWR3AV;#F>%]HH0%8[2."$V.+<2.3\X<HU
MB.!I2KIZ1'PRQ$L5F_ HY(A/:CIR!BCZJ,U+BB[HBR"7>BB**/A"RO?$>W_I
M^RB=*HL=^>6Z?1/C=')E^R:"L04MQS8))#N!T0 C@M#AN?HI?7">.25TH?V[
MD0Z :8^($6+>VTNR>6<3J44IYY,QRO8!J_$2K#Z:QLOH!=53YAP]=%&=>:]N
M."GED55;D[Q:;XMJ7[9/2@VOCG2OE,1%55>'=TF&-^ '5*:/'!="B$/D)WYB
M.J$9M2<T+O(PA'PIG&HTRG.^\:M /3P^T57N$#8-ULD3?))\0-Z\0C)^3:M_
MTJE!?V6<<I;QS\5$>B+E%S1[+F?J(>&S65LL,V7X!/[+^C';[+<4T\G"REO:
M '.T[G<2" $V8S]V<=)$'*<! :T81J'+I^>2!U<OW_NO7]/RF0I'=_D_W7:M
M@HSO>?UXU+U[2X^"Z\=T9X2FL4F?*R/?K;=[>J&=_FUY-V)E.Y$M!BSH/3[)
M[X&VSTZ=N:M%E+UIO;R8OO/1>4'.%?E%#_5695PQR[?-I\WG&Q ?1O8<'R//
M<ER2\_L1](!O)OW(.(QM/D&6,:)R%?[]T"=]D]T=^EK6S\)]TZ4PS:::<U/,
M)Y47>Z(O+I$,W%W019G,ZR&&4BTJU'VG?++7=O)HLM]X2[*K_#ZG3[S0)N#T
M8?E]NOV]3;.>$Y(X'REQF. HMFA[#^3B" 0FL%$/*72!PZ>'2J',F:ZN#XA'
M2>I?C?3U?!?54+5N8Q-7;?S%I[HCV,8!-WWU:H3<Z*$;%/OB6CR%Z@LB/8L'
M]5#O>4PM%I@A?'K_.4NW^9_9YK<TWWTLJNIZ-P)YA, )L1N;3A !-R%1)XAL
M.^P0) 0/YWZRS)&5J_G+%T:_'B7!HJHME7PVD5Z*=3Y-[E$:%*;QC@+]A3[V
M,M;JI368@\D+DJO"'WHHK!++"O5?\[%^CK^JC^17?_M+_R?D_^@!Q=_^\O]0
M2P,$%     @ ;H*92G2MA%>MB@  &A$' !4   !B:6EB+3(P,3<P,S,Q7W!R
M92YX;6SLO=MV&SFR)GP_3U%_SW5UX7S8:WIFX=CM-7;98[NZ9\\-%BVE).ZB
MF&J2<MG]]#] ,E,G'I+,3#!%]^J]R[8$(!%??  B@$#@?_RO;[>3G[X6L_FX
MG/[E3_#/X$\_%=.+\G(\O?[+GW[[]+/Z9-Z\^=/_^I__[7_\?S___'_UQ[<_
MV?+B_K:8+GXRLV*T*"Y_^F.\N/GI'Y?%_/>?KF;E[4__*&>_C[^.?OYY5>FG
MY5\FX^GO_Y'^\V4T+W[Z-A__Q_SBIK@=O2TO1HOEMV\6B[O_^.67/_[XX\_?
MOLPF?RYGU[\@ / O=:VM)=*_?JZ*_9Q^]#-$/V/XYV_SRS_]%"6<SI??;O"1
MJOBW%^7_P,O24$KYR_*W=='Y>%/!V"S\Y?^^>_MI*>?/X^E\,9I>%'_ZG__M
MIY]6<,S*2?&QN/HI_?G;QS=/&ODR+J^+Z?BRN/CS17G[2RKRB[J(R-]/$NCO
M%S?%S)2W=[/BIIC.QU^+-U%KM\7;<CYO6"QV?]F+FUEQ]9<_?1F/OT3D( =X
MA=M_[^=KB^]WQ5_^-!_?WDTBUK\,!0Q;+$;C269,GGUTV-# DV #!P[.Y]&7
M29&9-D^_V1DPIIQ,1E_*69R.OQ9JNNK"QV*RG)[G-^.[O6(V;R%CIP\J$7_2
M<";H_<.#@LC]\WZ\^/ZN6-R4EV^F7XOY(ED .;%JUH,.09M>QG%77,:_S,O)
M^#(-2CV:I!7\TTU1+.:_34?WE^/XT_W2']S4*<3X,)I%0&^*Q?AB-.E0IHWM
M]BO@IT7\[Y(>[Z_,:'[C)^4?+?75K,F,8KU<&CH4L$'C^43M6KJ^!;+%+'H_
MBR5T\\5LZ2OMG2)W5NJW:PTG\29U^^UH,UNK0=7NNKEVA>.*Y::+N#Z]F5Z5
ML]OEJK6WGPWJ=M91-YI-HT<__U#,/MW$"7E?Y[:5[ZU##4FXIUIOW6M&O=VU
MNNO<TA3:VYDGI3K^>%-U;2K<3U<^%]\6]_L-EUUU.NY80\YL*-M91_QH//O[
M:')?O"M&\_M9T6@IVEFIWZXUI%63NEDZNG=/I%'E+%U%;;J*LG:UX5 ^H(E^
MN]ULH#>HVETWQ]/HB8U'DP,LT%UU>NU8TT&_OVJ.;NX?\@WJYNCH_@'?H&Z.
MCN(6'<4Y.]IT7FK<0J^=WM^-HQAR0+.]BM=PTMU;L[-._JVX+>]NQI/QZ-/=
M>/K^ZNK%#_9UMGD+&3O=<'8^N*'\(C0<OL>VEU&@9MP_M)W.!%AML'T>?=O?
MQPU%^^A&0Q)OK]%CIQK2<F_%/KK8C&A;*W38I<5H>CV.;:OYO%C,U?3RKV5Y
M^<=XT@"WO55S=+,Q YNVD+'3>TW> YK(T>VFK&W80(==_AKMCW*V=^ON1<'N
MN]"8CYO+=]^AYU]J/"TVJ]]]AYNR;&/Q3KNS/@I_,_W[:#9.GXG4+F;QQ\MS
MA7&S3C9N)&_7#^#IH6UU)LC;V/IUHS.?ER5[Z$1#R+96Z*Q+ZQBFAU/8VANK
MCV-7G][7U8,;RB]"0]"/;2^_0(T+-IVI^_]R?I":K0%'-M>9.!]FY5TQ6WS_
M,!FMCIO_>3^^2U_=^HM]$AW?X@F%:CA$6S?<F8@?BWDQB^N:+V=V/+\H[Z=+
M*U5-)N4?*=!JKRB-&\C7Y89*.+2=[ +L]8D.;BB?",UFK0.;Z:S[R\@)/9JG
MR,'OC4ZNMM?HL5,-B;RW8O]=W$O5_35[[&0S,NZKUUT'[V]O1[/O[Z\^C:^G
MXZOQ19KK+Y;L'T^O/\05_**!0W58*YD[WZQ44W[W]\E!PM(M X[[YE' /+[M
M)E>X3(OK9(V^'7TIGEGOF^I-9K,GU=(U.YFNV4&VE'A3:QWW]-=BT6UGGS?8
M<7\_%+-Q>>FF'4.\N=E>^AX=E%G'F&]KN./^?RYF\Z+;GK]LLNL^EXO1I.,^
MOVBRNSX?08S%RVXV9,'=+-JCT\5RP^IM_,&Z?&KW1/=F5UTMOBV*Z65QN;S6
M6W5V4EYL0F6)R-5H_F4)R_W\Y^O1Z"Y""MDOQ60QKWZ25A+V,X#K"\S_??WC
MT+!_<5)[?_5Y]$U]F2]FHXO:]9XDG/_RI]BWT++%P(A@0B''H$%,$:B9(=AR
MQ)4UFA/R%*))NN)=SM;J[!>C#1+\6BZ*M%.DXQ=_WP'&OJK!4V8P)<XR0BP3
M5@K%*ZD59[B)U(]IK&87/Y6SRV+VES]%2SO^YJJ8S=8KZ(Z;ZDM*+U[,1:/9
MQ8O!\+3BNL0O=\L;63]?W(PG]>V7='$_,S?*7N&/PE;SQR\;)Y A3BT;+> ?
M<X9!$EEC)*"$6V.QA)JNE!WIQ*0_W0Q3[]DN/= =HC\M&*A6SEE%-8>"(F:X
M=+B22%K*_SU['*3WLD.P'^:*3-197?I(F)33M)FAOHWG39BTJ5Z@3!F/J/2
M1JP<A%";6E:*S7D1ZUA%;^-+!Y#FHL^SKMKR=C2>[J#-QO(!"^\$-YPX8!T"
M%%HE*]FL8XUFUE=(EW9Z+KM'-A=K'LW$<;;];3HK1I/QOXI'213^&CN?)N-W
MQ>V78M9L,6_45'"6&"009<!C*A&&7M>C4QBCSXMK+5E19@7[-/2KNNPC>+:8
MCZ^G2PMA]G_NHW!7W\?3ZRJYPM^*R^OB4$H>UWQ UDL#??0JXFQ G-,2U-.
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M\A #@2$$&'%B$-. $\XYJI%#Q)[9N5B?-,VB@%-M[;Z_C\9J \-VCS77IMD
ME(0 &&P TII"(J3W:Z2D%+#-C#I JG9D[&5$?.C<W&LTMFLXB+@&<2"QA51C
M9ZC$2E1H<0CH>:WX>8C5$9N/TM#0^;S70&C7<. $ $>  )1*!QWFP-D*+>.E
M^#>?CZ%61XP^2D>G8O1#?%I3\=XVB 'K\"O!:2FPP$PJ2"0GUK#:&Y9&R#9S
M]P"/A7NR+?(I(!>1?RVG*?O:*.5%6?78?;M+S_SMH.76.D$C 1"*_B@T!@*&
MB;:LDI$1W2;"^A5,J%G84?:CBUQ\JW.:K[NYCB+?P;8M-:*%!9GSP&(K,-"6
M0"9()9]5K7;&!^@L#8%KW6@BVWG,:%+,/Q9?B^E]D1*0I^.H7<<P&XH''U<'
MS30R!&KH(U"6F5JR.*3.:]$< L<Z4$.V<*EJWET/AUV6W(NR05O$,.;:<\Z(
M)XXI4CN(4*DV)\;- Z'VI78Z1X:U544VRZQ8O,R-M,D:>UPN.,=LA,$8'KTU
MBC7E"E:R $)MSIBF'V/&:H/_JPQDVI0A](<,8X)4.Z4TLLA"I"7 R*^B>*6!
M6B)YPC"FBYOB\GY2-!L"E4Z;)/-JV7+ $GA/!#$6\Q2!2I@E%68D3@#GY2'V
MSJSGUE-6[0Q]^[@QJ;OY0&#<4P(\HQ8!Z04#T*,U>L@QVL9;&*!'FIO;)U%2
MI@7:E)-(RS+9I5\+-5W)\K%8W7V>WXSO3K?<OI]=CZ;C?RU[\O#61F+G]/+#
M(Y'?7[U\?6/>8/'MI/V L<42,Z$X<-X : Q:Y3"4D6B8G#"B^*EJ9[/1]'KU
M,LEX?C$ITX/5S7)H-FXE8!AM3AU]&&2X0)I "TB%A9$^ZRGMUV+VI>QY(LK,
MH!?I-?O2S&#FGH-*Q)^<.MOFZYBR((LK(34(<@ M\2XN1UQ1QB(+O?!V$-[#
M-G*G!TM^+>/RNOG7R\0=4<9$AKT7*3K_6%#(^6BNQN%+B(7>1T#M"EE"#/6-
MD'T]/D9F-F[U.$ZDOOU.R,M')-)/0MK^NUC4#Y]\'M\6L5)17KT;3XKYHIQN
M"_4[H'90EG)'#54.2@>@8]'6K6314+7)!#1 *IZ2#&7?RNF1:%OC]@ZJ'Q1!
M1B %E7=41,&B'X_6\E 91_1YD*T7#1_&GJ/P/IH__C_3S[;&PKTH$VRT)H54
M!JBTE8-D&C>*<AV]:R=DJWV(U\>#0W55=H-JMKVQ-'7NBTFOR@0B2;J!23AF
M!*DTLS)8H\!HF]W7 >Y0#6 Y:JN"K#3:'V[[4"H ("S!C#,DN8<0&N=Y)4?\
M\9DL-BWTMXD!1V&7BP/OQM/Q[?WM7A8\*1>X\1HBB8FB%%-H$>>^DD5Q>&99
M\H_28MD=?MFX,/K6C N/RP5J<;KJI;0'V'$<9T?P( L@;78>![B\=,*%%OCE
MXH*/?%T4;^/2>/DF*F9Z/8XKH9K/B\5<?W\W^J]R9M+!S!XCY(!6 B=,64TE
M@@AZJ[GP1E8X",S;W,L88-C=@,R4_I0T +(^]/_748.[<@>V%*3QE LE.102
M(1O] U%/ =R9,_&Z>F5*<S9VH(&C_?$WT[?CBQ0Y&+W.11J=NUWS+<4#2 ?0
M<2Q*S+6 V"F%JS%*"2!G%@G3FR[+SJ'.-55]CE][?_5H'M^S@FXL'X0'!!$E
MK25& 2^LHZX>7)2VN7(SP(2* UHKNU!'MCP=+_ 9;89D?TJ.PUH*F@DD!/=&
M&$&-$9A*4 \]Z,[LI:*6G'B>?:-7K(]>__1L/%^4DW??(YR?_GD__O)E]P*X
MK7Q  .ET:X@Y)X&FGF-#:W<'NC,['.M-FV7W6!]O&Z5$QZ/I'HOH<:&@#%00
M&Q!-0T2LL)Y)4?6,:MIFAAC@ID$6%K0!^&C5JR]?_C[>OH?\HDQ@*0K*<\*M
M5]PJXR31=;\,.+/GF+(HO@6^QP_Y<CJ>?[@9S6Y'%\7]8GPQFNSSB+;6"!0H
M!;VV5ALC)6%0TNK -H) \]R*.R].=(9V+F/UPZR\O+]8O)]]*F9?HS^WQRW:
M5#P@2F1Z$8AY:C#V6%*JUI(Q(FF;EP<'> UN0%Y1!]K(S+,$S;JS\[V;@EOK
M!!1!(DH Z[4S'#BEZQ, YJ1H<_%R@,9L.S5OYDQK4(]>PCY]>//K1_7_U.YE
MZVFI@($AGADFM%%<$2*=J<PJAF&KQTV'J_ V.BJ[PC);!HDJ3/:O17D]&]W=
MI+6S:3;OYW6"%D!#[JFT#%H'B-2FQDECUH8O;'A\&="2U)5*LM&NN'[>V[WK
MTM8Z06FA89J(D2&<&^.HJ2=EI^"9K4L=Z/HY>SI"]C#VS(N+/U^77W^Y*.^G
MB]GW%7G6_WC.F_6/PV^?-A#DX9?!0FBME51BR)@5TCC%JOYZJ,\L>V<'>BM;
M0IAKPGB0T8[GB]GXR_WR@;)R5HROMV_%'5 [4(P8M8)Y284QQDH';6W9>=S&
M+1_@'EUWU.D/XUS<ZF#U?ML@TV67GPD@FJ/:0*J)H,DJE3Q%UZV0-+I5^! ?
M(%N'8VF=4(OY<E',B_BMFRB1+;X6D_)N^?[(*I64^W8QN;\<3Z_5Q3_OQ[,4
MZA#]IN@JS4TYWW6CM$6K@7G#H[92,')Z3"DE('+UG-3NW>\!+NNGH=B+5!2Y
MU'7\:<SEY3A).YK4-V'6=V2VGLULK1&7/2@E!(3PZ.I;CKPAM7O.<*L8DP$N
M_R>E6+>J./Z,?YDH8'X3 2NO+LJ["%*9>A3_<C5>S,O9I)QOSGAX2/40J0^<
M5 HZ9*7T%B)9H<,E!6<6Z'MZ8O6CEUQK[S+OQ.,$H;LSNFXJ'L>/L]I!R"6
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M%E@%L.6(2V.\LHWF\1P')5$C[V=+B2Z7+L2'8K;MB8O#&@C,&^4PPX(XSN,
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M*TM/HY\A\'M[7/7#]:X&+R!V]8D "$&2B.CS1%5"@JD2J$*0<GYVUSVR,^\
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M2&MN](ANUMVNQ]S>/:-L*AX81,!QR U3B$GF$:*^DLQ TR;7_R!OL7<VIW2
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M+<(08*L$4YHP4_6::- F>&5 *TL_6C\<ORQ:-P_/.6S2>OQUX)@@:R%6&A%
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M\ONM&37VTZA!]0 5<D)R;:+WST@R,JFN/0)"VIQ%#M!FZHE4W0.=[X!Q0[Q
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MCLO+W=/RQK*!2R*LHUP[BE7D)B2PFG"4%+*-<MGK5&X;?/K5\L-RX>-/-IT
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M!$DL*SFE,5D3.^<X:&BO\+(?:$\T6&VQ&(TGIPMBZ7+,1K6196X"J35/0?Z
MDQ7@0+"&R1+[/HA4<9*_'$_NTV'3I^(BW:@:%_/'H:=Q ;B[7RGW_=4+=J4
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MX&,T+RX_C+XOP]EFL_3HR+X\/.T;#T9PIAR0!F,A@.!65>'G0%$/SLX[[8)
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M,U@RRA%I<U%LD#9A'[0I<ZOAA)/&^G+ #S-W..X)!, QSQ#@$FC$G>!2:Z*
MCVH:@@^:R!9E>,:YYO<!=M0/$#L*1#HGEC+24VNF:24_8+9-VN@!'C'U08P=
M!G97L.<RG!_@^1R_NR>R_V7A(+FDBA"'G7/8 ZX,J#'#"IW9ZV4=:[KL&-[3
MD,9$!_*ZG(W_M53@WO12^RL';0'EW#%F-4-$J6A^BTIJ0LF9Q5ZW4?M.!G6
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MVG.3NH'#Z-]RK[WR'",+''.DEH.UNOPR2#.Z!PV7_6+>-7=^+:=MZ/.\>N!
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MD55**NN0M#5&!&6-'QQ4ZHC&Y"E/H8C3&T[+@(J/C^*!CC.E7C83".<X.C<
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MVS2E>.?Y:DUAUTY"J1#W?%]LUWI>Z1W[/"C"A2/.&LI0=%>)YUB6E!$,V]P
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M( P-*?FJO6L3$E/[K?>WYDXAP\9QBE66_DO4FMT1<133+6<,E (6O0XN%0?
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M4%,/G1U((AU"HV*?QE/C:Y1Q_*5%R7B;_<SF^4/A6E\,Q:LT/D# D<'6(DX
M<-"YHO+4CG;FS/5U=>D1':^0V#W_4V'O^W)RD]U/EO\JGJ>V?RD8<KK36Z5Q
M@4#@XDF#A0&6*N<4QB4GH_UCVD16C="S3(FU+OF>++*X$W.PQBP! \"-I%Y
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MTQHPQKQ[\E8]:9,_6_\U^]TJU0:B> +JP!T+7]0CNOJ6A4HKBHEE#@$FG'#
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M=NK$+?JM$=:+,JG'QN$C4[?7$JM?5W7]<:F ,\Z\()Q#9*A#4#IL.>+20HM
MI:.SXN7JQ4*96P%\CRS7<<9_G;IZK3E-0!Q+K"U"!H)H=$=_2HB20D5ITCZ
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MUNOYUIZXS9?WNVS8R(=+'?$NC@S12#::ZNA^8\D-]MH\T8"=;I.</\+PN?$
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MX01!2Z@C/M+BB6%["AP5_NJZ=W4AS+PW_J:Z+HENY[:WV*_,>+R,J7H3A,A
MK 34\>BR4BH/%18E]5%M)@UD>V/HZI73J7#VU.8K"J\ZNLX-"X)P1A5R# C!
MBYYVB/&24@5:]<VMG=+P1C'5(7]3(>F?J^(N>[6>W4_61U]8CW\8&(L$1(*0
M@9@QB9R(9M66&H&EAVUB7T99%K@'M+3B:"I\?,K^>D;Z,E_$/TYWEZYUS[:Z
M4P44?;-HMBN($8C<05;I T>T4DD3$P9UB)LBK&>.5_"4]O]0_%?Q5O!__M?_
M %!+ 0(4 Q0    ( &Z"F4HW4]H21*D! #09'@ 1              "  0
M  !B:6EB+3(P,3<P,S,Q+GAM;%!+ 0(4 Q0    ( &Z"F4I#A NDQ!(   OE
M   1              "  7.I 0!B:6EB+3(P,3<P,S,Q+GAS9%!+ 0(4 Q0
M   ( &Z"F4JKY;DM9"(  -Y] 0 5              "  6:\ 0!B:6EB+3(P
M,3<P,S,Q7V-A;"YX;6Q02P$"% ,4    " !N@IE*_-4ZOA]6  #88@0 %0
M            @ ']W@$ 8FEI8BTR,#$W,#,S,5]D968N>&UL4$L! A0#%
M  @ ;H*92@0#P0+'Y@  C>P+ !4              ( !3S4" &)I:6(M,C Q
M-S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( &Z"F4ITK817K8H  !H1!P 5
M          "  4D< P!B:6EB+3(P,3<P,S,Q7W!R92YX;6Q02P4&      8
,!@"* 0  *:<#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
